Archives

Guidelines for the Management of High Blood Cholesterol

ABSTRACT

 

The LDL-C hypothesis holds that high blood LDL-C levels are a major risk factor for atherosclerosis cardiovascular disease (ASCVD) and lowering LDL-C levels will reduce the risk for ASCVD. This hypothesis is based on epidemiological evidence that both within and between populations higher LDL-C levels increase the risk for ASCVD, and conversely, randomized clinical trials (RCTs) demonstrating that lowering LDL-C levels will reduce ASCVD risk. LDL-C levels can be reduced by both lifestyle interventions and cholesterol-lowering drugs. Widely used LDL-C lowering drugs are statins, ezetimibe, bempedoic acid, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. In this chapter we discuss the information provided in the two major guidelines on how to select and treat patients to lower LDL-C levels; the 2018 AHA/ACC/Multi-Society report and the European Society of Cardiology (ESC), the European Atherosclerosis Society (EAS), and representatives from other European organizations guidelines published in 2020. Additionally, we discuss the key principles that clinicians should utilize when deciding who to treat and how aggressively to treat hypercholesterolemia to lower the risk of ASCVD. Specifically, 1) the sooner one initiates LDL-C lowering therapy the greater the benefit, 2) the greater the decrease in LDL-C the greater the benefit, 3) the higher the LDL-C level the greater the benefit, and 4) the higher the absolute risk of ASCVD the greater the benefit. Following these general principles will help clinicians make informed decisions in deciding on their approach to lowering LDL-C levels and will facilitate discussions with patients on the benefits and risks of treatment. These decisions need to balance the benefits of treatment vs. the potential side effects and cost and the preferences of individual patients.

 

INTRODUCTION

 

Atherosclerotic cardiovascular disease (ASCVD) remains the foremost cause of death among chronic diseases. An aging population combined with an atherogenic lifestyle increases the risk of ASCVD. Even so, mortality from ASCVD has been declining in most developed countries. This decline comes from improvements in preventive measures and better clinical interventions. One of the most important advances in the cardiovascular field resulted from identifying risk factors for ASCVD. Risk factors directly or indirectly promote atherosclerosis, or they otherwise predispose to vascular events. The major risk factors are cigarette smoking, dyslipidemia, hypertension, hyperglycemia, and advancing age. Dyslipidemia consists of elevations of atherogenic lipoproteins (LDL, VLDL, Lp(a), and remnants) and low levels of HDL. Advancing age counts as a risk factor because it reflects the impact of all risk factors over the lifespan. Several other factors, called risk enhancing factors, associate with higher risk for ASCVD (1). Lifestyle factors (for example, overnutrition and physical inactivity) contribute importantly to both major and enhancing risk factors. Hereditary factors undoubtedly contribute to the identifiable risk factors; but genetic influences also affect ASCVD risk through other ways not yet understood (2).

 

THE CHOLESTEROL HYPOTHESIS AND CHOLESTEROL LOWERING THERAPY  

 

There is now indisputable evidence that elevated serum cholesterol levels increase the risk of ASCVD. The first evidence for a connection between serum cholesterol levels and atherosclerosis came from studies in laboratory animals (3). Feeding cholesterol to various animal species raises serum cholesterol and causes deposition of cholesterol in the arterial wall (3). The latter recapitulates the early stages of human atherosclerosis. Subsequently, in humans, severe hereditary hypercholesterolemia was observed to cause premature atherosclerosis and ASCVD (3).  Later, population surveys uncovered a positive association between serum cholesterol levels and ASCVD (4,5).  Finally, clinical trials with cholesterol-lowering agents documented that lowering serum cholesterol levels reduces the risk for ASCVD (6). These findings have convincing proven the cholesterol hypothesis. Moreover, the relationship between cholesterol levels and ASCVD risk is bidirectional; raising cholesterol levels increases risk, whereas reducing levels decreases risk (Figure 1).

 

Figure 1. The Cholesterol Hypothesis. Between the years 1955 and 1985, many epidemiologic studies showed a positive relation between cholesterol levels and atherosclerotic cardiovascular disease (ASCVD) events. Over the next 30 years, a host of randomized controlled clinical trials have demonstrated that lowering cholesterol levels will reduce the risk for ASCVD. This bidirectional relationship between cholesterol levels and ASCVD provides ample support for the cholesterol hypothesis.

 

Epidemiological Evidence

 

A relationship between cholesterol levels and ASCVD risk is observed in both developing and developed countries (4,5). Populations with the lowest cholesterol levels and LDL-C levels have the lowest rates of ASCVD. Within populations, individuals with the lowest serum cholesterol or LDL-C levels carry the least risk. In other words, “the lower, the better” for cholesterol levels holds, both between populations and for individuals within specific populations.

 

Pre-Statin Clinical Trial Evidence

 

Several earlier randomized controlled trials (RCTs) tested whether reducing cholesterol levels through diet, bile acid sequestrants, or ileal exclusion operation reduced ASCVD events. A summary of the results of these trials is shown in table 1 (4).

 

Table 1. Summary of Pre-Statin Clinical Trials of Cholesterol-Lowering Therapy

Intervention

No. trials

No. treated

Person-years

Mean cholesterol reduction (%)

CHD incidence

(% change)

CHD Mortality

(%change)

Surgery

1

421

4,084

22

-43

-30

Sequestrants

3

1,992

14,491

9

-21

-32

Diet

6

1,200

6,356

11

-24

-21

This table is derived from National Cholesterol Education Program Adult Treatment Panel III (4)

 

Statins and Clinical Trial Evidence

 

Statins were discovered in the 1970s by Endo of Japan (7). Seven statins have been approved for use in clinical practice by the FDA and they are now generic (for a detailed discussion of statins see the Endotext chapter on Cholesterol Lowering Drugs (8)). Statins inhibit HMG-CoA reductase decreasing cholesterol synthesis and increasing hepatic LDL receptors resulting in a decrease in LDL-C levels. Over the past three decades, a series of RCTs have been carried out that documents the efficacy and safety of statin therapy. In these RCTs, statin therapy has been shown to significantly reduce morbidity and mortality from ASCVD. Although individual RCTs produced significant results, the strongest evidence of benefit comes from meta-analysis. i.e., by combining data from all the trials (6). 

 Meta-analysis has shown that for every mmol/L (39 mg/dL) reduction in LDL-C with statin therapy there is an approximate 22% reduction in ASCVD events (6,9-12). Another report (13) showed that an almost identical relationship holds when several different kinds of LDL-lowering therapy were analyzed together. This response appears to be consistent throughout all levels of LDL-C.  Individual statins vary in their intensity of cholesterol-lowering at a given dose (1,8) (Table 2).  For example, per mg per day, rosuvastatin is twice as efficacious as atorvastatin, which in turn is twice as efficacious as simvastatin. Statins are best classified according to percentage reductions in LDL-C.  As shown in Table 2, moderate- intensity statins reduce LDL-C by 30-49 %, whereas high-intensity statins reduce LDL-C by > 50%.  Absolute reductions vary depending on baseline levels of LDL-C. For example, for a baseline LDL-C of 200 mg/dL, a 50% reduction in LDL-C equates to a 100 mg/dL (2.6 mmol/L) decline; this translates into a 59% reduction in 10-year risk for ASCVD events. In contrast, in a patient with a baseline LDL-C of 100 mg/dL, a 50% reduction in LDL-C equates to a 50 mg/dL (1.3 mmol/L) decline, which will reduce ASCVD risk by about 30%. Thus, at lower and lower levels of LDL-C, progressive reductions of LDL-C produce diminishing benefit from cholesterol-lowering therapy. This modifies the aphorism "lower is better".  Whereas the statement is true, it must be kept in mind that there are diminishing benefits from intensifying cholesterol-lowering therapy when LDL-C levels are already very low. One needs to balance the benefits of further reducing LDL-C levels with the side effects and costs of additional therapy. 

Table 2.  Categories of Intensities of Statins

Drug

Low-Intensity

20-25% LDL-C

Moderate-Intensity

30-49% LDL-C

High Intensity

>50% LDL-C

Lovastatin

10-20 mg

40-80 mg

 

Pravastatin

10-20 mg

40-80 mg

 

Simvastatin

10 mg

20-40 mg

 

Fluvastatin

20-40 mg

80 mg

 

Pitavastatin

 

1-4 mg

 

Atorvastatin

5 mg

10-20 mg

40-80 mg

Rosuvastatin

 

5-10 mg

20-40 mg

 

Non-Statin Cholesterol-Lowering Drugs

 

Other agents are currently available that lower LDL-C levels. Bile acid sequestrants inhibit intestinal absorption of bile acids, which like statins raise hepatic LDL receptors (8). They are moderately efficacious for reducing LDL-C concentrations. A large RCT showed that bile acid sequestrants significantly reduce risk for CHD in patients with baseline elevations in LDL-C (14). Theoretically, bile acid sequestrants could enhance risk reduction in patients with ASCVD who are treated with statins.

 

Ezetimibe blocks cholesterol absorption in the intestine and also raises hepatic LDL receptor activity (8). It moderately lowers LDL-C (15-25%). The combination of statin + ezetimibe is additive for LDL-C lowering (15).  A clinical trial (16)demonstrated that adding ezetimibe to moderate intensity statins in very high-risk patients with ASCVD is beneficial showing that combination therapy reduced risk of cardiovascular events more than a statin alone (16). In this trial, the higher the risk, the greater was risk reduction (17). Ezetimibe is a generic drug and relatively inexpensive.

 

Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes degradation of LDL receptors and raises LDL-C levels (8).  Inhibition of PCSK9 increases the number of hepatic LDL receptors and markedly lowers LDL-C concentrations (50-60% decrease) (8,18).  Studies have shown that PCSK9 inhibitors reduce risk in ASCVD patients at very high risk when combined with statins (19,20). PCSK9 inhibitors are relatively expensive drugs.  

Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor and thereby inhibits cholesterol synthesis leading to an increase in LDL receptor activity (8,21). Bempedoic acid typically lowers LDL-C by 15-25% (8,21). A RCT has demonstrated that bempedoic acid reduces ASCVD in statin intolerant patients (22). Bempedoic acid is not generic and therefore is relatively expensive.

 

For additional information on cholesterol and triglyceride lowering drugs see the chapters in Endotext that address these topics (8,23).

 

PRIOR U.S. GUIDELINES FOR CHOLESTEROL MANAGEMENT

 

National Cholesterol Education Program (NCEP)

 

The early guidelines for cholesterol management in the United States have been those developed by the NECP. This program was sponsored by the National Heart, Lung and Blood Institute (NHLBI) and included many health-related organizations in the United States (24).  Between 1987 and 2004, three major Adult Treatment Panel (ATP) reports (4,25,26) and one update were published (27) (Table 3). Over time the guidelines recommended more stringent LDL-C goals as the results of RCTs were published and added non-HDL-C levels as a goal.

 

Table 3. National Cholesterol Education Program’s Adult Treatment Panel (ATP) Reports

Guideline

ATP I

ATP II

ATP III

ATP III Update

Year

1987

1994

2001

2004

Thrust

Primary prevention

Secondary prevention

High-risk primary prevention

Very high risk

Drugs

Bile acid resins Nicotinic acid Fibrates

Same as ATPI   +Statins

Same as ATP II

 

Same as ATP III

Major Targets

LDL-C; HDL-C

LDL-C; HDL-C

LDL-C;                Non-HDL-C

LDL-C;         Non-HDL-C

LDL-C goal

     (mg/dL)

Low risk <190 Moderate risk <160              High risk < 130

Low risk   <160 Moderate risk <130             High risk <100

Low risk <160 Moderate risk <130          Moderately high risk <130    

High risk < 100

Low risk <160 Moderate risk <130

Moderately high    risk <130      High risk < 100   Very high risk < 70

 

Transfer of NHLBI Guidelines to American Heart Association (AHA) and the American College of Cardiology (ACC)

 

In 2013, NHLBI made the decision to remove treatment guidelines from its agenda. This was done even though it had almost finished writing prevention guidelines. These included guidelines for high blood cholesterol, high blood pressure, obesity, and nutrition. Late in this process, the guideline process was transferred to the American Heart Association (AHA) and American College of Cardiology (ACC). Then in 2013 the NHLBI guidelines for high blood cholesterol were modified to fit the criteria for guideline development required by AHA/ACC. The 2013 cholesterol guidelines (28) adhered closely to the Institute of Medicine (National Academy of Medicine) recommendations for evidence-based guidelines (29). These recommendations advocated priority to randomized controlled trials (RCTs) as the foundation of evidence-based medicine. The NHLBI cholesterol committee carried out an extensive review of the literature and limited recommendations based largely on RCTs. Most acceptable RCTs had utilized statin therapy in middle-aged people. Therefore, the 2013 report committee did not include detailed recommendations for younger or older adults. Recommendations were largely limited to the age range 40-75 years. High-intensity statin therapy was recommended for patients with established ASCVD. For primary prevention, risk was stratified by use of a pool cohort equation (PCE), which was derived from five large population studies in the United States (30). The PCE was an extension of the Framingham Heart Study risk equations. 10-year risk for ASCVD was based on the following risk factors: age, gender, cigarette smoking, blood pressure, total cholesterol, HDL cholesterol, and presence or absence of diabetes. Although the PCE was validated in another large study (31), it has been criticized by some investigators as being imprecise for many individuals or specific groups (32-36).

 

For primary prevention, an effort was made to determine what level 10-year risk is associated with efficacy of reduction of ASCVD from statin RCTs.  It was determined that statins are effective for risk reduction when 10-year risk for ASCVD is > 7.5%.  Most primary prevention trials employed moderate intensity statins, so these were recommended for most patients; but in one RCT (37), a high-intensity statin appeared to produce greater risk reduction than found with moderate-intensity statins. So high-intensity statins were considered a favorable option in patients at higher 10-year risk. Notably LDL-C goals were not emphasized. It was recognized that these recommendations may not be optimal for all patients; therefore, consideration should be given to any extenuating circumstances that could modify the translation of RCTs directly into clinical care. A clinician patient risk discussion thus was advocated for all patients to consider the pros and cons of statin therapy.

 

There are many guidelines discussing the management of LDL-C, but the 2 major guidelines are the 2018 AHA/ACC/Multi-Society report (1) and the European Society of Cardiology (ESC), the European Atherosclerosis Society (EAS), and representatives from other European organizations guidelines published in 2020 (38). In this chapter these two guidelines will be discussed.

 

2018 AHA/ACC/MULTI-SOCIETY REPORT

 

2013 cholesterol guidelines were revised by AHA/ACC in collaboration with multiple other societies concerned with preventive medicine (1). These guidelines extended those published in 2013. They expanded recommendations to include children, adolescents, young adults (20-39 years), and older patients (> 75 years). Although RCTs may be lacking in these categories, epidemiology and clinical studies indicate that high blood cholesterol is an important risk factor for future ASCVD in these age ranges. From the evidence acquired over many years related to the cholesterol hypothesis, it is reasonable to craft recommendations based on the totality of the evidence. These guidelines proposed a top 10 list of recommendations to highlight the key points. These key points will be examined.

 

Lifestyle Intervention

 

  • In all individuals emphasize a heart healthy lifestyle across the life-course.

 

There is widespread agreement in the cardiovascular field that lifestyle factors contribute to the risk for ASCVD. These factors include cigarette smoking, sedentary life habits, obesity, and an unhealthy eating pattern. The ACC/AHA strongly recommends that a healthy lifestyle be adopted throughout life. These recommendations are strongly supported by 2018 cholesterol guidelines. They are the foundation for cardiovascular prevention and should receive appropriate attention in clinical practice (39). For a detailed discussion of the effect of diet on lipid levels and atherosclerosis see the Endotext chapter The Effect of Diet on Cardiovascular Disease and Lipid and Lipoprotein Levels (40).

 

Secondary Prevention

 

  • In patients with clinical ASCVD reduce LDL-C with high-intensity statin or maximally tolerated statins to decrease ASCVD risk. The goal of therapy is to reduce LDL-C by 50% or greater. If necessary to achieve this goal consider adding ezetimibe to moderate statin therapy.

 

The strongest evidence for efficacy of statin therapy is a meta-analysis of RTCs carried out in patients with established ASCVD. As previously mentioned, the best fit line comparing percent ASCVD versus LDL-C in secondary prevention studies demonstrates that for every mmol/L (39mg/dL) reduction in LDL-C the risk for ASCVD is decreased by approximately 22% (9). High intensity statins typically reduce LDL-C by 50% or more; this percentage reduction occurs regardless of baseline levels of LDL-C. This explains why the guidelines set a goal for LDL-C secondary prevention to be a > 50% reduction in levels. There are two options to achieve such reductions. RCTs give priority to the use of high-intensity statins. But, if high-intensity statins are not tolerated, similar LDL-C lowering can be attained by combining a moderate-intensity statin with ezetimibe (15,16). The RACING trial, a randomized trial that compared rosuvastatin 10 mg plus ezetimibe 10 mg vs. rosuvastatin 20 mg, demonstrated a similar effect on ASCVD events (41). An approach to lowering LDL-C in patients with ASCVD is shown in Figure 2.

 

Figure 2. Secondary Prevention in Patients with Clinical ASCVD (1).

 

VERY HIGH-RISK PATIENTS WITH ASCVD

 

  • In very high-risk patients with ASCVD first use a maximally tolerated statin +/- ezetimibe to achieve an LDL-C goal of < 70mg/dL (<1.8mMol/L). If this goal is not achieved consider adding a PCSK9 inhibitor.

 

2018 guidelines defined very high risk of future ASCVD events as a history of multiple ASCVD events or one major event plus multiple high-risk conditions (Table 4). This definition is based in large part on subgroup analysis of the IMPROVE-IT trial (16,17).

 

Table 4. Very High Risk of Future ASCVD Events (1)

Major ASCVD Events

Recent ACS (within the past 12 months)

History of MI (other than recent acute coronary syndrome event listed above)

History of ischemic stroke

Symptomatic peripheral arterial disease (history of claudication with ABI <0.85, or previous revascularization or amputation)

High Risk Conditions

Age ≥65 y

Heterozygous familial hypercholesterolemia

History of prior coronary artery bypass surgery or percutaneous coronary intervention outside of the major ASCVD event(s)

Diabetes mellitus

Hypertension 

CKD (eGFR 15-59 mL/min/1.73 m2)

Current smoking

Persistently elevated LDL-C (LDL-C ≥100 mg/dL [≥2.6 mmol/L]) despite maximally tolerated statin therapy and ezetimibe

History of congestive heart failure

ABI indicates ankle-brachial index; CKD indicates chronic kidney disease.

 

Recent RCTs have demonstrated that the addition of non-statins to statin therapy can enhance risk reduction. These RCTs (and their add-on drugs) were IMPROVE-IT (ezetimibe) (16), FOURIER (evolocumab) (19), and ODYSSEY OUTCOMES (alirocumab) (20).  All RCTs were carried out in patients at very high-risk. For IMPROVE-IT, addition of ezetimibe to statin therapy produced an additional 6% reduction in ASCVD events. In this trial, baseline LDL-C on moderate-intensity statin alone averaged about 70 mg/dL; in spite of this low level, further LDL lowering with addition of ezetimibe enhanced risk reduction. RCTs with the two PCSK9 inhibitors (evolocumab and alirocumab) restricted recruitment to patients having LDL-C > 70 mg/dL on maximally tolerated statin+ ezetimibe. In these RCTs, the duration of therapy was only about 3 years. A marked additional LDL lowering was achieved. In both trials, the risk for ASCVD events was reduced by 15%.

 

2018 guidelines allow consideration of PCSK9 inhibitor as an add-on drug if patients are at very high risk for future ASCVD events and have an LDL-C > 70 mg/dL (or non-HDL-C > 100mg/dL) during treatment with maximally tolerated statin plus ezetimibe (Figure 3). This latter threshold LDL-C was chosen because it was a recruitment criterion for PCSK9 inhibitor therapy in reported RTCs (19,20)

 

An important question about the use of PCSK9 inhibitors is whether they are cost-effective. When they first became available, they were marketed at a very high cost, which was widely considered to be excessive. More recently, the cost of these drugs has declined considerably, and one can anticipate that the price will continue to decrease. An analysis of cost-effectiveness has shown that at current prices in very high-risk patients PCSK9 inhibitors can be cost-effective (42).  Another analysis (43) of approximately 1 million patients with ASCVD in the Veterans Affairs system indicate that approximately 10% of patients will be classified as very high risk and having LDL-C > 70 mg/dL while taking maximal statin therapy plus ezetimibe. These later patients are potential candidates for PCSK9 inhibitors. 

 

Figure 3. Secondary Prevention in Patients with Very High-Risk ASCVD (1).

 Primary Prevention

 

SEVERE PRIMARY HYPERCHOLESTEROLEMIA

 

  • In patients with severe primary hypercholesterolemia (LDL-C greater than 190mg/dL (>4.9mMol/L)) without concomitant ASCVD begin high-intensity statin therapy (or moderate intensity statin + ezetimibe) to achieve an LDL-C goal of < 100mg/dL; if this goal is not achieved consider adding a PCSK9 inhibitor in selected patients at higher risk. Measurement of 10-year risk for ASCVD is not necessary.

 

Patients with severe hypercholesterolemia are known to be at relatively high risk for developing ASCVD (44,45). In view of massive evidence that elevated LDL-C promotes atherosclerosis and predisposes to ASCVD, it stands to reason that such patients deserve intensive treatment with LDL-lowering drugs. RCTs with cholesterol-lowering drugs demonstrate benefit of statin therapy in patients with severe hypercholesterolemia (46,47). It is not necessary to calculate 10-year risk in such patients. Moreover, patients who have extreme elevations of LDL-C (e.g., heterozygous familial hypercholesterolemia) may be candidates for PCSK9 inhibitors if LDL-C cannot be lowered sufficiently with maximal statin therapy plus ezetimibe.

 

PATIENTS WITH DIABETES

 

  • In patients with diabetes mellitus aged 40 to 75 years with an LDL-C ≥70 mg/dL (≥1.8 mmol/L), without concomitant ASCVD, begin moderate-intensity statin therapy. For older patients (> 50 years), consider using high-intensity statin therapy (or moderate intensity statin plus ezetimibe) to achieve a reduction in LDL-C of > 50%. Measurement of 10-year risk for ASCVD is not necessary.

 

Middle-aged patients with diabetes have an elevated lifetime risk for ASCVD (48). The trajectory of risk is steeper in patients with diabetes than in those without. For this reason, estimation of 10-year risk for ASCVD with the pooled cohort equation (PCE) is not a reliable indicator of lifetime risk.  Meta-analysis of RCTs in middle-aged patients with diabetes treated with moderate intensity statins therapy shows significant risk reduction (12). Hence, most middle-aged patients with diabetes deserve statin therapy. With progression of age and accumulation of multiple risk factors, increasing the intensity of statin therapy or adding ezetimibe seems prudent (Tables 5 and 6). It is not necessary to measure 10-year risk before initiation of statin therapy in these patients with diabetes.

 

Table 5. Diabetes Specific Risk Enhancers That Are Independent of Other Risk Factors in Diabetes (1)

Long duration (≥10 years for type 2 diabetes mellitus or ≥20 years for type 1 diabetes mellitus

Albuminuria ≥30 mcg of albumin/mg creatinine

eGFR <60 mL/min/1.73 m2

Retinopathy

Neuropathy

ABI <0.9

ABI indicates ankle-brachial index.

 

Table 6. ASCVD Risk Enhancers (1)

Family history of premature ASCVD

Persistently elevated LDL > 160mg/dl (>4.1mmol/L

Chronic kidney disease*

Metabolic syndrome**

History of preeclampsia

History of premature menopause

Inflammatory disease (especially rheumatoid arthritis, psoriasis, HIV)

Ethnicity (e.g., South Asian ancestry)

Persistently elevated triglycerides > 175mg/dl (>2.0mmol/L)

Hs-CRP > 2mg/L

Lp(a) > 50mg/dl or >125nmol/L

Apo B > 130mg/dl

Ankle-brachial index (ABI) < 0.9

*Chronic kidney disease definition- eGFR 15–59 mL/min/1.73 m2 with or without albuminuria.

**Metabolic syndrome definition- increased waist circumference, elevated triglycerides [>175 mg/dL], elevated blood pressure, elevated glucose, and low HDL-C [<40 mg/dL in men; <50 in women mg/dL] are factors; tally of 3 makes the diagnosis).

 

Other factors that can increase the risk of ASCVD include social deprivation, physical inactivity,

psychosocial stress, major psychiatric disorders, obstructive sleep apnea syndrome, and metabolic associated fatty liver disease (38).

 

PRIMARY PREVENTION PATIENT WITHOUT OTHER FACTORS

 

  • Initiation of primary prevention should begin with a clinician-patient risk discussion.

 

This discussion is necessary to put a patient’s total risk status in perspective. The risk discussion should always begin with a review of the critical importance of lifestyle intervention. This is true for all age groups. Beyond the issue of lifestyle, the discussion can further consider the potential benefit of a cholesterol-lowering drug, especially statin therapy. When the latter may be beneficial, the provider should next review major risk factors and estimated 10-year risk for ASCVD derived from the pooled cohort equation (PCE) risk calculator (49)  (https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/). Estimation of lifetime risk is also useful, particularly in younger individuals who often have a low 10-year risk but a high lifetime risk. All major risk factors (e.g., cigarette smoking, elevated blood pressure, LDL-C, hemoglobin A1C [if indicated]), should be discussed.

 

In patients 40-75 years, the 10-year risk estimate is most useful. In these patients, four categories of 10-year risk for ASCVD are recognized: low risk (<5%); borderline risk (5-7.4%); intermediate risk (7.5-19.9 %), and high risk (> 20%). Estimates of lifetime risk for patients 20-39 years also are available (https://www.acc.org/guidelines/hubs/blood-cholesterol  or        https://qrisk.org/lifetime/index.php) and should be obtained in younger individuals. Three other components of the risk discussion are: risk enhancing factors (see #8), possible measurement of coronary artery calcium (CAC) (see #9), and a review of extenuating life circumstances (issues of cost and safety considerations, as well as patient motivation and preferences). The decision to initiate statin therapy should be shared between the clinician and patient. All of these factors deserve a full discussion in view of the fact that statin therapy represents a lifetime commitment to taking a cholesterol-lowering drug.

 

Patients should also recognize that atherosclerosis begins early in life and progresses overtime before manifesting as clinical disease. The cumulative LDL-C levels (“LDL-C years”) strongly influence the timing of clinical manifestations (figure 4). In patients with high LDL-C levels (homozygous and heterozygous familial hypercholesterolemia) ASCVD can occur early in life whereas in patients with loss of function mutations in PCSK9 and low LDL-C level have a reduced occurrence of ASCVD.

 

Figure 4. Relationship between cumulative LDL-C exposure, age, and the development of the clinical manifestations of ASCVD. Figure from reference (50).

Additionally, patients should be appraised of comparisons of the reduction in ASCVD events in individuals with genetic variations resulting in life-long reductions in LDL-C levels vs. individuals treated with statins to lower LDL-C later in life. Variants in the HMG-CoA reductase, NPC1L1, PCSK9, ATP citrate lyase, and LDL receptor genes result in a lifelong decrease in LDL-C and a 10mg/dL decrease in LDL-C with any of these genetic variants was associated with a 16-18% decrease in ASCVD events (51). As noted above, a 39mg/dL decrease in LDL-C in the statin trials resulted in a 22% decrease in ASCVD events. Thus, a life-long decrease in LDL-C levels results in a decrease in ASCVD events that is three to four times as great as that seen with short-term LDL-C lowering with drugs later in life suggesting that the sooner the LDL-C level is lowered the better the prevention of cardiovascular events.

 

  • In adults 40 to 75 years of age without diabetes and LDL-C ≥70 mg/dL (≥1.8 mmol/L), RTC's show that moderate intensity statin therapy is efficacious when 10-year risk for developing ASCVD is >5%.Therefore, initiating statin therapy should be considered in the risk discussion.

 

A 10-year risk > 7.5% does not mandate statin therapy but indicates that moderate-intensity statins can reduce risk by 30-40% with a minimum of side effects (52). This fact alone can justify moderate intensity statin therapy, but only if other considerations noted above (#6) are taken into account in the risk discussion. An approach to lipid lowering in primary prevention patients is shown in figure 5.

 

Figure 5. Approach to Primary Prevention in Patients without LDL-C >190mg/dl or Diabetes (1).

 

  • Determine presence of risk-enhancing factors in adults 40 to 75 years of age to inform the decision regarding initiation of statin therapy.

 

If risk assessment based on PCE is equivocal or ambiguous, the presence of risk enhancing factors in patients at intermediate risk (10-year risk 7.5 to 19.9%), can tip the balance in favor of statin therapy. Risk enhancing factors are shown in Table 6.

 

  • IF A DECISION ABOUT STATIN THERAPY IS UNCERTAIN IN ADULTS 40 TO 75 YEARS OF AGE WITHOUT DIABETES MELLITUS, WITH LDL-C LEVELS ≥ 70 MG/DL, AND WITH A 10 YEAR ASCVD RISK OF ≥ 7.5% TO 19.9% (INTERMEDIATE RISK) CONSIDER MEASURING Coronary Artery Calcium (CAC).

 

CAC measurements are a safe and inexpensive method to assess severity of coronary atherosclerosis. CAC scores generally reflect lifetime exposure to coronary risk factors and therefore in young individuals (men < 40 years of age; women < 50 years of age) the long-term predictive value is limited because the CAC score is often 0. Studies show that CAC accumulation is a strong predictor of probability of ASCVD events (53). A CAC core of zero generally is accompanied by few if any ASCVD events over the subsequent decade. Reevaluation in 5-10 years is indicated. A CAC score of 1-100 Agatston units is associated with relatively low rates of ASCVD, both in middle-aged and older patients. In contrast, a CAC >100 Agatston units carries a risk well into the statin-benefit zone. CAC > 300-400 is equivalent to clinical ASCVD. Data such as these led to the following recommendation of 2018 guidelines for patients at intermediate risk by PCE.

 

  1. If CAC is zero, treatment with statin therapy may be withheld or delayed, except in cigarette smokers, those with diabetes mellitus, those with a strong family history of premature ASCVD, and possibly chronic inflammatory conditions such as HIV.
  2. A CAC score of 1 to 99 Agatston units favors statin therapy in intermediate-risk patients ≥55 years of age, whereas benefit in 40-54 years is marginal (note this focuses on 10-year risk and a CAC score in this range in a younger individual is predictive of an increased long-term risk (54)).
  3. A CAC score ≥100 Agatston units (or ≥75th percentile), strongly favors statin therapy, unless otherwise countermanded by clinician–patient risk discussion.

 

Monitoring

 

  • Assess adherence and percentage response to LDL-C lowering medications and/or lifestyle changes with repeat lipid measurement 4 to 12 weeks after statin initiation or dose adjustment and every 3-12 months as needed.

 

Remember that the LDL-C goal for patients with ASCVD or severe hypercholesterolemia is a > 50% reduction in LDL-C. For most such patients, this goal can be achieved by high-intensity statin therapy + ezetimibe. In ASCVD patients at very high risk, the goal is an LDL-C lowering >50% and an LDL-C < 70 mg/dL. To achieve these goals, it may be necessary to combine a PCSK9 inhibitor with maximal statin therapy + ezetimibe.  For statin therapy in primary prevention, the goal is a lowering of > 35%. This goal can be achieved in most patients with a moderate intensity statin + ezetimibe

 

2018 guidelines did not set a precise on-treatment LDL-C target of therapy, but instead, offer percent reductions as goals of therapy. Baseline levels of LDL-C can be obtained either by chart review or withholding statin therapy for about two weeks. In addition, on-treatment LDL-C can provide useful information about efficacy of treatment (Figure 6). This figure shows expected LDL-C levels for 50% or 35% reductions at different baseline levels of LDL-C. For example, in secondary prevention, an on-treatment LDL-C of <70 mg/dL can be considered adequate treatment regardless of baseline LDL-C. On-treatment levels in the range of 70-100 mg/dL are adequate if baseline-LDL C is known to be in the range of 140- 200 mg/dL; if there is uncertainty about baseline levels, reevaluation of statin adherence and reinforcement of treatment regimen is needed. For optimal treatment, on-treatment levels in this range warrant consideration of adding ezetimibe to maximal statin therapy. If on treatment LDL-C is > 100 mg/dL, the treatment regimen is probably inadequate, and intensification of therapy is needed. For primary prevention, the LDL-C goal is a reduction > 35%, and a similar scheme for evaluating efficacy of therapy can be used.

Figure 6. Predicted on-treatment LDL-C compared to baseline LDL-C and suggested actions for each category of on-treatment LDL-C in secondary and primary prevention.

 

Other Issues

 

OTHER AGE GROUPS

 

2018 guidelines offered suggestions for management of high blood cholesterol in children, adolescents, young adults (20-39 years), and elderly patients > 75 years. There is no strong RCT evidence to underline cholesterol management in these populations. Instead, treatment suggestions depend largely on epidemiologic data. Lifestyle intervention is a primary method for cholesterol treatment in these age groups. However, under certain circumstances LDL-lowering drugs may be indicated. This is particularly the case for patients with familial hypercholesterolemia or similar forms of very high LDL-C. In young adults, particularly those with other risk factors, LDL lowering drug therapy (statin or ezetimibe) may be reasonable when LDL-C levels are in the range of 160-189 mg/dL or if the lifetime risk is high. Older adults who have concomitant risk factors are potential candidates for initiation of statins or continuation of existing statin therapy. In all cases, clinical estimation of risk status is critical in a decision to initiate statins.

 

For details on the approach to treating hypercholesterolemia in older adults see the Endotext chapter entitled “Management of Dyslipidemia in the Elderly” (55). For details on the approach to treating hypercholesterolemia children and adolescence see the Endotext section on Pediatric Lipidology.

 

STATIN NON-ADHERENCE     In spite of proven benefit of statin therapy in high-risk patients, there is a relatively high prevalence of nonadherence to the prescribed drug (56). Some studies suggest that up to 50% of patients discontinue use of prescribed statins over the long run (57-60). This finding creates a major challenge to the health care system for prevention of ASCVD. Table 7 lists several factors that may contribute to a high prevalence of nonadherence.  

Table 7. Factors Associated with Statin Nonadherence

Healthcare system factors

Accompanying medical care costs

Lack of medical oversight and follow-up (provider therapeutic inertia)

Provider concern for side effects

Patient factors

Uncertainty of benefit

Lack of health consciousness

Lack of motivation

Lack of perceived benefit

Perceived side effects

Nocebo effects

Myalgias

Myopathy

“Brain fog”

Misattributed symptoms or syndromes (arthritis, spondylosis, neuropathy, insomnia, mental confusion and memory loss, fibromyalgia, gastrointestinal symptoms, liver dysfunction, cataract; cancer).

 When a decision is made to initiate statin therapy, the presumption is that statins are a lifetime treatment. Their use is similar to other medications, such as antihypertensive drugs, which are expected to be taken for the rest of one’s life. Such treatments imply indefinite participation in the healthcare system. This means regular ongoing visits to a prescribing clinic. Even for those with medical insurance there are usually co-pays for the visit, not to mention the cost of transportation to and from the clinic. All of these cost-related issues can be an impediment to long-term statin usage. Provider therapeutic inertia (56) can result from lack of provider education, excessive workload, and concerns about statin side effects. From the patient’s point of view, common issues are lack of understanding of the potential benefits of therapy and lack of health consciousness and motivation. A related problem is the expectation of side effects because of preconditioning by information received from the news media, package inserts, Internet, family, and friends. This expectation can discourage individuals from continuation of statin therapy (nocebo effect) (61). The most common symptoms attributed to statin therapy are muscle pain and tenderness (myalgias) (8).  A complaint of statin intolerance is registered in about 5-15% of patients. If myalgias attributed to statins are due to actual pathological changes, the character of the changes is yet to be determined. In almost all cases, serum creatine kinase (CK) levels are not increased. Still, in rare cases, especially when blood levels of statins are raised, severe myopathy (rhabdomyolysis) can occur. This proves that statins can be myotoxic. Table 8 lists conditions associated with statin-induced severe myopathy (62,63). In most such cases, severe myopathy is reversible. If the cause can be identified and eliminated, a statin can be cautiously reinstituted. Alternatively, a non-statin LDL-lowering drug (e.g., ezetimibe, bempedoic acid, or PCSK9 inhibitor) can be substituted for the offending statin (8,64). For a detailed discussion of statin side effects and the management of patients with statin intolerance see the Endotext chapter on cholesterol lowering drugs (8).

 

Table 8. Factors Associated with Statin - Induced Rhabdomyolysis

Advanced age (>80 y)Small body frame and fragilityFemale sexAsian ethnicityPre-existing neuromuscular conditionKnown history of myopathy or family history of myopathy syndromePre-existing liver disease, kidney disease, hypothyroidismCertain rare genetic polymorphismsHigh-dose statinPostoperative periodsExcessive alcohol intakeDrug interactions (gemfibrozil, antipsychotics, amiodarone, verapamil, cyclosporine, macrolide antibiotics, azole antifungals, protease inhibitors)

 

EUROPEAN GUIDELINES FOR CHOLESTEROL MANAGEMENT

 

The most influential of European guidelines for management of cholesterol and dyslipidemia are those developed by the European Society of Cardiology (ESC), the European Atherosclerosis Society (EAS), and representatives from other European organizations (65). A task force appointed by these organizations have published an update on dyslipidemia management (38). The recommendations of this report resemble in many ways those of the 2018 AHA/ACC guidelines (1). But notable differences can be identified for specific recommendations. A review of these differences may help to identify gaps in knowledge needed to format best recommendations. In the following, recommendations proposed by AHA/ACC and by ESC/EAS will be compared. These comparisons should illuminate areas of uncertainty where more information is needed for definitive recommendations. At the same time, it is important to emphasize that in many critical areas the two sets of guidelines are in strong agreement. These will be noted first.

 

Agreement Between AHA/ACC and ESC/EAS Guidelines

 

There is agreement that elevated LDL-C is the major atherogenic lipoprotein and that LDL-C is the primary target of treatment. Likewise, both guidelines agree that the intensity of LDL-C lowering therapy should depend on absolute risk to patients. In other words, patients who have the highest risk should receive the most intensive cholesterol reduction. Both guidelines emphasize therapeutic lifestyle intervention as the foundation of risk reduction, both for elevated cholesterol and for other risk factors. The highest risk patients are those with ASCVD and are potential candidates for combined drug therapy for LDL-C lowering. For primary prevention, the intensity of treatment depends on absolute risk as determined by population-based algorithms.  For drug therapy, statins are first-line treatment, but in highest risk patients, consideration can be given to adding non-statin drugs (e.g., ezetimibe and PCSK9 inhibitors). Beyond population-based algorithms for primary prevention, measurement of other dyslipidemia markers, or other higher risk conditions can be used as risk- enhancing factors to modify intensity of lipid-lowering therapy.  

 

Differences Between AHA/ACC and ESC/EAS Guidelines

 

DEFINITION OF VERY HIGH RISK    

 

This definition is important because it sets the stage for considering intensive LDL-C lowering and the use of combined drug therapy for LDL-C lowering. AHA/ACC defines very high risk as a history of multiple ASCVD events or of one event + multiple high-risk conditions. This limits the definition of very high risk to the highest risk patients among those with ASCVD. In contrast, ESC/EAS considers all patients with clinical ASCVD or ASCVD on imaging as very high risk. Additionally, ESC/EAS allows extension of the definition to highest risk patients in primary prevention, that is, to patients with multiple risk factors and/or subclinical atherosclerosis (table 9). Overall, more patients will be identified as being at very high risk by ESC/EAS guidelines. This could enlarge the usage of PCSK9 inhibitors. AHA/ACC limits the use of PCSK9 inhibitors to patients at highest risk, because of their high cost. One recent study (43) showed that only about 10% of patients with established ASCVD will be eligible for PCSK9 inhibitors by AHA/ACC recommendations.

 

Table 9. ESC/EAS Cardiovascular Risk Categories

Very High-Risk

Ø  ASCVD, either clinical or unequivocal on imaging

Ø  DM with target organ damage or at least three major risk factors or T1DM of long duration (>20 years)

Ø  Severe CKD (eGFR <30 mL/min/1.73 m2)

Ø  A calculated SCORE >10% for 10-year risk of fatal CVD.

Ø  FH with ASCVD or with another major risk factor

High-Risk

Ø  Markedly elevated single risk factors, in particular Total Cholesterol >8 mmol/L (>310mg/dL), LDL-C >4.9 mmol/L (>190 mg/dL), or BP >180/110 mmHg.

Ø  Patients with FH without other major risk factors.

Ø  Patients with DM without target organ damage, with DM duration > 10 years or another additional risk factor.

Ø  Moderate CKD (eGFR 30-59 mL/min/1.73 m2).

Ø  A calculated SCORE >5% and <10% for 10-year risk of fatal CVD.

Moderate Risk

Ø  Young patients (T1DM <35 years; T2DM <50 years) with DM duration <10 years, without other risk factors.

Ø  Calculated SCORE >1 % and <5% for 10-year risk of fatal CVD*.

Low Risk

Ø  Calculated SCORE <1% for 10-year risk of fatal CVD

SCORE= Systematic Coronary Risk Estimation. * Total CVD event risk is approximately three times higher than the risk of fatal CVD.

  

GOALS FOR LDL-C    

 

In 2013, the AHA/ACC eliminated specific numerical goals for LDL-C in both primary and secondary prevention. Recommendations for LDL-C lowering therapy were based exclusively on RCTs of statin therapy. These recommendations have been criticized for lacking a means to evaluate the efficacy of statin therapy. In 2018, AHA/ACC identified 2 goals for LDL-C lowering, namely, > 50% LDL-C reduction in secondary prevention and > 35% reduction in primary prevention. These values are based on the expected reductions achieved by high-intensity statins for secondary prevention and by moderate-intensity statins for primary prevention.  Again, no numerical targets are identified. The only exception was the recognition of an LDL-C threshold goal of 1.8 mmol/L (70 mg/dL) for consideration of PCSK9 inhibitors in very high-risk patients on maximal statin therapy + ezetimibe.

 

ESC/EAS supports the 50% reduction of LDL-C in high-risk patients but also includes a goal of <1.8 mmol/L (70 mg/dL) (table 10). This goal applies to all high-risk patients, whether in primary or secondary prevention. For very high-risk patients, the goal is an LDL-C of < 1.4 mmol/L (55 mg/dL). For moderate-risk patients in primary prevention, the goal is LDL-C <2.6 mmol/L (100 mg/dL). The guideline task force presumably believed that having defined LDL-C goals facilitates cholesterol-lowering therapy in clinical practice. Additionally, following the ESC/EAS LDL-C goals will most likely result in lower LDL-C levels in many patients.  

 

Table 10. ESC/EAS LDL Cholesterol Goals

Very High Risk

LDL-C reduction of >50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) is recommended

High Risk

LDL-C reduction of >50% from baseline and an LDL-C goal of <1.8 mmol/L (<70 mg/dL) is recommended

Moderate Risk

LDL-C goal of <2.6 mmol/L (<100 mg/dL) should be considered

Low Risk

LDL-C goal <3.0 mmol/L (<116 mg/dL) may be considered.

 

In patients with ASCVD who experience a second vascular event within 2 years while on maximally tolerated statin therapy an LDL-C goal of < 1mMol/L (40mg/dL) may be considered.

 

In addition, the ESC/EAS also provided goals for non-HDL-C and apolipoprotein B (table 11).

 

Table 11. ESC/EAS Goals of Therapy

 

Non-HDL-C

Apo B

Very High Risk

<85mg/d;

<65mg/dL

High Risk

<100mg/dL

<80mg/dL

Moderate Risk

<130mg/dL

<100mg/dL

 

Figure 7 provides an overview of the ESC/EAS recommended treatment based on risk and baseline LDL-C levels.

Figure 7. ESC/EAS treatment recommendations based on risk and baseline LDL-C levels.

RISK ESTIMATION FOR PRIMARY PREVENTION  

 

AHA/ACC employed a pooled cohort equation (PCE) developed from five large population groups in the USA to estimate 10-year risk (and lifetime risk) for ASCVD events. ESC/EAS for several years has employed a SCORE algorithm based on risk for ASCVD mortality in European populations. Both PCE and SCORE are used to define “statin eligibility” for primary prevention. A study suggests that more people are “eligible” for statin therapy using PCE compared to SCORE (66). If this finding can be confirmed, it suggests that ESC/EAS guidelines are less aggressive for reducing LDL-C in lower risk individuals (compared to AHA/ACC guidelines). In contrast, ESC/EAS appears to be more aggressive in use of non-statins for LDL lowering in higher risk patients than is AHA/ACC.

 

RISK ENHANCING FACTORS    

 

AHA/ACC proposed that several risk enhancing factors favor the decision to use statin therapy in patients at intermediate risk. The European guidelines provide a similar list of factors that should be considered in determining risk and modifying the SCORE result. Notable among risk enhancing factors were apolipoprotein B (apoB) and lipoprotein (a) (Lp[a]).

 

SUBCLINICAL ATHEROSCLEROSIS    

 

AHA/ACC propose that CAC measurement can assist in deciding whether to use statin therapy in patients at intermediate risk. AHA/ACC in particular noted that the absence of CAC justifies delaying statin therapy. No other modalities of measurement of subclinical atherosclerosis were advocated by AHA/ACC. In contrast, ESC/EAS supported use of both CAC and carotid or femoral plaque burden on ultrasonography to determine risk. These guidelines suggest that the finding of substantial subclinical atherosclerosis in any arterial bed elevates a patient’s risk to the category of established ASCVD and can justify adding non-statin therapy to statins in such patients.

 

GUIDELINE SPECIFICITY  

 

AHA/ACC guidelines place great emphasis on data from RCTs to justify its recommendations.  However, RTC’s related to specific questions typically are limited in number. AHA/ACC recommendations are highly codified and kept to a minimum. ESC/EAS in contrast bases its recommendations both on clinical trials and other types of evidence. It explores available evidence in greater detail, and many of its recommendations are more nuanced. This approach to guideline development has its advantages and disadvantages. For example, it gives the reader a broader base of information to assist in clinical decisions. On the other hand, many of its recommendations are made outside of an RCT-evidence base. Without doubt, cholesterol management in all age and gender groups with various risk factor profiles is complex. The ESC/EAS attempts to provide a rationale for management of this complexity. The AHA/ACC, on the other hand, simplifies management as much as possible; it is written specifically for the general practitioner, and leaves the complexities of management to a lipid specialist. ESC/EAS delves into the complexities in more detail so that its recommendations are applicable to both the general practitioner and specialist.

 

IMPORTANT CHANGES SINCE THESE GUIDELINES WERE PUBLISHED

 

Risk Calculators

 

PREVENT RISK CACULATOR

 

In the US there is a new risk calculator called PREVENT (67). The PREVENT risk calculator is based on a much larger and more contemporary sample than the pooled cohort equation (PCE) risk calculator (68). Prevent is based on data from more than 6 million individuals from 46 datasets, including both population research studies and health system electronic medical records. In contrast, PCE was derived from approximately 25,000 individuals from 5 research datasets.

 

There are several notable differences between the PREVENT and PCE risk calculators.

 

1)         PREVENT calculates risk in patients age 30-79 whereas PCE calculates risk in patients age 40-75.

2)         The PCE calculator uses age, gender, white or African American, total cholesterol, HDL-C, systolic BP, whether on treatment for BP, whether diabetic, and whether smoker as the variables to calculate risk. PREVENT uses age, gender, total cholesterol, HDL-C, systolic BP, BMI, eGFR, whether on BP or lipid lowering medications (i.e., statins), whether diabetic, and whether a current smoker to calculate risk. In addition, PREVENT allows for the use of optional variables, HbA1c, urine albumin/creatinine ratio, and Zip Code (for estimating social deprivation index) for further personalization of risk assessment. Note that PREVENT does not use race or ethnicity but does include variables related to glucose metabolism, renal disease, and obesity and can be used in patients taking statins .

3)         The main result for the PCE calculator is the 10-year risk of cardiovascular disease. The main result of the PREVENT calculator is both the 10-year and 30-year risk (if <60 years of age) of cardiovascular disease, ASCVD only, and heart failure only.

 

It should be noted that fewer patients will be identified as eligible for statin therapy using the PREVENT calculator compared to the PCE calculator. A study found that 18.8% of patients eligible for statin therapy using the PCE calculator would not be identified using the PREVENT calculator (69). Another study found that using the PREVENT calculator would reclassify approximately half of US adults to lower risk categories compared to the PCE calculator (70). Additionally, studies have shown that the mean estimated 10-year ASCVD risk is approximately 50% lower with the PREVENT calculator compared to the PCE calculator (71,72).

 

The current recommendations for treatment were based on the PCE risk estimates and thus, there are concerns that using the PREVENT calculator may result in not treating as many patients. New AHA/ACC guidelines are being developed, and it is possible that the new recommendations will be adjusted to compensate for the differences in the risk calculated using the PCE and PREVENT calculators. Some experts recommend using the PCE calculator when deciding on treatment if one is following the current AHA/ACC guidelines.

 

SCORE2 RISK CALCULATOR

 

The SCORE risk calculator was developed in 2003 to determine the 10-year cardiovascular mortality in healthy individuals (73). In 2021 SCORE was replaced by SCORE2, which updated the risk prediction algorithms and in instead of determining cardiovascular mortality determines cardiovascular disease which includes cardiovascular mortality and non-fatal myocardial function and stroke endpoints (74). The prediction model in SCORE2 was based on 45 cohorts with 677,684 individuals from 13 countries. In addition, SCORE2-OP estimates cardiovascular risk in individuals greater than 70 years of age or older and SCORE2-Diabetes estimates cardiovascular risk in patients with type 2 diabetes (75,76)(https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Risk-assessment/esc-cvd-risk-calculation-app)

 

The variables used in SCORE2 to calculate risk are age (40-69), sex, smoking, systolic BP, total cholesterol, HDL-C, and whether they live in a low, moderate, high, or very high-risk region (see below). SCORE2 provides an estimate of the 10-year risk of cardiovascular disease. Low-risk countries: Belgium, Denmark, France, Israel, Luxembourg, Norway, Spain, Switzerland, the Netherlands, and the United Kingdom (UK). Moderate-risk countries: Austria, Cyprus, Finland, Germany, Greece, Iceland, Ireland, Italy, Malta, Portugal, San Marino, Slovenia, and Sweden. High-risk countries: Albania, Bosnia and Herzegovina, Croatia, Czech Republic, Estonia, Hungary, Kazakhstan, Poland, Slovakia, and Turkey. Very high-risk countries: Algeria, Armenia, Azerbaijan, Belarus, Bulgaria, Egypt, Georgia, Kyrgyzstan, Latvia, Lebanon, Libya, Lithuania, Montenegro, Morocco, Republic of Moldova, Romania, Russian Federation, Serbia, Syria, The Former Yugoslav Republic (Macedonia), Tunisia, Ukraine, and Uzbekistan.

 

In individuals 70 years of age or older one should use the SCORE2-OP calculator and for individuals with type 2 diabetes one should use the SCORE2-Diabetes calculator. SCORE2-OP uses the same variables as SCORE2, but SCORE2-Diabetes includes HbA1c, age at diagnosis of diabetes, and eGFR. Both provide an estimate of the 10-year risk of cardiovascular disease.

 

In conjunction with the development of SCORE2 the European Society of Cardiology developed guidelines for healthy individuals (77). The conversion of 10-year risk to CVD risk categories for healthy individuals is shown in Table 12 and LDL-C goals for these CVD risk categories are shown in table 13. Note that the use of very high risk and high risk is not equivalent to the use of these terms in the  ESC/EAS lipid guidelines discussed above.

 

Table 12. Cardiovascular Disease Risk Categories Based on SCORE2 and SCORE2-OP in Healthy Individuals

 

<50 years

50–69 years

≥70 years

Low-to-moderate CVD risk: risk factor treatment generally not recommended

<2.5%

<5%

<7.5%

High CVD risk: risk factor treatment should be considered

2.5 to <7.5%

5 to <10%

7.5 to <15%

Very high CVD risk: risk factor treatment generally recommended

≥7.5%

≥10%

≥15%

 

Table 13. LDL-C Goal Less Than 100mg/dL

Age

Low-to-moderate CVD risk

High CVD risk

Very high CVD risk

< 50

Usually not indicated

Consider

Recommended

50-69

Usually not indicated

Consider

Recommended

>70

Usually not indicated

Consider

Recommended

In all age groups, consideration of risk modifiers, lifetime CVD risk, treatment benefit, comorbidities, frailty, and patient preferences may further guide treatment decisions.

 

KEY PRINCIPLES 

 

There are certain key principles that clinicians should utilize when deciding who to treat and how aggressively to treat hypercholesterolemia. Understanding these principles will allow clinicians to help their patients decide on the best approach to LDL-C lowering.

 

The Sooner the Better

 

It is widely recognized that atherosclerosis begins early in life and slowly progresses ultimately resulting in clinical manifestations later in life (78). Several studies have demonstrated the presence of atherosclerosis in young individuals (79-83). The extent of the atherosclerotic lesions correlates positively with total cholesterol and LDL-C and negatively with HDL-C levels (79,80,83-90). These studies clearly demonstrate that atherosclerosis begins early in life with the prevalence increasing with age and the extent and onset of lesions is influenced by total cholesterol and LDL-C levels. Moreover, an increased total cholesterol early in life also predicted an increased risk of developing cardiovascular disease later in life (91-93).

 

Genetic studies have further illustrated the key role of exposure to total cholesterol and LDL-C in determining the time when clinical manifestations of ASCVD occur. In patients with homozygous familial hypercholesterolemia (FH), LDL-C are markedly elevated, and cardiovascular events can occur early in life. Greater than 50% of untreated patients with homozygous FH develop clinically significant ASCVD by the age of 30 and cardiovascular events can occur before age 10 in some patients (45). In patients with heterozygous FH LDL-C levels are elevated but not to the levels seen with homozygous FH and cardiovascular events occur later in life but still at a relatively younger age. Untreated males with heterozygous FH have a 50% risk for a fatal or non-fatal myocardial infarction by 50 years of age whereas untreated females have a 30% chance by age 60 (45). Conversely, individuals with genetic variants in PCSK9, HMG-CoA reductase, LDL receptor, NPC1L1, or ATP citrate lyase that lead to a decrease in LDL-C levels have a reduced risk of developing cardiovascular events (50,51). The relationship between genetic disorders that alter LDL-C levels and the time to develop clinical cardiovascular events is illustrated in figure 4. The figure clearly illustrates that the age when one clinically manifests ASCVD depends on the level of LDL-C. With very high LDL-C levels clinical events occur early in life and with low LDL-C levels events will occur at an older age leading to the concept of LDL years.

 

Of major importance is that the reduction in ASCVD events is much greater in individuals with lifelong decreases in LDL-C compared to the reductions in ASCVD events seen with statin treatment (Table 14). A lifelong 10mg/dL decrease in LDL-C due to polymorphisms in genes that affect LDL-C is associated with a 16-18% decrease in ASCVD events (51). In contrast, a decrease in LDL-C of 39mg/dL over 4-5 years with statin therapy results in only a 22% decrease in ASCVD events (6,9). Thus, a life-long decrease in LDL-C levels results in a decrease in cardiovascular events that is three to four times as great as that seen with short-term LDL-C lowering with drugs. Figure 8 illustrates the benefits of early treatment in reducing LDL-C years and delaying the development of ASCVD.

 

Table 14.  Effect of Reduction in LDL-C by Genetic Variants on the Risk of ASCVD

Gene

Odds ratio for ASCVD events per 10mg/dL decrease in LDL-C

(95% CI)

ATP citrate lyase

0.82 (0.78–0.87)

HMG CoA reductase

0.84 (0.82–0.87)

NPC1L1

0.84 (0.79–0.89)

PCSK9

0.83 (0.80–0.87)

LDL receptor

0.83 (0.80–0.87)

Statin treatment decreases ASCVD by approximately 22% per 39mg/dL decrease in LDL-C.

 

Figure 8. The effect of early lowering of LDL-C on the development of ASCVD.

In addition to calculating the 10-year risk of ASCVD events it is important to calculate either the lifetime or 30-year risk. This is particularly important in younger individuals where the 10-year risk of ASCVD events may be relatively low, but the long-term risk may be high. In the discussion of therapy with patients they need to be aware of their long-term risk and the potential advantages of early treatment.

 

Lowering LDL-C levels by lifestyle changes early in life will have long-term benefits.  Additionally, in selected individuals initiating drug therapy sooner rather than latter will reduce ASCVD events later in life.

 

The Lower the Better

 

A variety of different types of studies have clearly demonstrated that more robust lowering of LDL-C results in an increased decrease in ASCVD events.

 

  • Statin trials have demonstrated that ASCVD events are decreased even in patients with low LDL-C levels (10). In patients with an LDL-C less than 70mg/dL, statin treatment resulted in a 37% decrease in ASCVD events despite the patients having a low LDL-C.
  • Intensive statin therapy results in a greater decrease in LDL-C levels compared to moderate statin therapy. Moreover, intensive therapy also results in a greater decrease in ASCVD events (10).
  • Adding ezetimibe to statin therapy resulted in a lower LDL-C than statin therapy alone and furthermore decreased ASCVD events (16).
  • Adding a PCSK9 inhibitor to statin therapy decreases LDL-C levels and results in a greater reduction in ASCVD events than statins alone (19,20).

 

Taken together these studies clearly demonstrate that the lower the LDL-C level the greater the decrease in ASCVD events. However, there may be a threshold where further lowering of LDL-C does not result in further benefits. In the ODYSSEY trial using the PCSK9 inhibitor alirocumab, the decrease in ASCVD events was similar in patients with an LDL-C less than 25mg/dL and those with an LDL-C between 25-50mg/dL (94). Future studies are required to define if there is a threshold where further LDL-C lowering is not beneficial.

 

Clinicians need to balance the benefits of more aggressively lowering LDL-C levels with the risks and costs of high dose or additional drug therapy. Both statins and ezetimibe are generic drugs and very inexpensive. Thus, in many patients the use of the combination of a statin (either high intensity or moderate intensity) and ezetimibe will maximize the decrease in LDL-C and more effectively reduce ASCVD events, with minimal risk and at low cost. In contrast, PCSK9 inhibitors and bempedoic acid are relatively expensive and clinicians will need to balance the benefits and the increased costs.

 

The Higher the LDL-C the Greater the Benefit

 

The percent decrease in LDL-C levels that occurs with statin treatment or the use of other LDL-C lowering drugs is similar regardless of the baseline LDL-C level. However, the absolute decrease in LDL-C will be greater if the starting LDL-C is higher. As discussed earlier, the Cholesterol Treatment Trialists demonstrated that the relative risk reduction in cardiovascular events per 39mg/dL (1mmol/L) decrease in LDL-C is similar in patients with a low or high baseline LDL-C level. Thus, as shown in table 15 the treatment of patients with high baseline LDL-C levels will result in greater decreases in ASCVD events. A meta-analysis of 34 trials with 270,288 individuals found that LDL-C lowering was associated with a progressively greater relative risk reduction in ASCVD events in patients with increased baseline LDL-C levels (95).

 

Table 15. The Higher the Baseline LDL-C the Greater the Reduction in ASCVD

Baseline LDL-C 80mg/dL

Baseline LDL-C 160mg/dL

Atorvastatin 80mg reduces LDL-C by 50% to 40mg/dl (40mg/dL decrease)

Atorvastatin 80mg reduces LDL-C by 50% to 80mg/dl (80mg/dL decrease)

A 40mg/dL decrease in LDL-C will result in an approximate 22% decrease in ASCVD events

An 80mg/dL decrease in LDL-C will result in an approximate 44% decrease in ASCVD events

 

The Greater the Risk of ASCVD the Greater the Benefit

 

Analysis by the Cholesterol Treatment Trialists found that the relative risk reduction was similar regardless of the underlying ASCVD risk (9). However, the absolute risk reduction was much greater in patients with a high risk of ASCVD (table 16) (9). Additionally, studies have shown that in patients with a high polygenic risk score for ASCVD events statin therapy reduces ASCVD events to a greater extent again indicating the higher the risk the greater the benefit of lowering LDL-C (96,97).

 

Table 16. Risk of Cardiovascular Events in High and Low Risk Patients

5-year event risk

Relative Risk (CI) per 39mg/dL reduction in LDL-C

Absolute Decrease in Events per Annum*

<10%

0.68 (0.62-0.74)

0.3%

10-20%

0.79 (0.75-0.84)

0.5%

20-30%

0.81 (0.78-0.85

1.1%

>30%

0.79 (0.75-0.83

2.2%

*Percent of patients on placebo having an event minus percent of patients on statin therapy having an event. Data from Cholesterol Treatment Trialists (9).

 

In the IMPROVE-IT trial lowering LDL-C with ezetimibe and the ODYSSEY and FOURIER trials using PCSK9 inhibitors a greater reduction in ASCVD events was observed in high risk patients (see reference (98) for discussion of these studies). Table 17 provides a list of indicators of high risk.

 

Table 17. High Risk Indicators for ASCVD Events

Diabetes

Atherosclerosis in multiple sites (peripheral arterial disease, cerebral vascular disease, coronary arteries)

History of prior coronary artery bypass graft surgery

Acute coronary syndrome

Multiple MIs

Recent ASCVD events

Genetic lipid disorders

High polygenic risk score

 

Following these general principles will help clinicians make informed decisions in deciding on their approach to lowering LDL-C levels and will facilitate discussions with patients on the benefits and risks of treatment. For an in-depth discussion of these key principles see the following references (98,99).    

 

SUMMARY

 

Advances in the drug therapy of elevated cholesterol levels offer great potential for reducing both new-onset ASCVD and recurrent ASCVD events in those with established disease. This benefit can be enhanced by judicious use of lifestyle intervention. But among drugs, statins are first-line therapy. They are generally safe and inexpensive. They have been shown to reduce ASCVD events in both secondary and primary prevention. Ezetimibe has about half the LDL-lowering efficacy of statins; it too is generally safe and is a relatively inexpensive genetic drug. Ezetimibe can be used as an add-on drug to moderate intensity statins, especially for those who do not tolerate a high-intensity statin or in combination with high intensity statins to markedly decrease LDL-C levels. PCSK9 inhibitors are powerful LDL-lowering drugs, and they appear to be safe. The major drawback is cost. If the cost of these inhibitors can be reduced, they too have the potential for wide usage, especially in patients who are “statin intolerant”. Bempedoic acid has been shown to reduce ASCVD events in statin intolerant patients and in combination with ezetimibe can result in significant decreases in LDL-C levels. A major challenge for use of cholesterol-lowering drugs is the problem of long-term non-adherence.

 

ACKNOWLEDGEMENTS

 

Dr. Scott Grundy, who recently died, was the original author of this chapter and this chapter is an update of his chapter. This chapter is dedicated to Dr. Grundy who has been an inspiration to lipidologists worldwide.

 

This work was supported by grants from the Northern California Institute for Research and Education.

 

REFERENCES

 

  1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139:e1082-e1143
  2. Aragam KG, Natarajan P. Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications. Circ Res 2020; 126:1159-1177
  3. Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell 2015; 161:161-172
  4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106:3143-3421
  5. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308:367-372
  6. Cholesterol Treatment Trialists Collaboration, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380:581-590
  7. Endo A. The discovery and development of HMG-CoA reductase inhibitors. Journal of Lipid Research 1992; 33:1569-1582
  8. Feingold KR. Cholesterol Lowering Drugs. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, DP W, eds. Endotext. South Dartmouth (MA)2024.
  9. Cholesterol Treatment Trialists Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385:1397-1405
  10. Cholesterol Treatment Trialists’ C, Baigent Collaboration, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681
  11. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019; 393:407-415
  12. Cholesterol Treatment Trialists Collaboration, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117-125
  13. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. JAMA2016; 316:1289-1297
  14. The Lipid Research Clinics Coronary Primary Prevention Trial Results. JAMA 1984; 251:351-364
  15. Lakoski SG, Xu F, Vega GL, Grundy SM, Chandalia M, Lam C, Lowe RS, Stepanavage ME, Musliner TA, Cohen JC, Hobbs HH. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab 2010; 95:800-809
  16. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine 2015; 372:2387-2397
  17. Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park J-G, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald E. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. Journal of the American College of Cardiology 2017; 69:911-921
  18. Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A, Carfí A. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep2011; 12:1300-1305
  19. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine 2017; 376:1713-1722
  20. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby J-F, Tricoci P, White HD, Zeiher AM. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine 2018; 379:2097-2107
  21. Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 2019; 30:1-9
  22. Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, Ray KK, Mason D, Kastelein JJP, Cho L, Libby P, Li N, Foody J, Louie MJ, Lincoff AM. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA 2023; 330:131-140
  23. Feingold KR. Triglyceride Lowering Drugs. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, DP W, eds. Endotext. South Dartmouth (MA)2024.
  24. Cleeman JI, Lenfant C. New guidelines for the treatment of high blood cholesterol in adults from the National Cholesterol Education Program. From controversy to consensus. Circulation 1987; 76:960-962
  25. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Archives of Internal Medicine 1988; 148:36-69
  26. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89:1333-1445
  27. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology 2004; 44:720-732
  28. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PWF. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Journal of the American College of Cardiology 2014; 63:2889-2934
  29. Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. In: Graham R MM, Miller Wolman D, Greenfield S, Steinberg E, eds. Clinical Practice Guidelines We Can Trust. National Academies Press; 2011.
  30. Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Sr., Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Jr., Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2014; 63:2935-2959
  31. Muntner P, Colantonio LD, Cushman M, Goff DC, Jr., Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA2014; 311:1406-1415
  32. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. The Lancet2013; 382:1762-1765
  33. Kavousi M, Leening MJG, Nanchen D, Greenland P, Graham IM, Steyerberg EW, Ikram MA, Stricker BH, Hofman A, Franco OH. Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort. JAMA2014; 311:1416-1423
  34. DeFilippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, Blumenthal RS, Kronmal RA, McClelland RL, Nasir K, Blaha MJ. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med 2015; 162:266-275
  35. Damen JA, Pajouheshnia R, Heus P, Moons KGM, Reitsma JB, Scholten RJPM, Hooft L, Debray TPA. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. BMC Med 2019; 17:109-109
  36. Rana JS, Tabada GH, Solomon MD, Lo JC, Jaffe MG, Sung SH, Ballantyne CM, Go AS. Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population. Journal of the American College of Cardiology 2016; 67:2118-2130
  37. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine 2008; 359:2195-2207
  38. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESCSD Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41:111-188
  39. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Jr., Virani SS, Williams KA, Sr., Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140:e596-e646
  40. Feingold KR. The Effect of Diet on Cardiovascular Disease and Lipid and Lipoprotein Levels. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, DP W, eds. Endotext. South Dartmouth (MA)2024.
  41. Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, Heo JH, Rha SW, Cho YH, Lee SJ, Ahn CM, Kim JS, Ko YG, Choi D, Jang Y, Hong MK, Racing investigators. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet 2022; 400:380-390
  42. Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol 2017; 2:1069-1078
  43. Virani SS, Akeroyd JM, Smith SC, Al-Mallah M, Maddox TM, Morris PB, Petersen LA, Ballantyne CM, Grundy SM, Stone NJ. Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines. Journal of the American College of Cardiology 2019; 74:712-714
  44. Khera AV, Won H-H, Peloso GM, Lawson KS, Bartz TM, Deng X, van Leeuwen EM, Natarajan P, Emdin CA, Bick AG, Morrison AC, Brody JA, Gupta N, Nomura A, Kessler T, Duga S, Bis JC, van Duijn CM, Cupples LA, Psaty B, Rader DJ, Danesh J, Schunkert H, McPherson R, Farrall M, Watkins H, Lander E, Wilson JG, Correa A, Boerwinkle E, Merlini PA, Ardissino D, Saleheen D, Gabriel S, Kathiresan S. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. Journal of the American College of Cardiology 2016; 67:2578-2589
  45. Warden BA, Fazio S, Shapiro MD. Familial Hypercholesterolemia: Genes and Beyond. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, DP W, eds. Endotext. South Dartmouth (MA)2024.
  46. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet 1994; 344:1383-1389
  47. Kashef MA, Giugliano G. Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS). Glob Cardiol Sci Pract 2016; 2016:e201635-e201635
  48. Feingold KR. Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, DP W, eds. Endotext. South Dartmouth (MA)2023.
  49. Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC, Sperling LS, Virani SS, Blumenthal RS. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. Circulation 2019; 139:e1162-1177
  50. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50 Suppl:S172-177
  51. Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Kastelein JJP, Nicholls SJ. Mendelian Randomization Study of ACLY and Cardiovascular Disease. N Engl J Med 2019; 380:1033-1042
  52. Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American Heart Journal 2019; 210:18-28
  53. Tota-Maharaj R, Blaha MJ, Blankstein R, Silverman MG, Eng J, Shaw LJ, Blumenthal RS, Budoff MJ, Nasir K. Association of coronary artery calcium and coronary heart disease events in young and elderly participants in the multi-ethnic study of atherosclerosis: a secondary analysis of a prospective, population-based cohort. Mayo Clin Proc 2014; 89:1350-1359
  54. Stone NJ, Smith SC, Jr., Orringer CE, Rigotti NA, Navar AM, Khan SS, Jones DW, Goldberg R, Mora S, Blaha M, Pencina MJ, Grundy SM. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. J Am Coll Cardiol 2022; 79:819-836
  55. Streja E, Feingold KR. Evaluation and Treatment of Dyslipidemia in the Elderly. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  56. Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. International Journal of Cardiology 2016; 225:184-196
  57. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. Persistence of Use of Lipid-Lowering Medications. JAMA 1998; 279:1458
  58. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid‐lowering drugs. Medical Journal of Australia 1996; 164:208-211
  59. Gamboa CM, Safford MM, Levitan EB, Mann DM, Yun H, Glasser SP, Woolley JM, Rosenson R, Farkouh M, Muntner P. Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease. Am J Med Sci 2014; 348:108-114
  60. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 2005; 21:485-488
  61. Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. Journal of Clinical Lipidology 2016; 10:739-747
  62. Fitchett DH, Hegele RA, Verma S. Statin Intolerance. Circulation 2015; 131:e389-391
  63. Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, American College of Cardiology, American Heart Association, National Heart Lung, Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002; 106:1024-1028
  64. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceška R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance. JAMA2016; 315:1580-1590
  65. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen M-R, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal2016; 37:2999-3058
  66. Lee JC, Zdrojewski T, Pencina MJ, Wyszomirski A, Lachacz M, Opolski G, Bandosz P, Rutkowski M, Gaciong Z, Wyrzykowski B, Navar AM. Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States. JAMA Cardiol 2016; 1:700-707
  67. Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, Blaha MJ, Carson AP, Chang AR, Ciemins E, Go AS, Gutierrez OM, Hwang SJ, Jassal SK, Kovesdy CP, Lloyd-Jones DM, Shlipak MG, Palaniappan LP, Sperling L, Virani SS, Tuttle K, Neeland IJ, Chow SL, Rangaswami J, Pencina MJ, Ndumele CE, Coresh J, Chronic Kidney Disease Prognosis Consortium, the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and Validation of the American Heart Association's PREVENT Equations. Circulation 2024; 149:430-449
  68. Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Jr., Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC, Jr., Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S49-73
  69. Heaton J, Alshami A, Imburgio S, Upadhyaya V, Saybolt M, Apolito R, Hansalia R, Selan J, Almendral J, Sealove B. Comparison of pooled cohort equation and PREVENT risk calculator for statin treatment allocation. Atherosclerosis 2024; 399:118626
  70. Diao JA, Shi I, Murthy VL, Buckley TA, Patel CJ, Pierson E, Yeh RW, Kazi DS, Wadhera RK, Manrai AK. Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations. JAMA 2024; 332:989-1000
  71. Anderson TS, Wilson LM, Sussman JB. Atherosclerotic Cardiovascular Disease Risk Estimates Using the Predicting Risk of Cardiovascular Disease Events Equations. JAMA Intern Med 2024; 184:963-970
  72. Carrillo-Larco RM. Cardiovascular predicted risk: A population-based comparison of the pooled cohorts equation and PREVENT. Int J Cardiol 2024; 414:132423
  73. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM, SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003
  74. Score working group, E. S. C. Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021; 42:2439-2454
  75. Score Op working group, E. S. C. Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 2021; 42:2455-2467
  76. S. CORE2-Diabetes Working Group, the E. S. C. Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J 2023; 44:2544-2556
  77. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, E. S. C. National Cardiac Societies, E. S. C. Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42:3227-3337
  78. Wilson DP. Is Atherosclerosis a Pediatric Disease? In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2020.
  79. Berenson GS, Srinivasan SR, Bao W, Newman WP, 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338:1650-1656
  80. McGill HC, Jr., McMahan CA, Malcom GT, Oalmann MC, Strong JP. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol 1997; 17:95-106
  81. Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, Young JB, Nissen SE. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001; 103:2705-2710
  82. McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in combat casualties in Vietnam. JAMA 1971; 216:1185-1187
  83. Webber BJ, Seguin PG, Burnett DG, Clark LL, Otto JL. Prevalence of and risk factors for autopsy-determined atherosclerosis among US service members, 2001-2011. JAMA 2012; 308:2577-2583
  84. Newman WP, 3rd, Freedman DS, Voors AW, Gard PD, Srinivasan SR, Cresanta JL, Williamson GD, Webber LS, Berenson GS. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med 1986; 314:138-144
  85. McGill HC, Jr., McMahan CA. Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am J Cardiol 1998; 82:30T-36T
  86. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 2001; 104:2815-2819
  87. Juonala M, Magnussen CG, Venn A, Dwyer T, Burns TL, Davis PH, Chen W, Srinivasan SR, Daniels SR, Kahonen M, Laitinen T, Taittonen L, Berenson GS, Viikari JS, Raitakari OT. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. Circulation 2010; 122:2514-2520
  88. Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, Berenson GS. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 2003; 290:2271-2276
  89. Magnussen CG, Venn A, Thomson R, Juonala M, Srinivasan SR, Viikari JS, Berenson GS, Dwyer T, Raitakari OT. The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Determinants of Adult Health) study. J Am Coll Cardiol 2009; 53:860-869
  90. Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, Maki-Torkko N, Jarvisalo MJ, Uhari M, Jokinen E, Ronnemaa T, Akerblom HK, Viikari JS. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003; 290:2277-2283
  91. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, Levine DM. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993; 328:313-318
  92. Pletcher MJ, Vittinghoff E, Thanataveerat A, Bibbins-Domingo K, Moran AE. Young Adult Exposure to Cardiovascular Risk Factors and Risk of Events Later in Life: The Framingham Offspring Study. PLoS One 2016; 11:e0154288
  93. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000; 284:311-318
  94. Schwartz GG, Gabriel Steg P, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M, Odyssey Outcomes Committees Investigators. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation 2021; 143:1109-1122
  95. Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, Tantry U, Kubica J, Raggi P, Gurbel PA. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. JAMA 2018; 319:1566-1579
  96. Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, Nordio F, Hyde C, Cannon CP, Sacks F, Poulter N, Sever P, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015; 385:2264-2271
  97. Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, Sartori S, Fuster V, Reilly DF, Butterworth A, Rader DJ, Ford I, Sattar N, Kathiresan S. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. Circulation 2017; 135:2091-2101
  98. Feingold KR, Chait A. Approach to patients with elevated low-density lipoprotein cholesterol levels. Best Pract Res Clin Endocrinol Metab 2022:101658
  99. Feingold KR. Maximizing the benefits of cholesterol-lowering drugs. Curr Opin Lipidol 2019; 30:388-394

Skin Manifestations of Diabetes Mellitus

ABSTRACT

 

Diabetes mellitus is a common and debilitating disease that affects a variety of organs including the skin. Between thirty and seventy percent of patients with diabetes mellitus, both type 1 and type 2, will present with a cutaneous complication of diabetes mellitus at some point during their lifetime. A variety of dermatologic manifestations have been linked with diabetes mellitus; these conditions vary in severity and can be benign, deforming, and even life-threatening. Such skin changes can offer insight into patients’ glycemic control and may be the first sign of metabolic derangement in undiagnosed patients with diabetes. Recognition and management of these conditions is important in maximizing the quality of life and in avoiding serious adverse effects in patients with diabetes mellitus.

 

INTRODUCTION

 

The changes associated with diabetes mellitus can affect multiple organ systems. Between thirty and seventy percent of patients with diabetes mellitus, both type 1 and type 2, will present with a cutaneous complication of diabetes mellitus at some point during their lifetime (1). Dermatologic manifestations of diabetes mellitus have various health implications ranging from those that are aesthetically concerning to those that may be life-threatening. Awareness of cutaneous manifestations of diabetes mellitus can provide insight into the present or prior metabolic status of patients. The recognition of such findings may aid in the diagnosis of diabetes or may be followed as a marker of glycemic control. The text that follows describes the relationship between diabetes mellitus and the skin, more specifically: (1) skin manifestations strongly associated with diabetes, (2) non-specific dermatologic signs and symptoms associated with diabetes, (3) dermatologic diseases associated with diabetes, (4) common skin infections in diabetes, and (5) cutaneous changes associated with diabetes medications.

 

SKIN MANIFESTATIONS STRONGLY ASSOCIATED WITH DIABETES MELLITUS

 

Acanthosis Nigricans

 

EPIDEMIOLOGY

 

Acanthosis nigricans (AN) is a classic dermatologic manifestation of diabetes mellitus that affects men and women of all ages. AN is more common in type 2 diabetes mellitus (2) and is more prevalent in those with darker skin color. AN occurs more frequently in African Americans, Hispanics, and Native Americans (3). AN is observed in a variety of endocrinopathies associated with resistance to insulin such as acromegaly, Cushing syndrome, obesity, polycystic ovarian syndrome, and thyroid dysfunction. Unrelated to insulin resistance, AN can also be associated with malignancies such as gastric adenocarcinomas and genitourinary cancers, as well as with autoimmune disorders, various medications, and familial disorders (4-4F).

 

PRESENTATION

 

AN presents chronically as multiple poorly demarcated plaques with grey to dark brown hyperpigmentation and a thickened velvety to verrucous texture (figure 1). Classically, AN has a symmetrical distribution and is located in intertriginous or flexural surfaces such as the back of the neck, axilla, elbows, palmar hands (also known as “tripe palms”), inframammary creases, umbilicus, or groin. Affected areas are asymptomatic; however, extensive involvement may cause discomfort or fetor. Microscopy shows hyperkeratosis and epidermal papillomatosis with acanthosis. The changes in skin pigmentation are primarily a consequence of hyperkeratosis, not changes in melanin. AN can present prior to the clinical diagnosis of diabetes; the presence of AN should prompt evaluation for diabetes mellitus and for other signs of insulin resistance.

Figure 1. Acanthosis nigricans. From Wikipedia.

 

PATHOGENESIS

 

The pathogenesis of AN in diabetes is multifactorial. It is well-established that a hyperinsulin state directly activates insulin growth factor receptors (IGF), specifically IGF-1, on keratinocytes and fibroblasts, provoking cell proliferation, resulting in the aforementioned cutaneous manifestations of AN (5,6). Hyperinsulinemia also decreases circulating levels of IGF binding protein 1 and 2, increasing IGF-1 blood levels for the same effect (6A).

 

TREATMENT

 

Treatment of AN may improve current lesions and prevent future cutaneous manifestations. AN is best managed with lifestyle changes such as dietary modifications, increased physical activity, and weight reduction. In patients with diabetes, pharmacologic adjuvants, such as metformin, that improve glycemic control and reduce insulin resistance are also beneficial (7). One case report demonstrated the effectiveness of the glucagon peptide receptor 1 (GLP-1) receptor agonist liraglutide in improving the clinical appearance of AN (7A). Primary dermatologic therapies are usually ineffective especially in patients with generalized involvement. However, in those with thickened or macerated areas of skin, topical retinoids, topical vitamin D analogs such as calciprotriol, or topical keratolytics such as ammonium lactate and salicylic acid are the primary treatments used for localized lesions (8-10). Systemic retinoids such as isotretinoin and acitretin have been associated with improvement in patients with extensive involvement but are not often used due to risk of systemic adverse effects and relapse upon discontinuation (10A). Topical urea, trichloroacetic acid, glycolic acid peels, and laser therapy have also been suggested as localized treatment modalities, though addressing the underlying disorder remains the most effective intervention.

 

Diabetic Dermopathy

 

EPIDEMIOLOGY

 

Diabetic dermopathy (DD), also known as pigmented pretibial patches or diabetic shin spots, is the most common dermatologic manifestations of diabetes, occurring in as many as one-half of those with diabetes (11). Although disputed, some consider the presence of DD to be pathognomonic for diabetes. DD has a strong predilection for men and those older than 50 years of age, with the number of lesions increasing with the duration of diabetes, increasing age, and HbA1C levels (12, 12A). Although DD may antecede the onset of diabetes, it occurs more frequently as a late complication of diabetes and in those with microvascular disease. DD often occurs prior to the onset of neuropathy and retinopathy; nephropathy is also regularly present in patients with DD (12A). An association with cardiovascular disease has also been identified, with one study showing 53% of non- insulin-dependent diabetes mellitus with DD had coexisting coronary artery disease (13).

 

PRESENTATION

 

DD initially presents with rounded, dull, red papules that progressively evolve over one-to-two weeks into well-circumscribed, atrophic, brown macules with a fine scale (figure 2). Normally after about eighteen to twenty-four months, lesions dissipate and leave behind an area of concavity and hyperpigmentation. At any time, different lesions can present at different stages of evolution. The lesions are normally distributed bilaterally and localized over bony prominences. The pretibial area is most commonly involved, although other bony prominences such as the forearms, lateral malleoli, or thighs may also be involved. Aside from the aforementioned changes, patients are otherwise asymptomatic. DD is a clinical diagnosis that should not require a skin biopsy, which should be especially avoided in patients with poor wound healing (12A). Histologically, DD is rather nonspecific; it is characterized by lymphocytic infiltrates surrounding vasculature, engorged blood vessels in the papillary dermis, and dispersed hemosiderin deposits. Moreover, the histology varies based on the stage of the lesion. Immature lesions present with epidermal edema as opposed to epidermal atrophy which is representative of older lesions (14).

 

Figure 2. Diabetic Dermopathy.

 

PATHOGENESIS

 

The origin of DD remains unclear, however, mild trauma to affected areas (15), hemosiderin and melanin deposition (16), microangiopathic changes (12A, 17), and destruction of subcutaneous nerves (18) have all been suggested.

 

TREATMENT

 

Treatment is typically avoided given the asymptomatic and self-resolving nature of DD as well as the ineffectiveness of available treatments. However, DD often occurs in the context of microvascular complications and neuropathies (12); hence, patients need to be examined and followed more rigorously for these complications. Although improvement of DD lesions is variable with glycemic control, managing blood glucose can help prevent progression of microvascular complications (18A).

 

Diabetic Foot Syndrome

 

EPIDEMIOLOGY

 

Diabetic Foot Syndrome (DFS) encompasses the neuropathic and vasculopathic complications that develop in the feet of patients with diabetes. Although preventable, DFS is a significant cause of morbidity, mortality, hospitalization, and reduction in quality of life of patients with diabetes. The incidence and prevalence of DFS in patients with diabetes is 1% to 4% and 4% to 10%, respectively (19). Furthermore, DFS is slightly more prevalent in type 1 diabetes compared with type 2 diabetes (20). A more comprehensive review of diabetic foot syndrome can be found in The Diabetic Foot chapter of Endotext (20A).

 

PRESENTATION

 

DFS presents initially with callosities and dry skin related to diabetic neuropathy. In later stages, chronic ulcers and a variety of other malformations of the feet develop. Between 15% and 25% of patients with diabetes will develop ulcers (21). Ulcers may be neuropathic, ischemic, or mixed. The most common type of ulcers are neuropathic ulcers, a painless ulceration resulting from peripheral neuropathy. Ulcers associated with peripheral vascular ischemia are painful but less common. Ulcers tend to occur in areas prone to trauma, classically presenting at the site of calluses or over bony prominences. It is common for ulcers to occur on the toes, forefoot, and ankles. Untreated ulcers usually heal within one year, however, fifty percent of patients with diabetes will have recurrence of the ulcer within three years (22). The skin of affected patients, especially in those with type 2 diabetes, is more prone to fungal infection and the toe webs are a common port of entry for fungi which can then infect and complicate ulcers (23). Secondary infection of ulcers is a serious complication that can result in gangrenous necrosis, osteomyelitis, and may even require lower extremity amputation. Another complication, diabetic neuro-osteoarthropathy (also known as Charcot foot), is an irreversible debilitating and deforming condition involving progressive destruction of weight-bearing bones and joints. Diabetic neuro-osteoarthropathy occurs most frequently in the feet and can result in collapse of the midfoot, referred to as “rocker-bottom foot.” Moreover, a reduction of the intrinsic muscle volume and thickening of the plantar aponeurosis can cause a muscular imbalance that produces a clawing deformation of the toes. An additional complication of diabetes and neuropathy involving the feet is erythromelalgia. Erythromelalgia presents with redness, warmth, and a burning pain involving the lower extremities, most often the feet. Symptoms may worsen in patients with erythromelalgia with exercise or heat exposure and may improve with cooling (24).

 

PATHOGENESIS

 

The pathogenesis of DFS involves a combination of inciting factors that coexist together: neuropathy (25), atherosclerosis (25), and impaired wound healing (26). In the setting of long-standing hyperglycemia, there is an increase in advanced glycosylation end products, proinflammatory factors, and oxidative stress which results in the demyelination of nerves and subsequent neuropathy (27,28). Single-cell RNA sequencing revealed that there is a unique subset of fibroblasts that overexpress factors associated with healing within the wound bed as opposed to the wound edge (28A). Additionally, wound healers demonstrate an increase in M1 macrophages as opposed to non- wound healers which have an increase in M2 macrophages. The effect on sensory and motor nerves can blunt the perception of adverse stimuli and produce an altered gait, increasing the likelihood of developing foot ulcers and malformations. Also, damage to autonomic nerve fibers causes a reduction in sweating which may leave skin in the lower extremity dehydrated and prone to fissures and secondary infection (29). In addition to neuropathy, accelerated arterial atherosclerosis can lead to peripheral ischemia and ulceration (30). It has been reported that there is an association between diabetic patients with Charcot neuroarthropathy and greater impairment of cutaneous microvascular reactivity when compared to non-complicated diabetic groups (30A). Finally, hyperglycemia impairs macrophage functionality as well as increases and prolongs the inflammatory response, slowing the healing of ulcers (31).

 

TREATMENT

 

Treatment should involve an interdisciplinary team-based approach with a focus on prevention and management of current ulcers. Prevention entails daily surveillance, appropriate foot hygiene, and proper footwear, walkers, or other devices to minimize and distribute pressure. An appropriate wound care program should be used to care for ongoing ulcers. Different classes of wound dressing should be considered based on the type of wound. Hydrogels, hyperbaric oxygen therapy, topical growth factors, and biofabricated skin grafts are also available (19). The clinical presentation should indicate whether antibiotic therapy or wound debridement is necessary (19). In patients with chronic treatment resistant ulcers, underlying ischemia should be considered; these patients may require surgical revascularization or bypass.

 

Diabetic Thick Skin

 

Skin thickening is frequently observed in patients with diabetes. Affected areas of skin can appear thickened, waxy, or edematous. These patients are often asymptomatic but can have a reduction in sensation and pain. Although different parts of the body can be involved, the hands and feet are most frequently involved. Ultrasound evaluation of the skin can be diagnostic and exhibit thickened skin. Subclinical generalized skin thickening is the most common type of skin thickening. Diabetic thick skin may represent another manifestation of scleroderma-like skin changes, limited joint mobility, or scleredema diabeticorum, which are each described in more detail below.

 

SCLERODERMA-LIKE SKIN CHANGES

 

Epidemiology

 

Scleroderma-like skin changes are a distinct and easily overlooked group of findings that are commonly observed in patients with diabetes. Ten to fifty percent of patients with diabetes present with the associated skin findings (32). Scleroderma-like skin changes occur more commonly in those with type 1 diabetes and in those with longstanding disease (33). There is no known variation in prevalence between males and females, or between racial groups.

 

Presentation

 

Scleroderma-like skin changes develop slowly and present with painless, indurated, occasionally waxy appearing, thickened skin. These changes occur symmetrically and bilaterally in acral areas. In patients with scleroderma-like skin changes the acral areas are involved, specifically the dorsum of the fingers (sclerodactyly), proximal interphalangeal, and metacarpophalangeal joints. Severe disease may extend centrally from the hands to the arms or back. A small number of patients with diabetes may develop more extensive disease, which presents earlier and with truncal involvement. The risk of developing nephropathy and retinopathy is increased in those with scleroderma-like skin changes who also have type 1 diabetes (33,34). The aforementioned symptoms are also associated with diabetic hand syndrome which may present with limited joint mobility, palmar fibromatosis (Dupuytren's contracture), and stenosing tenosynovitis (“trigger finger”) (35). The physical exam finding known as the “prayer sign” (inability to flushly press palmar surfaces on each hand together) may be present in patients with diabetic hand syndrome and scleroderma-like skin changes (36). On histology, scleroderma-like skin changes reveal thickening of the dermis, minimal-to-absent mucin, and increased interlinking of collagen. Although on physical exam scleroderma may be difficult to distinguish from these skin changes, scleroderma-like skin changes are not associated with atrophy of the dermis, Raynaud’s syndrome, pain, or telangiectasias.

 

Pathogenesis

 

Although not fully understood, the pathogenesis is believed to involve the strengthening of collagen as a result of reactions associated with advanced glycosylation end products or a buildup of sugar alcohols in the upper dermis (37,38).

 

Treatment

 

Scleroderma-like skin changes is a chronic condition that is also associated with joint and microvascular complication. Therapeutic options are extremely limited. One observational report has suggested that very tight blood glucose control may result in the narrowing of thickened skin (39). In addition, aldose reductase inhibitors, which limit increases in sugar alcohols, may be efficacious (38). In patients with restricted ranges of motions, physical therapy can help to maintain and improve joint mobility.

 

LIMITED JOINT MOBILITY

 

Epidemiology

 

Limited Joint Mobility (LJM), also known as diabetic cheiroarthropathy, is a relatively common complication of long-standing diabetes mellitus. The majority of patients with LJM also present with scleroderma-like skin changes (38,40). The prevalence of LJM is 4% to 26% in patients without diabetes and 8% to 58% in patients with diabetes (41).

 

Presentation

 

LJM presents with progressive flexed contractures and hindered joint extension, most commonly involving the metacarpophalangeal and interphalangeal joints of the hand. The earliest changes often begin in the joints of the fifth finger before then spreading to involve the other joints of the hand (38). Patients may present with an inability to flushly press the palmar surfaces of each of their hands together (“prayer sign”) (figure 3) or against the surface of a table when their forearms are perpendicular to the surface of the table (“tabletop sign”) (42).

 

Pathogenesis

 

These changes occur as a result of periarticular enlargement of connective tissue. Pathogenesis likely involves hyperglycemia induced formation of advanced glycation end-products, which accumulate to promote inflammation and the formation of stiffening cross-links between collagen (43). LJM is strongly associated with microvascular and macrovascular changes and diagnosis of LJM should prompt a workup for related sequela (44). Patients with LJM may also be at an increased risk for falls (45).

 

Treatment

 

There are no curative treatments. Symptomatic patients may benefit from non-steroidal anti-inflammatory drugs or targeted injection of corticosteroids (43). LJM is best managed with improved glycemic control (46), as well as regular stretching to maintain and minimize further limitations in joint mobility.

 

Figure 3. Limited Joint Mobility.

 

SCLEREDEMA DIABETOCORUM

 

Epidemiology

 

Scleredema is a chronic and slowly progressive sclerotic skin disorder that is often seen in the context of diabetes, in which case it is classified as scleredema diabeticorum (SD). Whereas 2.5% to 14% of all patients with diabetes have scleredema, over 50% of those with scleredema present with concomitant diabetes (47). SD has a proclivity for men with a long history of diabetes (47A). It remains unclear whether there is a predilection for SD in those with type 1 diabetes (48) compared to those with type 2 diabetes (48).

 

Presentation

 

SD presents with gradually worsening indurated and thickened skin. These skin changes occur symmetrically and diffusely. The most commonly involved areas are the upper back, shoulders, and back of the neck. The face, chest, abdomen, buttocks, and thighs may also be involved; however, the distal extremities are classically spared. The affected areas are normally asymptomatic but there can be reduced sensation. Patients with severe longstanding disease may develop a reduced range of motion, most often affecting the trunk. In extreme cases, this can lead to restrictive respiratory problems. A full-thickness skin biopsy may be useful in supporting a clinical presentation. The histology of SD differentiates it from the autoimmune disease scleroderma, displaying increased collagen and a thickened reticular dermis, with a surrounding mucinous infiltrate, without edema or sclerosis.

 

Pathogenesis

 

Although many theories center on abnormalities in collagen, there is no consensus regarding the pathogenesis of SD. The pathogenesis of SD may involve an interplay between non-enzymatic glycosylation of collagen, increased fibroblast production of collagen and mucin, or decreases in collagen breakdown (50-51A).

 

Treatment

 

SD is normally unresolving and slowly progressive over years. Improved glycemic control may be an important means of prevention but evidence has not shown clinical improvements in those already affected by SD. A variety of therapeutic options have been proposed with variable efficacy. The 2024 European Dermatology Forum Guidelines (51A) recommend medium-to-high dose phototherapy with UVA1 or PUVA as first-line therapy, methotrexate as second-line therapy, and other treatments including immunosuppressants, corticosteroids, intravenous immunoglobulin, and electron-beam therapy as advanced therapies (52). Independent of other treatments, physical therapy is an important therapeutic modality for patients with SD and reduced mobility (51A, 53).

 

Necrobiosis Lipoidica

 

EPIDEMIOLOGY

 

Necrobiosis lipoidica (NL) is a rare chronic granulomatous dermatologic disease that is seen most frequently in patients with diabetes.  Although nearly one in four patients presenting with NL will also have diabetes, only 0.3% to 1.6% of patients with diabetes will develop NL (47A,54). For unknown reasons, NL expresses a strong predilection for women compared to men (55). NL generally occurs in type 1 diabetes during the third decade of life, as opposed to type 2 diabetes in which it commonly presents in the fourth or fifth decades of life (54). The majority of cases of NL presents years after a diagnosis of diabetes mellitus; however, NL may precede diabetes, with 7% to 42% of patients with initial NL going on to develop impaired glucose tolerance or diabetes (47A,56). One study evaluating comorbidities and diabetic complications in patients with NL found high rates of smoking, hypertension, hyperlipidemia, obesity, coronary artery disease, myocardial infarction, thyroid disease, poor kidney function, and poor glucose control (56A). The highest comorbidity rates in patients with NL were patients with type 2 diabetes.

 

PRESENTATION

 

NL begins as a single or group of firm well-demarcated rounded erythematous papules (figure 4). The papules then  expand  and  aggregate into plaques characterized by circumferential red-brown borders and a firm yellow-brown waxen atrophic center containing telangiectasias. NL occurs bilaterally and exhibits Koebnerization. Lesions are almost always found on the pretibial areas of the lower extremities. Additional involvement of the forearm, scalp, distal upper extremities, face, or abdomen may be present on occasion, and the heel of the foot or glans penis even more infrequently. If left untreated, only about 15% of lesions will resolve within twelve years. Despite the pronounced appearance of the lesions, NL is often asymptomatic. However, there may be pruritus and hypoesthesia of affected areas, and pain may be present in the context of ulceration. Ulceration occurs in about one-third of lesions and has been associated with secondary infections and squamous cell carcinoma. The histology of NL primarily involves the dermis and is marked by palisading granulomatous inflammation, necrobiotic collagen, a mixed inflammatory infiltrate, blood vessel wall thickening, and reduced mucin.

 

Figure 4. Necrobiosis Lipoidica.

 

PATHOGENESIS

 

The pathogenesis of NL is not well understood. The relationship between diabetes and NL has led some to theorize that diabetes-related microangiopathy is related to the development of NL (54). Other theories focus on irregularities in collagen, autoimmune disease, neutrophil chemotaxis, or blood vessels (57).

 

TREATMENT

 

NL is a chronic, disfiguring condition that can be debilitating for patients and difficult for clinicians to manage. Differing degrees of success have been reported with a variety of treatments; however, the majority of such reports are limited by inconsistent treatment responses in patients and a lack of large, controlled studies. Corticosteroids are often used in the management of NL and may be administered topically, intralesionally, or orally. Corticosteroids can be used to manage active lesions but is best not used in areas that are atrophic. Success has also been reported with calcineurin inhibitors (e.g., cyclosporine), anti-tumor necrosis factor inhibitors (e.g., infliximab), pentoxifylline, antimalarials (e.g., hydroxychloroquine), PUVA, granulocyte colony stimulating factor, dipyridamole, and low-dose aspirin (54). Appropriate wound care is important for ulcerated lesions; this often includes topical antibiotics, protecting areas vulnerable to injury, emollients, and compression bandaging. Surgical excision of ulcers typically has poor results. Some ulcerated lesion may improve with split-skin grafting. Although still recommended, improved control of diabetes has not been found to lead to an improvement in skin lesions. Patients with newly diagnosed NL should be screened for hypertension, hyperlipidemia, and thyroid disease (56A).

 

Bullosis Diabeticorum

 

EPIDEMIOLOGY

 

Bullosis diabeticorum (BD) is an uncommon eruptive blistering condition that presents in those with diabetes mellitus. Although BD can occasionally present in early-diabetes (58), it often occurs in long-standing diabetes along with other complications such as neuropathy, nephropathy, and retinopathy. In the United States, the prevalence of BD is estimated to be around 0.5% amongst patients with diabetes and is believed to be higher in those with type 1 diabetes (13); however, underreporting of blistering cases in patients with diabetes may indicate a higher prevalence (58A). BD is significantly more common in male patients than in female patients (59). The average age of onset is between 50 and 70 years of age (59).

 

PRESENTATION

 

BD presents at sites of previously healthy-appearing skin with the abrupt onset of one or more non-erythematous, firm, sterile bullae. Shortly after forming, bullae increase in size and become more flaccid, ranging in size from about 0.5 cm to 5 cm. Bullae frequently present bilaterally involving the acral areas of the lower extremities. However, involvement of the upper extremities and even more rarely the trunk can be seen. The bullae and the adjacent areas are nontender. BD often presents acutely, classically overnight, with no history of trauma to the affected area. Generally, the bullae heal within two to six weeks, but then commonly reoccur. Histological findings are often non-specific but are useful in distinguishing BD from other bullous diseases. Histology typically shows an intraepidermal or subepidermal blister, spongiosis, no acantholysis, minimal inflammatory infiltrate, and normal immunofluorescence.

 

PATHOGENESIS

 

There is an incomplete understanding of the underlying pathogenesis of BD and no consensus regarding a leading theory. Various mechanisms have been proposed, some of which focus on autoimmune processes, exposure to ultraviolet light, variations in blood glucose, neuropathy, or changes in microvasculature (60).

 

TREATMENT

 

BD resolve without treatment and are therefore managed by avoiding secondary infection and the corresponding sequelae (e.g., necrosis, osteomyelitis). This involves protection of the affected skin, leaving blisters intact (except for large blisters, which may be aspirated to prevent rupture), and monitoring for infection. Topical antibiotics are not necessary unless specifically indicated, such as with secondary infection or positive culture.

 

NONSPECIFIC DERMATOLOGIC SIGNS AND SYMPTOMS

 

Ichthyosiform Changes of the Shins

 

Ichthyosiform changes of the shins presents with large bilateral areas of dryness and scaling (sometimes described as “fish scale” skin) (figure 5). Although cutaneous changes may occur on the hands or feet, the anterior shin is most classically involved. These cutaneous changes are related to rapid skin aging and adhesion defects in the stratum corneum (61). The prevalence of ichthyosiform changes of the shins in those with type 1 diabetes has been reported to be between 22% to 48% (33,62). These changes present relatively early in the disease course of diabetes. There is no known difference in prevalence between males and females (33). The development of ichthyosiform changes of the shins is related to production of advanced glycosylation end products and microangiopathic changes. Treatment is limited but topical emollients or keratolytic agents may be beneficial (61).

 

Figure 5. Acquired ichthyosiform changes.

 

Xerosis

 

Xerosis is one of the most common skin presentations in patients with diabetes and has been reported to be present in as many as 40% of patients with diabetes (63). Xerosis refers to skin that is abnormally dry. Affected skin may present with scaling, cracks, or a rough texture. These skin changes are most frequently located on the feet of patients with diabetes. It has been reported that diabetic patients that are obese will experience more severe hypohidrosis of the feet (63A). In patients with diabetes, xerosis occurs often in the context of microvascular complications (40). To avoid complications such as fissures and secondary infections, xerosis can be managed with emollients like ammonium lactate (64).

 

Acquired Perforating Dermatosis

 

EPIDEMIOLOGY

 

Perforating dermatoses refers to a broad group of chronic skin disorders characterized by a loss of dermal connective tissue. A subset of perforating dermatoses, known as acquired perforating dermatoses (APD), encompasses those perforating dermatoses that are associated with systemic diseases. Although APD may be seen with any systemic diseases, it is classically observed in patients with chronic renal failure or long-standing diabetes (65). APD occurs most often in adulthood in patients between the ages of 30 and 90 years of age (65,66). The overall prevalence of APD is unknown due to rarity and/or underdiagnosis of the disease. It is estimated that of those diagnosed with APD about 15% also have diabetes mellitus (67). In a review, 4.5% to 10% of patients with chronic renal failure presented with concurrent APD (68,69).

 

PRESENTATION

 

APD presents as groups of hyperkeratotic umbilicated-nodules and papules with centralized keratin plugs. The lesions undergo Koebnerization and hence the extensor surfaces of the arms and more commonly the legs are often involved; eruptions also occur frequently on the trunk. However, lesions can develop anywhere on the body. Lesions are extremely pruritic and are aggravated by excoriation. Eruptions may improve after a few months, but an area of hyperpigmentation typically remains. Histologically, perforating dermatoses are characterized by a lymphocytic infiltrate, an absence or degeneration of dermal connective tissue components (e.g., collagen, elastic fibers), and transepidermal extrusion of keratotic material.

 

PATHOGENESIS

 

The underlying pathogenesis is disputed and not fully understood. It has been suggested that repetitive superficial trauma from chronic scratching may induce epidermal or dermal derangements (70). The glycosylation of microvasculature or dermal components has been suggested as well. Other hypotheses have implicated additional metabolic disturbances, or the accumulation of unknown immunogenic substances that are not eliminated by dialysis (65). APD is also considered a form of prurigo nodularis (70A).

 

TREATMENT

 

APD can be challenging to treat and many of the interventions have variable efficacy. Minimizing scratching and other traumas to involved areas can allow lesions to resolve over a period of months. This is best achieved with symptomatic relief of pruritus. Individual lesions can be managed with topical agents such as keratolytics (e.g., 5% to 7% salicylic acid), retinoids (e.g., 0.01% to 0.1% tretinoin), or high-potency steroids (71). Refractory lesions may respond to intralesional steroid injections or cryotherapy (71). A common initial approach is a topical steroid in combination with emollients and an oral antihistamine. Generalized symptoms may improve with systemic therapy with oral retinoids, psoralen plus UVA light (PUVA), allopurinol (100 mg daily for 2 to 4 months), or oral antibiotics (doxycycline or clindamycin) (72). Additionally, as APD is a form of prurigo nodularis, the use of immunomodulating agents such as dupilumab may be effective in treating the condition. There is evidence of dupilumab monotherapy effectively treating certain forms of APD (72A). Nevertheless, effective management of the underlying systemic disease is fundamental to the treatment of APD. In those with diabetes, APD is unlikely to improve without improved blood glucose control. Moreover, dialysis does not reduce symptoms; however, renal transplantation can result in the improvement and resolution of cutaneous lesions.

 

Eruptive Xanthomas

 

EPIDEMIOLOGY

 

Eruptive xanthomas (EX) are a clinical presentation of hypertriglyceridemia, generally associated with serum triglycerides above 2,000 mg/dL (73). However, in patients with diabetes, lower levels of triglycerides may be associated with EX. The prevalence of EX is around one percent in type 1 diabetes and two percent in type 2 diabetes (74,75). Serum lipid abnormalities are present in about seventy-five percent of patients with diabetes (76). For a detailed discussion of lipid abnormalities in patients with diabetes see the Endotext chapter entitled “Dyslipidemia in Patients with Diabetes” (76A).

 

PRESENTATION

 

EX has been reported as the first presenting sign of diabetes mellitus, granting it can present at any time in the disease course. EX presents as eruptions of clusters of glossy pink-to-yellow papules, ranging in diameter from 1 mm to  4 mm,  overlying an erythematous area (figure 6). The lesions can be found on extensor surfaces of the extremities, the buttocks, and in areas susceptible in Koebnerization. EX is usually asymptomatic but may be pruritic or tender. Histology reveals a mixed inflammatory infiltrate of the dermis which includes triglyceride containing macrophages, also referred to as foam cells.

 

Figure 6. Eruptive Xanthomas

 

PATHOGENESIS

 

Lipoprotein lipase, a key enzyme in the metabolism of triglyceride rich lipoproteins, is stimulated by insulin. In an insulin deficient state, such as poorly controlled diabetes, there is decreased lipoprotein lipase activity resulting in the accumulation of chylomicrons and other triglyceride rich lipoproteins (77). Increased levels of these substances are scavenged by macrophages (78). These lipid-laden macrophages then collect in the dermis of the skin where they can lead to eruptive xanthomas.

 

TREATMENT

 

EX can resolve with improved glycemic control and a reduction in serum triglyceride levels (79). This may be achieved with fibrates or omega-3-fatty acids in addition to an appropriate insulin regimen (80). A more comprehensive review of the treatment of hypertriglyceridemia can be found in the Endotext chapter entitled “Triglyceride Lowering Drugs” (80A).

 

Acrochordons

 

Acrochordons (also known as soft benign fibromas, fibroepithelial polyps, or skin tags) are benign, soft, pedunculated growths that vary in size and can occur singularly or in groups (figure 7). The neck, axilla, and periorbital area are most frequently involved, although other intertriginous areas can also be affected. Skin tags are common in the general population but are more prevalent in those with increased weight or age, and in women. It has been reported that as many as three out of four patients presenting with acrochordons also have diabetes mellitus (81). Patients with acanthosis nigricans may have acrochordons overlying the affected areas of skin. Although disputed, some studies have suggested that the amount of skin tags on an individual may correspond with an individual's risk of diabetes or insulin resistance (82). Excision or cryotherapy is not medically indicated but may be considered in those with symptomatic or cosmetically displeasing lesions.

 

Figure 7. Acrochordons.

 

Diabetes-Associated Pruritus

 

Diabetes can be associated with pruritus, more often localized than generalized. Affected areas can include the scalp, ankles, feet, trunk, or genitalia (83,84). Pruritus is more likely in patients with diabetes who have dry skin or diabetic neuropathy. Other neuropathic conditions may arise in diabetes, such as scalp dysesthesia and meralgia paresthetica; these conditions often present with pruritus, burning, or pain (84A-B). Specifically, for type 2 diabetes, risk factors for pruritus were identified to be age, duration of disease, diabetic peripheral neuropathy, diabetic retinopathy, diabetic chronic kidney disease, peripheral arterial disease, and fasting plasma glucose levels (84C,D,E). Involvement of the genitalia or intertriginous areas may occur in the setting of infection (e.g., candidiasis). Treatments include topical capsaicin, topical ketamine-amitriptyline-lidocaine, oral anticonvulsants (e.g., gabapentin or pregabalin), and, in the case of candida infection, antifungals.

 

Huntley’s Papules (Finger Pebbles)

 

Huntley’s papules, also known as finger pebbles, are a benign cutaneous finding affecting the hands. Patients present with clusters of non-erythematous, asymptomatic, small papules on the dorsal surface of the hand, specifically affecting the metacarpophalangeal joints and periungual areas. The clusters of small papules can develop into coalescent plaques. Other associated cutaneous findings include hypopigmentation and induration of the skin. Huntley’s papules are strongly associated with type 2 diabetes and may be an early sign of diabetic thick skin (85,86). Topical therapies are usually ineffective; however, patients suffering from excessive dryness of the skin may benefit from 12% ammonium lactate cream (87).

 

Keratosis Pilaris

 

Keratosis pilaris is a very common benign keratotic disorder. Patients with keratosis pilaris classically present with areas of keratotic perifollicular papules with surrounding erythema or hyperpigmentation (figure 8). The posterior surfaces of the upper arms are often affected but involvement of the thighs, face, and buttocks can also be seen. Compared to the general population, keratosis pilaris occurs more frequently and with more extensive involvement of the skin in those with diabetes (33,62). Keratosis pilaris can be treated with various topical therapies, including salicylic acid, moisturizers, and emollients.

 

Figure 8. Keratosis Pilaris.

 

Pigmented Purpuric Dermatoses

 

Pigmented purpuric dermatoses (also known as pigmented purpura) are associated with diabetes, more often in the elderly, and frequently coexist with diabetic dermopathy (88,89). Pigmented purpura presents with non-blanching copper-colored patches involving the pretibial areas of the legs or the dorsum of the feet. The lesions are usually asymptomatic but may be pruritic. Pigmented purpuric dermatoses occur more often in late-stage diabetes in patients with nephropathy and retinopathy as a result of microangiopathic damage to capillaries and sequential erythrocyte deposition (90).

 

Palmar Erythema

 

Palmar erythema is a benign finding that presents with symmetric redness and warmth involving the palms (figure 9). The erythema is asymptomatic and often most heavily affects the hypothenar and thenar eminences of the palms. The microvascular complications of diabetes are thought to be involved in the pathogenesis of palmar erythema (91). Although diabetes associated palmar erythema is distinct from physiologic mottled skin, it is similar to other types of palmar erythema such as those related to pregnancy and rheumatoid arthritis.

 

Figure 9. Palmar erythema. From Wikipedia.

 

Periungual Telangiectasias

 

As many as one in every two patients with diabetes are affected by periungual telangiectasias (92). Periungual telangiectasias presents asymptomatically with erythema and telangiectasias surrounding the proximal nail folds (71). Such findings may occur in association with “ragged” cuticles and fingertip tenderness. The cutaneous findings are due to venous capillary dilatation that occurs secondary to diabetic microangiopathy. Capillary abnormalities, such as venous capillary tortuosity, may differ and can represent an early manifestation of diabetes-related microangiopathy (93).

 

Rubeosis Faciei

 

Rubeosis faciei is a benign finding present in about 7% of patients with diabetes; however, in hospitalized patients, the prevalence may exceed 50% (94). Rubeosis faciei presents with chronic erythema of the face or neck. Telangiectasias may also be visible. The flushed appearance is often more prominent in those with lighter colored skin. The flushed appearance is thought to occur secondary to small vessel dilation and microangiopathic changes. Complications of diabetes mellitus, such as retinopathy, neuropathy, and nephropathy are associated with rubeosis faciei (90). Facial erythema may improve with better glycemic control and reduction of caffeine or alcohol intake.

 

Yellow Skin and Nails

 

It is common for patients with diabetes, particularly elderly patients with type 2 diabetes, to present with asymptomatic yellow discolorations of their skin or fingernails. These benign changes commonly involve the palms, soles, face, or the distal nail of the first toe. The accumulation of various substances (e.g., carotene, glycosylated proteins) in patients with diabetes may be responsible for the changes in complexion; however, the pathogenesis remains controversial (95).

 

Onychocryptosis

 

Onychocryptosis, or ingrown toenails, have been reported in patients with diabetes, specifically type 2 diabetes (95A). The great toes are most affected. It is hypothesized that this nail change can occur in diabetic patients because onychocryptosis is correlated with increased body mass index, trauma, weak vascular supply, nail plate dysfunction, and subungual hyperkeratosis.

 

DERMATOLOGIC DISEASES ASSOCIATED WITH DIABETES

 

Generalized Granuloma Annulare

 

EPIDEMIOLOGY

 

Although various forms of granuloma annulare exist, only generalized granuloma annulare (GGA) is thought to be associated with diabetes. It is estimated that between ten and fifteen percent of cases of GGA occur in patients with diabetes (96). Meanwhile, less than one percent of patients with diabetes present with GGA. GGA occurs around the average age of 50 years. It occurs more frequently in women than in men, and in those with type 1 diabetes (97).

 

PRESENTATION

 

GGA initially presents with groups of skin-colored or reddish, firm papules which slowly grow and centrally involute to then form hypo- or hyper-pigmented annular rings with elevated circumferential borders (figure 10). The lesions can range in size from 0.5 cm to 5.0 cm. The trunk and extremities are classically involved in a bilateral distribution. GGA is normally asymptomatic but can present with pruritus. The histology shows dermal granulomatous inflammation surrounding foci of necrotic collagen and mucin. Necrobiosis lipoidica can present similarly to GGA; GGA is distinguished from necrobiosis lipoidica by its red color, the absence of an atrophic epidermis, and on histopathology: the presence of mucin and lack of plasma cells.

 

Figure 10. Generalized granuloma annulare. From Wikipedia.

 

PATHOGENESIS

 

The pathogenesis of GGA is incompletely understood. It is believed to involve an unknown stimulus that leads to the activation of lymphocytes through a delayed- type hypersensitivity reaction, ultimately initiating a proinflammatory cascade and granuloma formation (98). Recent studies have identified Th1, JAK-STAT, and perhaps also Th2 pathway dysregulation in GA lesional skin (97A).

 

TREATMENT

 

GGA has a prolonged often unresolving disease course and multiple treatments have been suggested to better manage GGA. However, much of the information stems from small studies and case reports. Several large retrospective studies suggest the efficacy of intralesional and topical corticosteroids in some patients, with phototherapy being an option for GA refractory to corticosteroids (97A). Antimalarials, retinoids, dapsone, methotrexate, cyclosporine, and calcineurin inhibitors have also been suggested as therapies (97A,98).

 

Psoriasis

 

Psoriasis is a chronic immune-mediated inflammatory disorder that may present with a variety of symptoms, including erythematous, indurated, and scaly areas of skin. Psoriasis has been found to be associated with a variety of risk factors, such as hypertension, obesity, and metabolic syndrome, that increase the likelihood of cardiovascular disease. The development of diabetes mellitus, an additional cardiovascular risk factor, has been strongly associated with psoriasis (99). In particular, younger patients and those with severe psoriasis may be more likely to develop diabetes in the future (99).

 

Lichen Planus

 

Lichen planus is a mucocutaneous inflammatory disorder characterized by firm, erythematous, polygonal, pruritic, papules. These papules classically involve the wrists or ankles, although the trunk, back, and thighs can also be affected. A number of studies have cited an association between lichen planus and abnormalities in glucose tolerance testing. Approximately one in four patients with lichen planus have diabetes mellitus (100). Although the association is contested, it has been reported that patients with diabetes may also be more likely to develop oral lichen planus (101).

 

Vitiligo

 

Vitiligo is an acquired autoimmune disorder involving melanocyte destruction. Patients with vitiligo present with scattered well-demarcated areas of depigmentation that can occur anywhere on the body but frequently involves the acral surfaces and the face (figure 11). Whereas about 1% of the general population is affected by vitiligo, vitiligo is much more prevalent in those with diabetes mellitus. Vitiligo occurs more frequently in women and is also more common in type 1 than in type 2 diabetes mellitus (96,98). Coinciding vitiligo and type 1 diabetes mellitus may be associated with endocrine autoimmune abnormalities of the gastric parietal cells, adrenal, or thyroid (102). A more comprehensive review of polyglandular autoimmune disorders can be found in the Autoimmune Polyglandular Syndromes section of Endotext (102A).

 

Figure 11. Vitiligo. From Wikipedia.

 

Hidradenitis Suppurativa

 

Hidradenitis suppurativa (HS) is a chronic inflammatory condition characterized by inflamed nodules and abscesses located in intertriginous areas such as the axilla or groin (figure 12). These lesions are often painful and malodorous. HS is frequently complicated by sinus formation and the development of disfiguring scars. HS occurs more often in women than men and usually presents in patients beginning in their twenties (103). The prevalence of HS is 0.095% in White populations, increasing more than 3-fold in Black populations (103A). Compared to the general population, diabetes mellitus is three times more common in patients with HS; HS has also been associated with cigarette smoking, diabetes, and low socioeconomic status (103A,104). It is recommended that patients with HS be screened for diabetes mellitus. Although there is no standardized approach to the treatment of HS, a multimodal approach may address underlying follicular occlusion, inflammation, bacterial overgrowth, hormonal and metabolic dysregulation and lifestyle modifications (103A). Some benefits have been reported with the use of antibiotics, retinoids, antiandrogens, or immunomodulators such as tumor necrosis factor (TNF) inhibitors (105).

 

Figure 12. Hidradenitis suppurativa. From Wikipedia.

 

Glucagonoma

 

Glucagonoma is a rare neuroendocrine tumor that most frequently affects patients in their sixth decade of life (106). Patients with glucagonoma may present with a variety of non-specific symptoms. However, necrolytic migratory erythema (NME) is classically associated with glucagonoma and presents in 70% to 83% of patients (106) (107). NME is characterized by erythematous erosive crusted or vesicular eruptions of papules or plaques with irregular borders (figure 13). The lesions may become bullous or blistered and may be painful or pruritic. The abdomen, groin, genitals, or buttocks are frequently involved, although cheilitis or glossitis may also be present. Biopsy at the edge of the lesion may demonstrate epidermal pallor, necrolytic edema, and a perivascular inflammatory infiltrate (108). Patients with glucagonoma may also present with diabetes mellitus. In patients with glucagonoma, diabetes mellitus frequently presents prior to NME (107). Approximately 20% to 40% of patients will present with diabetes mellitus before the diagnosis of glucagonoma (107,109). Of those patients diagnosed with glucagonoma but not diabetes mellitus, 76% to 94% will eventually develop diabetes mellitus (110). A more comprehensive review of glucagonoma can be found in the Glucagonoma section of Endotext (110A).

 

Figure 13. Necrolytic migratory erythema. From Endotext chapter entitled Glucagon & Glucagonoma Syndrome.

 

Melanoma

 

Type 2 diabetes mellitus does not increase the risk of melanoma, but it is associated with more advanced melanoma stages at the time of diagnosis as well as the presence of ulceration (110B). Furthermore, type 2 diabetes mellitus may promote more aggressive melanoma, but further research is needed to better understand the mechanisms involved (110C).

 

Skin Infections

 

The prevalence of cutaneous infections in patients with diabetes is about one in every five patients (111). Compared with the general population, patients with diabetes mellitus are more susceptible to infections and more prone to repeated infections. A variety of factors are believed to be involved in the vulnerability to infection in patients with uncontrolled diabetes, some of these factors include angiopathy, neuropathy, hindrance of the antioxidant system, abnormalities in leukocyte adherence, chemotaxis, and phagocytosis, as well as a glucose-rich environment facilitates the growth of pathogens. Host risk factors associated with skin and soft tissue in patients with DM are uncontrolled hyperglycemia, disruption of skin barrier,  elevated skin pH sensory or autonomic neuropathy, trauma/pressure, venous or arterial insufficiency, and immune system dysfunction (111A).

 

BACTERIAL

 

Erysipelas and Cellulitis

 

Erysipelas and cellulitis are cutaneous infections that occur frequently in patients with diabetes. Erysipelas presents with pain and well-demarcated superficial erythema. Cellulitis is a deeper cutaneous infection that presents with pain and poorly demarcated erythema. Folliculitis is common among patients with diabetes, and is characterized by inflamed, perifollicular, papules and pustules. Treatment for the aforementioned conditions depends on the severity of the infection. Uncomplicated cellulitis and erysipelas are typically treated empirically with oral antibiotics, whereas uncomplicated folliculitis may be managed with topical antibiotics. Colonization with methicillin- resistant Staphylococcus aureus (MRSA) is not uncommon among patients with diabetes (112); however, it is debated as to whether colonized patients are predisposed to increased complications (113) such as bullous erysipelas, carbuncles, or perifollicular abscesses. Regardless, it is important that appropriate precautions are taken in these patients and that antibiotics are selected that account for antimicrobial resistance.

 

Diabetic Foot Infection

 

Infection of the foot is the most common type of soft tissue infection in patients with diabetes. If not managed properly, diabetic foot infections can become severe, possibly leading to osteomyelitis, sepsis, amputation, or even death. Although less severe, the areas between the toes and the toenails are also frequently infected in patients with diabetes. Infections can stem from monomicrobial or polymicrobial etiologies. Staphylococcal infections are the most common (114), although complications with infection by Pseudomonas aeruginosa are also common (115). Pseudomonal infection of the toenail may present with a green discoloration, which may become more pronounced with the use of a Wood’s light. Treatment frequently requires coordination of care from multiple medical providers. Topical or oral antibiotics and surgical debridement may be indicated depending on the severity of the infection.

 

Necrotizing Fasciitis

 

Necrotizing fasciitis is an acute life-threatening infection of the skin and the underlying tissue. Those with poorly controlled diabetes are at an increased risk for necrotizing fasciitis. Necrotizing fasciitis presents early with erythema, induration, and tenderness which may then progress within days to hemorrhagic bullous. Patients will classically present with severe pain out of proportion to their presentation on physical exam. Palpation of the affected area often illicit crepitus. Involvement can occur on any part of the body but normally occurs in a single area, most commonly affecting the lower extremities. Fournier’s gangrene refers to necrotizing fasciitis of the perineum or genitals, often involving the scrotum and spreading rapidly to adjacent tissues. The infection in patients with diabetes is most often polymicrobial. Complications of necrotizing fasciitis include thrombosis, gangrenous necrosis, sepsis, and organ failure. Necrotizing fasciitis has a mortality rate of around twenty percent (116). In addition, those patients with diabetes and necrotizing fasciitis are more likely to require amputation during their treatment (117). Treatment is emergent and includes extensive surgical debridement and broad-spectrum antibiotics.

 

Erythrasma

 

Erythrasma is a chronic asymptomatic cutaneous infection, most often attributed to Corynebacterium minutissimum. Diabetes mellitus, as well as obesity and older age are  associated with erythrasma. Erythrasma presents with non-pruritic non-tender clearly demarcated red brown finely scaled patches or plaques. These lesions are commonly located in intertriginous areas such as the axilla or groin. Given the appearance and location, erythrasma can be easily mistaken for tinea or Candida infection; in such cases, the presence of coral-red fluorescence under a Wood’s light can confirm the diagnosis of erythrasma. Treatment options include topical erythromycin or clindamycin, Whitfield’s ointment, and sodium fusidate ointment. More generalized erythrasma may respond better to oral erythromycin.

 

Malignant Otitis Externa

 

Malignant otitis externa is a rare but serious infection of the external auditory canal that occurs most often in those with a suppressed immune system, diabetes mellitus, or older age. Malignant otitis externa develops as a complication of otitis externa and is associated with infection by Pseudomonas aeruginosa. Patients with malignant otitis externa present with severe otalgia and purulent otorrhea. The infection can spread to nearby structures and cause complications such as chondritis, osteomyelitis, meningitis, or cerebritis. If untreated, malignant otitis externa has a mortality rate of about 50%; however, with aggressive treatment the mortality rate can been reduced to 10% to 20% (118). Treatment involves long-term systemic antibiotics with appropriate pseudomonal coverage, hyperbaric oxygen, and possibly surgical debridement.

 

FUNGAL

 

Candida

 

Candidiasis is a frequent presentation in patients with diabetes. Moreover, asymptomatic patients presenting with recurrent candidiasis should be evaluated for diabetes mellitus. Elevated salivary glucose concentrations (119) and elevated skin surface pH in the intertriginous regions of patients with diabetes (120) may promote an environment in which candida can thrive. Candida infection can involve the mucosa (e.g., thrush, vulvovaginitis), intertriginous areas (e.g., intertrigo, erosion interdigital, balanitis), or nails (e.g., paronychia). Mucosal involvement presents with pruritus, erythema, and white plaques which can be removed when scraped. Intertriginous Candida infections may be pruritic or painful and present with red macerated, fissured plaques with satellite vesciulopustules. Involvement of the nails may present with periungual inflammation or superficial white spots. Onychomycosis may be due to dermatophytes (discussed below) or Candidal infection. Onychomycosis, characterized by subungual hyperkeratosis and onycholysis, is present in nearly one in two patients with type 2 diabetes mellitus. Candidiasis is treated with topical or oral antifungal agents. Patients also benefit from improved glycemic control and by keeping the affected areas dry.

 

Dermatophytes

 

Although it remains controversial, dermatophyte infections appear to be more prevalent among patients with diabetes (121-123). Various regions of the body may be affected but tinea pedis (foot) is the most common dermatophyte infection affecting patients; it presents with pruritus or pain and erythematous keratotic or bullous lesions. Relatively benign dermatophyte infections like tinea pedis can lead to serious sequela, such as secondary bacterial infection, fungemia, or sepsis, in patients with diabetes if not treated hastily. Patients with diabetic neuropathy may be especially vulnerable (124). Treatment may include topical or systemic antifungal medications depending on the severity.

 

Mucormycosis

 

Mucormycosis is a serious infection that is associated with type 1 diabetes mellitus, particularly common in those who develop diabetic ketoacidosis. A variety of factors including hyperglycemia and a lower pH, create an environment in which Rhizopus oryzae, a common pathogen responsible for mucormycosis, can prosper. Mucormycosis may present in different ways. Rhino-orbital-cerebral mucormycosis is the most common  presentation;  it  develops  quickly  and presents with acute sinusitis, headache, facial edema, and tissue necrosis. The infection may worsen and cause extensive necrosis and thrombosis of nearby structures such as the eye. Mucormycosis should be treated urgently with surgical debridement and intravenous amphotericin B. When it is not suitable to administer amphotericin B in patients, the alternative use of new triazoles, posaconazole and isavuconazole, may be beneficial (124A).

 

Toe Web Findings

 

Lastly, abnormal toe web findings (e.g., maceration, scale, or erythema) may be an early marker of irregularities in glucose metabolism and of undiagnosed diabetes mellitus (125). Additionally, such findings may be a sign of epidermal barrier disruption, a precursor of infection (125).

 

CUTANEOUS CHANGES ASSOCIATED WITH DIABETES MEDICATIONS

 

Insulin

 

A number of localized changes are associated with the subcutaneous injection of insulin. The most common local adverse effect is lipohypertrophy, which affects less than thirty percent of patients with diabetes that use insulin (126,127). Lipohypertrophy is characterized by localized adipocyte hypertrophy and presents with soft dermal nodules at injection sites. Continued injection of insulin at sites of lipohypertrophy can result in delayed systemic insulin absorption and capricious glycemic control. With avoidance of subcutaneous insulin at affected sites, lipohypertrophy normally improves over the course of a few months.

 

Furthermore, lipoatrophy is an uncommon cutaneous finding which occurred more frequently prior to the introduction of modern purified forms of insulin. Lipoatrophy presents at insulin injection sites over a period of months with round concave areas of adipose tissue atrophy. Allergic reactions to the injection of insulin may be immediate (within one hour) or delayed (within one day) and can present with localized or systemic symptoms. These reactions may be due to a type one hypersensitivity reaction to insulin or certain additives. However, allergic reactions to subcutaneous insulin are rare, with systemic allergic reactions occurring in only 0.01% of patients (126). Other cutaneous changes at areas of injection include the development of pruritus, induration, erythema, nodular amyloidosis, or calcification.

 

Oral Medications

 

Oral hypoglycemic agents may cause a number of different cutaneous adverse effects such as erythema multiforme or urticaria. DPP-4 inhibitors, such as vildagliptin, can be associated with inflamed blistering skin lesions, including bullous pemphigoid and Stevens-Johnson syndrome, as well as angioedema (128,129). Allergic skin and photosensitivity reactions may occur with sulfonylureas (130). The sulfonylureas, particularly the first-generation drugs chlorpropamide and tolbutamide, are associated with the development of a maculopapular rash during the initial two months of treatment; the rash quickly improves with stoppage of the medication (131,132). In certain patients with genetic predispositions, chlorpropamide may also cause acute facial flushing following alcohol consumption (133). SGLT-2 inhibitors have been associated with an increased risk of genital fungal infections and Fournier’s gangrene (134) (for details see Endotext chapter Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes) (135). Fixed drug eruptions, drug-induced pruritus, and Sweet syndrome/acute febrile neutrophilic dermatosis have also been observed in patients with type 2 diabetes using SGLT2 inhibitors, among other skin lesions (135A). 

 

Glucagon-like Peptide-1 Receptor Agonists

 

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, liraglutide, exenatide, and dulaglutide, are primarily used to manage type 2 diabetes and support weight loss. They can be administered via subcutaneous or oral routes. Dermatologists should be prepared to counsel patients about the possibility of rapid weight loss leading to facial fat loss; this can manifest as the “development of wrinkles, sunken eyes, a hollowed appearance, sagging jowls around the neck and jaw, and alterations in the cheeks, lips, and chin,” with effects also often noticed in the buttocks (135C). This phenomenon is thought to be due to a natural consequence of rapid weight loss combined with slow elastin turnover, rather than a direct effect of these drugs on adipocytes of the face or buttocks and may resolve with weight gain upon drug cessation (135B). While the common drug-related side effects of GLP-1 receptor agonists are gastrointestinal, there have been reports of dermatologic reactions, though these are relatively rare (136,137). Altered skin sensation (including dysesthesia, hyperesthesia, allodynia, and paresthesia) and alopecia were found to be significantly associated with a 50mg weekly dose of oral semaglutide, though the mechanisms and risk factors for these events remain to be characterized (136). Among the few case reports of severe cutaneous adverse events in patients taking GLP-1 agonists, exenatide was the most mentioned drug (136,137). Cases included angioedema, bullous pemphigoid, dermal hypersensitivity, eosinophilic fasciitis, and leukocytoclastic vasculitis, with >90% recovering within days to months of discontinuing the drug (136,137). Despite the side effects, GLP-1 agonists have been used off label in several cases to effectively manage diabetes-associated cutaneous conditions including psoriasis, hidradenitis suppurativa, and acanthosis nigricans (138).

 

Diabetes Devices

 

Continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusions (CSIIs) are devices used in the treatment of type 1 diabetes. Contact dermatitis is associated with both CGMs and CSIIs, while CSIIs inject insulin subcutaneously and thus carry the risk of insulin-associated skin changes (139).

 

CONCLUSION

 

Diabetes mellitus is associated with a broad array of dermatologic conditions (Table 1). Many of the sources describing dermatologic changes associated with diabetes mellitus are antiquated; larger research studies utilizing modern analytic tools are needed to better understand the underlying pathophysiology and treatment efficacy. Although each condition may respond to a variety of specific treatments, many will improve with improved glycemic control. Hence, patient education and lifestyle changes are key in improving the health and quality of life of patients with diabetes mellitus.

 

Table 1. Frequent Skin Manifestations of Diabetes Mellitus

DISEASE

APPEARANCE

COMMON

LOCATIONS

SYMPTOMS

TREATMENT

Acanthosis Nigricans

Multiple poorly- demarcated plaques with grey to dark-brown hyperpigmentation, and a thickened velvety to verrucoustexture

Back of the neck, axilla, elbows, palmar hands, inframammary creases, umbilicus, groin

Typically, asymptomatic

Improved glycemic control, oral retinoids, ammonium lactate, retinoic acid, salicylic acid

Diabetic Dermopathy

Rounded, dull, red papules that progressively

evolve over one- to-two weeks into well-circumscribed, atrophic, brown macules with a fine scale; lesions present in different stages ofevolution at the sametime

Pretibial area, lateral malleoli, thighs

Typically, asymptomatic

Self-resolving

Diabetic Foot Syndrome

Chronic ulcers, secondary infection,diabetic neuro- osteoarthropathy, clawing deformity

Feet

Typically, asymptomatic but may have abnormal gait

Interdisciplinary team-based approach involving daily surveillance, appropriate foot hygiene, proper footwear/walker, wound care,antibiotics, wound debridement, surgery

Scleroderma- like Skin Changes

Slowly developing painless, indurated, occasionally waxy appearing, thickened skin

Acral areas: dorsum of the fingers, proximal interphalangeal areas, metacarpophalangeal joints

Typically, asymptomatic but may have reduced range of motion

Improved glycemic control, aldose reductase inhibitors, physical therapy

Ichthyosiform Skin Changes

Large bilateral areas of dryness andscaling (may be described as “fishscale” skin)

Anterior shins, hands, feet

Typically, asymptomatic

Emollients, Keratolytics

Xerosis

Abnormally dry skinthat may also present with

scaling or fissures

Most common on thefeet

Typically, asymptomatic

Emollients

Pruritus

Normal or excoriatedskin

Often localized to the scalp, ankles, feet, trunk, or genitalia; however, it may be generalized

Pruritus

Topical capsaicin,topical ketamine-

amitriptyline-lidocaine, oral anticonvulsants, antifungals

 

REFERENCES

 

  1. Meurer M, Stumvoll M, Szeimies R-M. Hautveränderungen bei Diabetes mellitus. Der Hautarzt 2004;55(5):428-35
  2. Stuart CA, Gilkison CR, Smith MM, Bosma AM, Keenan BS, Nagamani M. Acanthosis nigricans as a risk factor for non-insulin dependent diabetes mellitus. Clinical Pediatrics 1998;37(2):73-79
  3. Stuart CA, Driscoll MS, Lundquist KF, Gilkison CR, Shaheb S, Smith MM. Acanthosis nigricans. Journal of basic and clinical physiology and pharmacology 1998;9(2-4):407-18
  4. Yeh JS, Munn SE, Plunkett TA, Harper PG, Hopster DJ, du Vivier AW. Coexistence of acanthosis nigricans and the sign of Leser-Trelat in a patient with gastric adenocarcinoma: a case report and literature review. Journal of the American Academy of Dermatology 2000;42(2):357-62

4A.    Kondo Y, Umegaki N, Terao M, Murota H, Kimura T, Katayama I. A case of generalized acanthosis nigricans with positive lupus erythematosus-related autoantibodies and antimicrosomal antibody: autoimmune acanthosis nigricans? Case Rep Dermatol. 2012 Jan;4(1):85-91.

4B.    Yu Q, Li XL, Ji G, Wang Y, Gong Y, Xu H, Shi YL. Malignant acanthosis nigricans: an early diagnostic clue for gastric adenocarcinoma. World J Surg Oncol. 2017 Nov 25;15(1):208.

4C.    Stals H, Vercammen C, Peeters C, Morren MA. Acanthosis nigricans caused by nicotinic acid: case report and review of the literature. Dermatology. 1994;189(2):203-6

4D.    Mellor-Pita S, Yebra-Bango M, Alfaro-Martínez J, Suárez E. Acanthosis nigricans: a new manifestation of insulin resistance in patients receiving treatment with protease inhibitors. Clin Infect Dis. 2002 Mar 01;34(5):716-7.

4E.    Fleming MG, Simon SI. Cutaneous insulin reaction resembling acanthosis nigricans. Arch Dermatol. 1986 Sep;122(9):1054-6.

4F.    Fukuchi K, Tatsuno K, Matsushita K, Kubo A, Ito T, Tokura Y. Familial acanthosis nigricans with p.K650T FGFR3 mutation. J Dermatol. 2018 Feb;45(2):207-210.

  1. Bhagyanathan M, Dhayanithy D, Parambath VA, Bijayraj R. Acanthosis nigricans: A screening test for insulin resistance–An important risk factor for diabetes mellitus type-2. Journal of family medicine and primary care 2017;6(1):43
  2. Hermanns-Lê T, Scheen A, Piérard GE. Acanthosis nigricans associated with insulin resistance. American journal of clinical dermatology 2004;5(3):199-203

6A.    Das A, Datta D, Kassir M, et al. Acanthosis nigricans: A review. J Cosmet Dermatol. 2020;19(8):1857-1865. doi:10.1111/jocd.13544

  1. Higgins SP, Freemark M, Prose NS. Acanthosis nigricans: a practical approach to evaluation and management. Dermatology online journal 2008;14(9)

7A.    Malisiewicz B, Boehncke S, Lang V, Boehncke WH, Buerger C. Epidermal insulin resistance as a therapeutic target in acanthosis nigricans?. Acta Derm Venereol. 2014;94(5):607-608. doi:10.2340/00015555-1778

  1. Blobstein SH. Topical therapy with tretinoin and ammonium lactate for acanthosis nigricans associated with obesity. Cutis 2003;71(1):33-34
  2. Ehsani A, Noormohammadpour P, Goodarzi A, et al. Comparison of long-pulsed alexandrite laser and topical tretinoin-ammonium lactate in axillary acanthosis nigricans: A case series of patients in a before-after trial. Caspian journal of internal medicine 2016;7(4):290
  3. Sinha S, Schwartz RA. Juvenile acanthosis nigricans. Journal of the American Academy of Dermatology 2007;57(3):502-08

10A.  Walling HW, Messingham M, Myers LM, Mason CL, Strauss JS. Improvement of acanthosis nigricans on isotretinoin and metformin. J Drugs Dermatol. 2003 Dec;2(6):677-81. PMID: 14711151.

  1. Bustan RS, Wasim D, Yderstræde KB, Bygum A. Specific skin signs as a cutaneous marker of diabetes mellitus and the prediabetic state-a systematic review. Danish medical journal 2017;64(1)
  2. Morgan AJ, Schwartz RA. Diabetic dermopathy: A subtle sign with grave implications. Journal of the American Academy of Dermatology 2008;58(3):447-51

12A.  Naik PP, Farrukh SN. Clinical Significance of Diabetic Dermatopathy. Diabetes Metab Syndr Obes. 2020;13:4823-4827. Published 2020 Dec 8. doi:10.2147/DMSO.S286887

  1. Romano G, Moretti G, Di Benedetto A, et al. Skin lesions in diabetes mellitus: prevalence and clinical correlations. Diabetes research and clinical practice 1998;39(2):101-06
  2. Huntley AC. The cutaneous manifestations of diabetes mellitus. Journal of the American Academy of Dermatology 1982;7(4):427-55
  3. Houck GM, Morgan MB. A reappraisal of the histologic findings of pigmented pretibial patches of diabetes mellitus. Journal of cutaneous pathology 2004;31(2):141-44
  4. McCASH S, Emanuel PO. Defining diabetic dermopathy. The Journal of dermatology 2011;38(10):988-92
  5. Kaňková K, Záhejský J, Márová I, et al. Polymorphisms in the RAGE gene influence susceptibility to diabetes- associated microvascular dermatoses in NIDDM. Journal of Diabetes and its Complications 2001;15(4):185-92
  6. Kiziltan M, Benbir G. Clinical and nerve conduction studies in female patients with diabetic dermopathy. Acta diabetologica 2008;45(2):97-105

18A.  Naik PP, Farrukh SN. Clinical Significance of Diabetic Dermatopathy. Diabetes Metab Syndr Obes. 2020;13:4823-4827. Published 2020 Dec 8. doi:10.2147/DMSO.S286887

  1. Amin N, Doupis J. Diabetic foot disease: from the evaluation of the “foot at risk” to the novel diabetic ulcer treatment modalities. World journal of diabetes 2016;7(7):153
  2. Sämann A, Tajiyeva O, Müller N, et al. Prevalence of the diabetic foot syndrome at the primary care level in Germany: a cross‐sectional study. Diabetic Medicine 2008;25(5):557-63

20A.  Boulton AJM, Whitehouse RW. The Diabetic Foot. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2023

  1. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. Jama 2005;293(2):217-28
  2. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. The Lancet 2005;366(9498):1719-24
  3. Mlinarić-Missoni E, Kalenić S, Važić-Babić V. Species distribution and frequency of isolation of yeasts and dermatophytes from toe webs of diabetic patients. Acta dermatovenerologica Croatica 2005;13(2):0-0
  4. Davis MD, O'fallon WM, Rogers III RS, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Archives of Dermatology 2000;136(3):330-36
  5. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. The lancet 2003;361(9368):1545-51
  6. Lobmann R, Schultz G, Lehnert H. Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes care 2005;28(2):461-71
  7. Volmer-Thole M, Lobmann R. Neuropathy and diabetic foot syndrome. International journal of molecular sciences 2016;17(6):917
  8. Sandireddy R, Yerra VG, Areti A, Komirishetty P, Kumar A. Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets. International journal of endocrinology 2014;2014

28A.  Theocharidis G, Thomas BE, Sarkar D, Mumme HL, Pilcher WJR, Dwivedi B, Sandoval-Schaefer T, Sîrbulescu RF, Kafanas A, Mezghani I, Wang P, Lobao A, Vlachos IS, Dash B, Hsia HC, Horsley V, Bhasin SS, Veves A, Bhasin M. Single cell transcriptomic landscape of diabetic foot ulcers. Nat Commun. 2022 Jan 10;13(1):181. doi: 10.1038/s41467-021-27801-8. PMID: 35013299; PMCID: PMC8748704.

  1. Vinik AI, Erbas T. Recognizing and treating diabetic autonomic neuropathy. Cleve Clin J Med 2001;68(11):928- 30, 32, 34-44
  2. Peripheral Arterial Disease in People With Diabetes. Diabetes Care 2003;26(12):3333-4

30A.  Lanting SM, Chan TL, Casey SL, Peterson BJ, Chuter VH. Cutaneous microvascular reactivity in Charcot neuroarthropathy: a systematic review and meta-analysis. J Foot Ankle Res. 2022 Mar 1;15(1):17. doi: 10.1186/s13047-022-00522-x. PMID: 35232466; PMCID: PMC8886937.

  1. Khanna S, Biswas S, Shang Y, et al. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PloS one 2010;5(3):e9539
  2. Ahn C, Yosipovitch G, Huang W. Diabetes and the Skin. In: Callen J, Jorizzo J, Zone J, Piette W, Rosenbach M, Vleugels RA, eds. Dermatological Signs of Systemic Disease. Edinburgh: Elsevier, 2017:205-14.
  3. Yosipovitch G, Hodak E, Vardi P, et al. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Diabetes care 1998;21(4):506-09
  4. Brik R, Berant M, Vardi P. The scleroderma‐like syndrome of insulin‐dependent diabetes mellitus. Diabetes/Metabolism Research and Reviews 1991;7(2):121-28
  5. Yosipovitch G, Yosipovitch Z, Karp M, Mukamel M. Trigger finger in young patients with insulin dependent diabetes. The Journal of rheumatology 1990;17(7):951-52
  6. Kim RP, Edelman SV, Kim DD. Musculoskeletal complications of diabetes mellitus. Clinical Diabetes 2001;19(3):132-35
  7. Haustein UF. Scleroderma‐like lesions in insulin‐ dependent diabetes mellitus. Journal of the European Academy of Dermatology and Venereology 1999;13(1):50- 53
  8. Yosipovitch G, Loh KC, Hock OB. Medical pearl: Scleroderma-like skin changes in patients with diabetes mellitus. Journal of the American Academy of Dermatology 2003;49(1):109-11
  9. Rho YW, Suhr KB, Lee JH, Park JK. A clinical observation of scleredema adultorum and its relationship to diabetes. The Journal of dermatology 1998;25(2):103-07
  10. Sawatkar G, Kanwar A, Dogra S, Bhadada S, Dayal D. Spectrum of cutaneous manifestations of type 1 diabetes mellitus in 500 south Asian patients. British Journal of Dermatology 2014;171(6):1402-06
  11. Gerrits EG, Landman GW, Nijenhuis-Rosien L, Bilo HJ. Limited joint mobility syndrome in diabetes mellitus: A minireview. World journal of diabetes 2015;6(9):1108
  12. Fitzgibbons PG, Weiss A-PC. Hand manifestations of diabetes mellitus. The Journal of hand surgery 2008;33(5):771-75
  13. Abate M, Schiavone C, Pelotti P, Salini V. Limited joint mobility in diabetes and ageing: recent advances in pathogenesis and therapy: SAGE Publications Sage UK: London, England, 2010.
  14. Frost D, Beischer W. Limited joint mobility in type 1 diabetic patients. Diabetes care 2001;24(1):95-99
  15. Lopez-Martin I, Benito Ortiz L, Rodriguez-Borlado B, Cano Langreo M, Garcia-Martinez FJ, Martin Rodriguez MF. (Association between limited joint mobility syndrome and risk of accidental falls in diabetic patients). Semergen 2015;41(2):70-5
  16. Lindsay JR, Kennedy L, Atkinson AB, et al. Reduced prevalence of limited joint mobility in type 1 diabetes in a UK clinic population over a 20-year period. Diabetes Care 2005;28(3):658-61
  17. Rongioletti F, Kaiser F, Cinotti E, et al. Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients. Journal of the European Academy of Dermatology and Venereology 2015;29(12):2399-404

47A.  Hines A, Alavi A, Davis MDP. Cutaneous Manifestations of Diabetes. Med Clin North Am. 2021;105(4):681-697. doi:10.1016/j.mcna.2021.04.008

  1. Cole GW, Headley J, Skowsky R. Scleredema Diabeticorum: A Common and Distinct Cutaneous Manifestation of Diabetes Mellitus. Diabetes Care 1983;6(2):189-92.
  2. Carrington PR, Sanusi I, Winder PR, Turk LL, Jones C, Millikan LE. Scleredema adultorum. International journal of dermatology 1984;23(8):514-22
  3. Martin C, Requena L, Manrique K, Manzarbeitia F, Rovira A. Scleredema diabeticorum in a patient with type 2 diabetes mellitus. Case reports in endocrinology 2011;2011
  4. Varga J, Gotta S, Li L, Sollberg S, Leonardo M. Scleredema adultorum: case report and demonstration of abnormal expression of extracellular matrix genes in skin fibroblasts in vivo and in vitro. British Journal of Dermatology 1995;132(6):992-99

51A.  Knobler R, Geroldinger-Simić M, Kreuter A, et al. Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema. J Eur Acad Dermatol Venereol. 2024;38(7):1281-1299. doi:10.1111/jdv.19937

  1. Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clinical Reviews in Allergy & Immunology 2017:1-31
  2. Bray SM, Varghese S, English JC. Ultrasonic massage and physical therapy for scleredema: improving activities of daily living. Archives of dermatology 2010;146(4):453-54
  3. Reid SD, Ladizinski B, Lee K, Baibergenova A, Alavi A. Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. Journal of the American Academy of Dermatology 2013;69(5):783-91
  4. O’toole E, Kennedy U, Nolan J, Young M, Rogers S, Barnes L. Necrobiosis lipoidica: only a minority of patients have diabetes mellitus. Br J Dermatol 1999;140(2):283-6
  5. Muller SA, Winkelmann R. Necrobiosis lipoidica diabeticorum: a clinical and pathological investigation of 171 cases. Archives of dermatology 1966;93(3):272-81

56A.  Severson KJ, Patel MH, Brumfiel CM, Breen I, Butterfield RJ, Nelson SA, Sekulic A, Pittelkow MR, Mangold AR. Comorbidities and diabetic complications in patients with necrobiosis lipoidica. J Am Acad Dermatol. 2022 Apr;86(4):891-894. doi: 10.1016/j.jaad.2021.03.026. Epub 2021 Mar 17. PMID: 33722550.

  1. Kota SK, Jammula S, Kota SK, Meher LK, Modi KD. Necrobiosis lipoidica diabeticorum: A case-based review of literature. Indian journal of endocrinology and metabolism 2012;16(4):614
  2. Lopez PR, Leicht S, Sigmon JR, Stigall L. Bullosis diabeticorum associated with a prediabetic state. Southern medical journal 2009;102(6):643-44

58A.  Chouk C, Litaiem N. Bullosis Diabeticorum. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 10, 2024.

  1. Larsen K, Jensen T, Karlsmark T, Holstein PE. Incidence of bullosis diabeticorum–a controversial cause of chronic foot ulceration. International wound journal 2008;5(4):591- 96
  2. Lipsky BA, Baker PD, Ahroni JH. Diabetic bullae: 12 cases of a purportedly rare cutaneous disorder. International journal of dermatology 2000;39(3):196-200
  3. Patel N, Spencer LA, English JC, Zirwas MJ. Acquired ichthyosis. Journal of the American Academy of Dermatology 2006;55(4):647-56
  4. Pavlović MD, Milenković T, Dinić M, et al. The prevalence of cutaneous manifestations in young patients with type 1 diabetes. Diabetes care 2007;30(8):1964-67
  5. Goyal A, Raina S, Kaushal SS, Mahajan V, Sharma NL. Pattern of cutaneous manifestations in diabetes mellitus. Indian journal of dermatology 2010;55(1):39

63A.  Iacopi E, Riitano N, Dini V, Berta R, Pieruzzi L, Janowska A, Anselmino M, Piaggesi A, Romanelli M. Using Skin Bioengineering to Highlight How Weight and Diabetes Mellitus Modify the Skin in the Lower Limbs of Super- Obese Patients. Diabetes Metab Syndr Obes. 2020 Mar 16;13:729-738.  doi:  10.2147/DMSO.S229042.  PMID: 32214836; PMCID: PMC7083633.

  1. Pavicic T, Korting HC. Xerosis and callus formation as a key to the diabetic foot syndrome: dermatologic view of the problem and its management. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2006;4(11):935-41
  2. Saray Y, Seçkin D, Bilezikçi B. Acquired perforating dermatosis: clinicopathological features in twenty‐two cases. Journal of the European Academy of Dermatology and Venereology 2006;20(6):679-88
  3. Karpouzis A, Giatromanolaki A, Sivridis E, Kouskoukis C. Acquired reactive perforating collagenosis: current status. The Journal of dermatology 2010;37(7):585-92
  4. Poliak SC, Lebwohl MG, Parris A, Prioleau PG. Reactive perforating collagenosis associated with diabetes mellitus. New England Journal of Medicine 1982;306(2):81-84
  5. Abdelbaqi‐Salhab M, Shalhub S, Morgan MB. A current review of the cutaneous manifestations of renal disease. Journal of cutaneous pathology 2003;30(9):527-38
  6. Robles-Mendez J, Vazquez-Martinez O, Ocampo-Candiani J. Skin manifestations of chronic kidney disease. Actas Dermo-Sifiliográficas 2015;106(8):609-22
  7. Morton C, Henderson I, Jones M, Lowe J. Acquired perforating dermatosis in a British dialysis population. British Journal of Dermatology 1996;135(5):671-77

70A.  Forouzandeh M, Stratman S, Yosipovitch G. The treatment of Kyrle's disease: a systematic review. J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1457-1463. doi: 10.1111/jdv.16182. Epub 2020 Feb 5. PMID: 31919924.

  1. Van Hattem S, Bootsma AH, Thio HB. Skin manifestations of diabetes. Cleve Clin J Med 2008;75(11):772-74
  2. Wagner G, Sachse MM. Acquired reactive perforating dermatosis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2013;11(8):723-29 doi: 10.1111/ddg.12131(published Online First: Epub Date)|.

72A.  Ying Y, Shuang C, Zhen-Ying Z. Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD. Immun Inflamm Dis. 2022 Mar;10(3):e574. doi: 10.1002/iid3.574. Epub 2021 Dec 24. PMID: 34953055; PMCID: PMC8926492.

  1. Sugandhan S, Khandpur S, Sharma VK. Familial chylomicronemia syndrome. Pediatric dermatology 2007;24(3):323-25
  2. Mahajan S, Koranne R, Sharma S. Cutaneous manifestation of diabetes melitus. Indian Journal of Dermatology, Venereology, and Leprology 2003;69(2):105
  3. Ahmed K, Muhammad Z, Qayum I. Prevalence of cutaneous manifestations of diabetes mellitus. J Ayub Med Coll Abbottabad 2009;21(2):76-9
  4. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia 2015;58(5):886-99

76A.  Feingold KR. Dyslipidemia in Patients with Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2023

  1. Naik NS. Eruptive xanthomas. Dermatology online journal 2001;7(2)
  2. Zaremba J, Zaczkiewicz A, Placek W. Eruptive xanthomas. Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii 2013;30(6):399
  3. Parker F. Xanthomas and hyperlipidemias. Journal of the American Academy of Dermatology 1985;13(1):1-30
  4. Ales Z, Zeman M, Slaby A, Vecka M. Xanthomas: clinical and pathophysiological relations. Biomedical Papers 2014;158(2):181-88

80A.  Feingold KR. Triglyceride Lowering Drugs. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2024

  1. Margolis J. Letter: Skin tags in diabetes mellitus. N Engl J Med 1976;295:172-3
  2. Levy L, Zeichner JA. Dermatologic manifestation of diabetes. Journal of diabetes 2012;4(1):68-76
  3. Yamaoka H, Sasaki H, Yamasaki H, et al. Truncal pruritus of unknown origin may be a symptom of diabetic polyneuropathy. Diabetes care 2010;33(1):150-55
  4. Valdes-Rodriguez R, Mollanazar NK, González-Muro J, et al. Itch prevalence and characteristics in a Hispanic geriatric population: a comprehensive study using a standardized itch questionnaire. Acta dermato- venereologica 2015;95(4):417-21

84A. Ju T, Does AV, G. Yosipovitch. Scalp dysesthesia: a neuropathic phenomenon. Journal of the European Academy of Dermatology and Venereology. 2022;36(6):790-796. doi:https://doi.org/10.1111/jdv.17985

84B.  Parisi TJ, Mandrekar J, Dyck PJB, Klein CJ. Meralgia paresthetica: Relation to obesity, advanced age, and diabetes mellitus. Neurology. 2011;77(16):1538-1542. doi:https://doi.org/10.1212/wnl.0b013e318233b356

84C.  Yang QP, Chen YY, Li Z, Xu M. Major Risk Factors Analysis of Pruritus Complicated by Type 2 Diabetes Mellitus and the Effect of Comprehensive Nursing Intervention. Front Surg. 2022 Feb 15;9:842884. doi: 10.3389/fsurg.2022.842884. PMID: 35242808; PMCID: PMC8887712.

84D.  Merdin FA, Aydemir AT, Korkmaz FN, et al. Evaluation of chronic pruritus and associated skin findings in patients with diabetes mellitus. Turkish Journal of Medical Sciences. 2023;53(5):1489-1497. doi:https://doi.org/10.55730/1300-0144.5716

84E.  Yang QP, Chen YY, Li Z, Xu M. Major Risk Factors Analysis of Pruritus Complicated by Type 2 Diabetes Mellitus and the Effect of Comprehensive Nursing Intervention. Front Surg. 2022 Feb 15;9:842884. doi: 10.3389/fsurg.2022.842884. PMID: 35242808; PMCID: PMC8887712.

  1. Guarneri C, Guarneri F, Borgia F, Vaccaro M. Finger pebbles in a diabetic patient: Huntley's papules. International journal of dermatology 2005;44(9):755-56
  2. Tabor CA, Parlette EC. Cutaneous manifestations of diabetes: signs of poor glycemic control or new-onset disease. Postgraduate medicine 2006;119(3):38-44
  3. Murphy-Chutorian B, Han G, Cohen SR. Dermatologic manifestations of diabetes mellitus. Endocrinology and Metabolism Clinics 2013;42(4):869-98
  4. Liau M, Long V, Yang S, Tan K, Aw D. Pigmented purpuric dermatosis  in  Singapore:  a  clinic-epidemiological characterisation. Hong Kong Journal of Dermatology & Venereology 2016;24(2):65-69
  5. Lithner F. Purpura, pigmentation and yellow nails of the lower extremities in diabetics. Journal of Internal Medicine 1976;199(1‐6):203-08
  6. Demirseren DD, Emre S, Akoglu G, et al. Relationship between skin diseases and extracutaneous complications of diabetes mellitus: clinical analysis of 750 patients. American journal of clinical dermatology 2014;15(1):65-70
  7. Serrao R, Zirwas M, English JC. Palmar erythema. American journal of clinical dermatology 2007;8(6):347-56
  8. Landau J, Davis E. The small blood-vessels of the conjunctiva and nailbed in diabetes mellitus. The Lancet 1960;276(7153):731-34
  9. Oumeish OY. Skin disorders in patients with diabetes. Clinics in dermatology 2008;26(3):235-42
  10. Duff M, Demidova O, Blackburn S, Shubrook J. Cutaneous manifestations of diabetes mellitus. Clinical Diabetes 2015;33(1):40-48
  11. Bristow I. Non‐ulcerative skin pathologies of the diabetic foot. Diabetes/metabolism research and reviews 2008;24(S1)

95A.  Yesudian PD, Nwabudike LC, de Berker D. Nail changes in diabetes. Clin Exp Dermatol. 2022 Jan;47(1):9-15. doi: 10.1111/ced.14859. Epub 2021 Sep 21. PMID: 34293827.

  1. Mendes AL, Miot HA, Haddad Junior V. Diabetes mellitus and the skin. Anais brasileiros de dermatologia 2017;92(1):8-20
  2. Yun JH, Lee JY, Kim MK, et al. Clinical and pathological features of generalized granuloma annulare with their correlation: a retrospective multicenter study in Korea. Annals of dermatology 2009;21(2):113-19

97A.  Joshi TP, Duvic M. Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options. Am J Clin Dermatol. 2022;23(1):37-50. doi:10.1007/s40257-021-00636-1

  1. Cyr PR. Diagnosis and management of granuloma annulare. American family physician 2006;74(10)
  2. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: A systematic review and meta-analysis. JAMA Dermatology 2013;149(1):84-91
  3. Seyhan M, Özcan H, Sahin I, Bayram N, Karincaoğlu Y. High prevalence of glucose metabolism disturbance in patients with lichen planus. Diabetes research and clinical practice 2007;77(2):198-202
  4. Guggenheimer J, Moore PA, Rossie K, et al. Insulin- dependent diabetes mellitus and oral soft tissue pathologies: I. Prevalence and characteristics of non- candidal lesions. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2000;89(5):563-69
  5. Van den Driessche A, Eenkhoorn V, Van Gaal L, De Block C. Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. Neth J Med 2009;67(11):376- 87

102A. Sperling MA, Angelousi A, Yau M. Autoimmune Polyglandular Syndromes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2024

  1. Von der Werth J, Williams H. The natural history of hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology 2000;14(5):389-92

103A. Jenkins T, Isaac J, Edwards A, Okoye GA. Hidradenitis Suppurativa. Dermatol Clin. 2023;41(3):471-479. doi:10.1016/j.det.2023.02.001

  1. Bui T-L, Silva-Hirschberg C, Torres J, Armstrong AW. Hidradenitissuppurativa  and  diabetes  mellitus: A systematic review and meta-analysis. Journal of the American Academy of Dermatology 2017
  2. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. Journal of the American Academy of Dermatology 2009;60(4):539-61
  3. Eldor R, Glaser B, Fraenkel M, Doviner V, Salmon A, Gross DJ. Glucagonoma and the glucagonoma syndrome–cumulative experience with an elusive endocrine tumour. Clinical endocrinology 2011;74(5):593-98
  4. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The Glucagonoma Syndrome Clinical and Pathologic Features in 21 Patients. Medicine 1996;75(2):53-63
  5. Kovács RK, Korom I, Dobozy A, Farkas G, Ormos J, Kemény L. Necrolytic migratory erythema. Journal of cutaneous pathology 2006;33(3):242-45
  6. Kindmark H, Sundin A, Granberg D, et al. Endocrine pancreatictumors  with  glucagon  hypersecretion:  a retrospective study of 23 cases during 20 years. Medical Oncology 2007;24(3):330-37
  7. Halvorson SA, Gilbert E, Hopkins RS, et al. Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. Journal of general internal medicine 2013;28(11):1525-29

110A de Herder WW, Hofland J. Glucagon & Glucagonoma Syndrome. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2023

110B. Tønder JE, Bønnelykke-Behrndtz ML, Laurberg T, Røssell EL, Sollie M. Melanoma risk, tumour stage, and melanoma-specific mortality in individuals with diabetes: a systematic review and meta-analysis. BMC Cancer. 2024;24(1). doi:https://doi.org/10.1186/s12885-024-12598-8

110C. Kaneko A, Hisashi Kanemaru, Satoru Mizuhashi, et al. Relationship between Type 2 diabetes mellitus and aggressiveness of melanoma. Journal of Dermatological Science. 2022;106(1):65-67. doi:https://doi.org/10.1016/j.jdermsci.2022.03.006

  1. Macedo GMC, Nunes S, Barreto T. Skin disorders in diabetes mellitus: an epidemiology and physiopathology review. Diabetology & metabolic syndrome 2016;8(1):63

111A. Polk C, Sampson MM, Roshdy D, Davidson LE. Skin and Soft Tissue Infections in Patients with Diabetes Mellitus. Infect Dis Clin North Am. 2021 Mar;35(1):183-197. doi: 10.1016/j.idc.2020.10.007. Epub 2020 Dec 7. PMID: 33303332.

  1. Kutlu SS, Cevahir N, Akalin S, et al. Prevalence and risk factors for methicillin-resistant Staphylococcus aureus colonizationin  a  diabetic  outpatient  population:  a prospective cohort study. American journal of infection control 2012;40(4):365-68
  2. Hartemann‐Heurtier A, Robert J, Jacqueminet S, et al. Diabetic foot ulcer and multidrug‐resistant organisms: risk factors and impact. Diabetic Medicine 2004;21(7):710-15
  3. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian journal of endocrinology and metabolism 2012;16(Suppl1):S27
  4. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007;67(3):351-68
  5. Bonne SL, Kadri SS. Evaluation and management of necrotizing soft tissue infections. Infectious Disease Clinics 2017;31(3):497-511
  6. Dworkin M, Westercamp M, Park L, McIntyre A. The epidemiology of necrotizing fasciitis including factors associated with death and amputation. Epidemiology & Infection 2009;137(11):1609-14
  7. Bhandary S, Karki P, Sinha B. Malignant otitis externa: a review. Pacific health dialog 2002;9(1):64-67
  8. Sashikumar R, Kannan R. Salivary glucose levels and oral candidal carriage in type II diabetics. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2010;109(5):706-11
  9. Yosipovitch G, Tur E, Cohen O, Rusecki Y. Skin surface pH in intertriginous areas in NIDDM patients: possible correlation to candidal intertrigo. Diabetes Care 1993;16(4):560-63
  10. SaunteDML, Holgersen  JB, Hædersdal M, et al. Prevalence of toe nail onychomycosis in diabetic patients. Acta dermato-venereologica 2006;86(5):425-28
  11. Alteras I, Saryt E. Prevalence of pathogenic fungi in the toe-webs and toe-nails of diabetic patients. Mycopathologia 1979;67(3):157-59
  12. Romano C, Massai L, Asta F, Signorini A. Prevalence of dermatophytic skin and nail infections in diabetic patients. Mycoses 2001;44(3‐4):83-86
  13. Rich P. Onychomycosis and tinea pedis in patients with diabetes. Journal of the American Academy of Dermatology 2000;43(5):S130-S34

124A. Sharma A, Goel A. Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiol (Praha). 2022 Feb 26:1–25. doi: 10.1007/s12223-021-00934-5. Epub ahead of print. PMID: 35220559; PMCID: PMC8881997.

  1. Sinikumpu S-P, Auvinen J, Jokelainen J, et al. Abnormal skin in toe webs is a marker for abnormal glucose metabolism. A cross-sectional survey among 1,849 adults in Finland. Scientific reports 2017;7:9125
  2. Richardson T, Kerr D. Skin-related complications of insulin therapy.American  journal of  clinical   dermatology 2003;4(10):661-67
  3. Lima AL, Illing T, Schliemann S, Elsner P. Cutaneous Manifestations of Diabetes Mellitus: A Review. American Journal of Clinical Dermatology 2017:1-13
  4. Attaway A, Mersfelder TL, Vaishnav S, Baker JK. Bullous pemphigoidassociated  with  dipeptidyl  peptidase  IV inhibitors. A case report and review of literature. Journal of dermatological case reports 2014;8(1):24
  5. Byrd JS, Minor DS, Elsayed R, Marshall GD. DPP-4 inhibitors and angioedema: a cause for concern? Annals of Allergy, Asthma & Immunology 2011;106(5):436-38
  6. Hitselberger JF, Fosnaugh RP. Photosensitivity due to chlorpropamide. JAMA 1962;180(1):62-63
  7. Walker G, Kinsell LW. Clinical experience with chlorpropamide. California medicine 1961;94(6):344
  8. Walker G, Slater J, Westlake E, Nabarro J. Clinical experience with tolbutamide. British medical journal 1957;2(5040):323
  9. Leslie R, Pyke D. Chlorpropamide-alcohol flushing: a dominantly inherited trait associated with diabetes. Br med J 1978;2(6151):1519-21
  10. Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current medical research and opinion 2014;30(6):1109-19
  11. Feingold KR. Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes. In: Feingold KR, Anawalt B, Boyce A, et al editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2024

135A. Mederle AL, Dumitrescu P, Borza C, Nilima Rajpal Kundnani. Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors. Journal of Clinical Medicine. 2024;14(1):188-188. doi:https://doi.org/10.3390/jcm14010188

135B. Carboni A, Woessner S, Martini O, Marroquin NA, Waller J. Natural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon. J Drugs Dermatol. 2024;23(1):1367-1368. doi:10.36849/JDD.7613

135C. Mansour MR, Hannawa OM, Yaldo MM, Nageeb EM, Chaiyasate K. The rise of "Ozempic Face": Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. J Plast Reconstr Aesthet Surg. 2024;96:225-227. doi:10.1016/j.bjps.2024.07.051‌

  1. Tran MM, Mirza FN, Lee AC, Goldbach HS, Libby TJ, Wisco OJ. Dermatologic findings associated with semaglutide use: A scoping review. Journal of the American Academy of Dermatology. 2024;91(1):166-168. doi:https://doi.org/10.1016/j.jaad.2024.03.021
  2. Salazar CE, Patil MK, Osaigbokan Aihie, Cruz N, Nambudiri VE. Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature. Archives of Dermatological Research. 2024;316(6). doi:https://doi.org/10.1007/s00403-024-02969-3
  3. Lal K, Herringshaw E. The Use of GLP-1 Agonists in the Management of Cutaneous Disease. J Clin Aesthet Dermatol. 2024;17(9):34-37.
  4. Podwojniak A, Flemming J, Tan IJ, Ghani H, Neubauer Z, Jones A. Cutaneous adverse effects from diabetes devices in pediatric patients with type 1 diabetes mellitus: Systematic review. JMIR Dermatology. 2024;7. doi:10.2196/59824

 

Atypical Forms of Diabetes

ABSTRACT

 

While most patients with diabetes have Type 1 diabetes (T1D) or Type 2 diabetes (T2D) there are other etiologies of diabetes that occur less frequently. In this chapter we will discuss a number of these less common causes of diabetes. It is clinically very important to recognize these uncommon causes of diabetes as treatment directed towards the underlying etiology can at times result in the remission of diabetes (for example Cushing’s Syndrome) or be required to avoid other complications of the underlying disorder (for example hemochromatosis, which in addition to causing diabetes can lead to severe liver disease and congestive heart failure). In this chapter the following disorders that are associated with diabetes are discussed: 1) genetic disorders of insulin action (Type A insulin resistance, Donohue Syndrome/Leprechaunism, Rabson-Mendenhall syndrome); 2) maternally inherited diabetes mellitus and deafness syndrome; 3) disorders of the exocrine pancreas (pancreatitis, trauma/pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis); 4) endocrinopathies (acromegaly, Cushing’s syndrome, glucagonoma, pheochromocytoma, hyperthyroidism, somatostatinoma, primary hyperaldosteronism); 5) drug induced; 6) infections; 7) immune mediated (stiff-man syndrome, anti-insulin receptor antibodies); 8) ketosis prone diabetes (Flatbush diabetes); and 9) genetic disorders sometimes associated with diabetes (Down syndrome, Klinefelter syndrome, Turner syndrome, Wilsons syndrome, Wolfram syndrome, Friedreich ataxia, Bardet-Biedl syndrome [Laurence-Moon-Biedl syndrome], myotonic dystrophy, Prader-Willi syndrome, Alström syndrome, and Werner syndrome). Gestational diabetes, monogenic diabetes (maturity onset diabetes of the young (MODY) and neonatal diabetes), lipodystrophy, fibrocalculous pancreatic disease, diabetes associated with HIV infection, diabetes due to the autoimmune polyglandular syndromes, and post-transplant diabetes are not discussed in this chapter as they are discussed in other Endotext chapters.

 

INTRODUCTION

 

While most patients with diabetes have Type 1 diabetes (T1D) or Type 2 diabetes (T2D) there are other etiologies of diabetes that occur less frequently. In this chapter we will discuss a number of these less common causes of diabetes (see table 1). Note that gestational diabetes, monogenic diabetes (maturity onset diabetes of the young (MODY) and neonatal diabetes), lipodystrophy, fibrocalculous pancreatic disease, malnutrition related diabetes (being written), diabetes associated with HIV infection, diabetes due to the autoimmune polyglandular syndromes, and post-transplant diabetes are discussed in separate Endotext chapters (1-7). It is clinically very important to recognize these uncommon causes of diabetes as treatment directed towards the underlying etiology can at times result in the remission of diabetes (for example Cushing’s Syndrome) or be required to avoid other complications of the underlying disorder (for example hemochromatosis, which in addition to causing diabetes can lead to severe liver disease and congestive heart failure). Additionally, recognizing the type of diabetes can allow for the appropriate treatment. For example, recognizing ketosis prone diabetes facilitates discontinuing insulin therapy.

 

Table 1. Non-Type 1 Non-T2D Classification       

Genetic defects of beta-cell development and function

MODY (common causes- GCK, HNF1A, HNF4A, HNF1B) 

Neonatal Diabetes (common causes- KCNJ11, ABCC8, INS, 6q24)

1.     Mitochondrial DNA

Genetic defects in insulin action

1.     Type A insulin resistance

2.     Donohue Syndrome (Leprechaunism)

3.     Rabson-Mendenhall syndrome

4.     Lipoatrophic diabetes

Diseases of the exocrine pancreas

1.     Pancreatitis

2.     Fibrocalculous pancreatic disease

3.     Trauma/pancreatectomy

4.     Neoplasia

5.     Cystic fibrosis

6.     Hemochromatosis (iron overload)

Thalassemia (iron overload)

Endocrinopathies

1.     Acromegaly

2.     Cushing’s syndrome

3.     Glucagonoma

4.     Pheochromocytoma

5.     Hyperthyroidism

6.     Somatostatinoma

7.     Primary hyperaldosteronism

Drug- or chemical-induced hyperglycemia

1.     Vacor

2.     Pentamidine

3.     Nicotinic acid

4.     Glucocorticoids

5.     Diazoxide

6.     Check point inhibitors

7.     Phenytoin (Dilantin)

8.     Interferon alpha

9.     Immune suppressants

10.  Others (statins, psychotropic drugs, b-Adrenergic agonists, thiazides, fluoroquinolones, beta-adrenergic drugs, teprotumumab, etc.)

Infections

1.     Congenital rubella

2.     Hepatitis C virus

3.     HIV

COVID-19

Immune-mediated diabetes

1.     Stiff-man syndrome

2.     Anti-insulin receptor antibodies

3.     Autoimmune polyglandular syndromes

Diabetes of unknown cause

1.     Ketosis-prone diabetes (Flatbush diabetes)

Other genetic syndromes sometimes associated with diabetes

1.     Down syndrome

2.     Klinefelter syndrome

3.     Turner syndrome

4.     Wilsons syndrome

5.     Wolfram syndrome

6.     Friedreich ataxia

7.     Bardet-Biedl syndrome (Laurence-Moon-Biedl syndrome)

8.     Myotonic dystrophy

9.     Prader-Willi syndrome

10.  Alström syndrome

 

MATERNALLY INHERITED DIABETES MELLITUS AND DEAFNESS (MIDD)

 

Maternally inherited diabetes mellitus and deafness (MIDD) is a mitochondrial disorder characterized by diabetes and progressive sensorineural hearing loss (8-10). Mitochondrial DNA is only transmitted from the mother as the sperm lacks mitochondrial DNA (8). Therefore, over 50% of affected individuals with MIDD have a mother with diabetes. A mother with this disorder transmits the mutation to almost all of her offspring (11). However, the proportion of somatic cells with the mutation can vary considerably, a condition called heteroplasmy (9). The higher the number of somatic cells with a mutation the greater is the penetrance of symptoms and disease severity. Additionally, the proportion of somatic cells with a mutation can vary from tissue to tissue and may explain the variability in the manifestations of this disorder (9). The prevalence of mitochondrial diabetes in the diabetes population depends on ethnic background and ranges between 0.2% and 2%, with the highest prevalence in Japan (11).

 

MIDD is associated with a point mutation in a transfer ribonucleic acid (tRNA) gene at position 3243 with an A to G transition (8-10). In addition to diabetes and auditory impairment, the m.3243A>G mutation can cause other clinical manifestations including central neurological and psychiatric disorders, eye disease, myopathy, cardiac disorders, renal disease, endocrine disease, and gastrointestinal disease (8,9). Other point mutations in mitochondrial DNA can also result in diabetes and deafness but these mutations are rare in comparison to m.3243A>G (8,9,11).

 

It is thought that defects in mitochondrial function result in the decreased production of ATP following glucose uptake by beta cells resulting in decreased insulin secretion in response to elevated glucose levels (8,9). Additionally, mitochondrial dysfunction in the highly metabolically active pancreatic islets ultimately results in the loss of B‐cell mass further compromising insulin secretion (9). Insulin sensitivity is usually normal (11). Other tissues that are metabolically active may also be adversely effected by the inability of the mitochondria to produce ATP including the cells in the cochlea (9).

 

The clinical syndrome of MIDD can phenotypically resemble either T1D or T2D (9,11). The age of onset varies between childhood and mid-adulthood. Approximately 20% of patients present acutely with high glucose levels and even ketoacidosis (9). Most patients do not have islet cell antibodies but they are present in a small number of patients (9). This could be due to concomitant T1D or to the development of antibodies secondary to beta cell destruction due to mitochondria dysfunction. Patients tend to be thin rather than obese (9). This disorder can be distinguished from MODY by the presence of multi-organ involvement, particularly sensorineural hearing loss, and maternal rather than autosomal dominant transmission. Initially patients may be treated with diet and/or oral agents but overtime most patients with MIDD progress to requiring insulin therapy (8,9,11).

 

As the name implies, this disorder is recognized by the presence of diabetes and deafness and a family history of these conditions in maternal relatives (9,11). Hearing loss is present in approximately 75% of patients and typically precedes the development of diabetes (9). Hearing loss is more common and severe in males (9). Approximately 10-15% of patients, in addition to having diabetes and deafness, also have the syndrome of mitochondrial encephalomyopathy, lactic acidosis, and stroke‐like episodes (9). The m.3243A>G mutation can cause a wide spectrum of abnormalities that include neurological abnormalities (strokes, dementia, seizures), psychiatric disorders including recurrent major depression, schizophrenia and a variety of phobias, macular retinal dystrophy with pigmentation, proximal myopathy, cardiomyopathy, renal failure, short stature, endocrine dysfunction, and gastrointestinal complaints (9). The finding of classical retinal dystrophy and hyperpigmentation on routine eye exam should suggest the diagnosis of maternally inherited diabetes mellitus and deafness. Once suspected the diagnosis of MIDD should be confirmed by genetic testing for the mitochondrial DNA point mutation at position 3243 (A>G). This is usually initially carried out on blood cells but if negative, urinary cells or skeletal muscle can be tested and if necessary one can test for other mutations that cause similar phenotypes (12). Once a diagnosis is confirmed first-degree family members at risk should be screened for the mutation and provided with genetic counseling. For those carrying the mutation without clinical manifestations, screening for diabetes and monitoring of kidney function, hearing, and cardiac function should be carried out.

 

GENETIC DEFECTS IN INSULIN ACTION

 

Overview of Insulin Receptor Defects

 

Mutations in the insulin receptor can cause different degrees of insulin resistance but do not need to be associated with diabetes per se (13). A large number of different mutations have been described and they can be classified as mutations that prevent synthesis of the receptor, inhibit transport of the receptor to the plasma membrane, decrease insulin binding to the receptor, impair transmembrane signaling, or increase receptor degradation (14). Pancreatic beta cell hyperplasia and hyperinsulinemia can compensate for the insulin resistance preventing hyperglycemia. Fasting hypoglycemia and postprandial hyperglycemia may be observed. Over time the beta cells’ ability to secrete insulin diminishes and frank diabetes usually develops. Treatment of the diabetes may require very high doses of insulin (15). Unfortunately, insulin sensitizers have not been very effective in patients with insulin receptor defects. In contrast to the typical patients with insulin resistance, obesity, dyslipidemia, hypertension, and fatty liver are not usually present (15,16). Acanthosis nigricans, pigmentation in the neck or axillae, is a visible sign of severe insulin resistance (13,15). In females, severe insulin resistance is usually associated with hyperandrogenism, oligomenorrhea or amenorrhea, anovulation, hirsutism, acne, and masculinization (13,15). It is hypothesized that ovarian dysfunction and acanthosis nigricans are due to high levels of insulin acting via the IGF1 receptors (16). The amount of residual insulin receptor function determines the specific syndrome in patients with insulin receptor mutations (Figure 1).

 

 

Type A Insulin Resistance

 

This autosomal dominant disorder includes patients with severe insulin resistance and acanthosis nigricans (13,15). Patients have normal growth and females show ovarian hyperandrogenism that typically presents in the peripubertal period (15). In females, hyperglycemia develops after ovarian hyperandrogenism and acanthosis nigricans. Males display only acanthosis nigricans and they often remain undiagnosed even after the development of symptomatic diabetes, which may not occur until the patients are adults. These patients have mutations in the insulin receptor gene that decreases the activity of the insulin receptor (14,15). In addition, mutations in transcription factors that stimulate the expression of insulin receptors can lead to a similar phenotype as mutations in the insulin receptor (13,16). Inherited defects in pathways downstream of the insulin receptor can also lead to clinical abnormalities similar to mutations in the insulin receptor (13,16).

 

Donohue Syndrome (Leprechaunism)

 

Donohue syndrome is a rare congenital (1:1,000,000), autosomal recessive syndrome characterized by very severe insulin resistance due to mutations in the insulin receptor gene, dysmorphic features such as protuberant and low-set ears, flaring nostrils and thick lips, growth retardation, failure to thrive, and early death (14). The name leprechaunism relates to the elfin features of those affected. Clinical features include in addition to acanthosis nigricans, hypertrichosis, hirsutism, dysmorphic facies, breast enlargement, abdominal distension, and lipoatrophy. Patients have extremely high levels of insulin and can develop impaired glucose tolerance or overt diabetes. The prognosis for infants with this condition is very poor and most will die in the first year of life. When parents, who are heterozygous for mutations in the insulin receptor are studied, many of these individuals are insulin resistant (14).

 

Rabson-Mendenhall Syndrome

 

The Rabson-Mendenhall syndrome represents another disorder of extreme insulin resistance (15). This autosomal recessive syndrome is associated with mutations in the insulin receptor gene (13). Initially fasting hypoglycemia, postprandial hyperglycemia, and marked hyperinsulinemia may be observed (13). When beta-cells decompensate, hyperglycemia may become very difficult to treat. Clinical features include in addition to acanthosis nigricans, phallic enlargement, precocious pseudopuberty, short stature, and abnormal teeth, hair, and nails (14,15). Hyperplasia of the pineal gland is an unusual feature (14). Prognosis is poor as diabetes is difficult to control even with high insulin doses (14). Hyperglycemia leads to microvascular disease and/or diabetic ketoacidosis resulting in death in the second and third decades of life (13). Leptin administration has resulted in an improvement in this syndrome (17,18).

 

DISEASES OF THE EXOCRINE PANCREAS

 

Diseases that destroy the pancreas can cause diabetes even in individuals who do not have risk factors for diabetes (19). In the medical literature this is often referred to as Type 3C diabetes. Acquired causes of damage to the pancreas include pancreatitis, trauma, infection, pancreatic carcinoma, and pancreatectomy. Inherited disorders that affect the endocrine pancreas, such as hemochromatosis, thalassemia, and cystic fibrosis, can also cause insulin deficiency and diabetes. The distribution of causes for diabetes secondary to pancreatic disorders in one study was chronic pancreatitis (79%), pancreatic ductal adenocarcinoma (8%), hemochromatosis (7%), cystic fibrosis (4%), and previous pancreatic surgery (2%) (20). The prevalence of diabetes secondary to pancreatic disease is estimated to range from 1% to 9% and likely will depend on the patient population studied (21). In a population study carried out in New Zealand the prevalence of diabetes secondary to pancreatic disorders was close to that of T1D (22).

 

Pancreatitis

 

Pancreatitis may lead to the destruction of the beta cells due to inflammation and irreversible fibrotic damage (23). In addition to destroying the beta cells, pancreatitis also leads to the destruction of glucagon secreting alpha-cells and pancreatic polypeptide secreting cells (23). The decrease in insulin secretion is the primary mechanism leading to hyperglycemia. In addition, the decrease in secretion of pancreatic polypeptide leads to a decrease in hepatic insulin sensitivity resulting in increased hepatic glucose production (21,23,24). Nutrient malabsorption that occurs secondary to pancreatitis leads to impaired incretin secretion that can result in diminished insulin release by the remaining beta-cells (25). Acute pancreatitis can induce transient hyperglycemia (stress hyperglycemia) that can last for several weeks or permanent hyperglycemia (21,26,27). The risk of developing diabetes after acute pancreatitis is increased after severe pancreatitis, hypertriglyceridemia or alcohol as the etiology of pancreatitis, and the occurrence of pancreatic necrosis (28). Other predictors of the development of diabetes include obesity, a family history of diabetes, exocrine pancreatic insufficiency, history of pancreatic surgery, pancreatic calcifications, and long duration of pancreatitis (29).

 

The prevalence of diabetes secondary to pancreatitis varies greatly with studies in North America estimating a prevalence of 0.5%-1.15% whereas in Southeast Asia, where tropical or fibrocalcific pancreatitis is endemic, a prevalence of approximately 15%-20% has been reported (23) (see chapter in Tropical Endocrinology Section of Endotext entitled “Fibrocalculous Pancreatic Diabetes” for an in depth discussion of this entity (7). Recently, data from the UK Royal College of General Practitioners Research and Surveillance Centre found 559 cases of diabetes following pancreatic disease in 31,789 cases of adults newly diagnosed with diabetes (1.8%) (30). Most cases of diabetes following pancreatic disease were classified as T2D (30). In another study approximately 50% of the patients with diabetes secondary to pancreatitis were not recognized and were incorrectly thought to have T2D. It is very likely that many cases of diabetes secondary to pancreatitis are not recognized to be due to pancreatic disease.

 

The prevalence of diabetes in patients with diagnosed pancreatitis has ranged between 26-80%, depending on the cohort and duration of follow up (21,23,31). The prevalence of diabetes increases with the duration of pancreatitis and early onset of calcific disease (23). Because of the high risk of diabetes in patients with pancreatitis these patients should be periodically screened for the presence of diabetes with measurement of fasting glucose and/or A1c levels.

 

At times it can be difficult to distinguish diabetes secondary to pancreatitis from T1D or T2D. The following diagnostic criteria have been proposed (Table 2) (23).

 

Table 2. Proposed Diagnostic Criteria for Diabetes Secondary to Pancreatitis

Major Criteria (must be present)

Presence of exocrine pancreatic insufficiency (monoclonal fecal elastase-1 test or direct function tests)    

Pathological pancreatic imaging (endoscopic ultrasound, MRI, CT)    

Absence of T1D associated autoimmune markers

Minor Criteria

Absent pancreatic polypeptide secretion    

Impaired incretin secretion (e.g., GLP-1)    

No excessive insulin resistance (e.g., HOMA-IR)    

Impaired beta cell function (e.g., HOMA-B, C-Peptide/glucose-ratio)    

Low serum levels of lipid soluble vitamins (A, D, E and K)

 

It should be recognized that these proposed criteria have not been rigorously tested nor are all criteria available in routine clinical practice. In addition, there are a number of key considerations. First, long-standing T1D and T2D are associated with exocrine pancreatic failure (32). It has been estimated that 26% to 74% of patients with T1D and 28% to 36% of patients with T2D have evidence of exocrine pancreatic insufficiency (19). Second, patients with diabetes are at a higher risk for developing acute and/or chronic pancreatitis (33). Lastly, patients with previous episodes of pancreatitis may also develop T1D or T2D independently of their exocrine pancreatic disease. When diabetes occurs in patients with a pre-existing diagnosis of chronic pancreatitis it is likely that pancreatitis is an important contributor to the development of diabetes.

 

Testing for T1D associated autoimmune markers can be helpful in separating T1D from diabetes secondary to pancreatic disease. The presence of islet cell antibodies supports the diagnosis of T1D. The pancreatic polypeptide response to insulin-induced hypoglycemia, secretin-infusion, or a mixed nutrient ingestion can be helpful in separating T2D from diabetes secondary to pancreatic disease. Patients with diabetes secondary to pancreatitis have an absent or reduced pancreatic polypeptide response while patients with T2D have an elevated pancreatic polypeptide response (23,31). Studies have shown that pancreatic polypeptide regulates hepatic insulin sensitivity and the absence of pancreatic polypeptide leads to hepatic insulin resistance and enhances hepatic glucose production, which could contribute to the abnormal glucose metabolism that occurs with pancreatic disease (21).

 

In patients with diabetes secondary to pancreatitis hyperglycemia can be mild to very severe depending upon the degree of pancreatic destruction leading to impaired insulin production and secretion (19,21,23). Glycemic control may be unstable due to the loss of glucagon secretion in response to hypoglycemia, carbohydrate malabsorption, and inconsistent food intake due to pain and/or nausea secondary to pancreatitis (i.e., “brittle diabetes”) (19,21,23). Whether glycemic control is worse in patients with diabetes secondary to pancreatitis is uncertain as older studies reported worse glycemic control and more recent studies have reported that glycemic control was similar to other patients with diabetes (19). The ability to obtain good glycemic control is likely to be related to the degree of pancreatic insufficiency with patients with a total absence of pancreatic function being more difficult to control.

 

In patients with relatively mild diabetes treatment with metformin is indicated. A nationwide cohort study in New Zealand and Denmark reported that metformin increased survival in patients with post pancreatitis diabetes (34,35). The GI side effects (nausea, abdominal complaints, diarrhea) of metformin may not be tolerable in some patients with pancreatitis. In observational studies metformin therapy has been associated with a reduction in the development of pancreatic cancer in patients with diabetes (36). Given the increased risk of pancreatic cancer in patients with diabetes and/or pancreatitis, a reduction in the development of pancreatic cancer would be a potential added benefit of metformin therapy (37-39). There are conflicting data on whether treatment with DPP4-inhibitors or GLP1-analogues can cause pancreatitis, but until this issue has been unequivocally settled, it is wise to refrain from using these drugs in patients who have had pancreatitis without a clear reversible etiology (for example, gallstone pancreatitis status post cholecystectomy). Note that two meta-analyses have demonstrated an 80% increased risk of acute pancreatitis in patients using DPP-4 inhibitors compared with those receiving standard care (40,41). In contrast, meta-analyses of large cardiovascular outcome studies have not demonstrated an increase in pancreatitis in patients treated with GLP-1 receptor agonists, but these studies typically excluded patients with a history of pancreatitis (42,43). Thiazolidinediones should probably be avoided as patients with pancreatitis and malabsorption are at increased risk for osteoporosis and thiazolidinediones may potentiate this problem.

 

Chronic pancreatitis is a progressive disease and therefore it is likely that glycemic control will worsen overtime and most patients will eventually require insulin therapy (23). Many patients will have severe insulin deficiency and will need to be treated with insulin therapy using regimens employed in patients with T1D. Because of the absence of glucagon secretion patients with diabetes secondary to pancreatitis are more susceptible to severe hypoglycemia with insulin therapy but diabetic ketoacidosis is not commonly observed due to the absence of glucagon.

 

Patients with diabetes secondary to pancreatitis are at risk for microvascular complications and lower extremity arterial disease and therefore routine testing for eye disease, kidney disease, foot ulcers, and neuropathy should be instituted (44-47).

 

Finally, it should be recognized that patients with diabetes secondary to pancreatitis will almost always have exocrine pancreatic insufficiency (31). Many patients with chronic pancreatitis manifest fat malabsorption without symptoms and therefore a thorough evaluation is required. Oral pancreatic enzyme replacement is beneficial for these patients. Of note, pancreatic enzyme supplementation can improve incretin secretion and thereby may benefit glycemic control (21,25,48). Fat soluble vitamin deficiency commonly occurs (Vitamin A, D, and K) and many patients require supplementation with fat-soluble vitamins.

 

Pancreatectomy

 

The metabolic abnormalities that occur after pancreatic surgery depend on the amount and area of the pancreas removed and whether the remaining pancreas is normal or diseased (24). The basis for this variability is due to the distribution of β and non-β islet cell types in the pancreas. Islet density is relatively low in the head of the pancreas and gradually increases through the body toward the tail region by greater than 2-fold and thus α- and β-cells predominate in the tail. In contrast, the cells that secrete pancreatic polypeptide are mainly localized in the head of the pancreas. Distal pancreatectomy usually causes little change in the metabolic status unless more than 50% of parenchyma is excised in patients with diffuse disease or more than 80% in patients with normal pancreatic function (24). The risk of a patient developing diabetes after a distal pancreatectomy varies greatly (24,49). The risk of new diabetes is reduced with central pancreatectomy compared to distal pancreatectomy (50). Resection of the head of the pancreas results in a decrease in pancreatic polypeptide, hepatic insulin resistance, and fasting hyperglycemia. Approximately 20% of patients develop diabetes after resection of the head of the pancreas (24). It should also be recognized that removal of pancreatic tissue can accelerate the development of T2D by decreasing insulin secretion in patients with impaired glucose metabolism (51).

 

Patients who have undergone total surgical pancreatectomy have a deficiency of insulin, glucagon, and pancreatic polypeptide and require insulin treatment. In general, there are several differences from typical T1D, including exocrine deficiency, low insulin requirements, and a higher risk of hypoglycemia due to the decrease in glucagon, which stimulates hepatic glucose production (glycogenolysis and gluconeogenesis). Pancreatectomized patients are prone to hypoglycemia and a delayed recovery from hypoglycemia. In an evaluation of 180 patients post total pancreatectomy 42% experienced one or more hypoglycemic events on a monthly basis (52). In addition to treatment with insulin, pancreatic enzyme supplements are always needed. SGLT2 inhibitors and GLP-1 receptor agonists have been shown to improve glycemic control in patients with diabetes post pancreatectomy (53,54). GLP-1 receptor agonists improve postprandial glycemia by decreasing gastric emptying and reducing postprandial responses of gut-derived glucagon (54). Intraportal islet auto transplantation has been used to prevent the development of diabetes with total pancreatectomy and/or reduce the risk of developing difficult to control diabetes (55-57).

 

Pancreatic Cancer

 

A high percentage of patients with pancreatic carcinoma have diabetes (21,58). In one study 68% of patients with pancreatic cancer also had diabetes (59). The prevalence of diabetes in patients with pancreatic cancer is much higher than in other common malignancies (58,59). In patients with pancreatic cancer who also have diabetes, the diagnosis of diabetes occurred less than 2 years prior to the diagnosis of pancreatic cancer in 74% of patients (60). In a population-based study less than 1% of patients over the age of 50 with newly diagnosed diabetes were diagnosed with pancreatic cancer within 3 years (61). In a study of 115 patients over 50 years of age who were hospitalized for new-onset diabetes 5.6% were found to have a pancreatic cancer (62). Many patients with pancreatic cancer lose weight and therefore deteriorating glycemic control in conjunction with weight loss and anorexia should raise the possibility of an occult pancreatic cancer (58,63). Other clues to the presence of pancreatic cancer in a patient with new onset diabetes are the lack of a family history of diabetes, a BMI < 25, recent thromboembolism, history of pancreatitis, GI symptoms, and the absence of features of the metabolic syndrome such as dyslipidemia and hypertension. Given the high incidence of diabetes relative to the incidence of pancreatic cancer the routine screening of all patients who develop diabetes is not cost effective. However, in selected patients with the features described above screening is appropriate.

 

Conversely, long standing T2D increases the risk of developing pancreatic cancer by approximately 1.5 to 2-fold indicating a bidirectional relationship (24,58,64). This risk may persist even after adjustment for obesity and smoking, risk factors for pancreatic cancer. Diabetes is both a risk factor for the development of pancreatic cancer and a complication of pancreatic cancer.

 

As discussed above diabetes may develop secondary to chronic pancreatitis. Chronic pancreatitis increases the risk of pancreatic cancer. Thus, patients with diabetes secondary to chronic pancreatitis are at a higher risk of developing pancreatic cancer (65).  

 

The strongest evidence linking pancreatic cancer with incident diabetes is the beneficial effects of cancer resection on glycemic control (58). In a small study in 7 patients, Permert and colleagues reported an improvement in diabetes status and glucose metabolism after subtotal pancreatectomy (66). Similarly, Pannala and colleagues in a larger study reported that after pancreaticoduodenectomy, diabetes resolved in 17 of 30 patients (57%) with new-onset diabetes but was unaffected in patients with longstanding diabetes (60). Litwin and colleagues noted similar improvements in glucose metabolism after surgery in patients with pancreatic cancer but a deterioration in patients with chronic pancreatitis (67). Finally, studies have also shown that a good response to chemotherapy in patients with pancreatic cancer can also improve glucose levels (68). Taken together these results demonstrate a benefit from tumor removal and suggest that new-onset diabetes associated with pancreatic cancer may be a paraneoplastic phenomenon.

 

The mechanism accounting for the development of new onset diabetes by pancreatic cancers is unknown (58). In contrast to other pancreatic disorders the etiology of diabetes is not due to destruction of the pancreas as patients with new onset diabetes and pancreatic cancer have hyperinsulinemia rather than low insulin levels and as noted above the diabetes improves after resection (21). Additionally, pancreatic cancers may be very small and thus unlikely to cause pancreatic insufficiency. Pancreatic cancer is associated with insulin resistance but the factors leading to insulin resistance are unknown (21).

 

In patients with pancreatic cancer the main goal of the treatment of diabetes is to prevent the short- term metabolic complications and facilitate the ability of the patient to tolerate treatment of the pancreatic cancer (surgery and chemotherapy). Given the poor survival of patients with pancreatic cancer, prevention of the long-term sequelae of diabetes is not a major focus. Metformin is a preferred hypoglycemic agent because there are observational studies suggesting that metformin may improve survival in patients with pancreatic cancer (69-71). However, randomized trials have failed to demonstrate the benefit of metformin therapy in patients with pancreatic cancer (72,73).

 

Hemochromatosis

 

Hemochromatosis is an autosomal recessive disorder characterized by increased iron absorption by the GI tract and increased total body iron stores (74). The excess iron is sequestered in many different tissues including the liver, skin, heart, and pancreas. The classic triad of hemochromatosis is diabetes mellitus, hepatomegaly, and increased skin pigmentation (“bronze diabetes”), but clinical features also include gonadal failure, arthropathy, and cardiomyopathy (74).

 

In early studies diabetes was present in over 50% of patients with hemochromatosis (75,76). More recently the prevalence of diabetes in patients with hemochromatosis has decreased to approximately 20% of patients, presumably due to the early diagnosis and treatment of hemochromatosis due to genetic testing (75-78). In patients with hemochromatosis screening for the presence of diabetes should be periodically carried out.

 

Diabetes was typically observed in persons who also had severe iron overload and cirrhosis (76). It should be noted that iron overload from any cause can result in diabetes (79). For example, patients with thalassemia develop iron overload due to the need for frequent transfusions (80,81). The prevalence of diabetes in patients with thalassemia has been declining since the more aggressive and widespread use of iron chelation therapy (81).

 

There are two abnormalities that lead to abnormal glucose metabolism in patients with hemochromatosis and iron overload (75). First, iron overload leads to beta cell damage with decreased insulin production and secretion. Pathologic examination revealed hemosiderin deposition and iron-induced fibrosis of the islets (76). The decrease in insulin secretion is the primary defect leading to the development of diabetes (75,76,78). Of note glucagon secretion does not appear to be deficient in patients with diabetes and hemochromatosis suggesting that the iron overload has a preferential toxicity for beta cells compared to alpha cells (76,82,83). Similarly, basal and stimulated pancreatic polypeptide levels are also not decreased in diabetic patients with hemochromatosis (84). Thus, the hormonal abnormalities differ in patients with iron overload induced diabetes compared to patients with pancreatitis induced diabetes. The second abnormality is insulin resistance that occurs due to iron overload hepatic damage and/or secondary to obesity (75,76). In addition, a genetic predisposition to diabetes potentiates the development of metabolic dysfunction. Many patients with hemochromatosis and diabetes have a relative with diabetes (85).

 

The typical micro and macrovascular complications of diabetes occur in patients with hemochromatosis (76,85). In a study by Griffiths and colleagues, 11 of 49 patients with hemochromatosis and diabetes had diabetic retinopathy (86). Sixty percent of the patients with hemochromatosis who had diabetes for greater than 10 years had retinopathy. The incidence of retinopathy is similar to that observed in the general diabetes population (85,86). Similarly, Becker and Miller observed that 7 of 22 patients with diabetes and hemochromatosis had pathologic evidence of diabetic glomerulopathy (87).

 

The treatment of hemochromatosis by phlebotomy has a variable impact on glucose metabolism (75). In patients who do not yet have complications or organ damage an improvement of insulin secretory capacity and normalization of glucose tolerance has been observed (75,76). Glucose metabolism often improves in patients with impaired glucose tolerance (75,88). In patients with diabetes improvement in glucose metabolism by phlebotomy may occur but is not as common as in “pre-diabetics” (75,88,89). In one study 28% of patients with diabetes and hemochromatosis on insulin or oral agents showed improved glucose control following phlebotomy therapy (90).

 

Cystic Fibrosis

 

Cystic Fibrosis is an autosomal recessive disorder due to a defect in the chloride transport channel (91). Cystic fibrosis related diabetes is rare in children but is present in approximately 20% of adolescents and 40-50% of adults with cystic fibrosis (92,93). As patients with cystic fibrosis live longer it is likely that the number of patients with cystic fibrosis and diabetes will increase. The development of diabetes is associated with more severe cystic fibrosis gene mutations, increasing age, worse pulmonary function, undernutrition, liver dysfunction, pancreatic insufficiency, a family history of diabetes, female gender, and corticosteroid use (92,93).

 

The primary defect in patients with cystic fibrosis related diabetes is decreased insulin production and secretion due to fibrosis and atrophy of the pancreas with a reduction of islet mass (92). In addition, mutations in the cystic fibrosis transmembrane conductance regulator gene may have direct effects on the ability of beta cells to secrete insulin (93,94). Beta cell dysfunction is not complete with residual insulin secretion and thus patients with cystic fibrosis related diabetes do not typically develop ketosis (92). Reduced alpha cell mass also occurs so while fasting glucagon levels are normal, glucagon secretion in response to hypoglycemia is impaired (92). Peripheral and hepatic insulin resistance may also occur secondary to infections, inflammation, and cirrhosis (93).

 

Some of the clinical features of cystic fibrosis related diabetes are similar to T1D as patients are young, not obese, insulin deficiency is the primary defect, and features of the metabolic syndrome (hyperlipidemia, hypertension, visceral adiposity) are not usually present (92). However, cystic fibrosis related diabetes is not an autoimmune disease (islet cell antibodies are not present) and ketosis is rare because endogenous insulin is still produced (92). Fasting glucose levels are often normal initially with elevated postprandial glucose levels due to a reduced and delayed insulin response to carbohydrates while basal insulin is often adequate to maintain normal fasting glucose levels (95). Patients with cystic fibrosis related diabetes are not at high risk of developing atherosclerosis and heart disease is not a major issue (92-94). This is likely due to malabsorption leading to low life-long plasma cholesterol levels and the shortened length of life (92,93). As life expectancy increases and medical therapy with Cystic Fibrosis Transmembrane Regulator (CFTR) modulators improves, the risk of macrovascular disease may increase. Microvascular complications do occur in cystic fibrosis related diabetes and are related to the duration of diabetes and glycemic control (92,93,95). The American Diabetes Association recommends screening for complications of diabetes beginning 5 years after the diagnosis of cystic fibrosis related diabetes (96)

 

Lung disease is a major cause of morbidity and mortality in patients with cystic fibrosis and both insulin insufficiency and hyperglycemia negatively affect cystic fibrosis lung disease (97). Numerous studies have shown that the occurrence of diabetes in patients with cystic fibrosis is associated with more severe lung disease and increased mortality and this adverse effect disproportionately affects women (92,95,97). In patients with cystic fibrosis lung function is critically dependent on maintaining normal weight and lean body mass. Insulin deficiency leads to a catabolic state with the loss of protein and fat (92). Multiple studies have shown that insulin replacement therapy improves nutritional status and pulmonary function in patients with cystic fibrosis related diabetes (92). In addition, elevated blood glucose levels result in elevated blood glucose levels in the airways, which promotes the growth of pathogenic microorganisms and increases pulmonary infections (92,95). Of note recent studies have shown that the marked increase in mortality in patients with cystic fibrosis related diabetes compared to patients with cystic fibrosis only has decreased (98). It is likely that early diagnosis and aggressive treatment have improved survival in patients with cystic fibrosis related diabetes.

 

Because of the adverse effects of diabetes on lung function in patients with cystic fibrosis routine screening for diabetes is recommended (97). It is recommended that annual screening begin at age 10 (97). While fasting glucose and A1c levels are routine screening tests for diabetes, in patients with cystic fibrosis these tests are not sensitive enough (97). Fasting glucose and A1c testing will fail to diagnose approximately 50% of patients with cystic fibrosis related diabetes (94,97). However, recent studies have suggested that a screening A1c >5.5% would detect more than 90% of patients with diabetes and therefore with further confirming studies measuring A1c levels could become an initial screening approach (96).  As noted above, abnormalities in postprandial glucose characterizes cystic fibrosis related diabetes and it is therefore recommended that an oral glucose tolerance test (OGTT) be utilized for the diagnosis of diabetes in patients with cystic fibrosis (97). Studies have shown that the diagnosis of diabetes by OGTT correlates with clinically important cystic fibrosis outcomes including the rate of lung function decline, the risk of microvascular complications, and the risk of early death (97). Moreover, the OGTT identified patients who benefited from insulin therapy (97). Additional screening recommendations are shown in Table 3 and the interpretation of these tests are shown in Table 4.

 

Table 3. ADA and Cystic Fibrosis Foundation Recommendations for Screening for Cystic Fibrosis Related Diabetes (CFRD) (97)

1) The use of A1C as a screening test for CFRD is not recommended.

2) Screening for CFRD should be performed using a 2-h 75-g OGTT. 

3) Annual screening for CFRD should begin by age 10 years in all CF patients who do not have CFRD.

4) CF patients with acute pulmonary exacerbation requiring intravenous antibiotics and/or systemic glucocorticoids should be screened for CFRD by monitoring fasting and 2-h postprandial plasma glucose levels for the first 48 h. If elevated blood glucose levels are found by SMBG, the results must be confirmed by a certified laboratory.

5) Screening for CFRD by measuring mid- and immediate post-feeding plasma glucose levels is recommended for CF patients on continuous enteral feedings, at the time of gastrostomy feeding initiation, and then monthly by SMBG. Elevated glucose levels detected by SMBG must be confirmed by a certified laboratory.

6) Women with CF who are planning a pregnancy or confirmed pregnant should be screened for preexisting CFRD with a 2-h 75-g fasting OGTT if they have not had a normal CFRD screen in the last 6 months. 

7) Screening for gestational diabetes mellitus is recommended at both 12–16 weeks’ and 24–28 weeks’ gestation in pregnant women with CF not known to have CFRD, using a 2-h 75-g OGTT with blood glucose measures at 0, 1, and 2 h. 

8) Screening for CFRD using a 2-h 75-g fasting OGTT is recommended 6–12 weeks after the end of the pregnancy in women with gestational diabetes mellitus (diabetes first diagnosed during pregnancy). 

9) CF patients not known to have diabetes who are undergoing any transplantation procedure should be screened preoperatively by OGTT if they have not had CFRD screening in the last 6 months. Plasma glucose levels should be monitored closely in the perioperative critical care period and until hospital discharge. Screening guidelines for patients who do not meet diagnostic criteria for CFRD at the time of hospital discharge are the same as for other CF patients.

CF= cystic fibrosis; CRFD= cystic fibrosis related diabetes; OGTT= oral glucose tolerance test, SMBG= self-monitored blood glucose

 

Table 4. Criteria for the Diagnosis of Cystic Fibrosis Related Diabetes (97)

1) During a period of stable baseline health the diagnosis of CFRD can be made in CF patients according to standard ADA criteria. Testing should be done on 2 separate days to rule out laboratory error unless there are unequivocal symptoms of hyperglycemia (polyuria and polydipsia); a positive FPG or A1C can be used as a confirmatory test, but if it is normal the OGTT should be performed or repeated. If the diagnosis of diabetes is not confirmed, the patient resumes routine annual testing.

·       2-h OGTT plasma glucose >200 mg/dl (11.1 mmol/l)

·       FPG >126 mg/dl (7.0 mmol/l)

·       A1C > 6.5% (A1C <6.5% does not rule out CFRD because this value is often spuriously low in CF.)

·       Classical symptoms of diabetes (polyuria and polydipsia) in the presence of a casual glucose level >200 mg/dl (11.1 mmol/l)

2) The diagnosis of CFRD can be made in CF patients with acute illness (intravenous antibiotics in the hospital or at home, systemic glucocorticoid therapy) when FPG levels >126 mg/dl (7.0 mmol/l) or 2-h postprandial plasma glucose levels >200 mg/dl (11.1 mmol/ l) persist for more than 48 h.

3) The diagnosis of CFRD can be made in CF patients on enteral continuous drip feedings when mid- or post-feeding plasma glucose levels exceed 200 mg/dl (11.1 mmol/l) on 2 separate days.

4) Diagnosis of gestational diabetes mellitus is diagnosed based on 0-, 1-, and 2-h glucose levels with a 75-g OGTT if any one of the following is present:

·       FPG >92 mg/dl (5.1 mmol/l)

·       1-h plasma glucose >180 mg/dl (10.0 mmol/l)

·       2-h plasma glucose >153 mg/dl (8.5 mmol/l)

CF patients with gestational diabetes mellitus are not considered to have CFRD, but require CFRD screening 6–12 weeks after the end of the pregnancy.

5) The onset of CFRD should be defined as the date a person with CF first meets diagnostic criteria, even if hyperglycemia subsequently abates.

CF= cystic fibrosis; CRFD= cystic fibrosis related diabetes; OGTT= oral glucose tolerance test

 

There is evidence that elevations in glucose below the levels typically used to diagnose diabetes result in adverse effects on the lungs (95). Thus, some experts recommend that treatment should be considered for individuals with abnormal glucose levels which do not meet the criteria for diabetes if there is evidence of declining lung function or weight loss (95).

 

A unique feature in the treatment of patients with cystic fibrosis related diabetes is that insulin is the treatment of choice in all patients (97). Studies have shown that cystic fibrosis patients on insulin therapy who achieve good glycemic control demonstrate improvement in weight, protein anabolism, pulmonary function, and survival (97). No specific insulin treatment regimen is recommended, and the regimen should be individualized for the patient. For example, a patient with elevated postprandial glucose levels will benefit from mealtime rapid acting insulin. It should be noted that patients with cystic fibrosis induced diabetes still have endogenous insulin production, which allows for the achievement of good glycemic control. Oral diabetes agents are not as effective as insulin in improving nutritional and metabolic outcomes and therefore are not recommended (97). However, in patients who do not tolerate insulin (for example frequent hypoglycemia), oral agents, such as DPP4 inhibitors, may be beneficial (99). For most patients with cystic fibrosis related diabetes an A1c < 7% is recommended but the A1c goal can be higher or lower for certain patients based on clinical judgement. Also of note is that cystic fibrosis patients require a high-calorie, high-salt, high-fat diet.

 

Ivacaftor, a Cystic Fibrosis Transmembrane Conductance Regulator modulator, is a relatively new agent to treat cystic fibrosis and has been shown to partially reverse the disease. Interestingly in case reports ivacaftor has been shown to markedly improve glycemic control (93,100). In a recent retrospective observation study approximately 1/3 of patients with CFRD had either a resolution of their diabetes or marked improvement with ivacaftor therapy (101). Additionally, the risk of developing CFRD is decreased in patients treated with ivacaftor (102). Studies using three Cystic Fibrosis Transmembrane Regulator (CFTR) modulators (elexacaftor /tezacaftor/ ivacaftor) improved glycemic control and reduced insulin requirements (103-105). These beneficial effects are likely to be due to an improvement in insulin secretion and/or insulin sensitivity (93,106,107). Note the response to these Cystic Fibrosis Transmembrane Regulator (CFTR) modulators depends on the specific mutation causing cystic fibrosis (107).

 

INFECTIONS

 

Viral Infections

 

Viral infections, particularly enterovirus and herpes virus infections, have been postulated to play a role in triggering the autoimmune reaction that leads to the development of T1D (108-111). This phenomenon is discussed in detail in the Endotext chapter on changing the course of the disease in T1D (112). A phase 2 study with the anti-viral agents, pleconaril and ribavirin, demonstrated preservation of residual insulin production in children and adolescents with new-onset T1D (113). In rare instances a viral infection has been associated with the fulminant development of diabetes due to the destruction of beta cells (114). For a review of the link of viral infections with the development of diabetes see a review by Jeremiah and colleagues (111).

 

Congenital Rubella

 

Congenital rubella infection has been shown to predispose to the development of T1D that usually presents before five years of age (115). It has been estimated that approximately 1-6% of individuals with the rubella syndrome will develop diabetes in childhood or adolescence (115,116). The mechanism for this association is unknown. In addition, studies have also shown that patients with congenital rubella also develop T2D (116). In one series 22% of individuals with congenital rubella developed diabetes later in life (116). Fortunately, with increased vaccinations, congenital rubella has become a disease of the past in developed countries.

 

Hepatitis C Virus (HCV)

 

Meta-analyses and large database studies have demonstrated that hepatitis V virus (HCV) infection is associated with an increased risk of T2D (117-122). In a meta-analysis of 34 studies the risk of diabetes in patients with HCV infection was increased by approximately 70% (117). Moreover, HCV infection is associated with an increased risk of T2D independent of the severity of the associated liver disease (i.e. occurs in patients without liver disease) but the risk of T2D was higher in HCV patients with cirrhosis (118). As expected, the risk of diabetes is increased in HCV patients if the BMI is increased, there is a family history of diabetes, older age, more severe liver disease, and male sex. Conversely, the prevalence of HCV infection in patients with T2D is higher than in non-diabetic controls (118,122,123). In a meta-analysis of 22 studies with 78,051 individuals it was found that patients with T2D were at a higher risk of HCV infection than non-diabetic patients (OR = 3.50; CI = 2.54-4.82) (123). Finally, diabetes is a significant risk factor for the development of liver cirrhosis and hepatocellular carcinoma in HCV infected patients (122,124-127).

 

Given the increased risk of diabetes in HCV infected patients it seems prudent to routinely screen HCV positive patients for diabetes. Conversely, screening patients with diabetes for HCV infection seems reasonable given the availability of drugs that can effectively treat HCV infections.

 

Patients with diabetes and HCV infection are insulin resistant in the liver and peripheral tissues (122,127,128). Insulin resistance is present in HCV infection in the absence of significant liver dysfunction and prior to the development of diabetes (128). Treatment that reduces viral load decreases insulin resistance and the risk of developing diabetes in HCV (122,128,129). The insulin resistance in individuals with HCV infections may be due to inflammation induced by cytokines such as TNF-alpha or monocyte chemoattractant protein-1, released from HCV-induced liver inflammation (122,127). Additionally, HCV may directly activate the mTOR/S6K1 signaling pathway, inhibiting IRS-1 protein function and thereby down-regulating GLUT-4 and up-regulating the gluconeogenic enzyme phosphoenolpyruvate carboxykinase-2 (122,127). Beta cell dysfunction may also contribute to the development of diabetes during HCV infection (111,130).

 

Studies have shown that direct-acting antiviral agents that eradicate HCV infection are associated with improved glycemic control in patients with diabetes indicated by decreased A1c levels and decreased insulin use (127,131). Additionally, in a database study of anti-viral treatment for HCV infection, a decrease in end-stage renal disease, ischemic stroke, and acute coronary syndrome was reported in  patients with diabetes (132). These beneficial results on key outcomes need to be confirmed in randomized trials (this may be impossible as withholding treatment of HCV is not appropriate). Treatment of diabetes with metformin or thiazolidinediones is preferred as studies have suggested that these drugs may lower the risk of hepatocellular carcinoma, liver-related death, or liver transplantation in patients infected with HCV (133,134).

 

COVID-19

 

There is a bidirectional relationship between diabetes and COVID-19. Both T1D and T2D are important risk factors for morbidity and mortality with COVID-19 infections, which is discussed in the Endotext chapter entitled “Diabetes Mellitus and Infections” (135). Studies have also shown that COVID-19 infections are associated with hyperglycemia and new onset diabetes (136,137). In a large meta-analysis of 20 studies the risk of new incident type 1 diabetes was increased (HR1.44; 95% CI: 1.13-1.82) and the risk of new incident type 2 diabetes was also increased (HR 1.47; 95% CI: 1.36-1.59) (138). Other meta-analyses have reported similar results (139-142). A meta-analysis observed that the risk of diabetes increased 1.17-fold (1.02-1.34) after COVID-19 infection compared to patients with general upper respiratory tract infections (140). The risk of new diabetes in patients with COVID-19 was highest for patients in intensive care (HR 2.88) and hospitalized patients (HR 2.15) (138). For non-hospitalized patients the risk of developing new diabetes was much lower (HR=1.16; 95% CI: 1.07-1.26; p = 0.002) (138).

 

A very large data-based study with millions of patients found that the risk of developing T2D prior to the availability of COVID-19 vaccination was increased and that this increased risk was still elevated by approximately 30% 1 year after the COVID-19 infection (143). The risk of developing T2D is highest soon after COVID-19 infection (four times higher during the first 4 weeks) and 60% of those diagnosed with T2D after COVID-19 still had evidence of diabetes 4 months after infection (i.e. persistent T2D) (143). The risk of developing T1D was elevated but this increase was no longer seen one year after the COVID-19 infection (143). The increased risk of developing both T1D and T2D was greater in people who were hospitalized with COVID-19 and therefore the risk of developing diabetes was reduced, but not entirely ameliorated, in vaccinated individuals compared with unvaccinated people (143). The absolute risk of developing diabetes was greatest in patients at increased risk for diabetes (obesity, certain ethnic groups, individuals with “prediabetes”, etc. (143).

 

The mechanisms that account for an increased risk of diabetes following COVID-19 infections are unresolved. There are a number of suggested mechanisms.

 

  • Diabetes could be secondary to acute illness and stress induced hyperglycemia. Stress induced hyperglycemia has been observed after other acute conditions including other infections (137,144).
  • Pre-existing diabetes could first be recognized during a COVID-19 infection or during follow-up. This could account for some of the patients that appear to develop new T2D as many patients with T2D are unaware that they have diabetes (145).
  • COVID-19 infection could trigger beta cell autoimmunity. This is particularly relevant to the development of T1D as viral infections have been hypothesized to initiate beta cell autoimmunity (112,137).
  • The SARS-CoV-2 virus could directly damage the beta cells leading to decreased insulin secretion and hyperglycemia (137).
  • SARS-CoV-2 virus could lead to pancreatitis indirectly affecting beta cell function.
  • The strong immune response that is seen in COVID-19 infections (cytokine storm) could indirectly lead to beta cell dysfunction and insulin resistance. Additionally, elevated cytokines could persist for an extended period leading to insulin resistance and abnormal glucose metabolism (146)
  • SARS-CoV-2 virus infects adipose tissue and may cause adipose dysfunction (decreased adiponectin and increased insulin resistance) (147,148). Persistent adipose tissue infection could result in inflammation and alteration of adipokines and cytokines leading to diabetes.
  • The use of high dose glucocorticoids in patients with severe COVID-19 could lead to hyperglycemia and diabetes.
  • Changes in environment that occurred during the COVID-19 pandemic, such as decreased exercise, increased food intake, increased weight gain, etc., could enhance the risk of developing diabetes (149).

 

Hopefully, future studies will better characterize the mechanisms leading to new onset diabetes in patients with COVID-19 infections and determine whether there are unique mechanisms for this association.

 

ENDOCRINOPATHIES

 

A number of endocrine disorders are associated with an increased occurrence of diabetes (Table 1). Increased levels of growth hormone, glucocorticoids, catecholamines, and glucagon cause insulin resistance while increased levels of catecholamines, somatostatin, and aldosterone (by producing hypokalemia) decrease insulin secretion and hence can adversely affect glucose homeostasis. The disturbance in glucose metabolism occurring secondary to endocrine disorders may vary from a moderate degree of glucose intolerance to overt diabetes with symptomatic hyperglycemia. Additionally, endocrine disorders can worsen glycemic control in patients with pre-existing diabetes.

 

Acromegaly

 

This condition is caused by excessive production of growth hormone (GH) from the pituitary (150). The prevalence of DM in patients with acromegaly is between 10-40%; the prevalence of diabetes and glucose intolerance effects more than 50% of patients (150-153). As expected, there is an increased prevalence of diabetes with age, elevated BMI, a family history of diabetes, and longer duration of acromegaly (151). Diabetes may be present at the time of the diagnosis of acromegaly (154). Higher plasma IGF-1 concentrations correlate with an increased risk of diabetes, suggesting that the biochemical severity of acromegaly influences the risk of developing abnormalities of glucose metabolism (155). Patients with acromegaly should be screened for abnormalities in glucose metabolism (152). The prevalence of acromegaly in patients with diabetes is unknown but is likely to be very low given that acromegaly is an uncommon disorder (60 per million) and diabetes is very common (150).

 

GH is a counter regulatory hormone to insulin and is secreted during hypoglycemia (156,157). In patients with acromegaly insulin resistance is the major abnormality leading to disturbances in glucose metabolism (151,153,154,158). The insulin resistance is driven primarily through GH induced lipolysis, which results in glucose-fatty acid substrate competition leading to decreased glucose utilization in muscle (151,154,158). Additionally, inhibition of post receptor signaling pathway of the insulin receptor also likely plays a role in the insulin resistance (158). Increased hepatic gluconeogenesis also contributes to the hyperglycemia (151,158). Lipolysis increases the delivery of glycerol and fatty acids to the liver, which serves as a substrate and energy source for gluconeogenesis. In some patients with acromegaly increased insulin secretion compensates for the insulin resistance and glucose metabolism remains normal (151). If insulin secretion cannot increase sufficiently to compensate for the insulin resistance glucose intolerance or diabetes develops (151).

 

Treatment is directed at the cause of the acromegaly (150). Successful surgical removal of the pituitary adenoma improves hyperglycemia and glucose metabolism has been reported to normalize in 23–58% of people with pre-operative diabetes after surgical cure of acromegaly (151,152,154). Lower IGF-1 and growth hormone levels post operatively correlate with remission of diabetes (159). A meta-analysis of 31 studies with 619 patients treated with somatostatin analogues for acromegaly reported a decrease in insulin levels and glucose levels during a glucose tolerance test but no change in fasting glucose or A1c levels (160). Another meta-analysis of 47 studies with 1297 participants reported that somatostatin analogues also did not affect fasting plasma glucose but worsened 2 hour oral glucose tolerance test and resulted in a mild but significant increase in HbA1c (161) The absence of greater benefit in glucose homeostasis with somatostatin analogues could be secondary to somatostatin analogues inhibiting insulin secretion (150). Of note, while first generation somatostatin analogues appear to have mild or neutral effects on glucose metabolism in patients with acromegaly, treatment with pasireotide, a second-generation somatostatin analogue, aggravated glucose metabolism leading to the development of diabetes in some instances (162-164). The adverse effect of pasireotide is due to inhibiting insulin secretion and decreasing the incretin effect. There is little data on the impact of cabergoline on glucose homeostasis in patients with acromegaly, but the available studies suggest that it modestly improves glucose metabolism or has no effect (152,165). Studies have shown that bromocriptine can improve glucose homeostasis (151,152,166).  Finally, treatment with the growth hormone receptor antagonist, pegvisomant, has beneficial effects on glucose homeostasis (164,167,168).

 

The treatment of diabetes in patients with acromegaly is similar to the treatment in other patients with diabetes (151,153). Patients with acromegaly are often lean with low body fat and therefore dietary recommendations may need to be modified. Additionally, since insulin resistance is the primary defect in patients with acromegaly the use of insulin sensitizers may be especially effective but there are no studies comparing the efficacy of various hypoglycemic agents in patients with acromegaly (151). Data suggests that active acromegaly with elevated GH levels enhances the development of microvascular disease (154). The effect of acromegaly on the development of macrovascular disease is unclear (154). Ketoacidosis is uncommon in patients with diabetes and acromegaly.   

 

Cushing’s Syndrome

 

Cushing’s syndrome is due to elevated glucocorticoids that can be caused by the overproduction of ACTH by pituitary adenomas or ectopic ACTH producing tumors, overproduction of glucocorticoids by the adrenal glands due to adenomas or hyperplasia, or the exogenous administration of glucocorticoids (169). In patients with Cushing’s syndrome diabetes is present in 20-47% of the patients, while impaired glucose tolerance (IGT) is present in 21-64% of cases (170). Risk factors for the development of diabetes in patients with Cushing syndrome include age, obesity, and a family history of diabetes (170). The prevalence of diabetes varies depending on the etiology of Cushing’s syndrome (pituitary 33%, ectopic 74%, adrenal 34%) (171). In patients with endogenous Cushing’s syndrome the relationship of the degree of hypercortisolism and abnormalities in glucose metabolism has been inconsistent with some studies showing a correlation and other studies no relationship (172). For example, in one study, in patients with endogenous Cushing’s syndrome the prevalence of abnormalities in glucose metabolism and diabetes did not differ in patients with slightly elevated (not greater than 2x the upper limit of normal), moderately elevated (2-5X the ULN), and severely elevated (>5x the ULN) levels of urinary free cortisol (173). In patients with exogenous Cushing’s syndrome high doses of glucocorticoids and longer duration of treatment are more likely to cause diabetes (152,172). Elevated glucocorticoids are more likely to cause high glucose levels in the afternoon or evening and in the postprandial state (152). Hyperglycemia resulting from exogenous steroids occurs in concert with the time-action profile of the steroid regimen employed, such that once daily morning administration of an intermediate acting steroid (prednisone or methylprednisone) causes peak hyperglycemia within 12 hours (post-prandial) while long-acting or frequently administered steroids cause both fasting and postprandial hyperglycemia.

 

Patients with Cushing’s syndrome should be screened for the presence of abnormalities in glucose metabolism (172). It should be noted that fasting glucose levels are often normal with abnormalities present during an oral glucose tolerance test (170,172). Screening with A1c levels or with an oral glucose tolerance test are therefore preferred. The abnormalities in glucose metabolism may contribute to the increased risk of atherosclerosis in patients with Cushing’s syndrome.

 

The prevalence of Cushing’s syndrome in patients with diabetes is uncertain with studies reporting very different results ranging from 0 to 9% (172). The selection process used, and the criteria used to determine the presence of Cushing’s syndrome likely greatly influences the results with studies that select patients with marked obesity, poor glycemic control, and poorly controlled hypertension finding a higher percentage of patients with diabetes having Cushing’s syndrome. A recent meta-analysis of 14 studies with a total of 2827 patients with T2D reported that 1.4% had Cushing’s syndrome based on biochemical analysis (174). In a multicenter study carried out in Italy between 2006 and 2008, 813 patients with known T2D without clinically overt hypercortisolism were evaluated for Cushing’s syndrome (175). After extensive evaluation 6 patients (0.7%) were diagnosed with Cushing’s syndrome. Four patients had an adrenal adenoma and their diabetes was markedly improved with the disappearance of diabetes in three patients and discontinuation of insulin therapy in the remaining patient. One patient had bilateral macronodular adrenal hyperplasia and one patient had ACTH dependent Cushing’s syndrome with a normal pituitary MRI.

 

In approximately 15-35% of patients with an incidental adrenal nodule mild autonomous cortisol secretion with T2D is present (176,177). After surgical removal of the adenoma in patients with autonomous cortisol secretion diabetes normalized or improved in 62.5% of patients (5 of 8) (178). However, not all studies have seen such dramatic improvements in diabetes after adenoma removal (179). Clearly additional studies (preferably large, randomized trials) are required to better define the prevalence of mild subclinical Cushing’s syndrome in patients with diabetes and whether treating the subclinical Cushing’s syndrome in these patients will improve their glycemic control. For a detailed discussion of autonomous cortisol secretion see the chapter on Adrenal Incidentalomas in the Adrenal section of Endotext (180).

 

Currently, routinely screening patients with T2D for Cushing’s syndrome is not recommended (172). Nevertheless, clinicians should be aware of the possibility of Cushing’s syndrome and screen appropriate patients with T2D (young patients, negative family history of diabetes, patients with physical findings suggestive of Cushing’s syndrome, patients with difficult to control diabetes or hypertension) (172).    

 

Glucocorticoids function as a counter regulatory hormone to insulin and increase in response to hypoglycemia (181). Glucocorticoids disrupt glucose metabolism primarily by inducing insulin resistance in liver and muscle and by stimulating hepatic gluconeogenesis (170,172). The increase in hepatic gluconeogenesis is mediated by several mechanisms including a) directly stimulating the expression of gluconeogenic enzymes b) stimulating proteolysis and lipolysis leading to an increase delivery of amino acids, glycerol, and fatty acids to the liver that provides substrates and energy sources for gluconeogenesis c) inducing insulin resistance and d) enhancing the action of glucagon (170,172). The glucocorticoid induced increase in insulin resistance is due to inhibition of the post-receptor signaling pathway of the insulin receptor, which will result in a decrease in the uptake of glucose by skeletal muscle and adipose tissue (170). In addition to the above glucocorticoids can accelerate the degradation of Glut4 in beta cells, which impairs the ability of beta cells to secrete insulin in response to glucose (182).

 

Treatment of Cushing’s syndrome by removal of a pituitary tumor, an ectopic ACTH producing tumor, or an adrenal lesion result in a marked improvement in glucose metabolism and in many patients a remission of the diabetes (170,172). In patients with persistent Cushing’s syndrome drug therapy may be needed to normalize cortisol levels. Studies have shown that ketoconazole (200–1200 mg/day), levoketoconazole (150-600 mg twice daily), metyrapone (250–4500 mg/day), mifepristone (300–2000 mg/day) (approved to treat diabetes in patients with Cushing’s syndrome),osilodrostat (1-30 mg twice daily), or cabergoline (1-7mg/day) improves glucose metabolism in patients with Cushing’s syndrome (152,172,183).  In contrast, pasireotide has been shown to significantly worsen glucose tolerance, despite control of hypercortisolism, in patients with Cushing’s syndrome (152,172,183). In patients with exogenous Cushing’s syndrome it is important to use as low a dose as possible of glucocorticoids for the shortest period of time to avoid complications of therapy including disrupting glucose homeostasis (184).

 

The management of diabetes in patients with Cushing’s syndrome is similar to the treatment of other patients with diabetes (152,183). Since insulin resistance is a key defect in patients with Cushing’s syndrome the use of insulin sensitizers may be especially effective but there are no studies comparing the efficacy of various hypoglycemic agents in patients with Cushing’s syndrome (152). Pioglitazone and rosiglitazone can increase the risk of osteoporosis, and it should be noted that patients with Cushing’s syndrome also have a high risk of osteoporosis. As noted above, postprandial glucose levels are preferentially increased in Cushing’s syndrome and therefore drugs that lower postprandial glucose levels, such as DPP4 inhibitors, GLP1 receptor agonists, alpha glucosidase inhibitors, and rapid acting insulin may be very useful (152). In glucocorticoid-treated patients requiring a basal-bolus insulin regimen, a higher requirement of short-acting insulin than basal insulin is frequently required (usually approximately 70% of total insulin dose as prandial and 30% as basal) (152). Because of the insulin resistance in patients with Cushing’s syndrome higher doses of insulin are often required to achieve glycemic control. Patients with Cushing’s syndrome are at higher risk for developing macrovascular disease and therefore aggressive treatment of dyslipidemia and hypertension is required (185,186).  

 

Pheochromocytoma

 

Pheochromocytomas are rare neuroendocrine tumors that secrete norepinephrine, epinephrine, and dopamine (187). In pheochromocytomas the prevalence of diabetes has been estimated to be between 15-40% and impaired glucose tolerance as high as 50% (188-191). Patients with diabetes were older, had a longer known duration of hypertension, higher plasma epinephrine and norepinephrine levels, increased urinary metanephrine excretion, and larger tumors (189-191). Surprisingly the BMI did not differ between patients with and without diabetes perhaps because more active tumors with higher catecholamine levels lead to weight loss (189,190). In most instances the diabetes is relatively mild but in rare instances can be severe with ketoacidosis (192). The association of hypertension with diabetes in a young patient who is not overweight is a clue to the presence of a pheochromocytoma (189).

 

Catecholamines, acting primarily by the beta-adrenergic receptors, stimulate glucose production in the liver by increasing glycogenolysis and increase insulin resistance leading to a decrease in tissue disposal of glucose, which together result in elevations in glucose levels (193,194). In addition, catecholamines acting via the alpha-adrenergic receptors, inhibit insulin secretion by the beta cells and acting via the beta-adrenergic receptors, increase glucagon secretion by the alpha cells (195). A decrease in insulin secretion and an increase in glucagon secretion would facilitate the development of hyperglycemia.

 

With tumor resection diabetes resolves or markedly improves in the majority of patients (>50-90%) with a pheochromocytoma (189,190,196). A duration of diabetes of less than 3 years is associated with a remission of diabetes (197). It should be noted that post-surgical removal of a pheochromocytoma, hypoglycemia can occur in approximately 5% of patients (198). Most of these hypoglycemic episodes occur in the first 24 hours and are more likely to occur in patients with large tumors and high urinary metanephrine levels (198). If surgery is unsuccessful the use of alpha and beta blockers may improve insulin resistance and glucose homeostasis (199).

 

Hyperthyroidism 

 

Hyperthyroidism induces insulin resistance and hyperglycemia, by increasing intestinal glucose absorption and hepatic glucose production (200,201).  Thyroid hormones increase hepatic glucose production by stimulating endogenous glucose production by increasing gluconeogenesis and glycogenolysis (201). Hyperthyroidism in patients without diabetes may increase glucose intolerance (202). Whether hyperthyroidism causes frank diabetes is unclear because much of the older literature that purports that hyperthyroidism causes diabetes used criteria for diabetes that differs greatly from current guidelines. For example, the study of Kreines and colleagues reported that 57% of patients with hyperthyroidism had diabetes but the criteria for diabetes was a 1 hour glucose >160mg/dL plus a 2 hour value >120 mg/dL during an oral glucose tolerance test (203). A study from China using oral glucose tolerance tests did not find a major difference in the prevalence of diabetes in patients with Grave’s disease (11.3%) vs controls (10.0%) (204). In a careful review of the literature Roa Dueñas et al found that hyperthyroidism was not related to type 2 diabetes except for one study in which hyperthyroidism had a positive association with the risk of T2D (5 studies, with a total of 148,684 participants and 11,154 incident cases of type 2 diabetes) (200). In a meta-analysis of these studies the results showed a non-significant association with the risk of T2D (HR 1.16; 95% CI 0.90-1.49). A meta-analysis of 12 cohorts with 32,747 participants also failed to demonstrate that subclinical hyperthyroidism was associated with the development of T2D (205). In contrast, a large retrospective cohort study found that after 10 years of follow-up T2D was increased (HR 1.30; 95% CI 1.21-1.39) (206). Thus, the effect of hyperthyroidism on the development of T2D if present is likely to be modest with most studies demonstrating no relationship. The duration of hyperthyroidism may be a key variable and health care systems where hyperthyroidism is promptly treated may fail to demonstrate that hyperthyroidism leads to incident T2D.

 

It should be noted that hyperthyroidism may worsen glycemic control in patients with diabetes by increasing intestinal glucose absorption, decreasing insulin sensitivity, and increasing glucose production (207). Teprotumumab, which is used to treat thyroid eye disease, may worsen glycemic control in patients with diabetes and induce hyperglycemia in patients without diabetes (208,209) (discussed in drug induced diabetes section below).

 

Additionally, T1D and Grave’s disease can occur together as part of the autoimmune polyglandular syndrome (210).

 

Glucagonoma

 

Glucagonomas are extremely rare and are associated with a characteristic rash termed necrolytic migratory erythema (82% of patients), painful glossitis, cheilitis, angular stomatitis, normochromic normocytic anemia (50-60%), weight loss (60-90%), mild diabetes mellitus (68-80%), hypoaminoacidemia, low zinc levels, deep vein thrombosis (50%), and depression (50%) (211,212). Glucagon stimulates hepatic glucose production by increasing gluconeogenesis and glycogenolysis leading to an increase in plasma glucose levels (213). Removal of the tumor results in the remission of diabetes.

 

Somatostatinoma

 

Somatostatinomas are extremely rare tumors that may present with a triad of diabetes mellitus, diarrhea/steatorrhea, and gallstones, but weight loss and hypochlorhydria also occur (214). Approximately seventy-five percent of patients with pancreatic somatostatinomas have diabetes  while diabetes occurs in only approximately 10% of patients with intestinal tumors. Typically, the diabetes is relatively mild and can be controlled with diet, oral hypoglycemic agents, or small doses of insulin (214). Somatostatin inhibits insulin secretion which can result in elevations in plasma glucose levels (214). Increased secretion of somatostatin by cells in the pancreas may be in closer proximity to beta cells and more effective in inhibiting insulin secretion than somatostatin secreted by intestinal cells. Somatostatin also inhibits glucagon secretion and therefore diabetic ketoacidosis is very unusual but has been reported (214,215). Additionally, replacement of functional islet cell tissue by the pancreatic tumor may also contribute to the development of diabetes in patients with a pancreatic somatostatinoma (214). Removal of the tumor results in remission of diabetes.

 

Primary Hyperaldosteronism  

 

Hypokalemia secondary to hyperaldosteronism can impair insulin secretion and result in diabetes. Potassium replacement will improve glucose homeostasis. Additionally, aldosterone induces insulin resistance in adipocytes, skeletal muscle, and liver and decreases insulin secretion independent of potassium levels (216).

 

In a large meta-analysis the risk of diabetes (OR 1.33, 95% CI 1.01–1.74) and the metabolic syndrome (OR 1.53, 95% CI 1.22–1.91) was modestly increased in patients with primary hyperaldosteronism (217). Hyperaldosteronism increases the risk of cardiovascular disease and renal disease (216,218,219).

 

DRUG-INDUCED DIABETES

 

A large number of different drugs have been shown to adversely affect glucose homeostasis (Table 1). Most of these drug’s act in conjunction with other risk factors for T2D and are usually not the sole cause of diabetes. Drug-induced hyperglycemia is often mild and may be clinically asymptomatic, but in some instances can result in the development of severe hyperglycemia manifesting as diabetic ketoacidosis. There are a number of mechanisms by which drugs induce alterations in glucose metabolism including inducing insulin resistance or inhibiting insulin secretion. In most cases diabetes remits when the drug is stopped but in some instances diabetes can be permanent. Use of a rodenticide (N-3 pyridylmethyl-N’4 nitrophenylurea, VacorÒ), structurally related to streptozotocin, was removed from the market in the 1980s because the ingestion of this compound resulted in insulin-dependent diabetes due to beta cell destruction (220). In this section we will focus on drugs that cause major changes in glucose homeostasis or drugs that are commonly used in clinical practice.

 

Antihypertensive Drugs

 

In a meta-analysis the risk of developing diabetes varied between different classes of antihypertensive drugs (221).  The odds ratios were: angiotensin receptor blocker (ARB) 0.57; angiotensin converting enzyme (ACE) inhibitor 0.67; calcium channel blocker (CCB); 0.75; placebo; 0.77; beta blocker; 0.90 with the thiazide group set at 1.00. Similarly, in the ALLHAT study the risk of developing diabetes was greater in the thiazide group than in patients treated with an ACE inhibitor or a CCB (222). In a meta-analysis of 10 studies of beta-blockers and 12 studies of diuretics in patients without diabetes it was found that beta-blockers increased fasting blood glucose concentrations by 11.5 mg/dL and diuretics by 13.9 mg/dl (223). As one would expect, lower doses of thiazides (hydrochlorothiazide or chlorthalidone ≤25 mg daily) had less effect on glucose levels (224). In a meta-analysis of twelve studies with 94,492 patients beta-blocker therapy resulted in a 22% increased risk for new-onset diabetes compared with nondiuretic antihypertensive agents (225). Thus, both thiazide diuretics and beta blockers increase the risk of developing diabetes while ARBs and ACE inhibitors reduce the risk (226). CCB, alpha receptor blockers (prazosin and doxazosin), and clonidine do not increase the risk of developing of diabetes (227).

 

The hyperglycemia secondary to thiazide diuretics may in some instances be due to decreased insulin secretion secondary to potassium loss, which can be improved with potassium replacement (228). Studies have suggested that combining thiazides with potassium-sparing diuretics reduces the development of hyperglycemia (229). In addition, thiazides may directly affect insulin secretion similar to diazoxide (see below). Finally, thiazides also increase insulin resistance and enhance hepatic glucose production (228).

 

The effect on glucose metabolism differs between different beta-blockers and carvedilol, a third-generation beta-blocker, has beneficial effects on glucose metabolism (226,228). A greater inhibition of insulin secretion occurs with non-selective beta-blocking agents (228). Beta blockers decrease insulin secretion and increase insulin resistance (226,228). In addition, beta-blockers increase weight, which also could adversely affect glucose homeostasis (230). Finally, beta-blockers increase the risk of severe hypoglycemia by decreasing the recovery from hypoglycemia and masking the symptoms of hypoglycemia (231).

 

Diazoxide

 

Diazoxide is a non-diuretic benzothiadiazine derivative, which increases plasma glucose levels by inhibiting insulin secretion through opening the potassium/ATP channels in beta cells (232). Diazoxide is used to control hypoglycemia in patients with insulinomas (233).

 

Statins

 

In a meta-analysis of 13 trials with over 90,000 subjects, there was a 9% increase in the incidence of diabetes during follow-up among subjects receiving statin therapy (234). All statins appear to increase the risk of developing diabetes. A more recent meta-analysis comparing low or moderate intensity statin therapy vs. placebo found that there was a 10% increase in the incidence of new diabetes whereas with high intensity statin therapy there was a 36% increase (235). In patients on intensive vs. moderate statin therapy, Preiss et al observed that patients treated with intensive statin therapy had a 12% greater risk of developing diabetes compared to subjects treated with moderate dose statin therapy (236). Older subjects, obese subjects, and subjects with high glucose levels were at a higher risk of developing diabetes while on statin therapy (235,237). Thus, statins may be unmasking and accelerating the development of diabetes that would have occurred naturally in these subjects at some point in time. In patients without risk factors for developing diabetes, treatment with statins does not appear to increase the risk of developing diabetes.

 

The mechanism by which statins increase the risk of developing diabetes is unknown (237). Studies suggest that the inhibition of HMG-CoA reductase per se may be leading to the statin induced increased risk of diabetes via weight gain (237). However, a large number of studies have now shown that polymorphisms in a variety of different genes that lead to a decrease in LDL cholesterol levels are also associated with an increase in diabetes suggesting that decreases in LDL cholesterol levels per se alter glucose metabolism and increase the risk of diabetes (237). How decreased LDL cholesterol levels effect glucose metabolism is unknown.

 

In some studies statins have been shown to increase insulin resistance (238) and in some studies to decrease insulin secretion (239,240). Clearly further studies are required to understand the mechanisms by which statins increase the risk of developing diabetes.

 

Niacin

 

A meta-analysis examined the effect of niacin therapy on the development of new onset diabetes (241). In 11 trials with 26,340 non-diabetic participants, niacin therapy was associated with a 34% increased risk of developing diabetes. This increased risk results in one additional case of diabetes per 43 initially non-diabetic individuals who are treated with niacin for 5 years. Results were similar in patients who were receiving niacin therapy in combination with statin therapy. It has been recognized for many years that niacin induces insulin resistance (242). The mechanisms by which niacin induces insulin resistance are unknown but possible mechanisms include a rebound increase in free fatty acids with niacin therapy or the accumulation of diacylglycerol (242).

 

Pentamidine

 

Pentamidine is an antiprotozoal agent known to cause hypoglycemia and hyperglycemia (228). Pentamidine induces a direct cytolytic effect on pancreatic beta cells leading to insulin release and hypoglycemia, which is then followed by beta cell destruction and insulin deficiency resulting in diabetes (243,244).

 

Phenytoin (Dilantin)

 

Phenytoin can cause hyperglycemia and there have been cases of diabetic ketoacidosis (245,246). The adverse effect of phenytoin on glucose metabolism is mediated primarily by an inhibition of insulin secretion (228).

 

Alpha Interferon

 

Treatment with alpha interferon in rare instances can cause T1D. Of 987 patients treated with alpha interferon for chronic hepatitis C, 5 patients developed T1D (247). The clinical course is characterized by the abrupt development of severe hyperglycemia at times with ketoacidosis (248). High titers of anti-islet autoantibodies are present and almost all patients require permanent insulin therapy (248). Treatment with interferon alpha facilitates the development of autoimmune disorders including T1D (249). Other autoimmune disorders frequently occur, particularly thyroid dysfunction.

 

Checkpoint Inhibitors

 

There are several checkpoint inhibitors; ipilimumab a cytotoxic T-lymphocyte-associated protein 4 inhibitor (CTLA-4 inhibitor); nivolumab and pembrolizumab, programmed cell death protein 1 inhibitors (PD-1 inhibitors); atezolizumab, avelumab, and durvalumab. programmed cell death 1 ligand inhibitors (PD-L1 inhibitors) (250). Both CTLA-4 and PD-1 play a key role in the maintenance of immunological tolerance to self-antigens thereby preventing autoimmune disorders (250). Immune mediated hypothyroidism, hyperthyroidism, hypophysitis, primary adrenal insufficiency, hypoparathyroidism, and insulin-deficient diabetes have been reported as a complication of the use of these drugs (250,251). In a meta-analysis of 38 randomized clinical trials with 7551 patients, autoimmune diabetes occurred in only 0.2% of the patients and was primarily seen with the use of PD-1 inhibitors (250). In another meta-analysis of 101 studies with 19,922 patients the incidence of autoimmune diabetes was 2.0% (95% CI, 0.7–5.8) for nivolumab and 0.4% (95% CI, 0.2–1.3) for pembrolizumab (251). The occurrence of autoimmune diabetes with other checkpoint inhibitors was rare (251).

 

The onset of diabetes ranges from a few weeks up to one year after initiating therapy and typically presents with polyuria, polydipsia, weight loss, and dehydration (251,252). Severe hyperglycemia and ketoacidosis are commonly observed (252). Because of the acute occurrence, A1c levels may not be elevated. C-peptide levels are very low and approximately 50% of patients have islet cell antibodies (GAD, ICA, IAA or IA-2; GAD antibodies are the most commonly observed) (251,252). Insulin treatment is required, and it is likely that the diabetes will be irreversible (251,252).

 

For additional information on the checkpoint inhibitor associated diabetes see the Endotext chapter “Immune Checkpoint Inhibitors Related Endocrine Adverse Events” in the Disorders that Affect Multiple Organs section (253).

 

Antipsychotic Drugs

 

Many studies have linked second generation antipsychotic medications with the development of T2D (Table 5) (254,255). In a meta-analysis of a large number of studies it was reported that olanzapine and clozapine treatment resulted in a greater increase in glucose abnormalities than aripiprazole, quetiapine, risperidone and ziprasidone (256). Another meta-analysis has further shown that aripiprazole has a reduced risk of T2D compared to other antipsychotic agents (257). With regards to first generation antipsychotic drugs, chlorpromazine has a high risk of disrupting glucose metabolism while haloperidol, fluphenazine, and perphenazine have a low risk (254). It is thought that antipsychotic drugs induce diabetes by multiple mechanisms: (1) they inhibit insulin signalling in muscle cells, hepatocytes, and adipocytes thereby causing insulin resistance; (2) they induce obesity, which can also cause insulin resistance; and (3) they can cause direct damage to β-cells, leading to dysfunction and apoptosis of β-cells (255,258).

 

Table 5. Risk of Diabetes of Selected First- and Second-Generation Antipsychotics

 

Risk of diabetes*

First-generation antipsychotic

  Chlorpromazine

  Fluphenazine

  Perphenazine          

  Haloperidol  

 

+++

+

+

+

Second-generation antipsychotic

  Clozapine     

  Olanzapine  

  Quetiapine   

  Risperidone 

  Ziprasidone  

  Aripiprazole  

  Paliperidone 

  Lurasidone   

 

+++

+++

++

++

+

+

+

+

*Relative to other antipsychotics. Not all the risk of diabetes or weight gain are related to the antipsychotics. Table modified from (255)

 

Androgen Deprivation Therapy

 

A number of studies have shown that androgen deprivation therapy increases the risk of developing diabetes (259). For example, a study by Tsai reported that androgen deprivation therapy was associated with a 1.61-fold increased diabetes risk and the number needed to harm was 29 (260). The androgen deprivation induced diabetes typically develops after a year of treatment (259). Androgen deprivation therapy induces insulin resistance (259). The increase in insulin resistance may be due to an increase in visceral fat mass and/or an increase in pro-inflammatory adipokines such as TNF-a, IL-6, and resistin (259).

 

Immunosuppressive Drugs

 

Immunosuppressive drugs used after organ transplantations increase the risk of diabetes (261). In general, tacrolimus has been associated with a greater risk of developing diabetes compared to cyclosporine (261,262). The calcineurin inhibitors, tacrolimus and cyclosporine, decrease insulin secretion and synthesis (261,262). Additionally, tacrolimus and cyclosporine inhibit glucose uptake in human subcutaneous and omental adipocytes (262).

 

Mechanistic Target of Rapamycin Inhibitors (mTOR inhibitors)

 

mTOR inhibitors, sirolimus and everolimus, can induce diabetes (263). The adverse effect of mTOR inhibitors on glucose metabolism is due to insulin resistance secondary to a reduction of the post receptor insulin signalling pathway and a reduction of insulin secretion via a direct effect on the pancreatic beta cells (261,263).

 

Asparaginase

 

Hyperglycemia is common with the use of asparaginase treatment ranging from 2.5% to 23% in the pediatric population and as high as 76% in adults with PEG-asparaginase use (264,265). Hyperglycemia usually resolves within 12 days after the last dose (264). Risk factors predisposing to hyperglycemia with asparaginase treatment include a history of impaired glucose tolerance, age >10 years, obesity, family history of diabetes mellitus, and history of Down syndrome (264,265). Diabetic ketoacidosis has been described with asparaginase treatment but is not a common occurrence (264). Decreased insulin secretion, increased insulin resistance, and increased glucagon secretion may contribute to the hyperglycemia observed with asparaginase. Additionally, asparaginase can induce pancreatitis, which can also lead to hyperglycemia (264).

 

Antibiotics

 

Fluoroquinolones have been associated with an increased risk of hyperglycemia, particularly in the elderly (228). The risk of developing hyperglycemia is greatest with gatifloxacin (228).

 

Beta-Adrenergic Drugs

 

High doses of beta-adrenergic drugs can lead to hyperglycemia likely due to the stimulation of hepatic gluconeogenesis (228).

 

Teprotumumab

 

Teprotumumab blocks the activation of the insulin-like growth factor-1 receptor (IGF-1 receptor). Initial studies in patients with thyroid eye disease found that approximately 10% of patients had hyperglycemia and one-third of these individuals with hyperglycemia did not have pre-existing diabetes or impaired glucose tolerance but the study by Amarikwa et al found a higher risk of hyperglycemia (209,266,267). Older age, prediabetes/diabetes, and Asian and Hispanic ethnicity may increase the risk of hyperglycemia. Case reports of diabetic ketoacidosis and hyperglycemic hyperosmolar state have been reported (268,269). In some but not all patients glycemia returns towards normal when teprotumumab treatment is completed. Blocking the activation of the IGF-1 receptor may lead to an increase in growth hormone secretion leading to hyperglycemia (270). Additionally, adverse effects on insulin receptors that interact with the IGF-1 receptor may lead to insulin resistance (270).

 

Glucocorticoids, Somatostatin, Growth Hormone, and Glucagon

 

The effects of these hormones on glucose metabolism were discussed in the section on Endocrinopathies.

 

HIV Antiretroviral Therapy

 

The effect of the drugs used to treat patients living with HIV on the development of diabetes is discussed in the Endotext chapter “Diabetes in People Living with HIV” in the Diabetes section (6).

 

IMMUNE-MEDIATED

 

Latent Autoimmune Diabetes in Adults (LADA)

 

LADA is an autoimmune disorder that resembles T1D but shows a later onset and slower progression towards requiring insulin therapy (271-273). The ADA includes LADA as T1D whereas WHO classifies LADA as a hybrid form of diabetes (T1D and T2D) (96) (https://www.who.int/publications/i/item/classification-of-diabetes-mellitus). Epidemiological studies suggest that LADA may account for 2–12% of all cases of diabetes in the adult population (271,272,274). To differentiate LADA from T1D and T2D, the Immunology of Diabetes Society has proposed three criteria: (a) adult age of onset (> 30 years of age); (b) presence of at least one circulating autoantibody (GAD, ICA, IAA or IA-2) and; (c) insulin independence for the first 6 months after the time of diagnosis (271,272). Of the various antibodies associated with autoimmune diabetes, GAD antibodies are present in most patients with LADA (271,272,274). Patients with high titers of GAD antibodies progress to requiring insulin more rapidly (273). LADA subjects appear to have a faster decline in C-peptide levels compared to autoantibody negative patients with T2D (274). It should be noted that classic T1D can occur in adults and this is defined as those adult patients with antibodies (GAD, ICA, IAA or IA-2) that require insulin therapy at diagnosis or soon after diagnosis (272,274). In contrast, patients with LADA can often go many years before requiring insulin therapy (272). Whether LADA is just a slowly progressing form of T1D or a hybrid T1D and T2D is unclear (Table 6).

 

Table 6. Comparison of T1D, LADA, and T2D

 

T1D

LADA

T2D

Age of onset

Tend to be young

>age 25

Tend to be adult

Family history

Occasional

Occasional

Usually

C-peptide

Low, often undetectable

Varies

Normal or high

Auto-ab

+

+

-

Weight

Tend to be lean

Tend to be lean

Usually overweight

Metabolic syndrome

No

Varies

Usually

Insulin requirement

Yes

Varies

Varies

Genetic risk

HLA

PTPN22

INS

SH283

PFKFB3

Intermediate between T1D & T2D

TCF7L2

FTO

SLC30A8

 

In a retrospective study, Fourlanos and colleagues pointed out several features that increase the likelihood of a patient with “T2D” having LADA (275). These features include age of onset <50 years of age,  acute symptoms (polyuria, polydipsia, weight loss), BMI <25 kg/m2, personal history of autoimmune disease, and family history of autoimmune disease (275). The presence of at least two of these clinical features indicated a 90% sensitivity and 71% specificity for identifying a patient with LADA (275). As compared to patients with T2D, LADA patients have a lower rate of hypertension, lower total cholesterol levels, higher HDL cholesterol levels, and a decreased frequency of the metabolic syndrome (272,274). HLA-DQB1 risk genotypes have been consistently positively associated and protective genotypes have been negatively associated with LADA (273). However, in addition to genotypes that are associated with T1D, patients with LADA also have an increased frequency of genotypes that are associated with T2D (TCF7L2, FTO, and SLC30A8) (273). Having a healthy lifestyle and a BMI<25 is associated with a reduced risk of LADA including in individuals with a genetic susceptibility (276). Individuals with other autoimmune diseases are more likely to develop LADA (277).

 

Some have proposed GAD antibody testing all patients with T2D (278) to diagnose LADA but given the given the increased costs and the relatively frequent occurrence of false positive tests compared to true positives in a low-risk population this strategy is not widely accepted (279). The ADA suggests selective testing in adults without traditional risk factors for T2D and/or younger age (96). 

 

In LADA patients glycemic control can initially be achieved with hypoglycemic agents other than insulin but overtime patients progress to requiring insulin therapy. Sulfonylureas seem to accelerate the progress to requiring insulin therapy and therefore should be avoided (280). Because of the progressive loss of beta cell function there is an increased risk of diabetic ketoacidosis with SGLT2 inhibitors and therefore these drugs should be used with caution. Monitoring ketone levels in patients with LADA treated with SGLT2 inhibitors would be prudent. Novel therapies to preserve beta cell function would be ideal for patients with LADA but at this time there are no proven strategies to preserve beta cell function. However, there are several studies from China that suggest that vitamin D may slow the loss of beta cell function (281-283)

 

In a long- term follow-up (median 17.3 years) comparing microvascular outcomes in patients with LADA or T2D it was observed that the risk of renal failure/death, blindness, vitreous hemorrhage, or retinal photocoagulation was decreased in the patients with LADA during the first 9 years (adjusted HR 0.45; p<0.0001), whereas in subsequent years their risk was higher (HR 1·25; p=0.047) (284). This difference was attributed to higher A1c levels in the LADA patients. The prevalence of coronary heart disease and cardiovascular mortality is similar in patients with LADA and T2D (285,286). Mortality is increased in patients with LADA (HR 1.44), compared to controls (287).

 

Autoimmune Polyglandular Syndromes

 

T1D can occur as part of the autoimmune polyglandular syndromes. These disorders are discussed in the Endotext chapter “Autoimmune Polyglandular Syndromes” in the Disorders that Affect Multiple Organs section (4).

 

Stiff-Person syndrome

 

Stiff-person syndrome is a rare autoimmune disorder of the nervous system with fluctuating stiffness and spasm of the skeletal muscles that occurs more frequently in females than males (approximately 2/3 women) (288). Rigidity is caused by simultaneous contracture of agonist and antagonist muscles. Muscle involvement is symmetrical, and the lower extremities are affected more commonly than the upper extremities and proximal limb and axial muscles are affected more severely than distal muscles (288). Most patients have very high levels of anti-glutamic acid decarboxylase (GAD) antibodies (288). 30-65% of these individuals also develop beta cell destruction and T1D (289). Diabetes may occur several years prior to the development of the stiff-person syndrome (60%) or after the development of the stiff-person syndrome (288,289). The stiff person syndrome without GAD antibodies is not associated with diabetes (289). The GAD antibodies in patients with T1D and stiff-person syndrome recognize a different set of epitopes and have distinct biological effects (290). Other autoimmune manifestations are also common, particularly thyroid disorders and pernicious anemia (288,289). It should be noted that a variety of neurological disorders (cerebellar ataxia, limbic and extra-limbic encephalitis, nystagmus/oculomotor dysfunction, drug-resistant epilepsy, etc.) are associated with GAD antibodies (290).

 

Autoimmune Insulin Resistance Type B Syndrome

 

Insulin resistance can result from autoantibodies directed against the insulin receptor, which either inhibit insulin from binding to the receptor or stimulate the receptor (291). Thus, they can cause either hyperglycemia or hypoglycemia, even alternating in the same patient. Low titers of insulin receptor antibodies typically lead to hypoglycemia while high titers result in hyperglycemia but the possibility of epitope switching may also determine if hyperglycemia or hypoglycemia is manifest (292,293). The patients usually present with very high glucose levels with high fasting insulin levels  and significant weight loss (291,293). Serum triglyceride levels are typically low and HDL cholesterol levels normal, which contrasts with typical patients with insulin resistance who usually have high triglyceride levels and low HDL cholesterol levels. This difference is explained by post receptor insulin resistance stimulating lipogenesis whereas insulin resistance localized to the receptor does not (294). The diagnosis can be confirmed by demonstrating the presence of autoantibodies to the insulin receptor. The prevalence of type B insulin resistance syndrome is unknown but is quite rare (291). Middle-aged women are most often affected and often have other manifestations of autoimmune disease such as SLE or Sjogren’s. However, this disorder can also affect males and younger patients. In some instances, the type B insulin resistance syndrome occurs as a paraneoplastic manifestation of lymphoma or multiple myeloma. Patients may have signs of insulin resistance including acanthosis nigricans and ovarian hyperandrogenism. Of note the acanthosis nigricans may involve the lips and the periocular region resulted in a typical facial appearance (291). Serum testosterone levels are often elevated in females (291). Patients often need excessive amounts of insulin (1,000 U or more per day). One can add insulin sensitizers such as metformin and/or thiazolidinediones to try to reduce the insulin dose, which can in some patients be greater than 10,000U per day (291). Treatment includes immunosuppression and/or plasmapheresis to halt the autoantibody production and decrease antibody levels (295). Treatment with rituximab, high-dose steroids, and cyclophosphamide until remission, followed by maintenance therapy with azathioprine is very effective in inducing and maintaining remissions. Approximately 1/3 of patients will undergo a spontaneous remission with reversal of the hyperglycemia/hypoglycemia and the clinical manifestations (291).

 

DIABETES OF UNKNOWN CAUSE

 

Ketosis-Prone Diabetes in Adults (Flatbush Diabetes)

 

This syndrome is characterized by the acute onset of severe hyperglycemia with or without ketoacidosis, which after several weeks to months no longer requires insulin therapy and can be treated with diet or oral hypoglycemic agents (296,297). These patients typically have a history of polyuria, polydipsia, and weight loss for less than 4 to 6 weeks indicating an abrupt onset of the disorder in glucose metabolism and no history of an event that could have precipitated the hyperglycemia (297). The initial presentation is suggestive of T1D. While in most patients insulin therapy can be stopped there are some patients who continue to require insulin treatment (296). This syndrome occurs in black populations (African American, African-Caribbean, sub-Saharan African), Hispanic populations, and Asian (Chinese, Indian, and Japanese) populations but is not typically seen in Caucasians (296,297).  The typical patient is male, middle-aged, overweight or modestly obese with a strong family history of diabetes (296,297). Patients are negative when tested for islet cell antibodies (GAD, ICA, IAA or IA-2) (296). Recurrent episodes of ketoacidosis can occur, but the clinical course is typical of patients with T2D (296,297). Treatment with hypoglycemic agents reduces the risk of recurrence (297,298). SGLT2 inhibitors should be used with caution given the risk of recurrent ketoacidosis. With long-term follow-up many patients eventually require insulin therapy similar to what is observed in patients with T2D (298).

 

During the episode of severe hyperglycemia patients with ketosis-prone diabetes have lost the ability of glucose to stimulate beta cell insulin secretion but nonglycemic pharmacologic agents (glucagon and arginine) can stimulate insulin secretion (296). After restoration of normal glycemia the ability of glucose to stimulate insulin secretion returns towards normal and by 8-12 weeks has maximally improved (296). Usually patients with this syndrome have a modest reduction in stimulated insulin secretion (296). Why these patients temporarily lose the ability for glucose to stimulate insulin secretion is unknown. Additionally, during the acute episode of hyperglycemia the patients are severely insulin resistant, which improves during a period of euglycemia (297,298).

 

Clinically, it is important to recognize this syndrome as some patients presenting with diabetic ketoacidosis, particularly if they are non-Caucasians, may not have T1D but rather have ketosis-prone diabetes. It is estimated that between 20% and 50% of African-American and Hispanic patients with a new diagnosis of diabetic ketoacidosis have ketosis-prone diabetes (297). After restoration of euglycemia the management of these patients is similar to the management of patients with T2D, and they frequently do not require permanent insulin treatment.

 

OTHER GENETIC SYNDROMES SOMETIMES ASSOCIATED WITH DIABETES

 

There are a number of inherited monogenic disorders that secondarily can be associated with diabetes. The mechanisms linking these disorders with diabetes are often not clear.

 

Chromosomal Abnormalities

 

DOWN SYNDROME

 

Down syndrome is due to trisomy of chromosome 21 and occurs in 1 in every 787 liveborn babies (299). Down syndrome is often associated with autoimmune disorders like T1D and thyroiditis (299,300). The prevalence rate of T1D in patients with Down syndrome has been estimated to be between 1.4 and 10.6%, which is higher than in the general population (301). In another study there was a 4-fold increased prevalence of diabetes in patients with Down syndrome (302). Diabetes in patients with Down syndrome often presents earlier in life with 22% of participants developing diabetes by 2 years of age (303). The presence of diabetes is often associated with other autoimmune disorders, particularly hypothyroidism and celiac disease (300). Anti-glutamic acid decarboxylase antibodies (GAD antibodies) are very frequently present in Down syndrome subjects who develop diabetes (300). Downs syndrome patients with diabetes have similar HLA genotypes as non-Down syndrome patients with T1D (300). Interestingly, while patients with Down syndrome and diabetes are typically treated with simpler regimens their glycemic control tends to be as good or better than the usual patient with T1D, perhaps related to a simpler lifestyle and acceptance of routine (300). The cause of the increased autoimmunity in patients with Down syndrome may be due to the abnormal expression of the AIRE gene, which regulates T-cell function and self-recognition and is located on chromosome 21 (21q22.3 region) (299,300).

 

While the incidence of T2D is similar between patients with Down syndrome and controls, the onset of T2D occurs at a much earlier age (304). The incidence for T2D is >10 times higher in patients aged 5–14 years with Down syndrome compared to controls. In individuals under the age of 45, Down syndrome is associated with an increased incidence of diabetes while over the age of 45, the incidence of diabetes is increased in controls.  Notable the BMI in increased in younger patients with Down syndrome compared to controls and could contribute to the increase in T2D.

 

KLINEFELTER SYNDROME

 

Klinefelter syndrome is due to an extra X chromosome in men (XXY) resulting in hypergonadotropic hypogonadism, low testosterone levels, gynecomastia, and reduced intelligence (305,306). The prevalence of Klinefelter syndrome is approximately 1 in 500 to 1 in 1000 males (305,306). Patients with Klinefelter syndrome are frequently obese, insulin resistant, and at increased risk to develop T2D (50% have the metabolic syndrome) (307,308). The decreased muscle mass and increased fat mass that often occur in patients with Klinefelter syndrome contribute to the high prevalence of insulin resistance and metabolic syndrome. The prevalence of overt diabetes in Klinefelter syndrome is estimated to be between 10-39% (307,309). Additionally, the prevalence of diabetes is even higher (up to 57%) in patients with more severe karyotypes (48, or 49 chromosomes) (307). Klinefelter syndrome patients develop diabetes earlier in life (onset around 30 years) and their BMI is lower than what is usually observed in patients with T2D (307). Hypogonadism is associated with insulin resistance and an increased risk of diabetes and whether testosterone therapy will be of benefit in preventing or treating diabetes in patients with Klinefelter syndrome is uncertain (309). Given the increased risk of developing T2D, patients with Klinefelter syndrome should be periodically screened for diabetes.

 

Interestingly, one study reported an increased prevalence of T1D in patients with Klinefelter syndrome (310). Furthermore, a study reported that 8.2% of patients with Klinefelter syndrome had autoantibodies specific to T1D (Insulin Abs, GAD Abs, IA-2 Abs, Znt8 Abs) (311). Additional studies are required to better elucidate whether Klinefelter syndrome increases the risk of developing T1D.

 

TURNER SYNDROME

 

Turner syndrome is the most common chromosomal abnormality in girls, affecting approximately 1:2,500 female live births (312). The condition is caused by complete or partial deletion of an X chromosome (312). The incidence of both T1D and T2D has been reported to be increased in patients with Turner syndrome (313). However, the link between T1D and Turner syndrome is not well characterized while the link with T2D is clearly established (314,315). For example, in a study of 224 patients with Turner syndrome 56 (25%) had T2D whereas only 1 patient (<0.5%) had T1D (316). Patients with Turner syndrome have an increased risk of autoimmune disorders, particularly hypothyroidism and celiac disease, but the prevalence of autoimmune T1D is much less (315,317). Four percent of patients with Turner syndrome have been shown to have GAD antibodies, which is greater than the 1% prevalence seen in the general population (317).

 

The prevalence of glucose intolerance is estimated to be from 15-50% while the prevalence of T2D is estimated to be approximately 10-25% (315,316). T2D occurs at a relatively young age in patients with Turner syndrome. A 25%-70% lifetime risk for diabetes has been described (318). Decreased beta cell function and decreased insulin sensitivity was observed in teenagers with Turner syndrome and was accompanied by an increased prevalence of impaired fasting glucose and impaired glucose tolerance compared to controls (319). Increased obesity is common in patients with Turner syndrome, which likely contributes to the abnormalities in glucose metabolism (314). Both insulin resistance and decreased insulin secretion are present in patients with Turner syndrome but the development of hyperglycemia in patients with T2D appears to be driven by decreased insulin secretion (314,315). Because of the high prevalence of diabetes, it is recommended to screen A1c with or without fasting glucose levels annually beginning at 10-12 years of age or sooner with symptoms of diabetes and then every 1-2 years (315,318). When diabetes is diagnosed,measuring diabetes auto-antibodies is helpful in differentiating T1D vs, T2D in patients with Turner syndrome (318). Growth hormone therapy does not appear to increase the risk or worsen diabetes (314,315). Growth hormone therapy may lead to a decrease in adiposity and impaired glucose tolerance, which suggests it may actually improve glucose homeostasis (315). Similarly, sex steroid hormone replacement therapy also does not appear to have major adverse effects on glucose metabolism in patients with Turner syndrome (314).

 

WILLIAMS SYNDROME

 

Williams syndrome (Williams-Beuren syndrome) is a multisystem disorder characterized by transient infantile hypercalcemia, distinctive facial dysmorphism, and supravalvular aortic stenosis (320,321). In addition, gastrointestinal problems, dental anomalies, developmental delay/intellectual disability, anxiety disorders, and attention deficit disorder may occur as well as a variety of endocrine abnormalities including reduced statural growth, obesity, dyslipidemia, early pubertal development, hypothyroidism, and decreased bone density (320,322). Williams syndrome is due to a deletion on chromosome 7q, leading to the loss of 25–27 contiguous genes and thus individuals with Williams syndrome have only a single copy of these genes (321). This deletion almost always arises de novo in the affected individual. The estimated prevalence of Williams syndrome is ~1/7,500 and effects both males and females (321).

 

Numerous studies have shown a high prevalence of T2D and impaired glucose tolerance in patients with Williams syndrome (320). The abnormalities in glucose metabolism occur during adolescence and are not necessarily associated with obesity (320). Of note insulin resistance is observed initially followed by a loss of insulin secretion (320). Markers of islet autoimmunity are not observed (320). In a review of 7 studies with 154 participants with Williams syndrome and an average age ranging from 13 to 35 years of age it was observed that 18% had diabetes and 42% impaired glucose tolerance (320). Because of this high risk for diabetes, it is recommended that patients with Williams syndrome be screened for diabetes beginning in adolescence (320). Note-worthy is that A1c was frequently not abnormal and therefore screening should be with fasting glucose levels or an oral glucose tolerance test (320).

 

Diseases of the Endoplasmic Reticulum

 

The endoplasmic reticulum folds and modifies newly formed proteins to make them function properly. Therefore, diseases affecting the endoplasmic reticulum usually affect many organs. Wolfram syndrome is the best known but there are other genetic syndromes that affect the endoplasmic reticulum and cause diabetes (323).

 

WOLFRAM SYNDROME 

 

Wolfram syndrome is a rare autosomal recessive genetic disorder characterized by T1D, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration (324,325). There are also rare autosomal dominant forms of this disorder (325). This syndrome is sometimes called DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness). The prevalence is approximately one per 770,000 but varies depending upon the specific population (324,325). The onset of the clinical picture is highly variable in both severity and clinical manifestations (325). This disorder typically has a very poor prognosis with the median age at death being 30 years (324). Diabetes mellitus is usually the first manifestation, typically diagnosed around age 6 (324). The diabetes is not immune mediated but is characterized by insulin deficiency (325). Almost all patients require insulin therapy (325). Residual beta cell function persists and therefore good glycemic control tends to be easier to achieve in Wolfram syndrome than immune mediated T1D (325). However, over time C-peptide levels decrease (326). The development of optic atrophy and hearing loss in children with diabetes are clues to the presence of this syndrome. Until the onset of optic atrophy and hearing loss these patients are usually thought to have typical T1D with an absence of antibodies (325). Confirmation of the diagnosis can be made by identifying mutations in the WFS1 gene (Wolfram syndrome type 1) (324). The WFS1 gene encodes a transmembrane protein (wolframin) localized to the ER (endoplasmic reticulum) and mutations result in ER stress leading to beta cell dysfunction and death (324).

 

Mutations in CISD2 gene cause a similar recessive type of Wolfram syndrome (Wolfram syndrome type 2) with patients exhibiting bleeding from upper intestinal ulcers and defective platelet aggregation without diabetes insipidus and psychiatric disorders (325). CISD2 encodes for a protein that moves between the ER and mitochondrial outer membrane (325).  

 

Unfortunately, there are currently no specific treatments to restore ER function and prevent the complications of this disorder.

 

Base Pair Repeat Syndromes     

 

FRIEDRICHS ATAXIA

 

Friedreich ataxia is a rare recessive disorder caused by triplet repeats (GAA) in the mitochondrial frataxin gene characterized by slowly progressive ataxia associated with dysarthria, muscle weakness, spasticity particularly in the lower limbs, scoliosis, bladder dysfunction, absent lower limb reflexes, and loss of position and vibration sense (327). The onset usually occurs before 25 years of age (327). Cardiomyopathy occurs in 2/3 of patients and up to 30% of patients have diabetes (327). The disorder affects approximately 1 in 30,000 Caucasians.

 

Diabetes occurs in 8-32% of patients with Friedrichs ataxia, and an even higher percentage have impaired glucose tolerance (328,329). Hyperglycemia commonly develops approximately 15 years after the manifestation of neurological symptoms often presenting acutely with patients requiring insulin therapy (328,329). In a number of instances patients present with ketoacidosis (329). Both insulin deficiency and insulin resistance have been reported in patients with Friedreich ataxia (329). It is hypothesized that mutations in frataxin result in alterations in mitochondria function that impair the ability of beta cells to secrete insulin in response to glucose and increase the risk of beta cell death (329). Diabetes is an independent predictor of reduced survival in Friedrichs ataxia (330).

 

There are no controlled studies comparing different diabetes therapies in patients with Friedreich ataxia. Metformin and thiazolidinediones inhibit the mitochondrial respiratory chain and therefore they should probably be used with caution in patients with mitochondrial disease (329). Additionally, thiazolidinediones increase the risk of congestive heart failure and patients with Friedreich ataxia have a high risk of cardiomyopathies and therefore should be avoided. Insulin is often required to achieve glycemic control.

 

HUNTINGTON’S DISEASE

 

Huntington’s disease is an autosomal dominant disorder that begins in adulthood (usually 30-50 years of age) and has distinctive motor defects (chorea, dystonia, and dyskinesia), psychiatric symptoms (depression and anxiety), and cognitive decline (331). This disorder is due to an unstable expansion of CAG repeats in the first exon of the gene that encodes the protein huntingtin (331). The prevalence of this disorder is approximately 5-12 per 100,000 (331,332). While an early study reported that approximately 10% of patients with Huntington’s disease have diabetes a careful review of recent studies reached the conclusion that the prevalence of diabetes in patients with Huntington’s disease is not increased and might actually be decreased (332,333).

 

MYOTONIC DYSTROPHY

 

Myotonic dystrophy type 1 is an autosomal-dominantly inherited disease characterized by myotonia, distal muscular dystrophy, cataracts, hypogonadism, and frontal hair loss that occurs in middle age (334). The disease is due to a CTG triplet repeat expansion in the myotonic dystrophy protein kinase gene (334). In genetic new-born screening the estimated prevalence is  approximately 1:2100 individuals (335). Diabetes is not a characteristic finding in myotonic dystrophy type 1, but the prevalence is increased 2-4-fold in patients with this disorder compared to the general population (334,336,337). A large study in Korea with 387 patients with myotonic dystrophy type 1 found that 27% had diabetes (338). Patients with myotonic dystrophy type 1 and diabetes have elevated insulin levels suggesting insulin resistance (334,336). Pioglitazone alone and in combination with metformin has been reported to improve glycemic control in patients with myotonic dystrophy and diabetes (339,340).

 

Obesity Syndromes

 

BARDET-BIEDLE SYNDROME (BBS)

 

Bardet-Biedl syndrome (BBS), also earlier referred to as Laurence Moon Biedl syndrome, is a rare autosomal recessive disease with a prevalence of about 1/125,000 (341,342). BBS belongs to the group of ciliopathies characterized by obesity, retinal degeneration, finger anomalies, hypogonadism, renal abnormalities, and intellectual impairment (341,342). It can result from autosomal recessive mutations in at least 26 genes (BBS), which play a key role in the structure and function of cilia (341-343). In a study of 152 patients with BBS it was reported that approximately 75% were obese and the average BMI was 35.7kg/m2 (342). Twenty-five of these patients with BBS had diabetes (16.4%) with 24 having T2D and 1 having T1D (342). Of the 24 patients with T2D six patients were diet controlled, eight were taking metformin, and 10 were on insulin therapy. The mean A1c of subjects with T2D was 7.8 (342). The risk of developing diabetes increases with age. In the BBS patients without diabetes fasting glucose, insulin levels, and HOMA-IR were significantly increased in the BBS group compared with an age and BMI matched control group (342). The metabolic syndrome was present in 54% of the patients with BBS (342). There is evidence that BBS genes affect cilia that alter leptin trafficking and signaling thereby impacting the melanocortin 4 receptor (MC4R) pathway (344). In a small trial setmelanotide reduced body weight (16.3% decrease at 12 months) and hunger in individuals with BBS (345). Other trials also observed a decrease in body weight and hunger in individuals with BBS treated with setmelanotide (346,347). One would anticipate that weight loss will reduce the risk of diabetes on patients with BBS. Setmelanotide is approved by the FDA for the treatment of BBS.

 

PRADER WILLI SYNDROME (PWS)

 

PWS is a rare autosomal dominant disorder, affecting 1 in 15,000 newborns, due to a mutation or deletion of several genes in an imprinting region on chromosome 15 (344,348). PWS in children is associated with excessive eating and morbid obesity, hypogonadism, low muscle tone, growth hormone deficiency, and short stature (344,348). The hyperphagia that occurs in PWS is believed to be due to a hypothalamic abnormality resulting in lack of satiety. This leads to excessive obesity in children, which is often associated with T2D due to severe insulin resistance (348). Approximately 20- 25% of adults with PWS have T2D with a mean age of onset of 20 years (348,349). Individuals with PWS who develop early diabetes have severe obesity, a high prevalence of psychiatric and metabolic disorders, and a family history of overweight and T2D (349). Screening for diabetes is recommended annually if obese or beginning in adolescence or with rapid significant weight gain or other symptoms. In recent years the earlier diagnosis and education of parents, use of growth hormone therapy, and the frequency of group homes specific for PWS have led to a reduction in the development of morbid obesity resulting in a decrease in the development of T2D among individuals with PWS (348). Metformin has been shown to be effective in the treatment of PWS patients with diabetes (350). Studies of GLP1 receptor agonists demonstrated lowering of A1c levels and weight loss is some patients (351,352).

 

ALSTROM SYNDROME

 

Alstrom syndrome is a rare autosomal recessive disorder with a prevalence of less than one per million characterized by retinal dystrophy, hearing loss, childhood truncal obesity, insulin resistance and hyperinsulinemia, T2D, hypertriglyceridemia, short stature in adulthood, cardiomyopathy, and progressive pulmonary, hepatic, and renal dysfunction (353-355). Symptoms appear in infancy and multi-organ pathology lead to a decreased life expectancy (353,354). The syndrome is caused by mutations in ALMS1, which is a ciliary protein and hence many of the features of Alstrom syndrome resemble those seen in the Bardet-Biedl syndrome (353-355). Diagnosis is confirmed by finding biallelic pathogenic variants in ALMS1 gene.

 

Severe insulin resistance secondary to abnormalities in GLUT4 trafficking, hyperinsulinemia, and impaired glucose tolerance frequently present in early childhood and are often accompanied by acanthosis nigricans (353,355). T2D develops early in life with a mean age of onset at 16 years (353). In one study 82% of patients with Alstrom syndrome older than 16 years of age had T2D (356). Weight loss with diet, exercise, and medications is indicated (357). Therapy with oral agents, particularly insulin sensitizing agents, may be effective but insulin therapy may be required (353,357). GLP-1 receptor agonists induced weight loss and improved glycemic control (358).

 

Miscellaneous

 

WERNER SYNDROME (WS)

 

Werner syndrome (WS) is an autosomal recessive progeroid syndrome due to biallelic WRN pathogenic variants (359). Clinical features include accelerated aging, short stature, skin atrophy, decreased skeletal muscle mass, hair graying and baldness, partial loss of subcutaneous fat, and cataracts (359). Clinical problems include hypogonadism, osteoporosis, dyslipidemia, atherosclerosis, and cancer (359). Diabetes occurs in 50-75% of patients with WS (360). It is recommended that patients with WS be screened yearly for diabetes (359). The mean age of onset of diabetes is 30-40 years (360). The BMI of most patients with WS is low to normal but patients with diabetes have a higher BMI that is still in the normal range and increased visceral fat (360). It is thought that a decrease in subcutaneous fat leads to visceral fat and insulin resistance ultimately resulting in diabetes. Treatment with thiazolidines (TZDs) or metformin is felt to be beneficial but one needs to balance the beneficial effects of TZDs on glucose metabolism with the risk of osteoporosis associated with TZDs in WS patients who are increased risk for osteoporosis (360). In a case report metreleptin improved glycemia and reduced triglyceride and cholesterol levels (361).

 

PORPHYRIA

 

Porphyria cutanea tarda has been associated with diabetes (362), but given that many patients with this disorder also have iron overload, genes for hemochromatosis, and HCV and HIV infection it is very difficult to tell if porphyria cutanea tarda per se is responsible for the association with diabetes (363,364).

 

ACKNOWLEDGEMENTS

 

This work was supported by grants from the Northern California Institute for Research and Education.

 

REFERENCES

 

  1. Akinci B, Sahinoz M, Oral E. Lipodystrophy Syndromes: Presentation and Treatment. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  2. Naylor RN, Philipson LH. Diagnosis and Clinical Management of Monogenic Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2020.
  3. Pham PT, Sidhu HS, Pham PM, Pham PC. Diabetes Mellitus After Solid Organ Transplantation. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2022.
  4. Sperling MA, Angelousi A, Yau M. Autoimmune Polyglandular Syndromes. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  5. Wang XY, Cleary EM, Thung SF, KK V, Buschur EO. Gestational Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  6. Sarkar S, Brown TT. Lipid Disorders in People with HIV. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.
  7. Unnikrishnan AG, R.C. B, Kumaran S, Kalra S. Fibrocalculous Pancreatic Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  8. Li HZ, Li RY, Li M. A review of maternally inherited diabetes and deafness. Front Biosci (Landmark Ed) 2014; 19:777-782
  9. Murphy R, Turnbull DM, Walker M, Hattersley AT. Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation. Diabet Med2008; 25:383-399
  10. Chanoine JP, Thompson DM, Lehman A. Diabetes Mellitus Associated with Maternally Inherited Diabetes and Deafness (MIDD): From Pathogenic Variant to Phenotype. Diabetes 2025; 74:153-163
  11. Maassen JA, Jahangir Tafrechi RS, Janssen GM, Raap AK, Lemkes HH, t Hart LM. New insights in the molecular pathogenesis of the maternally inherited diabetes and deafness syndrome. Endocrinol Metab Clin North Am2006; 35:385-396, x-xi
  12. Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, Saneto R, Anselm I, Cohen BH, Falk MJ, Greene C, Gropman AL, Haas R, Hirano M, Morgan P, Sims K, Tarnopolsky M, Van Hove JL, Wolfe L, DiMauro S. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med 2015; 17:689-701
  13. Semple RK, Savage DB, Cochran EK, Gorden P, O'Rahilly S. Genetic syndromes of severe insulin resistance. Endocr Rev 2011; 32:498-514
  14. Taylor SI. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992; 41:1473-1490
  15. Musso C, Cochran E, Moran SA, Skarulis MC, Oral EA, Taylor S, Gorden P. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore)2004; 83:209-222
  16. Stears A, O'Rahilly S, Semple RK, Savage DB. Metabolic insights from extreme human insulin resistance phenotypes. Best Pract Res Clin Endocrinol Metab 2012; 26:145-157
  17. Cochran E, Young JR, Sebring N, DePaoli A, Oral EA, Gorden P. Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. J Clin Endocrinol Metab 2004; 89:1548-1554
  18. Okawa MC, Cochran E, Lightbourne M, Brown RJ. Long-term effects of metreleptin in Rabson-Mendenhall Syndrome on glycemia, growth, and kidney function. J Clin Endocrinol Metab 2021;
  19. Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (Type 3c)--are we neglecting an important disease? Eur J Intern Med 2013; 24:203-206
  20. Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, Hardt PD. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev 2012; 28:338-342
  21. Hart PA, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Forsmark CE, Goodarzi MO, Habtezion A, Korc M, Kudva YC, Pandol SJ, Yadav D, Chari ST, Consortium for the Study of Chronic Pancreatitis D, Pancreatic C. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol 2016; 1:226-237
  22. Pendharkar SA, Mathew J, Petrov MS. Age- and sex-specific prevalence of diabetes associated with diseases of the exocrine pancreas: A population-based study. Dig Liver Dis 2017; 49:540-544
  23. Ewald N, Hardt PD. Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. World J Gastroenterol2013; 19:7276-7281
  24. Salvatore T, Marfella R, Rizzo MR, Sasso FC. Pancreatic cancer and diabetes: A two-way relationship in the perspective of diabetologist. Int J Surg 2015; 21 Suppl 1:S72-77
  25. Ebert R, Creutzfeldt W. Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia 1980; 19:198-204
  26. Petrov MS. DIAGNOSIS OF ENDOCRINE DISEASE: Post-pancreatitis diabetes mellitus: prime time for secondary disease. Eur J Endocrinol 2021; 184:R137-R149
  27. Hart PA, Bradley D, Conwell DL, Dungan K, Krishna SG, Wyne K, Bellin MD, Yadav D, Andersen DK, Serrano J, Papachristou GI. Diabetes following acute pancreatitis. Lancet Gastroenterol Hepatol 2021; 6:668-675
  28. Zahariev OJ, Bunduc S, Kovacs A, Demeter D, Havelda L, Budai BC, Veres DS, Hosszufalusi N, Eross BM, Teutsch B, Juhasz MF, Hegyi P. Risk factors for diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis. Front Med (Lausanne) 2023; 10:1257222
  29. Goodarzi MO, Petrov MS, Andersen DK, Hart PA. Diabetes in chronic pancreatitis: risk factors and natural history. Curr Opin Gastroenterol 2021; 37:526-531
  30. Woodmansey C, McGovern AP, McCullough KA, Whyte MB, Munro NM, Correa AC, Gatenby PAC, Jones SA, de Lusignan S. Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): A Retrospective Cohort Study. Diabetes Care 2017; 40:1486-1493
  31. Rickels MR, Bellin M, Toledo FG, Robertson RP, Andersen DK, Chari ST, Brand R, Frulloni L, Anderson MA, Whitcomb DC. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology 2013; 13:336-342
  32. Hardt PD, Krauss A, Bretz L, Porsch-Ozcurumez M, Schnell-Kretschmer H, Maser E, Bretzel RG, Zekhorn T, Klor HU. Pancreatic exocrine function in patients with type 1 and type 2 diabetes mellitus. Acta Diabetol 2000; 37:105-110
  33. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32:834-838
  34. Cho J, Scragg R, Pandol SJ, Goodarzi MO, Petrov MS. Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study. Diabetes Care 2019; 42:1675-1683
  35. Davidsen L, Jensen MH, Cook ME, Vestergaard P, Knop FK, Drewes AM, Olesen SS. Metformin treatment is associated with reduced risk of hypoglycaemia, major adverse cardiovascular events, and all-cause mortality in patients with post-pancreatitis diabetes mellitus: a nationwide cohort study. Eur J Endocrinol 2024; 190:44-53
  36. Wang Z, Lai ST, Xie L, Zhao JD, Ma NY, Zhu J, Ren ZG, Jiang GL. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 2014; 106:19-26
  37. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andren-Sandberg A, Domellof L. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328:1433-1437
  38. Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg? Pancreas 2011; 40:339-351
  39. Cho J, Scragg R, Petrov MS. Postpancreatitis Diabetes Confers Higher Risk for Pancreatic Cancer Than Type 2 Diabetes: Results From a Nationwide Cancer Registry. Diabetes Care 2020; 43:2106-2112
  40. Roshanov PS, Dennis BB. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials. Diabetes Res Clin Pract 2015; 110:e13-17
  41. Tkac I, Raz I. Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes. Diabetes Care 2017; 40:284-286
  42. Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Ohman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2018; 6:105-113
  43. Liu Y, Tian Q, Yang J, Wang H, Hong T. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials. Diabetes Metab Res Rev 2018; 34:e3061
  44. Couet C, Genton P, Pointel JP, Louis J, Gross P, Saudax E, Debry G, Drouin P. The prevalence of retinopathy is similar in diabetes mellitus secondary to chronic pancreatitis with or without pancreatectomy and in idiopathic diabetes mellitus. Diabetes Care 1985; 8:323-328
  45. Tiengo A, Segato T, Briani G, Setti A, Del Prato S, Devide A, Padovan D, Virgili F, Crepaldi G. The presence of retinopathy in patients with secondary diabetes following pancreatectomy or chronic pancreatitis. Diabetes Care1983; 6:570-574
  46. Briani G, Riva F, Midena E, Trevisan R, Sgnaolin E, Jori E, Munari R, Bruttomesso D, Segato T, Tiengo A. Prevalence of microangiopathic complications in hyperglycemia secondary to pancreatic disease. J Diabet Complications 1988; 2:50-52
  47. Ziegler O, Candiloros H, Guerci B, Got I, Crea T, Drouin P. Lower-extremity arterial disease in diabetes mellitus due to chronic pancreatitis. Diabete Metab 1994; 20:540-545
  48. Kuo P, Stevens JE, Russo A, Maddox A, Wishart JM, Jones KL, Greville H, Hetzel D, Chapman I, Horowitz M, Rayner CK. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis--effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab 2011; 96:E851-855
  49. Imamura S, Niwano F, Babaya N, Hiromine Y, Matsumoto I, Kamei K, Yoshida Y, Taketomo Y, Yoshida S, Takeyama Y, Noso S, Maeda N, Ikegami H. High Incidence of Diabetes Mellitus After Distal Pancreatectomy and Its Predictors: A Long-term Follow-up Study. J Clin Endocrinol Metab 2024; 109:619-630
  50. Klotz R, Schilling C, Kuner C, Hinz U, Klaiber U, Holze M, Tjaden C, Loos M, Buchler MW, Hackert T. Central pancreatectomy prevents postoperative diabetes. J Hepatobiliary Pancreat Sci 2023; 30:951-961
  51. Mezza T, Cefalo CMA, Cinti F, Quero G, Pontecorvi A, Alfieri S, Holst JJ, Giaccari A. Endocrine and Metabolic Insights from Pancreatic Surgery. Trends Endocrinol Metab 2020; 31:760-772
  52. Suto H, Kamei K, Kato H, Misawa T, Unno M, Nitta H, Satoi S, Kawabata Y, Ohtsuka M, Rikiyama T, Sudo T, Matsumoto I, Hirao T, Okano K, Suzuki Y, Sata N, Isaji S, Sugiyama M, Takeyama Y. Diabetic control and nutritional status up to 1 year after total pancreatectomy: a nationwide multicentre prospective study. Br J Surg2021; 108:e237-e238
  53. Baekdal M, Nielsen SW, Hansen CP, Storkholm JH, van Hall G, Hartmann B, Holst JJ, Vilsboll T, Lund A, Knop FK. Empagliflozin Normalizes Fasting Hyperglycemia and Improves Postprandial Glucose Tolerance in Totally Pancreatectomized Patients: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. Diabetes Care2024; 47:71-80
  54. Juel CTB, Lund A, Andersen MM, Hansen CP, Storkholm JH, Rehfeld JF, van Hall G, Hartmann B, Wewer Albrechtsen NJ, Holst JJ, Vilsboll T, Knop FK. The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial. Diabetologia 2020; 63:1285-1298
  55. Chaouch MA, Leon P, Cassese G, Aguilhon C, Khayat S, Panaro F. Total pancreatectomy with intraportal islet autotransplantation for pancreatic malignancies: a literature overview. Expert Opin Biol Ther 2021:1-7
  56. Robertson GS, Dennison AR, Johnson PR, London NJ. A review of pancreatic islet autotransplantation. Hepatogastroenterology 1998; 45:226-235
  57. Jablonska B, Mrowiec S. Total Pancreatectomy with Autologous Islet Cell Transplantation-The Current Indications. J Clin Med 2021; 10
  58. Andersen DK, Korc M, Petersen GM, Eibl G, Li D, Rickels MR, Chari ST, Abbruzzese JL. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes 2017; 66:1103-1110
  59. Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 2013; 42:198-201
  60. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134:981-987
  61. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005; 129:504-511
  62. Damiano J, Bordier L, Le Berre JP, Margery J, Dupuy O, Mayaudon H, Bauduceau B. Should pancreas imaging be recommanded in patients over 50 years when diabetes is discovered because of acute symptoms? Diabetes Metab 2004; 30:203-207
  63. Hart PA, Kamada P, Rabe KG, Srinivasan S, Basu A, Aggarwal G, Chari ST. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas 2011; 40:768-772
  64. Song S, Wang B, Zhang X, Hao L, Hu X, Li Z, Sun S. Long-Term Diabetes Mellitus Is Associated with an Increased Risk of Pancreatic Cancer: A Meta-Analysis. PLoS One 2015; 10:e0134321
  65. Roy A, Sahoo J, Kamalanathan S, Naik D, Mohan P, Kalayarasan R. Diabetes and pancreatic cancer: Exploring the two-way traffic. World J Gastroenterol 2021; 27:4939-4962
  66. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993; 80:1047-1050
  67. Litwin J, Dobrowolski S, Orlowska-Kunikowska E, Sledzinski Z. Changes in glucose metabolism after Kausch-Whipple pancreatectomy in pancreatic cancer and chronic pancreatitis patients. Pancreas 2008; 36:26-30
  68. Gardner TB, Hessami N, Smith KD, Ripple GH, Barth RJ, Klibansky DA, Colacchio TA, Zaki B, Tsapakos MJ, Suriawinata AA, Putra J, Tsongalis GJ, Mody K, Gordon SR, Pipas JM. The effect of neoadjuvant chemoradiation on pancreatic cancer-associated diabetes mellitus. Pancreas 2014; 43:1018-1021
  69. Zhou PT, Li B, Liu FR, Zhang MC, Wang Q, Li YY, Xu C, Liu YH, Yao Y, Li D. Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. Oncotarget2017; 8:25242-25250
  70. Jian-Yu E, Graber JM, Lu SE, Lin Y, Lu-Yao G, Tan XL. Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. Curr Med Chem 2018; 25:2595-2607
  71. Wan G, Sun X, Li F, Wang X, Li C, Li H, Yu X, Cao F. Survival Benefit of Metformin Adjuvant Treatment For Pancreatic Cancer Patients: a Systematic Review and Meta-Analysis. Cell Physiol Biochem 2018; 49:837-847
  72. Reni M, Dugnani E, Cereda S, Belli C, Balzano G, Nicoletti R, Liberati D, Pasquale V, Scavini M, Maggiora P, Sordi V, Lampasona V, Ceraulo D, Di Terlizzi G, Doglioni C, Falconi M, Piemonti L. (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. Clin Cancer Res 2016; 22:1076-1085
  73. Kordes S, Pollak MN, Zwinderman AH, Mathot RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2015; 16:839-847
  74. Kawabata H. The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis. Int J Hematol 2018; 107:31-43
  75. Pelusi C, Gasparini DI, Bianchi N, Pasquali R. Endocrine dysfunction in hereditary hemochromatosis. J Endocrinol Invest 2016; 39:837-847
  76. Barton JC, Acton RT. Diabetes in HFE Hemochromatosis. J Diabetes Res 2017; 2017:9826930
  77. O'Sullivan EP, McDermott JH, Murphy MS, Sen S, Walsh CH. Declining prevalence of diabetes mellitus in hereditary haemochromatosis--the result of earlier diagnosis. Diabetes Res Clin Pract 2008; 81:316-320
  78. McClain DA, Abraham D, Rogers J, Brady R, Gault P, Ajioka R, Kushner JP. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 2006; 49:1661-1669
  79. Simcox JA, McClain DA. Iron and diabetes risk. Cell Metab 2013; 17:329-341
  80. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with Thalassaemia Major. Pediatr Endocrinol Rev 2007; 5:642-648
  81. Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev 2008; 6 Suppl 1:158-169
  82. Nelson RL, Baldus WP, Rubenstein AH, Go VL, Service FJ. Pancreatic alpha-cell function in diabetic hemochromatotic subjects. J Clin Endocrinol Metab 1979; 49:412-416
  83. Passa P, Luyckx AS, Carpentier JL, Lefebvre PJ, Canivet J. Glucagon secretion in diabetic patients with idiopathic haemochromatosis. Diabetologia 1977; 13:509-513
  84. Lassmann V, Passa P, Vague P, Vialettes B. Pancreatic polypeptide secretion in diabetic patients with idiopathic haemochromatosis. Diabete Metab 1987; 13:106-109
  85. Dymock IW, Cassar J, Pyke DA, Oakley WG, Williams R. Observations on the pathogenesis, complications and treatment of diabetes in 115 cases of haemochromatosis. Am J Med 1972; 52:203-210
  86. Griffiths JD, Dymock IW, Davies EW, Hill DW, Williams R. Occurrence and prevalence of diabetic retinopathy in hemochromatosis. Diabetes 1971; 20:766-770
  87. Becker D, Miller M. Presence of diabetic glomerulosclerosis in patients with hemochromatosis. N Engl J Med1960; 263:367-373
  88. Hatunic M, Finucane FM, Norris S, Pacini G, Nolan JJ. Glucose metabolism after normalization of markers of iron overload by venesection in subjects with hereditary hemochromatosis. Metabolism 2010; 59:1811-1815
  89. Buysschaert M, Paris I, Selvais P, Hermans MP. Clinical aspects of diabetes secondary to idiopathic haemochromatosis in French-speaking Belgium. Diabetes Metab 1997; 23:308-313
  90. Bomford A, Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med 1976; 45:611-623
  91. Sferra TJ, Collins FS. The molecular biology of cystic fibrosis. Annu Rev Med 1993; 44:133-144
  92. Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, Slovis B, Committee CCC. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care2010; 33:2677-2683
  93. Yoon JC. Evolving Mechanistic Views and Emerging Therapeutic Strategies for Cystic Fibrosis-Related Diabetes. J Endocr Soc 2017; 1:1386-1400
  94. Kayani K, Mohammed R, Mohiaddin H. Cystic Fibrosis-Related Diabetes. Front Endocrinol (Lausanne) 2018; 9:20
  95. Bridges N, Rowe R, Holt RIG. Unique challenges of cystic fibrosis-related diabetes. Diabet Med 2018;
  96. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D, Das S, Kosiborod M. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45:S17-S38
  97. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33:2697-2708
  98. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009; 32:1626-1631
  99. Santhakumar A, Lewis F, Pickles J, Winterbottom H, Punt S, Beynon J, Tofeec K, Barry P, Brennan A. Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: A single centre experience. J Cyst Fibros 2024; 23:853-856
  100. Hayes D, Jr., McCoy KS, Sheikh SI. Resolution of cystic fibrosis-related diabetes with ivacaftor therapy. Am J Respir Crit Care Med 2014; 190:590-591
  101. Gaines H, Jones KR, Lim J, Medhi NF, Chen S, Scofield RH. Effect of CFTR modulator therapy on cystic fibrosis-related diabetes. J Diabetes Complications 2021; 35:107845
  102. Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C, Higgins M, Konstan MW, Sawicki GS, Elbert A, Charman SC, Marshall BC, Bilton D. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. J Cyst Fibros 2020; 19:68-79
  103. Aguilera Garcia I, Garcia Moreno RM, Lopez Plaza B, Barquiel Alcala B, Vazquez Perez P, Barreda Bonis AC, Zamarron de Lucas E, Palma Milla S, Prados Sanchez MC, Gonzalez Perez de Villar N. Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice. Diabetes Res Clin Pract 2024; 216:111839
  104. Taelman V, Declercq D, Van Biervliet S, Weygaerde YV, Lapauw B, Van Braeckel E. Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis. Clin Nutr ESPEN 2023; 58:73-78
  105. Nielsen BU, Olsen MF, Mabuza Mathiesen IH, Pressler T, Ritz C, Katzenstein TL, Olesen HV, Skov M, Jensen-Fangel S, Almdal TP, Faurholt-Jepsen D. Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment. J Cyst Fibros 2024; 23:103-108
  106. Bellin MD, Laguna T, Leschyshyn J, Regelmann W, Dunitz J, Billings J, Moran A. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes 2013; 14:417-421
  107. Lurquin F, Buysschaert M, Preumont V. Advances in cystic fibrosis-related diabetes: Current status and future directions. Diabetes Metab Syndr 2023; 17:102899
  108. Richardson SJ, Morgan NG. Enteroviral infections in the pathogenesis of type 1 diabetes: new insights for therapeutic intervention. Curr Opin Pharmacol 2018; 43:11-19
  109. Principi N, Berioli MG, Bianchini S, Esposito S. Type 1 diabetes and viral infections: What is the relationship? J Clin Virol 2017; 96:26-31
  110. Rodriguez-Calvo T, Sabouri S, Anquetil F, von Herrath MG. The viral paradigm in type 1 diabetes: Who are the main suspects? Autoimmun Rev 2016; 15:964-969
  111. Jeremiah SS, Moin ASM, Butler AE. Virus-induced diabetes mellitus: revisiting infection etiology in light of SARS-CoV-2. Metabolism 2024; 156:155917
  112. VanBuecken D, Lord S, Greenbaum CJ. Changing the Course of Disease in Type 1 Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2022.
  113. Krogvold L, Mynarek IM, Ponzi E, Mork FB, Hessel TW, Roald T, Lindblom N, Westman J, Barker P, Hyoty H, Ludvigsson J, Hanssen KF, Johannesen J, Dahl-Jorgensen K. Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial. Nat Med 2023; 29:2902-2908
  114. Yoon JW, Austin M, Onodera T, Notkins AL. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 1979; 300:1173-1179
  115. Gale EA. Congenital rubella: citation virus or viral cause of type 1 diabetes? Diabetologia 2008; 51:1559-1566
  116. Burgess MA, Forrest JM. Congenital rubella and diabetes mellitus. Diabetologia 2009; 52:369-370; author reply 373
  117. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49:831-844
  118. Fabiani S, Fallahi P, Ferrari SM, Miccoli M, Antonelli A. Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature. Rev Endocr Metab Disord 2018; 19:405-420
  119. Choi HY, Kim Y, Cho H, Kim BH, Ki M. Risk of diabetes in viral hepatitis B or C patients compared to that in noninfected individuals in Korea, 2002-2013: A population-based cohort study. J Viral Hepat 2018; 25:272-280
  120. Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol 2012; 18:1642-1651
  121. Lin YJ, Shaw TG, Yang HI, Lu SN, Jen CL, Wang LY, Wong KH, Chan SY, Yuan Y, L'Italien G, Chen CJ, Lee MH, Group REVEALHS. Chronic hepatitis C virus infection and the risk for diabetes: a community-based prospective study. Liver Int 2017; 37:179-186
  122. Gastaldi G, Goossens N, Clement S, Negro F. Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. J Adv Res 2017; 8:149-159
  123. Guo X, Jin M, Yang M, Liu K, Li JW. Type 2 diabetes mellitus and the risk of hepatitis C virus infection: a systematic review. Sci Rep 2013; 3:2981
  124. Li X, Gao Y, Xu H, Hou J, Gao P. Diabetes mellitus is a significant risk factor for the development of liver cirrhosis in chronic hepatitis C patients. Sci Rep 2017; 7:9087
  125. Li X, Xu H, Gao Y, Pan M, Wang L, Gao P. Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naive chronic hepatitis C patients in China. Medicine (Baltimore) 2017; 96:e6508
  126. Cao LH, Lu FM, Lu XJ, Zhu LY. Study on the relationship between insulin growth factor 1 and liver fibrosis in patients with chronic hepatitis C with type 2 diabetes mellitus. J Cell Biochem 2018; 119:9513-9518
  127. Colaci M, Malatino L, Antonelli A, Fallahi P, Giuggioli D, Ferri C. Endocrine disorders associated with hepatitis C virus chronic infection. Rev Endocr Metab Disord 2018; 19:397-403
  128. Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality? Dig Liver Dis 2016; 48:105-111
  129. Delgado-Borrego A, Jordan SH, Negre B, Healey D, Lin W, Kamegaya Y, Christofi M, Ludwig DA, Lok AS, Chung RT. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8:458-462
  130. Narita R, Abe S, Kihara Y, Akiyama T, Tabaru A, Otsuki M. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol 2004; 41:132-138
  131. Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD, Chang M, Ioannou GN. Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. Diabetes Care 2017; 40:1173-1180
  132. Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology2014; 59:1293-1302
  133. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012; 107:46-52
  134. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne-Carrie N, Grando-Lemaire V, Vicaut E, Trinchet JC, Beaugrand M. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011; 96:2601-2608
  135. Zhou K, Lansang MC. Diabetes Mellitus and Infection. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  136. Khunti K, Del Prato S, Mathieu C, Kahn SE, Gabbay RA, Buse JB. COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care 2021; 44:2645-2655
  137. Hirani D, Salem V, Khunti K, Misra S. Newly detected diabetes during the COVID-19 pandemic: What have we learnt? Best Pract Res Clin Endocrinol Metab 2023; 37:101793
  138. Zhou J, Wang Y, Xu R. Association of COVID-19 infection and the risk of new incident diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2024; 15:1429848
  139. Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes Metab 2021; 23:870-874
  140. Zhang T, Mei Q, Zhang Z, Walline JH, Liu Y, Zhu H, Zhang S. Risk for newly diagnosed diabetes after COVID-19: a systematic review and meta-analysis. BMC Med 2022; 20:444
  141. Lai H, Yang M, Sun M, Pan B, Wang Q, Wang J, Tian J, Ding G, Yang K, Song X, Ge L. Risk of incident diabetes after COVID-19 infection: A systematic review and meta-analysis. Metabolism 2022; 137:155330
  142. Wong R, Lam E, Bramante CT, Johnson SG, Reusch J, Wilkins KJ, Yeh HC. Does COVID-19 Infection Increase the Risk of Diabetes? Current Evidence. Curr Diab Rep 2023; 23:207-216
  143. Taylor K, Eastwood S, Walker V, Cezard G, Knight R, Al Arab M, Wei Y, Horne EMF, Teece L, Forbes H, Walker A, Fisher L, Massey J, Hopcroft LEM, Palmer T, Cuitun Coronado J, Ip S, Davy S, Dillingham I, Morton C, Greaves F, Macleod J, Goldacre B, Wood A, Chaturvedi N, Sterne JAC, Denholm R. Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people. Lancet Diabetes Endocrinol 2024; 12:558-568
  144. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet 2009; 373:1798-1807
  145. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993; 16:642-652
  146. Montefusco L, Ben Nasr M, D'Addio F, Loretelli C, Rossi A, Pastore I, Daniele G, Abdelsalam A, Maestroni A, Dell'Acqua M, Ippolito E, Assi E, Usuelli V, Seelam AJ, Fiorina RM, Chebat E, Morpurgo P, Lunati ME, Bolla AM, Finzi G, Abdi R, Bonventre JV, Rusconi S, Riva A, Corradi D, Santus P, Nebuloni M, Folli F, Zuccotti GV, Galli M, Fiorina P. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab 2021; 3:774-785
  147. Martinez-Colon GJ, Ratnasiri K, Chen H, Jiang S, Zanley E, Rustagi A, Verma R, Chen H, Andrews JR, Mertz KD, Tzankov A, Azagury D, Boyd J, Nolan GP, Schurch CM, Matter MS, Blish CA, McLaughlin TL. SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages. Sci Transl Med 2022; 14:eabm9151
  148. Reiterer M, Rajan M, Gomez-Banoy N, Lau JD, Gomez-Escobar LG, Ma L, Gilani A, Alvarez-Mulett S, Sholle ET, Chandar V, Bram Y, Hoffman K, Bhardwaj P, Piloco P, Rubio-Navarro A, Uhl S, Carrau L, Houhgton S, Redmond D, Shukla AP, Goyal P, Brown KA, tenOever BR, Alonso LC, Schwartz RE, Schenck EJ, Safford MM, Lo JC. Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. Cell Metab 2021; 33:2174-2188 e2175
  149. Valabhji J, Barron E, Bradley D, Bakhai C, Khunti K, Jebb S. Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme. Lancet Diabetes Endocrinol 2021; 9:649-651
  150. Carroll PV, MN J. Acromegaly. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2022.
  151. Hannon AM, Thompson CJ, Sherlock M. Diabetes in Patients With Acromegaly. Curr Diab Rep 2017; 17:8
  152. Baroni MG, Giorgino F, Pezzino V, Scaroni C, Avogaro A. Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly. J Endocrinol Invest 2016; 39:235-255
  153. Esposito D, Boguszewski CL, Colao A, Fleseriu M, Gatto F, Jorgensen JOL, Ragnarsson O, Ferone D, Johannsson G. Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management. Nat Rev Endocrinol 2024; 20:541-552
  154. Frara S, Maffezzoni F, Mazziotti G, Giustina A. Current and Emerging Aspects of Diabetes Mellitus in Acromegaly. Trends Endocrinol Metab 2016; 27:470-483
  155. Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 2014; 17:81-89
  156. Lim CT, Khoo B. Normal Physiology of ACTH and GH Release in the Hypothalamus and Anterior Pituitary in Man. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2025.
  157. Yuen KCJ. Growth hormone Stimulation Tests in Assessing Adult Growth Hormone Deficiency. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2019.
  158. Olarescu N, Gunawardane K, Hansen T, Møller N, Jørgensen J. Normal Physiology of Growth Hormone in Adults. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2019.
  159. Dutta P, Hajela A, Gupta P, Rai A, Sachdeva N, Mukherjee KK, Pathak A, Dhandapani S. The predictors of recovery from diabetes mellitus following neurosurgical treatment of acromegaly: A prospective study over a decade. Neurol India 2019; 67:757-762
  160. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009; 94:1500-1508
  161. Cozzolino A, Feola T, Simonelli I, Puliani G, Pozza C, Giannetta E, Gianfrilli D, Pasqualetti P, Lenzi A, Isidori AM. Somatostatin Analogs and Glucose Metabolism in Acromegaly: A Meta-analysis of Prospective Interventional Studies. J Clin Endocrinol Metab 2018;
  162. Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2:875-884
  163. Schmid HA, Brue T, Colao A, Gadelha MR, Shimon I, Kapur K, Pedroncelli AM, Fleseriu M. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 2016; 53:210-219
  164. Gatto F, Arecco A, Amaru J, Arvigo M, Campana C, Milioto A, Esposito D, Johannsson G, Cocchiara F, Maggi DC, Ferone D, Puddu A. Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism. Int J Mol Sci 2025; 26
  165. Varaldo E, Prencipe N, Bona C, Cuboni D, Aversa LS, Sibilla M, Bioletto F, Berton AM, Gramaglia C, Gasco V, Ghigo E, Grottoli S. Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly. J Endocrinol Invest 2024; 47:3019-3028
  166. Wass JA, Cudworth AG, Bottazzo GF, Woodrow JC, Besser GM. An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clin Endocrinol (Oxf) 1980; 12:53-59
  167. Urbani C, Sardella C, Calevro A, Rossi G, Scattina I, Lombardi M, Lupi I, Manetti L, Martino E, Bogazzi F. Effects of medical therapies for acromegaly on glucose metabolism. Eur J Endocrinol 2013; 169:99-108
  168. Brue T, Lindberg A, Jan van der Lely A, Akerblad AC, Koltowska-Haggstrom M, Gomez R, Droste M, Hey-Hadavi J, Strasburger CJ, Camacho-Hubner C. Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. Endocrine 2019; 63:563-572
  169. Juszczak A, Morris D, Grossman A. Cushing's Syndrome. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  170. Ferrau F, Korbonits M. Metabolic Syndrome in Cushing's Syndrome Patients. Front Horm Res 2018; 49:85-103
  171. Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA, Tsagarakis S, Trainer PJ, Franz H, Zopf K, Zacharieva S, Lamberts SW, Tabarin A, Webb SM. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 2011; 165:383-392
  172. Scaroni C, Zilio M, Foti M, Boscaro M. Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management. Endocr Rev 2017; 38:189-219
  173. Guarnotta V, Amato MC, Pivonello R, Arnaldi G, Ciresi A, Trementino L, Citarrella R, Iacuaniello D, Michetti G, Simeoli C, Colao A, Giordano C. The degree of urinary hypercortisolism is not correlated with the severity of cushing's syndrome. Endocrine 2017; 55:564-572
  174. Steffensen C, Pereira AM, Dekkers OM, Jorgensen JO. DIAGNOSIS OF ENDOCRINE DISEASE: Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis. Eur J Endocrinol 2016; 175:R247-R253
  175. Terzolo M, Reimondo G, Chiodini I, Castello R, Giordano R, Ciccarelli E, Limone P, Crivellaro C, Martinelli I, Montini M, Disoteo O, Ambrosi B, Lanzi R, Arosio M, Senni S, Balestrieri A, Solaroli E, Madeo B, De Giovanni R, Strollo F, Battista R, Scorsone A, Giagulli VA, Collura D, Scillitani A, Cozzi R, Faustini-Fustini M, Pia A, Rinaldi R, Allasino B, Peraga G, Tassone F, Garofalo P, Papini E, Borretta G. Screening of Cushing's syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. J Clin Endocrinol Metab 2012; 97:3467-3475
  176. Aresta C, Favero V, Morelli V, Giovanelli L, Parazzoli C, Falchetti A, Pugliese F, Gennari L, Vescini F, Salcuni A, Scillitani A, Persani L, Chiodini I. Cardiovascular complications of mild autonomous cortisol secretion. Best Pract Res Clin Endocrinol Metab 2021; 35:101494
  177. Elhassan YS, Alahdab F, Prete A, Delivanis DA, Khanna A, Prokop L, Murad MH, O'Reilly MW, Arlt W, Bancos I. Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis. Ann Intern Med 2019; 171:107-116
  178. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg 2009; 249:388-391
  179. Sereg M, Szappanos A, Toke J, Karlinger K, Feldman K, Kaszper E, Varga I, Glaz E, Racz K, Toth M. Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study. Eur J Endocrinol 2009; 160:647-655
  180. Chatzellis E, Kaltsas G. Adrenal Incidentalomas. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  181. Babic N, Yeo K, Hannoush Z, Weiss R. Endocrine Testing Protocols: Hypothalamic Pituitary Adrenal Axis. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.
  182. Gremlich S, Roduit R, Thorens B. Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids. J Biol Chem 1997; 272:3216-3222
  183. Mehlich A, Bolanowski M, Mehlich D, Witek P. Medical treatment of Cushing's disease with concurrent diabetes mellitus. Front Endocrinol (Lausanne) 2023; 14:1174119
  184. Nicolaides NC, Pavlaki AN, Maria Alexandra MA, Chrousos GP. Glucocorticoid Therapy and Adrenal Suppression. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2018.
  185. Juszczak A, Sulentic P, Grossman A. Cushing's Syndrome. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2004.
  186. Feingold K. The Effect of Endocrine Disorders on Lipids and Lipoproteins. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  187. Pacak K, Tella SH. Pheochromocytoma and Paraganglioma. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2018.
  188. Adlan MA, Bondugulapati LN, Premawardhana LD. Glucose intolerance and diabetes mellitus in endocrine disorders - two case reports and a review. Curr Diabetes Rev 2010; 6:266-273
  189. La Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens 2003; 21:1703-1707
  190. Beninato T, Kluijfhout WP, Drake FT, Lim J, Kwon JS, Xiong M, Shen WT, Gosnell JE, Liu C, Suh I, Duh QY. Resection of Pheochromocytoma Improves Diabetes Mellitus in the Majority of Patients. Ann Surg Oncol 2017; 24:1208-1213
  191. Zhang W, Yu J, Chen Y, Zhou Y, Cui Y, Li T, Wang Y, Ren W, Tong A, Li Y. Glucose Disorders in Patients With Pheochromocytoma/Paraganglioma: Profile and Influence Effects in a Large Cohort With 705 Patients. Endocr Pract 2024;
  192. Douma S, Petidis K, Kartali N, Mahera K, Sabanis C, Zamboulis C. Pheochromocytoma presenting as diabetic ketoacidosis. J Diabetes Complications 2008; 22:295-296
  193. Deibert DC, DeFronzo RA. Epinephrine-induced insulin resistance in man. J Clin Invest 1980; 65:717-721
  194. Rizza RA, Cryer PE, Haymond MW, Gerich JE. Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man. J Clin Invest 1980; 65:682-689
  195. Halter JB, Beard JC, Porte D, Jr. Islet function and stress hyperglycemia: plasma glucose and epinephrine interaction. Am J Physiol 1984; 247:E47-52
  196. Araujo-Castro M, Minguez Ojeda C, Garcia Centeno R, Lopez-Garcia MC, Lamas C, Hanzu FA, Mora M, Del Castillo Tous M, Rodriguez de Vera Gomez P, Parra Ramirez P, Alvarez-Escola C, Blanco Carrera C, Barahona San Millan R, Recasens M, Valdes N, Gracia Gimeno P, de Miguel Novoa P, Vicente A, Manjon L, Garcia Sanz I, Michalopoulou T, Calatayud M. Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas. Endocr Relat Cancer 2022; 29:645-655
  197. Khatiwada S, Agarwal S, Kandasamy D, Jyotsna VP, Kumar R, Kumar Bansal V, Pandey RM, Gupta N, Tandon N. Diabetes mellitus in pheochromocytoma and paraganglioma: Prevalence, dynamics of insulin secretion / sensitivity and predictors of remission. Diabetes Metab Syndr 2020; 14:2169-2175
  198. Chen Y, Hodin RA, Pandolfi C, Ruan DT, McKenzie TJ. Hypoglycemia after resection of pheochromocytoma. Surgery 2014; 156:1404-1408; discussion 1408-1409
  199. Diamanti-Kandarakis E, Zapanti E, Peridis MH, Ntavos P, Mastorakos G. Insulin resistance in pheochromocytoma improves more by surgical rather than by medical treatment. Hormones (Athens) 2003; 2:61-66
  200. Roa Duenas OH, Van der Burgh AC, Ittermann T, Ligthart S, Ikram MA, Peeters R, Chaker L. Thyroid Function and the Risk of Prediabetes and Type 2 Diabetes. J Clin Endocrinol Metab 2022; 107:1789-1798
  201. Nishi M. Diabetes mellitus and thyroid diseases. Diabetol Int 2018; 9:108-112
  202. Andersen OO, Friis T, Ottesen B. Glucose tolerance and insulin secretion in hyperthyroidism. Acta Endocrinol (Copenh) 1977; 84:576-587
  203. Kreines K, Jett M, Knowles HC, Jr. Observations in hyperthyroidism of abnormal glucose tolerance and other traits related to diabetes mellitus. Diabetes 1965; 14:740-744
  204. Yang L, Shen X, Yan S, Yuan X, Lu J, Wei W. HbA1c in the diagnosis of diabetes and abnormal glucose tolerance in patients with Graves' hyperthyroidism. Diabetes Res Clin Pract 2013; 101:28-34
  205. Alwan H, Villoz F, Feller M, Dullaart RPF, Bakker SJL, Peeters RP, Kavousi M, Bauer DC, Cappola AR, Yeap BB, Walsh JP, Brown SJ, Ceresini G, Ferrucci L, Gussekloo J, Trompet S, Iacoviello M, Moon JH, Razvi S, Bensenor IM, Azizi F, Amouzegar A, Valdes S, Colomo N, Wareham NJ, Jukema JW, Westendorp RGJ, Kim KW, Rodondi N, Del Giovane C. Subclinical thyroid dysfunction and incident diabetes: a systematic review and an individual participant data analysis of prospective cohort studies. Eur J Endocrinol 2022; 187:S35-S46
  206. Sarabhai T, Kostev K. Thyroid disorders and the incidence of type 2 diabetes: insights from a 10-year cohort study in Germany. Endocr Connect 2025; 14
  207. Mouradian M, Abourizk N. Diabetes mellitus and thyroid disease. Diabetes Care 1983; 6:512-520
  208. Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med 2017; 376:1748-1761
  209. Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marino M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med 2020; 382:341-352
  210. Sperling M, A. A, Yau M. Autoimmune Polyglandular Syndromes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  211. de Herder WW, Hofland J. Glucagon & Glucagonoma Syndrome. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.
  212. Song X, Zheng S, Yang G, Xiong G, Cao Z, Feng M, Zhang T, Zhao Y. Glucagonoma and the glucagonoma syndrome. Oncol Lett 2018; 15:2749-2755
  213. Wewer Albrechtsen NJ, Kuhre RE, Pedersen J, Knop FK, Holst JJ. The biology of glucagon and the consequences of hyperglucagonemia. Biomark Med 2016; 10:1141-1151
  214. de Herder WW, Hofland J. Somatostatinoma. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.
  215. Theodoraki A, Khoo B, Hamda A, Grillo F, Meyer T, Bouloux PM. Malignant somatostatinoma presenting with diabetic ketoacidosis and inhibitory syndrome: pathophysiologic considerations. Endocr Pract 2010; 16:835-837
  216. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150:776-783
  217. Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6:41-50
  218. Katsuragawa S, Tsurutani Y, Takiguchi T, Saito J, Nishikawa T. Impact of primary aldosteronism on renal function in patients with type 2 diabetes. J Diabetes Investig 2021; 12:217-225
  219. Papadopoulou-Marketou N, Vaidya A, Dluhy R, Chrousos GP. Hyperaldosteronism. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2020.
  220. Feingold KR, Lee TH, Chung MY, Siperstein MD. Muscle capillary basement membrane width in patients with vacor-induced diabetes mellitus. J Clin Invest 1986; 78:102-107
  221. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207
  222. Allhat Officers Coordinators for the Allhat Collaborative Research Group The Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997
  223. Hirst JA, Farmer AJ, Feakins BG, Aronson JK, Stevens RJ. Quantifying the effects of diuretics and beta-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis. Br J Clin Pharmacol 2015; 79:733-743
  224. Zhang X, Zhao Q. Association of Thiazide-Type Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. J Clin Hypertens (Greenwich)2016; 18:342-351
  225. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007; 100:1254-1262
  226. Rizos CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol 2014; 6:517-530
  227. Li Z, Wei H, Li R, Wu B, Xu M, Yang X, Zhang Y, Liu Y. The effects of antihypertensive drugs on glucose metabolism. Diabetes Obes Metab 2024; 26:4820-4829
  228. Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-Induced Hyperglycaemia and Diabetes. Drug Saf2015; 38:1153-1168
  229. Martins VM, Ziegelmann PK, Ferrari F, Bottino LG, Lucca MB, Correa HLR, Blum GB, Helal L, Fuchs SC, Fuchs FD. Thiazide diuretics alone or combined with potassium-sparing diuretics to treat hypertension: a systematic review and network meta-analysis of randomized controlled trials. J Hypertens 2023; 41:1108-1116
  230. Verhaegen AA, Van Gaal LF. Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2019.
  231. Davis H, Spanakis E, Cryer P, Siamashvili M, Davis S. Hypoglycemia During Therapy of Diabetes. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  232. Koch-Weser J. Diazoxide. N Engl J Med 1976; 294:1271-1273
  233. de Herder WW, Hofland J. Insulinomas. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.
  234. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375:735-742
  235. Cholesterol Treatment Trialists Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol 2024; 12:306-319
  236. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305:2556-2564
  237. Feingold KR. Cholesterol Lowering Drugs. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  238. Abbasi F, Lamendola C, Harris CS, Harris V, Tsai MS, Tripathi P, Abbas F, Reaven GM, Reaven PD, Snyder MP, Kim SH, Knowles JW. Statins Are Associated With Increased Insulin Resistance and Secretion. Arterioscler Thromb Vasc Biol 2021; 41:2786-2797
  239. Cederberg H, Stancakova A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015; 58:1109-1117
  240. Carmena R, Betteridge DJ. Diabetogenic Action of Statins: Mechanisms. Curr Atheroscler Rep 2019; 21:23
  241. Goldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart 2016; 102:198-203
  242. Feingold KR, Grunfeld C. Triglyceride Lowering Drugs. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.
  243. Shen M, Orwoll ES, Conte JE, Jr., Prince MJ. Pentamidine-induced pancreatic beta-cell dysfunction. Am J Med1989; 86:726-728
  244. Bouchard P, Sai P, Reach G, Caubarrere I, Ganeval D, Assan R. Diabetes mellitus following pentamidine-induced hypoglycemia in humans. Diabetes 1982; 31:40-45
  245. Carter BL, Small RE, Mandel MD, Starkman MT. Phenytoin-induced hyperglycemia. Am J Hosp Pharm 1981; 38:1508-1512
  246. Gharib H, Munoz JM. Endocrine manifestations of diphenylhydantoin therapy. Metabolism 1974; 23:515-524
  247. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25:283-291
  248. Zornitzki T, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol 2015; 21:233-239
  249. Lombardi A, Tsomos E, Hammerstad SS, Tomer Y. Interferon alpha: The key trigger of type 1 diabetes. J Autoimmun 2018; 94:7-15
  250. Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol 2018; 4:173-182
  251. de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm Metab Res 2019; 51:145-156
  252. Venetsanaki V, Boutis A, Chrisoulidou A, Papakotoulas P. Diabetes mellitus secondary to treatment with immune checkpoint inhibitors. Curr Oncol 2019; 26:e111-e114
  253. Elshimy G, Raj R, Akturk HK, Schriber A, Sisterna N, Ahmad I, Jacob A, Michels AW, Correa R. Immune Checkpoint Inhibitors Related Endocrine Adverse Events. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2022.
  254. Whicher CA, Price HC, Holt RIG. Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and impaired glucose regulation. Eur J Endocrinol 2018; 178:R245-R258
  255. Holt RIG. Association Between Antipsychotic Medication Use and Diabetes. Curr Diab Rep 2019; 19:96
  256. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123:225-233
  257. Citrome L, Kalsekar I, Baker RA, Hebden T. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Curr Med Res Opin 2014; 30:1629-1641
  258. Chen J, Huang XF, Shao R, Chen C, Deng C. Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes. Front Neurosci 2017; 11:643
  259. Tzortzis V, Samarinas M, Zachos I, Oeconomou A, Pisters LL, Bargiota A. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications. Hormones (Athens) 2017; 16:115-123
  260. Tsai HT, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Smith MR, Potosky AL. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol 2015; 193:1956-1962
  261. Pham P, Sarkar M, Pham P, Pham P. Diabetes Mellitus After Solid Organ Transplantation. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2022.
  262. Chakkera HA, Kudva Y, Kaplan B. Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus. Clin Pharmacol Ther2017; 101:114-120
  263. Verges B. mTOR and Cardiovascular Diseases: Diabetes Mellitus. Transplantation 2018; 102:S47-S49
  264. Ahmad MH, Shafiq I. Diabetic ketoacidosis following PEG-asparaginase therapy. Endocrinol Diabetes Metab Case Rep 2018; 2018:18-0064
  265. Pui CH, Burghen GA, Bowman WP, Aur RJ. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr 1981; 99:46-50
  266. Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol 2021; 9:360-372
  267. Amarikwa L, Mohamed A, Kim SH, Kossler AL, Dosiou C. Teprotumumab-Related Hyperglycemia. J Clin Endocrinol Metab 2023; 108:858-864
  268. Carter C, Marks M, Bundeff AW, Adewodu T, Alderman L. A case of rapidly declining glycemic control and diabetic ketoacidosis in a newly diagnosed diabetes patient after starting teprotumumab for thyroid eye disease. Endocrine 2024; 83:65-68
  269. Shah K, Charitou M. A Novel Case of Hyperglycemic Hyperosmolar State After the Use of Teprotumumab in a Patient With Thyroid Eye Disease. AACE Clin Case Rep 2022; 8:148-149
  270. Stan MN, Krieger CC. The Adverse Effects Profile of Teprotumumab. J Clin Endocrinol Metab 2023; 108:e654-e662
  271. Guglielmi C, Palermo A, Pozzilli P. Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy. Diabetes Metab Res Rev 2012; 28 Suppl 2:40-46
  272. Kumar A, de Leiva A. Latent autoimmune diabetes in adults (LADA) in Asian and European populations. Diabetes Metab Res Rev 2017; 33
  273. Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes: a disease with increasing heterogeneity. Lancet 2014; 383:1084-1094
  274. Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab 2009; 94:4635-4644
  275. Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 2006; 29:970-975
  276. Herzog K, Ahlqvist E, Alfredsson L, Groop L, Hjort R, Lofvenborg JE, Tuomi T, Carlsson S. Combined lifestyle factors and the risk of LADA and type 2 diabetes - Results from a Swedish population-based case-control study. Diabetes Res Clin Pract 2021; 174:108760
  277. Santoso C, Wei Y, Ahlqvist E, Tuomi T, Carlsson S. Autoimmune diseases and the risk and prognosis of latent autoimmune diabetes in adults. Diabetologia 2025; 68:331-341
  278. Buzzetti R, Tuomi T, Mauricio D, Pietropaolo M, Zhou Z, Pozzilli P, Leslie RD. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel. Diabetes 2020; 69:2037-2047
  279. Jones AG, McDonald TJ, Shields BM, Hagopian W, Hattersley AT. Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes. Diabetes Care 2021; 44:1243-1251
  280. Brophy S, Davies H, Mannan S, Brunt H, Williams R. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev 2011:CD006165
  281. Li X, Liao L, Yan X, Huang G, Lin J, Lei M, Wang X, Zhou Z. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 2009; 25:411-416
  282. Zhang Z, Yan X, Wu C, Pei X, Li X, Wang X, Niu X, Jiang H, Zeng X, Zhou Z. Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect beta-cell function in LADA patients: A 1-year pilot study. Diabetes Metab Res Rev 2020; 36:e3298
  283. Yan X, Li X, Liu B, Huang J, Xiang Y, Hu Y, Tang X, Zhang Z, Huang G, Xie Z, Zhou H, Liu Z, Wang X, Leslie RD, Zhou Z. Combination therapy with saxagliptin and vitamin D for the preservation of beta-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial. Signal Transduct Target Ther 2023; 8:158
  284. Maddaloni E, Coleman RL, Agbaje O, Buzzetti R, Holman RR. Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). Lancet Diabetes Endocrinol 2020; 8:206-215
  285. Isomaa B, Almgren P, Henricsson M, Taskinen MR, Tuomi T, Groop L, Sarelin L. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 1999; 22:1347-1353
  286. Maddaloni E, Coleman RL, Pozzilli P, Holman RR. Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85). Diabetes Obes Metab 2019; 21:2115-2122
  287. Wei Y, Herzog K, Ahlqvist E, Andersson T, Nystrom T, Zhan Y, Tuomi T, Carlsson S. All-Cause Mortality and Cardiovascular and Microvascular Diseases in Latent Autoimmune Diabetes in Adults. Diabetes Care 2023; 46:1857-1865
  288. McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Lennon VA, Ahlskog JE, Pittock SJ. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol 2012; 69:230-238
  289. Rathbun JT, Imber J. Stiff Person Syndrome and Type 1 Diabetes Mellitus: a Case of the Chicken or the Egg? J Gen Intern Med 2019;
  290. Baizabal-Carvallo JF. The neurological syndromes associated with glutamic acid decarboxylase antibodies. J Autoimmun 2019; 101:35-47
  291. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 2002; 81:87-100
  292. Taylor SI, Shahidzadeh Yazdi Z, Oral EA. Letter to the Editor From Taylor et al "Type B Insulin Resistance Syndrome: A Rare Cause of Hypoglycemia". JCEM Case Rep 2024; 2:luae001
  293. Brown N, Elston MS. Systematic Review-Type B Insulin Resistance With Isolated Hypoglycemia and Suppressed Insulin. J Clin Endocrinol Metab 2024; 109:936-943
  294. Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, Vottero A, Kanabar D, Charlton-Menys V, Durrington P, Soos MA, Carpenter TA, Lomas DJ, Cochran EK, Gorden P, O'Rahilly S, Savage DB. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest 2009; 119:315-322
  295. Klubo-Gwiezdzinska J, Lange M, Cochran E, Semple RK, Gewert C, Brown RJ, Gorden P. Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study. Diabetes Care 2018; 41:2353-2360
  296. Lebovitz HE, Banerji MA. Ketosis-Prone Diabetes (Flatbush Diabetes): an Emerging Worldwide Clinically Important Entity. Curr Diab Rep 2018; 18:120
  297. Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med2006; 144:350-357
  298. Smiley D, Chandra P, Umpierrez GE. Update on diagnosis, pathogenesis and management of ketosis-prone Type 2 diabetes mellitus. Diabetes Manag (Lond) 2011; 1:589-600
  299. Whooten R, Schmitt J, Schwartz A. Endocrine manifestations of Down syndrome. Curr Opin Endocrinol Diabetes Obes 2018; 25:61-66
  300. Guaraldi F, Rossetto Giaccherino R, Lanfranco F, Motta G, Gori D, Arvat E, Ghigo E, Giordano R. Endocrine Autoimmunity in Down's Syndrome. Front Horm Res 2017; 48:133-146
  301. Anwar AJ, Walker JD, Frier BM. Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications. Diabet Med 1998; 15:160-163
  302. Bergholdt R, Eising S, Nerup J, Pociot F. Increased prevalence of Down's syndrome in individuals with type 1 diabetes in Denmark: A nationwide population-based study. Diabetologia 2006; 49:1179-1182
  303. Aitken RJ, Mehers KL, Williams AJ, Brown J, Bingley PJ, Holl RW, Rohrer TR, Schober E, Abdul-Rasoul MM, Shield JP, Gillespie KM. Early-onset, coexisting autoimmunity and decreased HLA-mediated susceptibility are the characteristics of diabetes in Down syndrome. Diabetes Care 2013; 36:1181-1185
  304. Aslam AA, Baksh RA, Pape SE, Strydom A, Gulliford MC, Chan LF, Consortium G-D. Diabetes and Obesity in Down Syndrome Across the Lifespan: A Retrospective Cohort Study Using U.K. Electronic Health Records. Diabetes Care 2022; 45:2892-2899
  305. Behre HM, Bergmann M, Simoni M, Tuttelmann F. Primary Testicular Failure. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2015.
  306. Blackburn J, Ramakrishnan A, Graham C, Bambang K, Sriranglingam U, Senniappan S. Klinefelter Syndrome: A Review. Clin Endocrinol (Oxf) 2025;
  307. Salzano A, D'Assante R, Heaney LM, Monaco F, Rengo G, Valente P, Pasquali D, Bossone E, Gianfrilli D, Lenzi A, Cittadini A, Marra AM, Napoli R. Klinefelter syndrome, insulin resistance, metabolic syndrome, and diabetes: review of literature and clinical perspectives. Endocrine 2018; 61:194-203
  308. Groth KA, Skakkebaek A, Host C, Gravholt CH, Bojesen A. Clinical review: Klinefelter syndrome--a clinical update. J Clin Endocrinol Metab 2013; 98:20-30
  309. Gravholt CH, Chang S, Wallentin M, Fedder J, Moore P, Skakkebaek A. Klinefelter Syndrome: Integrating Genetics, Neuropsychology, and Endocrinology. Endocr Rev 2018; 39:389-423
  310. Bojesen A, Juul S, Birkebaek NH, Gravholt CH. Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses. J Clin Endocrinol Metab 2006; 91:1254-1260
  311. Panimolle F, Tiberti C, Granato S, Semeraro A, Gianfrilli D, Anzuini A, Lenzi A, Radicioni A. Screening of endocrine organ-specific humoral autoimmunity in 47,XXY Klinefelter's syndrome reveals a significant increase in diabetes-specific immunoreactivity in comparison with healthy control men. Endocrine 2016; 52:157-164
  312. Sybert VP, McCauley E. Turner's syndrome. N Engl J Med 2004; 351:1227-1238
  313. Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol 1998; 51:147-158
  314. Sun L, Wang Y, Zhou T, Zhao X, Wang Y, Wang G, Gang X. Glucose Metabolism in Turner Syndrome. Front Endocrinol (Lausanne) 2019; 10:49
  315. Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, Lin AE, Mauras N, Quigley CA, Rubin K, Sandberg DE, Sas TCJ, Silberbach M, Soderstrom-Anttila V, Stochholm K, van Alfen-van derVelden JA, Woelfle J, Backeljauw PF, International Turner Syndrome Consensus G. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 2017; 177:G1-G70
  316. Bakalov VK, Cheng C, Zhou J, Bondy CA. X-chromosome gene dosage and the risk of diabetes in Turner syndrome. J Clin Endocrinol Metab 2009; 94:3289-3296
  317. Mortensen KH, Cleemann L, Hjerrild BE, Nexo E, Locht H, Jeppesen EM, Gravholt CH. Increased prevalence of autoimmunity in Turner syndrome--influence of age. Clin Exp Immunol 2009; 156:205-210
  318. Gravholt CH, Andersen NH, Christin-Maitre S, Davis SM, Duijnhouwer A, Gawlik A, Maciel-Guerra AT, Gutmark-Little I, Fleischer K, Hong D, Klein KO, Prakash SK, Shankar RK, Sandberg DE, Sas TCJ, Skakkebaek A, Stochholm K, van der Velden JA, International Turner Syndrome Consensus G, Backeljauw PF. Clinical practice guidelines for the care of girls and women with Turner syndrome. Eur J Endocrinol 2024; 190:G53-G151
  319. Sheanon N, Elder D, Khoury J, Casnellie L, Gutmark-Little I, Cernich J, Backeljauw PF. Increased Prevalence of Beta-Cell Dysfunction despite Normal HbA1c in Youth and Young Adults with Turner Syndrome. Horm Res Paediatr 2021; 94:297-306
  320. Stanley TL, Leong A, Pober BR. Growth, body composition, and endocrine issues in Williams syndrome. Curr Opin Endocrinol Diabetes Obes 2021; 28:64-74
  321. Kozel BA, Barak B, Kim CA, Mervis CB, Osborne LR, Porter M, Pober BR. Williams syndrome. Nat Rev Dis Primers 2021; 7:42
  322. Morris CA. Williams Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, eds. GeneReviews((R)). Seattle (WA)2017.
  323. Stone SI, Abreu D, McGill JB, Urano F. Monogenic and syndromic diabetes due to endoplasmic reticulum stress. J Diabetes Complications 2021; 35:107618
  324. Urano F. Wolfram Syndrome: Diagnosis, Management, and Treatment. Curr Diab Rep 2016; 16:6
  325. Rigoli L, Bramanti P, Di Bella C, De Luca F. Genetic and clinical aspects of Wolfram syndrome 1, a severe neurodegenerative disease. Pediatr Res 2018; 83:921-929
  326. Ray MK, Chen L, White NH, Ni R, Hershey T, Marshall BA. Longitudinal progression of diabetes mellitus in Wolfram syndrome: The Washington University Wolfram Research Clinic experience. Pediatr Diabetes 2022; 23:212-218
  327. Bidichandani SI, Delatycki MB. Friedreich Ataxia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, eds. GeneReviews((R)). Seattle (WA)1993.
  328. Pappa A, Hausler MG, Veigel A, Tzamouranis K, Pfeifer MW, Schmidt A, Bokamp M, Haberland H, Wagner S, Bruckel J, de Sousa G, Hackl L, Bollow E, Holl RW. Diabetes mellitus in Friedreich Ataxia: A case series of 19 patients from the German-Austrian diabetes mellitus registry. Diabetes Res Clin Pract 2018; 141:229-236
  329. Cnop M, Mulder H, Igoillo-Esteve M. Diabetes in Friedreich ataxia. J Neurochem 2013; 126 Suppl 1:94-102
  330. Bidichandani SI, Delatycki MB, Napierala M, Duquette A. Friedreich Ataxia. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews((R)). Seattle (WA)1993.
  331. Pandey M, Rajamma U. Huntington's disease: the coming of age. J Genet 2018; 97:649-664
  332. Montojo MT, Aganzo M, Gonzalez N. Huntington's Disease and Diabetes: Chronological Sequence of its Association. J Huntingtons Dis 2017; 6:179-188
  333. Farrer LA. Diabetes mellitus in Huntington disease. Clin Genet 1985; 27:62-67
  334. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med (Berl) 2004; 82:510-529
  335. Hartman J, Patki T, Johnson NE. Diagnosis and Management of Myotonic Dystrophy Type 1. JAMA 2024; 331:1227-1228
  336. Winters SJ. Endocrine Dysfunction in Patients With Myotonic Dystrophy. J Clin Endocrinol Metab 2021; 106:2819-2827
  337. Alsaggaf R, Pfeiffer RM, Wang Y, St George DMM, Zhan M, Wagner KR, Amr S, Greene MH, Gadalla SM. Diabetes, metformin and cancer risk in myotonic dystrophy type I. Int J Cancer 2020; 147:785-792
  338. Lee JY, Jeong HN. Nationwide incidence of myotonic dystrophy type 1 and the status of multi-organ involvement. J Neurol 2021;
  339. Abe H, Mita T, Kudo K, Funayama T, Tokoro M, Kaga H, Ikeda F, Kanazawa A, Hirose T, Kawamori R, Watada H. Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy. Endocr J 2009; 56:911-913
  340. Takeshima K, Ariyasu H, Ishibashi T, Kawai S, Uraki S, Koh J, Ito H, Akamizu T. Myotonic dystrophy type 1 with diabetes mellitus, mixed hypogonadism and adrenal insufficiency. Endocrinol Diabetes Metab Case Rep 2018; 2018
  341. Tsang SH, Aycinena ARP, Sharma T. Ciliopathy: Bardet-Biedl Syndrome. Adv Exp Med Biol 2018; 1085:171-174
  342. Mujahid S, Hunt KF, Cheah YS, Forsythe E, Hazlehurst JM, Sparks K, Mohammed S, Tomlinson JW, Amiel SA, Carroll PV, Beales PL, Huda MSB, McGowan BM. The Endocrine and Metabolic Characteristics of a Large Bardet-Biedl Syndrome Clinic Population. J Clin Endocrinol Metab 2018; 103:1834-1841
  343. Dollfus H, Lilien MR, Maffei P, Verloes A, Muller J, Bacci GM, Cetiner M, van den Akker ELT, Grudzinska Pechhacker M, Testa F, Lacombe D, Stokman MF, Simonelli F, Gouronc A, Gavard A, van Haelst MM, Koenig J, Rossignol S, Bergmann C, Zacchia M, Leroy BP, Mosbah H, Van Eerde AM, Mekahli D, Servais A, Poitou C, Valverde D. Bardet-Biedl syndrome improved diagnosis criteria and management: Inter European Reference Networks consensus statement and recommendations. Eur J Hum Genet 2024; 32:1347-1360
  344. Esbati R, Yazdani O, Simonetti J. Management of Obesity-Related Genetic Disorders. Endocrinol Metab Clin North Am 2025; 54:17-38
  345. Haws R, Brady S, Davis E, Fletty K, Yuan G, Gordon G, Stewart M, Yanovski J. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes Metab 2020; 22:2133-2140
  346. Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GA, Poitou C, Yanovski JA, Mittleman RS, Yuan G, Forsythe E, Clement K, Argente J. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol 2022; 10:859-868
  347. Argente J, Verge CF, Okorie U, Fennoy I, Kelsey MM, Cokkinias C, Scimia C, Lee HM, Farooqi IS. Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. Lancet Diabetes Endocrinol 2025; 13:29-37
  348. Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, eds. GeneReviews((R)). Seattle (WA)1993.
  349. Clerc A, Coupaye M, Mosbah H, Pinto G, Laurier V, Mourre F, Merrien C, Diene G, Poitou C, Tauber M. Diabetes Mellitus in Prader-Willi Syndrome: Natural History during the Transition from Childhood to Adulthood in a Cohort of 39 Patients. J Clin Med 2021; 10
  350. Chan NN, Feher MD, Bridges NA. Metformin therapy for diabetes in Prader-Willi syndrome. J R Soc Med 1998; 91:598
  351. Ng NBH, Low YW, Rajgor DD, Low JM, Lim YY, Loke KY, Lee YS. The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review. Clin Endocrinol (Oxf) 2022; 96:144-154
  352. Gimenez-Palop O, Romero A, Casamitjana L, Pareja R, Rigla M, Caixas A. Effect of semaglutide on weight loss and glycaemic control in patients with Prader-Willi Syndrome and type 2 diabetes. Endocrinol Diabetes Nutr (Engl Ed) 2024; 71:83-87
  353. Marshall JD, Maffei P, Collin GB, Naggert JK. Alstrom syndrome: genetics and clinical overview. Curr Genomics2011; 12:225-235
  354. Hearn T. ALMS1 and Alstrom syndrome: a recessive form of metabolic, neurosensory and cardiac deficits. J Mol Med (Berl) 2019; 97:1-17
  355. Dassie F, Favaretto F, Bettini S, Parolin M, Valenti M, Reschke F, Danne T, Vettor R, Milan G, Maffei P. Alstrom syndrome: an ultra-rare monogenic disorder as a model for insulin resistance, type 2 diabetes mellitus and obesity. Endocrine 2021; 71:618-625
  356. Marshall JD, Bronson RT, Collin GB, Nordstrom AD, Maffei P, Paisey RB, Carey C, Macdermott S, Russell-Eggitt I, Shea SE, Davis J, Beck S, Shatirishvili G, Mihai CM, Hoeltzenbein M, Pozzan GB, Hopkinson I, Sicolo N, Naggert JK, Nishina PM. New Alstrom syndrome phenotypes based on the evaluation of 182 cases. Arch Intern Med 2005; 165:675-683
  357. Tahani N, Maffei P, Dollfus H, Paisey R, Valverde D, Milan G, Han JC, Favaretto F, Madathil SC, Dawson C, Armstrong MJ, Warfield AT, Duzenli S, Francomano CA, Gunay-Aygun M, Dassie F, Marion V, Valenti M, Leeson-Beevers K, Chivers A, Steeds R, Barrett T, Geberhiwot T. Consensus clinical management guidelines for Alstrom syndrome. Orphanet J Rare Dis 2020; 15:253
  358. Ali S, Baig S, Wanninayake S, da Silva Xavier G, Dawson C, Paisey R, Geberhiwot T. Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alstrom syndrome patients. Diabetes Obes Metab 2024; 26:989-996
  359. Oshima J, Martin GM, Hisama FM. Werner Syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews((R)). Seattle (WA)1993.
  360. Takemoto M, Kubota Y, Taniguchi T, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Tsukamoto K, Mori S, Kuzuya M, Yokote K. Management guideline for Werner syndrome 2020. 3. Diabetes associated with Werner syndrome. Geriatr Gerontol Int 2021; 21:142-145
  361. Atallah I, McCormick D, Good JM, Barigou M, Fraga M, Sempoux C, Superti-Furga A, Semple RK, Tran C. Partial lipodystrophy, severe dyslipidaemia and insulin resistant diabetes as early signs of Werner syndrome. J Clin Lipidol 2022; 16:583-590
  362. Christiansen AL, Bygum A, Hother-Nielsen O, Rasmussen LM. Diagnosing diabetes mellitus in patients with porphyria cutanea tarda. Int J Dermatol 2018; 57:763-769
  363. Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med 2017; 377:862-872
  364. Singal AK. Porphyria cutanea tarda: Recent update. Mol Genet Metab 2019;

Sexual Dysfunction in Female Patients with Diabetes

ABSTRACT

 

Female sexual dysfunction (FSD) is a significant complication of diabetes mellitus, affecting 20-80% of women with type 2 diabetes. The condition stems from multiple factors including vascular damage, neuropathy, hormonal imbalances, and psychological aspects. Sustained hyperglycemia leads to blood vessel damage and reduces nitric oxide bioavailability, affecting vaginal blood flow and lubrication. Management requires a comprehensive approach focusing on glycemic control, lifestyle modifications, and specific interventions including lubricants, medications, and psychological support. Treatment outcomes vary based on factors such as age, diabetes duration, and complication severity. Early intervention and regular screening are essential for improved outcomes.

 

INTRODUCTION AND EPIDEMIOLOGY

 

Female sexual dysfunction (FSD) represents a significant yet often overlooked complication of diabetes mellitus that substantially impacts quality of life and relationship satisfaction. Studies indicate that women with diabetes have a markedly higher prevalence of sexual dysfunction compared to normal women. In women with type 2 diabetes mellitus (T2DM), the prevalence of FSD is about 20–80%, compared to the general female population where it is about 40% (1). However, a recent study by Derosa et al. showed that the prevalence of FSD is about 87% (2). T2DM is a bigger burden in developed regions (Europe, North America), with approximately equal gender distribution (3). The relationship between diabetes and FSD is complex and multifactorial, involving physiological, psychological, and social components. Diabetes can affect sexual function through multiple pathways including vascular complications, neurological damage, hormonal imbalances, and psychological factors associated with a chronic disease. The duration of diabetes, glycemic control, and the presence of other diabetes-related complications all play crucial roles in the development and severity of FSD. Understanding these relationships is essential for healthcare providers to effectively address this important aspect of women's health in the context of diabetes care.

 

DEFINITION

 

The definition of female sexual dysfunction (FSD) includes female sexual interest/arousal disorder (FSIAD), female orgasmic disorder, and genitopelvic pain/penetration disorder. To be considered dysfunctional, these symptoms must cause distress and must occur at least 75% of the time over a 6-month period. This definition has been in place since the development of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) in 2013. Thus, incidence and prevalence data based on this definition are developing (4) Prevalence of FSD is seen in women of reproductive age, which also include perimenopausal women although menopausal and postmenopausal women are also affected by FSD. Female Sexual Dysfunction is classified as Primary (occurring independently without medical or psychiatric causes) or Secondary (resulting from medical conditions, psychiatric disorders, or medications/ substances) (5).

 

PATHOPHYSIOLOGY AND CLINICAL MANIFESTATIONS

 

The World Health Organization (WHO) declared human sexuality to be part of health quality and well-being in 1974 (WHO meeting on education and treatment in human sexuality) (6). In women, sexual function depends on different physiological circumstances such as vaginal hemodynamics and neurologic innervation, and the activity of genital and pelvic structures (7). Female sexual dysfunction in women with diabetes stems from decreased clitoral blood flow due to vascular damage and peripheral neuropathy affecting the hypo gastric- vaginal/clitoral arterial bed. Despite these known mechanisms, research remains limited, with most studies having small sample sizes and focusing on specific factors rather than comprehensive analysis (8). Blood vessel damage from diabetes is a major cause of sexual problems in both men and women. Underlying atherosclerosis may be suggested by measuring two enzymes called paraoxonase-1 (PON-1) and arylesterase (ARE), which are usually lower in diabetic patients with blood vessel problems (9). PON is an enzyme that helps break down harmful substances, particularly one called paraoxon. PON comes in three forms (PON-1, PON-2, and PON-3). Low levels of PON-1 signal various health problems, including diabetes, heart disease, kidney problems, arthritis, metabolic issues, or thyroid dysfunction (10). PON-1 and ARE contribute to the protective effect of HDL against atherosclerosis. A study by Ciftci and colleagues observed a negative correlation between PON-1 activity and erectile dysfunction (ED), along with a correlation between PON-1 activity and HDL levels, while LDL levels were higher in the ED group compared with the control group (11).

 

When blood glucose levels stay high for a long time, it damages cells in two main ways: by creating advanced glycation end products (AGEs), and by causing oxidative stress. This damages blood vessels and nerves that are important for the sexual response. High blood glucose also makes the vagina dry and more prone to infections, which can make sex uncomfortable. Research shows that keeping blood glucose levels steady and well-controlled can help prevent or reduce these sexual problems (12). There are some studies that correlate better glycemic control with lower incidence of FSD and better outcomes (13).

 

In diabetes, endothelial damage makes it harder for blood vessels to relax and allow proper blood flow during sexual arousal. This happens because nitric oxide causes vasodilation and in patients with diabetes reduced nitric oxide bioavailability and reduced endothelial signaling hinder normal blood vessel relaxation during sexual excitation, resulting in decreased vaginal blood flow and lubrication. At the same time, diabetes harms nerves in the genital area, reducing sensation and natural sexual responses. Both issues together make sexual function more difficult (14).

 

Dyspareunia in postmenopausal women primarily stems from genitourinary syndrome of menopause (GSM), characterized by progressive vulvovaginal atrophy due to estrogen deficiency. The decline in estrogen leads to thinning of vaginal epithelium, reduced elasticity, decreased lubrication, and increased vaginal pH. These changes result in symptoms including vaginal dryness, burning, irritation, and pain during intercourse. This condition affects postmenopausal women and often goes underreported and undertreated. Unlike vasomotor symptoms, GSM is progressive and doesn't resolve without intervention. The impact on sexual function can be significant, leading to reduced sexual activity, relationship strain, and decreased quality of life.

 

T2DM frequently causes hormonal abnormalities, which might contribute to sexual dysfunction. Insulin resistance and hyperinsulinemia affect the hypothalamic–pituitary–ovarian axis, altering sex hormone levels (mainly estrogen) and to lessor degree progesterone and testosterone. Women with androgen excess and males with androgen insufficiency have the same cardiometabolic characteristics. The proper balance of estrogens and androgens is critical for maintaining energy metabolism, body composition, and sexual function. These changes can lead to diminished sexual desire, vaginal dryness, and poor genital responsiveness. (15)

 

Many women report a combination of symptoms that may worsen with poor glycemic control and duration of diabetes. The interaction between physiological changes and psychological factors, such as diabetes-related stress, body image concerns, and relationship dynamics, creates a complex clinical picture that requires comprehensive evaluation and management (figure 1).

 

Figure 1. Proposed mechanisms of FSD in patients with Type 2 DM.

 

DIAGNOSIS AND ASSESSMENT

 

A systematic approach to diagnosing FSD in women is essential for effective management. The diagnostic process should begin with a detailed medical history, including diabetes control, complications, medications, and comorbidities. Sexual history should be obtained sensitively, addressing the nature and timeline of sexual concerns, relationship factors, and impact on quality of life. Validated assessment tools such as the Female Sexual Function Index (FSFI) (16), the Sexual Function Questionnaire (16), female Orgasm Scale (17), and Multidimensional Vaginal Penetration Disorder Questionnaire (18) can provide objective measures of sexual dysfunction and help monitor treatment outcomes. Physical examination should include evaluation of vaginal health, signs of neuropathy, and vascular status. Laboratory assessments should include glycemic control markers (HbA1c), hormonal status (especially in perimenopausal women), and screening for other endocrine disorders that may contribute to sexual dysfunction. Psychological assessment is crucial, as depression, anxiety, and diabetes-related distress frequently co-exist with FSD. The diagnostic process should also consider cultural and social factors that may influence sexual function and help-seeking behavior. Healthcare providers should maintain a non- judgmental, culturally sensitive approach while conducting these assessments to ensure accurate diagnosis and appropriate treatment planning.

 

DIFFERENT DOMAINS OF FEMALE SEXUAL DYSFUNCTION

 

Sexual dysfunction (SD) is classified by two main medical systems (19):

 

  1. DSM (The Diagnostic and Statistical Manual of Mental Disorders)
  2. ICD (International Classification of Diseases), version 11

 

Both systems organize sexual problems based on the natural stages of sexual activity, from initial arousal through to orgasm. The conditions are divided into four main groups of sexual disorders (20).

 

DOMAIN 1: DESIRE PROBLEMS

 

  • Definition: Persistent lack of sexual thoughts/fantasies
  • Types:
    • Hypoactive Sexual Desire Disorder (HSDD)
    • Sexual Aversion Disorder (SAD)
  • Assessment Tool: Sexual Function Questionnaire (SFQ-V1) (16)

 

DOMAIN 2: AROUSAL ISSUES

 

  • Definition: Problems with physical/mental sexual excitement
  • Symptoms: Poor genital response, lack of interest
  • Assessment Tool: Female Sexual Function Index (FSFI) (16)

 

DOMAIN 3: ORGASM DIFFICULTIES

  • Types:
    • Primary: Lifelong inability
    • Secondary: Acquired problem
  • Definition: Absent/delayed/reduced orgasms
  • Assessment Tool: Female Orgasm Scale (17)

 

DOMAIN 4: PAIN CONDITIONS

  • Definition: Pain during sexual activity
  • Symptoms:
    • Pelvic muscle spasms
    • Entry pain
    • Fear of penetration
  • Assessment Tool: Multidimensional Vaginal Penetration Disorder Questionnaire (18)

 

Female sexual dysfunction classifications have evolved significantly. Recent systems (ICSM, ISSWSH, ICD-11) separate desire from arousal issues and emphasize sexual distress as crucial for diagnosis. ICD-11 introduced a new sexual health chapter, while experts have defined new subtypes of arousal disorders (FCAD, FGAD) (19,20) (table 1).

 

Table 1. The Main Classifications of Female Sexual Dysfunction

ICD

DSM

ICSM

ISSWSH

ICD-10

ICD-11(PROPOSED)

DSM-V

Fourth ICSM

ISSWSH-2016

ISSWSH-2018

Lack or loss of sexual desire

Hypoactive sexual desire disorder

Female sexual interest/arousal disorder

Hypoactive sexual desire dysfunction

Hypoactive sexual desire disorder

Hypoactive sexual desire disorder

Sexual aversion

Recommended for deletion

Female orgasmic    disorder

Female sexual arousal dysfunction

Female genital arousal disorder

Female sexual arousal disorder:

-female cognitive arousal disorder

-female genital arousal disorder

Lack of sexual enjoyment

Female sexual arousal dysfunction

Genito-pelvic penetration disorder

Female orgasmic dysfunction

Persistent genital arousal disorder

Persistent genital arousal disorder

Failure of sexual response

Female genital-pelvic pain dysfunction

Female orgasm disorder

Female orgasm disorder

Orgasmic dysfunction

Orgasmic dysfunction

Persistent genital arousal disorder

Female orgasmic illness syndrome

Female orgasmic illness syndrome

Non organic vaginismus

Sexual pain penetration disorder

Postcoital syndrome(post-orgasmic illness syndrome)

 

TREATMENT STRATEGIES AND MANAGEMENT

 

Management of FSD in  women requires a comprehensive, individualized approach addressing the underlying diabetes-related factors and specific sexual concerns. The cornerstone of treatment is optimizing glycemic control through appropriate diabetes management, as improved metabolic control often correlates with better sexual function. Lifestyle modifications, including regular exercise, smoking cessation, and stress reduction, can improve glycemic control and sexual health.

 

Specific treatments for sexual dysfunction may include vaginal moisturizers and lubricants for vaginal dryness, pelvic floor physical therapy for dyspareunia, and medications to address specific sexual concerns where appropriate. Hormonal therapy may be considered in post-menopausal women after careful risk assessment. For female sexual dysfunction in diabetes, treatments include PDE-5 inhibitors. Studies using animal models of female sexual response suggest the physiological effects of PDE5 on vaginal and clitoral tissues are similar to those observed in males (figure 2); therefore, it is unlikely that the lack of effects of PDE5 on women's sexual functioning could be related to gender differences in the physiological effects of PDE5. NO synthase (NOS) is active in the vaginal epithelium, and the PDE5 enzyme has been identified in vaginal smooth muscle tissue and the clitoral shaft (21). The various PDE5 inhibitors that have been evaluated in clinical trials in this population have included sildenafil, tadalafil, vardenafil, udenafil, mirodenafil and avanafil (21,32).

 

Figure 2. Mechanism of PDE-5 in Female Sexual dysfunction.

 

Blood flow for better arousal and orgasm, while topical estrogen treatments address vaginal dryness and tissue health. Sexual aids such as vibrators or other similar devices can be beneficial for some women in enhancing sexual pleasure (21,22). Psychological interventions, including cognitive behavioral therapy, sex therapy, and relationship counseling play vital roles in addressing the psychological aspects of FSD. Management of concurrent conditions such as depression, anxiety, and other diabetes complications is essential. Patient education about the relationship between diabetes and sexual health, along with strategies for maintaining intimate relationships despite chronic illness, should be integrated into the treatment plan. Regular follow-up is necessary to monitor progress and adjust interventions as needed.

 

PREVENTION, PROGNOSIS, AND FUTURE DIRECTIONS

 

Prevention of FSD in  women focuses on maintaining optimal glycemic control, early detection of complications, and addressing modifiable risk factors. Regular screening for sexual concerns should be integrated into routine diabetes care to enable early intervention. The prognosis varies depending on multiple factors including age, duration, severity of diabetes, presence of complications, and effectiveness of interventions. Research suggests that early intervention and comprehensive management can improve sexual function and quality of life for many women (23). Emerging areas of research include novel therapeutic approaches such as growth factors for vaginal health, new drug delivery systems, and innovative psychological interventions.

 

Pharmacological strategies include ospemifene, a selective estrogen receptor modulator, that has been shown to be effective for the treatment of vulvovaginal atrophy in postmenopausal women with vaginal dryness (24) or flibanserin, a 5-HT1A agonist/5-HT2A antagonist, for women with hypoactive sexual desire (25) Future directions in management may involve personalized medicine approaches based on individual risk factors and response patterns. Additionally, there is a growing recognition of the need for better integration of sexual health care into diabetes management programs and improved training for healthcare providers in addressing these concerns. The development of new assessment tools and treatment modalities specifically tailored for diabetic women with FSD continues to be an active area of research. Understanding the long-term outcomes of various interventions and identifying factors that predict treatment success remain important goals for future studies.

 

Table 2. Recent Advances in Pharmacotherapy  For FSD

Drug name

Flibanserin (26.27)

Bremelanotide (27,28)

Testosterone (Off-label) (27,29,30)

Ospemifene

(31)

PDE5 Inhibitors

(32)

Brand Name

Addyi

Vyleesi

Various

Osphena

Viagra , Cialis

Indication

Premenopausal HSDD

Premenopausal HSDD

Postmenopausal sexual dysfunction

• Low libido

• Used off-label in US

Moderate-severe dyspareunia and VVA in postmenopausal women

• SSRI-induced FSD

• Diabetic FSD

• Arousal disorders

Administration

100mg oral daily at bedtime

1.75mgSC injection 45 min before activity; max 8/month

• Various formulations

• Creams, gels, implants

• 0.5-2% of male doses

60mg oral daily with food

Viagra:

• Start 25mg 1-2 hours before activity

Cialis:

• 2.5-5mg daily

 

Mechanism

• 5-HT1A agonist

• 5-HT2A antagonist

• Modulates serotonin, dopamine, norepinephrine

Melanocortin-4 receptor agonist

Androgenic effects on sexual response and libido

• SERM

• Vaginal estrogen agonist

• Breast estrogen antagonist

FIG 2

Common Side Effects

• Dizziness

• Somnolence

• Nausea

• Hypotension

• Nausea (40%)

• Flushing

• Injection site reactions

• Headache

• Acne

• Hirsutism

• Voice changes

• Clitoral enlargement

• Hot flashes

• Vaginal discharge

• Muscle spasms

• Hyperhidrosis

• Headache

•Flushing

• Nasal congestion

•Dyspepsia

• Visual changes

Contraindications

• Alcohol use

• Hepatic impairment

• Hypotension

• Uncontrolled hypertension

• CVD

• hypersensitivity

• Active breast cancer

• Severe liver disease

• Pregnancy

• Abnormal bleeding

• Estrogen-dependent neoplasia

• Active DVT/PE

• Arterial thromboembolism

• Nitrate use

•Hypotension

• Recent stroke/MI

• High-risk cardiac disease

Drug Interactions

• CYP3A4 modulators

• CNS depressants

• Alcohol (severe)

• Limited

• Caution with antihypertensives

• Anticoagulants

• Insulin

• Corticosteroids

•CYP3A4/2C9/2C19 inhibitors

• Estrogens

• High-fat meals affect absorption

• Nitrates

• Alpha blockers

• Strong CYP3A4 inhibitors

• HIV protease inhibitors

Monitoring Needs

• BP monitoring

• Liver function

• Alcohol use

• BP monitoring

• Nausea management

• Testosterone levels

• Lipids

• Liver function

• CBC

• Breast exams

• Annual gynecologic exam

• Abnormal bleeding

• Thromboembolic symptoms

• BP monitoring

• Nausea monitoring

Best Use Case

Premenopausal women who can abstain from alcohol

Premenopausal women who prefer on-demand treatment

Postmenopausal women with low T and no contraindications

Postmenopausal women with VVA who can't use vaginal estrogen

•SSRI-induced FSD

• Diabetic FSD

• Arousal disorders

FDA approved

In 2015, flibanserin became the first agent to gain approval from the U.S. Food and Drug Administration (FDA) for the treatment of HSDD

A newly approved pharmaceutical option for treatment of HSDD in premenopausal women

The off-label use of testosterone to increase sexual desire in postmenopausal women is supported by evidence as well as several professional societies.

Approved by the FDA for the treatment of dyspareunia (painful intercourse) in postmenopausal women

Not FDA approved for FSD

 

ASSOCIATION OF FSD IN TYPE 1 DIABETES MELLITUS

 

Female sexual dysfunction (FSD) in Type 1 diabetes mellitus represents a complex clinical challenge affecting reproductive health, quality of life, and intimate relationships. The condition encompasses multiple sexual health disorders including decreased libido, arousal difficulties, orgasmic dysfunction, and dyspareunia (33).

 

The pathophysiological mechanisms are intricate and interconnected:

 

Vascular Changes: Chronic hyperglycemia causes endothelial dysfunction and reduced nitric oxide production, leading to decreased vaginal and clitoral blood flow. This impairs arousal response and natural lubrication, often resulting in vaginal dryness and discomfort during intercourse.

 

Neurological Impact: Diabetic neuropathy affects both autonomic and peripheral nervous systems. Autonomic neuropathy disrupts sexual response by impairing genital blood flow regulation and vaginal lubrication. Peripheral neuropathy reduces genital sensation, affecting arousal and orgasmic capacity.

 

Hormonal Alterations: Type 1 DM can affect hypothalamic-pituitary-ovarian axis function, potentially leading to irregular menstruation and altered sex hormone levels. This may contribute to reduced libido and vaginal atrophy.

 

Psychological Factors: Women with Type 1 DM often experience higher rates of depression, anxiety, and poor body image, which significantly impact sexual desire and satisfaction. The burden of disease management and fear of complications can create psychological barriers to intimate relationships.

 

Treatment Considerations: Management requires a comprehensive approach including:

  • Optimal glycemic control
  • Regular screening for complications
  • Psychological support
  • Sexual health counseling
  • Treatment of specific symptoms (e.g., lubricants for vaginal dryness)
  • Partner involvement in treatment planning

 

Early recognition and intervention are crucial for preventing progression and maintaining sexual health in women with Type 1 DM.

 

REFERENCES

 

  1. Pontiroli, A.E.; Cortelazzi, D.; Morabito, A. Female Sexual Dysfunction and Diabetic Review and Meta-Analysis. J. Sex. Med. 2013, 10, 1044–1051.
  2. Derosa, G.; Romano, D.; D’angelo, A.; Maffioli, P. Female Sexual Dysfunction in Subjects with Type 2 Diabetes Mellitus. Sex. Disabil. 2023, 41, 221–233.
  3. Ong, K.L.; Stafford, L.K.; McLaughlin, S.A.; Boyko, E.J.; Vollset, S.E.; Smith, A.E.; Dalton, B.E.; Duprey, J.; Cruz, J.A.; Hagins, H.; et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 2023, 402, 203–234.
  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition, Text Revision. Washington, DC: American Psychiatric Publishing; 2022.)
  5. Rahmanian, E.; Salari, N.; Mohammadi, M.; Jalali, R. Evaluation of Sexual Dysfunction and Female Sexual Dysfunction Indicators in Women with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetol. Metab. Syndr. 2019, 11, 1–17.
  6. Education and treatment in human sexuality: the training of health professionals. Geneva: World Health Organization; 1975 (http://apps.who. int/iris/bitstream/10665/38247/1/WHO_TRS_572_eng.pdf, accessed 14 June 2017)).
  7. Cortelazzi D, Marconi A, Guazzi M, Cristina M, Zecchini B, Veronelli A, et al. Sexual dysfunction in pre-menopausal diabetic women: clinical, metabolic, psychological, cardiovascular, and neurophysiologic correlates. Acta Diabetol. 2013;50(6):911-7.
  8. Kaya C, Yilmaz G, Nurkalem Z, Ilktac A, Karaman M. Sexual function in women with coronary artery disease: a preliminary study. Int J Impot Res. 2007;19(3):326-9.
  9. Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important?
  10. Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med. 2005;38(2):153-63
  11. Ciftci H, Yeni E, Savas M, Verit A, Celik H. Paraoxonase activity in patients with erectile dysfunction. Int J Impot Res. 2007;19(5):517-20.
  12. Faselis, C.; Katsimardou, A.; Imprialos, K.; Deligkaris, P.; Kallistratos, M.; Dimitriadis, K. Microvascular Complications of Type 2 Diabetes Mellitus. Curr. Vasc. Pharmacol. 2019, 18, 117–
  13. Veronelli, A.; Mauri, C.; Zecchini, B.; Peca, M.G.; Turri, O.; Valitutti, M.T.; Dall’Asta, C.; Pontiroli, E. Sexual Dysfunction Is Frequent in Premenopausal Women with Diabetes, Obesity, and Hypothyroidism, and Correlates with Markers of Increased Cardiovascular Risk. A Preliminary Report. J. Sex. Med. 2009, 6, 1561–1568.
  14. Gardner, D.G.; Shoback, D. Greenspan’ s Basic & Clinical Endocrinology, 10th ed.; McGraw-Hill Education: New York, NY, USA, 2018.
  15. Rogoznica M, Perica D, Borovac B, Belančić A, Matovinović M. Sexual dysfunction in female patients with type 2 diabetes mellitus—sneak peek on an important quality of life determinant. Diabetology (Internet). 2023 (cited 2024 Nov 5);4(4):527–36
  16. Rosen, R.; Brown, C.; Heiman, J.B.; Leiblum, S.; Meston, C.; Shabsigh, R.; Ferguson, D.; D’Agostino, R., Jr. The Female Sexual Function Index (FSFI): A Multidimensional Self-Report Instrument for the Assessment of Female Sexual Function. J. Sex Marital Ther. 2000, 26, 191– 208.
  17. Mcintyre-Smith A, Fisher WA. Female orgasm scale. In: Handbook of Sexuality-Related Measures. 3rd ed. New York, NY: Routledge; 2011
  18. Molaeinezhad M, Roudsari RL, Yousefy A, Salehi M, Khoei EM. Development and validation of the multidimensional vaginal penetration disorder questionnaire (MVPDQ) for assessment of lifelong vaginismus in a sample of Iranian women. J Res Med Sci. 2014; 19:336-348.
  19. Parish, S.J.; Goldstein, A.T.; Goldstein, S.W.; Goldstein, I.; Pfaus, J.; Clayton, A.H.; Giraldi, A.; Simon, J.A.; Althof, S.E.; Bachmann, G.; et al. Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions: Part II. J. Sex. Med. 2016, 13, 1888–1906. (Google Scholar) (CrossRef) (PubMed) (Green Version)
  20. Zamponi, V.; Mazzilli, R.; Bitterman, O.; Olana, S.; Iorio, C.; Festa, C.; Giuliani, C.; Mazzilli, F.; Napoli, A. Association between type 1 diabetes and female sexual dysfunction. BMC Womens Health 2020, 20, 73. (Google Scholar) (CrossRef) (PubMed) (Green Version)
  21. Rosen, R. C., & Kostis, J. B. (2003). Overview of phosphodiesterase 5 inhibition in erectile dysfunction. The American Journal of Cardiology, 92(9), 9–18. https://doi.org/10.1016/s0002-9149(03)00824-5)
  22. Bhugra, D.; Colombini, G. Sexual Dysfunction: Classification and Assessment. Adv. Psychiatr. Treat. 2013, 19, 48–55.
  23. Vafaeimanesh, J.; Raei, M.; Hosseinzadeh, F.; Parham, M. Evaluation of Sexual Dysfunction in Women with Type 2 Diabetes. Indian J. Endocrinol. Metab. 2014, 18, 175–179.
  24. Portman, D.; Palacios, S.; Nappi, R.E.; Mueck, A.O. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: A randomised, placebo-controlled, phase III trial. Maturitas 2014, 78, 91–98.
  25. Katz, M.; DeRogatis, L.R.; Ackerman, R.; Hedges, P.; Lesko, L.; Garcia, M., Jr.; Sand, M. BEGONIA trial investigators. Efficacy of flibanserin in women with hypoactive sexual desire disorder: Results from the BEGONIA trial. J. Sex. Med. 2013, 10, 1807–1815
  26. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R. Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT1A receptors. British Journal of Pharmacology. 2003;139(7):1281– 1288. (PubMed: 12890707)
  27. Pettigrew, J. A., & Novick, A. M. (2021). Hypoactive sexual desire disorder in women: Physiology, assessment, diagnosis, and treatment. Journal of Midwifery & Women’s Health, 66(6), 740–748. https://doi.org/10.1111/jmwh.13283
  28. Vyleesi: Highlights of Prescribing Information. In: Cranbury, NJ: Palatin Technologies, Inc.; 2021.
  29. Davis SR, Worsley R, Miller KK, Parish SJ, Santoro N. Androgens and Female Sexual Function and Dysfunction—Findings From the Fourth International Consultation of Sexual Medicine. The Journal of Sexual Medicine. 2016;13(2):168–178. (PubMed: 26953831)
  30. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. The Journal of Clinical Endocrinology & Metabolism. 2019;104(10):4660–4666. (PubMed: 31498871)
  31. Elliott, W. T. A. D. C. (2013, March). Pharmacology Update: Ospemifene Tablets (OsphenaTM). 35(6)
  32. Balhara, Y. P., Sarkar, S., & Gupta, R. (2015). Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Indian Journal of Endocrinology and Metabolism, 19(4), 451. https://doi.org/10.4103/2230-8210.159023
  33. Zhang, X., Zhu, Z., Tang, G., & Xu, H. (2023). Prevalence and predictors of sexual dysfunction in females with type 1 diabetes: a systematic review and meta-analysis. The Journal of Sexual Medicine, 20(9), 1161–1171. https://doi.org/10.1093/jsxmed/qdad104

Growth and Growth Disorders

ABSTRACT

 

The process of growth is complex and is influenced by various factors that act centrally and peripherally.  In this chapter, we describe conditions associated with multiple pituitary hormone deficiency, isolated growth hormone deficiency, and abnormal growth without growth hormone deficiency, discuss the genes that are associated with these conditions, and prepare guidelines for the clinicians to evaluate a child with poor growth. In addition, we review treatment modalities, daily vs weekly, for growth hormone deficiency and their side effects.

 

INTRODUCTION

 

Human growth starts at conception and proceeds through various identifiable developmental stages. The process of growth depends on both genetic and environmental factors that combine to determine an individual’s eventual height. Genetic control of statural growth is becoming increasingly clear. Many genes have been identified that are required for normal development and function of the pituitary in general, and that control the growth hormone/insulin-like growth factor axis in particular and many more that are involved in numerous cascades of intracellular processes “downstream” of GH/IGF1 action. Mutations of these genes have been shown to be responsible for abnormal growth in humans and animals.

 

Growth hormone (GH) has been used to treat short children since the late 1950’s (1,2). Initially only those children with the most pronounced growth failure due to severe growth hormone deficiency (GHD) were considered appropriate candidates, but with time children with growth failure from a range of conditions have been shown to benefit from GH treatment. GH has also been used to treat several catabolic diseases including cystic fibrosis, inflammatory bowel disease and AIDS wasting (3–7). Here we review the physiology of growth, the diagnosis of GH deficiency, treatment options and genetic growth hormone disorders.

 

GROWTH DISORDERS

 

Growth failure may be due to genetic mutations, acquired disease and/or environmental deficiencies. Growth failure may result from a failure of hypothalamic growth hormone-releasing hormone (GHRH) production or release, from (genetic or sporadic) mal-development of the pituitary somatotropes, secondary to ongoing chronic illness, malnutrition, intrinsic abnormalities of cartilage and/or bone such as osteo-chondrodysplasias, and from genetic disorders affecting growth hormone production and responsiveness. Children without any identifiable cause of their growth failure are commonly labeled as having idiopathic short stature (ISS).

 

Genetic factors affecting growth include pituitary transcription factors (PROP1, POU1F1, HESX1, LHX3, and LHX4), GHRH, the GH secretagogue (GHS), GH, insulin like growth factor-1 (IGF1), insulin like growth factor-2 (IGF2), insulin (INS) and their receptors (GHRHR, GHSR, GHR, IGF1R, IGF2R and INSR) as well as transcription factors controlling GH signaling, including STAT1, STAT3, STAT5a, and STAT5b. Growth is also influenced by other factors such as the Short Stature Homeobox, sex steroids (estrogens and androgens), glucocorticoids and thyroid hormone.

 

Since the replacement of human pituitary-derived GH with recombinant human GH, much experience has been gained with the use of GH therapy. The Food and Drug Administration (FDA) had expanded GH use for the following conditions for children (8).

 

  1. GH deficiency/insufficiency
  2. Chronic renal insufficiency (pre-transplantation)
  3. Turner syndrome
  4. SHOX haploinsufficiency
  5. Short stature from Prader-Willi Syndrome (PWS)
  6. Children with a history of fetal growth restriction (SGA, IUGR) who have not caught up to a normal height range by age 2 years
  7. Children with idiopathic short stature (ISS): height > 2.25 SD below the mean in height and unlikely to catch up in height.
  8. Noonan Syndrome
  9.  Short Bowel Syndrome

 

FDA approved conditions for GH treatment for adults:

 

  1. Adults with GH deficiency
  2. Adults with AIDS wasting

 

The efficacy of GH treatment has been investigated in children whose height has been compromised due to chronic illnesses such as Crohn’s disease, cystic fibrosis, glucocorticoid-induced suppression of growth in other disorders (asthma and juvenile idiopathic arthritis (JIA), also known as juvenile rheumatoid arthritis (JRA)), and adrenal steroid disorders such as congenital adrenal hyperplasia (CAH). Studies have shown both anabolic effects and improvement of growth velocity after GH treatment in children with glucocorticoid dependent Crohn’s disease (3,9,10). Improvement in linear growth has also been observed after GH treatment in children with cystic fibrosis and JIA (4–6). The same studies have shown significant improvement in weight gain and body composition, changes that have been variably correlated with improvement in life expectancy and quality of life.

 

The growth-suppressing effects of glucocorticoids are also seen in children affected with CAH where high androgens both increase short-term growth velocity and limit the height potential. Most patients with CAH complete their growth prematurely and are ultimately short adults. Lin-Su et al, showed that GH in combination with LHRHa significantly improved their final adult height in children with CAH (11).

 

Larger, long-term prospective studies are needed to determine the safety and efficacy of GH treatment in these populations of children.

 

The key mediator of GH action in the periphery for both prenatal and postnatal mammalian growth is IGF system. GH exerts its direct effects at the growth plate and indirect effects via IGF1. Better understanding the role of IGF1 on growth had led to the concept of IGF1 deficiency in addition to GH deficiency. With the introduction of recombinant human (rh) IGF1, today, it is possible to treat conditions due to genetic GH resistance or insensitivity caused by GH receptor defects, and the presence of neutralizing GH antibodies (12). 

 

MULTIPLE PITUITARY HORMONE DEFICIENCY (MPHD)

 

GH deficiency may occur in combination with other pituitary hormone deficiencies and is often referred to as hypopituitarism, panhypopituitarism or multiple pituitary hormone deficiency (MPHD).

 

The anterior portion of pituitary gland forms from Rathke's pouch around the third week of gestation (13). It is influenced by the expression of numerous transcription factors and signaling molecules; some of them required for continued normal function of pituitary gland.  Mutations have been identified in the genes encoding several pituitary transcription factors and signaling molecules, including GLI2, LHX3, LHX4, HESX1, PROP1, POU1F1, SOX2, PITX2, OTX2 and SOX3 (Table 1). The most frequently mutated gene is PROP1 (6.7% in sporadic and 48.5% in familial cases) (14).

 

Most cases of hypopituitarism are idiopathic in origin; however, familial inheritance, which may be either dominant or recessive, accounts for between 5 and 30% of all cases (15).  It may present early in the neonatal period with symptoms of hypoglycemia, micropenis in males, prolonged jaundice, with/without midline defects or later in childhood with poor feeding, growth failure, or delayed puberty.  It can be associated with single or multiple pituitary hormone deficiencies, and endocrinopathy.  It may be associated with several other congenital anomalies such as optic nerve hypoplasia, anophthalmia, microphthalmia, agenesis of the corpus callosum, and absence of the septum pellucidum. 

 

Table 1. Transcription Factors Required for Normal Pituitary Development

Transcription Factors 

Function

GLI2

Essential for the forebrain and early stages of the anterior pituitary development

LHX3

Essential for the early development of the anterior pituitary, including the somatotrope, thyrotrope, lactotrope and the gonadotrope (but not the corticotrope)

LHX4

Essential for the proliferation of the anterior pituitary cell types, including the somatotrope, thyrotrope and the corticotrope

 

HESX1

Essential for the development of the anterior pituitary, including the somatotrope, thyrotrope, lactotrope and the gonadotrope

PROP1

Essential for the development of most cell types of the anterior pituitary, including the somatotrope, the thyrotrope, the lactotrope and the gonadotrope (but not the corticotrope). Also essential for the expression of the PIT1 protein and the extinction of HESX1 in the anterior pituitary

POU1F1 (PIT1)

Necessary for somatotrope, lactotrope and thyrotrope development and for their continued function

SOX2

Essential for the expression of POU1F1 and the development of the gonadotrope

PITX2

Necessary for the development of gonadotrope, somatotrope, lactotrope and thyrotrope

OTX2

Transactivates HESX1 and POU1F1

SOX3

Essential for the early formation of hypothalamic-pituitary axis

 

GLI2

 

GLI2 is a transcription factor, mediating Sonic Hedgehog (SHH) signaling and is necessary for forebrain development as well as for the early stages of pituitary development (16).  It is located on the long arm of chromosome 2 at position q14, (Figure 1). The clinical phenotype of persons with mutations in GLI2 may vary from asymptomatic individuals to isolated GH deficiency to hypopituitarism in combination with a small anterior pituitary, ectopic posterior pituitary, midfacial hypoplasia, anophthalmia, holoprosencephaly, and polydactyly (17–19).

Figure 1. The GLI2 gene.

LHX3

 

LHX3 is a member of the LIM family of HomeoboX transcription factors. The LHX3 gene is located on 9q34.3, comprises 7 exons (including two alternative exon 1's, 1a and 1b) and encodes a protein of 402 amino acids (Figure 2. LHX3 is expressed in the developing Rathke's pouch and is required for the development of most anterior pituitary cell types, including the somatotrope, the thyrotrope, the lactotrope and the gonadotrope (but notably not the corticotrope). LHX3binds as a dimer, synergizing with POU1F1 (PIT1). Two unrelated families with MPHD were identified in 2000 (20) as harboring mutations in LHX3. The affected members of the family manifested severe growth retardation in association with restricted rotation of the cervical spine and a variable degree of sensory neural hearing loss. Inheritance is consistent with an autosomal recessive pattern of inheritance and of note one individual was found to have an enlarged pituitary. Recently, a new mutation in LHX3 was described in a child with hypointense pituitary lesion, focal amyotrophy and mental retardation in addition to neck rigidity and growth retardation (21). These clinical findings expand the phenotype associated with mutations in LHX3.

Figure 2. The LHX3 Gene.

LHX4

 

LHX4 also has a critical role in the development of anterior pituitary cells and is co-expressed with LHX3 in Rathke's pouch in an overlapping but not wholly redundant pattern. Raetzman et al showed overlapping functions with PROP1 in early pituitary development but also observed that their mechanisms of action were not identical (22). While LHX4 is necessary for cell survival, LHX3 expression is required for cell differentiation (23). The pituitary hypoplasia seen in LHX4 mutants results from increased cell death and reduced differentiation due to loss of LHX3 (22). However, PROP1mutants exhibit normal cell proliferation and cell survival but show evidence of defective dorsal-ventral patterning (22). In the absence of both LHX4 and LHX3 genes, no specification of corticotropes, gonadotropes or thyrotropes occurs in the anterior lobe. Although both LHX3 and LHX4 are crucial for the development of pituitary gland, LHX3 is expressed at all stages studied, whereas LHX4 expression is transient at 6 weeks of development (24). LHX4 is located on 1q25 and comprises 6 exons spread over a 45 kb genomic region (Figure 3). An intronic splice site mutation has been described in one family, manifesting GH, TSH and ACTH deficiency, along with cerebellar and skull defects. The mutation is transmitted as an autosomal dominant condition, with complete penetrance. Interestingly, a heterozygous mutant mouse model had no discernable phenotype, while homozygous loss of function in the mouse was fatal (25).

Figure 3. The LHX4 Gene.

HESX1

 

HESX1 (HomeoboX gene expressed in Embryonic Stem cells), also referred to as RPX1 (Rathke's Pouch HomeoboX) is necessary for the development of the anterior pituitary. RPX1 comprises 4 exons and encodes a protein of 185 amino acids that features both a homeodomain as well as a repressor domain and is located on chromosome 3p21.2 (Figure 4). The extinguishing of HESX1 requires the appearance of another pituitary transcription factor, PROP1. A mutation has been described in two children of a consanguineous union who had optic nerve hypoplasia, agenesis of the corpus callosum and panhypopituitarism, with an apparent autosomal recessive mode of inheritance (26).  This Arg → Cys mutation lies between the repressor and homeodomains, but the mutant protein was shown in vitro to be unable to bind to its cognate sequences. A novel homozygous missense mutation (126T) of the critical engrailed homology repressor domain (eh1) of HESX1 was described in a girl born to consanguineous parents (27). Neuroimaging revealed a thin pituitary stalk with anterior pituitary hypoplasia and an ectopic posterior pituitary. Unlike previous cases, she did not have midline or optic nerve abnormalities. Although 126T mutation did not affect the DNA-binding ability of HESX1, it impaired ability of HESX1 to recruit Groucho-related corepressor, thereby leading to partial loss of repression. It appears that HESX1 mutations exhibit a variety of clinical phenotypes with no clear genotype-phenotype correlation

Figure 4. The HESX1 Gene.

PROP1

 

PROP1 (the Prophet of PIT-1) encodes a transcription factor required for the development of most pituitary cell lines, including the somatotrope (GH secretion), lactotrope (prolactin (PRL) secretion), thyrotrope (TSH secretion), and the gonadotrope (FSH and LH secretion). Mutation of PROP1, therefore, results in the deficiency of GH, TSH, PRL, FSH and LH although some individuals with PROP1 mutations have been described with ACTH deficiency (30). Since PROP1 does not appear to be required for the development of the corticotrope cell line, the etiology of ACTH deficiency is unclear. It appears that the ACTH deficiency here is a consequence of the compensatory pituitary hyperplasia that develops over time. Significantly, the degree of TSH deficiency appears to be quite variable, even within mutation-identical individuals, suggesting that the general phenotype associated with PROP1 mutations is also quite variable. PROP1 is encoded by three exons and is located on 5q. Many mutations have been described in PROP1-all inherited in an autosomal recessive manner. Although several studies suggest that mutation of PROP1 is the most common cause of familial MPHD, it is less common in sporadic cases of MPHD (14,31). Two recurrent mutations have been described, both involving exonic runs of GA tandem repeats (Figure 5). In both cases, the loss of a tandem unit at either locus results in a frameshift and premature termination, and a protein incapable of transactivation.

Figure 5. The PROP1 Gene.

POU1F1

 

POU1F1 encodes the POU1F1 transcription factor, also known as PIT1, which is required for the development and function of three major cell lines of anterior pituitary: somatotropes, lactotropes and thyrotropes. Various mutations in the gene encoding POU1F1 have been described, resulting in a syndrome of multiple pituitary hormone deficiency involving GH, PRL and TSH hormones. POU1F1 is located on 3p11 and consists of six exons encoding 291 amino acids (Figure 6). Many mutations of POU1F1 have been described; some are inherited as autosomal recessive and some as autosomal dominant. There is a wide variety of clinical presentations in patients with POUF1 mutations. Generally, GH and prolactin deficiencies are seen early in life. However, TSH deficiency can be highly variable with presentation later in childhood or normal T4 secretion can be preserved into the 3rd decade (32,33). POU1F1 mutations have been described in a total of 46 patients from 34 families originating in 17 different countries (34). Recessive mutations are generally associated with decreased activation, while dominant mutations have been shown to bind but not transactivate - i.e. act as dominant-negative mutations, rather than through haploinsufficiency. One such mutation is the recurrent Arg271Trp (R271W), located in exon 6, which results from a C T transition at a CpG dinucleotide, i.e. a region predisposed to spontaneous mutagenesis. Another interesting mutation is the Lys216Glu mutation of exon 5. This mutation is unique in that the mutant transcription factor activates both the GH and PRL promoters at levels greater than wild-type (i.e. acts as a super-agonist), but down-regulates its own (i.e. the POU1F1) promoter-leading to decreased expression of PIT1. R271W is the most frequent mutation of POU1F1. Another report described a novel mutational hot spot (E230K) in Maltese patients suggests a founder effect (33). The same group reported two additional novel mutations within POU1F1 gene; an insertion of a single base pair (ins778A) and a missense mutation (R172Q) (31).

Figure 6. The POU1F1 gene.

SOX3

 

SOX3 encodes a single-exon gene SOX3, an HMG box protein, located on the X chromosome (Xq26.3) in all mammals(35). It is believed to be the gene from which SRY, testis–determining gene evolved (36). Based on sequence homology, SOX, however, is more closely related to SOX1 and SOX2, together comprising the SOXB1 subfamily and are expressed throughout the developing CNS (37,38). In humans, mutations in the SOX3 gene have been implicated in X-linked hypopituitarism and mental retardation. In a single family, a SOX3 gene mutation was shown in affected males who had mental retardation and short stature due to GH deficiency (39). The mutation was an in-frame duplication of 33 bp encoding for an additional 11-alanine, causing an expansion of a polyalanine tract within SOX3. Other mutations including a submicroscopic duplication of Xq27.1 containing SOX3, a novel 7-alanine expansion within the polyalanine tract, and a novel polymorphism (A43T) in the SOX3 gene were described in males with hypopituitarism (40). Phenotypes of these patients include severe short stature, anterior pituitary hypoplasia, ectopic posterior pituitary, hypoplastic corpus callosum, and infundibular hypoplasia. Although duplications of SOX3 have been implicated in the etiology of X-linked hypopituitarism with mental retardation, in at least one study, none of the affected individuals had mental retardation or learning difficulties (40). Taken together, the data suggests that SOX3 has a critical role in the development of the hypothalamic-pituitary axis in humans, and mutations in SOX3 gene are associated with X-linked hypopituitarism but not necessarily mental retardation (40).

 

ISOLATED GH DEFICIENCY (IGHD)

 

Abnormalities either in the synthesis or the activity of GH can cause a wide variation in the clinical phenotype of the patient. Most frequently, it occurs as a sporadic condition of unknown etiology but severe forms of IGHD may result from mutations or deletions in GH1 or GHRHR gene.  General clinical features of IGHD deficiency include proportionate growth retardation accompanied by a decreased growth velocity, puppet-like facies, mid-facial hypoplasia, frontal bossing, thin hair, a high-pitched voice, microphallus, moderate trunk obesity, acromicria, delayed bone maturation and dentition. Most children with IGHD have normal birth weight and length, however, some newborns may present with hypoglycemia, microphallus, and prolonged jaundice. Patients with IGHD appear younger than their chronological age. Puberty may be delayed until late teens, but usually fertility is preserved.

 

To date, four Mendelian patterns of inheritance for IGHD have been identified based on the type of defect, mode of inheritance, and degree of deficiency.

 

  • Type 1 GH deficiency is an autosomal recessively inherited condition, which exists as either complete, or partial loss of GH expression.

 

  1. a) Type 1a deficiency is characterized by the complete absence of measurable GH. Infants born with a type 1a defect are generally of normal length and weight, suggesting that, in utero, GH is not an essential growth factor (41,42). Growth immediately after birth and during infancy may also be less dependent on circulating GH levels than during other phases of life. Patients with Type 1a deficiency initially respond to rhGH treatment well. However, about 1/3 of patients develop antibodies to GH which leads to markedly decreased final height as adults (34). The exact prevalence of Type 1a deficiency is not known, and most reported families are consanguineous (34). Mutations in Type 1a have been described in GH1 and GHRHR-including nonsense mutations, microdeletions/frameshifts, and missense mutations.
  2. b) Type 1b deficiency represents a state of partial - rather than an absolute - deficiency of GH, with measurable (but insufficient) serum GH. Therefore, Type 1b is milder than Type 1a deficiency. Patients with Type 1b deficiency do not typically present with mid-facial hypoplasia or microphallus. They also have a good response to GH treatment without developing GH antibodies. Most cases of Type 1b GH deficiency are caused by missense and/or splice site mutations in the GH1 and GHRHR genes (43).

 

  • Type 2 GH deficiency is an autosomal dominantly inherited disorder with reduced secretion of GH. Patients with Type 2 GHD usually do not have any pituitary abnormality (44). However, recently, it has been shown that their pituitary may become small over time (45). They have a good response to GH treatment. This type of GH deficiency is intuitively less clear, since autosomal dominant conditions generally occur because of either haploinsufficiency or secondary to dominant-negative activity. Haploinsufficiency, however, has not been demonstrated in the obligate heterozygote carriers of individuals harboring GH1 deletions, and is therefore an unlikely explanation. Dominant-negative activity is usually associated with multimeric proteins, also making this explanation less intuitive. Type 2 GHD appears to be the most common form of IGHD, and many mutations have been identified in GH1 including splicing and missense mutations (46–53). Recent studies suggest that GH1 may not be the only gene involved in Type 2 GHD. Screening 30 families with autosomal dominant IGHD did not show any GH1 mutations, raising the possibility of other gene(s) being involved (54).

 

  • Type 3 growth hormone deficiency is inherited in an X-linked recessive manner. There are no candidate genes and no compelling explanations for this condition. There are no reported mutations of the GH-1 gene in Type 3 GHD. In addition to short stature, patients may also have agammaglobulinemia (34).

 

Table 2 summarizes the phenotypes of mutations involved in human pituitary transcription factors causing IGHD and MPHD and their mode of inheritance.

 

Table 2. Genotype and Phenotype Correlations in Human Pituitary Transcription Factors

Gene

Phenotype

Mode of Inheritance

  IGHD

GH-1

IGHD type 1a/1b

IGHD type 2

IGHD type 3

AR

AD

X-linked

GHRHR

IGHD type 1b

AR

  MPHD

  LHX3 

Deficiencies of GH, TSH, LH, FSH, PRL, rigid neck, small/normal/or enlarged anterior pituitary

AR

  LHX4

Deficiencies of GH, TSH and ACTH, small anterior pituitary, cerebellar and skull defects

AD

  HESX1 

Hypopituitarism, optic nerve hypoplasia, agenesis of the corpus callosum, ectopic posterior pituitary

AR/AD

  PROP1 

Hypopituitarism except ACTH deficiency, small/normal/or enlarged anterior pituitary

AR

  POU1F1   (PIT1)

Deficiencies of GH, TSH, PRL, small or normal anterior pituitary

AR/AD

  SOX3

Hypopituitarism, mental retardation, learning difficulties, small anterior pituitary, ectopic posterior pituitary, 

X-linked recessive

  OTX2

Hypopituitarism, microphthalmia, microcephaly, cleft palate

AD

  GLI2

Hypopituitarism, small anterior pituitary, ectopic posterior pituitary, holoprosencephaly, polydactyly

AD

AR: Autosomal Recessive; AD: Autosomal Dominant.

 

HYPOTHALAMIC GH DEFICIENCY

 

Synthesis and Secretion of GH

 

GH is synthesized within the somatotropes of the anterior pituitary gland and is secreted into circulation in a pulsatile fashion under tripartite control, stimulated by growth hormone releasing hormone (GHRH), Growth Hormone Secretagogues (GHS) such as Ghrelin and inhibited by somatostatin (SST) (Figure 7). GHRH, GHS and SST secretion are themselves regulated by numerous central nervous system neurotransmitters (Table 3). GH, via a complex signal transduction, exerts direct metabolic effects on target tissues and exerts many of its growth effects through releasing of IGF1 which is mainly produced by the liver and the target tissues (e.g. growth plates).  Additional regulation of GH secretion is achieved through feedback control by IGF1 and GH at the pituitary and at the hypothalamus.

Figure 7. Hypothalamic-pituitary-peripheral regulation of GH Secretion. SST, somatostatin; GHRH, growth hormone releasing hormone; IGF1, insulin-like growth factor type 1.

 

Table 3. Neurotransmitters and Neuropeptides Regulating GHRH Secretion from Hypothalamus

 Dopamine 

Gastrin

 GABA 

Neurotensin

 Substance-P 

Calcitonin

 TRH 

Neuropeptide-Y

 Acetylcholine 

Vasopressin

 VIP 

CRHs

 

Timing

 

In addition to the absolute GH levels reached, the timing of the GH pulse is also physiologically important. GH is secreted in episodic pulses throughout the day, and the basal levels of GH are often immeasurably low between these peaks (Figure 8). Figure 8 illustrates normal spontaneous daily GH secretion, while figure 9 represents that of a child with GH deficiency.

Figure 8. The characteristic pulsatile pattern of GH secretion in normal children. Note the maximal GH secretion during the night.

Figure 9. GH secretion in a child with GH deficiency. Note the loss (both qualitative and quantitative) of episodic pulses seen in normal children.

 

Approximately 67% or more of the daily production of GH in children and young adults occurs overnight, and most of that during the early nighttime hours that follow the onset of deep sleep. During puberty, there is an increase in GH pulse amplitude and duration, most likely due to estrogens (55). GH secretion is sexually dimorphic, with females having higher secretory burst mass per peak but no difference in the frequency of peaks, or basal GH release (56). In addition, GH secretion is stimulated by multiple physiological factors (Table 4). Overweight children, independent of pubertal status, have reduced GH levels mainly due to reduced GH burst mass with no change in frequency (57).

 

Table 4. Physiological Factors that Affect GH Secretion

Factors that stimulate GH secretion 

Factors that suppress GH secretion

Exercise 

Hypothyroidism

Stress 

Obesity

Hypoglycemia 

Hyperglycemia

Fasting 

High carbohydrate meals

High protein meals 

Excess glucocorticoids

Sleep

 

 

Growth Hormone Releasing Hormone

 

GHRH (also known as Somatocrinin) is the hypothalamic-releasing hormone isolated in 1982 (58) believed to be the chief mediator of GH secretion from the somatotrope. GHRH deficiency is thought to be the most common cause of 'acquired' GHRH deficiency, secondary to (even mild) birth trauma. GHRH includes 5 exons, with transcription of (the non-coding) exon 1 differing on a tissue-specific basis (59). The mature GHRH protein contains 44 amino acids, with an amidated carboxy terminus (Figure 10). Despite this post-translational modification, much of the GH-secreting ability resides in the (original) amino half, allowing the synthesis of shorter peptides retaining efficacy (e.g. 1-29 GHRH). Despite being cloned in 1985 (60), there are no reports of (spontaneous) mutations in humans or in any animal model. Individuals with mutations in GHRH are predicted to have isolated GH deficiency.

Figure 10. The growth hormone releasing hormone (GHRH) gene.

Growth Hormone Releasing Hormone Receptor

 

GHRHR was cloned in 1992 (61), described as the cause of isolated GH deficiency (IGHD) in the Little strain of dwarf mouse by 1993 (62,63), mapped in the human by 1994 (64), and demonstrated to be a cause of human GH deficiency in 1996 (43). GHRHR is located on 7p15 (64), comprises 13 exons and encodes a protein of 423 amino acids, belonging to the G-protein coupled, heptahelical transmembrane domain receptors (Figure 10). The initial reports of GHRHRmutations were in geographically isolated (and therefore endogamous) populations in South Asia (43,65,66) and later in Brazil (67). In fact, haplotype analysis of the GHRHR locus in three unrelated families from the Indian subcontinent, carrying the identical E72X nonsense mutation in GHRHR indicated that this represents a common ancient founder mutation (68). An independent analysis of patients with familial isolated GH deficiency from non-consanguineous families revealed that most patients carried the identical E72X mutation, suggesting that E72X mutation can be a reasonable candidate for isolated GH deficiency (69). There are now numerous other reports, making GHRHR one of the most mutated genes in IGHD. Roelfsema et al studied two members of a single family with an inactivating mutation of the GHRHR and noted that the 'normal' pattern of spontaneous GH production was preserved, although the absolute quantity of GH secreted was quite low and the approximate entropy significantly elevated (70); supporting the view that the amplitude of a GH pulse is the result of a GHRH burst, while the timing of GH pulses is the result of a somatostatin trough.

Figure 11. The growth hormone releasing hormone receptor (GHRHR) gene.

Ghrelin

 

In 1977 Bowers et al (71) reported on the ability of enkephalins to secrete GH and it was later demonstrated that this secretion was independent of GHRH. This sentinel finding gave rise to a new field of study, that of the growth hormone releasing peptides (GHRPs) or growth hormone secretagogues (GHSs). Twenty-two years later Kojima et al (72)reported the isolation of the endogenous ligand whose actions were mimicked by the enkephalins. They named the hormone Ghrelin, based on the Proto-Indian word for 'grow'. Ghrelin is located on 3p25-26 (73) (Figure 12), is processed from a ‘preproGhrelin’ precursor, and is primarily produced by the oxyntic cells of the stomach and to a lesser extent in the arcuate ventro-medial and infundibular nuclei of the hypothalamus (74). Ghrelin also plays a role in regulating food intake. In addition to its GH secreting actions, direct intracerebroventricular injection of Ghrelin in mice has potent orexigenic “appetite stimulating” action, and this action is mediated by NPY, which antagonizes the actions of Leptin.

 

Several studies have shown that, on a molar basis, Ghrelin is significantly more potent at inducing GH secretion than GHRH (75). Additionally, many of these studies have shown that Ghrelin and GHRH are synergistic, inducing a substantial GH response when given in combination (76–79). Several studies comparing GHRH and Ghrelin demonstrate that 1 ug/kg GHRH results in a GH peak of approximately 25 ng/ml, 1 ug/kg Ghrelin results in a GH peak of approximately 80 ng/ml GH, but when given together, 1ug/kg of GHRH +     1 ug/kg Ghrelin results in a GH peak of approximately 120 ng/ml (79,80). When short normal children were compared to children with neurosecretory GH deficiency, Ghrelin secretion was similar in both groups during daytime, but higher Ghrelin levels were detected during the night in short children with neurosecretory GH deficiency. The authors therefore suggest that Ghrelin is not involved in nighttime GH secretion (81), although these findings are also consistent with a relative Ghrelin insensitivity at night. In a group of boys with constitutional delay of puberty, testosterone administration caused the expected increase in GH concentrations but did not affect the 24-hour Ghrelin profile, suggesting that the testosterone-induced GH secretion was not mediated by Ghrelin (82). Another study demonstrated a decrease in Ghrelin concentrations following glucagon administration in a group of non-GH-deficient short children, suggesting that Ghrelin does not mediate glucagon-induced GH secretion (83).

 

A second hormone, Obestatin is also known to be produced from preproghrelin. Obestatin has anorexigenic effects, opposite those of Ghrelin (84). Several nucleotide changes have been identified in the preproghrelin locus, and some are associated with body mass index, BMI (85). It is not clear, however, whether these are polymorphisms, or distinct mutations. It is also not clear whether these nucleotide variants exert their effects solely via an altered Ghrelin, a corrupted Obestatin, or a combination of the two. A knockout mouse lacking the preproghrelin locus had no statural or weight phenotype, but this may well be the result of the simultaneous loss of both ghrelin and Obestatin. To this point, a transgenic mouse with abnormal ghrelin but normal Obestatin did indeed have poor weight gain, explained by either ghrelin deficiency, unopposed Obestatin, or both. There are no reports of (spontaneous) mutations in Ghrelin associated with short stature, either in humans or in any animal model, although polymorphisms have been associated with weight/metabolic syndrome. The theoretical phenotype of such an individual would presumably be that of isolated GH deficiency, most likely of post-natal onset and possibly with an abnormally low appetite.

Figure 11. The growth hormone releasing hormone receptor (GHRHR) gene.

Figure 12. The ghrelin (GHS) gene structure.

Ghrelin Receptor

 

The receptor for Ghrelin (GHSR) was identified in 1996 by Howard et al (74), prior to the identification of the ligand, and maps to 3q26-27 (Figure 13).  Mutations of the GHSR gene have been reported in individuals with isolated GH deficiency (86).

 

Combining data from numerous investigators, there appear to be differences in the specific roles of these parallel but independent pathways for GH secretion. Given that:

 

  1. Ghrelin induces a larger release of GH than GHRH,
  2. Both bolus and continuous GHRH infusion results in a chronic release of GH (87),
  3. A bolus of Ghrelin results in GH secretion, but continuous Ghrelin infusion does not; and
  4. Ghrelin administration (bolus or continuous) does not cause an increase in GH mRNA.

 

It is therefore likely that the GHRH/GHRHR arm of the somatotropin pathway serves primarily in the production of de novo GH, and secondarily in the release of (pre-made) GH while Ghrelin/GHSR may serve primarily in the release of stored GH, and only secondarily-if at all-in the production of de novo GH (80,88).

Figure 13. The Ghrelin receptor (GHSR) gene.

Somatostatin

 

The somatostatin gene (SST) is located on 3q28, and contains two exons, encoding a 116 amino acid pre-prosomatostatin molecule that is refined down to a 14 amino acid cyclic peptide (as well as a 28 amino acid precursor/isoform) (89) (see figure 14). Pancreatic somatostatin inhibits the release of both insulin and glucagon, while in the CNS, somatostatin inhibits the actions of several hypothalamic hormones, including GHRH. For this reason, somatostatin is also known as Growth Hormone Release Inhibiting Hormone. Somatostatin's widespread effects are mediated by five different receptors, all encoded by different genes (rather than through alternative splicing of a single gene). The anti-GHRH actions on the pituitary are primarily mediated by somatostatin receptors (SSTR) 2 and 5, which act by inhibiting cAMP as well as other pathways (90) (see figures 15 and 16). There is a single case report of a nucleotide variant in SSTR5, occurring in a subject with acromegaly. (This individual, however, was also reported as having a mutation in the GSP oncogene, placing the pathological nature of the SSTR5 variant in question). Whereas GHRH induces release of growth hormone stored in secretory vesicles by depolarization of the somatotrope, somatostatin inhibits GH release by hyperpolarizing the somatotrope, rendering it unresponsive to GHRH. There are no reports of mutations in the somatostatin gene, or in SSTR2.

 

All three of these hypothalamic modifiers of GH secretion act through cell-membrane receptors of the G-protein coupled receptor (GCPR) class. These receptors are characterized by seven membrane-spanning helical domains, an extracellular region that binds (but does not internalize) the ligand hormone, and an intracellular domain that interacts with a G-protein, which contains a catalytic subunit that generates a second messenger (e.g. cyclic AMP or inositol triphosphate).

Figure 14. The somatostatin (SST) gene.

Figure 15. The somatostatin receptor 2 (SSTR2) gene.

Figure 16. The somatostatin receptor 5 (SSTR5) gene.

PITUITARY GH DEFICIENCY

 

Human Growth Hormone

 

GH is critical for growth through (most of) childhood as well as for optimal metabolic, neurocognitive, cardiac, musculoskeletal and adipose function throughout life. GH acts through GH receptors on cells of a variety of target tissues. Many, but not all, actions of GH are mediated by insulin-like growth factor 1 (IGF1), also known as Somatomedin-C. IGF1 is released in response to GH and acts as both a hormone and an autocrine/paracrine factor. GH, directly and indirectly through the actions of IGF1, stimulates tissue growth and proliferation, most notably in the epiphyseal growth plates of children, increases lean muscle mass, decreases fat mass, and increases bone mineral density.

 

Growth hormone is a single-chain polypeptide that contains 191 amino acids with two intramolecular disulfide bonds and the molecular weight of 22,128 Daltons. The GH protein (GHN) is encoded by the GH1 gene located on chromosome 17q22-q24 (Figure 17) in a complex of five genes: two for the growth hormone/growth hormone variant (GH1, GH2), two for chorionic somatomammotropin (CS1, CS2), and one for the somatomammotropin pseudogene (CSL). GH2 encodes the GHV protein that is secreted by the placenta into maternal circulation. GHV has greater lactogenic properties than does GHN and may function to maintain the maternal blood sugar in a desirable range, thus ensuring sufficient nutrition for the fetus.

Figure 17. Growth hormone (GH1) gene.

PERIPHERAL GH RESISTANCE

 

Growth Hormone Receptor

 

Growth failure with normal serum GH levels is well known, both at the genetic and clinical level. Although such cases may be due to defects of GH1 (e.g. bio inactive GH), many such subjects have been shown to have mutations in the GH Receptor (GHR), i.e. Growth Hormone Insensitivity, known as Laron Syndrome. Biochemical hallmarks of this syndrome are increased or normal GH levels with low IGF1 and with absent or decreased response to GH treatment (91).

 

The growth hormone receptor gene (GHR) is located on 5p13-12 and contains 10 exons which span a physical distance of almost 300 kb of genomic DNA (Figure 18). The GHR consists of a ligand-binding extracellular domain, an 'anchoring' transmembrane domain and an intracellular domain with intrinsic tyrosine kinase activity. A monomeric GHR binds a single GH molecule, which then dimerizes a second GHR, and activates the JAK/STAT and MAPK pathways and is internalized. The internalization leads to extinguishing of the GH signal, and the GHR is recycled for further rounds of activity. Two naturally occurring isoforms of the GHR arise from alternative splicing-one with an alternate exon 3, and the other with an alternate exon 9. The alternative exon 9 isoform yields a protein with only amino acids 1-279, and virtually none of the intracellular domain. This isoform cannot transduce the GH signal and yields higher molar quantities of GHBP (than wild-type GHR) and therefore acts as a GH "sink" (92). The GHR isoform lacking exon 3 has a high prevalence, and may be associated with altered GH signaling, although the direction of the alteration is not clear (93–96).

Figure 18. The growth hormone receptor (GHR) gene.

Defects in the GH signaling pathway have been demonstrated to be associated with postnatal growth failure. Mutations of Stat5b were reported in patients with severe growth failure. Several mutations of Stat5b gene have been reported. Although patients had a phenotype similar to that of congenital GH deficiency or GHR dysfunction, clinical and biochemical features (including normal serum GHBP concentrations) and immune deficiency (97) distinguish patients with STAT5b defects from patients with GHR defects.  It also appears that STAT5b mutations are associated with hyperprolactinemia.  It remains unclear whether the hyperprolactinemia is a direct or indirect effect of STAT5b mutations (98).

 

In humans, the extracellular portion of GHR is enzymatically cleaved and functions as the GH-Binding Protein (GHBP)(99). GHBP presumably serves to maintain GH in an inactive form in the circulation and to prolong the half-life of GH. Serum levels of GHBP are therefore used as a surrogate marker for the presence of GHR, and abnormal levels-both elevated and decreased-may indicate abnormality in the GHR (100,101). Of note is that mutations have also been described in individuals with 'normal' GHBP levels. GHI secondary to GHR mutations are mostly autosomal recessive mutations, but dominant negative mutations have also been described. Individuals with heterozygote mutations in GHRmay present with significant short stature (102). Mutations in GHR have also been associated with idiopathic short stature (ISS) (103–105). The original reports of GHR mutation described limited elbow extension and blue sclera, but these findings are not universal.

 

Many genetic abnormalities have been described in GHR, including nonsense mutations, missense mutations, macrodeletions, microdeletions and splice site changes. Of the latter, one of the most interesting is the "E180E" mutation, wherein an exonic adenosine is converted to a guanine, converting GAA to GAG, which would be predicted to not change the amino acid structure of GHR (both GAA and GAG encode glutamic acid). On this basis, this "silent polymorphism" would be expected to have no phenotype, but in reality, causes GH resistance and extreme short stature by activation of a cryptic splice site. This mutation was noted in Loja and El Oro, Ecuador in two large cohorts. This identical mutation has also been identified in Jews of Moroccan descent, suggesting that this mutation dates to at least the 1400’s and that the Ecuadorian cohorts, therefore, likely represent Sephardic Jews who left Spain around the time of the Inquisition at the end of the fifteenth century, CE (106). Another splice site mutation at position 785-3 (C>A in the intron 7) was recently described in a patient and mother with short stature and extremely elevated GHBP (107). The consequence of this novel mutation is a truncated GHR which lacks the transmembrane domain (encoded by exon 8) and the cytoplasmic domain. It was hypothesized by the authors that this GHR variant cannot attach to the cell membrane, and the continual secretion into the circulation results in the elevated levels of serum GHBP detected in the patient and his mother. The presence of the wild-type GHR allele presumably permits some level of normal GH-induced action.

 

Insulin-Like Growth Factor 1 (IGF1)

 

Many of growth hormone's physiological actions are mediated through the insulin-like growth factor, IGF1 (formerly referred to as somatomedin C). Serum IGF1 levels are commonly measured as a surrogate marker of GH status since IGF1 displays minimal circadian fluctuation in serum concentration. IGF1 plays a critical role in both prenatal and postnatal growth, signaling through the IGF1 as well as the insulin receptors (Table 5). IGF1 circulates as a ternary complex consisting of IGF1, IGFBP3, and ALS. IGF bioavailability is regulated by a metalloprotease termed ‘pregnancy-associated plasma protein-A2’ (PAPPA2) (108). PAPPA2 cleaves IGFBP3 or IGFBP5 to free IGF1 from its ternary complex, allowing it to bind to its target tissues.  In addition to PAPPA2, stanniocalcin-2 (STC2) also plays a critical role in IGF1 bioavailability by inhibiting the proteolytic activity of PAPPA2 (109,110).

 

The IGF1 gene is located on 12q22-24.1, consists of six exons and spans over 45 kb of genomic DNA (Figure 19). Alternative splicing produces two distinct IGF1 transcripts, IGF1-A and IGF1-B. Woods et al described a male of a consanguineous union with prenatal (intrauterine) and postnatal growth retardation, sensorineural deafness and mental retardation (111). DNA analysis showed a homozygous partial deletion of the IGF1 gene (111,112). Subsequently, additional cases have been described (113,114).

Figure 19. The IGF1 gene.

Mice engineered to completely lack Igf1 (Igf1 knockouts) are born 40% smaller than their normal littermates (115,116). Recent studies of a hepatic-only Igf1 knockout (KO) mouse, however, demonstrate that IGF1 functions primarily in a paracrine or autocrine role, rather than in an endocrine role (117). Liver specific Igf1 knock-out mice, were found to have a 75% reduction in serum Igf1 levels but were able to grow and develop (nearly) normally (117,118) with a mild phenotype developing only late in life (117). A further decrease in serum IGF1 levels of 85% was observed when double gene KO mice were generated lacking both the acid labile subunit (ALS) and hepatic IGF1. Unlike the single hepatic-only IGF1-KO's, these mice showed significant reduction in linear growth as well as 10% decrease in bone mineral density (119). Thus, as illustrated by the combination liver specific IGF1+ALS knock-out mouse model, there likely exists a threshold concentration of circulating IGF1 that is necessary for normal bone growth and suggests that IGF1, IGFBP3, and ALS may play an important role in bone physiology and the pathophysiology of osteoporosis.

 

In humans, homozygous mutations in ALS result in mild postnatal growth retardation, insulin resistance, pubertal delay, unresponsiveness to GH stimulation tests, elevated basal GH levels, low IGF1 and IGFBP3 levels and undetectable ALS (120–122). Although it is not clear why postnatal growth is mildly affected, it may be due to increased GH secretion due to loss of negative feedback regulation by the low circulating IGF1. Increased GH secretion could then up-regulate the functional GH receptor increasing local IGF1 production, thus partially protecting linear growth (97) (Figure 20). Over a dozen inactivating mutations of the IGFALS gene have been described in patients with ALS deficiency (123). 

Figure 20. The effect of ALS mutations on the GH-IGF1 axis. Savage MO Camacho-Hubner C, David A, et al. 2007” Idiopathic short stature: will genetics influence the choice between GH and IGF1 therapy?” Eu J of Endocrine 157:S33 Society of European Journal of Endocrinology (2007). Reproduced by permission. Reprinted with permission (124).

Elevated IGF1 levels has recently been associated with colon, prostate and breast cancer (125–127) and the association was strongest when an elevated IGF1 was combined with a decreased IGFBP3 level. This combination-expected to yield more bioactive IGF1 may merely reflect the tumorigenic process, rather than demonstrate causality. Importantly, GH treatment induces a rise in both IGF1 as well as IGFBP3 (128) and therefore would not be expected to increase cancer risk in normal individuals.

 

Table 5. Summary of IGF1 Function in Different Systems and its Effects (129)

IGF1 Function 

IGF1 Deficiency

Intrauterine Growth

IUGR

Postnatal Growth

Short Stature

CNS

Neurodegenerative disease

Insulin sensitization/improvement of glucose disposal/beta cell proliferation

Type 1 and Type 2 Diabetes

 

IGF1 Excess

Mitosis/Inhibition of apoptosis 

Malignancy

 

IGF1 Deficiency

 

IGF1 deficiency can be classified based on decreased IGF1 synthesis (primary) or decreased IGF1 as a result of decreased or inactive GH (secondary) (130) (see Table 6).

 

Table 6.  IGF1 Deficiency

I.               Primary IGF1 Deficiency (normal or elevated GH levels) 

II.               

1.     Defects in IGF1 Production:

1.     Mutation in IGF1 gene or bio inactive IGF1

2.     GHR receptor signaling defects (JAK/STAT)

3.     Mutations in ALS gene

4.     Factors affecting IGF1 production (malnutrition, liver, inflammatory bowel

disorders, celiac disease)

 

Defects in IGF1 Action:

1.     IGF1 resistance due to receptor or post-receptor defects

2.     Factors inhibiting IGF1 binding to IGF1R (increased IGFBPs and presence of IGF1 antibodies)

3.      

Defects in GH Action:

1.     Factors inhibiting (increased GHBPs and presence of GH antibodies)

2.     GH receptor defects (decreased GH receptors, GHR antibodies, GHR gene defects)

III.            Secondary IGF1 Deficiency (decreased GH levels)

 

Decreased GH production

1.     Defects in GH gene

2.     Defects in GHRH or GHRH receptor

3.     Psychological disorders

 

Defects in hypothalamus and pituitary

 

 

Recombinant Human IGF1 (rhIGF1)

 

rhIGF1 is useful in the treatment of primary IGF1 deficiency resulting from abnormalities of the GH molecule (resulting in a bio inactive GH), the GH receptor (known as Laron syndrome) or GH signaling cascade (131). Studies have shown that rhIGF1 significantly improves height in children unresponsive to rhGH (132,133), and clinical trials clearly demonstrated better response to IGF1 therapy when initiated at an early age (134).

 

FDA approved conditions for rhIGF1 treatment for children with (135):

  1. Severe primary IGF1 deficiency
  2. GH gene deletions who have developed neutralizing antibodies to GH

 

Severe primary IGF1 deficiency is defined by:

  1. Height SD score is less than -3SD
  2. Basal IGF1 level is below -3SD
  3. Normal or elevated GH

 

The recommended starting dose of rhIGF1 is 40-80 microgram/kg twice daily by subcutaneous injection.  If it is tolerated well for at least one week, the dose may be increased by 40 microgram/kg per dose, to the maximum dose of 120 microgram/kg per dose (136).

 

The most common side effects of IGF1 treatment are pain at injection site and headaches which mostly diminish after the first month of treatment (131). Other less common side effects are lipohypertrophy at the injection site, pseudotumor cerebri, facial nerve palsy and hypoglycemia (134). Another effect of IGF1 treatment is a significant increase in fat mass and BMI (137) — in contradistinction to the lipolytic effect of rhGH treatment. Coarsening of facial features, increased hair growth, slipped capital femoral epiphysis, scoliosis, hypersensitivity, and allergic reactions including anaphylaxis are other prominent adverse effects and are most commonly seen during puberty. Growth of lymphoid tissue is a concern which may require tonsillectomy (131).  

 

Insulin-Like Growth Factor 1 Receptor (IGF1R)

 

The receptor for IGF1 is structurally related to the insulin receptor and similarly has tyrosine kinase activity (Figure 21). IGF1R is located on 15q25-26. The mature (human) IGF1 receptor contains 1337 amino acids and has potent anti-apoptotic activity (137). The IGF1 receptor transduces signals from IGF1, IGF2 and insulin. However, murine data suggest that initially (in the embryo) only the IGF2 signal is operational, while later on in development (i.e. the fetus), both IGF1 and IGF2 (and probably insulin) signal through the IGF1R (112). Hemizygosity for IGF1R has been reported in a single patient (and appears likely in others) with IUGR, microcephaly, micrognathia, renal anomalies, lung hypoplasia and delayed growth and development (138). Murine and human studies have shown that mutations in IGF1R result in combined intrauterine and postnatal growth failure (104), confirming the critical role of the IGF system on embryonic, fetal and postnatal growth. A novel heterozygous mutation in the tyrosine kinase domain of the IGF1R gene was recently identified in a family with short stature. The mutation, a heterozygous 19-nucleotide duplication within exon 18 of the IGF1R gene, results in haploinsufficiency of the IGF1R protein due to nonsense mediated mRNA decay (139).

Figure 21. The Insulin-Like Growth Factor 1 Receptor (IGF1R) gene.

In summary, IGF1 and IGF1R mutations should be considered if a child presents with the following:

 

  1. Intrauterine and postnatal growth retardation
  2. Microcephaly
  3. Mental retardation
  4. Developmental delay
  5. Sensorineural deafness
  6. Micrognathia
  7. Very low or very high levels of serum IGF1

 

High serum (total) IGF1 levels are observed in patients with loss-of-function mutations in pregnancy-associated plasma protein A2 (PAPPA2) (140). As noted earlier, PAPPA2 is responsible for cleaving IGFBP3 or IGFBP5 to free bioactive IGF1 from its ternary complex so that IGF1 binds to its target sites (108).  Loss-of-function mutations in PAPPA2 decrease biologically active (i.e. ‘free’) IGF1 levels and cause short stature (140,141). To date, a total of seven patients with PAPPA2 mutations have been reported from three unrelated families (141,142). Patients generally had similar clinical phenotypes with growth failure, microcephaly, micrognathia, delayed dental eruption, thin long bones, and decreased bone mineral density (141).  Their total serum IGF1, IGF2, IGFBP3, IGFBP5, and ALS levels were elevated but the affected individuals had decreased free IGFI levels and IGF1 bioactivity (141). Serum PAPPA2 levels were either undetectable or low (143).

 

Both short-term and long-term treatment with rhIGF1 has been shown to be effective improving linear growth in children with PAPPA2 deficiency with variable height gain results and positive effects on bone mineral density and bone structure (142,144–148). Although the majority of subjects tolerated rhIGF1 treatment with no adverse effects, pseudotumor cerebri was noted to be the most common adverse event (147).

 

A single patient with PAPPA2 deficiency was administered fresh frozen plasma with the goal to restore PAPPA2 activity. Interestingly, the patient responded with significantly increased free IGF1 levels, but her serum PAPPA2 levels did not measurably increase.in vitro addition of rhPAPPA2 to the patients serum similarly demonstrated an increase in free IGF1, as did the serum of patients with ISS, although the increase in ISS patients was less robust (149).  However, authors caution first establishing the normal ranges for PAPPA2 and free IGF1 before developing PAPPA2 as a potential novel treatment for growth.

 

Insulin-Like Growth Factor 2 (IGF2)

 

IGF2 is thought to be a major prenatal growth hormone and to be less critical for statural growth in post-natal life.

 

The human gene, IGF2, is located on 11p15.5 (Figure 22). Chromosome 11p15.5 carries a group of maternally (IGF2) and paternally (H19) imprinted genes that are crucial for embryonic and/or fetal growth. Genetic or epigenetic changes in the 11p15.5 region alter this growth (150). IGF2 is maternally imprinted, meaning that the maternal allele is unexpressed. The close proximity of INS to IGF2-in addition to nearly 50% amino acid identity-suggest that these genes arose through gene duplication events from a common ancestor gene. IGF2 acts via the IGF1 receptor (as well as the insulin receptor). Over-expression of IGF2 results in overgrowth, similar to that seen in Beckwith-Wiedemann Syndrome (which can be due to loss of imprinting, effectively doubling IGF2 expression). A mouse model overexpressing Igf2 demonstrates increased body size, organomegaly, omphalocele, cardiac, adrenal and skeletal abnormalities, suggestive of Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes (151). Interestingly, IGF2 expression is normally extinguished by the Wilm's Tumor protein (WT1), providing an explanation for the overgrowth (e.g. hemi-hypertrophy) typically seen in subjects with Wilm's Tumor (152). In contrast, mice without a functional Igf2 (Igf2 knockouts) are born 40% smaller than their normal littermates (identical to Igf1 knockouts).

Figure 22.The Insulin-Like Growth Factor 2 (IGF2) gene.

Recent reports on individuals with severe intrauterine growth retardation showed maternal duplication of 11p15 (153). Furthermore, individuals with Silver-Russell-syndrome (SRS, also known as Russell-Silver syndrome) have been found to have an epimutation (demethylation) associated with biallelic expression of H19 and down regulation of IGF2(154,155). Russell-Silver syndrome is a congenital disorder characterized by intrauterine and postnatal growth retardation, typical facial features (triangular face, micrognathia, frontal bossing, downward slanting of corners of the mouth), asymmetry, and clinodactyly. Other chromosomal abnormalities such as maternal uniparental disomy on chromosome 7 also have been shown in 10% of individuals with SRS (156).

 

A paternally derived balanced chromosomal translocation that disrupted the regulatory regions of the predominantly paternally expressed IGF2 gene was described in a woman with short stature, history of severe intrauterine growth retardation (-5.4 SDS), atypical diabetes and lactation failure (157).

 

Insulin-Like Growth Factor 2 Receptor (IGF2R)

 

A receptor for IGF2, the IGF2R, has been identified, but does not appear to be the mediator of IGF2's growth promoting action. IGF2R is located on 6q26 and encodes a receptor unrelated to the IGF1 or insulin receptor (Figure 23). IGF2R is also the mannose-6-phosphate receptor and serves as a negative modulator of growth (for all IGF's and insulin). Its main role in vivo is probably as a tumor suppressor gene. While IGF2 is maternally imprinted, mouse Igf2R is paternally imprinted. There is some evidence that (in a temporally limited fashion) IGF2R is also paternally imprinted in humans. Somatic mutations have been found in hepatocellular carcinoma tissue (heterozygous mutations associated with loss of the other allele), but no germ-line mutations have been identified in individuals with growth abnormalities.

Figure 23. The Insulin-Like Growth Factor 2 Receptor (IGF2R) gene.

Insulin

 

In addition to its glycemic and metabolic roles, insulin functions as a significant growth promoting/anabolic agent. The insulin gene (INS) is located on Chr 11p15.5 and comprises 3 exons (Figure 24). Insulin's role in fetal growth is quite significant, as demonstrated by hyper insulinemic babies (e.g. infants of diabetic mothers (IDM)). Insulin's growth promoting activity is mediated through a combination of insulin and the IGF1 receptors. Mutations in the INS gene have been described in subjects with hyperinsulinemia (and/or hyperproinsulinemia) and diabetes mellitus.

Figure 24. The insulin gene (INS).

Insulin Receptor

 

The insulin receptor is structurally related to the IGF1 receptor. The gene, INSR, is located on Chr 19p13.2 and contains 22 exons that span over 120 kilobases of genomic DNA (Figure 25). INSR encodes a transmembrane protein with tyrosine kinase activity which can transduce the signals of insulin, IGF1 and IGF2.

 

Individuals with a mutation in the insulin receptor have been identified and may be the basis for the mythological 'Leprechauns'. They typically have intrauterine growth retardation; small elfin facies with protuberant ears; distended abdomen; relatively large hands, feet, and genitalia; and abnormal skin with hypertrichosis, acanthosis nigricans, and decreased subcutaneous fat. At autopsy, several subjects have been found to have cystic changes in the membranes of gonads and hyperplasia of pancreatic islet cells. Severe mutations generally lead to death within months, but more mild mutations have been found in individuals with insulin resistance, hypoglycemia, acanthosis nigricans, normal subcutaneous tissue and may even be associated with a normal growth pattern! Individuals with even 'mild mutations' have been shown to have a thickened myocardium, enlarged kidneys and ovarian enlargement.

Figure 25. The insulin receptor gene (INSR).

SHORT STATURE WITH AN ADVANCED BONE AGE

 

Aggrecan

 

Aggrecan has also been shown to be involved in human height and the growth process.  The aggrecan protein is a major constituent of the extracellular matrix of articular cartilage, where it forms large multimeric aggregates.  The gene, ACAN, is located on Chr 15q26.1, comprising 19 exons spread over nearly 72 kilobases of genomic DNA.  Exon 1 is approximately 13 kilobases upstream of exons 2-19, which comprise the coding portion of ACAN (158).  ACANundergoes alternative splicing yielding several isoforms; the predominant isoform being 2132 amino acids long, with three globular domains (G1-3), an ‘interglobular’ (IG) domain, a keratan sulfate (KS) domain and a chondroitin sulfate (CS) domain, largely encoded in a modular fashion (Figure 26).

 

Domains G1 and G2 contain tandem repeat units rich in cysteine, which are necessary for disulfide bridging, the binding of hyaluronic acid and structural integrity, and are separated by the IGD, which provides a level of rigidity.  The KS domain contains 11 copies of a six amino acid motif, while the chondroitin sulfate (CS) domain contains over 100 (non-tandem repeated) copies of the dipeptide Serine-Glycine).  The G3 domain appears to function in maintaining proper protein folding and subsequent aggrecan secretion.  The attachment of hyaluronic acid, keratan and chondroitin sulfate lead to significant water retention, which is largely responsible for the shock-absorbing character of articular cartilage.  Aggrecan is also necessary for proper “chondroskeletal morphogenesis” (159), ensuring the proper organization and sequential maturation of the epiphysis.

 

In 1999, Kawaguchi reported a mutation in ACAN in subjects with lumbar disc herniation (160), then in 2005, both an autosomal dominant form of spondyloephiphyseal dysplasia (SED-Kimberly type) (161) and an autosomal recessive form (SED-Aggrecan type) (162) were shown to arise from mutations in ACAN.

 

In 2010, cases of autosomal dominant short stature with an advanced bone age were found to have mutations in ACAN, either with or without osteochondritis dissecans and/or (early-onset) osteoarthritis (163–167). 

 

Dateki identified a family of four affected where three members had short stature with an advanced bone age, midface hypoplasia, joint problems and brachydactyly, while the fourth had lumbar disc herniation without other findings (168), attesting to phenotypic heterogeneity, even within a family.

Figure 26. The aggrecan gene (ACAN).

The Short Stature Homeobox-Containing Gene (SHOX) Haploinsufficiency

 

The Short Stature Homeobox-containing gene (SHOX) was identified in the pseudo-autosomal region 1 on the distal end of the X and Y chromosomes at Xp22.3 and Yp11.3 (Figure 27) (169). Mutations in SHOX were observed in 60-100% of Léri-Weill dyschondrosteosis and Langer mesomelic dysplasia (170,171).  Turner syndrome is almost always associated with the loss of SHOX gene because of numerical or structural aberration of X chromosome (172).The most common genetic defects leading to growth failure in humans are due to SHOX mutations with the incidence of 1:1,000 (173).

Figure 27. The Short Stature Homeobox-containing gene (SHOX). Reprinted with Permission. www.shox.uni.hd.de.

Genes in pseudoautosomal region 1 do not undergo X inactivation, therefore, healthy individuals express two copies of the SHOX gene, one from each of the sex chromosomes in both 46,XX and 46,XY individuals. The SHOX gene plays an important role in linear growth and is involved in the following:

 

  1. Intrauterine linear skeletal growth
  2. Fetal and childhood growth plate in a developmentally specificpattern and responsible for chondrocytedifferentiation and proliferation (174).
  3. A dose effect: SHOX haploinsufficiency is associated with short stature. In contrast, SHOX overdose as seen in sex chromosome polyploidy is associated with tall stature.

 

A large number of unique mutations (mostly deletions and point mutations) of SHOX have been described (170,172,175). SHOX abnormalities are associated with a broad phenotypic spectrum, ranging from short stature without dysmorphic signs as seen in idiopathic short stature (ISS) to profound Langer’s mesomelic skeletal dysplasia, a form of short stature characterized by disproportionate shortening of the middle segments of the upper arms (ulna) and lower legs (fibula) (176).  In contrast to many other growth disorders such as growth hormone deficiency, SHOX deficiency is more common in girls.

 

Rappold et al developed a scoring system to determine the phenotypic spectrum of SHOX deficiency in children with short stature and identify patients for SHOX molecular testing (175).  The authors recommend a careful examination including measurement of body proportions and X-ray of the lower legs and forearm before making the diagnosis of ISS. The scoring system consists of three anthropometric variables (arm span/height ratio, sitting height/height ratio and BMI), and five clinical variables (cubitus valgus, short forearm, bowing of forearm, muscular hypertrophy and dislocation of the ulna at the elbow). Based on the scoring system, authors recommend testing for SHOX deficiency for the individuals with a score greater than four or seven out of a total score of 24 (Table 7).

 

The recent data show that GH treatment is effective in improving linear growth of patients with SHOX mutations (176).

 

Table 7.  Scoring system for identifying patients that qualify for short-stature homeobox containing gene (SHOX) testing based on clinical criteria. Reprinted with permission (176).

Score item       

Criterion

Score points

Arm span/height ratio

<96.5%

2

Sitting height/height ratio

>55.5%

2

Body–mass index

>50th percentile

4

Cubitus valgus

Yes

2

Short forearm

Yes

3

Bowing of forearm

Yes

3

Appearance of muscular hypertrophy

Yes

3

Dislocation of ulna (at elbow)

Yes

5

Total

24

 

Noonan Syndrome

 

Noonan syndrome (NS) is a relatively common genetic disorder with the incidence of between 1:1000 and 1:4000 (177). NS is inherited in an autosomal dominant manner, and sporadic cases are not uncommon (50-60%) (178). NS is characterized by short stature, cardiac defects (most commonly pulmonary stenosis and hypertrophic cardiomyopathy), facial dysmorphism (down-slanting, antimongoloid palpebral fissures, ptosis, and low-set posteriorly rotated ears), webbed neck, mild mental retardation, cryptorchidism, feeding difficulties in infancy. The phenotype is variable between affected members of the same family and becomes milder with age (179).

 

Nearly 50% of patients with NS have gain-of-function mutations in protein tyrosine phosphatase nonreceptor type 11 (PTPN11), the gene encoding the cytoplasmic tyrosine phosphatase SHP-2, which regulates GH signaling by dephosphorylating STAT5b, resulting in down-regulation of GH activity (180). Mutations in four other genes (KRAS, SOS1, NF1 and RAF1) involved in RAS/MAPK signaling systems have been identified in patients with the NS phenotype and related disorders including LEOPORD, Costello, and cardio-facial-cutaneous syndromes (Figure 28) (181).

Figure 28. The RAS/MAPK signaling pathway. Reprinted with permission (181).

Although identifying these mutations has contributed to better understanding of the pathogenesis of NS, it appears that the genotype does not completely correlate with the phenotype, e.g. short stature in patients with NS. Several studies have shown that the subjects carrying gain of function mutations of PTPN11 had lower IGF1 levels, poor growth response, and resistance to GH therapy compared to subjects without PTPN11 mutations (182,183).  However, data from one large study of individuals with NS did not demonstrate the same correlation between PTPN11 mutations and short stature (177). However, more recent studies showed significant improvement in final adult height in individuals with NS regardless of their mutation type (184,185).

 

DIAGNOSIS

 

Diagnosis of GH deficiency during childhood and adolescence is frequently challenging. Children whose height are below the 3rd percentile or -2 SD and have decreased growth velocity require clinical evaluation. Evaluation should begin with a detailed past medical history, family history, diet history, detailed review of prior growth data (including the initial post-natal period) and a thorough physical examination (186). Together, these should help the clinician identify the pattern and cause of growth failure, such as fetal growth restriction (e.g. SGA and IUGR), chronic illness, malnutrition/malabsorption, hypothyroidism, skeletal abnormalities or other identifiable syndromes, such as Turner syndrome. Once growth hormone deficiency is suspected, further testing of the hypothalamic-pituitary axes (including but not limited to the GH-IGF axis) along with radiological evaluation, should be performed (Table 8). It is important to note that the tests cannot be performed simultaneously, or in random order. Certain conditions (e.g. Hypothyroidism and Celiac disease) may mask the presence of others (e.g. GH deficiency), therefore requiring a stepwise approach with screening tests preceding specific examinations. Since growth failure generally occurs outside of GHD, only those children with signs or symptoms undergo expensive, invasive and non-physiologic GH provocative testing.

 

Table 8. Guidelines for Initial Clinical Evaluation of a Child with Growth Failure

Evaluation 

Key elements

Birth history 

Gestational age, birth weight and length, head circumference, delivery type, birth trauma, hypoglycemia, prolonged jaundice.

Past medical and surgical history 

Head trauma, surgery, cranial radiation, CNS infection.

Review of systems 

Appetite, eating habits, bowel movements, headache, vision change.

Chronic illness 

Anemia, Inflammatory Bowel Disease, cardiovascular disease, renal insufficiency, etc.

Family history 

Consanguinity, parents and siblings’ heights, family history of short stature, delayed puberty.

Physical examination 

Body proportions (upper/lower segment ratios, arm span), head circumference, microphallus, dysmorphism, and midline craniofacial abnormalities.

Growth pattern 

Crossing of percentiles, failure to catch-up.

Screening Tests 

CBC, CMP, ESR/c-reactive protein, Celiac screening, TSH and Free T4, UA, IGF1, IGFBP3, Bone age (and a Karyotype for females)

 

Growth Charts

 

The growth pattern is a key element of growth assessment and is best studied by plotting growth data on an appropriate growth chart. US growth charts were developed from cross-sectional data provided by the National Center for Health Statistics and updated in 2000 (187), with body mass index included in this newest set. The supine length should be plotted for children from birth through age 3 years and standing height plotted when the child is old enough to stand, generally after 2 years of age. Ideally, growth data is determined by evaluating subjects at regular (optimally at 3 month) intervals, with the same stadiometer, and with the same individual obtaining the measurements, whenever possible. Three months is the minimal time interval needed between measurements to calculate a reliable growth velocity, and a six-to-twelve-month interval is optimal. Age and pubertal staging must be considered when evaluating the growth velocity, with the understanding that there is great individual variation in the onset and rate of puberty (188).

 

Deviations across height percentiles should be noted and evaluated further when confirmed, with the understanding that during the first two years of life, the crossing of length and/or weight percentiles may reflect catch-up or catch-down growth. Crossing percentiles during this period is not always physiological, and must be examined in the context of family, prenatal, birth and medical histories. Additionally, between two and three years of age, statural growth measurement changes from supine to erect, and may also introduce variation. Growth below the normal range (e.g.>-2SD) even without further deviation is consistent with (but not pathognomonic of) GH deficiency. Short stature with a low BMI suggests an abnormality of nutrition/GI tract (e.g. malnutrition, Celiac Disease, etc.), while short stature with an elevated BMI suggests hypothyroidism, Cushing’s syndrome or a central eating disorder, such as Prader-Willi syndrome, etc.

 

Figures 29-31 represent growth charts of children studied by the authors who have genetic defects leading to isolated growth hormone deficiency.

Figure 29. Growth pattern in children with isolated GH deficiency (Type 1A).

Growth failure can manifest as severe growth delay (Figure 29), gradual deceleration (“falling off the curve”) (Figure 30), or alternatively, maintaining a growth pattern parallel to the 3rd percentile, but without catch-up growth (Figure 31).

Figure 30. Growth pattern in children with isolated GH deficiency (Type 1B).

Figure 31. Growth pattern in children with isolated GH deficiency (Type 2).

Most children with GH deficiency have normal birth weight and length. However, in most cases, postnatal growth becomes severely compromised. This can be seen even in the first months of life. Although such children may show a normal growth pattern during the first 6 months, growth failure will eventually occur as GH takes on a more physiologically dominant role, and a child’s growth falls below the normal range.

 

Radiological Evaluation

 

The most commonly used system to assess skeletal maturity is to determine the ‘bone age’ of the left hand and wrist, using the method of Greulich and Pyle (189). Children younger than 2 years of age should have their bone age estimated from x-rays of the knee. Tanner and Whitehouse and their colleagues developed a scoring system for each of the hand bones as an alternative method to the method of Greulich and Pyle (190).

 

Adult height prediction methods estimate adult height by evaluating height at presentation relative to normative values for chronological or bone age. Such methods have been utilized for approximately 60 years (191) and are generally considered accurate in evaluating healthy children with a ‘normal’ growth potential (192,193). Several different methods have been produced and are currently in widespread use, including those of Bayley-Pinneau, the Tanner-Whitehouse-Marshall-Carter and Roche-Wainer-Thissen.

 

In 1946, Bayley initially described how final height could be estimated from the present height and the bone age, revising the method in 1952 to use the bone age assessment method of Greulich and Pyle (189). They developed what is commonly known as the predicted adult height (PAH) method of Bayley-Pinneau (BP). Tables have been developed for the BP method, listing the proportion of adult height attained at different bone ages, using longitudinal growth data on 192 healthy white children predominantly from North European ancestry in the US. Three tables – average, advanced and retarded – correct for possible differences between CA and BA of more than one year (194). The Bayley-Pinneau PAH method is applicable from age 8 years onwards.

 

Tanner, Whitehouse, Marshall and Carter developed an adult height prediction model based on current height, the mid-parental height, the age of menarche in girls and the ‘Tanner’ bone age (190). This PAH method (TW2) was developed on the longitudinal data of 211 healthy, British children. TW2 differs from the BP method in that the TW2 lowers the minimal age of prediction to 4 years, and allows for a quantitative effect of BA, while BP gives a semi-quantitative effect of bone age (i.e. delayed, normal or advanced).

 

The PAH method of Roche-Wainer-Thissen (RWT) was derived from longitudinal data on approximately 200 “normal” Caucasian American children in southwestern Ohio, at the Fels Research Institute (195). The RWT PAH method assesses the subject’s height, weight, BA and mid-parental height (MPH) and then applies regression techniques to determine the mathematical weighting to be applied to the four variables. The RWT method was designed to allow final height prediction from a single visit but is only applicable when greater than half of the bones are not fully mature.

 

Since both the bone age assessments and height prediction methods are created from healthy children (and often children from a single ethnic group and region), their use in ‘other’ populations is potentially inappropriate. In fact, Tanner et al state that their method is applicable to both boys and girls with short stature, but caution that “In clearly pathological children, such as those with endocrinopathies, they do not apply”. Similarly, Roche et al suggest caution when applying the RWT PAH method in ‘non-white and pathological populations’ (195). Zachmann et al reported that the RWT and TW2 methods (which are more BA-reliant) are better when growth potential is normal relative to the BA, however, in conditions with “…abnormal and incorrigible growth patterns…”, the BP method was more accurate, stating that with a “non-normal bone maturation to growth potential relationship, the ‘coefficient and regression equations’ (RWT and Tanner) cause an over-prediction of adult height” (196).

 

As stated above, these methods are based on healthy children and assume that the growth potential is directly proportional to the amount of time left prior to epiphyseal fusion as measured by the bone age. While this is correct for some of the children seen by the pediatric endocrinologist (e.g. healthy children, children with GH deficiency), it is not correct for many others with abnormal growth (e.g. children born SGA, children with idiopathic short stature, Turner syndrome and chronic renal failure). It is likely also inappropriate for children with an abnormal tempo of maturation (e.g.children with Russell-Silver syndrome, precocious puberty and congenital adrenal hyperplasia). In such children, standard growth prediction methods should be used only as ‘general guides’, if at all. Table 9 summarizes these 4 methods.

 

Table 9. Summary of Methods Used for PAH

Methods

Parameters

Bayley-Pinneau (BP)

Height, BA, CA

Tanner-Whitehouse- Marshall and Carter (TW2)

Height, BA, CA, MPH, the age of menarche in girls

Roche-Wainer-Thissen (RWT)

Height, weight, BA, MPH

Khamis-Roche

Height, weight, MPH

 

Biochemical Evaluation of GH Deficiency

 

As growth hormone is secreted in a pulsatile manner (usually 6 pulses in 24 hours and mainly during the night) with little serum GH at any given time, several methods have been developed to assess the adequacy of GH secretion:

 

  1. Stimulation testing: GH provocation utilizing arginine, clonidine, glucagon, L-Dopa, insulin, etc. This practice generally measures pituitary reserve-or GH secretory ability-rather than endogenous secretory status. It is labor intensive and trained individuals should perform the GH stimulation test according to a standardized protocol, with special care taken with younger children/infants (186).
  2. GH-dependent biochemical markers: IGF1 and IGFBP3: Values below a cut-off less than -2 SD for IGF1 and/or IGFBP3 strongly suggest an abnormality in the GH axis if other causes of low IGF have been excluded. Age and gender appropriate reference ranges for IGF1 and IGFBP3 are mandatory.
  3. 24-hour or Overnight GH sampling: Blood sampling at frequent intervals designed to quantify physiologic bursts of GH secretion.
  4. IGF generation test: This test is used to assess GH action and for the confirmation of suspected GH insensitivity. GH is given for several days (3-5 days) with serum IGF1 and IGFBP3 levels measured at the start and end of the test. A sufficient rise in IGF1 and IGFBP3 levels would exclude severe forms of GH insensitivity (103,188).

 

Failure to raise the serum GH level to the threshold level in response to provocation suggests the diagnosis of GH deficiency, while a low IGF1 and/or IGFBP3 level is supportive evidence. Although pharmacological GH stimulation tests have known deficiencies such as poor reproducibility, arbitrary cut-off limits, varying GH assays, side effects, and labor intensivity requiring trained staff, they remain the most easily available and accepted tools to evaluate pituitary GH secretory capacity. GH stimulation test results should be interpreted carefully in conjunction with pubertal status and body weight. Puberty and administration of sex steroids increase GH response to stimulation tests (197). To prevent false positive results, some centers use sex steroid priming in prepubertal children prior to GH stimulation testing (198). In obese children, the normal regulation of the GH/IGF1 axis is disturbed and GH secretion is decreased. IGF1 levels are very sensitive to nutritional status, while IGFBP3 are less so. Additionally, the normative range for IGF1 and IGFBP3 values are extremely wide, often with poor discrimination between normal and pathological. Age/pubertal stage and gender-specific threshold values must be utilized for both IGF1 and IGFBP3.

 

Due to the above limitations of current agents, the quest for new, more reliable agents that with fewer side effects and are less labor intensive has been ongoing. One of them is macimorelin acetate, a potent, orally administered growth hormone (GH) secretagogue approved by the FDA and European Medical Agency (EMA) for diagnosing adult growth hormone deficiency (199,200). It functions by increasing GH levels acutely via the ghrelin receptor GHSR1-a (199). Csákváry et al investigated the use of macimorelin as a diagnostic test in children with suspected GH deficiency, finding it to be safe and well-tolerated across different dosing cohorts (200). However, more research is needed to fully understand its efficacy in diagnosing pediatric GH deficiency and its potential therapeutic applications.

 

Growth hormone–releasing peptide-2 (GHRP2) is a potent stimulator of growth hormone secretion (201) and has been investigated its effectiveness diagnosing GH deficiency in children and adolescents (202). It is widely used in Japan for diagnosis of adult GH deficiency (203). GHRP2 also stimulates corticotropes along with somatotropes and maybe useful diagnosis of adrenal insufficiency which is concomitant with GHD in many hypothalamic-pituitary disorders (204).

 

Summary of Diagnosis of GH Deficiency

 

Children with severe GH deficiency can usually be diagnosed easily on clinical grounds and failed GH stimulation tests. Studies have shown that despite clinical evidence of GH deficiency, some children may pass GH stimulation tests (188). In the case of unexplained short stature, if the child meets most of the following criteria, a trial of GH treatment should be initiated (8):

  1. Height >2.25 SD below the mean for age or >2 SD below the mid-parental height percentile,
  2. Growth velocity <25th percentile for bone age,
  3. Bone age >2 SD below the mean for age,
  4. Height prediction is significantly below the mid-parental height,
  5. Low serum insulin-like growth factor 1 (IGF1) and/or insulin-like growth factor binding protein 3 (IGFBP3) for bone age and gender
  6. Other clinical features suggestive of GH deficiency.

 

Key elements that may indicate GH deficiency are:

  1. Height more than 2 SD below the mean.
  2. Neonatal hypoglycemia, microphallus, prolonged jaundice, or traumatic delivery.
  3. Although not required, a peak GH concentration after provocative GH testing of less than 10 ng/ml.
  4. Consanguinity and/or a family member with GH deficiency.
  5. Midline CNS defects, pituitary hypo- or aplasia, pituitary stalk agenesis, empty sella, ectopic posterior pituitary (bright spot’) on MRI.
  6. Deficiency of other pituitary hormones: TSH, PRL, LH/FSH and/or ACTH deficiency.

 

Many practitioners consider GH stimulation tests to be optional in the case of clinical evidence of GH deficiency, in patients with a history of surgery or irradiation of the hypothalamus/pituitary region and growth failure accompanied by additional pituitary hormone deficiencies. Similarly, children born SGA, with Turner syndrome, PWS and chronic renal insufficiency do not require GH stimulation testing before initiating GH treatment (8).

 

TREATMENT

 

The principal objective of GH treatment in children with GH deficiency is to improve final adult height. Human pituitary-derived GH was first used in children with hypopituitarism over 60 years ago, and abruptly ceased in 1985, after the first cases of Creutzfeld-Jacob disease were recognized. Since 1986, recombinant human GH (rhGH) has been the exclusive form of growth hormone used to treat GH deficiency in the United States and most of the world.

 

Short stature without overt growth hormone deficiency is very well described, and occurs in Turner Syndrome, renal failure, malnutrition, cardiovascular disease, Prader-Willi syndrome, small for gestational age, inflammatory bowel disease, and osteodystrophies- clearly representing the majority of short/poorly growing children in the world. Although not the focus of this discussion, it is important to realize that - in clinical terms - GH therapy is used to treat growth failure, rather than a biochemical GH deficiency. GH therapy in this setting, in combination with disease-specific treatments, generally improves statural growth and final adult height.

 

The primary goals of the treatment of a child with GH deficiency are to achieve normal height during childhood and to attain normal adult height. Children should be treated with an adequate dose of rhGH, with the dose tailored to that child’s specific condition. FDA guidelines for daily rhGH dose vary according to the indication and are given in Table 10(8).

 

Administration of daily rhGH in the evening is designed to mimic physiologic hGH secretion. Treatment is continued until adult height or epiphyseal closure (or both) has been recorded. GH therapy, however, should be continued throughout adulthood in the case of GHD, to optimize the metabolic effects of GH and to achieve normal peak bone mass-albeit at significantly lower “adult” doses. Adult GH replacement should only be started after retesting the individual and again demonstrating a failure to reach the new age-appropriate GH threshold, if appropriate.

 

Table 10. GH Dosage for Daily rhGH

Indication 

Dose (mg/kg/wk)

GH Deficiency

     Children Pre-pubertal

     Pubertal

     Adults

 

0.16 – 0.35

0.16 – 0.70

0.04 – 0.175

Turner Syndrome

0.375

Chronic renal insufficiency

0.35

Prader-Willi Syndrome

0.24

SGA

0.48

Idiopathic short stature (ISS)

0.3 – 0.37

SHOX Deficiency

0.35

Noonan Syndrome

0.23 – 0.46

 

The growth response to daily GH treatment is typically maximal in the first year of treatment and then gradually decreases over the subsequent years of treatment. First year growth response to rhGH is generally 200% of the pre-treatment velocity, and after several years, averages 150% of the baseline. Height improvements of 1 SD are typically achieved in children with GHD after two years of treatment, and between 2 and 2.5 SD after five or seven years.

 

GH doses are often increased if catch-up growth is inadequate and/or to compensate for the waning effect of rhGH with time. Cohen et al reported a significant improvement in HV when GH dose was adjusted based on IGF1 levels (205). However, GH dose was almost 3 times higher than mean conventional GH dose when IGF1 levels were titrated to the upper limit of normal. The lack of long-term safety data on high doses of GH and high circulating levels of IGF1 levels should be considered. Therefore, weight-based GH dosing is still recommended by many as the standard of care (206).

 

It is critically important to maximize height with GH therapy before the onset of puberty. Several investigators have advocated modifying puberty or the production of estrogens by the use of GnRH analogues (207–209) and aromatase inhibitors (210–213), respectively, in order to expand the therapeutic window for GH treatment, especially in older males.

 

The response to daily rhGH, however, may vary in children (214). Factors may affect the response to GH therapy including

  1. The etiology of short stature
  2. Age at the start of treatment
  3. Height deficit at the start of treatment
  4. GH dose and frequency
  5. Duration of treatment
  6. Genetic factors

 

Several studies have reported the association between response to GH therapy and a GHR gene polymorphism, the deletion of exon 3 (GHRd3).  Although some reports showed better response to GH therapy in GHRd3 carriers with different clinical conditions including GHD, Turner syndrome, SGA, and ISS (93–95,215,216), many others failed to confirm positive effects of GHRd3 on response to GH treatment (96,217,218). 

 

Long-Acting GH Formulations

 

Daily GH injections can be inconvenient and lead to poor adherence over time in children, with a negative impact on their final adult height. To overcome these barriers, long-acting growth hormone (LAGH) formulations have been developed using various technologies including depot formulations, Pegylated formulations, pro-drug formulations, non-covalent albumin binding GH, and GH fusion proteins (219). It was noted that LAGH does not suppress endogenous GH secretion and can be used for treating non-GH deficient short stature, e.g., idiopathic short stature, with similar efficacy and safety compared to daily GH (220). In addition, the timing of LAGH administration does not appear to be a crucial factor in treatment efficacy, as no differences in growth rate or IGF1 concentrations were observed between morning and evening treatment schedules (221), this further improves compliance and ultimately adult height. In contrast, the typical bedtime administration of daily GH formulations may cause conflict during vacation, trip, or physical and social activities. 

 

Currently, several long-acting growth hormones are available worldwide, utilizing pegylation, prodrug formulations, noncovalent transient albumin binding, and GH fusion proteins and only last three of them are FDA approved in the United States (222,223). The goal of these new formulations is to improve patient compliance while maintaining the efficacy and safety of traditional daily GH therapy.

 

PRO-DRUG FORMULATIONS

 

 Long-acting prodrug growth hormone formulations, such as lonapegsomatropin (Skytrofaâ), are designed to release unmodified growth hormone over an extended period, typically one week, while maintaining similar efficacy and safety profiles as daily injections (224,225). It received FDA approval in August 2021 for treating pediatric patients at least 1 year old with GH deficiency (226,227).

 

 Lonapegsomatropin, also known as TransCon GH, consists of unmodified rhGH transiently attached to an inert carrier molecule, methoxypolyethylene glycol (mPEG), via a transient, low-molecular weight TransCon Linker (227). While the carrier molecule, mPEG, is responsible for decreasing GH receptor binding and renal excretion until its release, the linker determines when to release unmodified rhGH from its carrier prodrug, acts as a timer to allow controlled release of GH at body temperature and pH over one week (224,225,227).  Lonapegsomatropin is administered subcutaneously as daily GH. Because it releases unmodified rhGH over one week under physiologic conditions, it has the same actions as endogenous GH. . In a phase 2 trial comparing TransCon GH to daily growth hormone in children with GHD, the mean annualized height velocity for TransCon GH was 12.9 cm/y compared to 11.6 cm/y for daily growth hormone at an equivalent dose (228). The subsequent phase 3 heiGHt Trial investigated the safety, tolerability, and efficacy of weekly lonapegsomatropin versus daily GH over 52 weeks in treatment-naive prepubertal children with GHD (225,229,230).This trial enrolled 161 treatment-naïve, prepubertal children with GHD. Subjects were randomized 2:1 to receive lonapegsomatropin 0.24 mg/kg/week or daily somatropin (0.34 mg/kg/week). At 52 weeks, annualized height velocity was again better in lonapegsomatropin group (11.2 cm/year) compared to daily GH group 10.3 cm/year (p=0.009). This study confirmed noninferiority and further showed statistical superiority of lonapegsomatropin in annualized height velocity compared to daily GH, with similar safety, in treatment-naïve children with GHD (230).

 

Lonapegsomatropin injections were well tolerated and were not associated with increased adverse effects compared to daily GH. None of study subjects had pseudotumor cerebri, slipped capital femoral epiphysis or hyperglycemia; in contrast, these complications have been previously reported in daily GH therapy (231). However, transient hyperglycemia was recently reported in a child with obesity who was on Lonepegsomatropin suggesting the need for careful glucose monitoring while receiving lonepegsomatropin (232). In the lonapegsomatropin group, although study subjects had higher IGF1 SD and reached target IGF1 SD earlier compared to daily GH-treated group, IGF1/IGFBP3 ratios were similar between the lonapegsomatropin- and daily GH-treated groups. There were two children that required dose reduction due to IGF1 SD >2. In both groups, there were no neutralizing antibodies and low-affinity antibodies were observed.

 

While the phase 3 heiGHt Trial in children established non-inferiority and statistical superiority of height velocity compared to daily growth hormone therapy, with no concerning side effects (230), the fliGHt Trial showed that switching from daily somatropin to lonapegsomatropin resulted in a similar adverse event profile and maintained growth outcomes (233). Long-term data from the enliGHten trial showed continued improvement in height standard deviation scores through the third year of therapy (234).

 

NONVALENT TRANSIENT ALBUMIN BINDING FORMULATIONS

 

Somapacitan (Sogroyaâ) was developed using a well-established protraction method which previously has been used to extend half-lives of insulin detemir and glucagon like peptide 1 agonists (liraglutide and semaglutide). It is a novel albumin-binding GH derivative, with a small albumin-binding property attached to the GH molecule (235). Somapacitan consists of a human GH molecule and a single amino acid substitution at position 101 (leucine to cysteine) where a side chain has been attached (235). Amino acid substitution, Leu101Cys does not affect the binding to the GH receptor and the side chain consists of a hydrophilic spacer and an albumin-binding moiety (236). The reversible binding to endogenous albumin delays the elimination of somapacitan, extends its half-life and, therefore, duration of action, allowing once-weekly administration (237). Somapacitan was first approved for adult growth hormone deficiency in August 2020, and later for pediatric growth hormone deficiency in April 2023 by the US Food and Drug Administration.

 

Clinical trials have demonstrated somapacitan’s efficacy and safety compared to daily GH injections (238,239). In children with GHD, somapacitan showed similar height velocity and IGF1 increases as daily GH, with similar safety profiles including neutralizing antibodies, bone maturation, and metabolic profile over 1 year-2 years-and 4 years of treatment (238,240,241).  In addition, authors assessed disease burden and treatment burden on both patients and parents/guardians, at years 2, 3, 4 which showed both groups strongly preferred weekly somapacitan over daily GH injections (241). 

 

For adults with GHD, somapacitan improved body composition and IGF1 levels while being well-tolerated (242).Interestingly, somapacitan may have some advantages over daily GH. It showed neutral effects on glucose metabolism in adults with GHD, with no new cases of diabetes reported in long-term studies (243). In some patients switching from daily GH, somapacitan led to improvements in lipid metabolism and glucose tolerance, suggesting a potentially higher GH replacement effect (244). However, weekly injections may be easier to forget than daily ones for some patients (244).

 

GH FUSION PROTEIN FORMULATIONS

 

Somatrogon (NGENLA®) consists of rhGH combined with three copies of the carboxy terminal peptide (CTP) from human chorionic gonadotropin resulting in a fusion protein of approximately 41 kDa (245). The addition of the CTP moieties extends the half-life of the attached rhGH, allowing for once-weekly subcutaneous administration (246). Somatrogon is the last LAGH that received FDA approval in June 2023 for the treatment of pediatric GH deficiency.

 

Clinical trials have demonstrated the efficacy and safety of somatrogon. In a phase 3 randomized trial, once-weekly somatrogon was non-inferior to once-daily human GH in increasing height velocity in pediatric patients with GHD (247).The mean height velocity at 12 months was 10.12 cm/yr for somatrogon compared to 9.78 cm/yr for daily GH (247).Interestingly, a comparison with published literature and the KIGS database indicated that children treated with once-weekly somatrogon (0.66 mg/kg/week) showed good growth compared to children treated with once-daily human growth hormone (248) and sustained improvement in height SDS and delta height SDS up to 5 years of treatment (249).

 

Similar to other LAGH formulations, somatrogon is generally well-tolerated, with injection site pain being the most frequent treatment-emergent adverse event (246). Furthermore, somatrogon had a lower treatment burden with favorable treatment experience than daily GH (233).

 

SUMMARY

 

In summary, long-acting growth hormone formulations represent a significant advancement in the treatment of growth hormone deficiency. While long-acting growth hormone formulations offer a promising alternative to daily growth hormone injections as well as improving treatment adherence and quality of life due to less frequent injections, there are some concerns regarding their unphysiological profile. Ongoing research and long-term studies are necessary to fully understand their efficacy, safety, and optimal use in clinical practice (250,251). Additionally, cost-effectiveness and the identification of patient groups that may benefit most from weekly injections are areas that require further investigation (250,252). Table 11 summarizes the approved dosage for long-acting growth hormone formulations.

 

Table 11. GH dosage for long-acting growth hormone

Medication

Dose (mg/kg/wk)

Somapacitan (Sogroyaâ)

0.16

Somatrogon (NGENLA®)

0.66

Lonapegsomatropin (Skytrofaâ)

0.24

 

Monitoring GH Treatment

 

Children receiving GH therapy require periodic monitoring. Three-month intervals are commonly chosen to allow for sufficient growth for a meaningful measurement, while minimizing time between dose adjustments/intervention. During follow up visits, height, weight, pubertal status, inspection of injection sites, and a comprehensive clinical exam should be initiated. In clinical practice, there are several parameters to monitor the response to GH treatment; the determination of the growth response (i.e. change in height velocity, ∆HV) being the most important parameter.  These points are summarized in Table 12.

 

Table 12. Summary of Follow-Up Evaluation

Parameters 

Assessment

Bone age 

12-month intervals to assess the predicted height.

Thyroid Function Test 

6-month intervals, or immediately, if growth velocity decreases.

Serum IGF1

Most useful in maintaining GH dose in ‘safe’ region. It does not necessarily correlate with growth velocity.

12-month intervals for daily rhGH.

However, timing to assess IGF-1 varies for each long-acting GH formulations. Monitoring of IGF-1 should be based on the mean IGF-1 over the week, which is on day 4 for somatrogon and somapacitan, and day 4.5 for lonapegsomatropin.

Metabolic panel, HbA1C 

12-month intervals.

Dose adjustment 

Should be based on weight-change, growth response, pubertal stage, comparison to predicted height at each visit, and IGF1/IGFBP3 levels.

Adverse Events 

Every visit.

 

The Safety of GH Treatment

 

To date, multiple studies have demonstrated the safety of GH therapy (6,63,186,187,253–256). While rhGH treatment is generally considered safe, patients, however, should be monitored closely during treatment. Some of the common side effects seen during GH therapy are scoliosis, slipped capital femoral epiphysis (SCFE), pancreatitis, and pseudotumor cerebri (intracranial hypertension).   An analysis of Genentech’s National Cooperative Growth Study (NCGS) identified eleven cases of adrenal insufficiency (AI) resulting in four deaths.  All eleven cases of AI occurred in patients with organic GH deficiency (n=8,351), yielding an incidence of 132 per 100,000 in this subgroup, and an overall incidence of AI in NCGS was 20 per 100,000 (257). 

 

Another concern is the use of GH in patients with Prader-Willi syndrome. Early recognition of the syndrome allows earlier intervention to prevent morbidity. Previous studies and data from KIGS showed that earlier initiation of GH treatment in children with PWS significantly improved body composition, muscle tone, growth, and cognition (258). Fatalities have been reported in patients with Prader-Willi syndrome during or after rhGH therapy (259). Data for children aged 3 years and older showed no statistically significant differences between the GH-treated and untreated groups with respect to cause of death, including respiratory infection or insufficiency (259,260). Although there is no clear evidence that those deaths are related to GH therapy, it was postulated that GH/IGF1 may worsen sleep apnea or hypoventilation via increasing tonsillar/adenoid tissue or worsen pre-existing impaired respiration by increasing volume load (261). However, studies on respiratory function of subjects with Prader-Willi syndrome during rhGH therapy have only demonstrated improved respiratory drive and function (262). In fact, a recent study showed that all subjects tested had abnormal sleep studies/parameters prior to initiating GH treatment, and that GH treatment resulted in an improvement in sleep apnea in the majority of patients with PWS. Importantly, however, a subset had worsening of sleep disturbance shortly after (6 wk) starting GH when also developing a respiratory infection (263). Because it is difficult to predict who will worsen with GH treatment, these authors recommend that patients with Prader-Willi syndrome have polysomnography before and 6 wk after starting rhGH and should be monitored for sleep apnea during upper respiratory tract infections. IGF1 levels should also be monitored.

 

The data on the efficacy and safety of GH treatment in 5220 Turner Syndrome (TS) children during the last 20 years has been reported by NCGS. The incidence of various side effects known to be associated with GH including pseudotumor cerebri, slipped capital femoral epiphysis, and scoliosis was increased in TS patients treated with GH compared with non-TS patients, however, children with TS are known to have a higher incidence of these side effects independent of rhGH treatment (264). Interestingly, type 1 diabetes was increased in GH treated group, most likely unrelated to GH treatment since the predisposition to autoimmune disorders is one of the characteristics of TS. In addition, NCGS data demonstrate a slightly increased incidence of a variety of malignancies in TS, however, this may again be related to the underlying condition, (i.e. not necessarily the rhGH treatment) as girls with TS have been shown to have an increased risk for cancer compared to general population (265). In summary, twenty years of experience in 5220 patients seems reassuring and does not indicate any new rhGH-related safety signals in the TS population (264).

 

There has been ongoing concern about tumorigenicity of chronically elevated IGF1 levels. It would therefore seem prudent to maintain IGF1 levels in the mid-normal range for age/pubertal stage and gender. Although the long-term consequences of elevated IGF1 levels during childhood are not known, some investigators recommend that dose reductions be considered if IGF1 levels are above the normal range (8).  The report from the Safety and Appropriateness of Growth Hormone Treatments in Europe (SAGhE) in 2012, raised many concerns about the long-term safety of rhGH therapy in children.  SAGhE is a large database established by eight European countries to evaluate the long-term safety of childhood GH treatment between 1980s and 1990s in 30,000 patients.  Preliminary analysis of the patients in France revealed that among patients treated with rhGH, there was a 33% increased relative risk of mortality compared with French general population.  They also noted an increased incidence of bone malignancies and cardiovascular disease (266). However, the data from the Belgian, Swedish the Dutch portions of SAGhE did not support or corroborate the findings that were reported from France (267).

 

Real and Theoretical adverse events of GH therapy are summarized in Table13.

 

Table 13.  Real and Theoretical Adverse Events of GH Treatment

Side effects 

Comment

Slipped capital femoral epiphysis (SCFE) 

Unclear whether GH causes SCFE or if it is a result of diathesis and rapid growth induced by the GH. In addition, obesity, trauma, and previous radiation exposure increase the risk for SCFE.  At each visit, patients should be evaluated for knee or hip pain/limp.

Pseudotumor cerebri 

The mechanism is unclear, but it may be a result of GH induced salt and water retention within the CNS. Mostly occurs within the first months of treatment.  It is more common in patients with organic GH deficiency, chronic renal insufficiency, and Turner Syndrome (257).  Complaints of headache, nausea, dizziness, ataxia, or visual changes should be evaluated immediately.

Leukemia 

Numerous large studies have not shown any association between rhGH and leukemia in children without predisposing conditions (254,257,268).

Recurrence risk of CNS tumors 

Extensive studies did not support this possible side effect without risk factors (253,257,269–272)

Risk of primary malignancy

Studies have not shown a higher risk of all-site primary malignancy without a history of previous malignancy (273,274)

Insulin resistance 

Insulin resistance is associated with GH therapy, though it is generally transient and/or reversible and rarely leads to overt diabetes.  Patients with a limited insulin reserve may develop glucose intolerance. HbA1C should be monitored.

Pancreatitis

It may occur in patients with Turner syndrome, and associated risk factors (257).

Hypothyroidism 

Almost 25 % of children may develop declines in serum T4 levels, generally reflecting enhanced conversion of T4 to T3, rather than outright hypothyroidism.

Transient gynecomastia 

These are attributed to anabolic and metabolic effects of GH.

Scoliosis 

It is more common in Turner syndrome and PWS.  Patients should be evaluated for scoliosis at each visit and referred as appropriate

Adrenal Insufficiency

GH decreases the conversion of corticosterone to cortisol by a modulating effect on hepatic 11-beta hydroxysteroid dehydrogenase 1. Thus, endogenous cortisol levels can decrease in GHD patients after initiation of GH treatment. Furthermore, GH therapy may unmask previously unsuspected central ACTH deficiency.  Whether the patients with hypopituitarism are on GH or not, they have a lifelong risk for adrenal insufficiency.  Therefore, they should be monitored closely for adrenal insufficiency and their cortisol dose should be adjusted when GH therapy is started (257).

Sleep apnea/sleep disturbance

GH treatment might worsen sleep apnea/sleep disturbance in patients with Prader-Willi Syndrome, especially during a concomitant respiratory infection.

 

Transitioning GH Treatment from Childhood to Adulthood

 

Growing data support the need for continuation of GH treatment in individuals with childhood GH deficiency.  GH treatment provides significant benefits in body composition, bone mineralization, lean body mass, lipid metabolism, and quality of life in adults with GH deficiency (275,276). However, identifying appropriate patients for transitioning from childhood to adult GH therapy remains challenging. The majority of children with a diagnosis of GHD and who are treated with GH do not have permanent GHD and will not require treatment during adulthood.  Re-evaluation of GH secretory capacity is recommended after completion of linear growth in adolescents with history of childhood GHD (277). However, such re-evaluation requires cessation of GH treatment for at least one month.  Furthermore, there is no established optimal GH stimulation test identified and validated during this transition period.  The stimulation test results vary by protocol, and only a few secretagogues (insulin, arginine, and glucagon) are available to confirm GHD.  The cut-off values are also stricter; the peak GH level to establish GHD is <6 mcg/L for the insulin tolerance test and ≤ 3 mcg/L for the glucagon test in young adults (278,279).  It is generally agreed that patients with severe GHD secondary to organic defects (hypothalamic-pituitary abnormalities, tumors involving pituitary or hypothalamic area, infiltrative diseases, and cranial irradiation), genetic causes of GHD involving one or more additional pituitary hormone deficiencies and serum IGF-1 level below the normal range at least one month off therapy, are more likely to have permanent GHD and retesting to confirm GHD is unnecessary (275,279). However, children with idiopathic GHD are less likely to have permanent GHD.  In a US study, only one third of patients with idiopathic GHD retested as GHD (280).  In that cohort, authors found age <4 at diagnosis and IGFBP3 below -2.0 SDS were the strongest predictive factors (100% PPV) for permanent GHD.  In contrast to previous studies (277), low IGF-1 (< -2.0 SDS) did not have significant power to identify permanent GHD unless IGF-1 level was extremely low (-5.3 SDS) (280). 

 

In summary, current guidelines recommend the measurement of serum IGF-1 levels and a GH stimulation test after cessation of treatment for at least one month to determine whether the adolescents with childhood-onset GHD will need ongoing treatment unless they have known organic or genetic defects in the hypothalamic-pituitary region (275,276,279).

 

CONCLUSION

 

The control of human growth is becoming increasingly clear and involves both genetic and environmental factors. Many genes have been identified as being involved in normal growth and in the common phenotype of short stature.  Genetic analyses, however, should follow a detailed clinical, biochemical and radiological assessment in order to refine the phenotype and point to the relevant pathophysiology, e.g. genes involved in the development and function of the pituitary gland (e.g. POU1F1), those involved in transducing the GH signal (e.g. STAT5B) or the IGF1 signal (e.g. PAPPA2) and everything further “downstream”, e.g. the growth plate, (e.g. SHOX).  Clinical identification of patterns and unique findings can direct the genetic evaluation and narrow its focus – e.g. short stature with an advanced bone age may suggest mutations in the ACAN gene.

 

Identifying causes of short stature is challenging due to many factors, including the lack of ‘gold standard’ diagnostic criteria and limitations in available diagnostic tests (281). Clinical, biochemical and radiological evaluation continue to be the foundation for diagnosis. IGF1 and IGFBP3 measurements and neuroimaging play especially critical roles in defining the clinical phenotype, and in directing genetic testing to establish the diagnosis in children with abnormal growth and initiating appropriate treatment (281,282).

 

Treatment with rhGH has been shown to be effective and safe, improving linear growth and achieving adult heights in the normal range, as well as improving body composition, bone mineral density, cardiovascular outcomes, and quality of life (283–285). rhIGF1 may be considered for select children, especially those with primary severe IGF1 deficiency. The timing of treatment initiation and dosage are crucial factors in determining treatment outcomes (286). Additionally, continuing GH administration during the transition period between childhood and adulthood may be necessary for proper body composition, bone and muscle health, and metabolic parameters (287). Weekly GH preparations are now approved for the treatment of children with GH deficiency and offer the potential for reduced treatment burden, increased compliance and improved clinical outcomes (219,288). However, long-term safety concerns and non-physiological GH profiles, need to be carefully monitored and addressed in future studies; a growth hormone registry for daily and weekly GH preparations may help resolve these questions (250,289).

 

The understanding of growth remains complex, despite remarkable scientific advances in the last decades. Elucidation of new genetic factors, diagnostic tests and treatment options will provide us with a better understanding of the physiology of growth and should lead to improved diagnosis and treatment options, individualized to each patients’ unique situation.

 

REFERENCES

 

  1. Knobil E, Greep R. The physiology of growth hormone with particular reference to its action in the rhesus monkey and the’species specificity’problem. Recent Progr Horm Res. 1959;15(1).
  2. Ranke MB, Wit JM. Growth hormone - past, present and future. Nat Rev Endocrinol. 2018 May;14(5):285–300.
  3. Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinley MJ. A preliminary study of growth hormone therapy for Crohn’s disease. N Engl J Med. 2000;342(22):1633–7.
  4. Touati G, Prieur AM, Ruiz JC, Noel M, Czernichow P. Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition. J Clin Endocrinol Metab. 1998;83(2):403–9.
  5. Hardin DS, Stratton R, Kramer JC, de la Rocha SR, Govaerts K, Wilson DP. Growth hormone improves weight velocity and height velocity in prepubertal children with cystic fibrosis. Horm Metab Res. 1998;30(10):636–41.
  6. Hardin DS, Ellis KJ, Dyson M, Rice J, McConnell R, Seilheimer DK. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. J Pediatr. 2001;139(5):636–42.
  7. Gullett NP, Hebbar G, Ziegler TR. Update on clinical trials of growth factors and anabolic steroids in cachexia andwasting. Am J Clin Nutr. 2010 Apr;91(4):1143S-1147S.
  8. Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown R, et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr. 2003;143(4):415–21.
  9. Savage MO, Simon D, Czernichow PC. Growth hormone treatment in children on chronic glucorticoid therapy. Endocr Dev. 2011;20:194–201.
  10. Mauras N, George D, Evans J, Milov D, Abrams S, Rini A, et al. Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: A pilot study. Metabolism. 2002;51(1):127–35.
  11. Lin-Su K, Vogiatzi MG, Marshall I, Harbison MD, Macapagal MC, Betensky B, et al. Treatment with growth hormone and LHRH analogue improves final adult height in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2005;jc.2004-2128.
  12. Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Adv Ther. 2009;26(1):40.
  13. Larsen WJ. Human Embryology. Second. Churchhill Livingstone, Inc; 1997.
  14. De Rienzo F, Mellone S, Bellone S, Babu D, Fusco I, Prodam F, et al. Frequency of genetic defects in combined pituitary hormone deficiency: a systematic review and analysis of a multicentre Italian cohort. Clin Endocrinol. 2015;83(6):849–60.
  15. Phillips JA, Cogan JD. Genetic basis of endocrine disease. 6. Molecular basis of familial human growth hormone deficiency. J Clin Endocrinol Metab. 1994;78(1):11–6.
  16. Roessler E, Du Y-Z, Mullor JL, Casas E, Allen WP, Gillessen-Kaesbach G, et al. Loss-of-function mutations in the human GLI2 gene are associated with pituitary anomalies and holoprosencephaly-like features. Proc Natl Acad Sci U S A. 2003;100(23):13424–9.
  17. Roessler E, Ermilov AN, Grange DK, Wang A, Grachtchouk M, Dlugosz AA, et al. A previously unidentified amino-terminal domain regulates transcriptional activity of wild-type and disease-associated human GLI2. Hum Mol Genet. 2005;14(15):2181–8.
  18. França MM, Jorge AAL, Carvalho LRS, Costalonga EF, Vasques GA, Leite CC, et al. Novel heterozygous nonsense GLI2 mutations in patients with hypopituitarism and ectopic posterior pituitary lobe without holoprosencephaly. J Clin Endocrinol Metab. 2010;95(11):E384–91.
  19. Demiral M, Demirbilek H, Unal E, Durmaz CD, Ceylaner S, Ozbek MN. Ectopic posterior pituitary, polydactyly, midfacial hypoplasia and multiple pituitary hormone deficiency due to a novel heterozygous IVS11-2A>C(C.1957-2A>C) mutation in GLI2 gene. J Clin Res Pediatr Endocrinol. 2020;12(3):319-28.
  20. Netchine I, Sobrier ML, Krude H, Schnabel D, Maghnie M, Marcos E, et al. Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. Nat Genet. 2000;25(2):182–6.
  21. Bhangoo APS, Hunter CS, Savage JJ, Anhalt H, Pavlakis S, Walvoord EC, et al. Clinical case seminar: a novel LHX3 mutation presenting as combined pituitary hormonal deficiency. J Clin Endocrinol Metab. 2006;91(3):747–53.
  22. Raetzman LT, Ward R, Camper SA. Lhx4 and Prop1 are required for cell survival and expansion of the pituitary primordia. Development. 2002;129(18):4229–39.
  23. Mullen RD, Colvin SC, Hunter CS, Savage JJ, Walvoord EC, Bhangoo APS, et al. Roles of the LHX3 and LHX4 LIM-homeodomain factors in pituitary development. Mol Cell Endocrinol. 2007 Feb;265–266:190–5.
  24. Sobrier ML, Attié-Bitach T, Netchine I, Encha-Razavi F, Vekemans M, Amselem S. Pathophysiology of syndromic combined pituitary hormone deficiency due to a LHX3 defect in light of LHX3 and LHX4 expression during early human development. Gene Expr Patterns. 2004;5(2):279–84.
  25. Machinis K, Pantel J, Netchine I, Leger J, Camand OJ, Sobrier ML, et al. Syndromic short stature in patients with a germline mutation in the LIM homeobox LHX4. Am J Hum Genet. 2001;69(5):961–8.
  26. Dattani MT, Martinez-Barbera JP, Thomas PQ, Brickman JM, Gupta R, Martensson IL, et al. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet. 1998;19(2):125–33.
  27. Carvalho LR, Woods KS, Mendonca BB, Marcal N, Zamparini AL, Stifani S, et al. A homozygous mutation in HESX1 is associated with evolving hypopituitarism due to impaired repressor-corepressor interaction. J Clin Invest. 2003;112(8):1192–201.
  28. Parks JS, Brown MR, Hurley DL, Phelps CJ, Wajnrajch MP. Heritable disorders of pituitary development. J Clin Endocrinol Metab. 1999;84(12):4362–70.
  29. Thomas PQ, Dattani MT, Brickman JM, McNay D, Warne G, Zacharin M, et al. Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia. Hum Mol Genet. 2001;10(1):39–45.
  30. Rosenbloom A l., Almonte AS, Brown MR, Fisher DA, Baumbach L, Parks JS. Clinical and biochemical phenotype of familial anterior hypopituitarism from mutation of the PROP1 gene. J Clin Endocrinol Metab. 1999;84(1):50–7.
  31. Turton JPG, Mehta A, Raza J, Woods KS, Tiulpakov A, Cassar J, et al. Mutations within the transcription factor PROP1 are rare in a cohort of patients with sporadic combined pituitary hormone deficiency (CPHD). Clin Endocrinol (Oxf). 2005;63(1):10–8.
  32. Pfäffle RW, DiMattia GE, Parks JS, Brown MR, Wit JM, Jansen M, et al. Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science. 1992;257(5073):1118–21.
  33. Turton JPG, Reynaud R, Mehta A, Torpiano J, Saveanu A, Woods KS, et al. Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency. J Clin Endocrinol Metab. 2005;90(8):4762–70.
  34. Dattani MT. Growth hormone deficiency and combined pituitary hormone deficiency: does the genotype matter? Clin Endocrinol (Oxf). 2005;63(2):121–30.
  35. Rizzoti K, Brunelli S, Carmignac D, Thomas PQ, Robinson IC, Lovell-Badge R. SOX3 is required during the formation of the hypothalamo-pituitary axis. Nat Genet. 2004;36(3):247–55.
  36. Foster JW, Graves JA. An SRY-related sequence on the marsupial X chromosome: implications for the evolution of the mammalian testis-determining gene. Proc Natl Acad Sci U S A. 1994;91(5):1927–31.
  37. Stevanović M, Lovell-Badge R, Collignon J, Goodfellow PN. SOX3 is an X-linked gene related to SRY. Hum Mol Genet. 1993;2(12):2013–8.
  38. Collignon J, Sockanathan S, Hacker A, Cohen-Tannoudji M, Norris D, Rastan S, et al. A comparison of the properties of Sox-3 with Sry and two related genes, Sox-1 and Sox-2. Development. 1996;122(2):509–20.
  39. Laumonnier F, Ronce N, Hamel BCJ, Thomas P, Lespinasse J, Raynaud M, et al. Transcription factor SOX3 is involved in X-Linked mental retardation with growth hormone deficiency. Am J Hum Genet. 2002;71(6):1450–5.
  40. Woods KS, Cundall M, Turton J, Rizotti K, Mehta A, Palmer R, et al. Over- and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism. Am J Hum Genet. 2005;76(5):833–49.
  41. Goosens M, Brauner R, Czernichow P, Duquesnoy P, Rapaport R. Isolated growth hormone (GH) deficiency type 1A associated with a double deletion in the human GH gene cluster. J Clin Endocrinol Metab. 1986;62(4):712–6.
  42. Wagner JK, Eblé A, Hindmarsh PC, Mullis PE. Prevalence of human GH-1 gene alterations in patients with isolated growth hormone deficiency. Pediatr Res. 1998;43(1):105–10.
  43. Wajnrajch MP, Gertner JM, Harbison MD, Chua SC, Leibel RL. Nonsense mutation in the human growth hormone releasing hormone receptor causes growth failure analogous to the little (lit) mouse. Nat Genet. 1996;12:88–90.
  44. Binder G, Nagel BH, Ranke MB, Mullis PE. Isolated GH deficiency (IGHD) type II: imaging of the pituitary gland by magnetic resonance reveals characteristic differences in comparison with severe IGHD of unknown origin. Eur J Endocrinol. 2002;147(6):755–60.
  45. Mullis PE, Robinson ICAF, Salemi S, Eble A, Besson A, Vuissoz J-M, et al. Isolated autosomal dominant growth hormone deficiency: An evolving pituitary deficit? A multicenter follow-up study. J Clin Endocrinol Metab. 2005;90(4):2089–96.
  46. Cogan JD, Ramel B, Lehto M, Phillips J, Prince M, Blizzard RM, et al. A recurring dominant negative mutation causes autosomal dominant growth hormone deficiency--a clinical research center study. J Clin Endocrinol Metab. 1995;80(12):3591–5.
  47. Takahashi Y, Shirono H, Arisaka O, Takahashi K, Yagi T, Koga J, et al. Biologically inactive growth hormone caused by an amino acid substitution. J Clin Invest. 1997;100(5):1159–65.
  48. McCarthy EM, Phillips JA. Characterization of an intron splice enhancer that regulates alternative splicing of human GH pre-mRNA. Hum Mol Genet. 1998;7(9):1491–6.
  49. Cogan JD, Prince MA, Lekhakula S, Bundey S, Futrakul A, McCarthy EM, et al. A novel mechanism of aberrant pre-mRNA splicing in humans. Hum Mol Genet. 1997;6(6):909–12.
  50. Hayashi Y, Yamamoto M, Ohmori S, Kamijo T, Ogawa M, Seo H. Inhibition of growth hormone (GH) secretion by a mutant GH-I gene product in neuroendocrine cells containing secretory granules: An implication for isolated GH deficiency inherited in an autosomal dominant manner. J Clin Endocrinol Metab. 1999;84(6):2134–9.
  51. Kamijo T, Hayashi Y, Seo H, Ogawa M. Hereditary isolated growth hormone deficiency caused by GH1 gene mutations in Japanese patients. Growth Horm IGF Res. 1999;9(Suppl B):31–4.
  52. Lee MS, Wajnrajch MP, Kim SS, Plotnick LP, Wang J, Gertner JM, et al. Autosomal dominant growth hormone (GH) deficiency type II: the Del32-71-GH deletion mutant suppresses secretion of wild-type GH. Endocrinology. 2000;141(3):883–90.
  53. Vivenza D, Guazzarotti L, Godi M, Frasca D, di Natale B, Momigliano-Richiardi P, et al. A novel deletion in the GH1 gene including the IVS3 branch site responsible for autosomal dominant isolated growth hormone deficiency. J Clin Endocrinol Metab. 2006;91(3):980–6.
  54. Fintini D, Salvatori R, Salemi S, Otten B, Ubertini G, Cambiaso P, et al. Autosomal-dominant isolated growth hormone deficiency (IGHD type II) with normal GH-1 gene. Horm Res. 2006;65(2):76–82.
  55. Veldhuis JD, Roemmich JN, Rogol AD. Gender and sexual maturation-dependent contrasts in the neuroregulation of growth hormone secretion in prepubertal and late adolescent males and females--a general clinical research center-based study. J Clin Endocrinol Metab. 2000;85(7):2385–94.
  56. van den Berg G, Veldhuis JD, Frölich M, Roelfsema F. An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies, the gender difference in mean GH concentrations in men and premenapausal women. J Clin Endocrinol Metab. 1996;81(7):2460–7.
  57. Roemmich JN, Clark PA, Weltman A, Veldhuis JD, Rogol AD. Pubertal alterations in growth and body composition: IX. Altered spontaneous secretion and metabolic clearance of growth hormone in overweight youth. Metabolism. 2005;54(10):1374–83.
  58. Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276–8.
  59. Gonzalez-Crespo S, Boronat A. Expression of the rat growth hormone-releasing hormone gene in placenta is directed by an alternative promoter. Proc Natl Acad Sci U S A. 1991;88(19):8749-53.
  60. Rogol AD, Blizzard RM, Foley TPJ, Furlanetto R, Selden R, Mayo K, et al. Growth hormone releasing hormone and growth hormone: Genetic studies in familial growth hormone deficiency. Pediatr Res. 1985;19:489–92.
  61. Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6:1734–44.
  62. Godfrey P, Rahal JO, Beamer WG, Copeland NG, Jenkins NA, Mayo KE. GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nat Genet. 1993;4(3):227-32.
  63. Lin SC, Lin CR, Gukovsky I, Lusis AJ, Sawchenko PE, Rosenfeld MG. Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature. 1993;364(6434):208–13.
  64. Wajnrajch MP, Chua SC, Green ED, Leibel RL. Human growth hormone-releasing hormone receptor (GHRHR) maps to a YAC at Chromosome 7p15. Mamm Genome. 1994;5(9):595.
  65. Baumann G, Maheshwari H. The dwarfs of Sindh:severe growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene. Acta Pediatr Suppl. 1997;423:33–8.
  66. Netchine I, Talon P, Dastot F, Vitaux F, Goosens M, Amselem S. Extensive phenotypic analysis of a family with growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene. J Clin Endocrinol Metab. 1998;83(2):432–6.
  67. Salvatori R, Hayashida CY, Aguiar-Oliveira MH, Phillips JA, Souza AH, Gondo RG, et al. Familial dwarfism due to a novel mutation of the growth hormone-releasing hormone receptor gene. J Clin Endocrinol Metab. 1999;84(3):917–23.
  68. Wajnrajch MP, Gertner JM, Harbison MD, Netchine I, Maheshwari HG, Baumann G, et al. Haplotype analysis of the growth hormone releasing hormone receptor locus in three apparently unrelated kindreds from the Indian subcontinent with the identical mutation in the GHRH receptor. Am J Med Genet. 2003;120A:77–83.
  69. Desai MP, Upadhye PS, Kamijo T, Yamamoto M, Ogawa M, Hayashi Y, et al. Growth hormone releasing hormone receptor (GHRH-r) gene mutation in Indian children with familial isolated growth hormone deficiency: a study from western India. J Pediatr Endocrinol Metab. 2005;18(10):955–73.
  70. Roelfsema F, Biermasz NR, Veldman RG, Veldhuis JD, Frolich M, Stovkis-Brantsma WH, et al. Growth hormone (GH) secretion in patients with an inactivating defect of the GH-releasing hormone (GHRH) receptor is pulsatile: evidence for a role for non-GHRH inputs into the generation of GH pulses. J Clin Endocrinol Metab. 2001;86(6):2459–64.
  71. MacIntyre I, Szelke M, Royal Postgraduate Medical S, Bowers CY, Chang J, Momany FA, et al. Effects of the enkephalins and enkephalin-analog on release of pituitary hormones in vitro. In: Molecular Endocrinology: Proceedings of Endocrinology ’77 held at the Royal College of Physicians, London, England on 11-15 July, 1977. New York: Elsevier/North-Holland Biomedical Press; 1977.
  72. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–60.
  73. Wajnrajch MP, Gertner JM, Mullis PE, Cogan JD, Dannies PS, Kim S, et al. Arg183His, a new mutational hot-spot in the growth hormone gene causing isolated GH deficiency type II. J Endocr Genet. 2000;1(3):124–34.
  74. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273:974–7.
  75. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab. 2000;85(12):4908–11.
  76. Bercu B, Walker RF. Novel growth hormone secretagogues: Clinical applications. Endocrinologist. 1997;7(1):51-64.
  77. Giustina A, Bonfanti C, Licini M, Ragni G, Stefana B. Hexarelin, a novel GHRP-6 analog, stimulates growth hormone (GH) release in a GH-secreting rat cell line (GH1) insensitive to GH-releasing hormone. Rugul Pept. 1997;70(1):49–54.
  78. Tolis G, Karydis I, Markousis V, Karagiorga M, Mesimeris T, Lenaerts V, et al. Growth hormone release by the novel GH releasing peptide Hexarelin in patients with homozygous b-Thalassemia. J Pediatr Endocrinol Metab. 1997;10(1):35–40.
  79. Hataya Y, Akamizu T, Takaya K, Kanamoto N, Ariyasu H, Saijo M, et al. A low dose of ghrelin stimulates growth hormone (gh) release synergistically with gh-releasing hormone in humans. J Clin Endocrinol Metab. 2001;86(9):45524555.
  80. Arvat E, Di Vito L, Broglio F, Papotti M, Muccioli G, Dieguez C, et al. Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest. 2000;23(8):493–5.
  81. Ghizzoni L, Mastorakos G, Vottero A, Ziveri M, Ilias I, Bernasconi S. Spontaneous growth hormone (GH) secretion is not directly affected by ghrelin in either short normal prepubertal children or children with GH neurosecretory dysfunction. J Clin Endocrinol Metab. 2004;89(11):5488–95.
  82. Racine MS, Symons K V, Foster CM, Barkan AL. Augmentation of growth hormone secretion after testosterone treatment in boys with constitutional delay of growth and adolescence: Evidence against an increase in hypothalamic secretion of growth hormone-releasing hormone. J Clin Endocrinol Metab. 2004;89(7):3326–31.
  83. Hirsh D, Heinrichs C, Leenders B, Wong ACK, Cummings DE, Chanoine J-P. Ghrelin is suppressed by glucagon and does not mediate glucagon-related growth hormone release. Horm Res. 2005;63(3):111–8.
  84. Zhang J V, Ren P-G, Avsian-Kretchmer O, Luo C-W, Rauch R, Klein C, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. Science. 2005;310(5750):996–9.
  85. Ukkola O, Ravussin E, Jacobson P, Snyder EE, Chagnon M, Sjöström L, et al. Mutations in the preproghrelin/ghrelin gene associated with obesity in humans. J Clin Endocrinol Metab. 2001;86(8):3996–9.
  86. Pantel J, Legendre M, Cabrol S, Hilal L, Hajaji Y, Morisset S, et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J Clin Invest. 2006;116:760–8.
  87. Grossman A, Savage MO, Lytras N, Preece MA, Sueiras-Diaz J, Coy DH, et al. Responses to analogues of growth hormone-releasing hormone in normal subjects, and in growth-hormone deficient children and young adults. Clin Endocrinol. 1984;21(3):321–30.
  88. Date Y, Murakami N, Kojima M, Kuroiwa T, Matsukura S, Kangawa K, et al. Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. Biochem Biophys Res Commun. 2000;275(2):477–80.
  89. Shen LP, Pictet RL, Rutter WJ. Human somatostatin I: Sequence of the cDNA. Proc Natl Acad Sci USA. 1982;79(15):4575–9.
  90. Rosskopf D, Schurks M, Manthey I, Joisten M, Busch S, Siffert W. Signal transduction of somatostatin in human B lymphoblasts. Am J Physiol Cell Physiol. 2003;284(1):C179-190.
  91. Laron Z. Prismatic cases: Laron syndrome (primary growth hormone resistance) from patient to laboratory to patient. J Clin Endocrinol Metab. 1995;80(5):1526–31.
  92. Dastot F, Sobrier ML, Duquesnoy P, Duriez B, Goossens M, Amselem S. Alternatively spliced forms in the cytoplasmic domain of the human growth hormone (GH) receptor regulate its ability to generate a soluble GH-binding protein. Proc Natl Acad Sci U S A. 1996;93(20):10723–8.
  93. Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet. 2004;36(7):720–4.
  94. Binder G, Baur F, Schweizer R, Ranke MB. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J Clin Endocrinol Metab. 2006;91(2):659–64.
  95. Jorge AAL, Marchisotti FG, Montenegro LR, Carvalho LR, Mendonca BB, Arnhold IJP. Growth hormone (GH) pharmacogenetics: Influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab. 2006;91(3):1076–80.
  96. Pilotta A, Mella P, Filisetti M, Felappi B, Prandi E, Parrinello G, et al. Common polymorphisms of the Growth Hormone (GH) Receptor do not correlate with the growth response to exogenous recombinant human GH in GH deficient children. J Clin Endocrinol Metab. 2006;91(3):jc.2005-1308.
  97. Rosenfeld RG, Belgorosky A, Camacho-Hubner C, Savage MO, Wit JM, Hwa V. Defects in growth hormone receptor signaling. Trends Endocrinol Metab. 2007;18(4):134–41.
  98. Savage MO, Hwa V, David A, Rosenfeld RG, Metherell LA. Genetic defects in the growth hormone-IGF-I axis causing growth hormone insensitivity and impaired linear growth. Front Endocrinol (Lausanne). 2011;2:95.
  99. Ayling RM, Ross R, Towner P, von Laue S, Finidori J, Moutoussamy S, et al. A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet. 1997;16:13–4.
  100. Amselem S, Duquesnoy P, Attree O, Novelli G, Bousnina S, Postel-Vinay MC, et al. Laron dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med. 1989;321(15):989–95.
  101. Woods KA, Fraser NC, Postel-Vinay MC, Savage MO, Clark AJ. A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. J Clin Endocrinol Metab. 1996;81(5):1686–90.
  102. Woods KA, Dastot F, Preece MA, Clark AJ, Postel-Vinay MC, Chatelain PG, et al. Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab. 1997;82(11):3529–35.
  103. Salerno M, Balestrieri B, Matrecano E, Officioso A, Rosenfeld RG, Di Maio S, et al. Abnormal GH receptor signaling in children with idiopathic short stature. J Clin Endocrinol Metab. 2001;86(8):3882–8.
  104. Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med. 2003;349(23):2211–22.
  105. Bonioli E, Tarò M, Rosa C La, Citana A, Bertorelli R, Morcaldi G, et al. Heterozygous mutations of growth hormone receptor gene in children with idiopathic short stature. Growth Horm IGF Res. 2005;15(6):405–10.
  106. Rosenbloom AL, Guevara Aguirre J, Rosenfeld RG. The little women of Loja--growth hormone-receptor deficiency in an inbred population of southern Ecuador. N Engl J Med. 1990;323(20):1367–74.
  107. Aalbers AM, Chin D, Pratt KL, Little BM, Frank SJ, Hwa V, et al. Extreme elevation of serum growth hormone-binding protein concentrations resulting from a novel heterozygous splice site mutation of the growth hormone receptor gene. Horm Res Paediatr. 2009;71(5):276–84.
  108. Overgaard MT, Boldt HB, Laursen LS, Sottrup-Jensen L, Conover CA, Oxvig C. Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J Biol Chem. 2001;276(24):21849–53.
  109. Jepsen MR, Kløverpris S, Mikkelsen JH, Pedersen JH, Füchtbauer E-M, Laursen LS, et al. Stanniocalcin-2 inhibits mammalian growth by proteolytic inhibition of the insulin-like growth factor axis. J Biol Chem. 2015;290(6):3430–9.
  110. Fujimoto M, Hwa V, Dauber A. Novel modulators of the growth hormone - insulin-like growth factor axis: Pregnancy-associated plasma protein-A2 and stanniocalcin-2. J Clin Res Pediatr Endocrinol. 2017;9(Suppl 2):1–8.
  111. Woods KA, Camacho-Hübner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med. 1996;335(18):1363–7.
  112. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 1993;75(1):73–82.
  113. Bonapace G, Concolino D, Formicola S, Strisciuglio P. A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency. J Med Genet. 2003;40(12):913–7.
  114. Walenkamp MJE, Karperien M, Pereira AM, Hilhorst-Hofstee Y, van Doorn J, Chen JW, et al. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab. 2005;90(5):2855–64.
  115. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. 1993;75(1):59–72.
  116. Morison IM, Reeve AE. Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications. Mol Med Today. 1998;4(3):110–5.
  117. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A. 1999;96(13):7324–9.
  118. Sjögren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A. 1999;96(12):7088–92.
  119. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002;110(6):771–81.
  120. Domené HM, Bengolea S V, Martínez AS, Ropelato MG, Pennisi P, Scaglia P, et al. Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med. 2004;350(6):570–7.
  121. Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, Koller D, et al. Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab. 2006;91(5):1826–31.
  122. Domené HM, Scaglia PA, Lteif A, Mahmud FH, Kirmani S, Frystyk J, et al. Phenotypic effects of null and haploinsufficiency of acid-labile subunit in a family with two novel IGFALS gene mutations. J Clin Endocrinol Metab. 2007;92(11):4444–50.
  123. Domené HM, Hwa V, Jasper HG, Rosenfeld RG. Acid-labile subunit (ALS) deficiency. Best Pract Res Clin Endocrinol Metab. 2011;25(1):101–13.
  124. Savage MO, Camacho-Hübner C, David A, Metherell LA, Hwa V, Rosenfeld RG, et al. Idiopathic short stature: will genetics influence the choice between GH and IGF-I therapy? Eur J Endocrinol. 2007;157 Suppl:S33-37.
  125. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science. 1998;279(5350):563–6.
  126. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer. 2000;36(10):1224–8.
  127. Jernstrom H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, et al. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: Implications for premenopausal breast cancer risk. Mol Genet Metab. 2001;72(2):144–54.
  128. Cohen P, Clemmons DR, Rosenfeld RG. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res. 2000;10(6):297–305.
  129. Cohen P. Overview of the IGF-I system. Horm Res. 2006;65(Suppl 1):3–8.
  130. Ranke MB. Defining insulin-like growth factor-I deficiency. Horm Res. 2006;65(Suppl 1):9–14.
  131. Savage MO, Camacho-Hübner C, Dunger DB. Therapeutic applications of the insulin-like growth factors. Growth Horm IGF Res. 2004;14(4):301–8.
  132. Laron Z, Anin S, Klipper-Aurbach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet. 1992;339(8804):1258–61.
  133. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Blum WF, et al. Insulin-like growth factor I improves height in growth hormone insensitivity: two years’ results. Horm Res. 1995;44(6):253–64.
  134. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res. 1999;51(3):128–34.
  135. Collett-Solberg PF, Misra M, Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. The role of recombinant human insulin-like growth factor-I in treating children with short stature. J Clin Endocrinol Metab. 2008;93(1):10–8.
  136. Laron Z. Insulin-like growth factor-I (lGF-l): safety and efficacy. Pediatr Endocrinol Rev. 2004;2(Suppl 1):78–85.
  137. Backeljauw PF, Underwood LE, GHIS Collaborative Group. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: A clinical research center study. J Clin Endocrinol Metab. 2001;86(4):1504–10.
  138. Roback EW, Barakat AJ, Dev VG, Mbikay M, Chretien M, Butler MG. An infant with deletion of the distal long arm of chromosome 15 (q26.1----qter) and loss of insulin-like growth factor 1 receptor gene. Am J Med Genet. 1991;38(1):74–9.
  139. Fang P, Schwartz ID, Johnson BD, Derr MA, Roberts CT, Hwa V, et al. Familial short stature caused by haploinsufficiency of the insulin-like growth factor i receptor due to nonsense-mediated messenger ribonucleic acid decay. J Clin Endocrinol Metab. 2009;94(5):1740–7.
  140. Fujimoto M, Andrew M, Dauber A. Disorders caused by genetic defects associated with GH-dependent genes: PAPPA2 defects. Mol Cell Endocrinol. 2020 Dec;518:110967.
  141. Dauber A, Muñoz-Calvo MT, Barrios V, Domené HM, Kloverpris S, Serra-Juhé C, et al. Mutations in pregnancy-associated plasma protein A2 cause short stature due to low IGF-I availability. EMBO Mol Med. 2016 Apr;8(4):363–74.
  142. Babiker A, Al Noaim K, Al Swaid A, Alfadhel M, Deeb A, Martín-Rivada Á, et al. Short stature with low insulin-like growth factor 1 availability due to pregnancy-associated plasma protein A2 deficiency in a Saudi family. Clin Genet. 2021 Nov;100(5):601–6.
  143. Barrios V, Chowen JA, Martín-Rivada Á, Guerra-Cantera S, Pozo J, Yakar S, et al. Pregnancy-associated plasma protein (PAPP)-A2 in physiology and disease. Cells. 2021;10(12):3576.
  144. Muñoz-Calvo MT, Barrios V, Pozo J, Chowen JA, Martos-Moreno GÁ, Hawkins F, et al. Treatment With recombinant human insulin-like growth factor-1 improves growth inpatients with PAPP-A2 deficiency. J Clin Endocrinol Metab. 2016;101(11):3879–83.
  145. Martín-Rivada Á, Barrios V, Martínez Díaz-Guerra G, Pozo J, Martos-Moreno GÁ, Argente J. Adult height and long-term outcomes after rhIGF-1 therapy in two patients withPAPP-A2 deficiency. Growth Horm IGF Res. 2021;60–61:101419.
  146. Muthuvel G, Dauber A, Alexandrou E, Tyzinski L, Andrew M, Hwa V, et al. Five-year therapy with recombinant human insulin-like growth factor-1 in a patient with PAPP-A2 deficiency. Horm Res Paediatr. 2023;96(5):449–57.
  147. Cabrera-Salcedo C, Mizuno T, Tyzinski L, Andrew M, Vinks AA, Frystyk J, et al. Pharmacokinetics of IGF-1 in PAPP-A2-deficient patients, growth response, and effects on glucose and bone density. J Clin Endocrinol Metab. 2017;102(12):4568–77.
  148. Hawkins-Carranza FG, Muñoz-Calvo MT, Martos-Moreno GÁ, Allo-Miguel G, Del Río L, Pozo J, et al. rhIGF-1 treatment increases bone mineral density and trabecular bone structure in children with PAPP-A2 deficiency. Horm Res Paediatr. 2018;89(3):200–4.
  149. Andrew M, Liao L, Fujimoto M, Khoury J, Hwa V, Dauber A. PAPPA2 as a therapeutic modulator of IGF-I bioavailability: in vivo and in vitro evidence. J Endocr Soc. 2018;2(7):646–56.
  150. Fitzpatrick GV, Soloway PD, Higgins MJ. Regional loss of imprinting and growth deficiency in mice with a targeted deletion of KvDMR1. Nat Genet. 2002;32(3):426–31.
  151. Eggenschwiler J, Ludwig T, Fisher P, Leighton PA, Tilghman SM, Efstratiadis A. Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes. Genes Dev. 1997;11(23):3128–42.
  152. McElreavey K, Fellous M. Sex-determining genes. Trends Endocrinol Metab. 1997;8(9):342–5.
  153. Fisher AM, Thomas NS, Cockwell A, Stecko O, Kerr B, Temple IK, et al. Duplications of chromosome 11p15 of maternal origin result in a phenotype that includes growth retardation. Hum Genet. 2002;111(3):290–6.
  154. Gicquel C, Rossignol S, Cabrol S, Houang M, Steunou V, Barbu V, et al. Epimutation of the telomeric imprinting center region on chromosome 11p15 in Silver-Russell syndrome. Nat Genet. 2005;37(9):1003–7.
  155. Schönherr N, Meyer E, Eggermann K, Ranke MB, Wollmann HA, Eggermann T. (Epi)mutations in 11p15 significantly contribute to Silver-Russell syndrome: but are they generally involved in growth retardation? Eur J Med Genet. 2006;49(5):414–8.
  156. Hannula K, Lipsanen-Nyman M, Kontiokari T, Kere J. A narrow segment of maternal uniparental disomy of chromosome 7q31-qter in Silver-Russell syndrome delimits a candidate gene region. Am J Hum Genet. 2001;68(1):247–53.
  157. Murphy R, Baptista J, Holly J, Umpleby AM, Ellard S, Harries LW, et al. Severe intrauterine growth retardation and atypical diabetes associated with a translocation breakpoint disrupting regulation of the insulin-like growth factor 2 gene. J Clin Endocrinol Metab. 2008;93(11):4373–80.
  158. Valhmu WB, Palmer GD, Rivers PA, Ebara S, Cheng JF, Fischer S, et al. Structure of the human aggrecan gene: Exon-intron organization and association with the protein domains. Biochem J. 1995;309(2):535–42.
  159. Kiani C, Chen L, Wu YJ, Yee AJ, Yang BB. Structure and function of aggrecan. Cell Res. 2002;12:19.
  160. Kawaguchi Y, Osada R, Kanamori M, Ishihara H, Ohmori K, Matsui H, et al. Association between an aggrecan gene polymorphism and lumbar disc degeneration. Spine. 1999;24:2456–60.
  161. Gleghorn L, Ramesar R, Beighton P, Wallis G. A mutation in the variable repeat region of the aggrecan gene (AGC1) causes a form of spondyloepiphyseal dysplasia associated with severe, premature osteoarthritis. Am J Hum Genet. 2005;77:484–90.
  162. Tompson SW, Merriman B, Funari VA, Fresquet M, Lachman RS, Rimoin DL, et al. A recessive skeletal dysplasia, SEMD aggrecan type, results from a missense mutation affecting the C-type lectin domain of aggrecan. Am J Hum Genet. 2009;84:72–9.
  163. Stattin E-L, Wiklund F, Lindblom K, Önnerfjord P, Jonsson B-A, Tegner Y, et al. A missense mutation in the aggrecan c-type lectin domain disrupts extracellular matrix interactions and causes dominant familial osteochondritis dissecans. Am J Hum Genet. 2010;86(2):126–37.
  164. Nilsson O, Guo MH, Dunbar N, Popovic J, Flynn D, Jacobsen C, et al. Short stature, accelerated bone maturation, and early growth cessation due to heterozygous aggrecan mutations. J Clin Endocrinol Metab. 2014;99(8):E1510–8.
  165. Quintos JB, Guo. MH, Dauber A. Idiopathic short stature due to novel heterozygous mutation of the aggrecan gene. J Pediatr Endocrinol Metab. 2015;28(7-8):927–32.
  166. Gkourogianni A, Andrew M, Tyzinski L, Crocker M, Douglas J, Dunbar N, et al. Clinical characterization of patients with autosomal dominant short stature due to aggrecan mutations. J Clin Endocrinol Metab. 2017;102(2):460–9.
  167. van der Steen M, Pfundt R, Maas SJWH, Bakker-van Waarde WM, Odink RJ, Hokken-Koelega ACS. ACAN gene mutations in short children born SGA and response to growth hormone treatment. J Clin Endo Metab. 2017;102:1458–67.
  168. Dateki S, Nakatomi A, Watanabe S, Shimizu H, Inoue Y, Baba H, et al. Identification of a novel heterozygous mutation of the aggrecan gene in a family with idiopathic short stature and multiple intervertebral disc herniation. J Hum Genet. 2017;62:717–21.
  169. Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, et al. Pseudoautosomal deletions encompassing a novel homeobox gene causes growth failure in idiopathic short stature and Turner syndrome. Nat Genet. 1997;16:54–62.
  170. Huber C, Rosilio M, Munnich A, Cormier-Daire V. High incidence of SHOX anomalies in individuals with short stature. J Med Genet. 2006;43(9):735–9.
  171. Jorge AAL, Nishi MY, Funari MFA, Souza SC, Arnhold IJP, Mendonça BB. [Short stature caused by SHOX gene haploinsufficiency: from diagnosis to treatment]. Arq Bras Endocrinol Metabol. 2008;52(5):765–73.
  172. Binder G. Short stature due to SHOX deficiency: genotype, phenotype, and therapy. Horm Res Paediatr. 2011;75(2):81–9.
  173. Marchini A, Rappold G, Schneider KU. SHOX at a glance: From gene to protein. Arch Physiol Biochem. 2007;113(3):116–23.
  174. Munns CJF, Haase HR, Crowther LM, Hayes MT, Blaschke R, Rappold G, et al. Expression of SHOX in human fetal and childhood growth plate. J Clin Endocrinol Metab. 2004;89(8):4130–5.
  175. Rappold G, Blum WF, Shavrikova EP, Crowe BJ, Roeth R, Quigley CA, et al. Genotypes and phenotypes in children with short stature: Clinical indicators of SHOX haploinsufficiency. J Med Genet. 2007;44(5):306–13.
  176. Blum WF, Crowe BJ, Quigley CA, Jung H, Cao D, Ross JL, et al. Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial. J Clin Endocrinol Metab. 2007;92(1):219–28.
  177. Shaw AC, Kalidas K, Crosby AH, Jeffery S, Patton MA. The natural history of Noonan syndrome: A long-term follow-up study. Arch Dis Child. 2007;92(2):128–32.
  178. Allanson JE. Noonan syndrome. J Med Genet. 1987;24(1):9–13.
  179. Allanson JE, Hall JG, Hughes HE, Preus M, Witt RD. Noonan syndrome: The changing phenotype. Am J Med Genet. 1985;21(3):507–14.
  180. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29(4):465–8.
  181. Gelb BD, Tartaglia M. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Mol Genet. 2006;15 Spec No:R220-226.
  182. Ferreira LV, Souza SAL, Arnhold IJP, Mendonca BB, Jorge AAL. PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome. J Clin Endocrinol Metab. 2005;90(9):5156–60.
  183. Limal J-M, Parfait B, Cabrol S, Bonnet D, Leheup B, Lyonnet S, et al. Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab. 2006;91(1):300–6.
  184. Raaijmakers R, Noordam C, Karagiannis G, Gregory JW, Hertel NT, Sipilä I, et al. Response to growth hormone treatment and final height in Noonan syndrome in a large cohort of patients in the KIGS database. J Pediatr Endocrinol Metab. 2008;21(3):267–73.
  185. Noordam C, Peer PGM, Francois I, De Schepper J, van den Burgt I, Otten BJ. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11. Eur J Endocrinol. 2008;159(3):203–8.
  186. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000;85(11):3990–3.
  187. Kuczmarski RJ, Ogden C, Grummer-Strawn LM, Guo SS, Wei R, Mei Z, et al. CDC growth charts: United States. Hyattsville: U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics; 2000.
  188. Sizonenko PC, Clayton PE, Cohen P, Hintz RL, Tanaka T, Laron Z. Diagnosis and management of growth hormone deficiency in childhood and adolescence. Part 1: Diagnosis of growth hormone deficiency. Growth Horm IGF Res. 2001;11(3):137–65.
  189. Gruelich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. Stanford University Press; 1959.
  190. Tanner JM. Assessment of skeletal maturity and prediction of adult height (TW2 method). Tanner JM, editor. London ; New York: Academic Press ; 1983.
  191. Bayley N. Tables for predicting adult height from present height and skeletal age. J Pediat. 1946;28:49.
  192. Rosenfield R, Cutler L, Jameson JL, DeGroot L, Burger H. Somatic growth and maturation. In: Endocrinology. Philadelphia: W.B. Saunders Co.; 2001. p. 477-502.
  193. Underwood LE, Van Wyk JJ. Normal and aberrant growth. In: Williams Textbook Of Endocrinology. Philadelphia: W.B. Saunders Co.; 2003. p. 1079–138.
  194. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: Revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952;40(4):423–41.
  195. Roche AF, Wainer H, Thissen D. The RWT method for the prediction of adult stature. Pediatrics. 1975;56(6):1026–33.
  196. Zachmann M, Sobradillo B, Frank M, Frisch H, Prader A. Bayley-Pinneau, Roche-Wainer-Thissen, and Tanner height predictions in normal children and in patients with various pathologic conditions. J Pediatr. 1978;93(5):749–55.
  197. Marin G, Domené HM, Barnes KM, Blackwell BJ, Cassorla FG, Cutler GB. The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J Clin Endocrinol Metab. 1994;79(2):537–41.
  198. Molina S, Paoli M, Camacho N, Arata-Bellabarba G, Lanes R. Is testosterone and estrogen priming prior to clonidine useful in the evaluation of the growth hormone status of short peripubertal children? J Pediatr Endocrinol Metab. 2008;21(3):257–66.
  199. Agrawal V, Garcia JM. The macimorelin-stimulated growth hormone test for adult growth hormone deficiency diagnosis. Expert Rev Mol Diagn. 2014;14(6):647–54.
  200. Csákváry V, Muzsnai A, Raduk D, Chaychenko T, Damholt BB, Kelepouris N, et al. Pharmacokinetics and pharmacodynamics of macimorelin acetate (AEZS-130) in paediatric patients with suspected growth hormone deficiency (GHD). J Endocr Soc. 2021;5(Suppl 1):A682–A682.
  201. Roh S-G, Lee H-G, Phung LT, Hidari H. Characterization of growth hormone secretion to growth hormone-releasing peptide-2 in domestic animals - a review. Asian-Australasian J Anim Sci. 2002;15(5):757–66.
  202. Onuki T, Hiroaki T, Sawano K, Shibata N, Nyuzuki H, Ogawa Y, et al. Robust growth hormone responses to GH-releasing peptide 2 in adolescents. J Pediatr Endocrinol Metab. 2024;37(8):730–3.
  203. Chihara K, Shimatsu A, Hizuka N, Tanaka T, Seino Y, Katofor Y. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. 2007;157(1):19–27.
  204. Suzuki S, Ruike Y, Ishiwata K, Naito K, Igarashi K, Ishida A, et al. LBODP006 clinical usefulness of the growth hormone-releasing peptide-2 test for hypothalamic-pituitary disorder. J Endocr Soc. 2022;6(Suppl 1):A39–40.
  205. Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard A-M, Rosenfeld RG, et al. Insulin growth factor-based dosing of growth hormone therapy in children: A randomized, controlled study. J Clin Endocrinol Metab. 2007;92(7):2480–6.
  206. Baron J. Growth hormone therapy in childhood: Titration versus weight-based dosing? J Clin Endocrinol Metab. 2007;92(7):2436–8.
  207. Pasquino AM, Pucarelli I, Roggini M, Segni M. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone. J Clin Endocrinol Metab. 2000;85(2):619–22.
  208. Reiter EO. A brief review of the addition of gonadotropin-releasing hormone agonists(GnRH-Ag) to growth hormone (GH) treatment of children with idiopathic growth hormone deficiency: Previously published studies from America. Mol Cell Endocrinol. 2006;254–255:221–5.
  209. Li S, Wang X, Zhao Y, Ji W, Mao J, Nie M, et al. Combined therapy with GnRH analogue and growth hormone increases adult height inchildren with short stature and normal pubertal onset. Endocrine. 2020;69(3):615–24.
  210. Faglia G, Arosio M, Porretti S. Delayed closure of epiphyseal cartilages induced by the aromatase inhibitor anastrozole. Would it help short children grow up? J Endocrinol Invest. 2000;23(11):721–3.
  211. Dunkel L, Wickman S. Novel treatment of delayed male puberty with aromatase inhibitors. Horm Res. 2002;57(Suppl 2):44–52.
  212. Zung A, Zadik Z. New approaches in the treatment of short stature. Harefuah. 2002;141(12):1059–65.
  213. Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: A randomized controlled trial. J Clin Endocrinol Metab. 2005;90(12):6396–402.
  214. Wassenaar MJ, Dekkers OM, Pereira AM, Wit JM, Smit JW, Biermasz NR, et al. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2009;94(10):3721–30.
  215. Tauber M, Ester W, Auriol F, Molinas C, Fauvel J, Caliebe J, et al. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism. Clin Endocrinol. 2007;67(3):457–61.
  216. Braz AF, Costalonga EF, Montenegro LR, Trarbach EB, Antonini SR, Malaquias AC, et al. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome. J Clin Endocrinol Metab. 2012;97(4):E671-7.
  217. Blum WF, Machinis K, Shavrikova EP, Keller A, Stobbe H, Pfaeffle RW, et al. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor. J Clin Endocrinol Metab. 2006;91(10):4171–4.
  218. Carrascosa A, Esteban C, Espadero R, Fernández-Cancio M, Andaluz P, Clemente M, et al. The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: Results from a two-year controlled prospective. J Clin Endocrinol Metab. 2006;91(9):3281–6.
  219. Galetaki DM, Merchant N, Dauber A. Novel therapies for growth disorders. Eur J Pediatr. 2024;183(3):1121–8.
  220. Choi HS, Kwon A, Suh J, Song K, Chae HW, Kim H-S. Effect of long-acting growth hormone treatment on endogenous growth hormone secretion in prepubertal patients with idiopathic short stature: A preliminary study. Growth Horm IGF Res. 2022;66:101486.
  221. Matustik MC, Furlanetto RW, Meyer WJ 3rd. Chronobiologic considerations in human growth hormone therapy. J Pediatr. 1983;103(4):543–6.
  222. Lal RA, Hoffman AR. Perspectives on long-acting growth hormone therapy in children and adults. Arch Endocrinol Metab. 2019;63(6):601–7.
  223. Grillo MS, Frank J, Saenger P. Long acting growth hormone (LAGH), an update. Front Pediatr. 2023;11:1254231.
  224. Höybye C, Pfeiffer AFH, Ferone D, Christiansen JS, Gilfoyle D, Christoffersen ED, et al. A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency. Endocr Connect. 2017;6(3):129–38.
  225. Thornton P, Hofman P, Maniatis A, Aghajanova E, Chertok E, Korpal-Szczyrska M, et al. OR17-4 Transcon growth hormone in the treatment of pediatric growth hormone deficiency: Results of the phase 3 height trial. J Endocr Soc. 2019;3(Suppl 1).
  226. Lamb YN. Lonapegsomatropin: Pediatric first approval. Paediatr Drugs. 2022 Jan;24(1):83–90.
  227. Miller BS, Yuen KCJ. Spotlight on lonapegsomatropin once-weekly injection and its potential in the treatment of growth hormone deficiency in pediatric patients. Drug Des Devel Ther. 2022;16:2055–66.
  228. Chatelain P, Malievskiy O, Radziuk K, Senatorova G, Abdou MO, Vlachopapadopoulou E, et al. A randomized phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency. J Clin Endocrinol Metab. 2017;102(5):1673–82.
  229. Campbell DL, Walsh KJ, Herz C, Karpf DB, Beckert M, Leff JA, et al. 016–TransCon GH as a long-acting growth hormone for the treatment of pediatric growth hormone deficiency. J Pediatr Nurs. 2019;46:133.
  230. Thornton PS, Maniatis AK, Aghajanova E, Chertok E, Vlachopapadopoulou E, Lin Z, et al. Weekly lonapegsomatropin in treatment-naïve children with growth hormonedeficiency: The Phase 3 heiGHt Trial. J Clin Endocrinol Metab. 2021;106(11):3184–95.
  231. Stochholm K, Kiess W. Long-term safety of growth hormone-A combined registry analysis. Clin Endocrinol (Oxf). 2018;88(4):515–28.
  232. Alkhatib EH, Dauber A, Estrada DE, Majidi S. Weekly growth hormone (lonapegsomatropin) causes severe transient hyperglycemia in a child with obesity. Vol. 96, Hormone Research in Paediatrics. Switzerland; 2023. p. 542–6.
  233. Maniatis AK, Carakushansky M, Galcheva S, Prakasam G, Fox LA, Dankovcikova A, et al. Treatment burden of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: A randomized study. J Endocr Soc. 2022;6(10):bvac117.
  234. Maniatis AK, Casella SJ, Nadgir UM, Hofman PL, Saenger P, Chertock ED, et al. Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enliGHten Trial 2-year results. J Clin Endocrinol Metab. 2022;107(7):e2680-e2689.
  235. Miller BS, Blair J, Horikawa R, Linglart A, Yuen KCJ. Developments in the management of growth hormone deficiency: Clinical utility of somapacitan. Drug Des Devel Ther. 2024;18:291–306.
  236. Helleberg H, Bjelke M, Damholt BB, Pedersen PJ, Rasmussen MH. Absorption, metabolism and excretion of once-weekly somapacitan, a long-acting growth hormone derivative, after single subcutaneous dosing in human subjects. Eur J Pharm Sci. 2021;167:106030.
  237. Ramírez-Andersen HS, Behrens C, Buchardt J, Fels JJ, Folkesson CG, Jianhe C, et al. Long-acting human growth hormone analogue by noncovalent albumin binding. Bioconjug Chem. 2018;29(9):3129–43.
  238. Savendahl LS, Rasmussen MH. SAT-LB12 Once-weekly somapacitan vs daily growth hormone in growth hormone deficiency: 2-year safety results from REAL 3, a randomized phase 2 trial. J Endocr Soc. 2020 8;4(Suppl 1).
  239. Savendahl L, Højby Rasmussen M, Horikawa R, Khadilkar V, Battelino T, Saenger P. SUN-247 Once-weekly somapacitan in childhood growth hormone deficiency: Efficacy and safety results of a randomized, open-label, controlled phase 2 trial (REAL 3). J Endocr Soc. 2019;3(Suppl 1).
  240. Sävendahl LS, Battelino T, Rasmussen MH, Horikawa R, Saenger P. Once-weekly somapacitan versus daily growth hormone in growth hormone deficiency: 2-year efficacy results from REAL 3, a Randomized Phase 2 Trial. J Endocr Soc. 2021;5(Suppl 1):A680–A680.
  241. Sävendahl L, Battelino T, Højby Rasmussen M, Brod M, Röhrich S, Saenger P, et al. Weekly somapacitan in GH deficiency: 4-year efficacy, safety, andtreatment/disease burden results from REAL 3. J Clin Endocrinol Metab. 2023;108(10):2569–78.
  242. Yuen KCJ. Utilizing somapacitan, a long-acting growth hormone formulation, for thetreatment of adult growth hormone deficiency: A guide for clinicians. Endocr Pract. 2024;30(10):1003–10.
  243. Takahashi Y, Biller BMK, Fukuoka H, Ho KKY, Rasmussen MH, Nedjatian N, et al. Weekly somapacitan had no adverse effects on glucose metabolism in adults withgrowth hormone deficiency. Pituitary. 2023;26(1):57–72.
  244. Fujio S, Makino R, Sugata J, Hanada T, Hanaya R. 6731 Initial therapeutic effects of weekly growth hormone replacement therapy: Somapacitan. J Endocr Soc. 2024;8(Suppl 1).
  245. Hershkovitz O, Bar-Ilan A, Guy R, Felikman Y, Moschcovich L, Hwa V, et al. In vitro and in vivo characterization of MOD-4023, a long-acting carboxy-terminal peptide (CTP)-modified human growth hormone. Mol Pharm. 2016;13(2):631–9.
  246. Velazquez EP, Miller BS, Yuen KCJ. Somatrogon injection for the treatment of pediatric growth hormone deficiency with comparison to other LAGH products. Expert Rev Endocrinol Metab. 2024;19(1):1–10.
  247. Valluri S, Pastrak A, Wajnrajch M, Silverman L, Cara J, Deal C. Somatrogon growth hormone in the treatment of pediatric growth hormone deficiency: Results of the Pivotal Pediatric Phase 3 Clinical Trial. 2022;
  248. Cara J, Carlsson M, Rosenfeld RG, Wajnrajch MP, Wang R, Zadik Z. RF26 | PSAT150 Growth outcomes from the Phase 2 and Phase 3 studies of once weekly somatrogon vs daily genotropin in pediatric patients with growth hormone deficiency: Comparisons with published literature and an international growth study database. J Endocr Soc. 2022;6(Suppl 1):A647–A647.
  249. Zadik Z, Zelinska N, Iotova V, Skorodok Y, Malievsky O, Mauras N, et al. An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: Results following 5 years of treatment. J Pediatr Endocrinol Metab. 2023;36(3):261–9.
  250. Boguszewski MC da S, Boguszewski CL. Update on the use of long-acting growth hormone in children. Curr Opin Pediatr. 2024;36(4):437–41.
  251. Höybye C. Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: Challenging issues, benefits, and risks. Best Pract Res Clin Endocrinol Metab. 2023;37(6):101788.
  252. Maniatis A, Cutfield W, Dattani M, Deal C, Collett-Solberg PF, Horikawa R, et al. Long-acting growth hormone therapy in pediatric growth hormone deficiency: A consensus statement. J Clin Endocrinol Metab. 2024;1-9.
  253. Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study Experience. J Clin Endocrinol Metab. 1996;81(5):1704–10.
  254. Tuffli GA, Johanson A, Rundle AC, Allen DB. Lack of increased risk for extracranial, nonleukemic neoplasms in recipients of recombinant deoxyribonucleic acid growth hormone. J Clin Endocrinol Metab. 1995;80(4):1416–22.
  255. Cowell CT, Dietsch S. Adverse events during growth hormone therapy. J Pediatr Endocrinol Metab. 1995;8:243–52.
  256. Clayton PE, Cowell CT. Safety issues in children and adolescents during growth hormone therapy-a review. Growth Horm & IGF Res. 2000;10:306–10.
  257. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95(1):167–77.
  258. Craig ME, Cowell CT, Larsson P, Zipf WB, Reiter EO, Albertsson Wikland K, et al. Growth hormone treatment and adverse events in Prader-Willi syndrome: Data from KIGS (the Pfizer International Growth Database). Clin Endocrinol (Oxf). 2006;65(2):178–85.
  259. Tauber M, Diene G, Molinas C, Hébert M. Review of 64 cases of death in children with Prader-Willi syndrome (PWS). Am J Med Genet A. 2008;146A(7):881–7.
  260. Eiholzer U. Deaths in children with Prader-Willi syndrome. A contribution to the debate aboutthe safety of growth hormone treatment in children with PWS. Horm Res. 2005;63(1):33–9.
  261. Gerard JM, Garibaldi L, Myers SE, Aceto TJ, Kotagal S, Gibbons VP, et al. Sleep apnea in patients receiving growth hormone. Clin Pediatr. 1997;36(6):321–6.
  262. Lindgren AC, Hellström LG, Ritzén EM, Milerad J. Growth hormone treatment increases CO(2) response, ventilation and centralinspiratory drive in children with Prader-Willi syndrome. Eur J Pediatr. 1999;158(11):936–40.
  263. Miller J, Silverstein J, Shuster J, Driscoll DJ, Wagner M. Short-term effects of growth hormone on sleep abnormalities in Prader-Willi syndrome. J Clin Endocrinol Metab. 2006;91(2):413–7.
  264. Bolar K, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in Turner syndrome. J Clin Endocrinol Metab. 2008;93(2):344–51.
  265. Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA, UK Clinical Cytogenetics Group. Cancer incidence in women with Turner syndrome in Great Britain: A national cohort study. Lancet Oncol. 2008;9(3):239–46.
  266. Carel J-C, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: Preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012;97(2):416–25.
  267. Sävendahl L, Maes M, Albertsson-Wikland K, Borgström B, Carel JC, Henrard S, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: Preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endo Metab. 2012;97(2):213–7.
  268. Maneatis T, Baptista J, Connelly K, Blethen S. Growth hormone safety update from the National Cooperative Growth Study. J Pediatr Endocrinol Metab. 2000;13(Suppl 2):1035–44.
  269. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006;91(9):3494–8.
  270. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: A report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002;87(7):3136–41.
  271. Patterson BC, Chen Y, Sklar CA, Neglia J, Yasui Y, Mertens A, et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: A report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2014;99(6):2030–7.
  272. Sklar CA, Antal Z, Chemaitilly W, Cohen LE, Follin C, Meacham LR, et al. Hypothalamic–pituitary and growth disorders in survivors of childhood cancer: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(8):2761-84.
  273. Child CJ, Zimmermann AG, Jia N, Robison LL, Brämswig JH, Blum WF. Assessment of primary cancer incidence in growth hormone-treated children: Comparison of a multinational prospective observational study with population databases. Horm Res Paediatr. 2016;85(3):198–206.
  274. Raman S, Grimberg A, Waguespack SG, Miller BS, Sklar CA, Meacham LR, et al. Risk of neoplasia in pediatric patients receiving growth hormone therapy--a report from the Pediatric Endocrine Society Drug and Therapeutics Committee. J Clin Endocrinol Metab. 2015;100(6):2192–203.
  275. Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol. 2005;152(2):165–70.
  276. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(6):1587–609.
  277. Tauber M, Moulin P, Pienkowski C, Jouret B, Rochiccioli P. Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment. J Clin Endocrinol Metab. 1997;82(2):352–6.
  278. Colao A, Di Somma C, Savastano S, Rota F, Savanelli MC, Aimaretti G, et al. A reappraisal of diagnosing GH deficiency in adults: Role of gender, age, waist circumference, and body mass index. J Clin Endocrinol Metab. 2009;94(11):4414–22.
  279. Cook DM, Rose SR. A review of guidelines for use of growth hormone in pediatric and transition patients. Pituitary. 2012;15(3):301–10.
  280. Quigley CA, Zagar AJ, Liu CC, Brown DM, Huseman C, Levitsky L, et al. United States multicenter study of factors predicting the persistence of GH deficiency during the transition period between childhood and adulthood. Int J Pediatr Endocrinol. 2013;2013(1):6.
  281. Stanley T. Diagnosis of growth hormone deficiency in childhood. Curr Opin Endocrinol Diabetes Obes. 2012;19(1):47–52.
  282. Hage C, Gan H-W, Ibba A, Patti G, Dattani M, Loche S, et al. Advances in differential diagnosis and management of growth hormone deficiency in children. Nat Rev Endocrinol. 2021;17(10):608–24.
  283. Ranke MB, Lindberg A, Albertsson-Wikland K, Wilton P, Price DA, Reiter EO. Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH deficiency: Analysis of data from KIGS. J Clin Endocrinol Metab. 2005;90(4):1966–71.
  284. Stagi S, Scalini P, Farello G, Verrotti A. Possible effects of an early diagnosis and treatment in patients with growth hormone deficiency: The state of art. Ital J Pediatr. 2017;43(1):81.
  285. Boguszewski MCS. Growth hormone deficiency and replacement in children. Rev Endocr Metab Disord. 2021;22(1):101–8.
  286. Ross J, Fridman M, Kelepouris N, Murray K, Krone N, Polak M, et al. Factors associated with response to growth hormone in pediatric growth disorders: Results of a 5-year Registry Analysis. J Endocr Soc. 2023;7(5):bvad026.
  287. Yuen KCJ, Alter CA, Miller BS, Gannon AW, Tritos NA, Samson SL, et al. Adult growth hormone deficiency: Optimizing transition of care from pediatric to adult services. Growth Horm IGF Res. 2021;56:101375.
  288. Saenger PH, Mejia-Corletto J. Long-acting growth hormone: An update. Endocr Dev. 2016;30:79–97.
  289. Pampanini V, Deodati A, Inzaghi E, Cianfarani S. Long-acting growth hormone preparations and their use in children with growth hormone deficiency. Horm Res Paediatr. 2023;96(6):553–9.

 

Etiologic Classification of Diabetes Mellitus

Table 1 lists the various disorders that can either cause or contribute to the development of diabetes and the Endotext chapters where these disorders are discussed in detail. It should be noted that a patient can have characteristics of more than one type of diabetes. For example, a patient with Type 1 diabetes with positive antibodies can also be obese with the metabolic syndrome and have characteristics typical of Type 2 diabetes.

 

Table 1. Etiologic Classification Of Diabetes Mellitus

Disorders

 

Type 1 Diabetes

Pathogenesis of Type 1 Diabetes

Type 2 Diabetes

Pathogenesis of Type 2 Diabetes

Gestational Diabetes

Gestational Diabetes

Genetic defects of beta-cell development and function

MODY

Diagnosis and Clinical Management of Monogenic Diabetes

Neonatal Diabetes

Diagnosis and Clinical Management of Monogenic Diabetes

Mitochondrial DNA

Atypical Forms of Diabetes

Genetic defects in insulin action

Type A insulin resistance

Atypical Forms of Diabetes

Leprechaunism

Atypical Forms of Diabetes

Rabson-Mendenhall syndrome

Atypical Forms of Diabetes

Lipoatrophic diabetes

Lipodystrophy Syndromes: Presentation and Treatment*

Diseases of the exocrine pancreas

Pancreatitis

Atypical Forms of Diabetes

Trauma/pancreatectomy

Atypical Forms of Diabetes

Neoplasia

Atypical Forms of Diabetes

Cystic fibrosis

Atypical Forms of Diabetes

Iron overload (hemochromatosis, thalassemia, etc.)

Atypical Forms of Diabetes

Fibrocalculous pancreatic diabetes

Fibrocalculous Pancreatic Diabetes**

Endocrinopathies

Acromegaly

Cushing’s syndrome

Glucagonoma

Pheochromocytoma

Hyperthyroidism

Somatostatinoma

Primary Hyperaldosteronism

Atypical Forms of Diabetes

Diabetes Mellitus After Solid Organ Transplantation

Diabetes Mellitus After Solid Organ Transplantation

Drug- or chemical-induced hyperglycemia

Vacor

Pentamidine

Nicotinic acid

Glucocorticoids

Growth Hormone

Diazoxide

Check point inhibitors

Dilantin

Interferon alpha

Immune suppressants

Others (statins, psychotropic drugs, α-adrenergic agonists, β-Adrenergic agonists, thiazides, etc.)

Atypical Forms of Diabetes

Infections

Congenital rubella

Atypical Forms of Diabetes

HCV

Atypical Forms of Diabetes

COVID-19

Atypical Forms of Diabetes

HIV

Diabetes in People Living with HIV

Immune-mediated diabetes

Latent Autoimmune Diabetes in Adults (LADA)

Atypical Forms of Diabetes

Stiff-man syndrome

Atypical Forms of Diabetes

Anti-insulin receptor antibodies

Atypical Forms of Diabetes

Autoimmune Polyglandular Syndromes

Autoimmune Polyglandular Syndromes***

Diabetes of unknown cause

Ketosis-prone diabetes (Flatbush diabetes)

Atypical Forms of Diabetes

Other genetic syndromes sometimes associated with diabetes

Down syndrome

Klinefelter syndrome

Turner syndrome

Wolfram syndrome

Friedreich ataxia

Huntington chorea

Bardet-Biedl syndrome (Laurence-Moon-Biedl) syndrome)

Myotonic dystrophy

Porphyria

Prader-Willi syndrome

Alström syndrome

Others

Atypical Forms of Diabetes

Unless indicated chapters are located in the Diabetes section.

*Chapter in Diagnosis and Treatment of Diseases of Lipid and Lipoprotein Metabolism and Obesity section

**Chapter in Tropical Medicine section

***Chapter in Disorders that Affect Multiple Organs section

 

Pregestational Diabetes Mellitus

ABSTRACT

 

The physiological changes which occur during pregnancy with diabetes are vast and involve every body system. In this chapter, we will review the metabolic changes that occur during normal pregnancies and those affected by pregestational diabetes. Due to the significant overlap in maternal and perinatal risks secondary to pregestational diabetes and obesity, we will review the risks of maternal obesity and hyperglycemia on maternal, fetal, and infant outcomes. The management of pregestational diabetes in pregnancy will be reviewed in detail including up-to-date medications and diabetes technologies. Postpartum issues including changes in insulin sensitivity, breastfeeding, and contraception for individuals with pregestational diabetes will be discussed. 

 

ROLE OF PRECONCEPTION AND INTERPREGNANCY COUNSELING/CARE

 

In recent years, increasing focus has been placed on improving preconception and inter-pregnancy care for reproductive-age individuals (1,2).  Obstetric and perinatal outcomes are improved when an individual with pregestational diabetes enters pregnancy in a medically-optimized state (3–6). Since roughly 50% of pregnancies are unplanned, it is in the individual’s best interest if their team begins discussing contraception and family planning during adolescence and early adulthood, as recommended by the American Diabetes Association (ADA) (7).  Among those with pregestational diabetes, emphasis on strict glycemic control, folic acid supplementation, nutrition and physical activity, encouraging weight loss in overweight/obese individuals, discontinuation of potentially harmful medications (such as statins, angiotensin converting enzyme [ACE] inhibitors), and optimization of associated medical conditions, are all important components of preconception care. Those with pregestational diabetes mellitus (DM) who are planning pregnancy should ideally be engaged in multidisciplinary care in the preconception timeframe with a team that includes an endocrinology health care professional, maternal fetal medicine specialist, registered dietician, and diabetes care and education specialist (7). Counseling should include a review of diabetes-related short- and long-term risks to the pregnant individual and fetus and the relationship of such risk to glycemic control in the peripartum period.

 

Hyperglycemia in the months leading up to conception and through the first trimester confers a significant “dose-dependent” risk of congenital anomalies, including fetal cardiac and skeletal defects, as well as miscarriage (8–10). A glycosylated hemoglobin (A1c) value ≤6.0% around the time of conception is associated with a risk for congenital anomalies of 1-3%, similar to the baseline population risk (9). Hence, the ADA recommends achieving an A1c <6.5% prior to conception, while the American College of Obstetricians and Gynecologists (ACOG) recommends an even stricter target of an A1c <6.0% (7,11). Furthermore, if diabetes is poorly controlled or sequelae such as renal and cardiac disease are present at the time of conception, obstetric risks of hypertensive disorders of pregnancy (HDP), preterm delivery, and stillbirth are also increased (12,13).

 

We encourage health care providers to view every encounter with an individual of reproductive age as a pre-conception visit, in particular because nearly half of pregnancies in the US are not planned (Figure 1).  Socio-economic barriers including poor health literacy, smoking, being unmarried, lower family income, and poor relationship with their provider are associated with an absence of pre-pregnancy care, so increased efforts must be made to provide avenues to discuss family planning among these individuals (14). Some suggested solutions include app-based platforms to engage individuals and provide education on diet and lifestyle as well as pharmacy-based surveys to identify individuals who require folic acid supplements or other medication adjustments (15,16).

 

Figure 1. Adapted from Wilkie, G. & Leftwich, H. (2020). Optimizing Care Preconception for Individuals With Diabetes and Obesity. Clinical Obstetrics and Gynecology.

 

NORMAL GLUCOSE LEVELS IN PREGNANCY

 

Understanding normative glucose levels in pregnancy is important for setting glycemic targets in pregnant individuals with pregestational diabetes. The first change that happens is a fall in fasting glucose levels, which occurs early in the first trimester. In the second and third trimesters, glucose levels rise slightly due to insulin resistance. A review of the literature including all available trials using continuous glucose monitors (CGM), plasma glucose samples, and self-monitored blood glucose (SMBG) demonstrated that pregnant individuals without diabetes and obesity during the third trimester (~34 weeks) have on average a fasting blood glucose (FBG) of 71 mg/dl; a 1 hour postprandial (PP) glucose of 109 mg/dl; and a 2 hour value of 99 mg/dl, which are all much lower than the current targets for glycemic control for pregnant individuals with diabetes (17) (Figure 2). Increasing gestational age affects "normal" glucose levels. A longitudinal study of 32 healthy, normal weight pregnant individuals between 16 weeks’ gestation to 6 weeks postpartum demonstrated a rise in mean glucose levels using CGM from 16 weeks (82.3 mg/dl) to 36 weeks (94.0 mg/dl) which was maintained at 6 weeks postpartum (93.7 mg/dl) (18). Two-hour postprandial levels were increased rising from 95.7 mg/dl at 16 weeks to a peak of 110.6 mg/dl at 36 weeks. Although fasting blood glucose levels are lower in pregnancy, postprandial glucose levels are slightly elevated, which is likely related to the many impaired insulin action, altered β cell secretion, hepatic gluconeogenesis, and placentally-derived circulating hormones (19). Among those without pregestational or gestational diabetes, many CGM parameters are higher in individuals with obesity compared to those with a normal BMI (20).

 

Figure 2. Glucose Levels During Pregnancy not affected by diabetes. A. Patterns of glycemia in normal pregnancy (gestational week 33.8 ± 2.3) across 11 studies published between 1975 and 2008. B. Mean pattern of glycemia across 12 studies.

 

REDUCING THE RISK OF CONGENITAL ANOMALIES

 

Hyperglycemia is a teratogen and can result in complex cardiac defects, central nervous system (CNS) anomalies such as anencephaly and spina bifida, skeletal malformations, and genitourinary abnormalities (21–23). A systematic review of 13 observational studies of pregnant individuals with pregestational diabetes demonstrated that poor glycemic control resulted in a pooled odds ratio of 3.44 (95%CI 2.3-5.15) of a congenital anomaly, 3.23 (CI 1.64- 6.36) of spontaneous loss and 3.03 (1.87-4.92) of perinatal mortality compared to individuals with optimal glycemic control (24). Individuals with a normal A1c at conception and during the first trimester have no increased risk while individuals with an A1c of 10-12% or a fasting blood glucose >260 mg/dl have up to a 25% risk of major congenital malformations (25,26). A recent analysis of 1,676 deliveries to individuals with pregestational diabetes between 2009-2018 found a similar significant rate of congenital anomalies especially with increasing A1c at the first prenatal visit: individuals with an A1c of 10% had a major congenital anomaly rate of 10% while individuals with an A1c of 13% had a 20% major anomaly rate. The overall anomaly rate was 8% in this contemporary cohort of whom 91% had type 2 diabetes (T2DM) (27). The offspring of individuals with type 1 diabetes T1DM have higher prevalence of neonatal death as well as infant death compared with offspring of individuals without diabetes. Periconception A1c >6.5%, preconception retinopathy, and lack of preconception folic acid supplementation were all independently associated with risk of neonatal and infant death (28). A recent systematic review and meta-analysis also showed an increased risk of neonatal mortality and stillbirth in pregnancies affected by T2DM compared with those without diabetes (29). Most organizations recommend pregnant individuals with pregestational diabetes achieve an A1c of less than 6.5% prior to conception (30,31). For individuals with hypoglycemia unawareness, less stringent glycemic targets may need to be used such as an A1c <7.0%. The A1C falls in pregnancy and if it is possible without significant hypoglycemia, an A1c of less than 6% is recommended.

 

The mechanism of glucose-induced congenital anomalies has not been fully elucidated (32). It has been shown that diabetes-induced fetal abnormalities may be mediated by a number of metabolic disturbances, including elevated superoxide dismutase activity, reduced levels of myoinositol and arachidonic acid, and inhibition of the pentose phosphate shunt pathway. Oxidative stress appears to be involved in the etiology of fetal dysmorphogenesis and neural tube defects in the embryos of diabetic mice and are also associated with altered expression of genes which control development of the neural tube (33).

 

Individuals with T2DM are more likely to be treated for dyslipidemia and hypertension. Chronic hypertension occurs in 13-19% of individuals with T2DM and many of these individuals will be prescribed an ACE inhibitor or Angiotensin receptor blocker (ARB) (34). The data on risk for first trimester exposure to ACE inhibitors is conflicting (see nephropathy section). Depending on the indication for use, an informed discussion on the benefits and risks of stopping these agents before pregnancy must occur but they should certainly be stopped as soon as a missed period occurs. The data on teratogenicity of statins for treatment of hypercholesterolemia is also conflicting and is based on animal, not human, studies (35).  Pravastatin has had favorable effects on vascular endothelial growth factor in animal studies (36–38). A small multicenter pilot study examining pravastatin in prevention of HDP in high-risk pregnant individuals found that pravastatin was safe when started between 12-16 weeks gestation (39). There is a large randomized clinical trial of 1,550 pregnant individuals evaluating pravastatin to prevent HDP that is ongoing currently (ClinicalTrials.gov ID NCT03944512).  At this time, current guidelines recommend that statins be stopped prior to pregnancy, but definitely at diagnosis of pregnancy, for most individuals (7). Continuation of statins preconception and during pregnancy may be warranted through shared decision making and risk/benefit discussions in high-risk individuals (40).

 

INFLUENCE OF METABOLIC CHANGES IN PREGNANCY

 

Pregnancy is a complex metabolic state that involves dramatic alterations in the hormonal milieu in addition to changes in adipocytes and inflammatory cytokines. There are high levels of estrogen, progesterone, prolactin, cortisol, human chorionic gonadotropin, placental growth hormone, human chorionic somatomammotropin (human placental lactogen), leptin, TNFα, and oxidative stress biomarkers. In addition, decreases in adiponectin worsen maternal insulin resistance in the second trimester to facilitate fuel utilization by the fetus (41).

 

Metabolically, the first trimester is characterized by increased insulin sensitivity, which promotes adipose tissue accretion in early pregnancy. What mediates this increased insulin sensitivity remains unclear. Pregnant individuals are at an increased risk for hypoglycemia, especially if accompanied by nausea and vomiting in pregnancy. Although most pregnant individuals show an increase in insulin sensitivity between 6-20 weeks’ gestation and report more frequent episodes of hypoglycemia, especially at night, there is a transient increase in insulin resistance very early in pregnancy (prior to 10 weeks), usually followed by increased insulin sensitivity up until 14-20 weeks (42).

 

In the fasting state, pregnant individuals deplete their glycogen stores quickly due to the fetoplacental glucose demands, and switch from carbohydrate to fat metabolism within 12 hours, resulting in increased lipolysis and ketone production (43–45). In pregnant individuals without diabetes, the second and third trimesters are characterized by insulin resistance with a 200-300% increase in the insulin response to glucose (46).  This serves to meet the metabolic demands of the fetus, which requires 80% of its energy as glucose, while maintaining euglycemia in the mother. The placental and fetal demands for glucose are considerable and approach the equivalent of ~150 grams per day of glucose in the third trimester (44). In addition, the maternal metabolic rate increases by ~150-300 kcal/day in the third trimester, depending on the amount of gestational weight gain. These increased nutritional needs place the pregnant individual at risk for ketosis, which occurs much earlier than usual without adequate oral or intravenous nutrients, frequently referred to as "accelerated starvation of pregnancy" (43).  See “Diabetic Ketoacidosis in Pregnancy” section for further details.

 

DIABETES COMPLICATIONS AND TREATMENT OPTIONS IN INDIVIDUALS WITH PREGESTATIONAL DIABETES AND THE ROLE OF PRECONCEPTION COUNSELING

 

Although historically, T1DM has been more prevalent than T2DM in individuals of child-bearing age, this is changing with increased obesity rates worldwide. The prevalence of prediabetes and diabetes is a burgeoning global epidemic (47,48). In the United States, the prevalence of diabetes among adults between 1980 and 2020 has quadrupled with an estimated 21.9 million adults living with diabetes, including reproductive aged individuals (48). There was higher prevalence of diabetes among non-Hispanic blacks and Mexican Americans (49). Similar temporal trends, as well as racial and ethnic disparities, have been observed in the rate of pregestational diabetes among pregnant individuals in the US (Figures 3 and 4) (50).

 

Figure 3. Rate of pregestational diabetes in the United States, 2016-2021.

Figure 4. Rate of pregestational diabetes by race and Hispanic origin in the United States, 2021.

Both pregnant individuals with T1DM and T2DM are at increased risk of poor obstetrical outcomes, and both can have improved outcomes with optimized care (5,51). The White Classification (Table 1) was developed decades ago by Priscilla White at the Joslin Clinic to stratify risk of adverse pregnancy outcomes in individuals with T1DM according to the age of the individual, duration of diabetes, and presence of vascular complications of diabetes. Although recent evidence suggests that the classification does not predict adverse pregnancy outcomes better than taking into account the increased risk of micro- and macrovascular disease (e.g. retinopathy, nephropathy, hypertension, coronary artery disease, etc.), it is still often used in the U.S. to indicate level of risk for adverse pregnancy outcomes (52).  Although it was developed for use in individuals with T1DM rather than T2DM, given the very low prevalence of T2DM in individuals of childbearing age decades ago when it was first established in 1949, many also apply it to this group of individuals. ACOG further modified it in 1986, and gestational diabetes (GDM) was added to the classification and designated as A1 (controlled by diet alone) and A2 (controlled by medication). Pregnant individuals with T2DM are at least as high of a risk of pregnancy complications as individuals with T1DM. The reasons for this may include older age, a higher incidence of obesity, a lower rate of preconception counseling, disadvantaged socioeconomic backgrounds, and the co-existence of the metabolic syndrome including hyperlipidemia, hypertension, and chronic inflammation (34). Furthermore, the causes of pregnancy loss appear to differ in individuals with T1DM versus T2DM. In one series comparing outcomes, >75% of pregnancy losses in individuals with T1DM were due to major congenital anomalies or prematurity (53).  In individuals with T2DM, >75% were attributable to stillbirth or chorioamnionitis, suggesting that obesity may play a role.

 

Table 1. Modified White Classification of Pregnant Diabetic Individuals

Class

Diabetes onset age (year)

Duration (year)

Type of Vascular

Disease

Medication Need

Gestational Diabetes (GDM)

A1

Any

Pregnancy

None

None

A2

Any

Pregnancy

None

Yes

Pregestational Diabetes

B

20

<10

None

Yes

C

10-19 OR

10-19

None

Yes

D

<10 OR

20

Benign

Retinopathy

Yes

F

Any

Any

Nephropathy

Yes

R

Any

Any

ProliferativeRetinopathy

Yes

T

Any

Any

Renal Transplant

Yes

H

Any

Any

Coronary Artery

Disease

Yes

 

MANAGEMENT OF PREGESTATIONAL DIABETES DURING PREGNANCY

 

Treatment Options in Achieving Glycemic Control

 

All pregnant individuals with T1DM and T2DM should target an A1c of <6.5% preconception and <6.0% during pregnancy when possible. For pregnant individuals with T2DM on oral or noninsulin injectable agents, consider switching to insulin prior to pregnancy, even in individuals with goal glycemic control. Insulin should be used for management of T1DM and is the preferred agent for management of T2DM in pregnancy.

 

ORAL AND NON-INSULIN INJECTABLE GLYCEMIC LOWERING AGENTS

 

No oral hypoglycemics, including metformin and glyburide, are approved for pregestational diabetes in pregnancy. There is no evidence that exposure to glyburide or metformin in the first trimester are teratogenic, but both do cross the placenta, metformin substantially more than glyburide (54–56). Both of these agents have been used in multiple randomized controlled trials (RCTs) for GDM and T2DM. Please see Endotext Gestational Diabetes chapter.

 

Metformin

 

Early studies on metformin use in pregnancy for individuals with pregestational diabetes found high failure rates of monotherapy and mixed results on the impact on pregnancy outcomes (57,58). Recent randomized trials have evaluated the safety and efficacy of metformin in pregnancy for individuals with T2DM (59,60). The Metformin in Women with Type 2 Diabetes in Pregnancy Trial (MiTy) enrolled 502 individuals with T2DM and randomized them to metformin 1000 mg twice daily or placebo, added to insulin (60). They found no difference in their primary outcome which was a composite of serious neonatal outcomes. They found that individuals treated with metformin achieved better glycemic control, required less insulin, had less gestational weight gain (GWG), and were less likely to deliver via cesarean. Neonates exposed to metformin were more likely to be SGA and had reduced adiposity. The Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD) trial enrolled 794 pregnant individuals with a diagnosis of T2DM prior to pregnancy or a diagnosis of diabetes early in pregnancy and randomized them to metformin 1000 mg twice daily or placebo (59). They found no difference in their primary composite neonatal outcome. Metformin exposed neonates were less likely to be LGA.

 

Data on long term outcomes for offspring exposed to metformin come from trials in both GDM and pregestational diabetes. Follow up from the Metformin in Gestational Diabetes (MiG) trial followed 208 children (28% of original trial) and found no differences in body composition or metabolic outcomes at 7 years (61). At 9 years the metformin offspring were slightly larger by measures of BMI and skinfolds. In 24 month follow up of the MiTy trial, 263 children (61% of original trial) were assessed and no differences in BMI Z score or mean sum of skinfolds was found (62). A systematic review and meta-analysis of neonatal and childhood outcomes following treatment with metformin versus insulin for GDM, demonstrated that while offspring exposed to metformin had lower birth weights, they were heavier as infants and had higher BMIs as children.

 

Metformin has historically been used preconception and throughout the first trimester in individuals with polycystic ovary syndrome (PCOS) to improve fertility and prevent early miscarriage. However, trials have not shown benefit in use of metformin for preventing spontaneous abortion and have demonstrated letrozole as the preferred agent for ovulation induction (63–65). Current guidelines therefore recommend the use of metformin in those with PCOS who demonstrate glucose intolerance but not as a primary agent to improve fertility or pregnancy outcomes (66). Per ADA recommendations, metformin prescribed for the purpose of ovulation induction should be discontinued by the completion of the first trimester (7).

 

When used in pregnancy, metformin is typically prescribed with a starting dose of 500 mg once or twice daily for 5-7 days. If well tolerated, the dose can subsequently be up titrated to a maximum dose of 2500 mg daily in divided doses with meals. The most common reported side effects are gastrointestinal complaints (67). Metformin should be avoided in those with renal insufficiency.

 

Glyburide

 

Data on glyburide in pregnancy comes from studies on its use in individuals with GDM. Briefly, meta-analyses have demonstrated increased risk of adverse neonatal outcomes such as neonatal hypoglycemia, macrosomia and increased neonatal abdominal circumference.(68,69) There is a dearth of evidence on long term outcomes of offspring exposed to glyburide.

 

Other Agents

 

There is minimal data on thiazolidinediones, metiglinides, dipeptidyl peptidase IV (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and sodium-glucose transport protein 2 (SGLT-2) inhibitors. A 2023 review of the evidence on GLP-1 agonist and SGLT-2 inhibitors found potential teratogenicity and adverse pregnancy outcomes based largely on animal data and more limited human data (70). Additional data on SGLT-2 inhibitors and DPP-4 inhibitors is reassuring but extremely limited (71).

 

GLP-1 agonist use, in particular, has increased in the general population over the last decade (72). Outside of pregnancy, these agents are approved for use in individuals with obesity and T2DM with HbA1c above goal, atherosclerotic cardiovascular disease, or chronic renal disease (73–75). Studies have shown their use can lead to a reduction in HbA1c, weight loss, and a decrease in athero-thrombotic events in nonpregnant individuals (73,74,76). Animal studies of exposure to GLP-1 agonists during pregnancy have shown associations with congenital anomalies, decreased fetal growth, and embryonic death (70,73,77). Two recent observational studies on periconceptual use of GLP-1 agonists in humans have not demonstrated an association between GLP-1 agonist use and major congenital malformations (71,78). However, these studies have limited data on maternal glycemic control and on other important adverse pregnancy outcomes such as HDP, preterm birth, and fetal growth restriction (73).

 

At this time, the use of these agents in pregnancy should ideally occur only in the context of approved clinical trials.

 

INSULIN USE IN PREGNANCY

 

Overall Approach

 

Both ADA and ACOG recommend insulin as first line therapy for pregnant individuals with pregestational diabetes while trying to conceive and during pregnancy (7,11). Unlike oral agents, insulin preparations commonly utilized in pregnancy do not cross the placenta (79–81).  It is recommended that individuals with T2DM who are actively trying to become pregnant should be switched from oral or noninsulin injectable hypoglycemic agents to insulin prior to conception if possible. This rationale is based on the fact that it may take some time to determine the ideal insulin dose prior to the critical time of embryogenesis. However, individuals who conceive on any oral agents should not stop them until they can be switched effectively to insulin because hyperglycemia is potentially more dangerous than any of the current available therapies to treat diabetes. Following a review of risks and benefits, oral agents, such as metformin, may be considered as a reasonable adjunct or alternative therapy for those unable or unwilling to use insulin while attempting to conceive or during pregnancy. 

 

Basal Insulin

 

Basal insulin is given 1-2 times daily or via a continuous insulin infusion pump. Intermediate-acting insulin, such as neutral protamine Hagedorn (NPH), and long-acting insulin analogues, such as detemir and glargine may be used. Compared to NPH, both detemir and glargine have a flatter, more consistent insulin activity (82). Studies have shown no difference in pregnancy and neonatal outcomes when comparing glargine to NPH (83). Despite a lack of trial data, both U100 and U300 glargine are commonly used in pregnancy given a reassuring safety profile in observational studies (84,85). Trials of detemir, compared to NPH, have demonstrated improved glycemic control as well as lower rates of adverse pregnancy and neonatal outcomes (86–88).  However, as of 2024, detemir has been discontinued on the US market. Limited data exists on the ultralong-acting insulin analog, degludec. A 2023 trial showed degludec was noninferior to determir when used in a basal-bolus regimen with respect to glycemic control and pregnancy outcomes (89). There have been no studies looking at the safety of newer basal insulins such as biosimilar glargine (Basaglar), however these are commonly used in pregnancy due to constraints of availability and insurance coverage.

 

Basal insulin may be provided as two doses of NPH or with one or two doses of a long-acting analogue. Fasting hyperglycemia may be best targeted by the use of NPH before bedtime to take advantage of its 8-hour peak. The evening dose of NPH should be administered at bedtime, rather than dinner, to avoid nocturnal hypoglycemia and prevent fasting hyperglycemia (81).

 

Bolus Insulin

 

Bolus insulin dosing is provided with short- or rapid-acting insulin with doses calculated based on pre-meal glucose and carbohydrate intake using a correction factor and insulin to carbohydrate ratio (90). Alternatively, fixed meal-time insulin dosing can be prescribed. Rapid-acting insulins, lispro and aspart, have been used in multiple trials in pregnancy, and their safety and efficacy are well-established. Lispro and aspart are preferred to short-acting regular insulin due to improvement in postprandial glycemia and reduced hypoglycemia, with equivalent fetal outcomes (91,92). Patient satisfaction has also been higher for individuals using lispro or aspart compared to regular insulin (87). Lispro or aspart insulin may be especially helpful in pregnant individuals with hyperemesis or gastroparesis because they can be dosed after a successful meal and still be effective. It has been demonstrated that rapid acting insulins may take longer to reach maximal concentrations (49 [37-55] vs 71 [52-108] min) in late gestation (93).  Thus, for some pregnant individuals it may be necessary to take mealtime insulin 15-30 minutes prior to the start of a meal (termed pre-bolusing). If used in conjunction with NPH, due to its longer duration of action, regular insulin should be taken twice a day with a second dose no sooner than 5 hours after the initial dose (94).  Regular insulin should generally be given 30-60 minutes prior to starting a meal. Despite limited data, both ultra rapid-acting aspart (Fiasp) and lispro (Lyumjev) are approved for use in Europe given similarities to their rapid-acting versions (95). A recent trial in pregnant individuals comparing rapid-acting aspart to ultra rapid-acting aspart found no difference in A1c or mean birthweight (96).

 

An understanding of behavior and lifestyle including mealtimes, sleep, work schedules, and physical activity, in conjunction with blood glucose data, may aid in the selection of an appropriate basal and bolus regimen. Pharmacologic therapy should occur in conjunction with ongoing nutritional therapy and lifestyle changes.

 

Continuous Subcutaneous Insulin Infusion (CSII) or Insulin Pump Therapy  

 

Many pregnant individuals with T1DM or long-standing T2DM require multiple daily injections (MDI, 4-5 injections per day) or a continuous subcutaneous insulin infusion pump (CSII) to achieve optimal glycemic control during pregnancy. Many individuals with T1DM use CSII and CGM during pregnancy (97). CGM will be reviewed in detail below. There have been several studies showing CSII use is safe in pregnancy. In a large multicenter trial of individuals with T1DM during pregnancy, individuals using CSII had improved A1c both in the first trimester as well as in the third trimester and there was no difference in rates of diabetic ketoacidosis (DKA) or severe hypoglycemia compared with individuals using MDI (98).  An analysis of data from 248 individuals with T1DM enrolled in the Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT) showed that pregnant individuals using MDI therapy versus CSII therapy had similar first trimester glycemia but MDI users had lower glycemia at 34 weeks and were more likely to achieve target A1c than CSII users. In this analysis, CSII users had an increased risk of NICU admission, neonatal hypoglycemia, and hypertensive disorders of pregnancy compared with MDI users (99). Several additional studies and a Cochrane review of MDI versus CSII generally have shown equivalent glycemic control, as well as maternal and perinatal outcomes (100–105). CSII can be especially useful for individuals with nocturnal hypoglycemia, gastroparesis, or a prominent dawn phenomenon (99). 

 

Disadvantages of CSII include cost and the risk for hyperglycemia or DKA as a consequence of insulin delivery failure from a kinked catheter or from infusion site problems, although rare (106). Pregnant individuals should be educated on how to quickly recognize and manage insulin pump failure. Therefore, it may be optimal to begin pump therapy before pregnancy due to the steep learning curve involved with its use and the need to continually adjust basal and bolus settings due to the changing insulin resistance in pregnancy. However, in motivated pregnant individuals with a multidisciplinary team of diabetes education specialists and pump trainers, insulin pump initiation is safe in pregnancy. Several studies demonstrate significant changes in bolus more than basal insulin requirements during pregnancy which should be understood to achieve optimal glycemic control(107,108). 

 

Automated Insulin Delivery

 

Automated insulin delivery (AID) systems are comprised of a CGM, an insulin pump, and an algorithm that uses CGM data to calculate insulin (109). Diabetes technology use in general, and AID use specifically, has become increasingly prevalent and is expected to continue to increase in the coming years (110,111). The existing data on AID use in pregnancy have shown improved or equivalent CGM metrics when compared with MDI (112–114). The Automated insulin Delivery Among Pregnant Women with TIDM (AiDAPT) trial was a multicenter, randomized controlled trial of 124 pregnant individuals with T1DM comparing MDI to AID with a pregnancy-specific target glucose range (112). Those using AID spent more time in range, spent less time above range, and had lower A1c levels. There were no safety concerns, including severe hypoglycemia or DKA associated with AID use. Other trials of AID use in pregnancy have not used pregnancy-specific glucose targets and participants in these studies have used assistive techniques that override algorithms such as ‘fake’ carbohydrate insulin boluses and use of mode with stricter ranges such as sleep mode. This includes CRISTAL, a randomized controlled trial of 95 pregnant individuals with T1DM comparing AID to MDI (113). There was no difference in the primary outcome of time in range, however those using AID had more overnight time in range and had less time below range. Studies have not yet demonstrated improvements in other pregnancy outcomes with AID use; however, several trials are ongoing (115,116). In 2024, the CamAPS FX algorithm, used in the AiDAPT trial was Food and Drug Administration (FDA) approved for use in pregnancy. There are several additional AID systems that are FDA approved for use outside of pregnancy. In the interim, pregnant individuals are also using do-it-yourself AID systems and while no observational study or trial data exist, case reports to date have shown positive outcomes and patient experiences (117–119). 

 

Few studies have evaluated patient perspectives and psychosocial implications of AID use in pregnancy. Those that do exist suggest both benefits and burdens of these systems (120–122). Benefits include improved well-being, greater flexibility, and more positive collaboration between pregnant individuals and their healthcare team. Burdens include technical failures, device maintenance, system bulk/visibility, and access to an overwhelming amount of data. Ongoing education and support for both patients and providers are necessary to optimize the balance of these positive and negative aspects of AID use in pregnancy (120,123).

 

The ADA recommends that AID systems with pregnancy specific targets are preferred for use in pregnancy; however, those without pregnancy specific targets may be considered for use in collaboration with experienced health care teams (7). Glycemic control, comfort with technology, social determinants of health, and individual preference should all be considered when evaluating individuals for AID use in pregnancy.  

 

Importance of Glycemic Control

 

Failure to achieve optimal control in early pregnancy may have teratogenic effects in the first 3-10 weeks of gestation or lead to early fetal loss. Poor glycemic control later in pregnancy increases the risk of intrauterine fetal demise, macrosomia, cardiac septal enlargement in the fetus, perinatal death, and metabolic complications such as hypoglycemia in the newborn. Target glucose values for fasting and postprandial times should be discussed with the pregnant individual. Current guidelines are that fasting and pre-meal blood glucose should be 70-95 mg/dl, the 1-hour postprandial glucose should be 110-140 mg/dl and the 2-hour postprandial glucose should be 100-120 mg/dl (7,11).

 

Although a review of the literature suggests that the mean fasting plasma glucose (FPG), 1 hour PP, and 2 hour PP +/- 1 SD glucose values are significantly lower in normal weight individuals in the 3rd trimester (FPG ~71 +/- 8 mg/dl; 1 hour PP ~109 +/- 13 mg/dl; 2 hour PP 99 +/- 10 mg/dl) than current therapeutic targets (19), no RCTs have been completed to determine whether lowering the therapeutic targets results in more favorable pregnancy outcomes. A prospective study in pregnant individuals with T1DM showed less HDP with glucose targets of fasting <92 mg/dl, pre-prandial <108 mg/dl and 1 hour postprandial <140 mg/dl (124).  An A1c should be done at the first visit and every 1-3 months thereafter depending on if at target or not (<6% if possible, with minimal hypoglycemia) (11,30).  Additional labs and exams recommended for individuals with pregestational diabetes during pregnancy are summarized in Table 2.

 

Table 2. Evaluation of Pregnant Individuals with Pregestational Diabetes

A1c

Initially and every 1 – 3 months

TSH

TSH every trimester if + TPO antibodies

TG

Repeat if borderline due to doubling in pregnancy

ALT; AST

For evaluation for MASLD and as baseline

HDP labs

Cr; Urine albumin or protein

If abnormal, obtain 24-hour urine for protein and estimated CrCl Repeat Prot/Cr ratio or 24-hour urine every 1 – 3 months if significant proteinuria or hypertension

Ferritin, B12

Obtain for anemia or abnormal MCV, especially B12 if T1DM DM

Baseline HDP labs

Consider Uric Acid; Obtain CBC with platelet count in addition to AST, ALT, BUN, Cr, 24-hour urine for protein, Cr

EKG

For individuals ≥35 years or CV risk factors; Consider further evaluation if indicated

Dilated Retinal Exam

Within 3 months of pregnancy or first trimester and repeat evaluation according to risk of progression

Abbreviations: glycosylated hemoglobin (A1c), thyroid stimulating hormone (TSH), thyroid peroxidase (TPO), triglycerides (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), metabolic dysfunction-associated steatotic liver disease (MASLD), creatinine (Cr), electrocardiogram (EKG).

 

The risk of maternal hypoglycemia needs to be weighed against the risk of maternal hyperglycemia. Maternal hypoglycemia is common and often severe in pregnancy in individuals with T1DM. During the first trimester, before the placenta increases the production of hormones, nausea and increased insulin sensitivity may place the mother at risk for hypoglycemia. Pregnant individuals must be counseled that their insulin requirements in the first trimester are likely to decrease by 10-20% (125). This is especially true at night when prolonged fasting and continuous fetal-placental glucose utilization places the pregnant individual at even higher risk for hypoglycemia. One of the highest risk periods for severe hypoglycemia is between midnight and 8:00 a.m. Pregnant individuals with diabetes complicated by gastroparesis or hyperemesis gravidarum are at the greatest risk for daytime hypoglycemia. In a series of 84 pregnant individuals with T1DM, hypoglycemia requiring assistance from another person occurred in 71% of individuals with a peak incidence at 10-15 weeks gestation (126). One third of individuals had at least one severe episode resulting in seizures, loss of consciousness, or injury. There are also data to suggest that the counterregulatory hormonal responses to hypoglycemia, particularly growth hormone and epinephrine, are diminished in pregnancy (127,128). This risk of hypoglycemia may be ameliorated if efforts are made to achieve good glycemic control in the preconception period, by the use of analogue insulins, and with the use of CGM (128,129). Insulin pumps with or without CGM may help achieve glycemic targets without increasing hypoglycemia (98,131,132). 

 

Use of CGM especially with real-time sensor glucose data shared with a partner has been shown to reduce fear of hypoglycemia in pregnancy. The risk of hypoglycemia is also present in pregnant individuals with T2DM but tends to be less so than in individuals with T1DM (133). The risk of hypoglycemia to the fetus is difficult to study but animal studies indicate that hypoglycemia is potentially teratogenic during organogenesis (134). Exposure to hypoglycemia in utero may have long-term effects on the offspring including neuropsychological defects (134). To help reduce risk of nocturnal hypoglycemia, individuals with T1DM may need a small bedtime snack and/or reduce overnight basal insulin doses. Every pregnant individual should have a glucagon emergency kit (intramuscular injection or intranasal) and carry easily absorbed carbohydrate at all times. Education of individuals and care providers to avoid hypoglycemia can reduce the incidence of hypoglycemia unawareness. The incidence of severe hypoglycemia in pregnant individuals with T1DM can be reduced without significantly increasing A1c levels and is a priority given hypoglycemic unawareness worsens with repeated episodes and can result in maternal seizures and rarely maternal death (135).

 

By 18-20 weeks of gestation, peripheral insulin resistance increases resulting in increasing insulin requirements so that it is not unusual for a pregnant individual to require 2-3 times as much insulin as she did prior to pregnancy depending on baseline insulin resistance, carbohydrate intake, and body mass index. In a study of 27 individuals with T1DM on an insulin pump, the carbohydrate-to-insulin ratio intensified 4-fold from early to late pregnancy (e.g. 1 unit for every 20 grams to 1 unit for every 5 grams), and the basal insulin rates increased 50% (107).

 

Glucose Monitoring Timing and Frequency

 

Pregnant individuals with diabetes must frequently self-monitor their glucose to achieve tight glycemic control. Since fetal macrosomia (overgrowth) is related to both fasting and postprandial glucose excursions, pregnant individuals with diabetes need to monitor their post-meal and fasting glucoses regularly and those using a flexible intensive insulin regimen also need to monitor their pre-meal glucose values (136).

 

Postprandial glucose measurements determine if the insulin to carbohydrate ratios is effective in meeting glycemic targets as optimal control is associated with less macrosomia, metabolic complications in the fetus, and possibly HDP (124,137).  Due to the increased risk of nocturnal hypoglycemia with intensive insulin therapy, glucose monitoring during the night is often necessary given the frequent occurrence of recurrent hypoglycemia and resulting hypoglycemic unawareness with the achievement of tight glycemic control.

 

Continuous Glucose Monitoring

 

CGM may help identify periods of hyper- or hypoglycemia and certainly confirm glycemic patterns and variability (138,139). In pregnancy, the mean sensor glucose may be better at estimating glycemic control than A1c (140). The previously mentioned CONCEPTT trial was a large multicenter trial that examined CGM use in individuals planning pregnancy as well as pregnant individuals with T1DM using either MDI or insulin pump therapy (139). This study found statistically significantly lower incidence of LGA infants, less neonatal intensive care unit stays, and less neonatal hypoglycemia with CGM used compared to capillary glucose monitoring. There was a small difference in A1c among the pregnant individuals using CGM, less time spent in hyperglycemia range, and more time spent in range. Importantly this was the first study to show improvement in non-glycemic clinical outcomes for CGM use in pregnancy (139). A follow-up study to the CONCEPTT trial found that pregnant individuals using real-time CGM compared to capillary glucose monitoring were more likely to achieve ADA and NICE (National Institute of Clinical Excellence) guidelines for A1c targets by 34 weeks gestation. Similar to CONCEPTT, additional observational studies have demonstrated that modest increases (5%) in TIR are associated with improved glycemic control and reduced neonatal morbidity (141,142). Data on the use of CGM for pregnant individuals with T2DM is more limited and has not consistently demonstrated improved outcomes (143–145).There are multiple ongoing trials investigating the impact of CGM on pregnancy outcomes in individuals with T2DM (146,147).

 

Given the improvement demonstrated in outcomes, the ADA recommends CGM for use in pregnant individuals with T1DM. However, due to insufficient data in pregnant individuals with T2DM, use of CGM in this population may be considered on an individualized basis. For pregnant individuals with T1DM, the International Consensus on Time in Range recommends increasing time in range in pregnancy quickly and safely with a pregnancy goal sensor glucose range of 63 to 140 mg/dl with >70% time in range, <25% time above range (>140 mg/dl), <4% of time below 63 mg/dl, and <1% time below 54 mg/dl (148). The expert guidance recommends the same glucose goal ranges for pregnant individuals with T2DM or GDM but do not specify goals for time spent in each range due to lack of clear evidence in these populations.

 

CGM has been an advancing technology with tremendous improvements in accuracy, comfort, longer duration, convenience, and insurance coverage over the past decade. Some newer CGM devices are factory calibrated and do not require fingerstick glucose calibrations. There are also flash CGM systems on the market which require scanning of the sensor with a receiver to display the sensor glucose. The Freestyle Libre and Dexcom G7 are now approved for use in pregnancy, while several others continue to be used during pregnancy off-label. Pregnant individuals with diabetes may use CGM either in conjunction with an insulin pump or with MDI therapy to help achieve glycemic control.

 

Sensor glucose values from CGM may not be as accurate at extremes of hypo- or hyperglycemia or with rapid changes in glucose, so individuals should always check fingerstick glucose if she feels the glucose value is different than the displayed sensor glucose value. CGM values may have a lag time behind actual plasma glucose values.

 

Glycosylated Hemoglobin (A1c)

 

A1c may be used as a secondary measure in pregnancy with a goal of <6% considered optimal if able to be achieved without increased risk of hypoglycemia (7,11). Improved pregnancy outcomes have been demonstrated with A1c <6-6.5% including lower risk of congenital anomalies, HDP, preterm delivery, shoulder dystocia, and NICU admission (8–10,149). However, A1c is a summative measure that may not capture fluctuations in hypo- and hyperglycemia. Due to physiological changes in red blood cell turnover during pregnancy, A1c levels fall during normal pregnancy and levels may require more frequent monitoring than in non-pregnant populations (150,151).

 

DIABETES MICROVASCULAR AND MACROVASCULAR COMPLICATIONS

 

Individuals should be up-to-date on screening for complications of diabetes prior to conceiving. Diabetes care providers should discuss risk of adverse pregnancy outcomes and progression of complications during pregnancy especially in individuals with retinopathy and nephropathy (152,153).

 

Retinopathy

 

Diabetic retinopathy may progress during pregnancy and throughout the first year postpartum. However, pregnancy does not cause permanent worsening in mild retinopathy (154,155). The cause for progression in moderate and especially severe proliferative retinopathy is likely due to a combined effect of the rapid and tight glycemic control, increased plasma volume, anemia, placental angiogenic growth factors, and the hypercoagulable state of pregnancy (156,157). In 179 pregnancies in individuals with T1DM who were followed prospectively, progression of retinopathy occurred in 5% of individuals. Risk factors for progression were duration of diabetes >10 years and moderate to severe background retinopathy (156). The risk of progression of retinopathy is most pronounced in individuals with more severe pregestational proliferative retinopathy, chronic hypertension, HDP, development of hypertension during pregnancy, and poor glycemic control prior to pregnancy (158). For these individuals, proliferative retinopathy may also progress during pregnancy, especially in individuals with hypertension or poor glycemic control early in pregnancy (159). Pregnancy can also contribute to macular edema, which is often reversible following delivery (160).

 

Therefore, individuals with T1DM and T2DM should have an ophthalmological assessment before conception. All guidelines recommend that individuals have a comprehensive eye exam or fundus photography before pregnancy and in the first trimester. Laser photocoagulation for severe non-proliferative or proliferative retinopathy prior to pregnancy reduces the risk of vision loss in pregnancy and should be done prior to pregnancy (31). Individuals with low-risk eye disease should be followed by an ophthalmologist during pregnancy, but significant vision-threatening progression of retinopathy is rare in these individuals. For vision-threatening retinopathy, laser photocoagulation can be used during pregnancy (160). Safety of bevacizumab injections during pregnancy is not clear with some case reports of normal pregnancy after bevacizumab injections for macular edema in pregnancy, and other early pregnancy loss following bevacizumab injection. In individuals with severe untreated proliferative retinopathy, vaginal delivery with the Valsalva maneuver has been associated with retinal and vitreous hemorrhage. Little data exist to guide mode of delivery in individuals with advanced retinal disease and some experts have suggested avoiding significant Valsalva maneuvers—instead offering assisted second-stage delivery or cesarean delivery (26).

 

Diabetic Nephropathy/Chronic Kidney Disease

 

Microalbuminuria and overt nephropathy are associated with increased risk of maternal and fetal complications including HDP, preterm birth, cesarean section, congenital abnormalities, SGA, NICU admission, and perinatal mortality (152,161–164). Although proteinuria increases during pregnancy in individuals with preexisting nephropathy, those with a normal glomerular filtration rate (GFR) rarely have a permanent deterioration in renal function provided blood pressure and blood glucose are well-controlled (165–167). Those with more severe renal insufficiency (creatinine >1.5 mg/dl) have a 30-50% risk of a permanent pregnancy-related decline in GFR (168). Among pregnant individuals with diabetes, nephropathy significantly increases the risk of HDP. Factors which may contribute to worsening nephropathy in pregnancy include the hyperfiltration of pregnancy, increase in protein intake, hypertension, and withdrawal of ACE Inhibitors or ARBs. More stringent control of blood pressure in pregnancy may reduce the likelihood of increasing protein excretion and reduced GFR. In a series of 36 pregnant individuals with T1DM and nephropathy, maternal and obstetric outcomes were strongly dependent on the degree of maternal renal function (169). In normal pregnancy, urinary albumin excretion increases up to 30 mg/day and total protein excretion increases up to 300 mg/day (170). Individuals with preexisting proteinuria often have a significant progressive increase in protein excretion, frequently into the nephrotic range, in part due to the 30-50% increase in GFR that occurs during pregnancy. Prior to conception, individuals should be screened for chronic kidney disease. Dipstick methods are unreliable and random urine protein/creatinine ratios are convenient but not as accurate as other methods in pregnancy to carefully quantify proteinuria using 24-hour urine excretion. There have not been studies looking at spot urine albumin to creatinine ratio versus 24-hour urine protein assessment in pregnant individuals with diabetes. In hypertensive pregnant individuals, one study found that the spot urine albumin to creatinine ratio had higher diagnostic accuracy than 24-hour urine protein assessment (171). It is reasonable to collect a spot urine albumin to creatinine ratio in individuals who have not followed through with collection of 24-hour urine specimens.

There is conflicting information on whether first-trimester exposure to ACE inhibitors and ARBs is associated with an increased risk of congenital malformations. A meta-analysis, limited by small study size (786 exposed infants), demonstrated a significant risk ratio (relative risk [RR] 1.78, 95% confidence interval [CI] 1.07–2.94) for increased anomalies in infants exposed to first-trimester ACE inhibitors and ARBs (172). However, the increased risk of congenital anomalies appears to be more related to hypertension itself, rather than drug exposure. There was no statistically significant difference when ACE inhibitor and ARB exposed pregnancies were compared with other hypertensive pregnancies. A large cohort study of individuals with chronic hypertension including over 4100 pregnant individuals exposed to ACE inhibitors during the first trimester of pregnancy found no significant increase in major congenital anomalies (173).  Exposure in the second and third trimesters is clearly associated with a fetal renin-angiotensin system blockade syndrome, which includes anuria in the 2nd and 3rd trimester, which may be irreversible. However, one recent case report of a pregnant individuals with anhydramnios who had ARB exposure at 30 weeks’ gestation had normalization of amniotic fluid volume after cessation of the medication. Furthermore, there were no apparent renal abnormalities at birth or 2-year follow-up (174). Individuals who are taking ACE inhibitors or ARBs should be counseled that these agents are contraindicated in the 2nd and 3rd trimesters of pregnancy. Individuals who are actively trying to get pregnant should be switched to calcium channel blockers (such as nifedipine or diltiazem), methyldopa, hydralazine, or selected B-adrenergic blockers (such as labetalol).

 

Individuals who are considering pregnancy but are not likely to become pregnant in a short time and who are receiving renal protection from ACE inhibitors or ARBs due to significant underlying renal disease can be counseled to continue these agents. However, they should closely monitor their menstrual cycles and stop these agents as soon as pregnancy is confirmed.

 

Individuals with severe renal insufficiency should be counseled that their chances for a favorable obstetric outcome may be higher with a successful renal transplant. Individuals with good function of their renal allografts who have only mild hypertension, do not require high doses of immunosuppressive agents, and are 1-2 years post-transplant have a better prognosis than individuals with severe renal insufficiency and who are likely to require dialysis during pregnancy. Successful pregnancy outcomes have been reported in 89% of these individuals who underwent renal transplant (175). Timing of conception in relation to transplant is controversial and should be individualized. Pre-pregnancy graft function can help predict risk of adverse pregnancy outcomes, including HDP and graft function (176).

 

Cardiovascular Disease

 

Although infrequent, cardiovascular disease (CVD) can occur in individuals of reproductive age with diabetes. The increasing prevalence of T2DM with associated hyperlipidemia, hypertension, obesity, and advanced maternal age (>35) is further increasing the prevalence of CVD. CVD most often occurs in individuals with long-standing diabetes, hypertension, and nephropathy (177). Because of the high morbidity and mortality of coronary artery disease in pregnancy, individuals with pregestational diabetes and cardiac risk factors such as hyperlipidemia, hypertension, smoking, advanced maternal age, or a strong family history should have their cardiac status assessed with functional testing prior to conception (11,178). There are limited case reports of coronary artery disease events during pregnancy, but with the increased oxygen demand from increased cardiac output, events do occur and need to be treated similarly to outside of pregnancy, trying to minimize radiation exposure to the fetus (177,179,180).  In a recent study of 79 individuals with history of coronary artery disease prior to pregnancy, there were low rates of cardiac events during pregnancy in all individuals with and without diabetes but more frequent poor obstetric and neonatal outcomes including SGA, HDP, and preterm delivery.

 

Due to the increased cardiac output of pregnancy, decrease in systemic vascular resistance, and increase in oxygen consumption, the risk of myocardial ischemia is higher in pregnancy. Myocardial oxygen demands are even higher at labor and delivery, and activation of catecholamines and stress hormones can cause myocardial ischemia. Coronary artery dissection is also more common in pregnancy and typical chest pain should be appropriately evaluated. An electrocardiogram (EKG) should be considered preconception for any individual with diabetes older than 35 years (26). Individuals with longstanding diabetes and especially those with other risk factors for coronary artery disease (hyperlipidemia or hypertension) should be evaluated for asymptomatic coronary artery disease before becoming pregnant. Individuals with atypical chest pain, significant dyspnea, or an abnormal resting EKG should also have a cardiology consultation for consideration of a functional cardiac stress test before pregnancy. As discussed above, statins are often discontinued before conception since there is limited data about their safety during pregnancy. However, a thorough discussion of risks and benefits of continuation versus discontinuation should occur for high-risk individuals such as those with familial hypercholesterolemia and prior atherosclerotic cardiovascular disease (7,40). If an individual has severe hypertriglyceridemia with random triglycerides (TG) >1000 or fasting >400 mg/dl, placing her at high risk for pancreatitis, it may be necessary to continue fibrate therapy if a low-fat diet, fish oil, or niacin therapy is not effective or tolerated. Triglycerides typically double to quadruple in pregnancy placing individuals at high risk for this condition. There is inadequate data on the use of ezetimibe in pregnancy.

 

Neuropathy

 

There are limited data on diabetic neuropathy during pregnancy. Neuropathy may manifest as peripheral neuropathy, gastroparesis, and cardiac autonomic neuropathy. Gastroparesis may present as intractable nausea and vomiting, and it can be particularly difficult to control both the symptoms and glucose values in individuals with gastroparesis during pregnancy. For individuals with gastroparesis, timing of insulin delivery in relation to the meal needs to carefully be weighed against the risk of hypoglycemia as discussed previously.

 

Associated Autoimmune Thyroid Disease

 

Up to 30-40% of young individuals with T1DM have accompanying thyroid disease, and individuals with T1DM have a 5-10% risk of developing autoimmune thyroid disease first diagnosed in pregnancy (most commonly Hashimoto's thyroiditis) (181). Thyroid stimulating hormone (TSH) should be checked prior to pregnancy since the fetus is completely dependent on maternal thyroid hormone in the first trimester (182,183). Pregnant individuals with positive thyroid peroxidase (TPO) antibodies should have their TSH checked in each trimester (Table 2) since the demands of pregnancy can unmask decreased thyroid reserve from Hashimoto’s thyroiditis. Thyroid hormone requirements increase by 30-50% in most pregnant individuals, often early in pregnancy due to increase in thyroid binding globulin stimulated by estrogen. For most individuals on thyroid hormone replacement prior to pregnancy, the American Thyroid Association (ATA) and ACOG recommend TSH be within the trimester-specific reference range for pregnancy at a particular lab, or if not provided, preconception and first trimester TSH <2.5 mU/L and second and third trimester TSH goals <3 mU/L, and thyroid hormone replacement should be adjusted to achieve these goals (184,185). For diagnosis of hypothyroidism during pregnancy, recent recommendations from the ATA recommend new reference ranges for TSH during pregnancy and screening in individuals with history of T1DM each trimester with reference range being 0.4 from the lower limit of the nonpregnant TSH reference range and 0.5 from the upper non-pregnant range which results in a new TSH range of ~0.1-4mUl/L (184,186). This recommendation is based on the TSH range in pregnant individuals in the Maternal Fetal Medicine Units Network in which there was no benefit in treating individuals with levothyroxine with TSH <4 (184,186).

 

Other Autoimmune Conditions

 

Other autoimmune conditions are also more common among individuals with T1DM compared with individuals without T1DM. Celiac disease has been estimated to have a prevalence of 3-9% in individuals with T1DM and is more common among females than males (187,188). This can often lead to vitamin D deficiency and iron deficiency, and it is reasonable to screen individuals with T1DM for vitamin D deficiency in pregnancy if they have not been previously screened.  Autoimmune gastritis and pernicious anemia are also more common among individuals with T1DM with a prevalence approximating 5-10% and 1-3%, respectively (189). Addison’s disease is also seen in 0.5-1% of individuals with T1DM (189).

 

Diabetic Ketoacidosis in Pregnancy

 

Pregnancy predisposes to accelerated starvation with enhanced lipolysis, which can result in ketonuria after an overnight fast. DKA may therefore occur at lower glucose levels (~200 mg/dl), often referred to as "euglycemic DKA" of pregnancy, and may develop more rapidly than it does in non-pregnant individuals(190,191). Up to 30% of episodes of DKA in pregnant individuals with diabetes occur with glucose values <250 mg/dl.  Pregnant individuals also have a lower buffering capacity due to the progesterone-induced respiratory alkalosis resulting in compensatory metabolic acidosis. Furthermore, euglycemic DKA is not uncommon in pregnancy due to the increased propensity to ketosis in pregnant individuals and glomerular hyperfiltration in pregnancy which causes glycosuria at lower serum glucoses. Any pregnant individual with T1DM with a glucose >200 mg/dL, with unexplained weight loss or who is unable to keep down food or fluids should check urine ketones at home. If positive, arterial pH, serum bicarbonate level, anion gap and serum ketones should be obtained to assess for DKA (11).

 

Maternal DKA is associated with significant risk to the fetus and poor neonatal outcomes including morbidity and mortality. Cardiotography of the fetus during maternal DKA may suggest fetal distress (as evidenced by late decelerations). In a study of 20 consecutive cases of DKA, only 65% of fetuses were alive on admission to the hospital (191). Risk factors for fetal loss included DKA presenting later in pregnancy (mean gestational age 31 weeks versus 24 weeks); glucose > 800 mg/dl; BUN > 20 mg/dl; osmolality > 300 mmol/L; high insulin requirements; and longer duration until resolution of DKA. The fetal heart rate must be monitored continuously until the acidosis has resolved. In another case series of DKA in pregnancy, almost all individuals presented with nausea and vomiting (97%) and the majority had improvement of hyperglycemia to <200 mg/dL within 6 hours of admission and resolution of acidosis within 12 hours(192). Causes of DKA in pregnancy vary widely with infection less common as a precipitant compared with cases outside of pregnancy (193). Of the infectious causes, pyelonephritis is the most common. However, there is often no precipitant other than emesis in the pregnant individual who can develop starvation ketosis very quickly. In a 2024 case series of 129 admissions for DKA, the most common precipitating factors were vomiting or gastrointestinal illness (38%), infection (26%), and insulin nonadherence (21%) (194). Those with T1DM had higher serum glucoses and serum ketones on admission but those with T2DM required intravenous insulin therapy for a longer duration. Overall, those pregnant individuals with at least one admission for DKA during pregnancy delivered preterm with a median gestational age of approximately 35 weeks.

 

Prolonged fasting is a common precipitant for DKA, and it has been shown that even individuals with GDM can become severely ketotic if they are given B-mimetic tocolytic medications or betamethasone (to accelerate fetal lung maturity) in the face of prolonged fasting (195). Pregnant individuals unable to take carbohydrates orally require an additional 100-150 grams of intravenous glucose to meet the metabolic demands of the pregnancy in the 2nd and 3rd trimester. Without adequate carbohydrate (often a D10 glucose solution is needed), fat will be burned for fuel and the individual in DKA will remain ketotic. Diabetic ketoacidosis carries the highest risk of fetal mortality in the third trimester thought in part due to the extreme insulin resistance and insulin requirements to treat DKA that are nearly twice as high as in the second trimester (191).

 

Hypertensive Disorders in Pregnancy

 

Pregnant individuals with pregestational diabetes are at increased risk of complications of pregnancy secondary to hypertensive disease (11,196).  Serum creatinine, AST, ALT, and platelets as well as proteinuria (24-hour collection or random protein to creatinine ratio) should be collected as early as possible in pregnancy to establish a baseline and provide counseling on risks associated with significant proteinuria or renal failure. The updated ACC/AHA categorization of normal and abnormal blood pressure ranges outside of pregnancy have not been adopted in the obstetric population (197). Normal blood pressure values in pregnancy are defined as <140/90 mmHg; blood pressures ≥160/110 mmHg are considered severely elevated and warrant prompt treatment for maternal stroke prevention (198).

 

Although outside of pregnancy achieving a BP < 120/80 mmHg is renal-protective, there are no prospective trials that have demonstrated that achieving this goal improves pregnancy outcomes. 

 

Historically, establishing blood pressure thresholds at which treatment should be initiated in those with chronic hypertension has been challenging due to the competing interests of the mother and fetus (198,199). Concerns include the potential for relative hypotension to increase the risk for poor uteroplacental perfusion and fetal growth restriction, balanced against the increased risk of stroke, placental abruption, and preterm delivery with poorly controlled blood pressure (200–202). The 2015 international Control of Hypertension in Pregnancy Study (CHIPS) trial compared less-tight blood pressure control (target diastolic 100 mm Hg) to tight control (target diastolic 85 mm Hg) and found that tighter control was associated with lower frequency of severe hypertension (203). There was no difference in the frequency of pregnancy loss, higher level neonatal care, or severe maternal complications. The US Chronic Hypertension and Pregnancy (CHAP) trial found that titration of antihypertensive therapy to achieve a systolic pressure <140 mm Hg and diastolic pressure <90 mm Hg, compared with treatment only for systolic pressure, ≥160 mm Hg or diastolic pressure, ≥105 mm Hg, led to lower rates of adverse pregnancy outcomes without an increased risk of fetal growth restriction (204). A secondary analysis of the CHAP trial showed that those who achieved a blood pressure below 130/80 mm Hg, compared to blood pressures of 130-139/80-89 mm Hg, were at lower risk of adverse pregnancy outcomes (205).

 

Thus, among individuals with pregestational diabetes and chronic hypertension, blood pressure treatment should be continued or initiated and titrated with a goal value of ~135/85 mmHg(7,167).  A lower goal of 120/80 mmHg should be achieved in the setting of diabetic nephropathy (167). Individuals with diabetic nephropathy are at extremely high risk of developing HDP which often leads to intrauterine growth restriction and prematurity. Even individuals with microalbuminuria are at a higher risk of HDP than individuals without microalbuminuria. Blood pressure control is imperative to try to minimize the deterioration of renal function. Preferred anti-hypertensive agents in pregnancy include calcium channel blockers (nifedipine, amlodipine), select beta-blockers (labetalol), and alpha-2 agonists (methyldopa) (198). ACE inhibitors and ARBs are contraindicated in all trimesters of pregnancy and diuretics are reserved for the treatment of pulmonary edema due to concerns that further decreasing the intravascular volume with diuretics could further compromise tissue and placental perfusion. All classes of hypertensive agents are safe in lactating mothers in the postpartum period (206).

 

After 20-24 weeks gestation, elevated blood pressure should prompt evaluation for HDP.  The etiology and pathophysiology of HDP continues to be incompletely characterized, though evidence strongly suggests the microvascular disease may begin early in pregnancy at the time of implantation and manifest in the second or third trimesters (198,207). As a result, treatment of elevated blood pressure has not been shown to prevent HDP. Since 2014, the US Preventative Task Force (USPSTF) recommends low dose aspirin of 81 mg daily after 12 weeks’ gestation for those at high risk of HDP who do not have a contraindication to aspirin use (198,208,209). High risk factors, including pregestational diabetes, chronic hypertension, history of HDP, and renal disease, should prompt low-dose aspirin initiation in the second trimester; ≥2 moderate risk factors such as nulliparity, obesity, age ≥35, family history of HDP, or personal socioeconomic or poor obstetric history should also prompt use of low-dose aspirin (208,209). Recent data suggests that doses of aspirin above 100 mg may be required for HDP reduction (210,211). However, recommendations for low dose 81 mg aspirin from USPSTF and ACOG remain unchanged.

 

FETAL SURVEILLANCE

 

Maternal hyperglycemia has temporal effects on the developing pregnancy based on gestational age at exposure (6,11,212). Hyperglycemia around the time of conception and early pregnancy is associated with increased risk of miscarriage, congenital anomalies, with cardiac malformations being most common, as well as placental dysfunction related to “end-organ damage” which could lead to growth-restricted fetuses (6). An early dating ultrasound in the first trimester is recommended to confirm gestational age of the fetus and to coordinate detailed anatomic survey at 18-20 weeks gestation. A fetal echocardiogram should be offered at 20-22 weeks if the A1c was elevated (>6.5-7.0%) during the first trimester (212).

 

Later in pregnancy, hyperglycemia is associated with excessive weight gain in the fetus, with abdominal circumference and shoulder girth primarily measuring larger than expected for gestational age (213–215). Consideration can be made for serial ultrasound evaluation of fetal growth if there is suspicion of abnormal growth, though at minimum, a growth ultrasound in the third trimester should be performed (11). Serial ultrasounds are used to monitor growth and if the estimated fetal weight is less than the 10th percentile (SGA), umbilical artery Doppler velocimetry as an adjunct antenatal test is recommended to estimate the degree of uteroplacental insufficiency, predict poor obstetric outcome and assist in determining the optimal timing of delivery (216).

 

The association of pregestational diabetes and increased risk for stillbirth was documented as early as the 1950s, leading to a historical practice of intense monitoring with weekly contraction stress test and fetal lung maturity testing prior to delivery (217). Data emerged identifying congenital anomalies as a key factor in stillbirth; with increased focus on improved glycemic control in early pregnancy, stillbirth rates were reduced significantly (218,219). Contemporary practice typically consists of non-stress testing 1-2 times per week, with or without biophysical profile testing, with initiation around 32 weeks gestation (220). However, due to the increased risk of uteroplacental insufficiency and intrauterine fetal demise in pregnant individuals with longstanding T1DM, especially in those with microvascular disease, diabetic nephropathy, hypertension, or evidence of poor intrauterine growth, fetal surveillance may be recommended earlier. While comorbidities such as poor glycemic control, vascular complications, hypertension, or nephropathy have a summative effect on risk for perinatal complications, antenatal testing is recommended for all individuals with pregestational diabetes (220). A positive correlation between HbA1c and stillbirth is observed- the higher the HbA1c >6.5%, the higher the risk (221,222). Fetal hypoxia and cardiac dysfunction secondary to poor glycemic control are probably the most important pathogenic factors in stillbirths among pregnant individuals with diabetes (223).

 

LABOR AND DELIVERY

 

Delivery management and the timing of delivery is made according to maternal well-being, the degree of glycemiccontrol, the presence of diabetic complications, growth of the fetus, evidence of uteroplacental insufficiency, and the results of fetal surveillance (224). A third trimester anesthesia consultation should be considered in the setting of concerns about cardiac dysfunction or ischemic heart disease, pulmonary hypertension from sleep apnea, hypertension, thromboembolic risks, potential desaturation while laying supine in individuals with severe obesity, or the possibility of difficult epidural placement or intubations.

 

Optimal delivery timing in the setting of pregestational diabetes requires a balance of perinatal risks, typically stillbirth versus risks of prematurity. In general, individuals with reassuring fetal status and adequate glycemic control can continue a pregnancy until 39 weeks gestation, though expectant management beyond the estimated due date is not advised (225). Concurrent medical complications of mother or fetus may take precedent and require consideration for delivery prior to 39 weeks (225). When late preterm delivery is necessary, it should not be delayed for administration of corticosteroids for fetal lung maturity, as this practice has not been evaluated in pregnancies complicated by pregestational diabetes, and neonatal hypoglycemia may result (226). 

 

With regards to route of delivery, vaginal delivery is preferred for pregnant individuals with diabetes due to the increased maternal morbidity of cesarean delivery such as infection, thromboembolic disease, and longer recovery time. Nevertheless, when the estimated fetal weight is >4500g in the setting of diabetes, an elective cesarean delivery may be offered (227).

 

The target range for glycemic control during labor and at the time of delivery is 70-125 mg/dL; maintenance in this physiological range aims to reduce to risk of neonatal hypoglycemia (228). To achieve this goal, most pregnant individuals with pregestational diabetes require management with an insulin drip and a dextrose infusion, though laboring individuals can eat and continue their home insulin regimen prior to admission. Ideally scheduled cesarean deliveries will occur in the morning, so that individuals can simply reduce their morning long-acting insulin dosing by half on the day of surgery, though consideration can be made to skip it in an individual with well controlled T2DM who hadn’t required medication prior to pregnancy. A pregnant individual being admitted for scheduled induction of labor can be instructed to reduce long-acting insulin dosing for both the night before and morning of the induction (229). Once the individual is eating, the insulin drip can be discontinued and subcutaneous insulin resumed. Alternative management options include ongoing use of insulin pump or subcutaneous insulin, though both often pose logistic challenges due to the unpredictable length of labor. One 2023 trial compared intravenous insulin infusion to CSII intrapartum and found no difference in neonatal hypoglycemia (230). Prevention of neonatal hypoglycemia must be weighed against risk of maternal hypoglycemia during labor.

 

With the delivery of the placenta, insulin requirements drop in an acute and dramatic fashion, with most individualsneeding roughly 10-30% less than their pre-pregnancy insulin doses or 1/2 to 1/3 of their third trimester insulin dosages; some individuals require no insulin for the first 24-48 hours (228). A glucose goal of 100-180 mg/dl postpartum seems prudent to avoid hypoglycemia given the high demands in caring for an infant and especially in nursing individuals as the increased caloric demands of lactation are known to reduce insulin requirements and can contribute to hypoglycemia.

 

Immediate Risks to Newborn

 

The immediate neonatal period is characterized by the transition from in-utero to independent physiology, with unique risks in neonates born to individuals with diabetes.  Glycemic control throughout the entire gestation as well as in the hours before birth both influence this transition. As previously described, hyperglycemia early in pregnancy may result in congenital anomalies, such as cardiac anomalies, which complicate the transition to post-natal circulation. Glycemic control in the second and third trimester may result in a macrosomic infant with increased adiposity in the shoulders and abdomen. And finally, hyperglycemia during labor exacerbates the adjustment of the neonatal pancreas when glucose delivery via the placenta abruptly ceases increasing the risk of neonatal hypoglycemia.

 

Even with aggressive management of diabetes, the incidence of neonatal complications ranges from 12-75% (231) In a large analysis of nearly 200,000 neonates, severe neonatal morbidity was increased in neonates born to individuals with pregestational diabetes compared to those with gestational diabetes or no diabetes at an odds ratio of 2.27 and 1.96 respectively (232).  Driving this relationship was the increased risks of respiratory distress syndrome, mechanical ventilation, and neonatal death (232). Additionally, neonates were more likely to be LGA and require neonatal intensive care unit admission (232). In the setting of poor glycemic control, respiratory distress syndrome may occur in up to 31% of infants due to known insulin antagonism of cortisol on fetal pneumocytes and surfactant production (233). The estimated odds ratio between pregestational diabetes and neonatal respiratory distress syndrome is 2.66 (234). With extremely poor glucose control, there is also an increased risk of fetal mortality due to fetal acidemia and hypoxia. One study found higher rates of neonatal hypoglycemia in individuals managed with continuous insulin infusion pump during pregnancy compared to multiple daily injection therapy, although confounders including early maternal BMI and duration of an insulin infusion play a role (235).

 

Macrosomia places the mother at increased risk of requiring a cesarean section and the infant at increased risk for shoulder dystocia. Shoulder dystocia can result in Erb’s palsy, Klumpke palsy, clavicular and humeral fractures, and hypoxic ischemic encephalopathy, with overall neonatal injury rate of 5.2% (236,237). Shoulder dystocia occurs nearly 20% of the time when a 4500-gram infant is delivered vaginally. Nevertheless, shoulder dystocia remains challenging to predict, with 60% of shoulder dystocias occurring in neonates weighing <4000g (238). There are a number of conflicting studies regarding induction versus cesarean section for suspected macrosomia (239–241).  A large RCT performed in France, Switzerland, and Belgium compared induction of labor at 39 weeks gestation to expectant management among individuals with LGA fetuses, though insulin-dependent diabetes was an exclusion factor (241). Induction of labor was associated with a significant reduction in the composite primary outcome (significant shoulder dystocia, fracture of the clavicle or long bone, brachial plexus injury, intracranial hemorrhage, or neonatal death), with a RR of 0.32 (95% CI 0.15-0.71) (241). While a small but significant difference in spontaneous vaginal delivery was noted between groups, rates of operative vaginal delivery and cesarean deliveries were not significantly different (241). Current guidelines from ACOG do not recommend delivery prior to 39 weeks for suspected macrosomia (242).

 

POSTPARTUM CARE AND CONCERNS FOR PREGESTATIONAL DIABETES

 

The postpartum care for mothers with diabetes should include counseling on a number of critical issues including maintenance of glycemic control, diet, exercise, weight loss, blood pressure management, breastfeeding, contraception/future pregnancy planning, and postpartum thyroiditis screening (for T1DM). It has been demonstrated that most individuals with pregestational diabetes, even those who have been extremely adherent and who have had optimal glycemic control during pregnancy, have a dramatic worsening of their glucose control after the birth of their infant (243,244). While previously many individuals utilizing public insurance lost access as early as 6 weeks postpartum in recent years, the majority of states in the US have implemented a 12-month extension of Medicaid postpartum coverage (245). Historically, the postpartum period has been relatively neglected, as both the new mother and her physician relax their vigilance. However, this period offers a unique opportunity to institute health habits that could have highly beneficial effects on the quality of life of both the mother and her infant and potentially achieve optimal glycemic control prior to asubsequent pregnancy.

 

Home glucose monitoring should be continued vigilantly in the postpartum period because insulin requirements drop almost immediately and often dramatically at this time, increasing the risk of hypoglycemia. Individuals with T1DM often need to decrease their third trimester insulin dosages by at least 50%, often to less than pre-pregnancy doses, immediately after delivery; they may have a "honeymoon" period for several days in which their insulin requirements are minimal. Some estimates of insulin requirements postpartum suggest that individuals may require as little as 60% of their pre-pregnancy doses, and requirements continue to be less than pre- pregnancy doses while breastfeeding (246). For individuals on an insulin pump, the postpartum basal rates can be discussed and preprogrammed prior to delivery to allow a seamless transition to the lower doses following delivery (247). If well controlled prior to pregnancy, pre-pregnancy insulin delivery settings can serve as an excellent starting point for the postpartum period, with an expected decrease in basal rates of 14% and increase in carb ratios by 10% (247).

 

Individuals with T1DM have been reported to have a between 3-25% incidence of postpartum thyroiditis (248). Hyperthyroidism can occur in the 2–4-month postpartum period and hypothyroidism may present in the 4-8 month period. Given the significance of this disorder, a TSH measurement should be offered at 3 and 6 months postpartum and before this time if an individual has symptoms (184).

 

Breastfeeding

 

Both the benefits of breastfeeding- and conversely, the risks of failing to do so- are profound and well documented for both mother and child (249).  Pregestational diabetes and obesity have been identified as independent risk factors for low milk supply, raising the question whether the metabolic milieu during lactogenesis I in mid-pregnancy or during the transition to lactogenesis II and III after delivery may be contributing (250). Additional challenges emerge at the time of delivery, with considerable separation of mothers and infants due to NICU admission and treatment for prematurity, respiratory distress syndrome, and hyperglycemia (232). Dyads can be set up for success with policies and procedures that encourage antenatal colostrum collection, early initiation of pumping if unable to directly breastfeed, and ample lactation consultant support. Individuals with both T1DM and T2DM have lower rates of breastfeeding despite good intentions (251,252).  When individuals have stopped breastfeeding, most stop due to low milk supply rather than diabetes specific reasons (253).

 

When individuals with diabetes are successful in breastfeeding their infants, benefits include reduction in postpartum weight retention, reduced risk for obesity and insulin resistance in offspring (254). Conflicting data exists on the relationship between breastfeeding and the incidence of T1DM in offspring of individuals with pregestational diabetes, though breastmilk induction at the time of complementary food introduction is linked to reduced risk of islet autoimmunity and T1DM (255,256).

 

Additional considerations must be made for individuals with T2DM as they consider pharmacotherapy in the postpartum period. Insulin dosing may require adjustment in the setting of breastfeeding due to increased risk of overnight hypoglycemia (7). With respect to oral agents, acceptable levels of metformin have been identified in breastmilk, rendering it a safe medication for lactating individuals (257,258). A small study suggested that glyburide and glipizide do not appreciably cross into breast milk and may be safe (259). There are no adequate data on the use of thiazolidinediones, meglitinides, incretin therapy, GLP-1 agonists, and SGLT2 inhibitors in nursing mothers.

 

Statins should not be started if the individual is nursing due to inadequate studies in breastfeeding mothers. Individuals who are candidates for an ACE inhibitor can be started on one of these agents at this time as they have not been shown to appear significantly in breast milk (206).

 

Contraception

 

Starting at puberty, it is recommended to provide individuals with diabetes preconception counseling including discussion of options for contraceptive use based on the Medical Eligibility Criteria (MEC) according to WHO and CDC (260,261).  Counseling on contraceptive choices should be patient-centered and focused on the short- and long-term reproductive goals of the individual, taking into consideration the alternative-no contraception- and associated individualized risks of carrying a pregnancy to term. A meta-analysis found that low-income individuals with diabetes had low rates of postpartum birth control and more often were offered permanent contraception rather than reversible options (262).

 

Taken in isolation, a diagnosis of diabetes without vascular complications is compatible with all hormonal and non-hormonal contraception options: copper intrauterine device (IUD), levonorgestrel-releasing IUD, progestin implant, depo medroxyprogesterone acetate, progestin only pills, and combined estrogen-progestin methods (261). Evidence of vascular disease is a contraindication to combined hormonal contraception and depo medroxyprogesterone acetate (261). A large study recently found an overall low risk of venous thromboembolism among individuals with T1DM and T2DM (263). Concurrent conditions and habits such as poorly controlled hypertension, hypertriglyceridemia, or smoking increase the risk of venous thromboembolic events (264). Systematic reviews failed to find sufficient evidence to assess whether progestogen-only and combined contraceptives differ from non-hormonal contraceptives in diabetes control, lipid metabolism, and complications in individuals with pregestational diabetes (265,266).

 

Long-acting reversible contraception (LARC) methods lasting 3-10 years include copper and hormonal IUDs as well as progestin implants. There is no increase in pelvic inflammatory disease with the use of IUDs in individuals with well controlled T1DM or T2DM after the post-insertion period. Immediate postpartum implants and IUDs are becoming increasingly available to individuals who desire LARCs and are effective in spacing pregnancies in high-risk populations (267). For individuals who have completed childbearing and desire permanent sterilization, laparoscopic methods are safe and effective (268).

 

OBESITY IN PREGNANCY

 

Obesity alone or accompanied by T1DM, T2DM, or GDM carries significant risks to both the mother and the infant, and obesity is the leading health concern in pregnant individuals (269–271). By the most recent NHANES statistics in individuals over age 20, 57% of black individuals, 44% of Hispanic or Mexican American individuals, and 40% of white individuals are obese (272). Independent of pregestational diabetes or GDM, obesity increases the maternal risks of hypertensive disorders, MASLD, proteinuria, gall bladder disease, aspiration pneumonia, thromboembolism, sleep apnea, cardiomyopathy, and pulmonary edema (270,273). In addition, it increases the risk of induction of labor, failed induction of labor, cesarean delivery, multiple anesthesia complications, postoperative infections including endometritis, wound dehiscence, postpartum hemorrhage, venous thromboembolism, postpartum depression and lactation failure. Maternal obesity independently increases the risk of first trimester loss, stillbirth, recurrent pregnancy losses, and congenital malformations including CNS, cardiac, and gastrointestinal defects and cleft palate, shoulder dystocia, meconium aspiration, and impaired fetal growth including macrosomia. Most significantly, obesity increases the risk of perinatal mortality (269). Because so many individuals with T2DM are also obese, all of these complications increase the risk of poor pregnancy outcomes in this population. The majority (50-60%) of individuals who are overweight or obese prior to pregnancy gain more than the recommended amount of gestational weight by the Institute of Medicine (IOM) guidelines (274,275). This results in higher weight retention postpartum and higher pre-pregnancy weight for subsequent pregnancies.

 

Obesity is an independent risk factor for congenital anomaly including spina bifida, neural tube defects, cardiac defects, cleft lip and palate, and limb reduction anomalies (276). Several reports have demonstrated an association of maternal BMI with neural tube defects and possibly other congenital anomalies (277). One study concluded that for every unit increase in BMI the relative risk of a neural tube defect increased 7% (277). In addition to an increased anomaly risk with maternal obesity, it is well known that detection of fetal anomalies in the first and second trimester is reduced by 20% due to difficulty in adequate visualization in the setting of maternal obesity (278,279). There is conflicting evidence on the role of folic acid in these obesity-associated congenital anomalies (280–283).

 

Obese individuals with normal glucose tolerance on a controlled diet have higher glycemic patterns throughout the day and night by CGM compared to normal weight individuals both early and late in pregnancy (284). The glucose area under the curve (AUC) was higher in the obese individuals both early and late in pregnancy on a controlled diet as were all glycemic values throughout the day and night. The mean 1 hour postprandial glucose during late pregnancy by CGM was 115 versus 102 mg/dl in the obese and normal weight individuals respectively and the mean 2-hour postprandial values were 107 mg/dl versus 96 mg/dl, respectively, both still much lower than current therapeutic targets (<140 mg/dl at 1 hour; < 120 mg/dl at 2 hours).

 

Individuals with Class III obesity (BMI>40) have improved pregnancy outcomes if they undergo bariatric surgery before becoming pregnant given such surgery decreases insulin resistance resulting in less diabetes, hypertension, and macrosomia compared to those who have not had the surgery (285,286).  In any individual who has had prior bariatric surgery, it has been shown in systematic review to reduce the rate of gestational diabetes and HDP in future pregnancies, however many studies are confounded given 80% of individuals post bariatric surgery remain obese (287). Following bariatric surgery, pregnancy should not be considered for 12-18 months post-operatively and after the rapid weight loss phase has been completed. Close attention to nutritional deficiencies must be maintained, especially with fat soluble vitamins D and K as well as folate, iron, thiamine, and B12. In a study of a cohort of infants born to obese individuals who had bariatric surgery, the offspring had improved fasting insulin levels and reduced measures of insulin resistance compared to siblings born prior to bariatric surgery (288). 

 

MEDICAL NUTRITION THERAPY, EXERCISE AND WEIGHT GAIN RECOMMENDATIONS FOR INDIVIDUALS WITH DIABETES OR OBESITY

 

Medical nutrition therapy in collaboration with a registered dietician nutritionist remains a crucial component of achieving glycemic control and optimizing outcomes in individuals with pregestational diabetes (7,11). Currently, there is no consensus on the ideal macronutrient prescription for pregnant individuals or individuals with diabetes, and there is concern that significant restriction of carbohydrate (33- 40% of total calories) leads to increased fat intake given protein intake is usually fairly constant at 15-20% (31,289,290). Severe restrictions or elimination of any macronutrient class is advised against (291). It is also important to assess intake along with energy requirements which is known to increase in pregnancy by approximately 200, 300, and 400 kcal/d in the first, second, and third trimesters, respectively, but thesevalues vary depending on BMI, total energy expenditure, and physical activity (292). Individuals with pregestational diabetes and GDM should receive individualized medical nutrition therapy (MNT) as needed to achieve treatment goals.

 

Pregravid BMI should be assessed and GWG recommendations should be consistent with the current IOM weight gain guidelines (See Table 3) due to adverse maternal, fetal and neonatal outcomes (293). However, there are many trials which support no weight gain for individuals with a BMI of ≥30 kg/m2 with improved pregnancy outcomes and the lack of weight gain or even modest weight loss, did not increase the risk for SGA infants in the obese cohort. Further, targeting GWG to the lower range of the IOM guidelines (~11 kg or 25 lbs. for normal weight individuals; ~7 kg or 15 lbs. for overweight individuals; and 5 kg (11 lbs.) for individuals with Class 1 obesity (BMI 30-34 kg/m2) has been shown in many trials to decrease the risk of HDP, cesarean delivery, GDM, and postpartum weight retention (294).  This is an increasing public health concern given risks of excessive weight gain (greater than IOM recommendations) including cesarean deliveries, postpartum weight retention for the mother and LGA infants, macrosomia, and childhood overweight or obesity for the offspring (292). Obese individuals are at increased risk of venous thromboembolism postpartum, and this risk is augmented in those who have had a cesarean section, resulting in ACOG’s recommendation for pneumatic sequential compression devices for those who have had cesarean section (295–297). 

 

Table 3. Institute of Medicine Weight Gain Recommendations in Singleton Pregnancy

BMI

Total weight gain

(lbs.)

2nd/3rd trimester rate of weight gain

(kg/week)

Low (<19.8 kg/m2)

28-40

1.0 (1-1.3 lb./week)

Normal (19.8-26 kg/m2)

25-35

1.0 (0.8-1 lb./week)

High (>26-29 kg/m2)

15-25

0.66 (0.5-0.7 lb./week)

Obese (>29 kg/m2)

11-20

0.5 (0.4-0.6 lb./week)

 

There is also increasing evidence that overweight or obese individuals with GDM may have improved pregnancy outcomes with less need for insulin if they gain weight less than the IOM recommendations without appreciably increasing the risk of SGA (298–300). For obese individuals, ~25 kcal/kg rather than 30 kcal/kg is currently recommended (301). However, other investigators would argue for a lower caloric intake (1600-1800 calories/day), which does not appear to increase ketone production (302).

 

The recommended diet should be culturally appropriate, and individuals should consume 150-175 grams of carbohydrate (40-50% of total calories), primarily as complex carbohydrate and limit simple carbohydrates, especially those with high glycemic indices (290,303). Protein intake should be at least 71 g per day (15-30% of total calories), unless individuals have severe renal disease. Individuals should be taught to control fat intake and to limit saturated fat to <10-15% of energy intake, trans fats to the minimal amount possible, and encourage consumption of the n-3 unsaturated fatty acids that supply a DHA intake of at least 200 mg/day (25). Diets high in saturated fat have been shown to worsen insulin resistance, provide excess TGs and FFAs for fetal fat accretion, increase inflammation, and have been implicated in adverse fetal programming effects on the offspring (see risk to offspring above). A fiber intake of at least 28 g/day is advised and the use of artificial sweeteners, other than saccharin, are deemed safe in pregnancy when used in moderation (26). Overall, a diet composed of whole grains, legumes, fruits, vegetables, lean protein and healthy fats is recommended with avoidance of processed foods and sweetened foods and beverages when possible (7,303).

 

For normal weight individuals with T1DM with appropriate gestational weight gain, carbohydrate and calorie restriction is not necessary, but carbohydrates need to be appropriately covered by insulin. Emphasizing consistent timing of mealswith at least a bedtime snack to minimize hypoglycemia in proper relation to insulin doses is important.  Many individuals who dose prandial insulin based on an insulin to carbohydrate ratio are skilled at carbohydrate counting. 

 

Exercise is an important component of healthy lifestyle and is recommended in pregnancy by ACOG, the ADA, and Society of Obstetricians and Gynaecologists of Canada (30,304). The U.S. Department of Health and Human Services issued physical activity guidelines for Americans and recommend healthy pregnant and postpartum individuals receive at least 150 minutes per week of moderate-intensity aerobic activity (i.e., equivalent to brisk walking) (305).  A large meta-analysis of all RCTs on diet and physical activity, which evaluated RCTs (using diet only n=13, physical activity n=18 or both n=13) concluded that dietary therapy was more effective in decreasing excess GWG and adverse pregnancy outcomes compared to physical activity (306). However, there was data suggesting that physical activity may decrease the risk of LGA infants (LGA, >90th percentile). There was no increase in SGA infants (<10th percentile) with physical activity. Submaximal exertion (≤70% maximal aerobic activity) does not appear to affect the fetal heart rate and although high intensity at maximal exertion has not been linked to adverse pregnancy outcomes, transient fetal bradycardia and shunting of blood flow away from the placenta and to exercising muscles has been observed with maximal exertion. Observational studies of individuals who exercise during pregnancy have shown benefits such as decreased GDM, cesarean and operative vaginal delivery, and postpartum recovery time, although evidence from RCTs is limited (307,308).

 

Some data suggest that individuals who continued endurance exercise until term gained less weight and delivered slightly earlier than individuals who stopped at 28 weeks but had a lower incidence of cesarean deliveries, shorter active labors, and fewer fetuses with intolerance of labor (309). Babies weighing less were born to individuals who continued endurance exercise during pregnancy compared with a group of individuals who reduced their exercise after the 20th week (3.39 kg versus 3.81 kg). Contraindications for a controlled exercise program include individuals at risk for preterm labor or delivery or any obstetric or medical conditions predisposing to growth restriction.

 

RISK TO OFFSPRING FROM AN INTRAUTERINE ENVIRONMENT CHARACTERIZED BY DIABETES OR OBESITY

 

Given the strong associations between maternal diabetes and obesity and the risk of childhood obesity and glucose intolerance, the metabolic milieu of the intrauterine environment is a critical risk factor for the genesis of adult diabetes and cardiovascular disease (270,310–313).  The evidence of this fetal programming and its contribution to the developmental origins of human disease (DoHAD) is one of the most compelling reasons why optimizing maternal glycemic control, identifying other nutrients contributing to excess fetal fat accretion, emphasizing weight loss efforts before pregnancy, ingesting a healthy low fat diet, and avoiding excessive weight gain are so critical and carry long term health implications to both the mother and her offspring. The emerging field of epigenetics has clearly shown in animal models and non-human primates that the intrauterine environment, as a result of maternal metabolism and nutrient exposure, can modify fetal gene expression (314,315).

 

Maternal hyperglycemia in early pregnancy has been associated with childhood leptin levels at 5 years of age, even when adjusted for maternal BMI and other confounders (β=0.09 ± 0.04, p=0.03) (316). In this study, higher maternal glucose levels post-75-gram glucose tolerance test in the second trimester were associated with greater total body fat percentage as measured by DXA in the children at 5 years of age.

 

There are data, especially in animal and non-human primate models, to support that a maternal high fat diet and obesitycan influence mesenchymal stems cells to differentiate along adipocyte rather than osteocyte pathways, invoke changes in the serotonergic system resulting in increased anxiety in non-human primate offspring, affect neural pathways involved with appetite regulation, promote lipotoxicity, regulate gluconeogenic enzymes in the fetal liver generating histology consistent with MASLD, alter mitochondrial function in skeletal muscle and program beta cell mass in the pancreas (312,317–324).  These epigenetic changes are being substantiated in human studies with evidence of differential adipokine methylation and gene expression in adult offspring of individuals with diabetes in pregnancy and through alterations in fetal placental DNA methylation of the lipoprotein lipase gene which are associated with the anthropometric profile in children at 5 years of age (325). These findings further support the concept of fetal metabolic programming through epigenetic changes (326). As a result, the intrauterine metabolic environment may have a transgenerational influence on obesity and diabetes risk in the offspring, influencing appetite regulation, beta cell mass, liver dysfunction, adipocyte metabolism, and mitochondrial function.

 

Offspring of mothers with T2DM and GDM have higher risk of childhood obesity, young adult or adolescent insulin resistance and diabetes, MASLD, hypertension, and cardiovascular disease (327–332) . The risk of youth onset diabetes is higher in offspring of mothers born with pregestational T2DM than with GDM (14-fold compared to 4-fold risk) (333). These epigenetic changes are not isolated to maternal BMI alone, but it has also been demonstrated that paternal factors impact offspring risk of obesity and diabetes (334,335). Offspring of individuals with T1DM have a risk of developing T1DM of about 1-3%. The risk is higher for the offspring if the father has T1DM rather than the mother (~3-6%) and if both parents have T1DM, the risk is ~20% (336,337).

 

CONCLUSION

 

The obstetric outlook for pregnancy in individuals with pregestational diabetes has improved over the last century and has the potential to continue to improve as rapid advances in diabetes technology and management, fetal surveillance, and neonatal care emerge. However, the greatest challenge health care providers face is the growing number of individuals developing GDM and T2DM as the obesity epidemic increases affecting individuals prior to pregnancy. In addition, the prevalence of T1DM is increasing globally. Furthermore, obesity-related complications exert a further deleterious effect on pregnancy outcomes. The development of T2DM in individuals with a history of GDM as well as obesity and glucose intolerance in the offspring of individuals with pregestational DM or GDM set the stage for a perpetuating cycle that must be aggressively addressed with effective primary prevention strategies that begin in-utero. Pregnancy is clearly a unique opportunity to implement strategies to improve the mother’s lifetime risk for CVD in addition to that of her offspring and offers the potential to decrease the intergenerational risk of obesity, diabetes, and other metabolic derangements.

 

REFERENCES

 

  1. Louis JM, Bryant A, Ramos D, Stuebe A, Blackwell SC. Interpregnancy Care. Am J Obstet Gynecol 2019;220(1):B2–B18.
  2. Practice AS for RM& AC of O and GC on G. Prepregnancy counseling: Committee Opinion No. 762. Fertil Steril 2019;111(1):P32-42.
  3. Buschur EO, Polsky S. Type 1 Diabetes: Management in Women From Preconception to Postpartum. J Clin Endocrinol Metab 2021;106(4):952–967.
  4. Wahabi HA, Fayed A, Esmaeil S, Elmorshedy H, Titi MA, Amer YS, Alzeidan RA, Alodhayani AA, Saeed E, Bahkali KH, Kahili-Heede MK, Jamal A, Sabr Y. Systematic review and meta-analysis of the effectiveness of pre-pregnancy care for women with diabetes for improving maternal and perinatal outcomes. PLoS One 2020:1–32.
  5. Temple R. Preconception care for women with diabetes: Is it effective and who should provide it? Best Pract Res Clin Obstet Gynaecol 2011;25(1):3–14.
  6. Ray JG, O’brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: A meta-analysis. QJM 2001;94(8):435–444.
  7. ElSayed NA, McCoy RG, Aleppo G, Balapattabi K, Beverly EA, Briggs Early K, Bruemmer D, Echouffo-Tcheugui JB, Ekhlaspour L, Garg R, Khunti K, Lal R, Lingvay I, Matfin G, Pandya N, Pekas EJ, Pilla SJ, Polsky S, Segal AR, Seley JJ, Stanton RC, Bannuru RR. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025. Diabetes Care 2025;48(Supplement_1):S306–S320.
  8. Suhonen L, Hiilesmaa V, Teramo K. Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus. Diabetologia 2000;43(1):79–82.
  9. Ludvigsson JF, Neovius M, Söderling J, Gudbjörnsdottir S, Svensson AM, Franzén S, Stephansson O, Pasternak B. Periconception glycaemic control in women with type 1 diabetes and risk of major birth defects: Population based cohort study in Sweden. BMJ (Online) 2018;362(26):k2638.
  10. Jovanovic L, Knopp RH, Kim H, Cefalu WT, Zhu XD, Young JL, Simpson JL, Mills JL. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy: Evidence for a protective adaptation in diabetes. Diabetes Care 2005;28(5):1113–1117.
  11. ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. Obstetrics and Gynecology 2018;132(6):E228–E248.
  12. Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC. Chronic hypertension and pregnancy outcomes: Systematic review and meta-analysis. BMJ (Online) 2014:348:g2301.
  13. Gonzalez Suarez ML, Kattah A, Grande JP, Garovic V. Renal Disorders in Pregnancy: Core Curriculum 2019. American Journal of Kidney Diseases 2019;73(1):119–130.
  14. Holing E V. Preconception care of women with diabetes: The unrevealed obstacles. Journal of Maternal-Fetal and Neonatal Medicine 2000;9(1):10–13.
  15. Reidenbach M, Bade L, Bright D, DiPietro Mager N, Ellis A. Preconception care needs among female patients of childbearing age in an urban community pharmacy setting. Journal of the American Pharmacists Association 2019;59(4S):S52–S56.
  16. Nwolise CH, Carey N, Shawe J. Exploring the acceptability and feasibility of a preconception and diabetes information app for women with pregestational diabetes: A mixed-methods study protocol. Digit Health 2017;3:1–11.
  17. Hernandez TL, Friedman JE, Van Pelt RE, Barbour LA. Patterns of glycemia in normal pregnancy: Should the current therapeutic targets be challenged? Diabetes Care 2011;34(7). doi:10.2337/dc11-0241.
  18. Siegmund T, Rad NT, Ritterath C, Siebert G, Henrich W, Buhling KJ. Longitudinal changes in the continuous glucose profile measured by the CGMS ® in healthy pregnant women and determination of cut-off values. European Journal of Obstetrics and Gynecology and Reproductive Biology 2008;139(1). doi:10.1016/j.ejogrb.2007.12.006.
  19. Angueira AR, Ludvik AE, Reddy TE, Wicksteed B, Lowe WL, Layden BT. New insights into gestational glucose metabolism: Lessons learned from 21st century approaches. Diabetes 2015;64(2). doi:10.2337/db14-0877.
  20. Price SA, Lewin A, Nankervis A, Barmanray R. Using continuous glucose monitoring (CGM) to understand glucose control in women with obesity during pregnancy. Clin Obes 2024. doi:10.1111/COB.12717.
  21. Yang J, Cummings EA, O’Connell C, Jangaard K. Fetal and neonatal outcomes of diabetic pregnancies. Obstetrics and Gynecology 2006;108(3). doi:10.1097/01.AOG.0000231688.08263.47.
  22. Temple RC, Aldridge VJ, Murphy HR. Prepregnancy care and pregnancy outcomes in women with type 1 diabetes. Diabetes Care 2006;29(8). doi:10.2337/dc05-2265.
  23. Wu Y, Liu B, Sun Y, Du Y, Santillan MK, Santillan DA, Snetselaar LG, Bao W. Association of Maternal Prepregnancy Diabetes and Gestational Diabetes Mellitus With Congenital Anomalies of the Newborn. Diabetes Care 2020;43(12):2983–2990.
  24. Inkster ME, Fahey TP, Donnan PT, Leese GP, Mires GJ, Murphy DJ. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: Systematic review of observational studies. BMC Pregnancy Childbirth 2006;6. doi:10.1186/1471-2393-6-30.
  25. Makrides M. Is there a dietary requirement for DHA in pregnancy? Prostaglandins Leukot Essent Fatty Acids 2009;81(2–3). doi:10.1016/j.plefa.2009.05.005.
  26. Kitzmiller JL, Block JM, Brown FM, Catalano PM, Conway DL, Coustan DR, Gunderson EP, Herman WH, Hoffman LD, Inturrisi M, Jovanovic LB, Kjos SI, Knopp RH, Montoro MN, Ogata ES, Paramsothy P, Reader DM, Rosenn BM, Thomas AM, Kirkman MS. Managing preexisting diabetes for pregnancy: Summary of evidence and consensus recommendations for care. Diabetes Care 2008;31(5). doi:10.2337/dc08-9020.
  27. Martin RB, Duryea EL, Ambia A, Ragsdale A, McIntire D, Wells CE, Spong CY, Dashe JS, Nelson DB. Congenital Malformation Risk According to Hemoglobin A1c Values in a Contemporary Cohort with Pregestational Diabetes. Am J Perinatol 2021;38(12):1217–1222.
  28. Tennant PWG, Glinianaia S V., Bilous RW, Rankin J, Bell R. Pre-existing diabetes, maternal glycated haemoglobin, and the risks of fetal and infant death: A population-based study. Diabetologia 2014;57(2). doi:10.1007/s00125-013-3108-5.
  29. Clement NS, Abul A, Farrelly R, Murphy HR, Forbes K, Simpson NAB, Scott EM. Pregnancy Outcomes in Type 2 Diabetes: a systematic review and meta-analysis. Am J Obstet Gynecol 2024. doi:10.1016/J.AJOG.2024.11.026.
  30. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. Diabetes Care 2021;44(Supplement 1):S15–S33.
  31. Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstetrics and gynecology 2018;131(2):e49–e64.
  32. Zabihi S, Loeken MR. Understanding diabetic teratogenesis: where are we now and where are we going? Birth Defects Res A Clin Mol Teratol 2010;88(10). doi:10.1002/bdra.20704.
  33. Dheen S, Tay S, Boran J, Ting L, Kumar S, Fu J, Ling E-A. Recent Studies on Neural Tube Defects in Embryos of Diabetic Pregnancy: An Overview. Curr Med Chem 2009;16(18). doi:10.2174/092986709788453069.
  34. Gonzalez-Gonzalez NL, Ramirez O, Mozas J, Melchor J, Armas H, Garcia-Hernandez JA, Caballero A, Hernandez M, Diaz-Gomez MN, Jimenez A, Parache J, Bartha JL. Factors influencing pregnancy outcome in women with type 2 versus type 1 diabetes mellitus. Acta Obstet Gynecol Scand 2008;87(1). doi:10.1080/00016340701778732.
  35. Kazmin A, Garcia-Bournissen F, Koren G. Motherisk Rounds: Risks of Statin Use During Pregnancy: A Systematic Review. Journal of Obstetrics and Gynaecology Canada 2007;29(11). doi:10.1016/S1701-2163(16)32656-1.
  36. Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, Devey LR, Wigmore SJ, Abbas A, Hewett PW, Ahmed A. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007;115(13). doi:10.1161/CIRCULATIONAHA.106.660134.
  37. Costantine MM, Cleary K. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstetrics and Gynecology 2013;121(2 PART 1). doi:10.1097/AOG.0b013e31827d8ad5.
  38. Costantine MM, Tamayo E, Lu F, Bytautiene E, Longo M, Hankins GDV, Saade GR. Using pravastatin to improve the vascular reactivity in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Obstetrics and Gynecology 2010;116(1). doi:10.1097/AOG.0b013e3181e10ebd.
  39. Costantine MM, West H, Wisner KL, Caritis S, Clark S, Venkataramanan R, Stika CS, Rytting E, Wang X, Ahmed MS, Welch E, Snodgrass W, Nanovskaya T, Patrikeeva S, Saade G, Hankins G, Pinheiro E, O’Shea K, Cattan M, Mesches G, Ciolino J, George AL, Fischer D, DeAngeles D, Ren Z. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. Am J Obstet Gynecol 2021;225(6):666.e1-666.e15.
  40. Agarwala A, Dixon DL, Gianos E, Kirkpatrick CF, Michos ED, Satish P, Birtcher KK, Braun LT, Pillai P, Watson K, Wild R, Mehta LS. Dyslipidemia management in women of reproductive potential: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol 2024;18(5). doi:10.1016/J.JACL.2024.05.005.
  41. Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care 2007;30(SUPPL. 2):S112–S119.
  42. García-Patterson A, Gich I, Amini SB, Catalano PM, De Leiva A, Corcoy R. Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: Three changes of direction. Diabetologia 2010;53(3). doi:10.1007/s00125-009-1633-z.
  43. de Veciana M. Diabetes ketoacidosis in pregnancy. Semin Perinatol 2013;37(4):267–273.
  44. Lain KY, Catalano PM. Metabolic changes in pregnancy. Clin Obstet Gynecol 2007;50(4):938–948.
  45. Diderholm B, Stridsberg M, Ewald U, Lindeberg-Nordén S, Gustafsson J. Increased lipolysis in non-obese pregnant women studied in the third trimester. BJOG 2005;112(6). doi:10.1111/j.1471-0528.2004.00534.x.
  46. Catalano PM, Huston L, Amini SB, Kalhan SC. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol 1999;180(4):903–916.
  47. Centers for Disease Control and Prevention UD of H and HS. National Diabetes Statistics Report, 2017. Estimates of Diabetes and Its Burden in the United States Background. Division of Diabetes Translation 2017. doi:10.2196/jmir.9515.
  48. CDC. National Diabetes Statistics Report 2020. Estimates of diabetes and its burden in the United States.; 2020.
  49. Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010. Ann Intern Med 2014;160(8). doi:10.7326/M13-2411.
  50. Gregory ECW, Ely DM. Trends and Characteristics in Gestational Diabetes: United States, 2016–2020. National Vital Statistics Reports 2022;71(3):1–14.
  51. Macintosh MCM, Fleming KM, Bailey JA, Doyle P, Modder J, Acolet D, Golightly S, Miller A. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: Population based study. Br Med J 2006;333(7560). doi:10.1136/bmj.38856.692986.AE.
  52. Cormier CM, Martinez CA, Refuerzo JS, Monga M, Ramin SM, Saade G, Blackwell SC. White’s classification of diabetes in pregnancy in the 21st century: Is it still valid? Am J Perinatol 2010;27(5). doi:10.1055/s-0029-1243307.
  53. Cundy TIM, Gamble G, Neale L, Elder R, McPherson P, Henley P, Rowan J. Differing causes of pregnancy loss in type 1 and type 2 diabetes. Diabetes Care 2007;30(10). doi:10.2337/dc07-0555.
  54. Paglia MJ, Coustan DR. The use of oral antidiabetic medications in gestational diabetes mellitus. Curr Diab Rep 2009;9(4). doi:10.1007/s11892-009-0044-3.
  55. Gutzin SJ, Kozer E, Magee LA, Feig DS, Koren G. The safety of oral hypoglycemic agents in the first trimester of pregnancy: A meta-analysis. Canadian Journal of Clinical Pharmacology 2003;10(4).
  56. Lautatzis ME, Goulis DG, Vrontakis M. Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: A systematic review. Metabolism 2013;62(11). doi:10.1016/j.metabol.2013.06.006.
  57. Ainuddin JA, Karim N, Zaheer S, Ali SS, Hasan AA. Metformin treatment in type 2 diabetes in pregnancy: An active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy. J Diabetes Res 2015;2015. doi:10.1155/2015/325851.
  58. Refuerzo JS, Gowen R, Pedroza C, Hutchinson M, Blackwell SC, Ramin S. A pilot randomized, controlled trial of metformin versus insulin in women with type 2 diabetes mellitus during pregnancy. Am J Perinatol 2015;30(2). doi:10.1055/s-0034-1378144.
  59. Boggess KA, Valint A, Refuerzo JS, Zork N, Battarbee AN, Eichelberger K, Ramos GA, Olson G, Durnwald C, Landon MB, Aagaard KM, Wallace K, Scifres C, Rosen T, Mulla W, Valent A, Longo S, Young L, Marquis MA, Thomas S, Britt A, Berry D. Metformin Plus Insulin for Preexisting Diabetes or Gestational Diabetes in Early Pregnancy: The MOMPOD Randomized Clinical Trial. JAMA 2023;330(22):2182–2190.
  60. Feig DS, Donovan LE, Zinman B, Sanchez JJ, Asztalos E, Ryan EA, Fantus GI, Hutton E, Armson AB, Lipscombe LL, Simmons D, Barrett JFR, Karanicolas PJ, Tobin S, McIntyre HD, Tian SY, Tomlinson G, Murphy KE, Donat D, Gandhi S, Cleave B, Zhou V, Viguiliouk E, Fong D, Strom M, Deans M, Kamath A, Godbout A, Weber F, Mahone M, Wo BL, Bedard MJ, Robinson M, Daigle S, Leblanc S, Ludwig S, Pockett S, Slater L, Oldford C, Young C, Virtanen H, Lodha A, Cooper S, Yamamoto J, Gougeon C, Verhesen C, Zahedi A, Taha N, Turner M, Neculau M, Robb C, Szwiega K, Lee G, Rey E, Perreault S, Coolen J, Ransom T, Dias R, Slaunwhite J, Baxendale D, Fanning C, Halperin I, Gale V, Kader T, Hirsimaki H, Long H, Lambert J, Castonguay A, Chalifoux S, McManus R, Watson M, Powell AM, Sultana M, ArthurHayward V, Marin M, Cauchi L, MacBean L, Keely E, Malcolm J, Clark H, Karovitch A, Belanger H, Champagne J, Schutt K, Sloan J, Mitchell J, Favreau C, O’Shea E, McGuire D, Peng M, St Omer D, Lee J, Klinke J, Young S, Barts A, Carr F, Subrt P, Miller D, Coles K, Capes S, Smushkin G, Phillips R, Fergusson C, Lacerte S, Houlden R, Breen A, Stone-Hope B, Kwong S, Rylance H, Khurana R, McNab T, Beauchamp S, Weisnagel SJ, D’Amours M, Allen C, Dubé MC, Julien VÈ, Lambert C, Bourbonniere MC, Rheaume L, Bouchard M, Carson G, Williams S, Wolfs M, Berger H, Cheng A, Ray J, Hanna A, De Souza L, Berndl L, Meltzer S, Garfield N, El-Messidi A, Bastien L, Segal S, Thompson D, Lim K, Kong J, Thompson S, Orr C, Galway B, Parsons M, Rideout K, Rowe B, Crane J, Andrews W, Joyce C, Newstead-Angel J, Brandt J, Meier S, Laurie J, Liley H, Fox J, Barrett H, Maguire F, Nerdal-Bussell M, Nie W, Bergan C, Cavallaro B, Tremellen A, Cook A, Rajagopal R, Vizza L, Mattick M, Bishop C, Nema J, Kludas R, McLean M, Hendon S, Sigmund A, Wong V, Lata P, Russell H, Singh R, McMurray K, Karanicolas P, Murphy H, Sanchez J, Klein G, Tian S, Mangoff K. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2020;8(10):834–844.
  61. Rowan JA, Rush EC, Plank LD, Lu J, Obolonkin V, Coat S, Hague WM. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. BMJ Open Diabetes Res Care 2018;6(1). doi:10.1136/BMJDRC-2017-000456.
  62. Feig DS, Sanchez JJ, Murphy KE, Asztalos E, Zinman B, Simmons D, Haqq AM, Fantus IG, Lipscombe L, Armson A, Barrett J, Donovan L, Karanicolas P, Tobin S, Mangoff K, Klein G, Jiang Y, Tomlinson G, Hamilton J, Galper A, Cleave B, Strom M, Poolman K, Fong D, Viguiliouk E, Legault L, Boutin L, Ho J, Virtanen H, Zahedi A, Szwiega K, Coolen J, Dias R, Sellers E, Fletcher B, Bourrier L, Haqq A, Rylance H, Hadjiyannakis S, Courtney J, McManus R, Halperin I, Miller D, Coles K, Simmons D, Nema J, Weisnagel SJ, Dubé MC, Chanoine JP, Kwan J, McIntyre HD, Laurie J, Maguire F, Soper J, Bridger T, Houlden R, Breen A, McLean M, Duke A, Hendon S, Sigmund A. Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial. Lancet Diabetes Endocrinol 2023;11(3):191–202.
  63. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356(6):551–566.
  64. Palomba S, Orio F, Falbo A, Manguso F, Russo T, Cascella T, Tolino A, Carmina E, Colao A, Zullo F. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90(7):4068–4074.
  65. Vanky E, Stridsklev S, Heimstad R, Romundstad P, Skogøy K, Kleggetveit O, Hjelle S, Von Brandis P, Eikeland T, Flo K, Berg KF, Bunford G, Lund A, Bjerke C, Almås I, Berg AH, Danielson A, Lahmami G, Carlsen SM. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab 2010;95(12). doi:10.1210/JC.2010-0853.
  66. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008;89(3):505–522.
  67. Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ 2015;350. doi:10.1136/BMJ.H102.
  68. Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ 2015;350. doi:10.1136/BMJ.H102.
  69. Tarry-Adkins JL, Aiken CE, Ozanne SE. Comparative impact of pharmacological treatments for gestational diabetes on neonatal anthropometry independent of maternal glycaemic control: A systematic review and meta-analysis. PLoS Med 2020;17(5). doi:10.1371/JOURNAL.PMED.1003126.
  70. Muller DRP, Stenvers DJ, Malekzadeh A, Holleman F, Painter RC, Siegelaar SE. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Front Endocrinol (Lausanne) 2023;14. doi:10.3389/FENDO.2023.1215356.
  71. Cesta CE, Rotem R, Bateman BT, Chodick G, Cohen JM, Furu K, Gissler M, Huybrechts KF, Kjerpeseth LJ, Leinonen MK, Pazzagli L, Zoega H, Seely EW, Patorno E, Hernández-Díaz S. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med 2024;184(2):144–152.
  72. Watanabe JH, Kwon J, Nan B, Reikes A. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc (2003) 2024;64(1):133–138.
  73. DRUMMOND RF, SEIF KE, REECE EA. Glucagon-like peptide-1 receptor agonist use in pregnancy: a review. Am J Obstet Gynecol 2025;232(1). doi:10.1016/J.AJOG.2024.08.024.
  74. Hinnen D. Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. Diabetes Spectr 2017;30(3):202–210.
  75. A Q, TJ W, D K, C H, MJ B, MA F, N F, K B, C B, LL H, A I, J L, M M, R M, R M, J T. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med 2018;168(8):569–576.
  76. Marx N, Husain M, Lehrke M, Verma infodh, Sattar N. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. Circulation 2022;146(24):1882–1894.
  77. Garcia-Flores V, Romero R, Miller D, Xu Y, Done B, Veerapaneni C, Leng Y, Arenas-Hernandez M, Khan N, Panaitescu B, Hassan SS, Alvarez-Salas LM, Gomez-Lopez N. Inflammation-Induced Adverse Pregnancy and Neonatal Outcomes Can Be Improved by the Immunomodulatory Peptide Exendin-4. Front Immunol 2018;9(JUN). doi:10.3389/FIMMU.2018.01291.
  78. Dao K, Shechtman S, Weber-Schoendorfer C, Diav-Citrin O, Murad RH, Berlin M, Hazan A, Richardson JL, Eleftheriou G, Rousson V, Diezi L, Haefliger D, Simões-Wüst AP, Addor MC, Baud D, Lamine F, Panchaud A, Buclin T, Girardin FR, Winterfeld U. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open 2024;14(4). doi:10.1136/BMJOPEN-2023-083550.
  79. Suffecool K, Rosenn B, Niederkofler EE, Kiernan UA, Foroutan J, Antwi K, Ribar A, Bapat P, Koren G. Insulin detemir does not cross the human placenta. Diabetes Care 2015;38(2):e20–e21.
  80. Pollex EK, Feig DS, Lubetsky A, Yip PM, Koren G. Insulin glargine safety in pregnancy: a transplacental transfer study. Diabetes Care 2010;33(1):29–33.
  81. Holcberg G, Tsadkin-Tamir M, Sapir O, Wiznizer A, Segal D, Polachek H, Zvi Z Ben. Transfer of insulin lispro across the human placenta. European Journal of Obstetrics and Gynecology and Reproductive Biology 2004;115(1):117–118.
  82. ElSayed NA, McCoy RG, Aleppo G, Bajaj M, Balapattabi K, Beverly EA, Briggs Early K, Bruemmer D, Echouffo-Tcheugui JB, Ekhlaspour L, Gaglia JL, Garg R, Girotra M, Khunti K, Lal R, Lingvay I, Matfin G, Neumiller JJ, Pandya N, Pekas EJ, Pilla SJ, Polsky S, Segal AR, Seley JJ, Stanton RC, Bannuru RR. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care 2025;48(Supplement_1):S181–S206.
  83. Lepercq J, Lin J, Hall GC, Wang E, Dain M-P, Riddle MC, Home PD. Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy. Obstet Gynecol Int 2012;2012. doi:10.1155/2012/649070.
  84. Pollex E, Moretti ME, Koren G, Feig DS. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. Ann Pharmacother 2011;45(1):9–16.
  85. Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat Rev Endocrinol 2017;13(7):385–399.
  86. Mathiesen ER, Hod M, Ivanisevic M, Garcia SD, Brøndsted L, Jovanovič L, Damm P, McCance DR. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care 2012;35(10). doi:10.2337/dc11-2264.
  87. Hod M, Mathiesen ER, Jovanovič L, McCance DR, Ivanisevic M, Durán-Garcia S, Brondsted L, Nazeri A, Damm P. A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. Journal of Maternal-Fetal and Neonatal Medicine 2014;27(1). doi:10.3109/14767058.2013.799650.
  88. Fishel Bartal M, Ward C, Blackwell SC, Ashby Cornthwaite JA, Zhang C, Refuerzo JS, Pedroza C, Lee KH, Chauhan SP, Sibai BM. Detemir vs neutral protamine Hagedorn insulin for diabetes mellitus in pregnancy: a comparative effectiveness, randomized controlled trial. Am J Obstet Gynecol 2021;225(1):87.e1-87.e10.
  89. Mathiesen ER, Alibegovic AC, Corcoy R, Dunne F, Feig DS, Hod M, Jia T, Kalyanam B, Kar S, Kautzky-Willer A, Marchesini C, Rea RD, Damm P. Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open label, multinational, randomised, controlled, non-inferiority trial. Lancet Diabetes Endocrinol 2023;11(2):86–95.
  90. Gabbe SG, Carpenter LB, Garrison EA. New strategies for glucose control in patients with type 1 and type 2 diabetes mellitus in pregnancy. Clin Obstet Gynecol 2007;50(4). doi:10.1097/GRF.0b013e31815a6435.
  91. Hod M, Damm P, Kaaja R, Visser GHA, Dunne F, Demidova I, Hansen ASP, Mersebach H. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 2008;198(2). doi:10.1016/j.ajog.2007.08.005.
  92. Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, Bellaire S, Raben A. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: A randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007;30(4). doi:10.2337/dc06-1887.
  93. Murphy HR, Elleri D, Allen JM, Harris J, Simmons D, Rayman G, Temple RC, Umpleby AM, Dunger DB, Haidar A, Nodale M, Wilinska ME, Hovorka R. Pathophysiology of postprandial hyperglycaemia in women with type 1 diabetes during pregnancy. Diabetologia 2012;55(2). doi:10.1007/s00125-011-2363-6.
  94. Valent AM, Barbour LA. Insulin Management for Gestational and Type 2 Diabetes in Pregnancy. Obstetrics and gynecology 2024;144(5). doi:10.1097/AOG.0000000000005640.
  95. Benhalima K, Beunen K, Siegelaar SE, Painter R, Murphy HR, Feig DS, Donovan LE, Polsky S, Buschur E, Levy CJ, Kudva YC, Battelino T, Ringholm L, Mathiesen ER, Mathieu C. Management of type 1 diabetes in pregnancy: update on lifestyle, pharmacological treatment, and novel technologies for achieving glycaemic targets. Lancet Diabetes Endocrinol 2023;11(7):490–508.
  96. Nørgaard SK, Søholm JC, Mathiesen ER, Nørgaard K, Clausen TD, Holmager P, Do NC, Damm P, Ringholm L. Faster-acting insulin aspart versus insulin aspart in the treatment of type 1 or type 2 diabetes during pregnancy and post-delivery (CopenFast): an open-label, single-centre, randomised controlled trial. Lancet Diabetes Endocrinol 2023;11(11):811–821.
  97. Hadar E, Stewart ZA, Hod M, Murphy HR. Technology and Pregnancy. Diabetes Technol Ther 2017;19(S1). doi:10.1089/dia.2017.2508.
  98. Kallas-Koeman MM, Kong JM, Klinke JA, Butalia S, Lodha AK, Lim KI, Duan QM, Donovan LE. Insulin pump use in pregnancy is associated with lower HbA1c without increasing the rate of severe hypoglycaemia or diabetic ketoacidosis in women with type 1 diabetes. Diabetologia 2014;57(4). doi:10.1007/s00125-014-3163-6.
  99. Feig DS, Corcoy R, Donovan LE, Murphy KE, Barrett JFR, Johanna Sanchez J, Wysocki T, Ruedy K, Kollman C, Tomlinson G, Murphy HR. Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial. Diabetes Care 2018;41(12):2471–2479.
  100. Kekäläinen P, Juuti M, Walle T, Laatikainen T. Continuous Subcutaneous Insulin Infusion during Pregnancy in Women with Complicated Type 1 Diabetes is Associated with Better Glycemic Control but Not with Improvement in Pregnancy Outcomes. Diabetes Technol Ther 2016;18(3). doi:10.1089/dia.2015.0165.
  101. Gabbe SG, Holing E, Temple P. Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus. Am J Obstet Gynecol 2000;182(6). doi:10.1067/mob.2000.106182.
  102. Farrar D, Tuffnell DJ, West J, West HM. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev 2016;(6). doi:10.1002/14651858.CD005542.pub3.
  103. Mathiesen JM, Secher AL, Ringholm L, Norgaard K, Hommel E, Andersen HU, Damm P, Mathiesen ER. Changes in basal rates and bolus calculator settings in insulin pumps during pregnancy in women with type 1 diabetes. J Matern Fetal Neonatal Med 2014;27(7):724–728.
  104. Abell SK, Suen M, Pease A, Boyle JA, Soldatos G, Regan J, Wallace EM, Teede HJ. Pregnancy Outcomes and Insulin Requirements in Women with Type 1 Diabetes Treated with Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections: Cohort Study. Diabetes Technol Ther 2017;19(5):280–287.
  105. Castorino K, Paband R, Zisser H, Jovanovič L. Insulin pumps in pregnancy: using technology to achieve normoglycemia in women with diabetes. Curr Diab Rep 2012;12(1):53–59.
  106. Mukhopadhyay A, Farrell T, Fraser RB, Ola B. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol 2007;197(5). doi:10.1016/j.ajog.2007.03.062.
  107. Mathiesen JM, Secher AL, Ringholm L, Norgaard K, Hommel E, Andersen HU, Damm P, Mathiesen ER. Changes in basal rates and bolus calculator settings in insulin pumps during pregnancy in women with type 1 diabetes. Journal of Maternal-Fetal and Neonatal Medicine 2014;27(7). doi:10.3109/14767058.2013.837444.
  108. Qiu L, Weng J, Zheng X, Luo S, Yang D, Xu W, Cai M, Xu F, Yan J, Yao B. Insulin dose analysis during pregnancy in type 1 diabetic patients treated with insulin pump therapy. National Medical Journal of China 2017;97(8). doi:10.3760/cma.j.issn.0376.2491.2017.08.004.
  109. Nally LM, Blanchette JE. Integrated Strategies to Support Diabetes Technology in Pregnancy. Obstetrics and gynecology 2024;144(5). doi:10.1097/AOG.0000000000005710.
  110. Kravarusic J, Aleppo G. Diabetes Technology Use in Adults with Type 1 and Type 2 Diabetes. Endocrinol Metab Clin North Am 2020;49(1):37–55.
  111. Ebekozien O, Mungmode A, Sanchez J, Rompicherla S, Demeterco-Berggren C, Weinstock RS, Jacobsen LM, Davis G, McKee A, Akturk HK, Maahs DM, Kamboj MK. Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016-2022) from the T1D Exchange Quality Improvement Collaborative. Diabetes Technol Ther 2023;25(11):765–773.
  112. Lee TTM, Collett C, Bergford S, Hartnell S, Scott EM, Lindsay RS, Hunt KF, McCance DR, Barnard-Kelly K, Rankin D, Lawton J, Reynolds RM, Flanagan E, Hammond M, Shepstone L, Wilinska ME, Sibayan J, Kollman C, Beck R, Hovorka R, Murphy HR. Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes. N Engl J Med 2023;389(17):1566–1578.
  113. Benhalima K, Beunen K, Van Wilder N, Ballaux D, Vanhaverbeke G, Taes Y, Aers XP, Nobels F, Marlier J, Lee D, Cuypers J, Preumont V, Siegelaar SE, Painter RC, Laenen A, Gillard P, Mathieu C. Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2024;12(6):390–403.
  114. Polsky S, Buschur E, Dungan K, Garcetti R, Nease E, Malecha E, Bartholomew A, Johnson C, Pyle L, Snell-Bergeon J. Randomized Trial of Assisted Hybrid Closed-Loop Therapy Versus Sensor-Augmented Pump Therapy in Pregnancy. Diabetes Technol Ther 2024;26(8):547–555.
  115. Study Details | Pregnancy Intervention With a Closed-Loop System (PICLS) Study | ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT03774186. Accessed December 18, 2024.
  116. Closed-loop Insulin Delivery In Type 1 Diabetes Pregnancies (CIRCUIT) | ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT04902378. Accessed December 18, 2024.
  117. Wang XS, Dunlop AD, McKeen JA, Feig DS, Donovan LE. Real-world use of Control-IQTM technology automated insulin delivery in pregnancy: A case series with qualitative interviews. Diabet Med 2023;40(6). doi:10.1111/DME.15086.
  118. Waikar AR, Arora T, Haynes M, Tamborlane W V., Nally LM. Case Report: Managing Pregnancy With Type 1 Diabetes Using a Do-It-Yourself Artificial Pancreas System. Clin Diabetes 2021;39(4):441–444.
  119. Morrison AE, Chong K, Senior PA, Lam A. A scoping review of Do-It-Yourself Automated Insulin Delivery system (DIY AID) use in people with type 1 diabetes. PLoS One 2022;17(8). doi:10.1371/JOURNAL.PONE.0271096.
  120. Lawton J, Kimbell B, Closs M, Hartnell S, Lee TTM, Dover AR, Reynolds RM, Collett C, Barnard-Kelly K, Hovorka R, Rankin D, Murphy HR. Listening to Women: Experiences of Using Closed-Loop in Type 1 Diabetes Pregnancy. Diabetes Technol Ther 2023;25(12):845–855.
  121. Farrington C, Stewart Z, Hovorka R, Murphy H. Women’s Experiences of Day-and-Night Closed-Loop Insulin Delivery During Type 1 Diabetes Pregnancy. J Diabetes Sci Technol 2018;12(6):1125–1131.
  122. Farrington C, Stewart ZA, Barnard K, Hovorka R, Murphy HR. Experiences of closed-loop insulin delivery among pregnant women with Type 1 diabetes. Diabet Med 2017;34(10):1461–1469.
  123. Lawton J, Rankin D, Hartnell S, Lee T, Dover AR, Reynolds RM, Hovorka R, Murphy HR, Hart RI. Healthcare professionals’ views about how pregnant women can benefit from using a closed-loop system: Qualitative study. Diabet Med 2023;40(5). doi:10.1111/DME.15072.
  124. Manderson JG, Patterson CC, Hadden DR, Traub AI, Ennis C, McCance DR. Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol 2003;189(2). doi:10.1067/S0002-9378(03)00497-6.
  125. Jovanovic L, Knopp RH, Brown Z, Conley MR, Park E, Mills JL, Metzger BE, Aarons JH, Holmes LB, Simpson JL. Declining insulin requirement in the late first trimester of diabetic pregnancy. Diabetes Care 2001;24(7). doi:10.2337/diacare.24.7.1130.
  126. Rosenn BM, Miodovnik M, Holcberg G, Khoury JC, Siddiqi TA. Hypoglycemia: The price of intensive insulin therapy for pregnant women with insulin-dependent diabetes mellitus. Obstetrics and Gynecology 1995;85(3). doi:10.1016/0029-7844(94)00415-A.
  127. Rosenn BM, Miodovnik M, Khoury JC, Siddiqi TA. Counterregulatory hormonal responses to hypoglycemia during pregnancy. Obstetrics and Gynecology 1996;87(4). doi:10.1016/0029-7844(95)00495-5.
  128. Björklund A, Adamson U, Andréasson K, Carlström K, Hennen G, Igout A, Lins PE, Westgren M. Hormonal counterregulation and subjective symptoms during induced hypoglycemia in insulin-dependent diabetes mellitus patients during and after pregnancy. Acta Obstet Gynecol Scand 1998;77(6). doi:10.1034/j.1600-0412.1998.770609.x.
  129. Heller S, Damm P, Mersebach H, Skjøth TV, Kaaja R, Hod M, Durán-García S, McCance D, Mathiesen ER. Hypoglycemia in type 1 diabetic pregnancy: Role of preconception insulin aspart treatment in a randomized study. Diabetes Care 2010;33(3). doi:10.2337/dc09-1605.
  130. Negrato CA, Rafacho A, Negrato G, Teixeira MF, Araújo CAR, Vieira L, Silva CA, Date SK, Demarchi AC, Gomes MB. Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: An observational cohort study. Diabetes Res Clin Pract 2010;89(1). doi:10.1016/j.diabres.2010.03.015.
  131. Gómez AM, Marín Carrillo LF, Arévalo Correa CM, Muñoz Velandia OM, Rondón Sepúlveda MA, Silva Herrera JL, Henao Carrillo DC. Maternal-Fetal Outcomes in 34 Pregnant Women with Type 1 Diabetes in Sensor-Augmented Insulin Pump Therapy. Diabetes Technol Ther 2017;19(7). doi:10.1089/dia.2017.0030.
  132. Stewart ZA, Wilinska ME, Hartnell S, Temple RC, Rayman G, Stanley KP, Simmons D, Law GR, Scott EM, Hovorka R, Murphy HR. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. New England Journal of Medicine 2016;375(7). doi:10.1056/nejmoa1602494.
  133. Murphy HR, Rayman G, Duffield K, Lewis KS, Kelly S, Johal B, Fowler D, Temple RC. Changes in the glycemic profiles of women with type 1 and type 2 diabetes during pregnancy. Diabetes Care 2007;30(11):2785–2791.
  134. Ter Braak EWMT, Evers IM, Erkelens DW, Visser GHA. Maternal hypoglycemia during pregnancy in type 1 diabetes: Maternal and fetal consequences. Diabetes Metab Res Rev 2002;18(2). doi:10.1002/dmrr.271.
  135. Ringholm L, Secher AL, Pedersen-Bjergaard U, Thorsteinsson B, Andersen HU, Damm P, Mathiesen ER. The incidence of severe hypoglycaemia in pregnant women with type 1 diabetes mellitus can be reduced with unchanged HbA1c levels and pregnancy outcomes in a routine care setting. Diabetes Res Clin Pract 2013;101(2). doi:10.1016/j.diabres.2013.06.002.
  136. de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT. Postprandial versus Preprandial Blood Glucose Monitoring in Women with Gestational Diabetes Mellitus Requiring Insulin Therapy. New England Journal of Medicine 1995;333(19):1237–1241.
  137. Jovanovic-Peterson L, Peterson CM, Reed GF, Metzger BE, Mills JL, Knopp RH, Aarons JH. Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development--Diabetes in Early Pregnancy Study. Am J Obstet Gynecol 1991;164(1 Pt 1).
  138. Murphy HR, Rayman G, Lewis K, Kelly S, Johal B, Duffield K, Fowler D, Campbell PJ, Temple RC. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: Randomised clinical trial. BMJ 2008;337(7675):907–910.
  139. Feig DS, Donovan LE, Corcoy R, Murphy KE, Amiel SA, Hunt KF, Asztalos E, Barrett JFR, Sanchez JJ, de Leiva A, Hod M, Jovanovic L, Keely E, McManus R, Hutton EK, Meek CL, Stewart ZA, Wysocki T, O’Brien R, Ruedy K, Kollman C, Tomlinson G, Murphy HR, Grisoni J, Byrne C, Davenport K, Neoh S, Gougeon C, Oldford C, Young C, Green L, Rossi B, Rogers H, Cleave B, Strom M, Adelantado JM, Isabel Chico A, Tundidor D, Malcolm J, Henry K, Morris D, Rayman G, Fowler D, Mitchell S, Rosier J, Temple R, Turner J, Canciani G, Hewapathirana N, Piper L, Kudirka A, Watson M, Bonomo M, Pintaudi B, Bertuzzi F, Daniela G, Mion E, Lowe J, Halperin I, Rogowsky A, Adib S, Lindsay R, Carty D, Crawford I, Mackenzie F, McSorley T, Booth J, McInnes N, Smith A, Stanton I, Tazzeo T, Weisnagel J, Mansell P, Jones N, Babington G, Spick D, MacDougall M, Chilton S, Cutts T, Perkins M, Scott E, Endersby D, Dover A, Dougherty F, Johnston S, Heller S, Novodorsky P, Hudson S, Nisbet C, Ransom T, Coolen J, Baxendale D, Holt R, Forbes J, Martin N, Walbridge F, Dunne F, Conway S, Egan A, Kirwin C, Maresh M, Kearney G, Morris J, Quinn S, Bilous R, Mukhtar R, Godbout A, Daigle S, Lubina A, Jackson M, Paul E, Taylor J, Houlden R, Breen A, Banerjee A, Brackenridge A, Briley A, Reid A, Singh C, Newstead-Angel J, Baxter J, Philip S, Chlost M, Murray L, Castorino K, Frase D, Lou O, Pragnell M. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. The Lancet 2017. doi:10.1016/S0140-6736(17)32400-5.
  140. Law GR, Gilthorpe MS, Secher AL, Temple R, Bilous R, Mathiesen ER, Murphy HR, Scott EM. Translating HbA1c measurements into estimated average glucose values in pregnant women with diabetes. Diabetologia 2017;60(4):618–624.
  141. Sanusi AA, Xue Y, McIlwraith C, Howard H, Brocato BE, Casey B, Szychowski JM, Battarbee AN. Association of Continuous Glucose Monitoring Metrics With Pregnancy Outcomes in Patients With Preexisting Diabetes. Diabetes Care 2024;47(1):89–96.
  142. Kristensen K, Ögge LE, Sengpiel V, Kjölhede K, Dotevall A, Elfvin A, Knop FK, Wiberg N, Katsarou A, Shaat N, Kristensen L, Berntorp K. Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies. Diabetologia 2019;62(7):1143–1153.
  143. Murphy HR, Rayman G, Lewis K, Kelly S, Johal B, Duffield K, Fowler D, Campbell PJ, Temple RC. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ 2008;337(7675):907–910.
  144. Secher AL, Ringholm L, Andersen HU, Damm P, Mathiesen ER. The effect of real-time continuous glucose monitoring in pregnant women with diabetes: a randomized controlled trial. Diabetes Care 2013;36(7):1877–1883.
  145. Voormolen DN, DeVries JH, Sanson RME, Heringa MP, de Valk HW, Kok M, van Loon AJ, Hoogenberg K, Bekedam DJ, Brouwer TCB, Porath M, Erdtsieck RJ, NijBijvank B, Kip H, van der Heijden OWH, Elving LD, Hermsen BB, Potter van Loon BJ, Rijnders RJP, Jansen HJ, Langenveld J, Akerboom BMC, Kiewiet RM, Naaktgeboren CA, Mol BWJ, Franx A, Evers IM. Continuous glucose monitoring during diabetic pregnancy (GlucoMOMS): A multicentre randomized controlled trial. Diabetes Obes Metab 2018;20(8):1894–1902.
  146. Murphy H, Scott E, Collett C. Continuous glucose monitoring amongst pregnant women with early-onset type 2 diabetes. https://www.isrctn.com/ISRCTN12804317.
  147. Venkatesh KK, Joseph JJ, Swoboda C, Strouse R, Hoseus J, Baker C, Summerfield T, Bartholomew A, Buccilla L, Pan X, Sieck C, McAlearney AS, Huerta TR, Fareed N. Multicomponent provider-patient intervention to improve glycaemic control in Medicaid-insured pregnant individuals with type 2 diabetes: clinical trial protocol for the ACHIEVE study. BMJ Open 2023;13(5). doi:10.1136/BMJOPEN-2023-074657.
  148. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, Hans DeVries J, Donaghue KC, Dovc K, Doyle FJ, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 2019;42(8):1593–1603.
  149. Finneran MM, Kiefer MK, Ware CA, Buschur EO, Thung SF, Landon MB, Gabbe SG. The use of longitudinal hemoglobin A1c values to predict adverse obstetric and neonatal outcomes in pregnancies complicated by pregestational diabetes. Am J Obstet Gynecol MFM 2020;2(1). doi:10.1016/J.AJOGMF.2019.100069.
  150. Mosca A, Paleari R, Dalfrà MG, Di Cianni G, Cuccuru I, Pellegrini G, Malloggi L, Bonomo M, Granata S, Ceriotti F, Castiglioni MT, Songini M, Tocco G, Masin M, Plebani M, Lapolla A. Reference intervals for hemoglobin A1c in pregnant women: data from an Italian multicenter study. Clin Chem 2006;52(6):1138–1143.
  151. Nielsen LR, Ekbom P, Damm P, Glümer C, Frandsen MM, Jensen DM, Mathiesen ER. HbA1c levels are significantly lower in early and late pregnancy. Diabetes Care 2004;27(5):1200–1201.
  152. Relph S, Patel T, Delaney L, Sobhy S, Thangaratinam S. Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: A systematic review and meta-analysis. PLoS Med 2021;18(11). doi:10.1371/JOURNAL.PMED.1003856.
  153. Widyaputri F, Rogers S, Lim L. Global Estimates of Diabetic Retinopathy Prevalence and Progression in Pregnant Individuals With Preexisting Diabetes: A Meta-analysis. JAMA Ophthalmol 2022;140(11):1137–1138.
  154. Rahman W, Rahman FZ, Yassin S, Al-Suleiman SA, Rahman J. Progression of retinopathy during pregnancy in type 1 diabetes mellitus. Clin Exp Ophthalmol 2007;35(3). doi:10.1111/j.1442-9071.2006.01413.x.
  155. Chew EY, Mills JL, Metzger BE, Remaley NA, Jovanovic-Peterson L, Knopp RH, Conley M, Rand L, Simpson JL, Holmes LB. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care 1995;18(5).
  156. Temple RC, Aldridge VA, Sampson MJ, Greenwood RH, Heyburn PJ, Glenn A. Impact of pregnancy on the progression of diabetic retinopathy in Type 1 diabetes. Diabetic Medicine 2001;18(7). doi:10.1046/j.1464-5491.2001.00535.x.
  157. Egan AM, McVicker L, Heerey A, Carmody L, Harney F, Dunne FP. Diabetic retinopathy in pregnancy: A population-based study of women with pregestational diabetes. J Diabetes Res 2015;2015. doi:10.1155/2015/310239.
  158. Toda J, Kato S, Sanaka M, Kitano S. The effect of pregnancy on the progression of diabetic retinopathy. Jpn J Ophthalmol 2016;60(6). doi:10.1007/s10384-016-0464-y.
  159. Ringholm L, Vestgaard M, Laugesen CS, Juul A, Damm P, Mathiesen ER. Pregnancy-induced increase in circulating IGF-I is associated with progression of diabetic retinopathy in women with type 1 diabetes. Growth Hormone and IGF Research 2011;21(1). doi:10.1016/j.ghir.2010.12.001.
  160. Vestgaard M, Ringholm L, Laugesen CS, Rasmussen KL, Damm P, Mathiesen ER. Pregnancy-induced sight-threatening diabetic retinopathy in women with Type 1 diabetes. Diabetic Medicine 2010;27(4). doi:10.1111/j.1464-5491.2010.02958.x.
  161. Ekbom P, Damm P, Feldt-Rasmussen B, Feldt-Rasmussen U, Molvig J, Mathiesen ER. Pregnancy Outcome in Type 1 Diabetic Women With Microalbuminuria. Diabetes Care 2001;24(10). doi:10.2337/diacare.24.10.1739.
  162. Dunne FP, Chowdhury TA, Hartland A, Smith T, Brydon PA, McConkey C, Nicholson HO. Pregnancy outcome in women with insulin-dependent diabetes mellitus complicated by nephropathy. QJM 1999;92(8). doi:10.1093/qjmed/92.8.451.
  163. Rossing K, Jacobsen P, Hommel E, Mathiesen E, Svenningsen A, Rossing P, Parving HH. Pregnancy and progression of diabetic nephropathy. Diabetologia 2002;45(1). doi:10.1007/s125-002-8242-4.
  164. Jensen DM, Damm P, Ovesen PER, Mølsted-Pedersen L, Beck-Nielsen H, Westergaard JG, Moeller M, Mathiesen ER. Microalbuminuria, preeclampsia, and preterm delivery in pregnant women with type 1 diabetes: Results from a nationwide Danish study. Diabetes Care 2010;33(1). doi:10.2337/dc09-1219.
  165. Reece EA, Leguizamon G, Homko C. Stringent controls in diabetic nephropathy associated with optimization of pregnancy outcomes. J Matern Fetal Med 1998;7(4). doi:10.1002/(sici)1520-6661(199807/08)7:4<213::aid-mfm11>3.0.co;2-e.
  166. Leguizamon G, Reece EA. Effect of medical therapy on progressive nephropathy: Influence of pregnancy, diabetes and hypertension. Journal of Maternal-Fetal and Neonatal Medicine 2000;9(1). doi:10.3109/14767050009020517.
  167. Ringholm Nielsen L, Damm P, Mathiesen ER. Improved Pregnancy Outcome in Type 1 Diabetic Women With Microalbuminuria or Diabetic Nephropathy: Effect of intensified antihypertensive therapy? Diabetes Care 2009;32(1):38–44.
  168. Gordon M, Landon MB, Samuels P, Hissrich S, Gabbe SG. Perinatal outcome and long-term follow-up associated with modern management of diabetic nephropathy. Obstetrics and Gynecology 1996;87(3). doi:10.1016/0029-7844(95)00420-3.
  169. Kimmerle R, Za RP, Cupisti S, Somville T, Bender R, Pawlowski B, Berger M. Pregnancies in women with diabetic nephropathy: long-term outcome for mother and child. Diabetologia 1995;38(2). doi:10.1007/BF00400099.
  170. Kattah A, Milic N, White W, Garovic V. Spot urine protein measurements in normotensive pregnancies, pregnancies with isolated proteinuria and preeclampsia. Am J Physiol Regul Integr Comp Physiol 2017;313(4):R418–R424.
  171. Waugh J, Hooper R, Lamb E, Robson S, Shennan A, Milne F, Price C, Thangaratinam S, Berdunov V, Bingham J. Spot protein-creatinine ratio and spot albumin-creatinine ratio in the assessment of pre-eclampsia: A diagnostic accuracy study with decision-analytic model-based economic evaluation and acceptability analysis. Health Technol Assess (Rockv) 2017;21(61). doi:10.3310/hta21610.
  172. Li DK, Yang C, Andrade S, Tavares V, Ferber JR. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: A retrospective cohort study. BMJ (Online) 2011;343(7829). doi:10.1136/bmj.d5931.
  173. Bateman BT, Patorno E, Desai RJ, Seely EW, Mogun H, Dejene SZ, Fischer MA, Friedman AM, Hernandez-Diaz S, Huybrechts KF. Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations. In: Obstetrics and Gynecology.Vol 129.; 2017. doi:10.1097/AOG.0000000000001775.
  174. Saar T, Levitt L, Amsalem H. Reversible Fetal Renal Impairment following Angiotensin Receptor Blocking Treatment during Third Trimester of Pregnancy: Case Report and Review of the Literature. Case Rep Obstet Gynecol 2016;2016. doi:10.1155/2016/2382031.
  175. Bar J, Ben-Rafael Z, Padoa A, Orvieto R, Boner G, Hod M. Prediction of pregnancy outcome in subgroups of women with renal disease. Clin Nephrol 2000;53(6). doi:10.1097/00006254-200103000-00004.
  176. Mohammadi FA, Borg M, Gulyani A, McDonald SP, Jesudason S. Pregnancy outcomes and impact of pregnancy on graft function in women after kidney transplantation. Clin Transplant 2017;31(10). doi:10.1111/ctr.13089.
  177. Gordon MC, Landon MB, Boyle J, Stewart KS, Gabbe SG. Coronary artery disease in insulin-dependent diabetes mellitus of pregnancy (class H): A review of the literature. Obstet Gynecol Surv 1996;51(7). doi:10.1097/00006254-199607000-00023.
  178. Jones TB, Savasan ZA, Johnson Q, Bahado-Singh R. Management of Pregnant Patients with Diabetes with Ischemic Heart Disease. Clin Lab Med 2013;33(2). doi:10.1016/j.cll.2013.03.020.
  179. Wilson JD, Moore G. Successful Pregnancy in the Didmoad Syndrome (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, Deafness). Australian and New Zealand Journal of Obstetrics and Gynaecology 1995;35(1). doi:10.1111/j.1479-828X.1995.tb01844.x.
  180. Pombar X, Strassner HT, Penner PC. Pregnancy in a woman with class H diabetes mellitus and previous coronary artery bypass graft: A case report and review of the literature. Obstetrics and Gynecology 1995;85(5). doi:10.1016/0029-7844(94)00440-O.
  181. Umpierrez GE, Latif KA, Murphy MB, Lambeth HC, Stentz F, Bush A, Kitabchi AE. Thyroid dysfunction in patients with type 1 diabetes: A longitudinal study. Diabetes Care 2003;26(4). doi:10.2337/diacare.26.4.1181.
  182. De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, Eastman CJ, Lazarus JH, Luton D, Mandel SJ, Mestman J, Rovet J, Sullivan S. Management of thyroid dysfunction during pregnancy and postpartum: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2012;97(8). doi:10.1210/jc.2011-2803.
  183. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid 2011;21(10). doi:10.1089/thy.2011.0087.
  184. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum. Thyroid 2017;27(3):315–389.
  185. ACOG Practice Bulletin, Number 223: Thyroid Disease in Pregnancy: Obstetrics and gynecology 2020;135(6). doi:10.1097/AOG.0000000000003893.
  186. Casey BM, Thom EA, Peaceman AM, Varner MW, Sorokin Y, Hirtz DG, Reddy UM, Wapner RJ, Thorp JM, Saade G, Tita ATN, Rouse DJ, Sibai B, Iams JD, Mercer BM, Tolosa J, Caritis SN, VanDorsten JP. Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy. New England Journal of Medicine 2017;376(9). doi:10.1056/nejmoa1606205.
  187. Pham-Short A, Donaghue KC, Ambler G, Phelan H, Twigg S, Craig ME. Screening for celiac disease in type 1 diabetes: A systematic review. Pediatrics 2015;136(1). doi:10.1542/peds.2014-2883.
  188. Craig ME, Prinz N, Boyle CT, Campbell FM, Jones TW, Hofer SE, Simmons JH, Holman N, Tham E, Fröhlich-Reiterer E, DuBose S, Thornton H, King B, Maahs DM, Holl RW, Warner JT. Prevalence of celiac disease in 52,721 youth with type-1 diabetes: International comparison across three continents. Diabetes Care 2017;40:1034-1040. Diabetes Care 2017;40(11). doi:10.2337/dci17-0040.
  189. Kahaly GJ, Hansen MP. Type 1 diabetes associated autoimmunity. Autoimmun Rev 2016;15(7). doi:10.1016/j.autrev.2016.02.017.
  190. Parker JA, Conway DL. Diabetic ketoacidosis in pregnancy. Obstetrics and Gynecology Clinics 2007;34(3):533–543.
  191. Montoro MN, Myers VP, Mestman JH, Yunhua X, Anderson BG, Golde SH. Outcome of Pregnancy in Diabetic Ketoacidosis. Am J Perinatol 1993;10(1). doi:10.1055/s-2007-994692.
  192. Bryant SN, Herrera CL, Nelson DB, Cunningham FG. Diabetic ketoacidosis complicating pregnancy. J Neonatal Perinatal Med 2017;10(1). doi:10.3233/NPM-1663.
  193. Rodgers BD, Rodgers DE. Clinical variables associated with diabetic ketoacidosis during pregnancy. Journal of Reproductive Medicine for the Obstetrician and Gynecologist 1991;36(11).
  194. Grasch JL, Lammers S, Scaglia Drusini F, Vickery SS, Venkatesh KK, Thung S, McKiever ME, Landon MB, Gabbe S. Clinical Presentation and Outcomes of Diabetic Ketoacidosis in Pregnancy. Obstetrics and gynecology 2024;144(5). doi:10.1097/AOG.0000000000005666.
  195. Mahoney CA. Extreme Gestational Starvation Ketoacidosis: Case Report and Review of Pathophysiology. American Journal of Kidney Diseases 1992;20(3). doi:10.1016/S0272-6386(12)80701-3.
  196. Colatrella A, Loguercio V, Mattei L, Trappolini M, Festa C, Stoppo M, Napoli A. Hypertension in diabetic pregnancy: Impact and long-term outlook. Best Pract Res Clin Endocrinol Metab 2010;24(4):635–651.
  197. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Williamson JD, Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Pr. J Am Coll Cardiol 2018;71(19):e127–e248.
  198. Committee on Practice Bulletins—Obstetrics. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstetrics and gynecology 2020;135(6):e237–e260.
  199. Nabhan AF, Elsedawy MM. Tight control of mild-moderate pre-existing or non-proteinuric gestational hypertension. Cochrane Database of Systematic Reviews 2011;(7):1465–1858.
  200. ACOG. Screening for Hepatitis C Infection. Practice Advisory 2020. Available at: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/04/screening-for-hepatitis-c-virus-infection. Accessed March 12, 2020.
  201. Von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fail in mean arterial pressure and fetal growth restriction in pregnancy hypertension: A meta-analysis. Lancet 2000;355(9198):87–92.
  202. Seely EW, Ecker J. Chronic hypertension in pregnancy. Circulation 2014;129(11):1254–1261.
  203. Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, Menzies J, Sanchez J, Singer J, Gafni A, Gruslin A, Helewa M, Hutton E, Lee SK, Lee T, Logan AG, Ganzevoort W, Welch R, Thornton JG, Moutquin J-M. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 2015;372(5):407–417.
  204. Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, Hughes BL, Bell J, Aagaard K, Edwards RK, Gibson K, Haas DM, Plante L, Metz T, Casey B, Esplin S, Longo S, Hoffman M, Saade GR, Hoppe KK, Foroutan J, Tuuli M, Owens MY, Simhan HN, Frey H, Rosen T, Palatnik A, Baker S, August P, Reddy UM, Kinzler W, Su E, Krishna I, Nguyen N, Norton ME, Skupski D, El-Sayed YY, Ogunyemi D, Galis ZS, Harper L, Ambalavanan N, Geller NL, Oparil S, Cutter GR, Andrews WW. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med 2022;386(19):1781–1792.
  205. Bailey EJ, Tita ATN, Leach J, Boggess K, Dugoff L, Sibai B, Lawrence K, Hughes BL, Bell J, Aagaard K, Edwards RK, Gibson K, Haas DM, Plante L, Metz TD, Casey BM, Esplin S, Longo S, Hoffman M, Saade GR, Foroutan J, Tuuli MG, Owens MY, Simhan HN, Frey HA, Rosen T, Palatnik A, Baker S, August P, Reddy UM, Kinzler W, Su EJ, Krishna I, Nguyen N, Norton ME, Skupski D, El-Sayed YY, Ogunyemi D, Galis ZS, Harper L, Ambalavanan N, Oparil S, Kuo HC, Szychowski JM, Hoppe K. Perinatal Outcomes Associated With Management of Stage 1 Hypertension. Obstetrics and gynecology 2023;142(6):1395–1404.
  206. Anderson PO. Treating Hypertension during Breastfeeding. Breastfeeding Medicine 2018;13(2):95–96.
  207. Stevens DU, de Nobrega Teixeira JA, Spaanderman MEA, Bulten J, van Vugt JMG, Al-Nasiry S. Understanding decidual vasculopathy and the link to preeclampsia: A review. Placenta 2020;97:95–100.
  208. LeFevre ML. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161(11):819–826.
  209. ACOG. Low-Dose Aspirin Use During Pregnancy: Committee Opinion No 743. Obstetrics and gynecology 2018;132:e44–e52.
  210. Ghesquiere L, Guerby P, Marchant I, Kumar N, Zare M, Foisy MA, Roberge S, Bujold E. Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: systematic review and meta-analysis. Am J Obstet Gynecol MFM 2023;5(7). doi:10.1016/J.AJOGMF.2023.101000.
  211. Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2018;218(3):287-293.e1.
  212. Starikov R, Bohrer J, Goh W, Kuwahara M, Chien EK, Lopes V, Coustan D. Hemoglobin A1c in pregestational diabetic gravidas and the risk of congenital heart disease in the fetus. Pediatr Cardiol 2013;34:1716–1722.
  213. Landon MB, Mintz MC, Gabbe SG. Sonographic evaluation of fetal abdominal growth: Predictor of the large-for-gestational-age infant in pregnancies complicated by diabetes mellitus. Am J Obstet Gynecol 1989;160(1):115–121.
  214. Herranz L, Pallardo LF, Hillman N, Martin-Vaquero P, Villarroel A, Fernandez A. Maternal third trimester hyperglycaemic excursions predict large-for-gestational-age infants in type 1 diabetic pregnancy. Diabetes Res Clin Pract 2007;75(1):42–46.
  215. Nelson LT, Wharton B, Grobman WA. Prediction of large for gestational age birth weights in diabetic mothers based on early third-trimester sonography. Journal of Ultrasound in Medicine 2011;30:1625–1628.
  216. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 204: Fetal Growth Restriction. Obstetrics and gynecology 2019;133(2):e97–e109.
  217. Jackson WP, Woolf N. Maternal prediabetes as a cause of the unexplained stillbirth. Diabetes 1958;7(6):446–448.
  218. Lagrew DC, Pircon RA, Towers C V., Dorchester W, Freeman RK. Antepartum fetal surveillance in patients with diabetes: When to start? Am J Obstet Gynecol 1993;168(6):1825–1826.
  219. Brecher A, Tharakan T, Williams A, Baxi L. Perinatal mortality in diabetic patients undergoing antepartum fetal evaluation: a case–control study. The Journal of Maternal-Fetal & Neonatal Medicine 2002;12(6):423–427.
  220. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. Practice bulletin no. 145: Antepartum fetal surveillance. Obstetrics and Gynecology 2014;124(1):182–192.
  221. Finneran MM, Kiefer MK, Ware CA, Buschur EO, Thung SF, Landon MB, Gabbe SG. The use of longitudinal hemoglobin A1c values to predict adverse obstetric and neonatal outcomes in pregnancies complicated by pregestational diabetes. Am J Obstet Gynecol MFM 2020;2(1):1–6.
  222. Damm P, Mersebach H, Råstam J, Kaaja R, Hod M, McCance DR, Mathiesen ER. Poor pregnancy outcome in women with type 1 diabetes is predicted by elevated HbA1c and spikes of high glucose values in the third trimester. Journal of Maternal-Fetal and Neonatal Medicine 2014;27(2):149–154.
  223. Mathiesen ER, Ringholm L, Damm P. Stillbirth in diabetic pregnancies. Best Pract Res Clin Obstet Gynaecol 2011;25(1):105–111.
  224. Thung SF, Landon MB. Fetal surveillance and timing of delivery in pregnancy complicated by diabetes mellitus. Clin Obstet Gynecol 2013;56(4):837–843.
  225. American College of Obstetricians and Gynecologists’. Medically Indicated Late-Preterm and Early-Term Deliveries: ACOG Committee Opinion, Number 818. Obstetrics and gynecology 2021;137(4):559–758.
  226. Gyamfi-Bannerman C, Thom EA, Blackwell SC, Tita ATN, Reddy UM, Saade GR, Rouse DJ, McKenna DS, Clark EAS, Thorp JM, Chien EK, Peaceman AM, Gibbs RS, Swamy GK, Norton ME, Casey BM, Caritis SN, Tolosa JE, Sorokin Y, VanDorsten JP, Jain L. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. New England Journal of Medicine 2016;374(14):1311–1320.
  227. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. Macrosomia: ACOG Practice Bulletin, Number 216. Obstetrics and Gynecology 2020;135(1):e18–e35.
  228. Landon MB, Galan HL, Jauniaux ERM, Driscoll DA, Berghella V, Grobman WA, Kilpatrick SJ, Cahill AG. Gabbe’s Obstetrics: Normal and Problem Pregnancies. 8th ed. Philadelphia: Elsevier; 2021.
  229. Kitzmiller JL, Gavin L. Manual of Endocrinology and Metabolism. 3rd ed. (Lavin N, ed.). Lippincott Williams & Wilkins; 2002.
  230. Wilkie GL, Delpapa E, Leftwich HK. Intrapartum continuous subcutaneous insulin infusion vs intravenous insulin infusion among pregnant individuals with type 1 diabetes mellitus: a randomized controlled trial. Am J Obstet Gynecol 2023;229(6):680.e1-680.e8.
  231. Landon MB. Obstetric management of pregnancies complicated by diabetes mellitus. Clin Obstet Gynecol 2000;43(1):65–74.
  232. Battarbee AN, Venkatesh KK, Aliaga S, Boggess KA. The association of pregestational and gestational diabetes with severe neonatal morbidity and mortality. Journal of Perinatology 2020;40:232–239.
  233. Robert MF, Neff RK, Hubbell JP, Taeusch HW, Avery ME. Association between Maternal Diabetes and the Respiratory-Distress Syndrome in the Newborn. New England Journal of Medicine 1976;294(7):357–360.
  234. Li Y, Wang W, Zhang D. Maternal diabetes mellitus and risk of neonatal respiratory distress syndrome: a meta-analysis. Acta Diabetol 2019;56:729–470.
  235. Sargent JA, Roeder HA, Ward KK, Moore TR, Ramos GA. Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin for the Management of Type 1 Diabetes Mellitus in Pregnancy: Association with Neonatal Chemical Hypoglycemia. Am J Perinatol 2015;32(14):1324–1330.
  236. Hoffman MK, Bailit JL, Branch DW, Burkman RT, Van Veldhusien P, Lu L, Kominiarek MA, Hibbard JU, Landy HJ, Haberman S, Wilkins I, Quintero VHG, Gregory KD, Hatjis CG, Ramirez MM, Reddy UM, Troendle J, Zhang J. A comparison of obstetric maneuvers for the acute management of shoulder dystocia. Obstetrics and Gynecology 2011;117(6):1272–1278.
  237. Acker DS, Sachs BP, Friedman EA. Risk factors for shoulder dystocia. Obstetrics and Gynecology 1985;66(6):762–768.
  238. Mendez-Figueroa H, Hoffman MK, Grantz KL, Blackwell SC, Reddy UM, Chauhan SP. Shoulder Dystocia and Composite Adverse Outcomes for the Maternal-Neonatal Dyad. Am J Obstet Gynecol MFM 2021. doi:10.1016/j.ajogmf.2021.100359.
  239. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. Practice Bulletin No 178: Shoulder Dystocia. Obstetrics & Gynecology 2017;129(5):e123–e133.
  240. Witkop CT, Neale D, Wilson LM, Bass EB, Nicholson WK. Active compared with expectant delivery management in women with gestational diabetes: A systematic review. Obstetrics and Gynecology 2009;113(1):206--217.
  241. Boulvain M, Senat MV, Perrotin F, Winer N, Beucher G, Subtil D, Bretelle F, Azria E, Hejaiej D, Vendittelli F, Capelle M, Langer B, Matis R, Connan L, Gillard P, Kirkpatrick C, Ceysens G, Faron G, Irion O, Rozenberg P. Induction of labour versus expectant management for large-for-date fetuses: A randomised controlled trial. The Lancet 2015;385(9987):2600–2605.
  242. Committee on Practice Bulletins—Obstetrics. Macrosomia: ACOG Practice Bulletin, Number 216. Obstetrics and Gynecology 2020;135(1):E18–E35.
  243. Gold AE, Reilly C, Walker JD. Transient improvement in glycemic control: The impact of pregnancy in women with IDDM. Diabetes Care 1998;21(3):374–378.
  244. Riskin-Mashiah S, Almog R. Missed opportunities for appropriate postpartum care in women with pregestational diabetes. Journal of Maternal-Fetal and Neonatal Medicine 2016;29(11):1715–1719.
  245. Chen J, Ouyang L, Goodman DA, Okoroh EM, Romero L, Ko JY, Cox S. Association of Medicaid Expansion Under the Affordable Care Act With Medicaid Coverage in the Prepregnancy, Prenatal, and Postpartum Periods. Womens Health Issues 2023;33(6):582–591.
  246. Ringholm L, Mathiesen ER, Kelstrup L, Damm P. Managing type 1 diabetes mellitus in pregnancy - From planning to breastfeeding. Nat Rev Endocrinol 2012;8(11):659–667.
  247. Nørgaard SK, Nørgaard K, Roskjær AB, Mathiesen ER, Ringholm L. Insulin Pump Settings during Breastfeeding in Women with Type 1 Diabetes. Diabetes Technol Ther 2020;22(4):314–320.
  248. Stagnaro-Green A. Approach to the patient with postpartum thyroiditis. Journal of Clinical Endocrinology and Metabolism 2012;97(2):334–342.
  249. Stuebe A. The risks of not breastfeeding for mothers and infants. Rev Obstet Gynecol 2009;2(4):222–231.
  250. Riddle SW, Nommsen-Rivers LA. A Case Control Study of Diabetes during Pregnancy and Low Milk Supply. Breastfeeding Medicine 2016;11(2):80–85.
  251. Cordero L, Thung S, Landon MB, Nankervis CA. Breast-feeding initiation in women with pregestational diabetes mellitus. Clin Pediatr (Phila) 2014;53(1):18–25.
  252. Finkelstein SA, Keely E, Feig DS, Tu X, Yasseen AS, Walker M. Breastfeeding in women with diabetes: Lower rates despite greater rewards. A population-based study. Diabetic Medicine 2013;30(9):1094–1101.
  253. Stage E, Nørgård H, Damm P, Mathiesen E. Long-term breast-feeding in women with type 1 diabetes. Diabetes Care 2006;29(4):771–774.
  254. Feig DS, Lipscombe LL, Tomlinson G, Blumer I. Breastfeeding predicts the risk of childhood obesity in a multi-ethnic cohort of women with diabetes. Journal of Maternal-Fetal and Neonatal Medicine 2011;24(3):511–515.
  255. Frederiksen B, Kroehl M, Lamb MM, Seifert J, Barriga K, Eisenbarth GS, Rewers M, Norris JM. Infant exposures and development of type 1 diabetes mellitus: The Diabetes Autoimmunity Study in the Young (DAISY). JAMA Pediatr 2013;167(9):808–815.
  256. Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. The Lancet 2016;387(10035):2340–2348.
  257. Gardiner SJ, Kirkpatrick CMJ, Begg EJ, Zhang M, Peter Moore M, Saville DJ. Transfer of metformin into human milk. Clin Pharmacol Ther 2003;73(1):71–77.
  258. Hale T, Kristensen J, Hackett L, Kohan R, Ilett K. Transfer of metformin into human milk. Diabetologia 2002;45:1509–1514.
  259. Feig DS, Briggs GG, Kraemer JM, Ambrose PJ, Moskovitz DN, Nageotte M, Donat DJ, Padilla G, Wan S, Klein J, Koren G. Transfer of glyburide and glipizide into breast milk. Diabetes Care 2005;28(8):1851–1855.
  260. Management of diabetes in pregnancy: Standards of medical care in diabetes-2020. Diabetes Care 2020. doi:10.2337/dc20-S014.
  261. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ, Whiteman MK. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recommendations and Reports 2016;65(3):1–103.
  262. Schwarz EB, Braughton MY, Riedel JC, Cohen S, Logan J, Howell M, Thiel de Bocanegra H. Postpartum care and contraception provided to women with gestational and preconception diabetes in California’s Medicaid program. Contraception 2017;96(6):432–438.
  263. O’Brien SH, Koch T, Vesely SK, Schwarz EB. Hormonal contraception and risk of thromboembolism in women with diabetes. Diabetes Care 2017. doi:10.2337/dc16-1534.
  264. Gourdy P. Diabetes and oral contraception. Best Pract Res Clin Endocrinol Metab 2013;27(1):67–76.
  265. Visser J, Snel M, Van Vliet HAAM. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2. Cochrane Database of Systematic Reviews 2013;(3). doi:10.1002/14651858.CD003990.pub4.
  266. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2014;(4). doi:10.1002/14651858.CD006133.pub5.
  267. Salinas A, Merino PM, Giraudo F, Codner E. Long-acting contraception in adolescents and young women with type 1 and type 2 diabetes. Pediatr Diabetes 2020;21:1074–1082.
  268. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins. ACOG Practice Bulletin No. 208: Benefits and Risks of Sterilization. Obstetrics and gynecology 2019;133(3):e194–e207.
  269. Committee on Practice Bulletins- Obetetrics. ACOG Practice Bulletin 230: Obesity in Pregnancy. Obstetrics & Gynecology 2021;137(6). doi:10.1097/AOG.0000000000004395.
  270. Dutton H, Borengasser SJ, Gaudet LM, Barbour LA, Keely EJ. Obesity in Pregnancy: Optimizing Outcomes for Mom and Baby. Medical Clinics of North America 2018;102(1). doi:10.1016/j.mcna.2017.08.008.
  271. Davies G AL, Cynthia Maxwell KO, Lynne McLeod TO, Gagnon R, Melanie Basso MQ, Hayley Bos VB, Marie-France Delisle LO, Dan Farine VB, Lynda Hudon TO, Savas Menticoglou MQ, William Mundle WM, Lynn Murphy-Kaulbeck WO, Annie Ouellet AN, Tracy Pressey SQ, Anne Roggensack VB, Leduc D, Charlotte Ballerman OO, Anne Biringer EA, Louise Duperron TO, Donna Jones MQ, Lily Shek-Yun Lee CA, Debra Shepherd VB, Kathleen Wilson RS. SOGC CLINICAL PRACTICE GUIDELINES Obesity in Pregnancy☆. International Journal of Gynecology and Obstetrics 2010;110.
  272. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of Obesity Among Adults and Youth: United States, 2011-2014. NCHS Data Brief 2015;(219).
  273. Yogev Y, Catalano PM. Pregnancy and Obesity. Obstet Gynecol Clin North Am 2009;36(2). doi:10.1016/j.ogc.2009.03.003.
  274. Gunderson EP. Childbearing and Obesity in Women: Weight Before, During, and After Pregnancy. Obstet Gynecol Clin North Am 2009;36(2). doi:10.1016/j.ogc.2009.04.001.
  275. Nohr EA, Vaeth M, Baker JL, Sørensen TIA, Olsen J, Rasmussen KM. Combined associations of prepregnancy body mass index and gestational weight gain with the outcome of pregnancy. American Journal of Clinical Nutrition 2008;87(6). doi:10.1093/ajcn/87.6.1750.
  276. Stothard KJ, Tennant PWG, Bell R, Rankin J. Maternal overweight and obesity and the risk of congenital anomalies: A systematic review and meta-analysis. JAMA - Journal of the American Medical Association 2009;301(6). doi:10.1001/jama.2009.113.
  277. Watkins ML, Rasmussen SA, Honein MA, Botto LD, Moore CA. Maternal obesity and risk for birth defects. Pediatrics 2003;111(5 II).
  278. Reddy UM, Abuhamad AZ, Levine D, Saade GR. Fetal imaging: Executive summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, society for maternal-fetal medicine, American Institute of ultrasound in medicine, American College of Obstetricians and gynecologists, American College of radiology, society for pediatric radiology, and society of radiologists in ultrasound fetal imaging workshop. Journal of Ultrasound in Medicine 2014;33(5). doi:10.7863/ultra.33.5.745.
  279. Dashe JS, McIntire DD, Twickler DM. Maternal obesity limits the ultrasound evaluation of fetal anatomy. Journal of Ultrasound in Medicine 2009;28(8). doi:10.7863/jum.2009.28.8.1025.
  280. Mojtabai R. Body mass index and serum folate in childbearing age women. Eur J Epidemiol 2004;19(11). doi:10.1007/s10654-004-2253-z.
  281. Laraia BA, Bodnar LM, Siega-Riz AM. Pregravid body mass index is negatively associated with diet quality during pregnancy. Public Health Nutr 2007;10(9). doi:10.1017/S1368980007657991.
  282. Parker SE, Yazdy MM, Tinker SC, Mitchell AA, Werler MM. The impact of folic acid intake on the association among diabetes mellitus, obesity, and spina bifida. Am J Obstet Gynecol 2013;209(3). doi:10.1016/j.ajog.2013.05.047.
  283. Correa A, Marcinkevage J. Prepregnancy obesity and the risk of birth defects: An update. Nutr Rev 2013;71(SUPPL1). doi:10.1111/nure.12058.
  284. Harmon KA, Gerard L, Jensen DR, Kealey EH, Hernandez TL, Reece MS, Barbour LA, Bessesen DH. Continuous glucose profiles in obese and normal-weight pregnant women on a controlled diet: Metabolic determinants of fetal growth. Diabetes Care 2011;34(10). doi:10.2337/dc11-0723.
  285. Beard JH, Bell RL, Duffy AJ. Reproductive considerations and pregnancy after bariatric surgery: Current evidence and recommendations. Obes Surg 2008;18(8). doi:10.1007/s11695-007-9389-3.
  286. Guelinckx I, Devlieger R, Vansant G. Reproductive outcome after bariatric surgery: A critical review. Hum Reprod Update 2009;15(2). doi:10.1093/humupd/dmn057.
  287. Wax JR, Cartin A, Pinette MG. Promoting preconception, pregnancy, and postpartum care following bariatric surgery: A best practice planning toolkit for patients and their physicians. Journal of Reproductive Medicine 2014;59(6).
  288. Guénard F, Deshaies Y, Cianflone K, Kral JG, Marceau P, Vohl MC. Differential methylation in glucoregulatory genes of offspring born before vs. after maternal gastrointestinal bypass surgery. Proc Natl Acad Sci U S A 2013;110(28). doi:10.1073/pnas.1216959110.
  289. Hernandez TL, Anderson MA, Chartier-Logan C, Friedman JE, Barbour LA. Strategies in the nutritional management of gestational diabetes. Clin Obstet Gynecol 2013;56(4):803–815.
  290. Metzger BE, Buchanan TA, Coustan DR, De Leiva A, Dunger DB, Hadden DR, Hod M, Kitzmiller JL, Kjos SL, Oats JN, Pettitt DJ, Sacks DA, Zoupas C. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 2007;30(SUPPL. 2). doi:10.2337/dc07-s225.
  291. Marshall NE, Abrams B, Barbour LA, Catalano P, Christian P, Friedman JE, Hay WW, Hernandez TL, Krebs NF, Oken E, Purnell JQ, Roberts JM, Soltani H, Wallace J, Thornburg KL. The importance of nutrition in pregnancy and lactation: lifelong consequences. Am J Obstet Gynecol 2022;226(5):607–632.
  292. Kominiarek MA, Peaceman AM. Gestational weight gain. Am J Obstet Gynecol 2017;217(6). doi:10.1016/j.ajog.2017.05.040.
  293. Committee to Reexamine IOM Pregnancy Weight Guidelines, Food and Nutrition Board, Board on Children Youth and Families. Weight Gain During Pregnancy. Reexamining the Guidelines. (Rasmussen KM, Yaktine AL, eds.). Washington, DC: The National Academies Press; 2009.
  294. Kominiarek MA, Seligman NS, Dolin C, Gao W, Berghella V, Hoffman M, Hibbard JU. Gestational weight gain and obesity: Is 20 pounds too much? In: American Journal of Obstetrics and Gynecology.Vol 209.; 2013. doi:10.1016/j.ajog.2013.04.035.
  295. Duhl AJ, Paidas MJ, Ural SH, Branch W, Casele H, Cox-Gill J, Hamersley SL, Hyers TM, Katz V, Kuhlmann R, Nutescu EA, Thorp JA, Zehnder JL. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007;197(5). doi:10.1016/j.ajog.2007.04.022.
  296. Larsen TB, Sørensen HT, Gislum M, Johnsen SP. Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: A population-based nested case-control study. Thromb Res 2007;120(4). doi:10.1016/j.thromres.2006.12.003.
  297. Committee on Practice Bulletins- Obstetrics. ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy. Obstetrics & Gynecology 2018;132(1). doi:10.1097/AOG.0000000000002706.
  298. Katon J, Reiber G, Williams MA, Yanez D, Miller E. Weight loss after diagnosis with gestational diabetes and birth weight among overweight and obese women. Matern Child Health J 2013;17(2):374–383.
  299. Park JE, Park S, Daily JW, Kim SH. Low gestational weight gain improves infant and maternal pregnancy outcomes in overweight and obese Korean women with gestational diabetes mellitus. Gynecological Endocrinology 2011;27(10):775–781.
  300. Cheng YW, Chung JH, Kurbisch-Block I, Inturrisi M, Shafer S, Caughey AB. Gestational weight gain and gestational diabetes mellitus: Perinatal outcomes. Obstetrics and Gynecology 2008;112(5):1015–1022.
  301. Uplinger N. The controversy continues: Nutritional management of the pregnancy complicated by diabetes. Curr Diab Rep 2009;9(4):291–295.
  302. Knopp RH, Magee MS, Raisys V, Benedetti T. Metabolic effects of hypocaloric diets in management of gestational diabetes. In: Diabetes.Vol 40.; 1991. doi:10.2337/diab.40.2.s165.
  303. US Department of Agriculture. US Department of Health and Human Services. Dietary Guidelines for Americans, 2020-2025. Diet and Health Relationships: Pregnancy and Lactation. Available at: https://www.https://www.dietaryguidelines.gov/sites/default/files/2020-12/Dietary_Guidelines_for_Americans_2020-2025.pdf. Accessed December 17, 2024.
  304. ACOG Committee Opinion 804: Physical Activity and Exercise During Pregnancy and the Postpartum Period. Obstetrics & Gynecology 2020;135(4). doi:10.1097/AOG.0000000000003772.
  305. U.S. Department of Health and Human Services. Physical Activity Guidelines Advisory Committee Report 2008. Washington DC US 2008;67(2).
  306. Thangaratinam S, Rogozińska E, Jolly K, Glinkowski S, Roseboom T, Tomlinson JW, Kunz R, Mol BW, Coomarasamy A, Khan KS. Effects of interventions in pregnancy on maternal weight and obstetric outcomes: Meta-analysis of randomised evidence. BMJ (Online) 2012;344(7858). doi:10.1136/bmj.e2088.
  307. Gregg VH, Ferguson JE. Exercise in Pregnancy. Clin Sports Med 2017;36(4). doi:10.1016/j.csm.2017.05.005.
  308. Carpenter MW. The Role of Exercise in Pregnant Women With Diabetes Mellitus. Clin Obstet Gynecol 2000;43(1):56–64.
  309. Clapp JF. The course of labor after endurance exercise during pregnancy. Am J Obstet Gynecol 1990;163(6 PART 1). doi:10.1016/0002-9378(90)90753-T.
  310. Catalano PM, Thomas A, Huston-Presley L, Amini SB. Phenotype of infants of mothers with gestational diabetes. Diabetes Care 2007;30(SUPPL. 2). doi:10.2337/dc07-s209.
  311. Simeoni U, Barker DJ. Offspring of diabetic pregnancy: Long-term outcomes. Semin Fetal Neonatal Med 2009;14(2):119–124.
  312. Friedman, Jacob E. Obesity and Gestational Diabetes Mellitus Pathways for Programming in Mouse, Monkey, and Man. Diabetes Care 2015;38(August).
  313. Catalano PM, Farrell K, Thomas A, Huston-Presley L, Mencin P, De Mouzon SH, Amini SB. Perinatal risk factors for childhood obesity and metabolic dysregulation. American Journal of Clinical Nutrition 2009;90(5). doi:10.3945/ajcn.2008.27416.
  314. Heerwagen MJR, Miller MR, Barbour LA, Friedman JE. Maternal obesity and fetal metabolic programming: A fertile epigenetic soil. Am J Physiol Regul Integr Comp Physiol 2010;299(3). doi:10.1152/ajpregu.00310.2010.
  315. Pinney SE, Simmons RA. Metabolic programming, Epigenetics, and gestational diabetes mellitus. Curr Diab Rep 2012;12(1). doi:10.1007/s11892-011-0248-1.
  316. Blais K, Arguin M, Allard C, Doyon M, Dolinsky VW, Bouchard L, Hivert MF, Perron P. Maternal glucose in pregnancy is associated with child’s adiposity and leptin at 5 years of age. Pediatr Obes 2021. doi:10.1111/ijpo.12788.
  317. Chen J, Zhang J, Lazarenko OP, Kang P, Blackburn ML, Ronis MJJ, Badger TM, Shankar K. Inhibition of fetal bone development through epigenetic down‐regulation of HoxA10 in obese rats fed high‐fat diet. The FASEB Journal 2012;26(3). doi:10.1096/fj.11-197822.
  318. Boyle KE, Patinkin ZW, Shapiro ALB, Baker PR, Dabelea D, Friedman JE. Mesenchymal stem cells from infants born to obese mothers exhibit greater potential for adipogenesis: The healthy start babybump project. Diabetes 2016;65(3). doi:10.2337/db15-0849.
  319. Sullivan EL, Grayson B, Takahashi D, Robertson N, Maier A, Bethea CL, Smith MS, Coleman K, Grove KL. Chronic consumption of a high-fat diet during pregnancy causes perturbations in the serotonergic system and increased anxiety-like behavior in nonhuman primate offspring. Journal of Neuroscience 2010;30(10). doi:10.1523/JNEUROSCI.5560-09.2010.
  320. McCurdy CE, Bishop JM, Williams SM, Grayson BE, Smith MS, Friedman JE, Grove KL. Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates. Journal of Clinical Investigation 2009;119(2). doi:10.1172/JCI32661.
  321. Suter MA, Chen A, Burdine MS, Choudhury M, Harris RA, Lane RH, Friedman JE, Grove KL, Tackett AJ, Aagaard KM. A maternal high-fat diet modulates fetal SIRT1 histone and protein deacetylase activity in nonhuman primates. FASEB Journal 2012;26(12). doi:10.1096/fj.12-212878.
  322. Portha B, Chavey A, Movassat J. Early-life origins of type 2 diabetes: Fetal programming of the beta-cell mass. Exp Diabetes Res 2011;2011. doi:10.1155/2011/105076.
  323. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: From pathophysiology to prevention and management. In: The Lancet.Vol 378.; 2011. doi:10.1016/S0140-6736(11)60614-4.
  324. Vrachnis N, Antonakopoulos N, Iliodromiti Z, Dafopoulos K, Siristatidis C, Pappa KI, Deligeoroglou E, Vitoratos N. Impact of maternal diabetes on epigenetic modifications leading to diseases in the offspring. Exp Diabetes Res 2012;2012. doi:10.1155/2012/538474.
  325. Houshmand-Oeregaard A, Hansen NS, Hjort L, Kelstrup L, Broholm C, Mathiesen ER, Clausen TD, Damm P, Vaag A. Differential adipokine DNA methylation and gene expression in subcutaneous adipose tissue from adult offspring of women with diabetes in pregnancy. Clin Epigenetics 2017;9(1). doi:10.1186/s13148-017-0338-2.
  326. Gagné-Ouellet V, Houde AA, Guay SP, Perron P, Gaudet D, Guérin R, Jean-Patrice B, Hivert MF, Brisson D, Bouchard L. Placental lipoprotein lipase DNA methylation alterations are associated with gestational diabetes and body composition at 5 years of age. Epigenetics 2017;12(8). doi:10.1080/15592294.2017.1322254.
  327. Nelson RG, Morgenstern H, Bennett PH. Intrauterine diabetes exposure and the risk of renal disease in diabetic Pima Indians. Diabetes 1998;47(9). doi:10.2337/diabetes.47.9.1489.
  328. Pavkov ME, Knowler WC, Hanson RL, Williams DE, Lemley K V., Myers BD, Nelson RG. Comparison of serum cystatin C, serum creatinine, measured GFR, and estimated GFR to assess the risk of kidney failure in American Indians with diabetic nephropathy. American Journal of Kidney Diseases 2013;62(1). doi:10.1053/j.ajkd.2012.11.044.
  329. Jaiswal M, Fufaa GD, Martin CL, Pop-Busui R, Nelson RG, Feldman EL. Burden of diabetic peripheral neuropathy in pima indians with type 2 diabetes. Diabetes Care 2016;39(4). doi:10.2337/dc16-0082.
  330. Sellers EAC, Dean HJ, Shafer LA, Martens PJ, Phillips-Beck W, Heaman M, Prior HJ, Dart AB, McGavock J, Morris M, Torshizi AA, Ludwig S, Shen GX. Exposure to gestational diabetes mellitus: Impact on the development of early-onset type 2 diabetes in Canadian first nations and non-first nations offspring. Diabetes Care 2016;39(12). doi:10.2337/dc16-1148.
  331. Bunt JC, Antonio Tataranni P, Salbe AD. Intrauterine exposure to diabetes is a determinant of hemoglobin A1c and systolic blood pressure in pima indian children. Journal of Clinical Endocrinology and Metabolism 2005;90(6). doi:10.1210/jc.2005-0007.
  332. Dabelea D, Mayer-Davis EJ, Lamichhane AP, D’Agostino RB, Liese AD, Vehik KS, Venkat Narayan KM, Zeitler P, Hamman RF. Association of intrauterine exposure to maternal diabetes and obesity with type 2 diabetes in youth: The SEARCH case-control study. Diabetes Care 2008;31(7). doi:10.2337/dc07-2417.
  333. Kue Young T, Martens PJ, Taback SP, Sellers EAC, Dean HJ, Cheang M, Flett B. Type 2 diabetes mellitus in children: Prenatal and early infancy risk factors among Native Canadians. Arch Pediatr Adolesc Med 2002;156(7). doi:10.1001/archpedi.156.7.651.
  334. Dunford AR, Sangster JM. Maternal and paternal periconceptional nutrition as an indicator of offspring metabolic syndrome risk in later life through epigenetic imprinting: A systematic review. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 2017;11. doi:10.1016/j.dsx.2017.04.021.
  335. Sharp GC, Lawlor DA. Paternal impact on the life course development of obesity and type 2 diabetes in the offspring. Diabetologia 2019;62(10). doi:10.1007/s00125-019-4919-9.
  336. Warram JH, Krolewski AS, Gottlieb MS, Kahn CR. Differences in risk of insulin-dependent diabetes in offspring of diabetic mothers and diabetic fathers. Obstet Gynecol Surv 1985;40(3). doi:10.1097/00006254-198503000-00011.
  337. Harjutsalo V, Reunanen A, Tuomilehto J. Differential transmission of type 1 diabetes from diabetic fathers and mothers to their offspring. Diabetes 2006;55(5). doi:10.2337/db05-1296.

 

Endocrine Hypertension in Childhood and Adolescence

ABSTRACT

 

Hypertension in children and adolescents is defined as a blood pressure ≥ 95th percentile (stage 1) or a blood pressure ≥ 95th percentile + 12 mmHg (stage 2), according to the Clinical Practice Guidelines of American Academy of Pediatrics published in 2017. Hypertension may be primary or idiopathic or secondary due to renal disease (including renal vascular abnormalities), cardiovascular disorders, or endocrine conditions. Endocrine hypertension might be caused by excess amount of steroid (aldosterone, deoxycorticosterone, cortisol, and other) or non-steroid hormones (such as catecholamines for example). In addition, a number of renal genetic disorders mimic adrenal diseases leading to hypertension. In this chapter, we provide an overview of the clinical manifestations of several nosological entities causing endocrine hypertension in children and adolescents and present the diagnostic work up and therapeutic management of these conditions.

 

INTRODUCTION

 

Hypertension occurs in 3.5% of children and adolescence worldwide (1). Its prevalence has increased due to the epidemic of pediatric obesity (2). The 2017 Clinical Practice Guidelines of American Academy of Pediatrics (APP) suggested an updated definition of hypertension in children and adolescent using tables containing values of systolic and diastolic blood pressure adjusted for gender, age, and height. According to these guidelines, children or adolescents with a blood pressure ≥ 95th percentile are classified as stage 1 hypertensive, whereas those with a blood pressure ≥ 95thpercentile + 12 mmHg are considered as stage 2 hypertensive (1).

 

Hypertension in children and adolescents might be primary or secondary. Causes of secondary hypertension include renal or renovascular diseases, heart diseases (e.g. aortic coarctation), or endocrine nosological entities (1, 2). Endocrine hypertension is defined as secondary hypertension caused by pathologies, such as various states of mineralocorticoid, glucocorticoid, or catecholamine excess, thyroid or pituitary hormone over-secretion, genetic disorders such as congenital adrenal hyperplasia (11β-hydroxylase deficiency and 17α-hydroxylase deficiency), and syndromes caused by molecular or chromosomal defects (3). Although the list of causes of endocrine hypertension is long, the prevalence of endocrine hypertension ranges between 0,05% to 6% among all causes of secondary hypertension (4). In addition to endocrine pathologies, the ever-increasing rates of obesity in childhood and adolescence have resulted in a dramatic increase of obesity-related hypertension with a prevalence of 25% ultimately leading to adverse cardiovascular outcomes (1, 2).

 

In this chapter, we review the most common causes of endocrine hypertension in children and adolescents.

 

DISORDERS OF THE ADRENAL CORTEX

 

Syndromes of Aldosterone Excess

 

PRIMARY ALDOSTERONISM

 

Less than 15% of cases in children and adolescents with hypertension have been attributed to primary aldosteronism, which is characterized by autonomous excessive biosynthesis and release of aldosterone by the zona glomerulosa of the adrenal cortex (5). Most cases of primary aldosteronism are sporadic due to a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia. Less commonly, primary aldosteronism results from unilateral adrenal hyperplasia (6).

 

Children and adolescents with primary aldosteronism are often asymptomatic; however, the presence of resistant hypertension with hypokalemia or an adrenal lesion is highly suggestive of the diagnosis (7). Endocrinologic evaluation includes the measurement of plasma aldosterone concentrations (PAC) and plasma renin activity (PRA). The Aldosterone-to-Renin Ratio (ARR) remains the most reliable hormonal test (8). Indeed, patients with ARR above 27 ng/dL per ng/mL/h and PAC above 20 ng/dL (hyperaldosteronism) or with ARR within the normal range and PAC below 9 ng/dL (not hyperaldosteronism) on two serial measurements do not need to undergo dynamic tests (9). The dynamic tests include salt loading, saline infusion, or fludrocortisone administration, which all normally cause aldosterone suppression. The patients then undergo adrenal imaging with computerized tomography (CT) to identify any adrenal nodules or unilateral or bilateral adrenal hyperplasia (10).

 

In cases of lateralization of aldosterone overproduction, unilateral laparoscopic adrenalectomy is a therapeutic option; otherwise, medical treatment with a mineralocorticoid receptor antagonist (spironolactone or eplerenone) is highly recommended. In patients who do not tolerate mineralocorticoid receptor antagonists, an epithelial sodium channel blocker, such as amiloride, might be administered (11)   

 

FAMILIAL HYPERALDOSTERONISM

 

Familial Hyperaldosteronism Type I (FH-I) or Glucocorticoid Remediable Aldosteronism (GRA)

 

FH-I or GRA is an autosomal dominant pathologic condition caused by the fusion of two genes, the cytochrome P450 family 11 subfamily B member 1 (CYP11B1) encoding for 11β-hydroxylase, and the CYP11B2 that expresses aldosterone synthase (12). The chimeric gene consists of the adrenocorticotropic hormone (ACTH)-responsive promoter region of the CYP11B1 gene and the coding region of CYP11B2 gene resulting in the expression of aldosterone synthase under the control of ACTH. Therefore, aldosterone is produced ectopically in zona fasciculata in an ACTH-dependent fashion (Figures 1 and 2).

 

Patients younger than 20 years with primary aldosteronism or with a family member with primary aldosteronism or history of hemorrhagic stroke before the age of 40 years should be screened for FH-I (13). Hormonal evaluation includes measurements of PAC and PRA, dexamethasone suppression of aldosterone, and genetic testing. According to the protocol of dexamethasone suppression of aldosterone, aldosterone is measured before and following the administration of 0,5 mg dexamethasone every 6 hours for 4 days (14, 15).

 

The cornerstone of therapeutic management is dexamethasone or prednisone at physiologic and below physiologic dosing to suppress ACTH, thereby leading to decreased production and release of aldosterone (16). Second-line options are spironolactone or eplerenone or amiloride (17), as above. Most of the time, treatment needs to be titrated to the individual carefully and over time, to avoid overtreatment with glucocorticoids and to achieve normal blood pressure in the long term.

 

Figure 1. Molecular events of Familial Hyperaldosteronism Type I (FH-I) or Glucocorticoid Remediable Aldosteronism (GRA). Fusion of CYP11B1 encoding for 11β-hydroxylase, and the CYP11B2 that expresses aldosterone synthase results in a chimeric gene leading to ACTH-dependent aldosterone secretion.

Familial Hyperaldosteronism Type II (FH-II)

 

FH-II is the most frequent form of familial hyperaldosteronism found in 10% of children and adolescents with primary aldosteronism (18, 19). In contradistinction to FH-I or GRA, patients with this FH type do not respond to synthetic long-acting glucocorticoids and do not harbor the chimeric CYP11B1/CYP11B2 gene (20). However, it remains difficult to distinguish FH-II from sporadic primary aldosteronism in terms of adrenal lesions found on CT. The molecular basis of FH-II has been attributed to gain-of-function mutations in the CLCN2 gene which encodes for the chloride channel 2 (Figure 2) (21, 22). The increased efflux of chloride in the zona glomerulosa results in continuous aldosterone secretion. Patients with FH-II are treated with mineralocorticoid receptor antagonists (23).    

 

Familial Hyperaldosteronism Type III (FH-III)

 

FH-III is an autosomal dominant form of FH caused by germline gain-of-function mutations in the potassium inwardly rectifying channel subfamily J member 5 (KCNJ5) gene that encodes for the potassium channel GIRK4 (Kir3.4) (Figure 2) (24). Patients with FH-III are characterized by early-onset severe to resistant hypertension, very high PAC, extremely high 18-oxocortisol and 18-hydroxycortisol concentrations, as well as marked bilateral adrenal hyperplasia (25). Treatment options include administration of mineralocorticoid receptor antagonists if the case is mild or bilateral adrenalectomy in severe cases (17).

 

Familial Hyperaldosteronism Type IV (FH-IV)

 

FH-IV should be suspected in children aged less than 10 years who present with early-onset hypertension and primary aldosteronism (13). Patients with FH-IV harbor mutations in the calcium voltage-gated channel subunit alpha 1H (CACNA1H) gene that encodes for the alpha subunit of the voltage-dependent T-type calcium channel Cav3.2 (Figure 2). These genetic defects resulted in increased calcium influx in the cytoplasm of cells within the zona glomerulosa, thereby facilitating continuous aldosterone secretion (26). Patients may respond to calcium channel blockers (4).

 

Primary Aldosteronism with Seizures and Neurologic Abnormalities (PASNA) or Familial Hyperaldosteronism Type V? (FH-V?)

 

Scholl and collaborators have described two children with primary aldosteronism, seizures, and neurologic abnormalities (27). The patients harbored mutations in the CACNA1D gene which encodes the alpha-1 subunit of the voltage dependent Ca2+ L-type Cav1.3 channel (27).

 

Figure 2. Genetic defects of the types of Familial Hyperaldosteronism (FH). FH-I is caused by the fusion of CYP11B1 encoding for 11β-hydroxylase, and the CYP11B2 that expresses aldosterone synthase. The molecular basis of FH-II has been attributed to activating mutations in the CLCN2 encoding for the chloride channel 2. FH-III is caused by germline activating mutations in the KCNJ5 that expresses the potassium channel GIRK4 (Kir3.4). FH-IV has been associated with mutations in the CACNA1H that encodes for the alpha subunit of the voltage-dependent T-type calcium channel Cav3.2.

 

Syndromes of Deoxycorticosterone Excess

 

CONGENITAL ADRENAL HYPERPLASIA

 

Congenital adrenal hyperplasia is a group of disorders characterized by defects in genes encoding for enzymes that participate in steroidogenesis (Figure 3). Two forms of congenital adrenal hyperplasia, 11β-hydroxylase deficiency and 17α-hydroxylase deficiency, both present with hypertension and hypokalemia (28).

 

Figure 3. Biochemical pathways of steroidogenesis.

11β-Hydroxylase Deficiency

 

This is the second most common form of congenital adrenal hyperplasia (5%-8%) which is inherited in an autosomal recessive fashion. 11β-hydroxylase deficiency results from genetic defects in CYP11B1 gene, and causes increased production of deoxycorticosterone, 11-deoxycortisol, and adrenal androgens (29). In addition, PRA is suppressed leading to decreased production of aldosterone in the zonal glomerulosa and hypokalemia. In girls, 11β-hydroxylase deficiency is a 46XX disorder of sex development (46XX DSD) leading to genital virilization. In boys, this form of congenital adrenal hyperplasia causes penile enlargement, precocious pubarche and puberty, as well as adrenal rests in the testicles (30). Hypertension may be present in up to 65% of patients (31). Treatment includes administration of synthetic glucocorticoids to decrease ACTH-mediated production of deoxycorticosterone and adrenal androgens.  

 

17α-Hydroxylase Deficiency

 

This form of congenital adrenal hyperplasia is also inherited in an autosomal recessive fashion and is caused by defects in the CYP17A gene that encodes for 17α-hydroxylase. This enzyme catalyzes 17-hydroxylation of pregnenolone and progesterone and cleaves the side chain of the steroid molecule at position 17, 20; thereby displaying lyase activity (28). 17α-hydroxylase deficiency leads to insufficient production of glucocorticoids and sex steroids and concurrent accumulation of deoxycorticosterone and corticosterone. Patients with 17α-hydroxylase may present with 46XY disorder of sex development (DSD) and absent Müllerian structures (28), hypergonadotropic hypogonadism with lack of development of secondary sex characteristics, and primary amenorrhea in 46XX individuals (32-34). They also display hypokalemic hypertension. The treatment basis of 17α-hydroxylase deficiency is supplementation with synthetic glucocorticoids.

 

PRIMARY GENERALIZED GLUCOCORTICOID RESISTANCE (CHROUSOS SYNDROME)

 

Initially described by Chrousos and collaborators (35), primary generalized glucocorticoid resistance or Chrousos syndrome is a rare endocrinologic condition characterized by incomplete resistance of target tissues to glucocorticoids (36). This syndrome is caused by genetic defects in NR3C1 gene which encodes for the human glucocorticoid receptor (37). The defective human glucocorticoid receptor (hGR) in both the hypothalamus and anterior pituitary causes impaired negative feedback loops leading to compensatory activation of the hypothalamus-pituitary-adrenal axis (Figure 4). The increased levels of CRH and AVP may cause depression and anxiety, while the elevated ACTH concentrations lead to adrenal hyperplasia, increased production of steroid precursors with mineralocorticoid activity (deoxycorticosterone, corticosterone), increased biosynthesis and release of adrenal androgens, and elevated concentrations of cortisol (38). Patients may be asymptomatic or display hypertension with hypokalemic alkalosis or present with ambiguous genitalia, peripheral precocious puberty, amenorrhea, oligoamenorrhea, and decreased fertility (Figure 4). As far as endocrinologic work-up is concerned, patients with Chrousos syndrome have increased urinary-free cortisol excretion, resistance of the hypothalamic-pituitary-adrenal axis to increasing concentrations of dexamethasone, without any stigmata of Cushing’s syndrome. Treatment consists of high doses of dexamethasone only in symptomatic patients to prevent the development of ACTH-dependent adrenal adenomas (39). Treatment needs to be titrated to the individual carefully and over time, to avoid overtreatment with glucocorticoids and achieve normal pressure in the long term.

 

Figure 4. Pathophysiology of Chrousos syndrome. ACTH: adrenocorticotropic hormone; AVP: arginine-vasopressin; CRH: corticotropin-releasing hormone; mGR: mutated Glucocorticoid Receptor; POMC: Pro-opiomelanocortin; wtGR: wild-type Glucocorticoid Receptor.

 

Syndromes of Cortisol Excess

 

The most common cause of Cushing’s in children and adolescents is chronic exogenous administration of synthetic glucocorticoids. As far as endogenous causes are concerned, hypercortisolism may be ACTH-dependent (such as in Cushing’s disease from pituitary tumors or ACTH-dependent Cushing syndrome from ectopic, non-pituitary tumors) or ACTH-independent (Cushing’s syndrome) (Figure 5) (40). Hypertension in these patients might be attributed to several pathophysiological mechanisms that influence substantially peripheral vascular resistance, plasma volume, and cardiac output. Independently of etiology, 11β-hydroxysteroid dehydrogenase type 2 (11HSD2) is less capable of converting the active cortisol to the inactive cortisone; therefore, the increased cortisol in the renal tubules binds to the mineralocorticoid receptor and leads to hypertension (41).  

 

ACTH-DEPENDENT CUSHING’S SYNDROME OR CUSHING’S DISEASE

 

Cushing’s disease remains the most common cause of endogenous hypercortisolism in children aged more than five years and adolescents (42, 43). Usually, an ACTH-producing corticotroph pituitary neuroendocrine tumor (PitNET) also termed as pituitary adenoma, leads to increased biosynthesis and secretion of cortisol by zona fasciculata and adrenal androgens by zona reticularis (44). Hyperandrogenism (testosterone, Δ4-androstenedione, DHEAS) results in virilization with pseudo precocious puberty. Hypokalemic hypertension is caused by the saturation of renal 11HSD2 due to increased cortisol concentrations. Another cause of ACTH dependent Cushing’s syndrome is the ectopic production and release of ACTH by carcinoid tumors in the thymus, bronchus, or pancreas; medullary carcinomas of the thyroid, small cell carcinoma of the lung, pheochromocytomas or other neuroendocrine tumors (45). Finally, pituitary blastomas, although extremely rare, represent a cause of Cushing’s disease in infants (46). The recommended therapy in patients with Cushing’s disease is transsphenoidal surgical excision of the adenoma with cure reaching the percentage of more than 75% in hands of high-volume surgeons (47). Up to 30% of ACTH-producing pituitary adenomas in children harbor somatic “hot-spot” mutations in the USP8 gene that encodes for the ubiquitin-specific protease 8 (Figure 5) which may lead to targeted medical therapies in the future (48, 49).

 

ACTH-INDEPENDENT CUSHING’S SYNDROME

 

Cushing’s syndrome in childhood and adolescence is caused by autonomous (ACTH-independent) secretion of cortisol by the adrenal cortex is an extremely rare condition. It accounts for 10%-15% of hypercortisolemia and is caused by unilateral adrenal lesions, including adrenocortical adenomas or carcinomas (discussed below), or bilateral adrenocortical disorders (50). Bilateral adrenocortical hyperplasias (BAHs) account for less than 2% of all cases of Cushing’s syndrome in pediatric and adult patients (50). BAHs are classified as macronodular (nodules with diameter greater than 1 cm) or micronodular (nodules with diameter less than 1 cm) (51). In addition to the size of nodules identified on high-resolution computed tomography (CT), BAHs are classified based on the existence of pigmentation on pathologic examination. The most common type of BAH in children is micronodular adrenocortical disease, which is further classified in primary pigmented nodular adrenocortical disease (PPNAD) and isolated micronodular adrenocortical disease (iMAD). PPNAD is characterized by dark brown pigmented adrenal micronodules that are surrounded by an atrophic cortex and is due to PRKAR1A mutations; in contrast, iMAD is characterized by the absence of extensive pigmentation and lack of PRKAR1A defects (52). Another cause of Cushing’s syndrome is primary bilateral macronodular adrenal hyperplasia (PBMAH) or massive macronodular adrenal hyperplasia (MMAD), which is characterized by adrenal nodules with a diameter greater than 1 cm. The molecular basis of this condition has been ascribed to ARMC5 gene mutations in about 50% of the cases (Figure 5) (53).

Figure 5. Genetic defects of Cushing’s disease and Cushing’s syndrome. AC: adenylate cyclase; ACTH: adrenocorticotropic hormone; AIP: aryl-hydrocarbon receptor-interacting protein; ARMC5: armadillo repeat containing 5; BMAH: bilateral macronodular adrenal hyperplasia; Brg1: Brahma‐related gene 1; Cα: catalytic subunit of PKA; CDKI: cyclin-dependent kinase inhibitor; CDKN1B (also known as p27Kip1); CTNNB1: catenin beta 1; DOT1: Disruptor of telomeric silencing 1; EGFR: epidermal growth factor receptor; GNAS: Guanine Nucleotide binding protein; GPCR: G-protein-coupled receptor; HDAC2: Histone Deacetylase 2; MC2R: melanocortin 2 receptor; MEN1: multiple endocrine neoplasia 1; PDEs: phosphodiesterases; PKA: protein kinase A; POMC: Pro-opiomelanocortin; PPNAD: primary pigmented nodular adrenocortical disease; PRUNE2: prune homologue 2; PTTG: pituitary transforming gene; Rlα: type 1α regulatory subunit of PKA; SDH: succinate dehydrogenase subunit; TR4: testicular orphan receptor 4; USP8: ubiquitin-specific peptidase 8.

ADRENOCORTICAL CARCINOMA

 

Adrenocortical carcinoma is a very rare pathologic condition which may occur at any age with a first peak before the age of 5 years and a second peak in adulthood between the fourth and fifth decades (54). It may be present in the context of Li-Fraumeni syndrome, which is caused by germline mutations in TP53 gene, a tumor suppressor gene located on chromosome 17. In contradistinction to adrenocortical carcinomas found in adults, mutations in the CTNNB1 gene that encodes for β-catenin are not frequently detected (55). Adrenocortical carcinoma in children usually presents with hypertension and increased concentrations of adrenal androgens, especially DHEAS, causing virilization, early pubarche, altered voice timber and irritability.

 

McCUNE-ALBRIGHT SYNDROME

 

This rare syndrome is characterized by the classic triad of cafe-au-lait skin macules, polyostotic fibrous dysplasia, and hyperfunctioning endocrinopathies (56). The molecular basis of this condition has been ascribed to postzygotic somatic activating mutations in the GNAS1 gene encoding for the alpha subunit of Gs protein (57). Hypertension in McCune-Albright syndrome has been associated with Cushing syndrome, often seen in infancy, thyrotoxicosis, or hypersecretion of growth hormone (58).  

 

CARNEY COMPLEX

 

Carney complex is inherited in an autosomal-dominant fashion and is caused by mutations in the PRKAR1A gene (17q22-24) encoding the regulatory subunit type I alpha of protein kinase A (59). The cardinal clinical manifestations often seen in patients with the complex include lentigines, cardiac and breast myxomas, and PPNAD that causes ACTH-independent Cushing’s syndrome (60, 61). The latter is responsible for hypertension in these patients.

 

DISORDERS OF THE ADRENAL MEDULLA

 

Conditions with Catecholamine Excess

 

PHEOCHROMOCYTOMA AND PARAGANGLIOMA

 

Pheochromocytomas and paragangliomas are rare tumors that produce and release excess amount of catecholamines into the systemic circulation. They both account for 0.5%-2% of hypertension in children and adolescents (62). According to Sarathi, 10% of pediatric pheochromocytomas and paragangliomas are malignant, 20% of them are synchronous bilateral, 30% are extra-adrenal, and 40% are familial (63). These tumors occur more frequently in boys (60%), present with hypertension (70%), and may be sporadic or in the context of specific syndromes, including neurofibromatosis type 1 caused by NF1 gene mutations, Von Hippel-Lindau disease type 2 due to VHL genetic defects, and multiple endocrine neoplasia type 2 caused by mutations in the RET gene (64). Rarely, pheochromocytomas and paragangliomas may present in paragangliomas syndromes caused by germline mutations in genes encoding the subunits D, AF2, C, B, and A of succinate dehydrogenase (SDH), or in the Pacak-Zhuang syndrome due to activating genetic defects in hypoxia-inducible factor 2 alpha (HIF2A), or in familial pheochromocytomas characterized by Myc-associated protein X (MAX) and transmembrane protein 127 (TMEM127) gene mutations. Although an ever-increasing number of predisposing genes have been identified so far, it is worth mentioning that most genetic defects in patients with pheochromocytomas and paragangliomas remain unidentified (65). Clinical manifestations include hypertension in 70%-90% of pediatric patients, flushing, hyperhidrosis, palpitations, tremors, headaches, nausea and/or vomiting during exercise, hyperactivity, or worsening of school performance. According to the recently published international consensus statement on the diagnostic work-up and the therapeutic management of pheochromocytomas and paragangliomas (66), the laboratory evaluation includes plasma-free or urine (spot or 24-h) levels of normetanephrine and metanephrine using liquid chromatography. In those children and adolescents with elevated concentrations of catecholamines, either MRI or CT should be performed for tumor localization (66). In cases of multiple and/or metastatic lesions, functional imaging, including [68Ga]DOTATATE, [18F]fluorodopa (FDOPA), and [18F]fluorodeoxyglucose (FDG) PET–CT, as well as [123I]MIBG scintigraphy, should be considered. All children with pheochromocytomas or paragangliomas are highly recommended to undergo genetic testing for germline mutations (65, 66). Surgical resection remains the treatment of choice in specialized centers with a multidisciplinary team. It is worth mentioning that minimally invasive procedures are preferred in cases with abdominal and pelvic pheochromocytomas and paragangliomas. Finally, special attention should be focused on preoperative treatment of hypertension using α-adrenoceptor blockers or calcium channel blockers or beta-adrenoceptor blockers especially in patients with persistent tachycardia (66, 67).

 

RENAL DISEASES MIMICKING ADRENAL DISORDERS

 

Syndromes of Inappropriate Salt Retention

 

LIDDLE SYNDROME

 

Patients with Liddle syndrome present with hypertension starting at about two years of age, although the average age of hypertension onset was 15.5 ± 3.3 years, according to the large series of cases (68). In addition to early-onset hypertension, patients with this condition display hypokalemia, metabolic alkalosis, and suppressed PAC. The genetic basis of Liddle syndrome has been ascribed to activating mutations in the sodium channel epithelial 1 alpha, beta and gamma (SCNN1A, SCNN1B, and SCNN1G) genes that encode for the α, β, and γ subunits, respectively, of the epithelial sodium channel (ENaC) of the renal tubule, also known as the amiloride-sensitive channel (Figure 6) (69). ENaC inhibitors, such as amiloride or triamterene, with low salt diet remain the only effective treatment in patients with Liddle syndrome (70).    

 

GORDON SYNDROME OR PSEUDOHYPOALDOSTERONISM TYPE 2 OR FAMILIAL HYPERKALEMIC HYPERTENSION

 

Gordon syndrome or type II pseudohypoaldosteronism (PHA II) is inherited in an autosomal dominant fashion and is characterized by hypertension, metabolic acidosis, hyperkalemia and hyperchloremia (71). Endocrinologic evaluation reveals low PRA and, usually, decreased serum aldosterone concentrations (71). Five subtypes of PHA II have been reported with distinct genetic defects (72). The genetic basis of PHA II-A is less known, since no genetic defect has been identified yet; however, this subtype has been associated with chromosome region 1q31-q42. PHA II-B has been linked to mutations in the with-no-lysine kinase (WNK4) gene (17q21), whereas genetic defects in the WNK1 gene (12p12.3.) have been associated with PHA II-C (Figure 6). WNK genes encode WNK proteins, which function as serine-threonine protein kinases regulating the expression and action of cation-Cl− cotransporters (CCCs) such as the sodium chloride cotransporter (NCC), basolateral Na-K-Cl symporter (NKCC1), and potassium chloride cotransporter (KCC1) located within the distal nephron. Patients with PHA II-D and -E harbor variations in kelch-like 3 (KLHL3) gene (5q31.2) that encodes for the adaptor protein KLHL3, and cullin-3 (CUL3) gene (2q36) expressing the ubiquitin scaffold protein CUL3, respectively (Figure 6) (73, 74). Generally, patients with Gordon syndrome respond adequately to low sodium diet and thiazide diuretics (28).    

 

GELLER SYNDROME (MR ACTIVATING MUTATION SYNDROME)

 

Geller syndrome is a rare autosomal dominant disorder characterized by hypertension, hypokalemia, low PRA, and low serum aldosterone concentrations (2). Patients with Geller syndrome harbor an activating mutation in the NR3C2 gene that encodes for the mineralocorticoid receptor (MR) (Figure 6) (75, 76). This genetic defect leads to aberrant activation of the MR by cortisone, 11-DOC, and progesterone, all acting as antagonists of the wild-type MR; therefore, hypertension worsens during pregnancy due to increased progesterone concentrations. The therapeutic management includes administration of amiloride and finerenone (77).   

 

APPARENT MINERALOCORTICOID EXCESS (AME) SYNDROME (11β-Hydroxysteroid Dehydrogenase Deficiency Type 2)

 

This syndrome is caused by inactivating genetic defects in the 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2) gene that encodes for the enzyme 11β-hydroxysteroid dehydrogenase type 2 converting cortisol to inactive cortisone in aldosterone-responsive target tissues (Figure 6) (e.g., kidney) (78). The resultant high concentrations of cortisol bind to mineralocorticoid receptors which induce the expression of several responsive genes leading to hypertension, low renin and aldosterone concentrations, hypernatremia, hypokalemia, and metabolic alkalosis. In addition to hypertension, patients with AME syndrome may present with short stature, failure to thrive, polyuria, polydipsia, as well as hypercalciuria and nephrocalcinosis (78). To reach the diagnosis, a high ratio of 5b and 5a-tetrahydrocortisol steroids to tetrahydrocortisone in the urine should be confirmed, followed by sequencing of the HSD11B2 gene. Treatment should begin early to prevent left ventricular hypertrophy and/or cerebrovascular events, and includes spironolactone to block mineralocorticoid receptor activation, restriction of dietary intake of sodium, and potassium supplementation. In cases of nephrocalcinosis, patients should also receive chlorothiazide or hydrochlorothiazide to minimize hypercalciuria (78). Dexamethasone might be also administered as monotherapy or in addition to spironolactone, since dexamethasone reduces the activity of the hypothalamic-pituitary-adrenal axis through negative feedback loops at the levels of hypothalamus and pituitary. Moreover, dexamethasone does not have any affinity to 11β-HSD2 (78).

Figure 6. Genetic defects of renal disorders mimicking adrenal diseases. Apparent Mineralocorticoid Excess (AME) syndrome is caused by inactivating genetic defects in the HSD11B2 that encodes for the 11β-hydroxysteroid dehydrogenase type 2 converting cortisol to inactive cortisone. The molecular basis of Gordon syndrome has been ascribed to mutations in the WNK genes expressing proteins that function as serine-threonine protein kinases regulating the expression and action of cation-Cl− cotransporters, such as the sodium chloride cotransporter. Gordon syndrome is also caused by mutations in KLHL3 that encodes for the adaptor protein KLHL3, as well as in CUL3 expressing the ubiquitin scaffold protein CUL3. Geller syndrome has been associated with activating mutations in the NR3C2 that encodes for the mineralocorticoid receptor. Liddle syndrome is caused by mutations in the SCNN1A, SCNN1B, and SCNN1G encoding for the α, β, and γ subunits, respectively, of the epithelial sodium channel (ENaC) of the renal tubule. HSD11B2: 11β-hydroxysteroid dehydrogenase type 2; HSPs: heat shock proteins; FKBP: immunophilin; KLHL3: kelch-like 3; MR: mineralocorticoid receptor; NR3C2: nuclear receptor subfamily 3 group C member 2; WNK: with-no-lysine kinase.

OTHER CAUSES OF ENDOCRINE HYPERTENSION

 

Acromegaly

 

In children and adolescents, growth hormone (GH) excess is rare. Its prevalence is approximately 30 cases per million in children aged 0-17 years in United States without any differences between males and females (79). Acromegaly is usually caused by a GH-secreting pituitary adenoma, but other less common causes include pituitary hyperplasia, multiple adenomas, or extremely rare cases of tumors secreting growth hormone-releasing hormone (GHRH) (80). In 45% of cases, the molecular basis of GH-secreting adenomas or hyperplasia has been attributed to identifiable genetic defects, including mutations in the AIP gene (˃20%), duplications in the GPR101 gene that cause X-LAG, post-zygotic mosaic GNAS mutations responsible for McCune-Albright syndrome (5%), whereas genetic defects in other genes, such as MEN1, CDKN1B, PRKAR1A, PRKACB and SDH contribute in less than 1% each (81). Typical clinical manifestations in children and adolescents with acromegaly include overgrowth and tall stature if excess secretion of GH occurs before epiphyseal closure, acral enlargement, rectangular face, prognathism, headache, visual filed defects, sweating, delayed puberty, left ventricular hypertrophy, diastolic dysfunction, sleep apnea, hypertension, as well as glucose intolerance or even diabetes (79). The biochemical diagnosis of GH excess relies on elevated age-adjusted serum IGF-1 concentrations and failure to suppress GH following an oral glucose tolerance test. Treatment options include surgery, medical therapy, and radiotherapy (79).      

 

Thyroid / Parathyroid Dysfunction

 

Thyroid or parathyroid dysfunction has been associated with hypertension in children and adolescents. Hypothyroidism is usually associated with increased diastolic blood pressure, whereas hyperthyroidism with elevated systolic blood pressure (82). In addition to thyroid disorders, hypertension has also been reported in patients with parathyroid dysfunction, although there are no data on its prevalence (83).  

 

CONCLUSIONS

 

Endocrine hypertension in children is most often caused by excess steroids, with other hormonal abnormalities far less frequent. The tremendous progress on endocrine genetics and molecular biology has enabled a deeper understanding of the genetic basis of several endocrine pathologic conditions leading to hypertension. A detailed medical history and physical examination, as well as a careful interpretation of laboratory and hormonal results may lead to an early and accurate diagnosis (Figure 7). The appropriate therapeutic management of these conditions is of paramount importance to prevent long term cardiovascular and other systemic complications.

Figure 7. Diagnostic approach to endocrine hypertension.

REFERENCES

 

  1. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM; SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017 Sep;140(3):e20171904.
  2. Kotanidou EP, Giza S, Tsinopoulou VR, Vogiatzi M, Galli-Tsinopoulou A. Diagnosis and Management of Endocrine Hypertension in Children and Adolescents. Curr Pharm Des 2020;26(43):5591-5608.
  3. Baracco R, Kapur G, Mattoo T, Jain A, Valentini R, Ahmed M, Thomas R. Prediction of primary vs secondary hypertension in children. J Clin Hypertens (Greenwich). 2012 May;14(5):316-21.
  4. Gupta-Malhotra M, Banker A, Shete S, Hashmi SS, Tyson JE, Barratt MS, Hecht JT, Milewicz DM, Boerwinkle E.Essential hypertension vs. secondary hypertension among children. Am J Hypertens. 2015 Jan;28(1):73-80.
  5. Pons Fernández N, Moreno F, Morata J, Moriano A, León S, De Mingo C, Zuñiga Á, Calvo F. Familial hyperaldosteronism type III a novel case and review of literature. Rev Endocr Metab Disord. 2019 Mar;20(1):27-36.
  6. He X, Modi Z, Else T. Hereditary causes of primary aldosteronism and other disorders of apparent excess mineralocorticoid activity. Gland Surg. 2020 Feb;9(1):150-158.
  7. Baguet JP, Steichen O, Mounier-Véhier C, Gosse P. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA? Ann Endocrinol (Paris). 2016 Jul;77(3):187-91.
  8. Li X, Goswami R, Yang S, Li Q. Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: A meta-analysis. J Renin Angiotensin Aldosterone Syst 2016 Aug 17;17(3):1470320316657450.
  9. Reznik Y, Amar L, Tabarin A. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 3: Confirmatory testing. Ann Endocrinol (Paris). 2016 Jul;77(3):202-7.
  10. Bardet S, Chamontin B, Douillard C, Pagny JY, Hernigou A, Joffre F, Plouin PF, Steichen O. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: Subtype diagnosis. Ann Endocrinol (Paris). 2016 Jul;77(3):208-13.
  11. Pechère-Bertschi A, Herpin D, Lefebvre H. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism. Ann Endocrinol (Paris) 2016 Jul;77(3):226-34.
  12. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992;355:262-5.
  13. Zennaro MC, Jeunemaitre X. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism. Ann Endocrinol (Paris). 2016 Jul;77(3):214-9.
  14. Stowasser M, Bachmann AW, Jonsson JR, et al. Clinical, biochemical and genetic approaches to the detection of familial hyperaldosteronism type I. J Hypertens 1995;13:1610-3.
  15. Mulatero P, Veglio F, Pilon C, et al. Diagnosis of Glucocorticoid-Remediable Aldosteronism in Primary Aldosteronism: Aldosterone Response to Dexamethasone and Long Polymerase Chain Reaction for Chimeric Gene. J Clin Endocrinol Metab 1998;83:2573-5.
  16. Nimkarn S, New M. Endocrine Hypertension in Childhood. Kenneth R Feingold, Bradley Anawalt, Marc R Blackman, Alison Boyce, George Chrousos, Emiliano Corpas, Wouter W de Herder, Ketan Dhatariya, Kathleen Dungan, Johannes Hofland, Sanjay Kalra, Gregory Kaltsas, Nitin Kapoor, Christian Koch, Peter Kopp, Márta Korbonits, Christopher S Kovacs, Wendy Kuohung, Blandine Laferrère, Miles Levy, Elizabeth A McGee, Robert McLachlan, Maria New, Jonathan Purnell, Rakesh Sahay, Amy S Shah, Frederick Singer, Mark A Sperling, Constantine A Stratakis, Dace L Trence, Don P Wilson, editors. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. 2017 Mar 3.
  17. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916.
  18. Scholl UI, Stolting G, Schewe J, Thiel A, Tan H, Nelson-Williams C, et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet. 2018;50(3):349-54.
  19. Fernandes-Rosa FL, Daniil G, Orozco IJ, Goppner C, El Zein R, Jain V, et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat Genet. 2018;50(3):355-61.
  20. Mulatero P, Williams TA, Monticone S, Veglio F. Is familial hyperaldosteronism underdiagnosed in hypertensive children? Hypertension. 2011 Jun;57(6):1053-5.
  21. Scholl UI, Stölting G, Schewe J, Thiel A, Tan H, Nelson-Williams C, Vichot AA, Jin SC, Loring E, Untiet V, Yoo T, Choi J, Xu S, Wu A, Kirchner M, Mertins P, Rump LC, Onder AM, Gamble C, McKenney D, Lash RW, Jones DP, Chune G, Gagliardi P, Choi M, Gordon R, Stowasser M, Fahlke C, Lifton RP. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet. 2018 Mar;50(3):349-354.
  22. Perez-Rivas LG, Williams TA, Reincke M. Inherited Forms of Primary Hyperaldosteronism: New Genes, New Phenotypes and Proposition of A New Classification. Exp Clin Endocrinol Diabetes. 2019 Feb;127(2-03):93-99.
  23. Hassan-Smith Z, Stewart PM. Inherited forms of mineralocorticoid hypertension. Curr Opin Endocrinol Diabetes Obes. 2011 Jun;18(3):177-85.
  24. Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Åkerström G, Wang W, Carling T, Lifton RP. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011 Feb 11;331(6018):768-72.
  25. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 2008 Aug;93(8):3117-23.
  26. Monticone S, Buffolo F, Tetti M, Veglio F, Pasini B, Mulatero P. GENETICS IN ENDOCRINOLOGY: The expanding genetic horizon of primary aldosteronism. Eur J Endocrinol. 2018 Mar;178(3):R101-R111.
  27. Scholl UI, Goh G, Stolting G, de Oliveira RC, Choi M, Overton JD, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013;45(9):1050-4.
  28. Costa-Barbosa FA, Giorgi RB, Kater CE. Focus on adrenal and related causes of hypertension in childhood and adolescence: Rare or rarely recognized? Arch Endocrinol Metab. 2022 Nov 17;66(6):895-907.
  29. Hinz L, Pacaud D, Kline G. Congenital adrenal hyperplasia causing hypertension: an illustrative review. J Hum Hypertens. 2018 Feb;32(2):150-157.
  30. Bulsari K, Falhammar H. Clinical perspectives in congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency. Endocrine. 2017;55(1):19-36.
  31. Mimouni M, Kaufman H, Roitman A, Morag C, Sadan N. Hypertension in a neonate with 11 beta-hydroxylase deficiency. Eur J Pediatr. 1985;143(3):231-3.
  32. Kater CE, Biglieri EG. Disorders of steroid 17 alpha-hydroxylase deficiency. Endocrinol Metab Clin North Am. 1994;23(2):341-57.
  33. Biglieri EG, Kater CE, Brust N, Chang B, Hirai J. The mineralocorticoid hormone pathways in hypertension with hyperaldosteronism. Clin Exp Hypertens A. 1982;4(9-10):1677 -83.
  34. Biglieri EG, Herron MA, Brust N. 17-hydroxylation deficiency in man. J Clin Invest. 1966;45(12):1946-54.
  35. Chrousos GP, Vingerhoeds A, Brandon D, Eil C, Pugeat M, DeVroede M, Loriaux DL, Lipsett MB. Primary cortisol resistance in man. A glucocorticoid receptor-mediated disease. J Clin Invest. 1982 Jun;69(6):1261-9.
  36. Nicolaides NC, Charmandari E. Primary Generalized Glucocorticoid Resistance and Hypersensitivity Syndromes: A 2021 Update. Int J Mol Sci. 2021 Oct 7;22(19):10839.
  37. Nicolaides NC, Charmandari E. Novel insights into the molecular mechanisms underlying generalized glucocorticoid resistance and hypersensitivity syndromes. Hormones (Athens) 2017 Apr;16(2):124-138.
  38. Nicolaides NC, Charmandari E. Chrousos syndrome: from molecular pathogenesis to therapeutic management. Eur J Clin Invest. 2015 May;45(5):504-14.
  39. Nicolaides N, Lamprokostopoulou A, Sertedaki A, Charmandari E. Recent advances in the molecular mechanisms causing primary generalized glucocorticoid resistance. Hormones (Athens). 2016 Jan-Mar;15(1):23-34.
  40. Guemes M, Murray PG, Brain CE, Spoudeas HA, Peters CJ, Hindmarsh PC, et al. Management of Cushing syndrome in children and adolescents: experience of a single tertiary centre. Eur J Pediatr. 2016;175(7):967-76.
  41. Cicala MV, Mantero F. Hypertension in Cushing’s syndrome: from pathogenesis to treatment. Neuroendocrinology. 2010;92 Suppl 1:44-9.
  42. Magiakou MA, Chrousos GP. Cushing’s syndrome in children and adolescents: current diagnostic and therapeutic strategies. J Endocrinol Invest. 2002;25(2):181-94.
  43. Greening JE, Brain CE, Perry LA, Mushtaq I, Sales Marques J, Grossman AB, et al. Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing’s disease. Horm Res. 2005;64(3):140-3.
  44. Tatsi C, Stratakis CA. Aggressive pituitary tumors in the young and elderly. Rev Endocr Metab Disord 2020;21(2):213–223
  45. Karageorgiadis AS, Papadakis GZ, Biro J, Keil MF, Lyssikatos C, Quezado MM, Merino M, Schrump DS, Kebebew E, Patronas NJ, Hunter MK, Alwazeer MR, Karaviti LP, Balazs AE, Lodish MB, Stratakis CA. Ectopic adrenocorticotropic hormone and corticotropin-releasing hormone co-secreting tumors in children and adolescents causing cushing syndrome: a diagnostic dilemma and how to solve it. J Clin Endocrinol Metab 2015;100(1):141-148.
  46. Tatsi C, Stratakis CA. Neonatal Cushing syndrome: a rare but potentially devastating disease. Clin Perinatol 2018;45:103–118.
  47. Chan LF, Storr HL, Grossman AB, Savage MO. Pediatric Cushing’s syndrome: clinical features, diagnosis, and treatment. Arq Bras Endocrinol Metabol. 2007;51(8):1261-71.
  48. Faucz FR, Tirosh A, Tatsi C, Berthon A, Hernández-Ramírez LC, Settas N, Angelousi A, Correa R, Papadakis GZ, Chittiboina P, Quezado M, Pankratz N, Lane J, Dimopoulos A, Mills JL, Lodish M, Stratakis CA. Somatic USP8 Gene Mutations Are a Common Cause of Pediatric Cushing Disease. J Clin Endocrinol Metab. 2017;102(8):2836-2843.
  49. Tatsi C, Flippo C, Stratakis CA. Cushing syndrome: Old and new genes. Best Pract Res Clin Endocrinol Metab. 2020 Mar;34(2):101418.
  50. Stratakis CA. Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin-independent Cushing syndrome). Endocr Dev 2008;13:117–132.
  51. De Venanzi A, Alencar GA, Bourdeau I, et al. Primary bilateral macronodular adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes 2014;21(3):177–184.
  52. Powell AC, Stratakis CA, Patronas NJ, et al. Operative management of Cushing syndrome secondary to micronodular adrenal hyperplasia. Surgery 2008; 143(6):750-758.
  53. Assie´ G, Libe´ R, Espiard S, et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome. N Engl J Med 2013;369(22):2105–2114.
  54. Pereira RM, Michalkiewicz E, Sandrini F, Figueiredo BC, Pianovski M, Franca SN, et al. [Childhood adrenocortical tumors]. Arq Bras Endocrinol Metabol. 2004;48(5):651-8.
  55. Leal LF, Mermejo LM, Ramalho LZ, Martinelli CE Jr, Yunes JA, Seidinger AL, et al. Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors. J Clin Endocrinol Metab. 2011;96(10):3106-14.
  56. Boyce AM, Collins MT. Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation. Endocr Rev. 2020 Apr 1;41(2):345-370.
  57. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991 Dec 12;325(24):1688-95.
  58. Ohata Y, Yamamoto T, Mori I, Kikuchi T, Michigami T, Imanishi Y, et al. Severe arterial hypertension: a possible complication of McCune-Albright syndrome. Eur J Pediatr. 2009;168(7):871-6.
  59. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, Stratakis CA. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet. 2000 Sep;26(1):89-92.
  60. Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore). 1985 Jul;64(4):270-83.
  61. Stratakis CA. Carney Complex. 2003 Feb 5 [updated 2023 Sep 21]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024.
  62. Havekes B, Romijn JA, Eisenhofer G, Adams K, Pacak K. Update on pediatric pheochromocytomas. Pediatr Nephrol. 2009;24(5):943-950
  63. Sarathi V. Characteristics of Pediatric Pheochromocytoma/paragangliomas. Indian J Endocrinol Metab. 2017;21(3):470-474.
  64. Bholah R and Bunchman TE. Review of Pediatric Pheochromocytoma and Paraganglioma. Front Pediatr. 2017;5:155.
  65. Pamporaki C, Casey RT. Current views on paediatric phaeochromocytoma and paraganglioma with a focus on newest guidelines. Best Pract Res Clin Endocrinol Metab 2024 Nov 14:101957.
  66. Casey RT, Hendriks E, Deal C, Waguespack SG, Wiegering V, Redlich A, et al. International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents. Nat Rev Endocrinol. 2024 Dec;20(12):729-748.
  67. Romero M, Kapur G, Baracco R, et al. Treatment of hypertension in children with catecholamine-secreting tumors: a systematic approach. J Clin Hypertens 2015;17(9):720-725.
  68. Cui Y, Tong A, Jiang J, Wang F, Li C. Liddle syndrome: clinical and genetic profiles. J Clin Hypertens (Greenwich). 2017;19(5):524-9.
  69. Tetti M, Monticone S, Burrello J, Matarazzo P, Veglio F, Pasini B, et al. Liddle Syndrome: Review of the Literature and Description of a New Case. Int J Mol Sci. 2018;19(3).
  70. Enslow BT, Stockand JD, Berman JM. Liddle’s syndrome mechanisms, diagnosis and management. Integr Blood Press Control. 2019;12:13-22.
  71. Gordon RD, Geddes RA, Pawsey CG, O'Halloran MW. Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med. 1970 Nov;19(4):287-94.
  72. Mabillard H, Sayer JA. The Molecular Genetics of Gordon Syndrome. Genes (Basel). 2019;10(12).
  73. Casas-Alba D, Vila Cots J, Monfort Carretero L, Martorell Sampol L, Zennaro MC, Jeunemaitre X, et al. Pseudohypoaldosteronism types I and II: little more than a name in common. J Pediatr Endocrinol Metab. 2017;30(5):597-601.
  74. Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature. 2012;482(7383):98-102.
  75. Ceccato F, Mantero F. Monogenic Forms of Hypertension. Endocrinol Metab Clin North Am. 2019;48(4):795-810.
  76. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289(5476):119-23.
  77. Zennaro MC, Boulkroun S, Fernandes-Rosa F. Inherited forms of mineralocorticoid hypertension. Best Pract Res Clin Endocrinol Metab. 2015 Aug;29(4):633-45.
  78. Lu YT, Zhang D, Zhang QY, Zhou ZM, Yang KQ, Zhou XL, Peng F. Apparent mineralocorticoid excess: comprehensive overview of molecular genetics. J Transl Med. 2022;20(1):500.
  79. Maiter D, Chanson P, Constantinescu SM, Linglart A. Diagnosis and management of pituitary adenomas in children and adolescents. Eur J Endocrinol. 2024 Sep 30;191(4):R55-R69.
  80. Asa SL, Ezzat S. An update on pituitary neuroendocrine tumors leading to acromegaly and gigantism. J Clin Med. 2021;10(11): 2254.
  81. Rostomyan L, Daly AF, Petrossians P, et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer. 2015;22(5):745-757.
  82. Berta E, Lengyel I, Halmi S, Zrínyi M, Erdei A, Harangi M, Páll D, Nagy EV, Bodor M. Hypertension in Thyroid Disorders. Front Endocrinol (Lausanne). 2019 Jul 17:10:482.
  83. de Freminville JB, Amar L, Azizi M, Mallart-Riancho J. Endocrine causes of hypertension: literature review and practical approach. Hypertens Res. 2023 Dec;46(12):2679-2692.

 

Hyperparathyroidism in Chronic Kidney Disease

ABBREVIATIONS

[Ca2+e] : extracellular  Ca2+ concentration

Calcidiol : 25 OH vitamin D3

Calcitriol : 1,25 diOH vitamin D3

CaSR : Ca2+-sensing receptor

CKD : chronic kidney disease

CKD-MBD : CKD-associated mineral and bone disorder

EGF-R : epidermal growth factor receptor

ESKD, end-stage kidney disease

FGF23: fibroblast growth factor-23

FGFR-1, fibroblast growth factor receptor-1

FGFR-3, fibroblast growth factor receptor-3

Ki67 : Ki-67 antigen (cell-cycle linked antigen)

MEN-1 : multiple endocrine neoplasia type-1

Klotho: α-Klotho

PCNA : proliferating cell nuclear antigen (cell-cycle linked antigen)

PTH : parathyroid hormone

iPTH : intact PTH

PTHrp : parathyroid hormone related peptide

PTX : parathyroidectomy

TGF-β : transforming growth factor-β

VDR : vitamin D receptor

 

ABSTRACT

 

Chronic kidney disease (CKD) is associated with mineral and bone disorders (CKD-MBD) which starts early in the course of the disease and worsens with its progression. The main initial serum biochemistry abnormalities are increases in fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH) and decreases in 1,25 dihydroxy vitamin D (calcitriol) and soluble α-Klotho (Klotho), allowing serum calcium and phosphate to stay normal for prolonged time periods. Subsequently, serum 25 hydroxy vitamin D (calcidiol) decreases and in late CKD stages hyperphosphatemia develops in the majority of patients. Serum calcium may stay normal, decrease, or increase. Sclerostin, Dickkopf-1, and activin A also play a role in the pathogenesis of CKD-MBD. Both the synthesis and the secretion of PTH are continuously stimulated in the course of CKD, resulting in secondary hyperparathyroidism. In addition to the above systemic disturbances downregulation of vitamin D receptor, calcium-sensing receptor and Klotho expression in parathyroid tissue further enhances PTH overproduction. Last but not least, miRNAs have also been shown to be involved in the hyperparathyroidism of CKD. The chronic stimulation of parathyroid secretory function is not only characterized by a progressive rise in serum PTH but also by parathyroid gland hyperplasia. It results from an increase in parathyroid cell proliferation which is not fully compensated for by a concomitant increase in parathyroid cell apoptosis. Parathyroid hyperplasia is initially of the diffuse, polyclonal type. In late CKD stages it often evolves towards a nodular, monoclonal or multiclonal type of growth. Enhanced parathyroid expression of transforming growth factor-β and its receptor, the epidermal growth factor receptor, is involved in polyclonal hyperplasia. Chromosomal changes have been found to be associated with clonal outgrowth in some, but not the majority of benign parathyroid tumors removed from patients with end-stage kidney disease. In initial CKD stages skeletal resistance to the action of PTH may explain why low bone turnover predominates in a significant proportion of patients, together with other conditions that inhibit bone turnover such as reduced calcitriol levels, sex hormone deficiency, diabetes, Wnt inhibitors and uremic toxins. High turnover bone disease (osteitis fibrosa) occurs only later on, when increased serum PTH levels are able to overcome skeletal PTH resistance. The diagnosis of secondary uremic hyperparathyroidism and osteitis fibrosa relies mainly on serum biochemistry. X-ray and other imaging methods of the skeleton provide diagnostically relevant information only in severe forms. From a therapeutic point of view, it is important to prevent the development of secondary hyperparathyroidism as early as possible in the course of CKD. A variety of prophylactic and therapeutic approaches are available, as outlined in the final part of the chapter.

 

INTRODUCTION

 

Chronic kidney disease (CKD) is almost constantly associated with a systemic disorder of mineral and bone metabolism, at present named CKD-MBD (1). According to this definition, the disorder is manifested by either one or a combination of biochemical abnormalities (abnormal calcium, phosphate, PTH, or vitamin D metabolism), bone abnormalities (abnormal bone turnover, mineralization volume, linear growth, or strength) and vascular or other soft tissue calcification. Subsequently, the underlying pathophysiology has become more complex, with the progressive awareness that fibroblast growth factor 23 (FGF23), a-Klotho (subsequently called "Klotho") as well as the Wnt-b-catenin signaling pathway also play an important role (see below). CKD-MBD generally becomes apparent in CKD stage G3, i.e. at a glomerular filtration rate between 60 and 30 ml/min x 1.73 m2. Initially, it is characterized by a tendency towards hypocalcemia, fasting normo- or hypophosphatemia, and diminished plasma 25OH vitamin D (calcidiol) and 1,25diOH vitamin D (calcitriol) concentrations, together with a progressive increase in plasma FGF23 and intact parathyroid hormone (iPTH), a decrease in plasma soluble Klotho (2–5) and the development of renal osteodystrophy. Renal osteodystrophy often presents initially as adynamic bone disease and subsequently transforms into osteitis fibrosa or mixed bone disease (6). Pure osteomalacia is seen only infrequently. The low bone turnover observed in a significant proportion of patients in early stages of CKD could be due to the initial predominance of bone turnover inhibitory conditions such as resistance to the action of PTH, reduced serum calcitriol levels, sex hormone deficiency, diabetes, inflammation and malnutrition, and uremic toxins leading to the repression of osteocyte Wnt--catenin signaling and increased expression of Wnt antagonists such as sclerostin, Dickkopf-1 and secreted frizzled-related protein 4 (7,8). According to this scenario, high turnover bone disease occurs only later on, when sufficiently elevated serum PTH levels are able to overcome the skeletal resistance to its action. Even at that stage, over suppression of PTH by the administration of excessive calcium and/or vitamin D supplements can again induce adynamic bone disease (9). Nephrologists became progressively aware of the fact that the abnormally high serum phosphorus levels in late CKD stages, associated with either hyperparathyroidism or (mostly iatrogenically induced) hypoparathyroidism, may be detrimental to the patients not only in terms of abnormal bone structure and strength, but also in terms of the relative risk of soft-tissue calcifications and cardiovascular as well as all-cause mortality (10–13). As regards serum PTH levels, observational studies have consistently reported an increased relative risk of death in patients with CKD stage G5  and PTH values at the extremes, that is less than two or greater than nine times the upper normal limit of the assay (14,15). For PTH values within the range of two to nine times the upper normal limit reports of associations with relative risk of cardiovascular events or death in patients with CKD have been inconsistent. A recent observational study done in a very large patient population undergoing hemodialysis therapy in 9 countries confirmed the J-shaped association of all-cause or cardiovascular mortality with PTH and pointed in addition to a direct, linear relationship with total alkaline phosphatase (16). Interestingly, a direct association between plasma iPTH in the normal range and cardiovascular mortality was found even in elderly men without CKD (17).

 

From a clinical point of view, it may be useful to complete the term CKD-MBD by two syndromes, namely CKD-associated osteoporosis and CKD-associated cardiovascular disease, as proposed in a recent KDIGO controversies conference (18). Both hyper and hypoparathyroidism contribute to these syndromes.

 

SECONDARY HYPERPARATHYROIDISM IN CKD – SEQUENCE OF PLASMA BIOCHEMISTRY CHANGES IN EARLY CKD STAGES

 

Phosphate Retention

 

The precise sequence of metabolic and endocrine anomalies in incipient CKD leading to secondary hyperparathyroidism remains a matter of debate. Many years ago, it was postulated that a retention of phosphate in the extracellular space due to the decrease in glomerular filtration rate and the accompanying reduction in plasma ionized calcium concentration was the primary event in the pathogenesis of secondary hyperparathyroidism. These anomalies would only be transient, and a new steady state would rapidly be reached, with normalization of plasma calcium and phosphate in response to increased PTH secretion and the well-known inhibitory effect of this hormone on the tubular reabsorption of phosphate (“trade-off hypothesis” of Bricker and Slatopolsky) (19). However, this hypothesis has become less attractive since it was demonstrated that plasma phosphate is only rarely elevated in early CKD, and phosphate balance was found to be not positive but negative, at least in rats with moderate-degree CKD (20). Most often, plasma phosphate remains normal until CKD stages G4-G5 (2,21). It may even be moderately diminished in CKD (22).  Oral phosphate absorption remains normal in early stages of experimental CKD (20), and urinary phosphate excretion after an oral overload in patients with mild CKD was actually found to be accelerated (22). Nonetheless, one could argue that in early kidney disease normal or even subnormal concentrations of plasma phosphate might be observed after a slight, initial plasma phosphate increase following phosphate ingestion and stimulation

 

Figure 1. Schematic view of the time profile of disturbances in mineral hormones and bone turnover with progression of chronic kidney disease (CKD). From Drueke & Massy (6).

 

of the secretion of FGF23 and PTH, which in turn could overcorrect plasma phosphate rapidly, due to a potent inhibition of tubular phosphate reabsorption. However, a subsequent study identified slight increases of plasma phosphate in a large US population sample (NHANES III) with CKD stage G3 as compared to a healthy control population without evidence of kidney disease (23). Probably both the time of plasma phosphate determinations during the day as well as subtle changes in circulating and local factors involved in the control of phosphate balance determine the actual plasma level of phosphate in patients with CKD.

 

Fibroblast Growth Factor 23 (FGF23) and Klotho

 

FGF23 is recognized at present as a major, if not the most important player in the control of phosphate metabolism. It is mainly produced by osteocytes and osteoblasts. It decreases plasma phosphate by reducing tubular phosphate reabsorption similar to, but independent of PTH. Moreover, in contrast to PTH it decreases the renal synthesis of calcitriol. To activate its receptors, FGFR-1 and FGFR-3 on tubular epithelial cells requires the presence of Klotho (or more precisely α-Klotho), which in its function as a co-receptor confers FGF receptor specificity for FGF23 (24). Although initially Klotho expression was found only in the distal tubule, it has subsequently been demonstrated to occur in the proximal tubule as well. In line with this finding, the ablation of Klotho specifically from the distal tubules certainly resulted in a hyperphosphatemic phenotype, but to a lesser degree than in systemic or whole nephron Klotho knockout models (25). The regulation of FGF23 production and its interrelations with PTH, calcitriol, calcium, phosphate, and Klotho are complex, being only progressively unraveled. Isakova et al. provided evidence that serum FGF23 increased earlier than serum iPTH in patients with CKD (4). This observation is also supported by experiments in an animal model of CKD and the use of anti-FGF23 antibodies (26). However, the authors of a subsequent large-scale population study took issue with the claim that the increase in circulating FGF23 preceded that of PTH (27). Klotho expression in kidney, Klotho plasma levels and Klotho urinary excretion decrease with progressive CKD (28,29). The presence of Klotho is required to allow FGF23 to exert its action in the kidney. In addition, Klotho also exerts FGF23 independent effects. It acts from the tubular luminal side as an autocrine or paracrine enzyme to regulate transporters and ion channels. By modifying the Na-phosphate co-transporter NaPi2a it can enhance phosphaturia directly (30). However, its purported glycosidase activity has been put into question recently (31).  The issue then arises which comes first in CKD, an increase in FGF23 or a decrease in Klotho ? The answer remains a matter of debate (32). Some studies showed that secreted soluble Klotho levels decrease  before FGF23 levels increase (33,34) but the sequence of events may differ depending on experimental models and diverse clinical conditions (35). CKD is probably the most common cause of chronically elevated serum FGF23 levels (36). FGF23 production in bone is increased by phosphate, calcitriol, calcium, PTH, Klotho, and iron. Not all of these effects are necessarily direct. The effect of PTH clearly is both direct, via stimulation of PTH receptor-1 (PTH-R1) (37) and the orphan nuclear receptor Nurr1 (38), and indirect, via an increase in calcitriol synthesis (39). On the other hand, FGF23 inhibits PTH synthesis and secretion although in CKD this effect is mitigated by reduced Klotho and FGFR-1 expression in parathyroid tissue (40-42).

 

The increase in circulating FGF23 with the progression of CKD is independently associated with serum phosphate, calcium, iPTH, and calcitriol (43,44). Despite its direct inhibitory action on the parathyroid tissue FGF23 contributes to the progression of secondary hyperparathyroidism by reducing renal calcitriol synthesis and subsequently decreasing active intestinal calcium transport. Figure 2 shows the complex interrelations between serum FGF23, Klotho, phosphate, calcium, calcitriol, and parathyroid function in CKD.

 

Figure 2. Chronic kidney disease-associated mineral and bone disorder (CKD-MBD). Complex interactions between phosphate, FGF23, FGF receptor-1c (FGFR1c), Klotho, 1,25diOH vitamin D (calcitriol), renal 1α 25OH vitamin D hydroxylase (1α hydroxylase), vitamin D receptor (VDR), calcium, Ca-sensing receptor (CaSR), and parathyroid hormone (PTH). From Komaba & Fukagawa (45), modified.

 

Calcium Deficiency

 

In early CKD stages, disturbances of calcium metabolism may already be present. They include a calcium deficiency state due to a negative calcium balance resulting from low oral calcium intakes and impaired active intestinal calcium absorption (although a positive calcium balance can be induced by the ingestion of high amounts of calcium-containing phosphate binders) (46,47), a tendency towards hypocalcemia due to skeletal resistance to the action of PTH (48), and reduced calcium-sensing receptor (CaSR) expression in the parathyroid cell. All these factors contribute to the development of parathyroid overfunction (48,49). Their relative importance increases with the progression of CKD. It also depends on individual patient characteristics such as the underlying type of nephropathy, comorbidities, dietary habits, and amount of food intake.

 

Inhibition of Calcitriol Synthesis

 

The progressive loss of functioning nephrons and increased production of FGF23 are mainly responsible for the reduction in renal calcitriol synthesis, favoring the development of hyperparathyroidism. Although PTH in turn stimulates renal tubular 1α-OH vitamin D hydroxylase activity resistance to its action probably attenuates this counter-regulatory mechanism. Whether the direct inhibition of  1α-OH vitamin D hydroxylase activity by FGF23 is more powerful than its stimulation by PTH depends on several other additional factors such as the presence of  hyperphosphatemia, metabolic acidosis, and uremic toxins. The marked disturbances of the calcitriol synthesis pathway probably explain the long reported direct relation in patients with CKD between plasma calcidiol and calcitriol, and between plasma calcitriol and glomerular filtration rate (50). Such relations are not observed in people with normal kidney function.

 

Yet another hypothesis is based on the observation that calcidiol does not penetrate into proximal tubular epithelium from the basolateral side, but only from the luminal side. The complex formed by calcidiol and its binding protein (DBP) is ultrafiltered by the glomerulus, subsequently enters the tubular epithelium from the apical side via the multifunctional brush border membrane receptor megalin, and then serves as substrate for the renal enzyme, 1α-OH vitamin D hydroxylase for calcitriol synthesis (Figure 3) (51).  Reduced glomerular filtration leads to a decrease in calcidiol-DBP complex transfer into the proximal tubular fluid and hence reduced availability of calcidiol substrate for luminal reabsorption and calcitriol formation. However, the validity for the human situation of this mechanism established in the mouse has subsequently been questioned since 1α-OH vitamin D hydroxylase expression was found not only in proximal, but also in distal tubular epithelium of human kidney, that is in tubular areas in which megalin apparently is not expressed (52).

 

Figure 3. Schematic representation of the role of megalin in renal tubular 25 OH vitamin D reabsorption. Megalin is a multifunctional brush border membrane receptor expressed in the proximal renal tubule. It enables endocytic reabsorption of 25 OH vitamin D (calcidiol) filtered by the glomerulus and the subsequent synthesis of 1,25 diOH vitamin D (calcitriol) by mitochondrial 1-α 25 OH vitamin D hydroxylase. After Nykjaer et al (51).

 

Finally, the concentration of plasma calcidiol is diminished in the majority of patients with CKD (53,54). The reasons for this vitamin D deficiency state include insufficient hours of sunshine or sun exposure especially in the elderly, skin pigmentation, intake of antiepileptic drugs (like in general population), and in addition enhanced urinary excretion of calcidiol complexed to vitamin D binding protein (DBP) in presence of proteinuria, and loss into the peritoneal cavity in those on peritoneal dialysis treatment. All these factors may also contribute to the reduction in calcitriol synthesis (55). However, low plasma calcidiol has also been postulated to be a risk factor per se for secondary hyperparathyroidism, as suggested by an observational study in Algerian patients on hemodialysis with insufficient exposure to sunshine (56) and the observation that calcidiol is able to directly suppress PTH synthesis and secretion in bovine parathyroid cells in vitro, although with much less potency than calcitriol (57).

 

SECONDARY HYPERPARATHYROIDISM IN CKD – PLASMA BIOCHEMISTRY CHANGES IN ADVANCED CKD STAGES

 

The above-mentioned roles of relative or absolute deficiency states of calcium and vitamin D are steadily gaining importance with the progression of CKD, and phosphate becomes a major player.

 

Role of Hyperphosphatemia

 

In CKD stages G4-G5 hyperphosphatemia becomes an increasingly frequent feature (21), due to phosphate retention caused by the progressive loss of functioning nephrons and the increasing difficulty in augmenting glomerular phosphate ultrafiltration and to further reduce its tubular reabsorption when it is already maximally inhibited by high serum FGF23 and PTH levels.

 

FGF23 Excess and Klotho Deficiency

 

Circulating FGF23 may reach extremely high, maladaptive concentrations in patients with end-stage kidney disease (ESKD) (58). In parallel, a reduction of Klotho expression is observed in kidney and parathyroid tissue, as well as of soluble Klotho in the plasma and urine of patients and animals with CKD (28,29,32). The reduction is particularly marked in advanced stages of CKD. The resulting resistance to the action of FGF23 in kidney and parathyroid tissue favors hyperparathyroidism (see below).

 

Uremic Syndrome

 

The uremic syndrome itself could also play a role. In addition to phosphate, many other so-called uremic toxins, that is substances which accumulate in the uremic state, are known to interfere with vitamin D metabolism and action (59,60). Indoxyl sulfate has been shown to participate in the pathogenesis of skeletal resistance to the action of PTH (61), in addition to direct inhibitory effects on bone turnover (62).

 

SECONDARY HYPERPARATHYROIDISM IN CKD – MORPHOLOGICAL PARATHYROID TISSUE CHANGES

 

Normal parathyroid glands are mainly composed of chief cells and few oxyphil cells. In patients with CKD and secondary hyperparathyroidism, the parathyroid oxyphil cell content often increases considerably. Studies showed that such patients whose parathyroid glands had high oxyphil cell counts were likely to be relatively refractory to drug treatment (63). A recent report demonstrated the existence of a chief-to-oxyphil cell trans-differentiation characterized by gradual mitochondrial enrichment associated with the uremic milieu. The mitochondrial enrichment and cellular proliferation of chief cell and oxyphil cell nodules decreased significantly after leaving the uremic milieu via transplantation into nude mice (64).

 

MECHANISMS INVOLVED IN THE PATHOGENESIS OF SECONDARY HYPERPARATHYROIDISM

 

Generally speaking, there are at least two major different mechanisms which determine the magnitude of secondary hyperparathyroidism in CKD. The first is an increase in PTH synthesis and secretion per cell, and the second an increase in parathyroid gland mass, mostly due to enhanced cell proliferation (hyperplasia), and to a lesser degree also an increase in cell size (hypertrophy) (see schematic representation in Figure 4). Whereas acute stimulation of PTH synthesis and/or release generally occurs in the absence of enhanced cell growth, these two processes appear to be tightly linked under conditions of chronic stimulation. The main factors involved in the control of the two processes are again calcitriol, calcium, and phosphate whereas the direct effects of FGF23 appear to be essentially limited to the control of PTH synthesis and secretion. In the following, the disturbances of the mechanisms controlling parathyroid function will be discussed subsequently for each of these three factors, although there are numerous interactions between them. Thereafter, the influence of other factors and comorbid conditions related to CKD will be presented.

 

Figure 4. Pathogenesis of secondary hyperparathyroidism. Schematic representation of parathyroid hormone (PTH) synthesis and secretion (upper part) and parathyroid cell proliferation and apoptosis (lower part), as regulated by a number of hormones and growth factors.

Calcitriol

 

The above-mentioned decrease in plasma calcitriol aggravates hyperparathyroidism via several mechanisms. The first is direct and results from an insufficient inhibition of PTH synthesis due to low circulating calcitriol levels and a disturbed action of calcitriol at the level of the preproPTH gene. It is well established that calcitriol, after forming a complex with its receptor, vitamin D receptor (VDR) and heterodimerizing with the retinoic acid receptor (RXR), directly inhibits preproPTH gene transcription by binding to a specific DNA response element (VDRE) located in the 5’-flanking region of the gene. In CKD, in addition to low extracellular concentrations of calcitriol, at least two other factors interfere with calcitriol’s action on the preproPTH gene (65). The first factor is a reduced expression of the VDR gene in hyperplastic parathyroid tissue of CKD patients (66). This reduction is particularly marked in nodular, as compared to diffusely hyperplastic parathyroid tissue. The second factor is reduced binding of calcitriol to VDR, slowed nuclear migration of the calcitriol–VDR complex and less efficient inhibitory action on the preproPTH gene, in association with the uremic state (60,67). Of note, the extracellular Ca2+ concentration [Ca2+e] appears to  play a role in the regulation of VDR expression. In rat parathyroid glands, low [Ca2+e] reduced VDR expression independently of calcitriol, whereas high [Ca2+e] increased it (68). Hypocalcemia may attenuate by this mechanism the feedback of increased plasma calcitriol concentrations on the parathyroids.

 

The second level at which calcitriol regulates PTH gene expression involves calreticulin. Calreticulin is a calcium binding protein which is present in the endoplasmic reticulum of the cell and also may have a nuclear function. It regulates gene transcription via its ability to bind a protein motif in the DNA-binding domain of nuclear hormone receptors of sterol hormones. Sela-Brown et al. proposed that calreticulin might inhibit vitamin D's action on the PTH gene, based on in vitro and in vivo experiments (69). They fed rats either a control diet or a low calcium diet, the latter leading to increased PTH mRNA levels despite high serum calcitriol levels that would be expected to inhibit PTH gene transcription. Their postulate that high calreticulin levels in the nuclear fraction might prevent the effect of calcitriol on the PTH gene was strongly supported by the observation that hypocalcemic rats had increased levels of calreticulin protein in parathyroid nuclear fraction. This could explain why hypocalcemia leads to increased PTH gene expression despite high serum calcitriol levels and might also be relevant for the refractoriness of secondary hyperparathyroidism to calcitriol treatment observed in many patients with CKD.

 

The third mechanism of calcitriol’s action could be indirect, via a stimulatory effect on parathyroid CaSR expression, as shown by Brown et al (70) and subsequently confirmed by Mendoza et al (71).

 

The fourth mechanism is again a direct one. It is due to the well-known inhibitory effect of vitamin D on cell proliferation and the induction of differentiation towards mature, slowly growing cells. A decrease in plasma calcitriol and a perturbed action at molecular targets favor abnormal cell growth in general. This is the case with parathyroid tissue as well, and parathyroid hyperplasia ensues (72). The important role of vitamin D in the pathogenesis of parathyroid hyperplasia of experimental uremia was first shown by Szabo et al (73). These authors administered increasing doses of calcitriol to rats either at the time of inducing chronic kidney failure or at a later time point, when uremia was already well established. They were able to prevent parathyroid cell proliferation entirely when calcitriol was given in initial CKD stages, but not when given later. Fukagawa et al showed that pharmacologic doses of calcitriol repressed c-myc expression in the parathyroid tissue of uremic rats and suggested that the hormone might suppress parathyroid hyperplasia by this pathway (74). In contrast, Naveh-Many et al. (75) failed to observe such an antiproliferative effect of calcitriol in parathyroid cells of uremic rats but they administered the hormone for only three days. The short-term administration may not have been sufficient for an efficacious suppression of cell turnover.

 

To answer the question of a possible direct calcitriol action on parathyroid cells, several studies were performed in experimental models in vitro. Nygren et al. (76) showed in primary cultures of bovine parathyroid cells, maintained in short-term culture, that these cells underwent significant increases both in number and size in response to fetal calf serum, and that the addition of 10-100 ng/mL calcitriol almost completely inhibited cell proliferation whereas cell hypertrophy was unaffected. Kremer et al (77) subsequently confirmed in same parathyroid cell model that calcitriol exerted an anti-proliferative action. They further suggested that this inhibition occurred via a reduction of c-myc mRNA expression. One report showed an inhibitory action under long-term culture conditions (up to 5 passages) of the effect of calcitriol on bovine parathyroid cell proliferation (78). Our group subsequently confirmed such a direct antiproliferative effect of calcitriol in a human parathyroid cell culture system derived from hyperplastic parathyroid tissue of patients with severe secondary uremic hyperparathyroidism (79) (Figure 5).

 

Figure 5. Antiproliferative effect of 1,25 diOH vitamin D on parathyroid cells. Reduction of parathyroid cell proliferation in response to increasing medium 1,25diOH vitamin D (calcitriol) concentrations in the incubation milieu of a human parathyroid cell culture system, with parathyroid cells derived from hyperplastic parathyroid tissue of patients with severe secondary uremic hyperparathyroidism. From Roussanne et al (79).

 

A fifth mechanism is the potential association between parathyroid function and vitamin D receptor (VDR) polymorphism. Fernandez et al (80) separated patients on hemodialysis therapy with similar serum calcium levels and dialysis vintage into two groups, according to their serum iPTH levels, namely low PTH (<12 pmol/L) or high PTH (>60 pmol/L). They found that the BB genotype and the B allele were significantly more frequent in the low PTH than in the high PTH group (32.3 % vs 12.5 %, and 58.8% vs 39.1%, respectively). This information suggests that VDR gene polymorphism influences parathyroid function in CKD. Similar results have been reported in a large sample of Japanese patients undergoing hemodialysis (81). In this latter study, after excluding patients with diabetes and patients with a dialysis vintage of less than 10 years, the authors observed lower plasma iPTH levels in ESKD patients with BB than with Bb or bb alleles. A relationship between Apa I polymorphism (A/a alleles) and the severity of hyperparathyroidism has also been sought in Japanese patients on hemodialysis (82). Plasma PTH levels in AA and Aa groups were approximately half that of the aa group. However, other groups found no difference in PTH levels for various VDR polymorphisms (83-85). Moreover, although in some clinical conditions VDR polymorphism may be associated with variations of the half-life of the VDR gene transcript (86) or of VDR function (87), there has been no report showing that in uremic patients with secondary hyperparathyroidism the density of parathyroid cell VDR varied with different VDR genotypes. In addition, although VDR genotypes may have some influence on the degree of parathyroid cell proliferation, the mechanism by which this could occur remains unknown.

 

Finally, Egstrand et al recently provided experimental evidence for the role of a circadian clock operating in parathyroid glands. This clock and downstream cell cycle regulators were shown to be disturbed in uremic rats, potentially contributing to dysregulated parathyroid cell proliferation in secondary hyperparathyroidism  (88,89).

 

Calcium

 

[Ca2+e] is the primary regulator of PTH secretion. Small changes in serum Ca2+ concentration result in immediate changes of PTH release, which are either short-lived or long-lived depending on the velocity of the restoration of serum Ca2+ towards normal. Thus, postprandial urinary calcium excretion was increased in patients with CKD as it was in healthy volunteers, but only in the patients was this accompanied by significantly reduced serum Ca2+ and increased PTH levels (90). The inverse relation between Ca2+ and PTH in the circulation obeys a sigmoidal curve (91). While the majority of in vitro studies have reported a decreased responsiveness of hyperplastic parathyroid cells to changes in [Ca2+e] in vivo studies have not always confirmed this. These discrepant findings are likely due to different methods used to assess the dynamics of PTH secretion (92).

 

Several in vitro studies have shown that the set point of calcium for PTH secretion (that is the Ca2+ concentration required to produce half maximal PTH secretion) is greater in parathyroid cells from primary adenomas and secondary (uremic) hyperplastic parathyroid glands than in normal parathyroid cells (93). Such a relatively poor response to [Ca2+e] should contribute to the increased PTH levels observed in uremic patients with secondary hyperparathyroidism.

 

We and others have demonstrated that both primary parathyroid adenoma and secondary uremic, hyperplastic parathyroid gland tissue exhibit a decrease in the expression of CaSR protein (94,95). In secondary uremic hyperparathyroidism, there is a significant decrease of CaSR in diffusely growing hyperplastic tissue, with the decrease being even more marked in nodular areas (characteristic of advanced hyperparathyroidism with autonomously growing cells) (94) (Figure 6). Since changes in intracellular Ca2+ elicited by hyper or hypocalcemia depend on the expression and activity of the CaSR, any decrease explains, at least in part, an impaired intracellular calcium response to [Ca2+e] and hence a reduced inhibitory effect of the cation on PTH secretion. Several factors contribute to the downregulation of CaSR expression and/or activity in CKD including reduced calcitriol levels (70,71), low magnesium levels (94), dietary phosphate intake (probably indirect action) (97), and metabolic acidosis (98). However, raising extracellular phosphate has been recently shown to also exert a direct inhibitory action on parathyroid cell CaSR activity of isolated human parathyroid cells and thus to increase PTH secretion (99). Almaden et al studied calcium-regulated PTH response in vitro, using respectively primary parathyroid adenoma and uremic hyperplastic tissue, the latter either of the nodular or the diffuse type (100). They found that in primary adenoma tissue PTH secretion was less responsive to an increase in [Ca2+e] than in uremic hyperplastic parathyroid tissue; among the latter, nodular tissue was less responsive than diffusely hyperplastic tissue. The decreased secretory response to Ca2+ observed in nodular uremic hyperplasia may be explained by the markedly reduced CaSR expression in CKD, as demonstrated by Gogusev et al (94). This decrease can be overcome, at least partially, by PTHrp, as shown by Lewin et al (101), who observed that the administration of PTHrp significantly stimulated the impaired secretory capacity of the parathyroid glands of uremic rats in response to hypocalcemia. Of note, this observation also implies that the PTH/PTHrp receptor is expressed on the parathyroid cell.

 

Figure 6. Calcium-sensing receptor (CaSR) expression in normal and hyperplastic parathyroid glands. Normal parathyroid tissue (in blue), secondary (2°) hyperparathyroidism from dialysis patients (glands with diffuse hyperplasia in yellow; glands with nodular hyperplasia in green), and primary (1°) adenomatous hyperparathyroidism from patients with conserved kidney function (in orange). Decreased expression of both CaSR protein and mRNA in the majority of hyperplastic glands, with a particularly marked decrease in nodular type secondary uremic hyperparathyroidism. After Gogusev et al (94).

 

The shift of the calcium set point to the right in patients on dialysis in vivo has been a much less constant finding than the right shift observed in the above-mentioned studies in uremic parathyroid tissue in vitro. While in patients with CKD and a mild to moderate degree of hyperparathyroidism the set point was most often found to be normal, an altered set point was observed in presence of severe parathyroid overfunction with hypercalcemia (102). This anomaly could at least in part be due to CaSR down-regulation. As regards CKD patients with less severe parathyroid overfunction, a considerable controversy took place regarding the results of in vivo assessments of parathyroid gland function (103,104). In part, disparities among study results reflected technical differences in experimental methods and/or variations in the mathematical modeling of PTH secretion in vivo (105).  Another difficulty in interpreting the results of in vivo dynamic tests of parathyroid gland function relates to the issue of parathyroid gland size.  Because there is a basal, or non-suppressible, component of PTH release from the parathyroid cell even at high [Ca2+e], excessive PTH secretion may result solely from increases in parathyroid gland mass (102). This can theoretically occur in the absence of any defect in calcium sensing at the level of the parathyroid cell.  Since parathyroid gland hyperplasia is present to some extent in nearly all patients with CKD stages G3-G5, alterations in PTH secretion due to increases in parathyroid gland mass cannot readily be distinguished from those attributable to changes in calcium-sensing by the parathyroid cell using the four-parameter model for in vivo studies (104).

 

The precise role of calcium in parathyroid cell proliferation is still a matter of discussion. On the one hand, calcium deficiency, in the presence or absence of hypocalcemia and vitamin D deficiency (or reduced production of calcitriol), is considered to be a stimulus of parathyroid hyperplasia. Thus Naveh-Many et al showed that calcium deprivation, together with vitamin D deficiency, greatly enhanced the rate of parathyroid cell proliferation in normal rats and also in rats with CKD, using the cell cycle-linked antigen, PCNA (75). The concomitant decrease in CaSR expression in CKD, as observed in parathyroid glands of both dialysis patients and uremic rats (94, 106), should theoretically enhance parathyroid tissue hyperplasia further. Indirect support for this contention came from the observation that the administration of the calcimimetic compound NPS R-568, a CaSR agonist, led to the suppression of parathyroid cell proliferation in rats with CKD (107). However, in the study by Naveh-Many et al the dietary regimen was poor in both calcium and vitamin D. On the other hand, Wernerson et al observed parathyroid cell hypertrophy, not hyperplasia when feeding normal rats on a calcium-deficient diet alone, in the absence of concomitant vitamin D deficiency (108).

 

The question of whether the effect of calcium is direct or indirect remains therefore unsolved at present. It can only be answered by in vitro studies. For a long time, available culture systems using normal parathyroid cells did not allow maintaining functionally active cells for prolonged time periods. They were all characterized by a rapid and significant loss of PTH secretion within 3 to 4 days (109-111). One culture model has been described using bovine parathyroid cell organoids, which maintained the ability to modulate PTH secretion in response to [Ca2+e] and tissue-like morphology for 2 weeks (112). However, only one long-term study using bovine parathyroid cells demonstrated a release of bioactive bovine PTH but with reduced sensitivity to [Ca2+e] (113). Other reports showed that the rapid decrease in PTH responsiveness of cultured bovine parathyroid cells to changes in [Ca2+e] was associated with a marked reduction in CaSR expression (114,115). Yet other parathyroid cell-derived culture models proposed in the literature were in fact devoid of any PTH secretory capacity (116,117).

 

To study direct effects of [Ca2+e] on the parathyroid cell in vitro, we developed a functional human parathyroid cell culture system capable of maintaining the regulation of its secretory activity and expression of extracellular CaSR mRNA and protein for several weeks. For this purpose, we used parathyroid cells derived from hyperplastic parathyroid tissue of patients on hemodialysis with severe secondary hyperparathyroidism (118). In a subsequent study with this experimental model, we surprisingly obtained evidence that parathyroid cell proliferation index, as estimated by [3H]-thymidine incorporation into an acid-precipitable fraction as a measure of DNA synthesis, could be directly stimulated by high [Ca2+e] in the incubation medium, compared with low [Ca2+e] (79) (Figure 7).

 

Figure 7. Effect of medium calcium concentration on parathyroid cell proliferation. Stimulatory effect on parathyroid cell proliferation (measured by KI-67 staining method) of high medium calcium concentrations in the incubation milieu of a human parathyroid cell culture system derived from hyperplastic parathyroid tissue of patients with severe secondary uremic hyperparathyroidism. From Roussanne et al (79).

 

We confirmed this finding in independent experiments using the cell cycle-linked antigen Ki-67 to determine parathyroid cell proliferation. However, the addition of the calcimimetic NPS R-467 to the incubation medium led to a decrease in cell proliferation (Figure 8).

 

Figure 8. Inhibitory effect of calcimimetic on parathyroid cell proliferation. Human parathyroid cells derived from hyperplastic parathyroid tissue of patients with severe secondary uremic hyperparathyroidism were maintained in high medium calcium incubation milieu and exposed to increasing concentrations of calcimimetic NPS R-467. Determination of cell proliferation by [3H]-thymidine incorporation method. After Roussanne et al (79).

 

Of interest, calcimimetics have subsequently been shown to upregulate the expression of  both CaSR (71,119) and VDR (67) in parathyroid glands of uremic rats. In an attempt to unify our apparently contradictory in-vitro observations with respect to findings made in vivo, we proposed the following hypothesis. The effect of calcium on parathyroid cell proliferation could occur along two different pathways, via two distinct mechanisms. Inhibition of proliferation would occur via the well-known parathyroid CaSR-dependent pathway, whereas stimulation of proliferation would occur via an alternative pathway (Figure 9). Note that the parathyroid tissue samples used in our study stemmed from uremic patients with long-term ESKD and severe secondary hyperparathyroidism. Since such parathyroid tissue generally exhibits decreased CaSR expression, it is possible that the number of CaSR expressed in the parathyroid cell membranes of our culture model was insufficient to inhibit cell proliferation. Of note, the human CaSR gene has two promoters and two 5’ untranslated exons; therefore, the alternative usage of these exons leads to production of multiple CaSR mRNAs in parathyroid cells (120). The expression of CaSR mRNA produced by one of the two promoters of CaSR gene is specifically reduced in parathyroid adenomas, suggesting a role in PTH hypersecretion and proliferation. Moreover, the membrane-bound 550-kD Ca2+-binding glycoprotein megalin, which belongs to the low-density lipoprotein receptor superfamily, has been identified in parathyroid chief cells as another putative calcium-sensing molecule. It could be involved in calcium-regulated cellular signaling processes as well (121). Based on these observations, it is possible that parathyroid cells express multiple CaSR-like molecules. Consequently, if the well-known parathyroid CaSR is downregulated, parathyroid cell proliferation induced by increases in [Ca2+e] may occur via a different type of CaSR. Another possibility is an alteration in post-receptor signal transduction that could occur in hyperparathyroid states or under cell culture conditions. Our observations are in line with findings by Ishimi et al. which were incompatible with a direct effect of low [Ca2+e] in the pathogenesis of parathyroid hyperplasia (78). However, any extrapolation from such in vitro observations to the in vivo setting should be done with caution. Further work is needed to define the precise pathway(s) by which calcium regulates parathyroid tissue growth.

 

The effect of CaSR activation by calcimimetics on parathyroid cell proliferation may also depend on the timing of calcimimetic administration since CaSR expression exhibits significant diurnal rhythmicity. Egstrand et al recently showed in rats with CKD that the inhibitory effect of cinacalcet administration on parathyroid cell proliferation effectively depended on its timing, suggesting a possible benefit of using chronotherapy (122).

 

Figure 9. Hypothesis of the regulation of parathyroid cell proliferation by extracellular [Ca2+]. 1) Inhibitory pathway via the calcium-sensing receptor (CaR). 2) Stimulatory pathway via an unknown transmembrane transduction mechanism. Physiologically, pathway 1 predominates over pathway 2. In presence of parathyroid hyperplasia with calcium-sensing receptor down-regulation pathway 2 could become dominant and favor parathyroid cell proliferation over suppression. After Roussanne et al (79).

 

Phosphate

 

A direct action of phosphate on PTH secretion by the parathyroid cell has long been suspected. However, it has been formally demonstrated in vitro only in 1996 (123-125). This demonstration required the use of either intact parathyroid glands (from rats) (Figure 10) or parathyroid tissue slices (from cows) whereas it had not been possible to obtain such direct stimulation using the classic model of isolated bovine parathyroid cells. Elevating plasma phosphate concentration in the incubation milieu of experimental models using intact (or partially intact) parathyroid tissue led to a stimulation of PTH secretion within some hours, in the absence of any change in [Ca2+e]. This effect could be abrogated by an increase in cytosolic Ca2+ concentration (126).

 

 

Figure 10. Direct inhibition of parathyroid hormone (PTH) secretion by phosphate. Intact parathyroid glands obtained from normal rats were maintained in culture and exposed to increasing phosphate concentrations in the incubation medium. After Almaden et al (126).

Silver’s group reported subsequently that phosphate, like calcium, regulates pre-pro-PTH gene expression post-transcriptionally by changes in protein-PTH mRNA interactions at the 3'-UTR which determine PTH mRNA stability. The authors identified the minimal sequence required for protein binding in the PTH mRNA 3'-UTR and determined its functionality. They found that the conserved PTH RNA protein-binding region conferred responsiveness to calcium and phosphate and determined PTH mRNA stability and levels (127). Thus, a low calcium diet increased stability, whereas a low phosphate diet decreased stability of PTH mRNA (128) (Figure 11). The PTH mRNA 3’-untranslated region-binding protein was subsequently identified by this research group as adenylate-uridylate-rich element RNA binding protein 1 (AUF1) (129).

 

Figure 11. Post-transcriptional regulation of PTH mRNA stability by calcium, phosphate, and kidney failure. Pre-pro-PTH gene expression is modulated via changes in protein-PTH mRNA interactions at the 3'-UTR region which determine PTH mRNA stability. Low calcium diet increases stability, whereas low phosphate diet decreases stability of PTH mRNA. PTH mRNA protective factor AUF1 in yellow, PTH mRNA degrading endonuclease in orange. After Yalcindag et al (128,129).

 

In addition to its stimulatory effect on PTH secretion, a high phosphate diet also rapidly induces parathyroid overfunction and hyperplasia, as shown in experimental animal models (130). Subsequent studies showed that hyperphosphatemia induced by phosphate-rich diets in animals with CKD led to parathyroid hyperplasia even when changes in plasma Ca2+ and calcitriol concentration were carefully avoided, pointing to a direct effect of phosphate on cell proliferation (75,125). Conversely, early dietary phosphate restriction in the course of CKD was capable of preventing both PTH oversecretion and parathyroid hyperplasia (75,125,131). Interestingly, dietary phosphate restriction following phosphate overload in rats led to an immediate decrease in PTH secretion despite no regression of parathyroid gland size (132).

 

Our group wished to know whether the stimulatory effect of phosphate on parathyroid cell proliferation was direct or indirect. To answer this question, we used the above-described in vitro model of human uremic parathyroid cells maintained in long-term culture (118). We could show that cell proliferation index was directly stimulated by high phosphate concentrations in the incubation medium, compared with low phosphate concentration (79) (Figure 12). These experiments demonstrated that phosphate is capable of stimulating not only PTH secretion, but also of inducing parathyroid tissue hyperplasia by a direct mode of action.

 

 

Figure 12. Direct stimulatory effect of extracellular phosphate on parathyroid cell proliferation. Response of parathyroid cell growth to increasing phosphate concentrations in the incubation milieu of a human parathyroid cell culture system derived from hyperplastic parathyroid tissue of patients with severe secondary uremic hyperparathyroidism. Determination of cell proliferation by [3H]-thymidine incorporation method. After Roussanne et al (133).

 

FGF23 plays an important role in the control of plasma phosphate. Elevated FGF23 in CKD allows efficient inhibition of proximal tubular phosphate reabsorption and maintenance of plasma phosphate in the normal range. However, since hyperphosphatemia directly stimulates PTH secretion, its correction by FGF23 indirectly leads to a reduction of PTH release, in addition to the direct inhibitory action of FGF23 on parathyroid secretory activity (see above).

 

FGF23 and Klotho

 

As mentioned before, FGF23 directly inhibits PTH synthesis and secretion via its action on parathyroid FGFR-1 (134). FGF23 also increases parathyroid CaSR and VDR expression, further contributing to the suppression of PTH by this hormone (135). In advanced stages of CKD FGF23’s effect is partially or even completely abolished owing to downregulation of the expression of its receptor and co-receptor Klotho (40-42). Of interest, in the early stages of CKD there could be an initial upregulation of FGFR-1 and Klotho, with enhanced PTH secretion in response to FGF23 via an Na+/K+ -ATPase driven pathway (136). Subsequent findings suggested a function for Klotho in suppressing PTH biosynthesis and parathyroid gland growth, even in the absence of CaSR (137). Moreover, they pointed to a physical interaction between Klotho and CaSR. Specific deletion of CaSR in parathyroid tissue led to elevated serum PTH levels and parathyroid gland hyperplasia, and additional deletion of Klotho in parathyroid glands exacerbated this condition. However, a more recent review concluded that the role of parathyroid Klotho remains controversial (138).

 

MicroRNAs

 

Shilo et al provided evidence for the important role of microRNAs (miRNAs) in the physiological regulation of parathyroid function, and its dysregulation in the secondary hyperparathyroidism of CKD (139,140). The authors found an abnormal regulation of many miRNAs in experimental uremic hyperparathyroidism supporting a key role for miRNAs in this condition. Specifically, their studies showed that inhibition of the abundant let-7 family increased PTH secretion in normal and uremic rats, as well as in mouse parathyroid organ cultures. Conversely, the inhibition of the upregulated miRNA-148 family prevented the increase in serum PTH of uremic rats, and inhibition of let-7 family also reduced PTH secretion in parathyroid organ cultures. Thus, miRNA dysregulation represents yet another crucial step in the pathogenesis of secondary hyperparathyroidism.

 

Other Factors and Conditions

 

As already pointed out above, the uremic state with its accumulation of numerous uremic toxins is another long suspected, albeit yet ill-defined factor in the pathogenesis of secondary hyperparathyroidism. Recently, several pieces of evidence have been provided in favor of the role of the uremic state which interferes with the binding of calcitriol to VDR (60) and with the nuclear uptake of the hormone-receptor complex (67). This should have consequences not only for PTH synthesis and secretion, but also for parathyroid cell proliferation. Another mechanism of excessive proliferation involves the mTOR pathway, which has been shown to be activated in secondary hyperparathyroidism (141). Inhibition of mTOR complex 1 (mTORC1) by rapamycin decreased parathyroid cell proliferation in vivo and in vitro. Parathyroid-specific genetic ablation of mTOR (PT-mTOR−/−) in mice resulted in disrupted gland structure but normal serum PTH levels. Conversely, mice with parathyroid-specific deletion of the tuberous sclerosis complex-1 gene (Tsc1) leading to mTORC1 hyperactivation, exhibited enlarged parathyroid glands and elevated serum PTH and calcium levels (142). Of note, despite impaired gland structure, PT-mTOR−/− mice with CKD were able to increase serum PTH to levels similar to controls (143). In keeping with this experimental finding, kidney transplant recipients treated with mTOR inhibitors, as compared to those treated with calcineurin inhibitors, had reduced serum PTH levels and a lower incidence of secondary hyperparathyroidism (143).

 

Patients with diabetes receiving dialysis therapy have relatively low plasma PTH levels, as compared to those without diabetes. The high incidence of low bone turnover in uremic patients with diabetes (144-147) has been attributed to low levels of biologically active PTH, possibly via an inhibition of PTH secretion or a modification of the PTH peptide by the accumulation of advanced glycation end-products such as pentosidine (140) or else oxidative modifications of PTH (149,150). However, experimental studies have demonstrated that the metabolic abnormalities associated with diabetes can also directly decrease bone turnover, independent of PTH (151). In general, patients with low bone turnover tend to develop hypercalcemia when on a normal or high dietary calcium intake, probably due to a diminished skeletal capacity of calcium uptake. This in turn tends to reduce plasma PTH. Thus, not only does hypoparathyroidism promote adynamic bone disease but adynamic bone disease also favors hypoparathyroidism. Another issue is whether in patients with diabetes abnormalities such as hyperglycemia and insulin deficiency or resistance may directly affect parathyroid function. In an in vitro study using dispersed bovine parathyroid cells, high glucose and low insulin concentrations suppressed the PTH response to low Ca2+ concentration (152). These results are compatible with the view that diabetes directly inhibits parathyroid function. However, when uremic rats were fed on a high phosphate diet to induce secondary hyperparathyroidism, the presence of diabetes did not prevent it (152).

 

Aluminum bone disease is generally associated with low serum PTH levels (153-154) and a decreased PTH response to stimulation by hypocalcemia (155,156). In aluminum intoxicated patients, high amounts of aluminum are also found in parathyroid tissue (157). The relatively low PTH levels may reflect either an inhibition of PTH secretion by the hypercalcemia commonly observed in this condition (158) or a direct inhibitory effect of aluminum on parathyroid cell function (159). Direct toxic effects of the trace element have also been demonstrated in studies in vitro (160,161). Observations made in experimental animals and results of clinical studies have been less clear. Whereas some authors found that aluminum overload did not decrease plasma PTH levels in vivo (160,161), others reported a decrease (162,163). Whatever the mechanisms involved, subsequent clinical data clearly showed that the introduction of an aluminum-free dialysis fluid and the discontinuation of aluminum contamination of the dialysate or aluminum removal with deferoxamine resulted in an increase in plasma PTH levels and in PTH response to hypocalcemia (164). Thus, although there appears to be an association between aluminum toxicity and parathyroid gland function, the interaction is complex.

 

Post-Receptor Mechanisms Involved in Polyclonal Parathyroid Tissue Growth

 

As pointed out above, calcitriol reduces parathyroid cell proliferation by decreasing the expression of the early gene, c-myc. This gene modulates cell cycle progression from G1 to S phase. A decrease in plasma calcitriol and/or a disturbance of its action at the level of the parathyroid cell, which are both frequently observed in uremic patients, may cause disinhibition of c-myc expression and progression into the cell cycle. Another mode of action involves the cyclin kinase inhibitor p21WAF1. Calcitriol has long been shown to induce the differential expression of p21WAF1 in the myelo-monocytic cell line U937 and to activate the p21 gene transcriptionally in a VDR-dependent, but p53-independent, manner, thereby arresting parathyroid growth (165). Slatopolsky’s group further showed that the administration of calcitriol to moderately uremic rats enhanced parathyroid p21 expression and prevented high phosphate-induced increase in parathyroid TGF-β content (165). In addition, these authors found that calcitriol altered membrane trafficking of the epithelial growth factor receptor (EGFR), which binds both EGF and TGF-β, and down-regulated EGFR mediated growth signaling (166). Induction of p21 and reduction of TGF-β content in the parathyroid glands also occurred when uremia-induced parathyroid hyperplasia was suppressed by high dietary Ca intake. The mechanisms by which a phosphate-rich diet and hyperphosphatemia induce parathyroid hyperplasia, and conversely a phosphate-poor diet  and hypophosphatemia inhibit parathyroid tissue growth, have also been examined by this group in a detailed fashion. Thus, Dusso et al showed that feeding a low phosphate diet to uremic rats increased parathyroid p21 gene expression through a vitamin D-independent mechanism (167). When administering a high phosphate diet, p21 expression was not suppressed. In this condition, they observed an increase in parathyroid tissue TGF-β expression and a direct correlation between this expression and parathyroid cell proliferation rate. This finding is in line with a previous observation by our group of de novo TGF-β expression in severely hyperplastic parathyroid tissue of patients with ESKD (168). The inducer of TGF-β gene transcription could be activator protein 2α (AP2), whose expression and transcriptional activity at the TGF-β promoter is increased in the secondary hyperparathyroidism of CKD (169).

 

Although these findings provide more insight into the pathways by which changes in phosphate intake, and ultimately variations in extracellular phosphate concentration, control parathyroid tissue growth, the exciting question of the transmembrane signal transduction mechanism and subsequent nuclear events triggered by phosphate remains yet to be answered. It is possible that phosphate acts as a partial, non-competitive CaSR antagonist to modulate PTH secretion (169a).

 

In addition to p21 and TGF-β, a variety of other growth factors and inhibitors are probably involved in polyclonal parathyroid hyperplasia. PTHrp has been proposed as a possible growth suppressor in the human parathyroid (170). PTHrp, and probably PTH itself, also exert an inhibitory effect on PTH secretion by acting via a negative feedback loop on PTH-R1 which appears to be expressed in the parathyroid cell membrane as well (107). Table 1 summarizes various changes in gene and growth factor expression, which are potentially involved in the parathyroid tissue hyperplasia of secondary uremic hyperparathyroidism. Gcm2 has been identified as a master regulatory gene of parathyroid gland development, since Gcm2 knockout mice lack parathyroid glands (171). Correa et al. found high Gcm2 mRNA expression in human parathyroid glands in comparison with other non-neural tissues and underexpression in parathyroid adenomas but not in lesions of hyperparathyroidism secondary to uremia (172). Gcm2 expression itself is regulated by Gata3, and Gata3, in cooperation with Gcm2 and MafB, stimulates PTH gene expression, by interacting with the ubiquitous transcription factor SP1 (173). MafB probably plays a role in uremic hyperparathyroidism as well. Thus stimulation of the parathyroid by CKD in MafB+/-mice resulted in an impaired increase in serum PTH, PTH mRNA, and parathyroid cell proliferation (174,175).

 

Table 1. Changes in Gene and Growth Factor Expression Potentially Involved in Parathyroid Tissue Hyperplasia of Secondary Uremic Hyperparathyroidism

Early immediate genes and receptor/coreceptor genes

-Enhanced c-myc gene expression (Fukagawa et al, Kidney Int 1991; 39: 874-81)

-Decreased calcium-sensing receptor (CaSR) gene expression (Kifor et al, J Clin Endocrinol Metab 1996; 81: 1598-1606. Gogusev et al, Kidney Int 1997; 51: 328-36)

-Decreased vitamin D receptor (VDR) gene expression (Fukuda et al, J Clin Invest 1993; 92: 1436-42)

-Decrease in parathyroid Klotho and FGFR1c gene expression (Galitzer et al, Kidney Int 2010; 77: 211-8. Canalejo et al, JASN 2010; 21: 1125-35. Komaba et al, Kidney Int 2010; 77: 232-8)

Gene polymorphisms

-Vitamin-D receptor (VDR) gene polymorphism (Olmos et al, Methods Find Exp Clin Pharmacol 1998; 20: 699-707. Fernandez et al, J Am Soc Nephrol 1997; 8: 1546-52. Tagliabue et al, Am J Clin Pathol 1999; 112: 366-70)

Growth factors and cell cycle inhibitors

-Increased acidic growth factor (aFGF) gene expression (Sakaguchi, J Biol Chem 1992; 267: 24554-62)

-Decreased parathyroid hormone-related peptide (PTHrp) gene expression (Matsushita et al, Kidney Int 1999; 55: 130-8)

-De novo transforming growth factor-α (TGF-α) gene expression (Gogusev et al, Nephrol Dial Transplant 1996; 11: 2155-62)

-Induction of TGF-α by high phosphate diet (Dusso et al, Kidney Int 2001; 59: 855-865)

-Insufficient inhibition of cyclin kinase inhibitor p21WAF1 (Dusso et al, Kidney Int 2001; 59: 855-65); p21WAF1can be induced by calcitriol (Cozzolino et al, Kidney Int 2001; 60: 2109-2117)

-mTOR activation and rpS6 phosphorylation (Volovelsky et al, JASN 2016; 27: 1091–1101)

Gene mutations: association with monoclonal or multiclonal growth

-Mutation of menin gene (Falchetti et al, J Clin Endocrinol Metab 1993; 76: 139-44. Tahara et al, J Clin Endocrinol Metab 2000; 85: 4113-7. Imanishi et al, J Am Soc Nephrol 2002;13:1490-8)

-Mutation of Ha-ras gene (Inagaki et al, Nephrol Dial Transplant 1998; 13: 350-7)

-No involvement of VDR or CaSR gene mutations (Degenhardt et al, Kidney Int 1998; 53: 556-61. Brown et al, J Clin Endocrinol Metab 2000; 85: 868-72)

 

SECONDARY HYPERPARATHYROIDISM IN CKD – MECHANISMS INVOLVED IN THE TRANSFORMATION OF POLYCLONAL TO MONOCLONAL PARATHYROID GROWTH

 

In severe forms of secondary hyperparathyroidism nodular formations within diffusely hyperplastic tissue are a frequent finding (176). This observation probably corresponds to the occurrence of a monoclonal type of cell proliferation within a given tissue, which initially exhibits polyclonal growth. Clonal, benign tumoral growth was initially shown by Arnold et al using chromosome X-inactivation analysis method (177) and subsequently confirmed by other groups (178,179).  After the initially diffuse, polyclonal hyperplasia, with the progression of CKD towards ESKD foci of nodular, monoclonal growth may arise within one or several parathyroid glands which eventually may transform to diffuse monoclonal neoplasia leading to an aspect comparable to that of primary parathyroid adenoma. Several different clones often coexist in the same patient, and sometimes even in a single parathyroid gland. Figure 13 shows the progression from polyclonal to monoclonal and/or multiclonal parathyroid hyperplasia (180). It also shows corresponding changes in ultrasonographic features.

 

Figure 13. Schematic representation of the transformation of parathyroid hyperplasia from polyclonal to nodular, monoclonal/multiclonal growth with the progression of CKD towards ESKD. After Tominaga et al (180).

 

Acquired mutations of tumor enhancer or tumor suppressor genes are almost certainly involved in the development of such cell clones but precise knowledge about acquired genetic abnormalities remains limited (178). To identify new locations of parathyroid oncogenes or tumor suppressor genes important in this disease, Imanishi et al performed both comparative genomic hybridization (CGH) and genome-wide molecular allelotyping on a large number of uremia-associated parathyroid tumors (181). One or more chromosomal changes were present in 24% of tumors, markedly different from the values in common sporadic adenomas (28%), whereas no gains or losses were found in 76% of tumors. Two recurrent abnormalities were found, namely gain of chromosome 7 (9% of tumors) and gain of chromosome 12 (11% of tumors).  Losses on chromosome 11, the location of the MEN1 tumor suppressor gene, occurred in only one uremia-associated tumor (2%), as compared to 34% in adenomas. The additional search for allelic losses with polymorphic microsatellite markers led to the observation of recurrent allelic loss on 18q (13% of informative tumors). Lower frequency loss was detected on 7p, 21q, and 22q. Interestingly, the cyclin D1 oncogene, activated and overexpressed by clonal gene rearrangement or other mechanisms in 20-40% of parathyroid adenomas (182,183) has not been found to be overexpressed in uremia-associated tumors (183).

 

Another interesting question was if somatic genes played a major role in the normal regulation of parathyroid function, such as the CaSR and VDR genes.  The expression of these two genes was found to be decreased in the hyperplastic parathyroid tissue of uremic patients (66,94,95). The decrease was particularly marked in nodular areas, as compared to diffuse areas of parathyroid gland hyperplasia. Moreover, in uremic rats the decrease in CaSR expression was inversely related to the degree of parathyroid cell proliferation (97). However, the search for mutations or deletions of the VDR gene or the CaSR gene in uremic hyperparathyroidism has remained unsuccessful (178,184,185). The question remains unsolved whether the downregulation of CaSR and VDR expression is a primary event or whether it is secondary to hyperplasia.

 

Whether benign parathyroid tumors may evolve towards malignant forms is still subject to debate. Since in patients on dialysis therapy parathyroid carcinoma is a rare event (186–188), malignant transformation of clonal parathyroid neoplasms is probably exceptional.

 

Genome-wide allelotyping and CGH have directly confirmed the presence of monoclonal parathyroid neoplasms in uremic patients with refractory secondary hyperparathyroidism whereas the candidate gene approach has led to only modest results. Somatic inactivation of the MEN1 gene does contribute to the pathogenesis of uremia-associated parathyroid tumors, but its role in this disease appears to be limited, and there is probably no role for DNA changes of the CaSR and VDR genes. Recurrent DNA abnormalities suggest the existence of new oncogenes on chromosomes 7 and 12, and tumor suppressor genes on 18q and 21q, involved in uremic hyperparathyroidism. Finally, patterns of somatic DNA alterations indicate that markedly different molecular pathogenetic pathways exist for clonal outgrowth in severe uremic hyperparathyroidism, as compared to common sporadic parathyroid adenomas. Our group did not find a correlation between the presence of microscopically evident nodules and the clonal character of resected parathyroid tissue, and appearances of several glands with histological patterns of diffuse hyperplasia also were unequivocally monoclonal in the absence of detectable nodular formations, suggesting that the current criteria for pathological diagnosis do not reflect the genetic differences among these two histopathological types (177).

 

Parathyroid Cell Apoptosis

 

It remains uncertain whether reduced apoptosis rates can also contribute to parathyroid tissue hyperplasia (68,181,182). One research group examined this issue in rats with short-term kidney failure (5 days). They were unable to detect apoptosis in hyperplastic parathyroid glands (183). However, this failure could be due to a lack of sensitivity of the employed methods.

 

Negative findings in rats, with no identifiable apoptotic figures at all in parathyroid glands (72,190,191), contrast with subsequent positive observations in rats by others (192,193) and with personal observations of significant apoptotic figures in hyperplastic parathyroid glands removed from uremic, severely hyperparathyroid patients during surgery (194). In our study of human parathyroid glands from patients with ESKD approximately ten times higher apoptotic cell numbers were observed than in normal parathyroid tissue, using TUNEL method (Figure 14) (194).

 

Figure 14. Increased proportion of apoptotic (TUNEL positive) cells in parathyroid glands from patients with primary or secondary uremic hyperparathyroidism, as compared to normal parathyroid tissue. After Zhang et al (194).

 

Of note, the uremic state appears to stimulate apoptosis in other cell types as well such as circulating monocytes (195), possibly via the well-known increase of cytosolic Ca2+ which has been observed in a variety of cell types in kidney failure (196), and also possibly via the noxious effect of bioincompatible dialysis membranes used for renal replacement therapy (197). The observed enhancement of parathyroid tissue apoptosis could compensate, at least in part, the increase in parathyroid cell proliferation observed in secondary uremic hyperparathyroidism.

 

SECONDARY HYPERPARATHYROIDISM IN CKD – REGRESSION OF PARATHYROID HYPERPLASIA ?

 

Whether regression of parathyroid hyperplasia occurs in animals or patients with advanced stages of CKD remains a matter of debate. According to some authors regression must be an extremely slow process, if it occurs at all (75,190). This is in sharp contrast to the rapid reversibility of excessive PTH secretion in uremic rats which was observed after normalization of renal function by kidney transplantation (198), although parathyroid mass probably did not rapidly decrease in this acute experimental model.

 

The issue of regression is of clinical importance. As an example, if a  patient on dialysis therapy has a dramatic increase in total parathyroid mass there is practically no chance to obtain gland mass regression after a successful kidney transplantation. In this condition it would seem appropriate to perform a surgical parathyroidectomy prior to transplantation. If however significant regression of hyperplasia can occur as an active or passive process, namely by enhanced apoptosis or reduced proliferation, prophylactic surgery could be avoided. That regression of parathyroid hyperplasia secondary to vitamin D deficiency can occur has been convincingly demonstrated many years ago in experiments done in chicks (199). The administration of cholecalciferol to these birds that had developed an increase in parathyroid gland mass when fed a rachitogenic, vitamin D-free diet for 8-10 weeks led to a significant (50%) reduction in gland weight. Calcitriol failed to achieve the same effect at low, albeit hypercalcemic, dose but was capable of reducing gland mass at higher dose. However, in an experimental dog model no parathyroid mass regression was found when the animals were first submitted to a low-calcium, low-sodium and vitamin D deficient diet for two years and subsequently to a normal diet for another 17 months (200). In uremic animals, evidence for or against the possibility of regression of increased parathyroid tissue mass remains sparse and inconclusive.

 

The calcimimetic drug NPS R-568 was shown to decrease parathyroid cell proliferation and to prevent parathyroid hyperplasia in 5/6th nephrectomized rats; however, it was unable to entirely revert established hyperplasia (191,201). In apparent contrast, Miller et al showed that in rats with established secondary hyperparathyroidism cinacalcet administration led to complete regression of parathyroid hyperplasia (202). The cinacalcet-mediated decrease in parathyroid gland size was accompanied by increased expression of the cyclin-dependent kinase inhibitor p21. However, these were short-term experiments over an 11-week time period. Interestingly, the prevention of cellular proliferation with cinacalcet occurred despite increased phosphorus and decreased calcium serum levels.

 

In patients with primary hyperparathyroidism spontaneous remission of overfunctioning parathyroid glands has been observed in rare instances, caused by parathyroid “ apoplexy ” due to tissue necrosis (203). The diagnosis of parathyroid tissue necrosis is more difficult to ascertain in secondary than in primary forms of hyperparathyroidism because the hyperplasia of the former is not limited to a single gland.

 

Regression of parathyroid hyperplasia in patients on hemodialysis in response to intravenous calcitriol pulse therapy for 12 weeks has been reported by Fukagawa et al using ultrasonography (204). These authors observed a significant decrease in mean gland volume from 0.87 to 0.51 cm3 over this time period, together with a reduction in serum iPTH of more than 50%. In contrast, Quarles et al who also examined parathyroid gland morphology in patients on hemodialysis in vivo in response to intermittent intravenous or oral calcitriol treatment for 36 weeks failed to observe a decrease in parathyroid gland size as assessed by high resolution ultrasound and/or magnetic resonance imaging (205). Mean gland size was 1.9 and 2.1 cm3 before and 3.3 and 2.3 cm3 after oral and intravenous calcitriol therapy, respectively. The authors achieved a maximum average serum PTH reduction of 43% over this time period. There were marked differences between these two studies, which may explain the apparently diverging results. Hyperparathyroidism probably was more severe in the latter than in the former. Although initial mean serum iPTH levels were similar, serum phosphorus was higher and the decrease in serum PTH achieved in response to calcitriol was less marked in the latter. Moreover, parathyroid mass was more than double. In another study, Fukagawa et al examined the possible relation between parathyroid size and the long-term outcome after calcitriol pulse therapy, by subdividing patients into different groups according to initial parathyroid gland volume assessments (206). In two patients on hemodialysis with detectable gland(s), in whom the size of all parathyroid glands as well as PTH hypersecretion regressed to normal, secondary hyperparathyroidism remained controllable for at least 12 months after switching to conventional oral active vitamin D therapy. In contrast, in seven patients on hemodialysis in whom the size of all parathyroid glands did not regress to normal by calcitriol pulse therapy, secondary hyperparathyroidism relapsed after switching to conventional therapy although PTH hypersecretion could be controlled temporarily. Similarly, Okuno et al. showed in a study in patients on hemodialysis that plasma PTH levels and the number of detectable parathyroid glands decreased in response to the active vitamin D derivative maxacalcitol (22-oxacalcitriol) given for 24 weeks only when the mean value of the maximum diameter of the parathyroid glands was less than 11.0 mm, but not when it was above that value (207).

 

Taken together, these findings suggest that the degree of parathyroid hyperplasia, as detected by ultrasonography, is an important determinant for regression in response to calcitriol therapy. It is probable, although not proven, that the type of hyperplasia, namely monoclonal/multiclonal vs polyclonal growth, is even more important as regards the potential of regression than the mere size of each gland.

 

Figure 2 (see above) summarizes in a schematic view the main mechanisms involved in abnormal PTH synthesis and secretion and in parathyroid tissue hyperplasia. It further points to the possible counterregulatory role of apoptosis.

 

Altered PTH Metabolism and Resistance to PTH Action

 

PTH metabolism is greatly disturbed in CKD. Normally, most of full-length PTH1-84 is transformed in the liver to the biologically active N-terminal PTH1-34 fragment and several other, inactive C-terminal fragments. The latter are mainly catabolized in the kidney and the degradation process involves solely glomerular filtration and tubular reabsorption, whereas the N-terminal PTH1-34 fragment undergoes both tubular reabsorption and peritubular uptake, as does the full-length PTH1-84 molecule (208). Tubular reabsorption involves the multifunctional receptor megalin (209).

 

With the progression of CKD, both pathways of renal PTH degradation are progressively impaired. This leads to a marked prolongation of the half-life of C-terminal PTH fragments in the circulation (210–212) and their accumulation in the extracellular space. Moreover, there is no peritubular metabolism of PTH1-84 in uremic non-filtering kidneys, in contrast to peritubular uptake by normal, filtering kidneys (213). Hepatic PTH catabolism appears however to be unchanged in CKD since uremic livers and control livers released equal amounts of immunoreactive C-terminal PTH fragments (213).

 

A decreased response to the action of PTH may be another factor involved in the stimulation of the parathyroid glands in CKD. A diminished calcemic response to the infusion of PTH has long been reported, suggesting that PTH oversecretion was necessary to maintain eucalcemia. The skeletal resistance to PTH has been attributed to various mechanisms, including impaired vitamin D action in association with hyperphosphatemia, overestimation of true PTH(1-84) by assays measuring iPTH (see below), accumulation of inhibitory PTH fragments, oxidative modification of PTH, increase in circulating osteoprotegerin and sclerostin levels, administration of active vitamin D derivatives and calcimimetics, and altered PTH-R1 expression (7,149,214,215). Concerning the latter mechanism, studies have suggested the presence of PTH receptor isoforms in various organs of normal rats. Downregulation of PTH-R1 mRNA has been observed in various tissues of uremic rats (216–219) and also in osteoblasts of patients with end-stage renal disease (220). However, the issue of PTH-R1 expression in bone tissue remains a matter of controversy since one group found it to be upregulated in patients with moderate to severe renal hyperparathyroid bone disease (221). A recent study claimed that the inhibition of PTH binding to PTH-R1 by soluble Klotho could represent yet another mechanism of PTH resistance (222). This observation would be compatible with the presence of an upregulated, yet biologically inactive PTH-R1.

 

Other mechanisms involved in the control of the normal balance between bone formation and resorption and their response to PTH are the Wnt-β-catenin signaling pathway and its inhibition by sclerostin and Dickkopf-related protein 1 (Dkk1) (7,58,223), and the activin A pathway with its inhibition by a decoy receptor (224). Wnt-β-catenin inhibitors  are expressed predominantly in osteocytes. Whereas reduced activity of sclerostin and Dkk1 leads to increased bone mass and strength, the opposite occurs with overexpression of both sclerostin and Dkk1 in animal models. In CKD, circulating levels of both Wnt-β-catenin inhibitors have generally been found to be increased (56), and serum sclerostin was found to correlate negatively with serum PTH (225,226), and PTH has been shown to blunt osteocytic production of this Wnt inhibitor (227). Since high PTH and sclerostin levels coexist in CKD this raises the suspicion that sclerostin contributes to PTH resistance in CKD (7). Calcitonin and bone morphogenetic proteins stimulate, whereas PTH and estrogens suppress the expression of sclerostin and/or Dkk1 (228,229). Bone formation induced by intermittent PTH administration to patients with osteoporosis could be explained, at least in part, by the ability of PTH to downregulate sclerostin expression in osteocytes, permitting the anabolic Wnt signaling pathway to proceed (230). In patients with ESKD sclerostin is a strong predictor of bone turnover and osteoblast number (231). Serum levels of sclerostin correlate negatively with serum iPTH in such patients. Sclerostin was superior to iPTH for the positive prediction of high bone turnover and number of osteoblasts. In contrast, iPTH was superior to sclerostin for the negative prediction of high bone turnover and had similar predictive values as sclerostin for the number of osteoblasts. Serum sclerostin levels increase after parathyroidectomy (7). As regards activin A, a member of the transforming growth factor-b superfamily, Hruska’s group has demonstrated increased serum levels and systemic activation of its receptors in mouse models of CKD (224). In humans, serum activin A levels increase already at early stages of CKD, before elevations in intact PTH and FGF23, supporting its role in CKD-MBD and PTH resistance (232). 

 

Interesting new pathways have recently been identified by Pacifici’s group. First, they used various mouse models to demonstrate a permissive activity of butyrate produced by the gut microbiota, required to allow stimulation of bone formation by PTH (233). Butyrate’s effect was mediated by short-chain fatty acid receptor GPR43 signaling in dendritic cells and by GPR43-independent signaling in T cells. Second, the group showed that intestinal segmented filamentous bacteria (SFB) enabled PTH to expand intestinal TNF+ T and Th17 cells and thereby increase their egress from the intestine and recruitment to the bone marrow to cause bone loss (234). Figure 15 shows these recently detected pathways involving the gut microbiota.

 

Figure 15. Importance of intestinal microbiota for PTH action in bone. The stimulation of bone anabolism by PTH requires butyrate formation by short chain fatty acid (SCFA) producing gut bacteria. CKD probably reduces its production. Butyrate increases the frequency of regulatory T (Treg) cells in the intestine and in the bone marrow and potentiates the capacity of intermittently administered PTH to induce the differentiation of naïve CD4+ T cells into Tregs, a population of T cells which induces conventional CD8+ T cells to release Wnt10b. This osteogenic Wnt ligand activates Wnt signaling in osteoblastic cells and stimulates bone formation. Butyrate enables intermittent PTH dosing to expand Tregs via GPR43 signaling in dendritic cells (DCs) and GPR43 independent targeting of T cells. Butyrate may also affect bone remodeling by modulating osteoclast genes. The stimulation of bone resorption by PTH requires the presence of segmented filamentous bacteria (SFB) within gut microbiota for the production of Th17 cells in intestinal Peyers' plaques. Continuously elevated PTH levels lead to TNF+ T cell expansion in the gut and the bone marrow via a microbiota-dependent, but SFB independent mechanism. Furthermore, intestinal TNF producing T cells are required for PTH to increase the number of intestinal Th17 cells, and TNF mediates the migration of intestinal Th17 cells to the bone marrow. This migration depends on the upregulation of chemokine receptor CXCR3 and chemokine CCL20. Bone marrow Th17 cells then induce osteoclastogenesis by secreting IL-17A, RANKL, TNF, IL-1, and IL-6. From Massy & Drueke (235).

 

It will be interesting to examine the hypotheses that the excessive bone resorption associated with secondary hyperparathyroidism in CKD is at least partially due to either insufficient intestinal butyrate availability, excessive intestinal SFB activity, or both (235).

 

Finally, the analysis of cohort studies performed in diverse populations point towards differences in mineral metabolism control, rather than genetic or environmental factors, as the main drivers of the variability of PTH responsiveness (236).

 

SECONDARY HYPERPARATHYROIDISM IN CKD – CLINICAL FEATURES

 

In most patients with ESKD, advanced secondary hyperparathyroidism remains a clinically silent disease. Clinical manifestations are generally related to severe osteitis fibrosa and to the consequences of hypercalcemia and/or hyperphosphatemia.

 

Osteoarticular pain may be present. When patients become symptomatic, they usually complain of pain on exertion in skeletal sites that are subjected to biomechanical stress. Pain at rest and localized pain are rather unusual and suggest other underlying causes. Severe proximal myopathy is seen in some patients, even in the absence of vitamin D deficiency. These symptoms and signs are more frequent in patients who suffer from mixed renal osteodystrophy, resulting from a combination of parathyroid overfunction and vitamin D deficiency. Skeletal fractures may occur after only minor injury. They may also develop on the ground of cystic bone lesions, the so-called “brown tumors”, which occur for still unknown reasons in a small number of uremic patients with secondary hyperparathyroidism. Rupture of the patella or avulsion of tendons may be seen in advanced cases. The relation between serum PTH levels and fracture risk of patients on dialysis has been examined in several observational studies, reporting either a linear or U-shaped relation, increased fracture risk with low PTH levels, or no relation at all. A new recent observational study from Japan in more than 180,000 patients on hemodialysis therapy showed a linear relationship, with a graded reduction towards lower PTH levels (237). The absolute risk difference associated with higher PTH levels was more pronounced in older individuals, female patients, and those with lower body mass index.

 

Uremic pruritus is most often associated with an elevated Ca x P product although other factors may also be involved. Related symptoms and signs are the red eye syndrome due to the deposition of calcium in the conjunctiva, cutaneous calcification, and pseudogout. The latter is a form of painful arthralgia of acute or subacute onset caused by intra-articular deposition of radio-opaque crystals composed of calcium pyrophosphate dehydrate.

 

The syndrome of “ calciphylaxis ” is an infrequent manifestation of cutaneous and vascular calcification in uremic patients which may occur in association with secondary hyperparathyroidism, although this association is by no means constant. It is characterized by rapidly progressive skin necrosis involving buttocks and the legs, particularly the thighs. It can produce gangrene and may be fatal. It occurs as the result of arteriolar calcification and has also been termed “calcific uremic arteriolopathy” to reflect more accurately the nature of the lesion (238). Of interest, a post-hoc analysis of the EVOLVE trial in patients on hemodialysis recently showed that cinacalcet administration, which allows improved PTH control, resulted in a significant decrease in the incidence of calcific uremic arteriolopathy as compared to placebo (239).

 

SECONDARY HYPERPARATHYROIDISM IN CKD -- DIAGNOSIS

 

The biochemical diagnosis relies on the determination of plasma iPTH. This is also true for primary hyperparathyroidism. In patients with CKD, there are several limitations to its measurement, in addition to the usual day-to-day variations in healthy people (240). Physiological iPTH plasma values are not "normal" for uremic patients since values in the normal range are often associated with low bone turnover (adynamic bone disease) whereas normal bone turnover may be observed in presence of elevated plasma intact PTH levels (241–244). It is currently unclear to what extent this is due to imperfections in the PTH assays used (see below), PTH receptor status, post-receptor events, non-PTH-mediated changes in bone metabolism (e.g. supply of vitamin D or its metabolites, supply of estrogens or androgens), or a combination of these factors.

 

The accumulation of a large non (1-84) molecular form of PTH, which is detected by iPTH (so-called "intact" PTH) assays, has been described in patients with CKD (245). The large PTH fragment was tentatively identified as hPTH(7-84) (246). This finding is of importance in the interpretation of PTH values, since true hPTH(1-84) represents only about 50-60% of the levels detected by current iPTH assays, and since PTH(7-84) antagonizes PTH(1-84) effects on serum calcium and on osteoblasts (247). Moreover, the secretory responses of hPTH(1-84) and non-hPTH(1-84) to changes in [Ca2+e] are not proportional for these two PTH moieties (87), and a large variability has been found between different assay methods used for plasma PTH measurement in patients with CKD, recognizing PTH(7-84) with various cross-reactivities (248). Varying plasma sampling and storage conditions may further complicate the interpretation of PTH results provided by clinical laboratories (249). The development of assays which detect full-length (whole) human PTH, but not amino-terminally truncated fragments (250), was initially considered as major progress in this field. To further improve the assessment of uremic hyperparathyroidism and the associated increase in bone turnover Monier-Faugere et al proposed to calculate the ratio of PTH-(1-84) to large c-terminal PTH fragments (251). The usefulness in the clinical setting of the whole PTH assay and of the ratio of whole PTH to PTH fragments has however not been convincingly established for the diagnosis of parathyroid overfunction in adult (252,253) or pediatric (254) patients on dialysis. From a practical point of view, it must be pointed out that at present the measurement of PTH with third-generation assays is not widely available. Another potential issue is the presence of oxidized, inactive PTH in the circulation of patients with CKD, its concentrations being much higher than those of iPTH (149), although with large interindividual variations (149). Whereas one study showed a U-shaped association of non-oxidized, but not oxidized, PTH with survival in patients on hemodialysis therapy (255), a subsequent study done in CKD stage 2-4 patients found iPTH, but not non-oxidized PTH, to be associated with all-cause death in multivariable analysis (256). The reason for these apparently opposite findings is unclear. The assertion that PTH oxidation is an vitro artifact has been disproved recently (257). Based on personal findings, Hocher and Zeng postulated that oxidized and non-oxidized PTH should be measured separately to correctly evaluate the degree of severity and clinical relevance of parathyroid overfunction in CKD (150). However, in a subsequent study Ursem et al observed a strong correlation between serum non-oxidized PTH and total PTH in patients with ESKD (258). Most importantly, they found that both histomorphometric and circulating bone turnover markers exhibited similar correlations with non-oxidized PTH and total PTH. The authors therefore concluded that non-oxidized PTH is not superior to total PTH as a biomarker of bone turnover in ESKD. However, presently available methods do not enable a precise distinction between biologically active and inactive PTH forms, be it through oxidative or other post-translational modifications of the hormone (259). A recent study has shown that it is now feasible to standardize all PTH assays by recalibrating PTH immunoassays using liquid chromatography coupled with mass spectrometry as the reference method, regardless of the assay methodology (second or third generation immunoassay) (260). The proposed approach may pave the way for accurate interpretation of PTH in clinical practice (261,262).

 

Most importantly, we will hopefully be able in the future to rely not only on serum PTH but also on appropriate direct markers of bone structure and function for the assessment of renal osteodystrophy and on markers of cardiovascular disease related to secondary hyperparathyroidism (263).

 

Bone x-ray diagnosis is impossible in mild to moderate forms of secondary hyperparathyroidism, but relatively easy in severe forms. Nevertheless, to date x-ray diagnosis is rarely used in routine clinical praxis. Typical lesions include resorptive defects on the external and internal surfaces of cortical bone, with the resorption particularly pronounced on the subperiosteal surface. Resorption within cortical bone enlarges the Haversian channels, resulting in longitudinal striation; resorption at the endosteal surface causes cortical thinning. These lesions can be generally detected first in the hand skeleton, most characteristically at the periosteal surface of the middle phalanges (Figure 16).

 

Accelerated bone deposition at this site (periosteal neostosis) can also be seen. Another characteristic feature is resorptive loss of acral bone (acro-osteolysis), in particular at the terminal phalanges, at the distal end of the clavicles, and in the skull (‘pepper-pot’ aspect) (Figure 17). Whereas cortical bone is progressively thinning, the mass of spongy bone tends to increase, particularly in the metaphyses. The latter phenomenon results in a characteristic sclerotic aspect of the upper and lower thirds of the vertebrae, contrasting with rarefaction of the vertebral center (‘rugger jersey spine’). Osteosclerosis is also commonly seen in radiographs of the metaphyses of the radius and tibia.

 

Figure 16. Periosteal resorption and small vessel calcification in severe secondary uremic hyperparathyroidism. (a) X-ray aspect of periosteal resorption within cortical bone of middle phalanges of the hand, indicative of osteitis fibrosa, and extensive finger artery calcification in a CKD stage 5 patient with severe secondary hyperparathyroidism. (b) Aspect one year after surgical parathyroidectomy: complete bone lesion healing and disappearance of arterial calcification.

Figure 17. X-ray pepper-and-salt aspect of the skull in a patient on long-term hemodialysis with severe secondary hyperparathyroidism.

 

In addition to the skeletal lesions, radiographs often reveal various types of soft tissue calcification. These comprise vascular calcifications, i.e. calcification of intimal plaques (aorta, iliac arteries) (Figure 18a), as well as diffuse calcification (Mönckeberg type) of the media of peripheral muscular arteries (Figure 18b).

 

Figure 18. Massive intima (a) and media (b) calcification of hypogastric artery in a patient on long-term hemodialysis. From Amann (264).

 

Of interest, media calcification of digital arteries can entirely regress after surgical parathyroidectomy (Figure 16). Calcium deposits may also be seen in periarticular tissue or bursas and may exhibit tumor-like features (Figure 19).

 

Figure 19. X-ray feature of a tumor-like periarticular calcification in the shoulder of a chronic hemodialysis patient with adynamic bone disease due to aluminum intoxication.

 

Since the development of electron-beam computed tomography (EBCT) and multiple slice computed tomography (MSCT), more reliable means have become available to assess quantitatively vascular calcification and its progression in uremic patients (265). However, these techniques are not universally available and costly. Moreover, they do not allow a distinction between arterial intima and media calcifications. Such a distinction can be obtained by radiograms of the pelvis and the thigh, combined with ultrasonography of the common carotid artery. Using these simple methods, London et al could show that patients on hemodialysis with arterial media calcification had a longer survival than hemodialysis patients with arterial intima calcification, but in turn their survival was significantly shorter than that of patients on hemodialysis without calcifications (266). Of note, both severe hyperparathyroidism and marked hypoparathyroidism favor the occurrence of the two types of calcifications in such patients (267–269). In contrast to permanently elevated serum PTH levels, the intermittent administration of PTH1-34 has been shown to decrease arterial calcification in uremic rats (270) and in diabetic mice with LDL receptor deletion (271). This observation tends to demonstrate that normal parathyroid function is required not only for the maintenance of optimal bone structure and function, but also as an efficacious defense against soft tissue calcification, and that intermittent PTH administration may not only improve osteoporosis (272), but also reduce vascular calcification, at least in experimental animals.

 

SECONDARY HYPERPARATHYROIDISM IN CKD – TREATMENT

 

Medical Management

 

Presently available options of medical treatment should take into account plasma biochemistry and x-ray findings, and if available also the dimensions of the largest parathyroid glands, as assessed by ultrasonography. A gland diameter of 5-10 mm or more is considered as being indicative of autonomous growth, which often is resistant to medical treatment (206).

 

Schematically, there are five major medical treatment options which can be combined in some cases, but not in others, namely the restriction of phosphate intake and/or the administration of calcium supplements, oral phosphate binders, vitamin D derivatives, and calcimimetics (273,274). In patients on dialysis the weekly dose of renal replacement therapy is an additional important factor. An optimal dialysis technique allows controlling hyperphosphatemia and providing enough calcium to avoid PTH stimulation by hypocalcemia during dialysis sessions.

 

To control hyperparathyroidism, it is important to avoid both hypocalcemia and hypercalcemia, and to reduce or correct hyperphosphatemia. In patients with controlled plasma phosphate, this can be achieved by giving either calcitriol or one of its synthetic analogs, or by administering oral calcium supplements. For a long time, calcitriol or alfacalcidol was the preferred therapy in uremic patients with high to very high plasma intact PTH values and normal to moderately elevated plasma calcium levels, when plasma phosphate did not exceed recommended levels, namely 1.5 mmol/L for CKD stages 3-4 and 1.8 mmol/L for CKD stage 5, according to the K/DOQI guidelines of 2003 (275). However, the administration of active vitamin D derivatives often induces hypercalcemia and/or hyperphosphatemia. The KDIGO CKD-MBD guideline of 2009 (276) and its subsequent updates in 2017/2018 and 2025 (277-279) suggest maintaining iPTH levels in CKD stage 5D patients (i.e. patients receiving dialysis therapy) in the range of approximately two to nine times the upper normal limit for the assay, to keep serum calcium normal, and to decrease serum phosphorus towards the normal range. Uncertainty prevails regarding ideal PTH and phosphorus targets in patients with CKD stages G3-G5 and those on dialysis therapy. Marked changes in iPTH levels in either direction within the newly defined, broadened range should prompt initiation or change in therapy to avoid progression to levels outside of this range. Patients with CKD stages G3a-G5 not on dialysis whose levels of intact PTH are progressively rising or persistently above the upper normal limit for the assay should be evaluated for modifiable factors, including hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin D deficiency.

 

Vitamin D and Active Vitamin D Derivatives

 

A satisfactory degree of vitamin D repletion should probably be aimed at in case of vitamin D deficiency, knowing that the majority of patients with CKD have at least some degree of vitamin D deficiency (53,280). Relative vitamin D depletion has been shown to be an independent risk factor for secondary hyperparathyroidism in patients on hemodialysis (56). Repletion with native vitamin D may lead to improved control of secondary hyperparathyroidism in patients not yet on dialysis (281) and in those treated by dialysis (282) but no beneficial effect has been observed in a subsequent meta-analysis (283). Vitamin D repletion may allow optimal bone formation, help to avoid osteomalacia, and exert numerous other positive effects due to the pleiotropic actions of vitamin D, but most of these presumably positive actions remain a matter of debate (283,282). Most importantly, randomized controlled trials with native vitamin D or calcidiol have not been performed so far to evaluate hard clinical outcomes of patients with CKD.

 

As regards the administration of active vitamin D sterols during the course of CKD, the updated KDIGO guidelines suggest that calcitriol and vitamin D analogues not be routinely used in patients with CKD G3a-G5. They further state that it is reasonable to reserve the use of these agents for patients with CKD G4-G5 having severe and progressive hyperparathyroidism (277-278).

 

To correct secondary hyperparathyroidism of moderate to severe degree the oral administration of active vitamin D derivatives is generally more efficient than that of native vitamin D. In patients on hemodialysis, calcitriol or its analogs can be given either orally or intravenously. The oral administration can be on a daily basis (for instance 0.125 to 0.5 µg of calcitriol) or as intermittent bolus ingestions (for instance 0.5 to 2.0 µg of calcitriol for each dose) whereas the intravenous administration is always intermittent (0.5 to 2.0 µg of calcitriol or more per injection). The route and mode of administration of calcitriol or alfacalcidol probably play only a minor role. Since the highly active 1α-hydroxylated vitamin D derivatives can easily induce hypercalcemia, intensive research has focused on the development of various non-hypercalcemic analogs, including the natural vitamin D compound 24,25(OH)2 vitamin D3, 22-oxa-calcitriol (maxacalcitol), 19-nor-1,25(OH)2 vitamin D3 (paricalcitol), and 1α-(OH) vitamin D2 (hectorol). Despite numerous studies done in many patients none of them has been shown to be entirely devoid of inducing increases in plasma calcium or phosphate, and none has been demonstrated so far to be superior to calcitriol or alfacalcidol in controlling secondary hyperparathyroidism in the long run (285,286). An observational study by Teng et al. showed that paricalcitol administration to a large cohort of patients on hemodialysis conferred a remarkable (16%) survival advantage over the administration of calcitriol (287). Numerous subsequent observational studies reported a survival benefit, either comparing treatment with active vitamin D derivatives to no treatment, or novel active vitamin D derivatives to calcitriol in CKD patients not yet on dialysis (288) or those receiving dialysis treatment (289–291). Another observational study conducted in patients on hemodialysis, however, did not find a survival advantage with paricalcitol, as compared to calcitriol (292). In the absence of randomized controlled trials, it is impossible to conclude that paricalcitol treatment is superior to calcitriol or alfacalcidol in terms of patient survival. Findings of observational studies can only be considered as hypothesis-generating. They need to be confirmed by a properly designed prospective investigation (293).

 

Calcimimetics

 

The introduction of the calcimimetic cinacalcet into clinical practice led to a change in the above treatment strategy since it enables controlling hyperparathyroidism without increasing plasma calcium or phosphorus. Calcimimetics modify the configuration of the CaSR, a receptor cloned by Brown et al in 1993 (294). They make the CaSR more sensitive to [Ca2+e], in contrast to the so-called calcilytics which decrease its sensitivity, as schematically shown in Figure 20.

 

Figure 20. Schematic representation of the modulation of the calcium-sensing receptor (CaSR) by calcimimetics and calcilytics. CaSR is expressed on the cell membrane. Calcimimetics increase its sensitivity to calcium ions whereas calcilytics decrease it.

 

Initial acute studies in patients on intermittent hemodialysis showed that the calcimimetic cinacalcet was capable of reducing plasma PTH within hours, immediately followed by a rapid decrease in plasma calcium and a minor decrease in plasma phosphate (295–297). In addition, calcimimetics can also reduce parathyroid cell proliferation. Both short-term and long-term studies performed in rats and mice with CKD showed that the administration of the calcimimetic NPS R-568, starting at the time of CKD induction, prevented parathyroid hyperplasia (191,201,298). This effect is probably due to a direct inhibitory action on the parathyroid cell, as shown by our group in an experimental study in which we exposed human uremic parathyroid cells to the calcimimetic NPS-R467 (79). An interesting finding of a yet unexplained mechanism and significance is the observation that calcimimetic treatment led to an approximately 5-fold increase in the proportion of oxyphil cells, as compared to chief cells, in parathyroid glands removed from CKD patients with refractory hyperparathyroidism  (299-301). Of note, oxyphil cells also exhibited higher CaSR expression than chief cells in such glands (302).

 

Perhaps more important from a clinical point of view, the administration of calcimimetics enabled an improvement of osteitis fibrosa (107), halted the progression of vascular calcification both in uremic animals (298,303) and probably also in patients undergoing dialysis (304), prevented vascular remodeling (305), improved cardiac structure and function (306), and prolonged survival (307) in uremic animals with secondary hyperparathyroidism.

 

The long-term administration of cinacalcet to patients on hemodialysis proved to be superior to « optimal » standard therapy in controlling secondary uremic hyperparathyroidism, in that it was able to induce not only a decrease in plasma PTH but also in plasma calcium and phosphate (308-311). Figure 21 shows the superior control of severe secondary hyperparathyroidism by cinacalcet as compared to placebo treatment with standard of care (312). The initial daily dose is 30 mg orally, which can be increased up to 180 mg if necessary. Cinacalcet is generally well tolerated, with the exception of gastrointestinal side effects, which however cease in the majority of patients with time. Since its administration generally leads to a decrease in serum calcium, a close follow-up is required, at least initially, to avoid severe hypocalcemia with possible adverse clinical consequences. Cinacalcet can be associated with calcium-containing and non-calcium containing phosphate binders and also with vitamin D derivatives. For PTH lowering a combination therapy may lead to more complete correction than single drug treatment because of less side-effects and greater efficacy in the control of hyperparathyroidism (313,314).

 

Figure 21. Effect of cinacalcet on need of parathyroidectomy in patients on hemodialysis therapy. In the EVOLVE trial, parathyroidectomy was performed in 140 (7%) cinacalcet-treated and 278 (14%) placebo-treated patients. Key independent predictors of parathyroidectomy included younger age, female sex, geographic region and absence of history of peripheral vascular disease. One hundred and forty-three (7%) cinacalcet-treated and 304 (16%) placebo-treated patients met the biochemical definition of severe, unremitting (« tertiary ») hyperparathyroidism. Considering the pre-specified biochemical composite or surgical parathyroidectomy as an endpoint, 240 (12%) cinacalcet-treated and 470 (24%) placebo-treated patients developed severe, unremitting hyperparathyroidism (312).

 

The subsequent development of an intravenously active calcimetic led to another series of clinical studies aimed at controlling secondary hyperparathyroidism in patients on hemodialysis with an easy access to parenteral drug administration, thereby reducing oral pill overload. Two randomized controlled trials were conducted in such patients with moderate to severe secondary hyperparathyroidism, evaluating the efficacy and safety of the intravenous calcimimetic, etelcalcetide as compared to placebo (315). Thrice weekly administration of active drug after hemodialysis led to a greater than 30% reduction in serum PTH compared with less than 8.9% of patients receiving placebo. The reduction in PTH was rapid and sustained over 26 weeks. Treatment with etelcalcetide lowered serum calcium in the majority of patients, with overt symptomatic hypocalcemia reported in 7%. Adverse events occurred in 92% of etelcalcetide-treated and 80% of placebo-treated patients. Nausea, vomiting, and diarrhea were more common in etelcalcetide-treated patients, as were symptoms potentially related to hypocalcemia. A subsequent double-blind, double-dummy randomized controlled trial compared intravenous etelcalcetide to oral cinacalcet in patients on hemodialysis with moderate to severe secondary hyperparathyroidism (316). It showed that the use of etelcalcetide was not inferior to cinacalcet in reducing serum PTH concentrations over 26 weeks. In addition, etelcalcetide met several superiority criteria, including a greater reduction in serum PTH concentrations from baseline, and more potent reductions in serum concentrations of FGF23 and two markers of high-turnover bone disease.

 

How about hard patient outcomes? The randomized controlled trial EVOLVE examined the question whether better control of secondary uremic hyperparathyroidism by cinacalcet, as compared to placebo treatment with standard of care, reduced the incidence of cardiovascular events and mortality (312). The study enrolled 3803 patients receiving long-term hemodialysis therapy. Using intention-to-treat analysis the study outcome was negative (Figure 22, upper part). However, after adjustment for age and other confounders, and also when using lag-censoring analysis (Figure 22, lower part), there was a nominally significant reduction in the primary cardiovascular endpoint including mortality in the cinacalcet treatment group in whom serum PTH, calcium, and phosphate were better controlled than in the placebo treatment group. Moreover, a post-hoc lag-censoring analysis of EVOLVE further showed that the incidence of clinically ascertained fractures was lower in the cinacalcet than the placebo arm (317).

 

Figure 22. Effect of cinacalcet on cardiovascular outcomes of patients on hemodialysis therapy. The randomized controlled trial EVOLVE examined the question of whether a better control of secondary uremic hyperparathyroidism by cinacalcet, as compared to placebo treatment with standard of care, reduced the incidence of cardiovascular events and mortality. The study enrolled 3803 patients receiving long-term hemodialysis therapy. Using intention-to-treat analysis the study outcome was negative (upper part of Figure). However, with lag-censoring analysis there was a nominally significant reduction in the primary composite cardiovascular endpoint in the cinacalcet treatment group in whom serum PTH, calcium, and phosphorus were better controlled than in the placebo treatment group (lower part of Figure). From Chertow et al (312).

 

Phosphate Binders, Inhibitors of Intestinal Phosphate Absorption, Oral Phosphate Restriction, and Phosphate Removal by Dialysis

 

Calcium-containing phosphate binders should be given, preferentially during or at the end of phosphate-rich meals, to patients with CKD and uncontrolled hyperphosphatemia who have no hypercalcemia or radiological evidence of marked soft tissue calcifications. In these latter cases non-calcium-containing phosphate binders should be preferred (see below). The administration of calcium salts alone such as calcium carbonate or calcium acetate is sufficient for the control of hyperphosphatemia in many instances, particularly in patients with CKD stages G3-G5 not yet on dialysis. At the same time these calcium salts will prevent serum iPTH from rising in the majority of patients (318). They may however lead to calcium overload (46,47) and excessive PTH suppression, resulting eventually in adynamic bone disease (319). In patients on hemodialysis, the efficacy and tolerance of this treatment may be enhanced by the concomitant use of low-calcium dialysate, for instance a calcium concentration of 1.25 mmol/L, especially if plasma intact PTH levels are not very high. However, long-term studies have shown that the continuous use of a dialysate calcium of only 1.25 mmol/L requires close monitoring of plasma calcium and PTH because of the risk of inducing excessive PTH secretion (320,321). A dialysate calcium concentration between 1.25 and 1.5 mmol/L is more appropriate in terms of optimal calcium balance and control of secondary hyperparathyroidism (322). The use of a low calcium dialysate also may require higher doses of active vitamin D derivatives (323) or cinacalcet (324) for the control of secondary hyperparathyroidism. Of note, the use of a low calcium bath favors hemodynamic instability during the hemodialysis session (325) and the occurrence of sudden cardiac arrest (326, 327). In patients on CAPD, the use of calcium carbonate, in the absence of vitamin D, together with a reduction of the dialysate calcium concentration from 1.75 to 1.45 mmol/L prevents the occurrence of hypercalcemia in most patients (328). However, the addition of daily low-dose alfacalcidol may lead to hypercalcemia, despite a further reduction of dialysate calcium to 1.0 mmol/L.

 

The development of calcium-free, aluminum-free oral phosphate binders such as sevelamer-HCl (329-331), sevelamer carbonate (332,333), lanthanum carbonate (334-336), sucroferric oxyhydroxide (337), and ferric citrate (338) allows controlling hyperphosphatemia without the potential danger of calcium overload. Their phosphate binding capacity is roughly equivalent to that of Ca carbonate or calcium acetate. Sevelamer offers in addition the advantage to lower serum total cholesterol and LDL-cholesterol and to increase serum HDL-cholesterol, to slow the progression of arterial calcification in dialysis patients (330), and possibly to improve survival in such patients (339). The administration of sevelamer is probably more efficient in halting the progression of vascular calcification than calcium carbonate or calcium acetate but this remains a matter of debate (14,340,341). The administration of lanthanum carbonate to uremic animals has been shown to also reduce progression of vascular calcification (342,344), but studies in patients with CKD have led to variable results (344-346). The effects of calcium-free, aluminum-free phosphate binders on serum iPTH are variable, depending on baseline iPTH and concomitant therapies. In general, iPTH levels are higher in response to these binders than to calcium-containing phosphate binders (Figure 23) (347,348).

 

Figure 23. Effect of oral calcium vs. sevelamer on serum intact PTH (iPTH) in CKD. In this 54-week, randomized, open-label study the effects of sevelamer hydrochloride on bone structure and various biochemical parameters were compared to that of calcium carbonate in 119 patients on long-term hemodialysis therapy. Serum iPTH was consistently lower with calcium carbonate than with sevelamer treatment. From Ferreira et al (347).

 

The administration of aluminum-containing phosphate binders should be avoided because of their potential toxicity. They may be given in some treatment resistant cases, but only for short periods of time (276).

 

Another approach chosen to control hyperphosphatemia and therefore to prevent or delay the development of secondary hyperparathyroidism is pharmacologic interference with active intestinal phosphate transport by oral inhibitors of the phosphate/sodium cotransporter NaPi2b, using either already available drugs such as niacin or nicotinamide (349-351), or more recently developed novel inhibitors such as tenapanor (352,353). The rather disappointing results of available studies have not led so far to their introduction into clinical practice (354).

 

Dietary phosphate intake should be assessed and diminished, if possible. Special attention should be given to the avoidance of foods containing phosphate additives (355). The spontaneous reduction of protein intake with age probably explains the often better control of serum phosphate in elderly as compared to younger patients with ESKD, and this may contribute to the relatively lower PTH levels of the former and their propensity to develop adynamic bone disease (356). However, when reducing dietary phosphate intake and concomitantly protein intake, one has to take care to avoid the induction of protein malnutrition. Restricting dietary protein intake excessively may increase the risk of mortality (357). In patients on dialysis therapy, an attempt should always be made to improve the efficiency of the dialysis procedure.

 

A better correction of metabolic acidosis by bicarbonate-buffered dialysate, as compared to acetate-buffered dialysate, probably helps to delay the progression of osteitis fibrosa in patients on hemodialysis (358). One possible mechanism for the beneficial role of acidosis correction is an increase in the sensitivity of the parathyroid gland to plasma ionized calcium (359).

Current recommendations for the medical treatment and prevention of patients with CKD-MBD, including secondary hyperparathyroidism, can be found in the 2009 KDIGO CKD-MBD                                                                                                                                                                                                                                                                                      guideline (276) and its subsequent updates (277,278). It must be pointed out though that there is no definitive proof of a beneficial effect of phosphate lowering on patient-level outcomes (257).

 

Local Injection of Alcohol and Active Vitamin D Derivatives

 

Since in advanced forms of secondary hyperparathyroidism the hyperplasia of parathyroid glands is asymmetrical, with some glands being grossly enlarged and others remaining relatively small, local injection of ethanol (360,361) or active vitamin D derivatives (362,363) has been proposed as an alternative therapy in patients who become resistant to medical treatment. However, the direct injection technique has not reached widespread use in clinical practice outside of Japan. Other research groups have been unable to obtain convincing results (364,365).

 

Despite major advances in the medical treatment of CKD-MBD the achievement of the targets for plasma calcium, phosphate, Ca x P product, and PTH, as recommended by the K/DOQI guidelines (275), was found to be far from being optimal in the DOPPS patient population for the years 2002-2004 (366). It was actually rare in the patients on hemodialysis of this international cohort to fall within recommended ranges for all four indicators of mineral metabolism, although consistent control of all three main CKD-MBD parameters calcium, phosphate, and PTH was found to be a strong predictor of survival in another observational study on patients undergoing hemodialysis (367). A recent report on such patients in France confirmed that a satisfactory control of serum calcium, phosphate, or PTH was achieved in less than 20% among them (368).

 

Surgical Treatment

 

Surgical correction remains the final, symptomatic therapy of the most severe forms of secondary hyperparathyroidism, which cannot be controlled by medical treatment (369). The most important goal remains to prevent or correct the development of major clinical complications associated with this disease. The presence of severe hyperparathyroidism must be demonstrated by clinical, biochemical and imaging evidence. In general, neck surgery should only be done when plasma iPTH values are greatly elevated (> 600-800 pg/mL), together with an increase in plasma total alkaline phosphatases (or better bone-specific alkaline phosphatase), and only after one or several medical treatment attempts have remained unsuccessful in decreasing plasma iPTH with cinacalcet (in patients on dialysis only) and/or active vitamin D derivatives or if their use is relatively or absolutely contraindicated, namely in presence of persistent hypercalcemia, marked hyperphosphatemia, or severe vascular calcifications. Bone histomorphometry examination is rarely needed. Clinical symptoms and signs such as pruritus and osteoarticular pain are non-specific and therefore no good criteria for operation on their own. Similarly, an isolated increase in plasma calcium and/or phosphate, even in case of coexistent soft tissue calcifications, is not a sufficient criterion alone for surgical parathyroidectomy. However, in the presence of a persistently high plasma PTH the latter disturbances may facilitate the decision to proceed to surgery. The results can be spectacular, including in rare instances the complete disappearance of soft tissue calcifications from small peripheral arteries (see Figure 15b). A concomitant aluminum overload should be excluded or treated, if present, before performing surgery.

 

Parathyroid gland imaging is useful for the indication of parathyroidectomy, especially for recurrent hyperparathyroidism. Ultrasound examination is the first-line technique but generally misses ectopic glands (370). CT scan or MRI can be used to visualize ectopic glands but often cannot differentiate parathyroid tissue from lymph node or thyroid nodule. Scintigraphy using 99mTc sestamibi coupled with 123I is a much more specific technique, allowing detection of parathyroid tissue with a false-positive rate inferior to 5% (371). More recently, this method has been replaced by parathyroid 18F-fluorocholine positron emission tomography (PET/CT), which shows even greater sensitivity and accuracy in detecting abnormal parathyroid glands (371, 372).

 

Two main surgical procedures are generally used, either subtotal parathyroidectomy or total parathyroidectomy with immediate autotransplantation. There is no substantial difference in operative difficulties and treatment results between the two procedures. We found that the long-term frequency of recurrent hyperparathyroidism was similar (373). One group of authors claimed superiority of total parathyroidectomy without reimplantation of parathyroid tissue in terms of long-term control of hyperparathyroidism, tolerance, and safety (374), but this claim has been questioned by us and others (375-377). We do not recommend the performance of total parathyroidectomy without autotransplantation in uremic patients since permanent hypoparathyroidism and adynamic bone disease may ensue, with possible harmful consequences especially for those patients who subsequently undergo kidney transplantation.

 

As regards the prevalence of parathyroidectomy, it was very high before the turn of the century. Moreover, it did not change significantly between 1983 and 1996. According to a survey from Northern Italy in 7371 dialysis patients (378) it was 5.5% in all patients together but increased with duration of RRT, from 9.2% after 10-15 years to 20.8% after 16-20 years of dialysis therapy. A subsequent survey from the US showed that parathyroidectomy rates were much lower in the first decade of the 21st century. It decreased from 7.9‰  in 2003 to a nadir of 3.3‰ in 2005 - most likely due to the commercial introduction of cinacalcet -, then rose again to 5.5‰ through 2006, and subsequently remained stable until 2011 (379). The authors concluded that despite the use of multiple medical therapies the rates of parathyroidectomy in patients with secondary hyperparathyroidism did not decline in recent years. These findings are in contrast with a Canadian study (380) and the international Dialysis Outcomes and Practice Patterns Study (DOPPS) (381). The Canadian study, although restricted to a single province (Quebec), showed a sustained reduction in parathyroidectomy rates after 2006. DOPPS reported that prescriptions of active vitamin D analogs and cinacalcet increased and that parathyroidectomy rates decreased. Difference in medical treatment modalities between geographic regions and different modes of data analysis may at least partially account for these apparent discrepancies. This is illustrated by the observation that parathyroidectomy rates in Japan fell abruptly after the advent of cinacalcet to approximately 2‰, with median serum iPTH around 150 pg/mL between 1996 and 2011 (381).

 

Parathyroidectomy was associated with higher short-term mortality, but lower long-term mortality among 4558 patients on dialysis in the US as compared to matched patients who did not undergo parathyroidectomy (382). However, that report did not contain information on serum PTH levels. Whether presently available therapeutic and prophylactic measures taken to attenuate secondary hyperparathyroidism play an important role in reducing cardiovascular morbidity and mortality among patients with ESKD remains a matter of debate. The EVOLVE trial points to better clinical outcomes with a more efficient control of hyperparathyroidism by cinacalcet than by optimal standard treatment but the results, although suggestive, must still be considered as not definitively conclusive (312,317).

 

Surgical Versus Medical Management

 

Whether surgical treatment is superior to medical treatment in controlling severe secondary hyperparathyroidism as regards hard clinical outcomes remains a matter of controversy. In the absence of randomized controlled trials, one has to rely on the results of observational studies. Two recent reports are available, exclusively on patients receiving dialysis therapy. The first study was performed in 209 patients in South Korea, either on hemodialysis or peritoneal dialysis (383). It showed that parathyroidectomy reduced the risk of new cardiovascular events by 86% compared to cinacalcet; however, all-cause mortality did not differ. However, the patients undergoing surgery had significantly higher iPTH levels than the patients on calcimimetic therapy (1,290 vs 719 pg/mL, P<0.001). The second study was performed in 3576 patients on hemodialysis in Japan (384). They were matched for serum iPTH levels (588 vs 566 pg/mL, P=NS). Here parathyroidectomy was associated with a lower risk of mortality compared with cinacalcet, particularly among patients with severe secondary hyperparathyroidism. It is impossible to draw firm conclusions from these two studies regarding the optimal treatment approach, all the more since no comparative information was provided on active vitamin D sterols as the other commonly used alternative medical treatment.

 

ACKNOWLEDGEMENTS

 

The author wishes to thank Mrs. Martine Netter, Paris for expert assistance in Figure design.

 

REFERENCES

 

  1. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G; Kidney Disease: Improving Global Outcomes (KDIGO). Defini-tion, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006 Jun;69(11):1945-53. doi: 10.1038/sj.ki.5000414. PMID: 16641930.
  2. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007 Jan;71(1):31-8. doi: 10.1038/sj.ki.5002009. Epub 2006 Nov 8. Erratum in: Kidney Int. 2009 Jun;75(11):1237. Erratum in: Kidney Int. 2009 Jun 1;75(11):1237. doi: 10.1038/ki.2009.100. PMID: 17091124.
  3. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F; MMKD Study Group; Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Rieg-ler P. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney dis-ease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007 Sep;18(9):2600-8. doi: 10.1681/ASN.2006080936. Epub 2007 Jul 26. PMID: 17656479.
  4. Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bel-lovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011 Jun;79(12):1370-8. doi: 10.1038/ki.2011.47. Epub 2011 Mar 9. Erratum in: Kidney Int. 2012 Aug;82(4):498. PMID: 21389978; PMCID: PMC3134393.
  5. Hu MC, Kuro-o M, Moe OW. The emerging role of Klotho in clinical nephrology. Nephrol Dial Transplant. 2012 Jul;27(7):2650-7. doi: 10.1093/ndt/gfs160. PMID: 22802580; PMCID: PMC3398064.
  6. Drüeke TB, Massy ZA. Changing bone patterns with progression of chronic kidney dis-ease. Kidney Int. 2016 Feb;89(2):289-302. doi: 10.1016/j.kint.2015.12.004. PMID: 26806832.
  7. Evenepoel P, D'Haese P, Brandenburg V. Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int. 2015 Aug;88(2):235-40. doi: 10.1038/ki.2015.156. Epub 2015 Jun 17. PMID: 26083653.
  8. Haarhaus M, Evenepoel P; European Renal Osteodystrophy (EUROD) workgroup; Chron-ic Kidney Disease Mineral and Bone Disorder (CKD-MBD) working group of the Euro-pean Renal Association–European Dialysis and Transplant Association (ERA-EDTA). Differentiating the causes of adynamic bone in advanced chronic kidney disease in-forms osteoporosis treatment. Kidney Int. 2021 Sep;100(3):546-558. doi: 10.1016/j.kint.2021.04.043. Epub 2021 Jun 5. PMID: 34102219.
  9. Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res. 2011 Jun;26(6):1368-76. doi: 10.1002/jbmr.309. Erratum in: J Bone Miner Res. 2011 Nov;26(11):2793. PMID: 21611975; PMCID: PMC3312761.
  10. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral me-tabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004 Aug;15(8):2208-18. doi: 10.1097/01.ASN.0000133041.27682.A2. PMID: 15284307.
  11. Moe SM, Drüeke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol. 2003 Nov-Dec;23(6):369-79. doi: 10.1159/000073945. Epub 2003 Oct 9. PMID: 14551461.
  12. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akiza-wa T, Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008 Sep;52(3):519-30. doi: 10.1053/j.ajkd.2008.03.020. Epub 2008 Jun 2. PMID: 18514987.
  13. Floege J. Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them? Nephrol Dial Transplant. 2008 Oct;23(10):3050-2. doi: 10.1093/ndt/gfn393. Epub 2008 Jul 14. PMID: 18625662.
  14. Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC; ARO Investigators. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodi-alysis population. Nephrol Dial Transplant. 2011 Jun;26(6):1948-55. doi: 10.1093/ndt/gfq219. Epub 2010 Apr 25. PMID: 20466670; PMCID: PMC3107766.
  15. Fernández-Martín JL, Martínez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G, Locatelli F, Gorriz JL, Rutkowski B, Ferreira A, Bos WJ, Covic A, Rodríguez-García M, Sánchez JE, Rodríguez-Puyol D, Cannata-Andia JB; COSMOS group. Improvement of mineral and bone metabolism markers is associated with better survival in haemodi-alysis patients: the COSMOS study. Nephrol Dial Transplant. 2015 Sep;30(9):1542-51. doi: 10.1093/ndt/gfv099. Epub 2015 Apr 28. PMID: 25920921.
  16. Yamamoto S, Jørgensen HS, Zhao J, Karaboyas A, Komaba H, Vervloet M, Mazzaferro S, Cavalier E, Bieber B, Robinson B, Evenepoel P, Fukagawa M. Alkaline Phosphatase and Parathyroid Hormone Levels: International Variation and Associations With Clinical Outcomes in the DOPPS. Kidney Int Rep. 2024 Jan 11;9(4):863-876. doi: 10.1016/j.ekir.2024.01.002. PMID: 38765600; PMCID: PMC11101738.
  17. Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, Melhus H, Held C, Lind L, Michaëlsson K, Arnlöv J. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009 Jun 2;119(21):2765-71. doi: 10.1161/CIRCULATIONAHA.108.808733. Epub 2009 May 18. PMID: 19451355.

18     Ketteler M, Evenepoel P, Holden RM, Isakova T, Jørgensen HS, Komaba H, Nickolas TL, Sinha S, Vervloet MG, Cheung M, King JM, Grams ME, Jadoul M, Moysés RMA; Conference Participants. Chronic kidney disease-mineral and bone disorder: conclu-sions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025 Jan 10:S0085-2538(24)00810-X. doi: 10.1016/j.kint.2024.11.013. Epub ahead of print. PMID: 39864017.

  1. Slatopolsky E, Caglar S, Pennell JP, Taggart DD, Canterbury JM, Reiss E, Bricker NS. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest. 1971 Mar;50(3):492-9. doi: 10.1172/JCI106517. PMID: 5545116; PMCID: PMC291955.
  2. Vorland CJ, Biruete A, Lachcik PJ, Srinivasan S, Chen NX, Moe SM, Hill Gallant KM. Kidney Disease Progression Does Not Decrease Intestinal Phosphorus Absorption in a Rat Model of Chronic Kidney Disease-Mineral Bone Disorder. J Bone Miner Res. 2020 Feb;35(2):333-342. doi: 10.1002/jbmr.3894. Epub 2019 Nov 15. PMID: 31618470; PMCID: PMC7012714.
  3. Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, M'rad MB, Jacquot C, Houillier P, Stengel B, Fouqueray B; NephroTest Study Group. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol. 2009 Jan;20(1):164-71. doi: 10.1681/ASN.2008020159. Epub 2008 Nov 12. PMID: 19005010; PMCID: PMC2615728.
  4. Bover J, Rodriguez M, Trinidad P, Jara A, Martinez ME, Machado L, Llach F, Felsenfeld AJ. Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat. Kidney Int. 1994 Apr;45(4):953-61. doi: 10.1038/ki.1994.129. PMID: 8007598.
  5. Hsu CY, Chertow GM. Elevations of serum phosphorus and potassium in mild to moder-ate chronic renal insufficiency. Nephrol Dial Transplant. 2002 Aug;17(8):1419-25. doi: 10.1093/ndt/17.8.1419. PMID: 12147789.
  6. Kurosu H, Kuro-O M. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol. 2009 Feb 5;299(1):72-8. doi: 10.1016/j.mce.2008.10.052. Epub 2008 Nov 21. PMID: 19063940.
  7. Ide N, Olauson H, Sato T, Densmore MJ, Wang H, Hanai JI, Larsson TE, Lanske B. In vivo evidence for a limited role of proximal tubular Klotho in renal phosphate han-dling. Kidney Int. 2016 Aug;90(2):348-362. doi: 10.1016/j.kint.2016.04.009. Epub 2016 Jun 9. PMID: 27292223.
  8. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fuku-moto S, Shimada T. Direct evidence for a causative role of FGF23 in the abnormal re-nal phosphate handling and vitamin D metabolism in rats with early-stage chronic kid-ney disease. Kidney Int. 2010 Nov;78(10):975-80. doi: 10.1038/ki.2010.313. Epub 2010 Sep 15. PMID: 20844473.
  9. Dhayat NA, Ackermann D, Pruijm M, Ponte B, Ehret G, Guessous I, Leichtle AB, Pac-caud F, Mohaupt M, Fiedler GM, Devuyst O, Pechère-Bertschi A, Burnier M, Martin PY, Bochud M, Vogt B, Fuster DG. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function. Kidney Int. 2016 Sep;90(3):648-57. doi: 10.1016/j.kint.2016.04.024. Epub 2016 Jun 28. PMID: 27370409.
  10. Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, Moe OW. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011 Jan;22(1):124-36. doi: 10.1681/ASN.2009121311. Epub 2010 Nov 29. PMID: 21115613; PMCID: PMC3014041.
  11. Lim K, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder D, Hsiao LL. Vascular Klotho defi-ciency potentiates the development of human artery calcification and mediates re-sistance to fibroblast growth factor 23. Circulation. 2012 May 8;125(18):2243-55. doi: 10.1161/CIRCULATIONAHA.111.053405. Epub 2012 Apr 5. PMID: 22492635.
  12. Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B, Razzaque MS, Rosenblatt KP, Baum MG, Kuro-o M, Moe OW. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 2010 Sep;24(9):3438-50. doi: 10.1096/fj.10-154765. Epub 2010 May 13. PMID: 20466874; PMCID: PMC2923354.
  13. Chen G, Liu Y, Goetz R, Fu L, Jayaraman S, Hu MC, Moe OW, Liang G, Li X, Moham-madi M. α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature. 2018 Jan 25;553(7689):461-466. doi: 10.1038/nature25451. Epub 2018 Jan 17. PMID: 29342138; PMCID: PMC6007875.
  14. Olauson H, Vervloet MG, Cozzolino M, Massy ZA, Ureña Torres P, Larsson TE. New insights into the FGF23-Klotho axis. Semin Nephrol. 2014 Nov;34(6):586-97. doi: 10.1016/j.semnephrol.2014.09.005. PMID: 25498378.
  15. Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, Serra AL. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant. 2013 Feb;28(2):352-9. doi: 10.1093/ndt/gfs460. Epub 2012 Nov 4. PMID: 23129826.
  16. Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, Kagawa T, Inoue M, Fujimoto S, Ikebe M, Yuasa K, Yamanaka S, Sugiura T, Terada Y. Serum levels of soluble se-creted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin Exp Nephrol. 2012 Oct;16(5):722-9. doi: 10.1007/s10157-012-0621-7. Epub 2012 Mar 29. PMID: 22457086.
  17. Smith ER, Holt SG, Hewitson TD. αKlotho-FGF23 interactions and their role in kidney disease: a molecular insight. Cell Mol Life Sci. 2019 Dec;76(23):4705-4724. doi: 10.1007/s00018-019-03241-y. Epub 2019 Jul 26. PMID: 31350618; PMCID: PMC11105488.
  18. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012 Oct;82(7):737-47. doi: 10.1038/ki.2012.176. Epub 2012 May 23. PMID: 22622492; PMCID: PMC3434320.
  19. Fan Y, Bi R, Densmore MJ, Sato T, Kobayashi T, Yuan Q, Zhou X, Erben RG, Lanske B. Parathyroid hormone 1 receptor is essential to induce FGF23 production and maintain systemic mineral ion homeostasis. FASEB J. 2016 Jan;30(1):428-40. doi: 10.1096/fj.15-278184. Epub 2015 Oct 1. PMID: 26428657; PMCID: PMC4684518.
  20. Meir T, Durlacher K, Pan Z, Amir G, Richards WG, Silver J, Naveh-Many T. Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int. 2014 Dec;86(6):1106-15. doi: 10.1038/ki.2014.215. Epub 2014 Jun 18. PMID: 24940803.

39   . López I, Rodríguez-Ortiz ME, Almadén Y, Guerrero F, de Oca AM, Pineda C, Shalhoub V, Rodríguez M, Aguilera-Tejero E. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int. 2011 Sep;80(5):475-82. doi: 10.1038/ki.2011.107. Epub 2011 Apr 27. PMID: 21525854.

  1. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2010 Feb;77(3):211-8. doi: 10.1038/ki.2009.464. Epub 2009 Dec 16. PMID: 20016468.
  2. Canalejo R, Canalejo A, Martinez-Moreno JM, Rodriguez-Ortiz ME, Estepa JC, Mendoza FJ, Munoz-Castaneda JR, Shalhoub V, Almaden Y, Rodriguez M. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol. 2010 Jul;21(7):1125-35. doi: 10.1681/ASN.2009040427. Epub 2010 Apr 29. PMID: 20431039; PMCID: PMC3152229.
  3. Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, Tominaga Y, Otsuki N, Nibu K, Nakagawa K, Tsugawa N, Okano T, Kitazawa R, Fukagawa M, Kita T. De-pressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2010 Feb;77(3):232-8. doi: 10.1038/ki.2009.414. Epub 2009 Nov 4. Erratum in: Kidney Int. 2010 May;77(9):834. Kita, Tomoyuki [added]. PMID: 19890272.
  4. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kid-ney Int. 2003 Dec;64(6):2272-9. doi: 10.1046/j.1523-1755.2003.00328.x. PMID: 14633152.
  5. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004 Aug;44(2):250-6. doi: 10.1053/j.ajkd.2004.04.029. PMID: 15264182.
  6. Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int. 2010 Feb;77(4):292-8. doi: 10.1038/ki.2009.466. Epub 2009 Dec 9. PMID: 20010546.
  7. Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int. 2012 Jun;81(11):1116-22. doi: 10.1038/ki.2011.490. Epub 2012 Feb 1. PMID: 22297674; PMCID: PMC3352985.
  8. Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, Peacock M. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int. 2013 May;83(5):959-66. doi: 10.1038/ki.2012.403. Epub 2012 Dec 19. PMID: 23254903; PMCID: PMC4292921.
  9. Koizumi M, Komaba H, Fukagawa M. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis. Contrib Nephrol. 2013;180:110-23. doi: 10.1159/000346791. Epub 2013 May 3. PMID: 23652554.
  10. Goodman WG, Quarles LD. Development and progression of secondary hyperparathy-roidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008 Aug;74(3):276-88. doi: 10.1038/sj.ki.5002287. Epub 2007 Jun 13. PMID: 17568787.
  11. Lucas PA, Brown RC, Woodhead JS, Coles GA. 1,25-dihydroxycholecalciferol and para-thyroid hormone in advanced chronic renal failure: effects of simultaneous protein and phosphorus restriction. Clin Nephrol. 1986 Jan;25(1):7-10. PMID: 3754187.
  12. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, Melsen F, Christensen EI, Willnow TE. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell. 1999 Feb 19;96(4):507-15. doi: 10.1016/s0092-8674(00)80655-8. PMID: 10052453.
  13. Zehnder D, Bland R, Walker EA, Bradwell AR, Howie AJ, Hewison M, Stewart PM. Ex-pression of 25-hydroxyvitamin D3-1alpha-hydroxylase in the human kidney. J Am Soc Nephrol. 1999 Dec;10(12):2465-73. doi: 10.1681/ASN.V10122465. PMID: 10589683.
  14. Cuppari L, Garcia-Lopes MG. Hypovitaminosis D in chronic kidney disease patients: prevalence and treatment. J Ren Nutr. 2009 Jan;19(1):38-43. doi: 10.1053/j.jrn.2008.10.005. PMID: 19121769.
  15. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, Takasu J, Adler S, Nor-ris K. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol. 2008 Jul;3(4):1144-51. doi: 10.2215/CJN.05781207. Epub 2008 Apr 16. PMID: 18417740; PMCID: PMC2440286.
  16. Cunningham J, Makin H. How important is vitamin D deficiency in uraemia? Nephrol Dial Transplant. 1997 Jan;12(1):16-8. doi: 10.1093/ndt/12.1.16. PMID: 9027765.
  17. Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Morinière P, Garabedian M, Eastwood J, Fournier A. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int. 1999 Jun;55(6):2169-77. doi: 10.1046/j.1523-1755.1999.00480.x. PMID: 10354266.
  18. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int. 2006 Aug;70(4):654-9. doi: 10.1038/sj.ki.5000394. Erratum in: Kidney Int. 2006 Sep;70(6):1190. PMID: 16807549.
  19. Vervloet MG, Massy ZA, Brandenburg VM, Mazzaferro S, Cozzolino M, Ureña-Torres P, Bover J, Goldsmith D; CKD-MBD Working Group of ERA-EDTA. Bone: a new endo-crine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol. 2014 May;2(5):427-36. doi: 10.1016/S2213-8587(14)70059-2. PMID: 24795256.
  20. Glorieux G, Hsu CH, de Smet R, Dhondt A, van Kaer J, Vogeleere P, Lameire N, Vanholder R. Inhibition of calcitriol-induced monocyte CD14 expression by uremic tox-ins: role of purines. J Am Soc Nephrol. 1998 Oct;9(10):1826-31. doi: 10.1681/ASN.V9101826. PMID: 9773783.
  21. Patel SR, Ke HQ, Vanholder R, Koenig RJ, Hsu CH. Inhibition of calcitriol receptor bind-ing to vitamin D response elements by uremic toxins. J Clin Invest. 1995 Jul;96(1):50-9. doi: 10.1172/JCI118061. PMID: 7615822; PMCID: PMC185172.
  22. Goto S, Fujii H, Hamada Y, Yoshiya K, Fukagawa M. Association between indoxyl sulfate and skeletal resistance in hemodialysis patients. Ther Apher Dial. 2010 Aug 1;14(4):417-23. doi: 10.1111/j.1744-9987.2010.00813.x. PMID: 20649763.
  23. Watanabe K, Tominari T, Hirata M, Matsumoto C, Hirata J, Murphy G, Nagase H, Miyaura C, Inada M. Indoxyl sulfate, a uremic toxin in chronic kidney disease, sup-presses both bone formation and bone resorption. FEBS Open Bio. 2017 Jul 20;7(8):1178-1185. doi: 10.1002/2211-5463.12258. PMID: 28781957; PMCID: PMC5536993.
  24. Sumida K, Nakamura M, Ubara Y, Marui Y, Tanaka K, Takaichi K, Tomikawa S, Inoshita N, Ohashi K. Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride. J Clin Pathol. 2011 Sep;64(9):756-60. doi: 10.1136/jclinpath-2011-200100. Epub 2011 May 12. PMID: 21565858.
  25. Mao J, You H, Wang M, Ba Y, Qian J, Cheng P, Lu C, Chen J. Single-cell RNA sequenc-ing reveals transdifferentiation of parathyroid chief cells into oxyphil cells in patients with uremic secondary hyperparathyroidism. Kidney Int. 2024 Mar;105(3):562-581. doi: 10.1016/j.kint.2023.11.027. Epub 2023 Dec 21. PMID: 38142040.
  26. Dusso AS. Vitamin D receptor: mechanisms for vitamin D resistance in renal failure. Kid-ney Int Suppl. 2003 Jun;(85):S6-9. doi: 10.1046/j.1523-1755.63.s85.3.x. PMID: 12753256.
  27. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993 Sep;92(3):1436-43. doi: 10.1172/JCI116720. PMID: 8397225; PMCID: PMC288288.
  28. Patel SR, Ke HQ, Vanholder R, Hsu CH. Inhibition of nuclear uptake of calcitriol receptor by uremic ultrafiltrate. Kidney Int. 1994 Jul;46(1):129-33. doi: 10.1038/ki.1994.252. PMID: 7933830.
  29. Garfia B, Cañadillas S, Canalejo A, Luque F, Siendones E, Quesada M, Almadén Y, Aguilera-Tejero E, Rodríguez M. Regulation of parathyroid vitamin D receptor expres-sion by extracellular calcium. J Am Soc Nephrol. 2002 Dec;13(12):2945-52. doi: 10.1097/01.asn.0000037676.54018.cb. PMID: 12444213.
  30. Sela-Brown A, Russell J, Koszewski NJ, Michalak M, Naveh-Many T, Silver J. Calreticu-lin inhibits vitamin D's action on the PTH gene in vitro and may prevent vitamin D's ef-fect in vivo in hypocalcemic rats. Mol Endocrinol. 1998 Aug;12(8):1193-200. doi: 10.1210/mend.12.8.0148. PMID: 9717845.
  31. Brown AJ, Zhong M, Finch J, Ritter C, McCracken R, Morrissey J, Slatopolsky E. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol. 1996 Mar;270(3 Pt 2):F454-60. doi: 10.1152/ajprenal.1996.270.3.F454. PMID: 8780248.
  32. Mendoza FJ, Lopez I, Canalejo R, Almaden Y, Martin D, Aguilera-Tejero E, Rodriguez M. Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats. Am J Physiol Renal Physiol. 2009 Mar;296(3):F605-13. doi: 10.1152/ajprenal.90272.2008. Epub 2008 Dec 17. PMID: 19091789.
  33. Silver J, Sela SB, Naveh-Many T. Regulation of parathyroid cell proliferation. Curr Opin Nephrol Hypertens. 1997 Jul;6(4):321-6. doi: 10.1097/00041552-199707000-00004. PMID: 9263680.
  34. Szabo A, Merke J, Beier E, Mall G, Ritz E. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int. 1989 Apr;35(4):1049-56. doi: 10.1038/ki.1989.89. PMID: 2709685.
  35. Fukagawa M, Kaname S, Igarashi T, Ogata E, Kurokawa K. Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int. 1991 May;39(5):874-81. doi: 10.1038/ki.1991.110. PMID: 2067203.
  36. Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest. 1995 Oct;96(4):1786-93. doi: 10.1172/JCI118224. PMID: 7560070; PMCID: PMC185815.
  37. Nygren P, Larsson R, Johansson H, Ljunghall S, Rastad J, Akerström G. 1,25(OH)2D3 inhibits hormone secretion and proliferation but not functional dedifferentiation of cul-tured bovine parathyroid cells. Calcif Tissue Int. 1988 Oct;43(4):213-8. doi: 10.1007/BF02555137. PMID: 3145126.
  38. Kremer R, Bolivar I, Goltzman D, Hendy GN. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cul-tures of bovine parathyroid cells. Endocrinology 1989; 125: 935–941.
  39. Ishimi Y, Russell J, Sherwood LM. Regulation by calcium and 1,25-(OH)2D3 of cell pro-liferation and function of bovine parathyroid cells in culture. J Bone Miner Res. 1990 Jul;5(7):755-60. doi: 10.1002/jbmr.5650050712. PMID: 2396502.
  40. Roussanne MC, Lieberherr M, Souberbielle JC, Sarfati E, Drüeke T, Bourdeau A. Human parathyroid cell proliferation in response to calcium, NPS R-467, calcitriol and phos-phate. Eur J Clin Invest. 2001 Jul;31(7):610-6. doi: 10.1046/j.1365-2362.2001.00809.x. PMID: 11454016.
  41. Fernández E, Fibla J, Betriu A, Piulats JM, Almirall J, Montoliu J. Association between vitamin D receptor gene polymorphism and relative hypoparathyroidism in patients with chronic renal failure. J Am Soc Nephrol. 1997 Oct;8(10):1546-52. doi: 10.1681/ASN.V8101546. PMID: 9335382.
  42. Nagaba Y, Heishi M, Tazawa H, Tsukamoto Y, Kobayashi Y. Vitamin D receptor gene polymorphisms affect secondary hyperparathyroidism in hemodialyzed patients. Am J Kidney Dis. 1998 Sep;32(3):464-9. doi: 10.1053/ajkd.1998.v32.pm9740163. PMID: 9740163.
  43. Yokoyama K, Shigematsu T, Tsukada T, Ogura Y, Takemoto F, Hara S, Yamada A, Ka-waguchi Y, Hosoya T. Apa I polymorphism in the vitamin D receptor gene may affect the parathyroid response in Japanese with end-stage renal disease. Kidney Int. 1998 Feb;53(2):454-8. doi: 10.1046/j.1523-1755.1998.00781.x. PMID: 9461106.
  44. Carling T, Rastad J, Akerström G, Westin G. Vitamin D receptor (VDR) and parathyroid hormone messenger ribonucleic acid levels correspond to polymorphic VDR alleles in human parathyroid tumors. J Clin Endocrinol Metab. 1998 Jul;83(7):2255-9. doi: 10.1210/jcem.83.7.4862. PMID: 9661591.
  45. Schmidt S, Chudek J, Karkoszka H, Heemann U, Reichel H, Rambausek M, Kokot F, Ritz E. The BsmI vitamin D-receptor polymorphism and secondary hyperparathyroid-ism. Nephrol Dial Transplant. 1997 Aug;12(8):1771-2. PMID: 9269677.
  46. Torres A, Machado M, Concepción MT, Martín N, Lorenzo V, Hernández D, Rodríguez AP, Rodríguez A, de Bonis E, González-Posada JM, Hernández A, Salido E. Influence of vitamin D receptor genotype on bone mass changes after renal transplantation. Kid-ney Int. 1996 Nov;50(5):1726-33. doi: 10.1038/ki.1996.492. PMID: 8914043.
  47. Hawa NS, Cockerill FJ, Vadher S, Hewison M, Rut AR, Pike JW, O'Riordan JL, Farrow SM. Identification of a novel mutation in hereditary vitamin D resistant rickets causing exon skipping. Clin Endocrinol (Oxf). 1996 Jul;45(1):85-92. PMID: 8796143.
  48. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA. Prediction of bone density from vitamin D receptor alleles. Nature. 1994 Jan 20;367(6460):284-7. doi: 10.1038/367284a0. Erratum in: Nature 1997 May 1;387(6628):106. PMID: 8161378.
  49. Egstrand S, Nordholm A, Morevati M, Mace ML, Hassan A, Naveh-Many T, Rukov JL, Gravesen E, Olgaard K, Lewin E. A molecular circadian clock operates in the parathy-roid gland and is disturbed in chronic kidney disease associated bone and mineral dis-order. Kidney Int. 2020 Dec;98(6):1461-1475. doi: 10.1016/j.kint.2020.06.034. Epub 2020 Jul 25. PMID: 32721445.
  50. Egstrand S, Mace ML, Morevati M, Nordholm A, Engelholm LH, Thomsen JS, Brüel A, Naveh-Many T, Guo Y, Olgaard K, Lewin E. Hypomorphic expression of parathyroid Bmal1 disrupts the internal parathyroid circadian clock and increases parathyroid cell proliferation in response to uremia. Kidney Int. 2022 Jun;101(6):1232-1250. doi: 10.1016/j.kint.2022.02.018. Epub 2022 Mar 9. PMID: 35276205.
  51. Isakova T, Gutierrez O, Shah A, Castaldo L, Holmes J, Lee H, Wolf M. Postprandial min-eral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol. 2008 Mar;19(3):615-23. doi: 10.1681/ASN.2007060673. Epub 2008 Jan 23. Erratum in: J Am Soc Nephrol. 2009 Jan;20(1):229. PMID: 18216315; PMCID: PMC2391049.
  52. Santamaria R, Almaden Y, Felsenfeld A, Martin-Malo A, Gao P, Cantor T, Aljama P, Ro-driguez M. Dynamics of PTH secretion in hemodialysis patients as determined by the intact and whole PTH assays. Kidney Int. 2003 Nov;64(5):1867-73. doi: 10.1046/j.1523-1755.2003.00262.x. PMID: 14531822.
  53. Moysés RM, Pereira RC, Machado dos Reis L, Sabbaga E, Jorgetti V. Dynamic tests of parathyroid hormone secretion using hemodialysis and calcium infusion cannot be compared. Kidney Int. 1999 Aug;56(2):659-65. doi: 10.1046/j.1523-1755.1999.00593.x. PMID: 10432406.
  54. Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal para-thyroid tissue. J Clin Endocrinol Metab. 1983 Mar;56(3):572-81. doi: 10.1210/jcem-56-3-572. PMID: 6822654.
  55. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drüeke TB. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997 Jan;51(1):328-36. doi: 10.1038/ki.1997.41. PMID: 8995751.
  56. Kifor O, Moore FD Jr, Wang P, Goldstein M, Vassilev P, Kifor I, Hebert SC, Brown EM. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. 1996 Apr;81(4):1598-606. doi: 10.1210/jcem.81.4.8636374. PMID: 8636374.
  57. Rodríguez-Ortiz ME, Canalejo A, Herencia C, Martínez-Moreno JM, Peralta-Ramírez A, Perez-Martinez P, Navarro-González JF, Rodríguez M, Peter M, Gundlach K, Steppan S, Passlick-Deetjen J, Muñoz-Castañeda JR, Almaden Y. Magnesium modulates para-thyroid hormone secretion and upregulates parathyroid receptor expression at moder-ately low calcium concentration. Nephrol Dial Transplant. 2014 Feb;29(2):282-9. doi: 10.1093/ndt/gft400. Epub 2013 Oct 8. PMID: 24103811; PMCID: PMC3910342.
  58. Brown AJ, Ritter CS, Finch JL, Slatopolsky EA. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int. 1999 Apr;55(4):1284-92. doi: 10.1046/j.1523-1755.1999.00386.x. PMID: 10200992.
  59. Campion KL, McCormick WD, Warwicker J, Khayat ME, Atkinson-Dell R, Steward MC, Delbridge LW, Mun HC, Conigrave AD, Ward DT. Pathophysiologic Changes in Extra-cellular pH Modulate Parathyroid Calcium-Sensing Receptor Activity and Secretion via a Histidine-Independent Mechanism. J Am Soc Nephrol. 2015 Sep;26(9):2163-71. doi: 10.1681/ASN.2014070653. Epub 2015 Jan 2. PMID: 25556167; PMCID: PMC4552114.
  60. Centeno PP, Herberger A, Mun HC, Tu C, Nemeth EF, Chang W, Conigrave AD, Ward DT. Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nat Commun. 2019 Oct 16;10(1):4693. doi: 10.1038/s41467-019-12399-9. PMID: 31619668; PMCID: PMC6795806.
  61. Almaden Y, Hernandez A, Torregrosa V, Canalejo A, Sabate L, Fernandez Cruz L, Campistol JM, Torres A, Rodriguez M. High phosphate level directly stimulates para-thyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol. 1998 Oct;9(10):1845-52. doi: 10.1681/ASN.V9101845. PMID: 9773785.
  62. Lewin E, Garfia B, Almaden Y, Rodriguez M, Olgaard K. Autoregulation in the parathy-roid glands by PTH/PTHrP receptor ligands in normal and uremic rats. Kidney Int. 2003 Jul;64(1):63-70. doi: 10.1046/j.1523-1755.2003.00056.x. PMID: 12787396.
  63. Goodman WG, Veldhuis JD, Belin TR, Van Herle AJ, Juppner H, Salusky IB. Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J Clin Endocrinol Metab. 1998 Aug;83(8):2765-72. doi: 10.1210/jcem.83.8.4999. PMID: 9709944.
  64. Rodriguez M, Caravaca F, Fernandez E, Borrego MJ, Lorenzo V, Cubero J, Martin-Malo A, Betriu A, Jimenez A, Torres A, Felsenfeld AJ. Parathyroid function as a deter-minant of the response to calcitriol treatment in the hemodialysis patient. Kidney Int. 1999 Jul;56(1):306-17. doi: 10.1046/j.1523-1755.1999.00538.x. PMID: 10411707.
  65. Goodman WG, Belin TR, Salusky IB. In vivo assessments of calcium-regulated para-thyroid hormone release in secondary hyperparathyroidism. Kidney Int. 1996 Dec;50(6):1834-44. doi: 10.1038/ki.1996.503. PMID: 8943464.
  66. Ouseph R, Leiser JD, Moe SM. Calcitriol and the parathyroid hormone-ionized calcium curve: a comparison of methodologic approaches. J Am Soc Nephrol. 1996 Mar;7(3):497-505. doi: 10.1681/ASN.V73497. PMID: 8704117.
  67. Mathias RS, Nguyen HT, Zhang MYH, Portale AA. Reduced expression of the renal calcium-sensing receptor in rats with experimental chronic renal insufficiency. J Amer Soc Nephrol 1998; 9: 2067–2074.
  68. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int. 1998 Feb;53(2):448-53. doi: 10.1046/j.1523-1755.1998.00782.x. PMID: 9461105.
  69. Wernerson A, Widholm SM, Svensson O, Reinholt FP. Parathyroid cell number and size in hypocalcemic young rats. APMIS. 1991 Dec;99(12):1096-102. doi: 10.1111/j.1699-0463.1991.tb01306.x. PMID: 1772646.
  70. LeBoff MS, Rennke HG, Brown EM. Abnormal regulation of parathyroid cell secretion and proliferation in primary cultures of bovine parathyroid cells. Endocrinology. 1983 Jul;113(1):277-84. doi: 10.1210/endo-113-1-277. PMID: 6407823.
  71. LeBoff MS, Shoback D, Brown EM, Thatcher J, Leombruno R, Beaudoin D, Henry M, Wilson R, Pallotta J, Marynick S, et al. Regulation of parathyroid hormone release and cytosolic calcium by extracellular calcium in dispersed and cultured bovine and patho-logical human parathyroid cells. J Clin Invest. 1985 Jan;75(1):49-57. doi: 10.1172/JCI111696. PMID: 3965511; PMCID: PMC423397.
  72. MacGregor RR, Sarras MP Jr, Houle A, Cohn DV. Primary monolayer cell culture of bovine parathyroids: effects of calcium, isoproterenol and growth factors. Mol Cell En-docrinol. 1983 Jun;30(3):313-28. doi: 10.1016/0303-7207(83)90067-9. PMID: 6862097.
  73. Ridgeway RD, Hamilton JW, MacGregor RR. Characteristics of bovine parathyroid cell organoids in culture. In Vitro Cell Dev Biol. 1986 Feb;22(2):91-9. doi: 10.1007/BF02623538. PMID: 3949675.
  74. Brandi ML, Fitzpatrick LA, Coon HG, Aurbach GD. Bovine parathyroid cells: cultures maintained for more than 140 population doublings. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1709-13. doi: 10.1073/pnas.83.6.1709. PMID: 3006065; PMCID: PMC323153.
  75. Brown AJ, Zhong M, Ritter C, Brown EM, Slatopolsky E. Loss of calcium responsive-ness in cultured bovine parathyroid cells is associated with decreased calcium receptor expression. Biochem Biophys Res Commun. 1995 Jul 26;212(3):861-7. doi: 10.1006/bbrc.1995.2048. PMID: 7626122.
  76. Mithal A, Kifor O, Kifor I, Vassilev P, Butters R, Krapcho K, Simin R, Fuller F, Hebert SC, Brown EM. The reduced responsiveness of cultured bovine parathyroid cells to ex-tracellular Ca2+ is associated with marked reduction in the expression of extracellular Ca(2+)-sensing receptor messenger ribonucleic acid and protein. Endocrinology. 1995 Jul;136(7):3087-92. doi: 10.1210/endo.136.7.7789335. PMID: 7789335.
  77. Brandi ML, Ornberg RL, Sakaguchi K, Curcio F, Fattorossi A, Lelkes PI, Matsui T, Zimering M, Aurbach GD. Establishment and characterization of a clonal line of para-thyroid endothelial cells. FASEB J. 1990 Oct;4(13):3152-8. doi: 10.1096/fasebj.4.13.1698682. PMID: 1698682.
  78. Sakaguchi K. Acidic fibroblast growth factor autocrine system as a mediator of calcium-regulated parathyroid cell growth. J Biol Chem. 1992 Dec 5;267(34):24554-62. PMID: 1280262.
  79. Roussanne MC, Gogusev J, Hory B, Duchambon P, Souberbielle JC, Nabarra B, Pier-rat D, Sarfati E, Drüeke T, Bourdeau A. Persistence of Ca2+-sensing receptor expres-sion in functionally active, long-term human parathyroid cell cultures. J Bone Miner Res. 1998 Mar;13(3):354-62. doi: 10.1359/jbmr.1998.13.3.354. PMID: 9525335.
  80. Mizobuchi M, Hatamura I, Ogata H et al. Calcimimetic compound upregulates de-creased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 2004; 15: 2579–2587.
  81. Chikatsu N, Fukumoto S, Takeuchi Y, Suzawa M, Obara T, Matsumoto T, Fujita T. Cloning and characterization of two promoters for the human calcium-sensing receptor (CaSR) and changes of CaSR expression in parathyroid adenomas. J Biol Chem. 2000 Mar 17;275(11):7553-7. doi: 10.1074/jbc.275.11.7553. PMID: 10713061.
  82. Lundgren S, Carling T, Hjälm G, Juhlin C, Rastad J, Pihlgren U, Rask L, Akerström G, Hellman P. Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing pro-tein. J Histochem Cytochem. 1997 Mar;45(3):383-92. doi: 10.1177/002215549704500306. PMID: 9071320.
  83. Egstrand S, Mace ML, Morevati M, Engelholm LH, Thomsen JS, Brüel A, Olgaard K, Lewin E. Chronotherapy with Cinacalcet has a striking effect on inhibition of parathy-roid gland proliferation in rats with secondary hyperparathyroidism. PLoS One. 2025 Jan 6;20(1):e0316675. doi: 10.1371/journal.pone.0316675. PMID: 39761264; PMCID: PMC11703009.
  84. Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro S, Torres A, Ro-driguez M. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res. 1996 Jul;11(7):970-6. doi: 10.1002/jbmr.5650110714. PMID: 8797118.
  85. Nielsen PK, Feldt-Rasmussen U, Olgaard K. A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells. Nephrol Dial Transplant. 1996 Sep;11(9):1762-8. PMID: 8918619.
  86. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest. 1996 Jun 1;97(11):2534-40. doi: 10.1172/JCI118701. PMID: 8647946; PMCID: PMC507339.
  87. Almadén Y, Canalejo A, Ballesteros E, Añón G, Cañadillas S, Rodríguez M. Regulation of arachidonic acid production by intracellular calcium in parathyroid cells: effect of ex-tracellular phosphate. J Am Soc Nephrol. 2002 Mar;13(3):693-698. doi: 10.1681/ASN.V133693. PMID: 11856773.
  88. Moallem E, Kilav R, Silver J, Naveh-Many T. RNA-Protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem. 1998 Feb 27;273(9):5253-9. doi: 10.1074/jbc.273.9.5253. PMID: 9478982.
  89. Yalcindag C, Silver J, Naveh-Many T. Mechanism of increased parathyroid hormone mRNA in experimental uremia: roles of protein RNA binding and RNA degradation. J Am Soc Nephrol. 1999 Dec;10(12):2562-8. doi: 10.1681/ASN.V10122562. PMID: 10589695.
  90. Sela-Brown A, Silver J, Brewer G, Naveh-Many T. Identification of AUF1 as a parathy-roid hormone mRNA 3'-untranslated region-binding protein that determines parathyroid hormone mRNA stability. J Biol Chem. 2000 Mar 10;275(10):7424-9. doi: 10.1074/jbc.275.10.7424. PMID: 10702317.
  91. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Miner Electrolyte Metab. 1995;21(1-3):91-6. PMID: 7565472.
  92. Yi H, Fukagawa M, Yamato H, Kumagai M, Watanabe T, Kurokawa K. Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phos-phorus. Nephron. 1995;70(2):242-8. doi: 10.1159/000188591. PMID: 7566311.
  93. Takahashi F, Denda M, Finch JL, Brown AJ, Slatopolsky E. Hyperplasia of the parathy-roid gland without secondary hyperparathyroidism. Kidney Int. 2002 Apr;61(4):1332-8. doi: 10.1046/j.1523-1755.2002.00265.x. PMID: 11918740.
  94. Roussanne M-C, Gogusev J, Sarfati E, Drüeke T, Bourdeau A. Effect of phosphate on PTH secretion and proliferation in human parathyroid cells in culture (Abstract). J Bone Min Res (suppl 1) 1997; 12: S387.
  95. Silver J, Naveh-Many T. FGF23 and the parathyroid. Adv Exp Med Biol. 2012;728:92-9. doi: 10.1007/978-1-4614-0887-1_6. PMID: 22396164.
  96. Canalejo R, Canalejo A, Martinez-Moreno JM, Rodriguez-Ortiz ME, Estepa JC, Mendo-za FJ, Munoz-Castaneda JR, Shalhoub V, Almaden Y, Rodriguez M. FGF23 fails to in-hibit uremic parathyroid glands. J Am Soc Nephrol. 2010 Jul;21(7):1125-35. doi: 10.1681/ASN.2009040427. Epub 2010 Apr 29. PMID: 20431039; PMCID: PMC3152229.
  97. Hofman-Bang J, Martuseviciene G, Santini MA, Olgaard K, Lewin E. Increased parathy-roid expression of klotho in uremic rats. Kidney Int. 2010 Dec;78(11):1119-27. doi: 10.1038/ki.2010.215. Epub 2010 Jul 14. PMID: 20631679.
  98. Fan Y, Liu W, Bi R, Densmore MJ, Sato T, Mannstadt M, Yuan Q, Zhou X, Olauson H, Larsson TE, Toka HR, Pollak MR, Brown EM, Lanske B. Interrelated role of Klotho and calcium-sensing receptor in parathyroid hormone synthesis and parathyroid hyperplas-ia. Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3749-E3758. doi: 10.1073/pnas.1717754115. Epub 2018 Apr 4. PMID: 29618612; PMCID: PMC5910831.
  99. Mace ML, Olgaard K, Lewin E. New Aspects of the Kidney in the Regulation of Fibro-blast Growth Factor 23 (FGF23) and Mineral Homeostasis. Int J Mol Sci. 2020 Nov 20;21(22):8810. doi: 10.3390/ijms21228810. PMID: 33233840; PMCID: PMC7699902.
  100. Shilo V, Ben-Dov IZ, Nechama M, Silver J, Naveh-Many T. Parathyroid-specific dele-tion of dicer-dependent microRNAs abrogates the response of the parathyroid to acute and chronic hypocalcemia and uremia. FASEB J. 2015 Sep;29(9):3964-76. doi: 10.1096/fj.15-274191. Epub 2015 Jun 8. PMID: 26054367.
  101. Shilo V, Mor-Yosef Levi I, Abel R, Mihailović A, Wasserman G, Naveh-Many T, Ben-Dov IZ. Let-7 and MicroRNA-148 Regulate Parathyroid Hormone Levels in Secondary Hyperparathyroidism. J Am Soc Nephrol. 2017 Aug;28(8):2353-2363. doi: 10.1681/ASN.2016050585. Epub 2017 Mar 15. PMID: 28298326; PMCID: PMC5533223.
  102. Volovelsky O, Cohen G, Kenig A, Wasserman G, Dreazen A, Meyuhas O, Silver J, Naveh-Many T. Phosphorylation of Ribosomal Protein S6 Mediates Mammalian Target of Rapamycin Complex 1-Induced Parathyroid Cell Proliferation in Secondary Hy-perparathyroidism. J Am Soc Nephrol. 2016 Apr;27(4):1091-101. doi: 10.1681/ASN.2015040339. Epub 2015 Aug 17. PMID: 26283674; PMCID: PMC4814192.
  103. Hassan A, Khalaily N, Kilav-Levin R, Del Castello B, Manley NR, Ben-Dov IZ, Naveh-Many T. Dicer-Mediated mTORC1 Signaling and Parathyroid Gland Integrity and Function. J Am Soc Nephrol. 2024 May 31;35(9):1183–97. doi: 10.1681/ASN.0000000000000394. Epub ahead of print. PMID: 38819931; PMCID: PMC11387037.
  104. Khalaily N, Hassan A, Khream Y, Naveh-Many T, Ben-Dov IZ. The roles of mTORC1 in parathyroid gland function in chronic kidney disease-induced secondary hyperparathy-roidism: Evidence from male genetic mouse models and clinical data. FASEB J. 2024 Nov 30;38(22):e70184. doi: 10.1096/fj.202401547RR. PMID: 39570083; PMCID: PMC11580712.
  105. Aubia J, Serrano S, Mariñoso L, Hojman L, Diez A, Lloveras J, Masramon J. Osteo-dystrophy of diabetics in chronic dialysis: a histomorphometric study. Calcif Tissue Int. 1988 May;42(5):297-301. doi: 10.1007/BF02556363. PMID: 3135097.
  106. Hernandez D, Concepcion MT, Lorenzo V, Martinez ME, Rodriguez A, De Bonis E, Gonzalez-Posada JM, Felsenfeld AJ, Rodriguez M, Torres A. Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant. 1994;9(5):517-23. doi: 10.1093/ndt/9.5.517. PMID: 7522307.
  107. Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, Fenton S, Sherrard D. Renal osteodystrophy in diabetic patients. Kidney Int. 1993 Jul;44(1):159-64. doi: 10.1038/ki.1993.226. PMID: 8355457.
  108. Vincenti F, Arnaud SB, Recker R, Genant H, Amend WJ Jr, Feduska NJ, Salvatierra O Jr. Parathyroid and bone response of the diabetic patient to uremia. Kidney Int. 1984 Apr;25(4):677-82. doi: 10.1038/ki.1984.73. PMID: 6482171.
  109. Panuccio V, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Asahi K, Miyata T, Zoccali C. Low parathyroid hormone and pentosidine in hemodialysis patients. Am J Kidney Dis. 2002 Oct;40(4):810-5. doi: 10.1053/ajkd.2002.35693. PMID: 12324917.
  110. Hocher B, Armbruster FP, Stoeva S, Reichetzeder C, Grön HJ, Lieker I, Khadzhynov D, Slowinski T, Roth HJ. Measuring parathyroid hormone (PTH) in patients with oxida-tive stress--do we need a fourth generation parathyroid hormone assay? PLoS One. 2012;7(7):e40242. doi: 10.1371/journal.pone.0040242. Epub 2012 Jul 6. PMID: 22792251; PMCID: PMC3391306.
  111. Hocher B, Zeng S. Clear the Fog around Parathyroid Hormone Assays: What Do iPTH Assays Really Measure? Clin J Am Soc Nephrol. 2018 Apr 6;13(4):524-526. doi: 10.2215/CJN.01730218. Epub 2018 Mar 5. PMID: 29507007; PMCID: PMC5969453.
  112. Jara A, Bover J, Felsenfeld AJ. Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. Kidney Int. 1995 Jun;47(6):1746-51. doi: 10.1038/ki.1995.241. PMID: 7643545.
  113. Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolsky E. Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int. 1990 Jun;37(6):1522-7. doi: 10.1038/ki.1990.144. PMID: 2194068.
  114. Cannata JB, Briggs JD, Junor BJ, Beastall G, Fell GS. The influence of aluminium on parathyroid hormone levels in haemodialysis patients. Proc Eur Dial Transplant Assoc. 1983;19:244-7. PMID: 6878239.
  115. Llach F, Felsenfeld AJ, Coleman MD, Keveney JJ Jr, Pederson JA, Medlock TR. The natural course of dialysis osteomalacia. Kidney Int Suppl. 1986 Feb;18:S74-9. PMID: 3458001.
  116. Andress D, Felsenfeld AJ, Voigts A, Llach F. Parathyroid hormone response to hypocalcemia in hemodialysis patients with osteomalacia. Kidney Int. 1983 Sep;24(3):364-70. doi: 10.1038/ki.1983.168. PMID: 6645210.
  117. Kraut JA, Shinaberger JH, Singer FR, Sherrard DJ, Saxton J, Miller JH, Kurokawa K, Coburn JW. Parathyroid gland responsiveness to acute hypocalcemia in dialysis osteomalacia. Kidney Int. 1983 May;23(5):725-30. doi: 10.1038/ki.1983.85. PMID: 6876568.
  118. Cann CE, Prussin SG, Gordan GS. Aluminum uptake by the parathyroid glands. J Clin Endocrinol Metab. 1979 Oct;49(4):543-5. doi: 10.1210/jcem-49-4-543. PMID: 479346.
  119. Rodriguez M, Felsenfeld AJ, Llach F. The role of aluminum in the development of hypercalcemia in the rat. Kidney Int. 1987 Mar;31(3):766-71. doi: 10.1038/ki.1987.64. PMID: 3573539.
  120. Morrissey J, Slatopolsky E. Effect of aluminum on parathyroid hormone secretion. Kidney Int Suppl. 1986 Feb;18:S41-4. PMID: 3457994.
  121. Alfrey AC, Sedman A, Chan YL. The compartmentalization and metabolism of aluminum in uremic rats. J Lab Clin Med. 1985 Feb;105(2):227-33. PMID: 3973462.
  122. Henry DA, Goodman WG, Nudelman RK, DiDomenico NC, Alfrey AC, Slatopolsky E, Stanley TM, Coburn JW. Parenteral aluminum administration in the dog: I. Plasma kinetics, tissue levels, calcium metabolism, and parathyroid hormone. Kidney Int. 1984 Feb;25(2):362-9. doi: 10.1038/ki.1984.25. PMID: 6427508.
  123. Smans KA, D'Haese PC, Van Landeghem GF, Andries LJ, Lamberts LV, Hendy GN, De Broe ME. Transferrin-mediated uptake of aluminium by human parathyroid cells results in reduced parathyroid hormone secretion. Nephrol Dial Transplant. 2000 Sep;15(9):1328-36. doi: 10.1093/ndt/15.9.1328. PMID: 10978387.
  124. Finch JL, Bergfeld M, Martin KJ, Chan YL, Teitelbaum S, Slatopolsky E. The effects of discontinuation of aluminum exposure on aluminum-induced osteomalacia. Kidney Int. 1986 Sep;30(3):318-24. doi: 10.1038/ki.1986.187. PMID: 3784278.
  125. Felsenfeld AJ, Rodriguez M, Coleman M, Ross D, Llach F. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease. Kidney Int. 1989 Jun;35(6):1371-8. doi: 10.1038/ki.1989.136. PMID: 2770115.
  126. Cozzolino M, Lu Y, Finch J, Slatopolsky E, Dusso AS. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int. 2001 Dec;60(6):2109-17. doi: 10.1046/j.1523-1755.2001.00042.x. PMID: 11737585.
  127. Cordero JB, Cozzolino M, Lu Y, Vidal M, Slatopolsky E, Stahl PD, Barbieri MA, Dusso A. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. J Biol Chem. 2002 Oct 11;277(41):38965-71. doi: 10.1074/jbc.M203736200. Epub 2002 Aug 13. PMID: 12181310.
  128. Dusso AS, Pavlopoulos T, Naumovich L, Lu Y, Finch J, Brown AJ, Morrissey J, Slatopolsky E. p21(WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int. 2001 Mar;59(3):855-65. doi: 10.1046/j.1523-1755.2001.059003855.x. PMID: 11231340.
  129. Gogusev J, Duchambon P, Stoermann-Chopard C, Giovannini M, Sarfati E, Drüeke TB. De novo expression of transforming growth factor-alpha in parathyroid gland tissue of patients with primary or secondary uraemic hyperparathyroidism. Nephrol Dial Transplant. 1996 Nov;11(11):2155-62. doi: 10.1093/oxfordjournals.ndt.a027131. PMID: 8941573.
  130. Arcidiacono MV, Cozzolino M, Spiegel N, Tokumoto M, Yang J, Lu Y, Sato T, Lomonte C, Basile C, Slatopolsky E, Dusso AS. Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism. J Am Soc Nephrol. 2008 Oct;19(10):1919-28. doi: 10.1681/ASN.2007111216. Epub 2008 Jun 25. PMID: 18579641; PMCID: PMC2551566.

169a. Centeno PP, Binmahfouz LS, Alghamdi K, Ward DT. Inhibition of the calcium-sensing receptor by extracellular phosphate ions and by intracellular phosphorylation. Front Physiol. 2023 Mar 31;14:1154374. doi: 10.3389/fphys.2023.1154374. PMID: 37064904; PMCID: PMC10102455.

  1. Matsushita H, Hara M, Endo Y, Shishiba Y, Hara S, Ubara Y, Nakazawa H, Suzuki N, Kawaminami K, Kido T, Li Q, Grimelius L. Proliferation of parathyroid cells negatively correlates with expression of parathyroid hormone-related protein in secondary parathyroid hyperplasia. Kidney Int. 1999 Jan;55(1):130-8. doi: 10.1046/j.1523-1755.1999.00230.x. PMID: 9893121.
  2. Günther T, Chen ZF, Kim J, Priemel M, Rueger JM, Amling M, Moseley JM, Martin TJ, Anderson DJ, Karsenty G. Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature. 2000 Jul 13;406(6792):199-203. doi: 10.1038/35018111. PMID: 10910362.
  3. Correa P, Akerström G, Westin G. Underexpression of Gcm2, a master regulatory gene of parathyroid gland development, in adenomas of primary hyperparathyroidism. Clin Endocrinol (Oxf). 2002 Oct;57(4):501-5. doi: 10.1046/j.1365-2265.2002.01627.x. PMID: 12354132.
  4. Han SI, Tsunekage Y, Kataoka K. Gata3 cooperates with Gcm2 and MafB to activate parathyroid hormone gene expression by interacting with SP1. Mol Cell Endocrinol. 2015 Aug 15;411:113-20. doi: 10.1016/j.mce.2015.04.018. Epub 2015 Apr 24. PMID: 25917456.
  5. Morito N, Yoh K, Usui T, Oishi H, Ojima M, Fujita A, Koshida R, Shawki HH, Hamada M, Muratani M, Yamagata K, Takahashi S. Transcription factor MafB may play an important role in secondary hyperparathyroidism. Kidney Int. 2018 Jan;93(1):54-68. doi: 10.1016/j.kint.2017.06.023. Epub 2017 Sep 28. PMID: 28964572.
  6. Naveh-Many T, Silver J. Transcription factors that determine parathyroid development power PTH expression. Kidney Int. 2018 Jan;93(1):7-9. doi: 10.1016/j.kint.2017.08.026. PMID: 29291826.
  7. Mendes V, Jorgetti V, Nemeth J, Lavergne A, Lecharpentier Y, Dubost C, Cournot-Witmer C, Bourdon R, Bourdeau A, Zingraff J, et al. Secondary hyperparathyroidism in chronic haemodialysis patients: a clinico-pathological study. Proc Eur Dial Transplant Assoc. 1983;20:731-8. PMID: 6657693.
  8. Arnold A, Brown MF, Ureña P, Gaz RD, Sarfati E, Drüeke TB. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest. 1995 May;95(5):2047-53. doi: 10.1172/JCI117890. PMID: 7738171; PMCID: PMC295791.
  9. Chudek J, Ritz E, Kovacs G. Genetic abnormalities in parathyroid nodules of uremic patients. Clin Cancer Res. 1998 Jan;4(1):211-4. PMID: 9516973.
  10. Tominaga Y, Kohara S, Namii Y, Nagasaka T, Haba T, Uchida K, Numano M, Tanaka Y, Takagi H. Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg. 1996 Sep;20(7):744-50; discussion 750-2. doi: 10.1007/s002689900113. PMID: 8678945.
  11. Tominaga Y, Takagi H. Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens. 1996 Jul;5(4):336-41. doi: 10.1097/00041552-199607000-00008. PMID: 8823531.
  12. Imanishi Y, Tahara H, Palanisamy N, Spitalny S, Salusky IB, Goodman W, Brandi ML, Drüeke TB, Sarfati E, Ureña P, Chaganti RS, Arnold A. Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Am Soc Nephrol. 2002 Jun;13(6):1490-8. doi: 10.1097/01.asn.0000018148.50109.c0. PMID: 12039978.
  13. Hsi ED, Zukerberg LR, Yang WI, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab. 1996 May;81(5):1736-9. doi: 10.1210/jcem.81.5.8626826. PMID: 8626826.
  14. Tominaga Y, Tsuzuki T, Uchida K, Haba T, Otsuka S, Ichimori T, Yamada K, Numano M, Tanaka Y, Takagi H. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int. 1999 Apr;55(4):1375-83. doi: 10.1046/j.1523-1755.1999.00396.x. PMID: 10201002.
  15. Brown SB, Brierley TT, Palanisamy N, Salusky IB, Goodman W, Brandi ML, Drüeke TB, Sarfati E, Ureña P, Chaganti RS, Pike JW, Arnold A. Vitamin D receptor as a candidate tumor-suppressor gene in severe hyperparathyroidism of uremia. J Clin Endocrinol Metab. 2000 Feb;85(2):868-72. doi: 10.1210/jcem.85.2.6426. PMID: 10690903.
  16. Degenhardt S, Toell A, Weidemann W, Dotzenrath C, Spindler KD, Grabensee B. Point mutations of the human parathyroid calcium receptor gene are not responsible for non-suppressible renal hyperparathyroidism. Kidney Int. 1998 Mar;53(3):556-61. doi: 10.1046/j.1523-1755.1998.00802.x. PMID: 9507199.
  17. Djema AI, Mahmoud MD, Collin P, Heymann MF. Hyperparathyroïdie tertiaire: cancer parathyroïdien avec métastases hépatiques chez un hémodialysé [Tertiary hyperparathyroidism: parathyroid cancer with liver metastases in a hemodialyzed patient]. Nephrologie. 1998;19(3):121-3. French. PMID: 9633054.
  18. Miki H, Sumitomo M, Inoue H, Kita S, Monden Y. Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis. Surgery. 1996 Nov;120(5):897-901. doi: 10.1016/s0039-6060(96)80101-2. PMID: 8909528.
  19. Takami H, Kameyama K, Nagakubo I. Parathyroid carcinoma in a patient receiving long-term hemodialysis. Surgery. 1999 Feb;125(2):239-40. doi: 10.1016/s0039-6060(99)70273-4. PMID: 10026762.
  20. Drüeke TB, Zhang P, Gogusev J. Apoptosis: background and possible role in secondary hyperparathyroidism. Nephrol Dial Transplant. 1997 Nov;12(11):2228-33. doi: 10.1093/ndt/12.11.2228. PMID: 9394304.
  21. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int. 1997 Jul;52(1):3-9. doi: 10.1038/ki.1997.297. PMID: 9211340.
  22. Wada M, Furuya Y, Sakiyama J et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J. Clin. Invest. 1997; 100: 2977–2983.
  23. Canalejo A, Almadén Y, Torregrosa V, Gomez-Villamandos JC, Ramos B, Campistol JM, Felsenfeld AJ, Rodríguez M. The in vitro effect of calcitriol on parathyroid cell proliferation and apoptosis. J Am Soc Nephrol. 2000 Oct;11(10):1865-1872. doi: 10.1681/ASN.V11101865. PMID: 11004217.
  24. Jara A, Bover J, Felsenfeld AJ. Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. Kidney Int. 1995 Jun;47(6):1746-51. doi: 10.1038/ki.1995.241. PMID: 7643545.
  25. Zhang P, Duchambon P, Gogusev J, Nabarra B, Sarfati E, Bourdeau A, Drüeke TB. Apoptosis in parathyroid hyperplasia of patients with primary or secondary uremic hyperparathyroidism. Kidney Int. 2000 Feb;57(2):437-45. doi: 10.1046/j.1523-1755.2000.00863.x. PMID: 10652020.
  26. Heidenreich S, Schmidt M, Bachmann J, Harrach B. Apoptosis of monocytes cultured from long-term hemodialysis patients. Kidney Int. 1996 Mar;49(3):792-9. doi: 10.1038/ki.1996.110. PMID: 8648922.
  27. Massry SG, Fadda GZ. Chronic renal failure is a state of cellular calcium toxicity. Am J Kidney Dis. 1993 Jan;21(1):81-6. doi: 10.1016/s0272-6386(12)80727-x. PMID: 8418632.
  28. Carracedo J, Ramírez R, Martin-Malo A, Rodríguez M, Aljama P. Nonbiocompatible hemodialysis membranes induce apoptosis in mononuclear cells: the role of G-proteins. J Am Soc Nephrol. 1998 Jan;9(1):46-53. doi: 10.1681/ASN.V9146. PMID: 9440086.
  29. Lewin E, Wang W, Olgaard K. Reversibility of experimental secondary hyperparathyroidism. Kidney Int. 1997 Nov;52(5):1232-41. doi: 10.1038/ki.1997.448. PMID: 9350646.
  30. Henry HL, Taylor AN, Norman AW. Response of chick parathyroid glands to the vitamin D metabolites, 1,25-dihydroxycholecalciferol and 24,25-dihydroxycholecalciferol. J Nutr. 1977 Oct;107(10):1918-26. doi: 10.1093/jn/107.10.1918. PMID: 903834.
  31. Cloutier M, Brossard JH, Gascon-Barré M, D'Amour P. Lack of involution of hyperplastic parathyroid glands in dogs: adaptation via a decrease in the calcium stimulation set point and a change in secretion profile. J Bone Miner Res. 1994 May;9(5):621-9. doi: 10.1002/jbmr.5650090506. PMID: 8053390.
  32. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005 Feb;67(2):467-76. doi: 10.1111/j.1523-1755.2005.67103.x. PMID: 15673294.
  33. Miller G, Davis J, Shatzen E, Colloton M, Martin D, Henley CM. Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD. Nephrol Dial Transplant. 2012 Jun;27(6):2198-205. doi: 10.1093/ndt/gfr589. Epub 2011 Oct 29. PMID: 22036941; PMCID: PMC3363978.
  34. E Nylen, A Shah, J Hall. Spontaneous remission of primary hyperparathroidism from parathroid apoplexy. J. Clin. Endocrinol. Metab. 1996; 81: 1326–1328.
  35. Fukagawa M, Okazaki R, Takano K, Kaname S, Ogata E, Kitaoka M, Harada S, Sekine N, Matsumoto T, Kurokawa K. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med. 1990 Aug 9;323(6):421-2. doi: 10.1056/NEJM199008093230617. PMID: 2370898.
  36. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994 Jun;45(6):1710-21. doi: 10.1038/ki.1994.223. PMID: 7933819.
  37. Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, Kurokawa K. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron. 1994;68(2):221-8. doi: 10.1159/000188261. PMID: 7830860.
  38. Okuno S, Ishimura E, Kitatani K, Chou H, Nagasue K, Maekawa K, Izumotani T, Yamakawa T, Imanishi Y, Shoji T, Inaba M, Nishizawa Y. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2003 Dec;18(12):2613-21. doi: 10.1093/ndt/gfg451. PMID: 14605286.
  39. Martin KJ, Hruska KA, Lewis J, Anderson C, Slatopolsky E. The renal handling of parathyroid hormone. Role of peritubular uptake and glomerular filtration. J Clin Invest. 1977 Oct;60(4):808-14. doi: 10.1172/JCI108834. PMID: 893678; PMCID: PMC372428.
  40. Hilpert J, Nykjaer A, Jacobsen C, Wallukat G, Nielsen R, Moestrup SK, Haller H, Luft FC, Christensen EI, Willnow TE. Megalin antagonizes activation of the parathyroid hormone receptor. J Biol Chem. 1999 Feb 26;274(9):5620-5. doi: 10.1074/jbc.274.9.5620. PMID: 10026179.
  41. Freitag J, Martin KJ, Hruska KA, Anderson C, Conrades M, Ladenson J, Klahr S, Slatopolsky E. Impaired parathyroid hormone metabolism in patients with chronic renal failure. N Engl J Med. 1978 Jan 5;298(1):29-32. doi: 10.1056/NEJM197801052980107. PMID: 337145.
  42. Hruska KA, Kopelman R, Rutherford WE, Klahr S, Slatopolsky E, Greenwalt A, Bascom T, Markham J. Metabolism in immunoreactive parathyroid hormone in the dog. The role of the kidney and the effects of chronic renal disease. J Clin Invest. 1975 Jul;56(1):39-48. doi: 10.1172/JCI108077. PMID: 1141439; PMCID: PMC436553.
  43. Martin KJ, Hruska KA, Freitag JJ, Klahr S, Slatopolsky E. The peripheral metabolism of parathyroid hormone. N Engl J Med. 1979 Nov 15;301(20):1092-8. doi: 10.1056/NEJM197911153012005. PMID: 386126.
  44. Daugaard H, Egfjord M, Lewin E, Olgaard K. Metabolism of intact PTH by isolated perfused kidney and liver from uremic rats. Exp Nephrol. 1994 Jul-Aug;2(4):240-8. PMID: 8069660.
  45. Fukagawa M, Kazama JJ, Shigematsu T. Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S152-5. doi: 10.1053/ajkd.2001.27426. PMID: 11576943.
  46. Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, Kawaguchi Y, Gejyo F, Kurokawa K, Fukagawa M. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis. 2002 Mar;39(3):525-32. doi: 10.1053/ajkd.2002.31402. PMID: 11877571.
  47. Smogorzewski M, Tian J, Massry SG. Down-regulation of PTH-PTHrP receptor of heart in CRF: role of [Ca2+]i. Kidney Int. 1995 Apr;47(4):1182-6. doi: 10.1038/ki.1995.168. PMID: 7783417.
  48. Ureña P, Ferreira A, Morieux C, Drüeke T, de Vernejoul MC. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats. Nephrol Dial Transplant. 1996 Oct;11(10):2008-16. doi: 10.1093/oxfordjournals.ndt.a027089. PMID: 8918715.
  49. Ureña P, Kubrusly M, Mannstadt M, Hruby M, Trinh MM, Silve C, Lacour B, Abou-Samra AB, Segre GV, Drüeke T. The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int. 1994 Feb;45(2):605-11. doi: 10.1038/ki.1994.79. PMID: 8164450.
  50. Ureña P, Mannstadt M, Hruby M, Ferreira A, Schmitt F, Silve C, Ardaillou R, Lacour B, Abou-Samra AB, Segre GV, et al. Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats. Kidney Int. 1995 Jun;47(6):1797-805. doi: 10.1038/ki.1995.248. PMID: 7643551.
  51. Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ, Gokal R, Hoyland JA. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int. 2000 Oct;58(4):1440-9. doi: 10.1046/j.1523-1755.2000.00306.x. PMID: 11012879.
  52. Langub MC, Monier-Faugere MC, Qi Q, Geng Z, Koszewski NJ, Malluche HH. Parathyroid hormone/parathyroid hormone-related peptide type 1 receptor in human bone. J Bone Miner Res. 2001 Mar;16(3):448-56. doi: 10.1359/jbmr.2001.16.3.448. PMID: 11277262.
  53. Takenaka T, Inoue T, Miyazaki T, Hayashi M, Suzuki H. Xeno-Klotho Inhibits Parathyroid Hormone Signaling. J Bone Miner Res. 2016 Feb;31(2):455-62. doi: 10.1002/jbmr.2691. Epub 2015 Sep 11. PMID: 26287968.
  54. Drüeke TB, Lafage-Proust MH. Sclerostin: just one more player in renal bone disease? Clin J Am Soc Nephrol. 2011 Apr;6(4):700-3. doi: 10.2215/CJN.01370211. Epub 2011 Mar 24. PMID: 21441122.
  55. Sugatani T. Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder. Int J Mol Sci. 2018 Aug 23;19(9):2490. doi: 10.3390/ijms19092490. PMID: 30142896; PMCID: PMC6163495.
  56. Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D'Haese PC. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant. 2013 Dec;28(12):3024-30. doi: 10.1093/ndt/gft039. Epub 2013 Apr 19. PMID: 23605174.
  57. Drechsler C, Evenepoel P, Vervloet MG, Wanner C, Ketteler M, Marx N, Floege J, Dekker FW, Brandenburg VM; NECOSAD Study Group. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant. 2015 Feb;30(2):288-93. doi: 10.1093/ndt/gfu301. Epub 2014 Sep 23. PMID: 25248363.
  58. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005 Nov;146(11):4577-83. doi: 10.1210/en.2005-0239. Epub 2005 Aug 4. PMID: 16081646.
  59. Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. 2010 Feb;25(2):178-89. doi: 10.1359/jbmr.090730. PMID: 19594304; PMCID: PMC3153379.
  60. Fujita K, Roforth MM, Demaray S, McGregor U, Kirmani S, McCready LK, Peterson JM, Drake MT, Monroe DG, Khosla S. Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women. J Clin Endocrinol Metab. 2014 Jan;99(1):E81-8. doi: 10.1210/jc.2013-3249. Epub 2013 Dec 20. PMID: 24170101; PMCID: PMC3879677.
  61. Silva BC, Bilezikian JP. Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol. 2015 Jun;22:41-50. doi: 10.1016/j.coph.2015.03.005. Epub 2015 Apr 5. PMID: 25854704; PMCID: PMC5407089.
  62. Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011 Apr;6(4):877-82. doi: 10.2215/CJN.06550810. Epub 2010 Dec 16. PMID: 21164019; PMCID: PMC3069382.
  63. Lima F, Mawad H, El-Husseini AA, Davenport DL, Malluche HH. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
. Clin Nephrol. 2019 Apr;91(4):222-230. doi: 10.5414/CN109650. PMID: 30862350; PMCID: PMC6595397.
  64. Lima F, Mawad H, El-Husseini AA, Davenport DL, Malluche HH. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
. Clin Nephrol. 2019 Apr;91(4):222-230. doi: 10.5414/CN109650. PMID: 30862350; PMCID: PMC6595397.
  65. Yu M, Malik Tyagi A, Li JY, Adams J, Denning TL, Weitzmann MN, Jones RM, Pacifici R. PTH induces bone loss via microbial-dependent expansion of intestinal TNF+ T cells and Th17 cells. Nat Commun. 2020 Jan 24;11(1):468. doi: 10.1038/s41467-019-14148-4. PMID: 31980603; PMCID: PMC6981196.
  66. Massy ZA, Drueke TB. Gut microbiota orchestrates PTH action in bone: role of butyrate and T cells. Kidney Int. 2020 Aug;98(2):269-272. doi: 10.1016/j.kint.2020.03.004. Epub 2020 Mar 25. PMID: 32600825.
  67. Evenepoel P, Jørgensen HS. Skeletal parathyroid hormone hyporesponsiveness: a neglected, but clinically relevant reality in chronic kidney disease. Curr Opin Nephrol Hypertens. 2024 Jul 1;33(4):383-390. doi: 10.1097/MNH.0000000000000992. Epub 2024 Apr 23. PMID: 38651491.
  68. Komaba H, Imaizumi T, Hamano T, Fujii N, Abe M, Hanafusa N, Fukagawa M. Lower Parathyroid Hormone Levels are Associated With Reduced Fracture Risk in Japanese Patients on Hemodialysis. Kidney Int Rep. 2024 Jul 18;9(10):2956-2969. doi: 10.1016/j.ekir.2024.07.008. PMID: 39430172; PMCID: PMC11489479.
  69. Llach F. Calcific uremic arteriolopathy (calciphylaxis): an evolving entity. J Kidney Dis. 1998 Sep;32(3):514-8. doi: 10.1053/ajkd.1998.v32.pm9740172. PMID: 9740172.
  70. Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Clin J Am Soc Nephrol. 2015 May 7;10(5):800-7. doi: 10.2215/CJN.10221014. Epub 2015 Apr 17. PMID: 25887067; PMCID: PMC4422249.
  71. Viljoen A, Singh DK, Twomey PJ, Farrington K. Analytical quality goals for parathyroid hormone based on biological variation. Clin Chem Lab Med. 2008;46(10):1438-42. doi: 10.1515/CCLM.2008.275. PMID: 18844499.
  72. Barreto FC, Barreto DV, Moysés RM, Neves KR, Canziani ME, Draibe SA, Jorgetti V, Carvalho AB. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008 Mar;73(6):771-7. doi: 10.1038/sj.ki.5002769. Epub 2008 Jan 9. PMID: 18185506.
  73. Solal ME, Sebert JL, Boudailliez B, Marie A, Moriniere P, Gueris J, Bouillon R, Fournier A. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab. 1991 Sep;73(3):516-24. doi: 10.1210/jcem-73-3-516. PMID: 1874930.
  74. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab. 1992 Jul;75(1):145-50. doi: 10.1210/jcem.75.1.1619003. PMID: 1619003.
  75. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis. 1995 Nov;26(5):836-44. doi: 10.1016/0272-6386(95)90453-0. PMID: 7485142.
  76. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barré M, D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab. 1996 Nov;81(11):3923-9. doi: 10.1210/jcem.81.11.8923839. PMID: 8923839.
  77. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, D'Amour P. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem. 1998 Apr;44(4):805-9. PMID: 9554492.
  78. Langub MC, Monier-Faugere MC, Wang G, Williams JP, Koszewski NJ, Malluche HH. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology. 2003 Apr;144(4):1135-8. doi: 10.1210/en.2002-221026. PMID: 12639892.
  79. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006 Jul;70(2):345-50. doi: 10.1038/sj.ki.5001606. Epub 2006 Jun 21. PMID: 16788691.
  80. Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, Massart C, Moe SM, Monge M, Souberbielle JC. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis. 2008 Jun;51(6):987-95. doi: 10.1053/j.ajkd.2008.01.017. Epub 2008 Apr 8. Erratum in: Am J Kidney Dis. 2008 Jul;52(1):199. PMID: 18430500.
  81. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab. 1999 Nov;84(11):4287-90. doi: 10.1210/jcem.84.11.6236. PMID: 10566687.
  82. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001 Oct;60(4):1460-8. doi: 10.1046/j.1523-1755.2001.00949.x. PMID: 11576360.
  83. Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA, Fischer MS, Lifrieri F, Manni M, Morosetti M, Moscaritolo E, Sardella D. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis. 2002 Aug;40(2):348-54. doi: 10.1053/ajkd.2002.34519. PMID: 12148108.
  84. Reichel H, Esser A, Roth HJ, Schmidt-Gayk H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003; 18: 759–768.
  85. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, Wang HJ, Elashoff RM, Jüppner H. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 2003 May;63(5):1801-8. doi: 10.1046/j.1523-1755.2003.00915.x. PMID: 12675856.
  86. Tepel M, Armbruster FP, Grön HJ, Scholze A, Reichetzeder C, Roth HJ, Hocher B. Nonoxidized, biologically active parathyroid hormone determines mortality in hemodialysis patients. J Clin Endocrinol Metab. 2013 Dec;98(12):4744-51. doi: 10.1210/jc.2013-2139. Epub 2013 Oct 30. PMID: 24171919.
  87. Seiler-Mussler S, Limbach AS, Emrich IE, Pickering JW, Roth HJ, Fliser D, Heine GH. Association of Nonoxidized Parathyroid Hormone with Cardiovascular and Kidney Disease Outcomes in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2018 Apr 6;13(4):569-576. doi: 10.2215/CJN.06620617. Epub 2018 Mar 5. PMID: 29507005; PMCID: PMC5968904.
  88. Vervloet MG, van Ballegooijen AJ. Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int. 2018 May;93(5):1060-1072. doi: 10.1016/j.kint.2017.11.036. Epub 2018 Mar 23. PMID: 29580635.
  89. Ursem SR, Heijboer AC, D'Haese PC, Behets GJ, Cavalier E, Vervloet MG, Evenepoel P. Non-oxidized parathyroid hormone (PTH) measured by current method is not superior to total PTH in assessing bone turnover in chronic kidney disease. Kidney Int. 2021 May;99(5):1173-1178. doi: 10.1016/j.kint.2020.12.024. Epub 2021 Jan 8. PMID: 33422551.
  90. Drüeke TB, Floege J. Parathyroid hormone oxidation in chronic kidney disease: clinical relevance? Kidney Int. 2021 May;99(5):1070-1072. doi: 10.1016/j.kint.2021.01.019. PMID: 33892858.
  91. Cavalier E, Farré-Segura J, Lukas P, Gendebien AS, Peeters S, Massonnet P, Le Goff C, Bouquegneau A, Souberbielle JC, Delatour V, Delanaye P. Unveiling a new era with liquid chromatography coupled with mass spectrometry to enhance parathyroid hormone measurement in patients with chronic kidney disease. Kidney Int. 2024 Feb;105(2):338-346. doi: 10.1016/j.kint.2023.09.033. Epub 2023 Oct 31. PMID: 37918791.
  92. Ulmer CZ, Kritmetapak K, Singh RJ, Vesper HW, Kumar R. High-Resolution Mass Spectrometry for the Measurement of PTH and PTH Fragments: Insights into PTH Physiology and Bioactivity. J Am Soc Nephrol. 2022 Aug;33(8):1448-1458. doi: 10.1681/ASN.2022010036. Epub 2022 Apr 8. PMID: 35396262; PMCID: PMC9342634.
  93. Nakagawa Y, Komaba H. Standardization of PTH measurement by LC-MS/MS: a promising solution for interassay variability. Kidney Int. 2024 Feb;105(2):244-247. doi: 10.1016/j.kint.2023.11.020. PMID: 38245214.
  94. Drüeke TB, Fukagawa M. Whole or fragmentary information on parathyroid hormone? Clin J Am Soc Nephrol. 2007 Nov;2(6):1106-7. doi: 10.2215/CJN.03140707. Epub 2007 Oct 10. PMID: 17928465.
  95. Amann K. Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol. 2008 Nov;3(6):1599-605. doi: 10.2215/CJN.02120508. Epub 2008 Sep 24. PMID: 18815240.
  96. Bellasi A, Raggi P. Techniques and technologies to assess vascular calcification. Semin Dial. 2007 Mar-Apr;20(2):129-33. doi: 10.1111/j.1525-139X.2007.00259.x. PMID: 17374086.
  97. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003 Sep;18(9):1731-40. doi: 10.1093/ndt/gfg414. PMID: 12937218.
  98. Rostand SG, Drüeke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 1999 Aug;56(2):383-92. doi: 10.1046/j.1523-1755.1999.00575.x. PMID: 10432376.
  99. Tsuchihashi K, Takizawa H, Torii T, Ikeda R, Nakahara N, Yuda S, Kobayashi N, Nakata T, Ura N, Shimamoto K. Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism: possible risk of vitamin D(3) analog administration in dialysis patients with end-stage renal disease. Nephron. 2000 Jan;84(1):13-20. doi: 10.1159/000045533. PMID: 10644903.
  100. Galassi A, Spiegel DM, Bellasi A, Block GA, Raggi P. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrol Dial Transplant. 2006 Nov;21(11):3215-22. doi: 10.1093/ndt/gfl395. Epub 2006 Jul 28. PMID: 16877490.
  101. Sebastian EM, Suva LJ, Friedman PA. Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure. Bone. 2008 Dec;43(6):1022-30. doi: 10.1016/j.bone.2008.07.250. Epub 2008 Aug 9. PMID: 18761112; PMCID: PMC2644420.
  102. Shao JS, Cheng SL, Charlton-Kachigian N, Loewy AP, Towler DA. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem. 2003 Dec 12;278(50):50195-202. doi: 10.1074/jbc.M308825200. Epub 2003 Sep 22. PMID: 14504275.
  103. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007 Aug 30;357(9):905-16. doi: 10.1056/NEJMra067395. PMID: 17761594.
  104. Drüeke TB, Ritz E. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol. 2009 Jan;4(1):234-41. doi: 10.2215/CJN.04520908. Epub 2008 Dec 3. PMID: 19056615.
  105. Malluche HH, Mawad H, Monier-Faugere MC. Effects of treatment of renal osteodystrophy on bone histology. Clin J Am Soc Nephrol. 2008 Nov;3 Suppl 3(Suppl 3):S157-63. doi: 10.2215/CJN.02500607. PMID: 18988701; PMCID: PMC3152281.
  106. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201. PMID: 14520607.
  107. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009 Aug;(113):S1-130. doi: 10.1038/ki.2009.188. PMID: 19644521.
  108. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017 Jul;92(1):26-36. doi: 10.1016/j.kint.2017.04.006. Erratum in: Kidney Int. 2017 Dec;92(6):1558. doi: 10.1016/j.kint.2017.10.001. PMID: 28646995.
  109. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB. Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann Intern Med. 2018 Mar 20;168(6):422-430. doi: 10.7326/M17-2640. Epub 2018 Feb 20. PMID: 29459980.
  110. Ketteler M, Evenepoel P, Holden RM, Isakova T, Jørgensen HS, Komaba H, Nickolas TL, Sinha S, Vervloet MG, Cheung M, King JM, Grams ME, Jadoul M, Moysés RMA; Conference Participants. Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025 Jan 10:S0085-2538(24)00810-X. doi: 10.1016/j.kint.2024.11.013. Epub ahead of print. PMID: 39864017.
  111. Bhan I, Thadhani R. Vitamin D therapy for chronic kidney disease. Semin Nephrol. 2009 Jan;29(1):85-93. doi: 10.1016/j.semnephrol.2008.10.010. PMID: 19121478.
  112. Kooienga L, Fried L, Scragg R, Kendrick J, Smits G, Chonchol M. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kidney Dis. 2009 Mar;53(3):408-16. doi: 10.1053/j.ajkd.2008.09.020. Epub 2009 Jan 29. PMID: 19185400.
  113. Jean G, Souberbielle JC, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant. 2009 Dec;24(12):3799-805. doi: 10.1093/ndt/gfp370. Epub 2009 Jul 21. PMID: 19622574.
  114. Agarwal R, Georgianos PI. Con: Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant. 2016 May;31(5):706-13. doi: 10.1093/ndt/gfw080. Erratum in: Nephrol Dial Transplant. 2021 Feb 20;36(3):566-567. doi: 10.1093/ndt/gfaa172. PMID: 27190392.
  115. Goldsmith DJ. Pro: Should we correct vitamin D deficiency/insufficiency in chronic kidney disease patients with inactive forms of vitamin D or just treat them with active vitamin D forms? Nephrol Dial Transplant. 2016 May;31(5):698-705. doi: 10.1093/ndt/gfw082. PMID: 27190390.
  116. Drüeke TB. Calcimimetics versus vitamin D: what are their relative roles? Blood Purif. 2004;22(1):38-43. doi: 10.1159/000074922. PMID: 14732810.
  117. Hansen D, Rasmussen K, Danielsen H, Meyer-Hofmann H, Bacevicius E, Lauridsen TG, Madsen JK, Tougaard BG, Marckmann P, Thye-Roenn P, Nielsen JE, Kreiner S, Brandi L. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int. 2011 Oct;80(8):841-50. doi: 10.1038/ki.2011.226. Epub 2011 Aug 10. PMID: 21832979.
  118. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003 Jul 31;349(5):446-56. doi: 10.1056/NEJMoa022536. PMID: 12890843.
  119. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol. 2008 Aug;19(8):1613-9. doi: 10.1681/ASN.2007111164. Epub 2008 May 7. PMID: 18463168; PMCID: PMC2488261.
  120. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004 Jan;19(1):179-84. doi: 10.1093/ndt/gfg513. PMID: 14671054.
  121. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Amer Soc Nephrol 2005; 16: 1115–1125.
  122. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiv-ing different vitamin D analogs. Kidney Int 2006; 70: 1858–1865.
  123. Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, Akiba T, Greenwood RN, Kimata N, Levin NW, Piera LM, Saran R, Wolfe RA, Port FK. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2009 Mar;24(3):963-72. doi: 10.1093/ndt/gfn592. Epub 2008 Nov 21. PMID: 19028748.
  124. Drüeke TB, McCarron DA. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. N Engl J Med. 2003 Jul 31;349(5):496-9. doi: 10.1056/NEJMe038104. PMID: 12890849.
  125. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993 Dec 9;366(6455):575-80. doi: 10.1038/366575a0. PMID: 8255296.
  126. Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int. 1998 Jan;53(1):223-7. doi: 10.1046/j.1523-1755.1998.00735.x. PMID: 9453023.
  127. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int. 2000 Jul;58(1):436-45. doi: 10.1046/j.1523-1755.2000.00183.x. PMID: 10886592.
  128. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol. 2002 Apr;13(4):1017-1024. doi: 10.1681/ASN.V1341017. PMID: 11912261.
  129. Ivanovski O, Nikolov IG, Joki N, Caudrillier A, Phan O, Mentaverri R, Maizel J, Hamada Y, Nguyen-Khoa T, Fukagawa M, Kamel S, Lacour B, Drüeke TB, Massy ZA. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis. 2009 Jul;205(1):55-62. doi: 10.1016/j.atherosclerosis.2008.10.043. Epub 2008 Nov 18. PMID: 19118829.
  130. Basile C, Lomonte C. The function of the parathyroid oxyphil cells in uremia: still a mystery? Kidney Int. 2017 Nov;92(5):1046-1048. doi: 10.1016/j.kint.2017.06.024. PMID: 29055426.
  131. Lomonte C, Vernaglione L, Chimienti D, Bruno A, Cocola S, Teutonico A, Cazzato F, Basile C. Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism? Clin J Am Soc Nephrol. 2008 May;3(3):794-9. doi: 10.2215/CJN.04150907. Epub 2008 Mar 5. PMID: 18322048; PMCID: PMC2386693.
  132. Ritter C, Miller B, Coyne DW, Gupta D, Zheng S, Brown AJ, Slatopolsky E. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease. Kidney Int. 2017 Nov;92(5):1217-1222. doi: 10.1016/j.kint.2017.05.003. Epub 2017 Jul 24. PMID: 28750928.
  133. Ritter CS, Haughey BH, Miller B, Brown AJ. Differential gene expression by oxyphil and chief cells of human parathyroid glands. J Clin Endocrinol Metab. 2012 Aug;97(8):E1499-505. doi: 10.1210/jc.2011-3366. Epub 2012 May 14. PMID: 22585091; PMCID: PMC3591682.
  134. Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriguez M. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol. 2006 Mar;17(3):795-804. doi: 10.1681/ASN.2005040342. Epub 2006 Feb 8. PMID: 16467452.
  135. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J; ADVANCE Study Group. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011 Apr;26(4):1327-39. doi: 10.1093/ndt/gfq725. Epub 2010 Dec 8. PMID: 21148030.
  136. Koleganova N, Piecha G, Ritz E, Schmitt CP, Gross ML. A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int. 2009 Jan;75(1):60-71. doi: 10.1038/ki.2008.490. Epub 2008 Oct 1. PMID: 19092814.
  137. Koleganova N, Piecha G, Ritz E, Bekeredjian R, Schirmacher P, Schmitt CP, Gross ML. Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calcimimetic. Lab Invest. 2009 May;89(5):520-30. doi: 10.1038/labinvest.2009.7. Epub 2009 Feb 2. PMID: 19188910.
  138. Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int. 2008 Feb;73(3):300-7. doi: 10.1038/sj.ki.5002675. Epub 2007 Nov 14. PMID: 18004298.
  139. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004 Apr 8;350(15):1516-25. doi: 10.1056/NEJMoa031633. PMID: 15071126.
  140. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003 Jan;63(1):248-54. doi: 10.1046/j.1523-1755.2003.00720.x. PMID: 12472790.
  141. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003 Mar;14(3):575-83. doi: 10.1097/01.asn.0000050224.03126.ad. PMID: 12595492.
  142. Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Dehmel B, Trotman ML, Modafferi DM, Goodman WG. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J Clin Endocrinol Metab. 2013 Dec;98(12):4834-44. doi: 10.1210/jc.2013-2975. Epub 2013 Oct 9. PMID: 24108314.
  143. EVOLVE Trial Investigators; Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3. PMID: 23121374.
  144. Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinsky DA; TARGET Investigators. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2008 Jul;23(7):2311-8. doi: 10.1093/ndt/gfn026. Epub 2008 Feb 29. PMID: 18310602.
  145. Wilkie M, Pontoriero G, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Zani VJ, Carter D, Messa P. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet. Nephron Clin Pract. 2009;112(1):c41-50. doi: 10.1159/000212102. Epub 2009 Apr 10. PMID: 19365139.
  146. Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Mix TC, Moe SM, Patel UD, Silver J, Spiegel DM, Sterling L, Walsh L, Chertow GM. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA. 2017 Jan 10;317(2):146-155. doi: 10.1001/jama.2016.19456. PMID: 28097355.
  147. Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017 Jan 10;317(2):156-164. doi: 10.1001/jama.2016.19468. PMID: 28097356.
  148. Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drüeke TB; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol. 2015 Jun;26(6):1466-75. doi: 10.1681/ASN.2014040414. Epub 2014 Dec 11. PMID: 25505257; PMCID: PMC4446874.
  149. Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K, Oprisiu R, Bonne JF, Monge M, El Esper N, Presne C, Moriniere P, Choukroun G, Fournier A. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Semin Dial. 2005 May-Jun;18(3):226-38. doi: 10.1111/j.1525-139X.2005.18318.x. PMID: 15934970.
  150. Cannata Andia JB. Adynamic bone and chronic renal failure: an overview. Am J Med Sci 2000; 320: 81–84.
  151. Argilés A, Kerr PG, Canaud B, Flavier JL, Mion C. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int. 1993 Mar;43(3):630-40. doi: 10.1038/ki.1993.92. PMID: 8455362.
  152. Arenas MD, Alvarez-Ude F, Gil MT, Soriano A, Egea JJ, Millán I, Amoedo ML, Muray S, Carretón MA. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant. 2006 Jun;21(6):1663-8. doi: 10.1093/ndt/gfl006. Epub 2006 Feb 7. PMID: 16464885.
  153. Basile C, Libutti P, Di Turo AL, Vernaglione L, Casucci F, Losurdo N, Teutonico A, Lomonte C. Effect of dialysate calcium concentrations on parathyroid hormone and calcium balance during a single dialysis session using bicarbonate hemodialysis: a crossover clinical trial. Am J Kidney Dis. 2012 Jan;59(1):92-101. doi: 10.1053/j.ajkd.2011.08.033. Epub 2011 Oct 14. PMID: 22000728.
  154. Sonikian M, Metaxaki P, Karatzas I, Vlassopoulos D. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients on sevelamer hydrochloride: which dialysate calcium concentration to use? Blood Purif. 2009;27(2):182-6. doi: 10.1159/000190785. Epub 2009 Jan 14. PMID: 19141997.
  155. Touam M, Menoyo V, Attaf D, Thebaud HE, Drüeke TB. High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism. Kidney Int. 2005 May;67(5):2065; author reply 2065-6. doi: 10.1111/j.1523-1755.2005.310_1.x. PMID: 15840060.
  156. Drüeke TB, Touam M. Calcium balance in haemodialysis--do not lower the dialysate calcium concentration too much (con part). Nephrol Dial Transplant. 2009 Oct;24(10):2990-3. doi: 10.1093/ndt/gfp365. Epub 2009 Aug 7. PMID: 19666667.
  157. Pun PH, Horton JR, Middleton JP. Dialysate calcium concentration and the risk of sudden cardiac arrest in hemodialysis patients. Clin J Am Soc Nephrol. 2013 May;8(5):797-803. doi: 10.2215/CJN.10000912. Epub 2013 Jan 31. PMID: 23371957; PMCID: PMC3641623.
  158. Pun PH, Lehrich RW, Honeycutt EF, Herzog CA, Middleton JP. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int. 2011 Jan;79(2):218-27. doi: 10.1038/ki.2010.315. Epub 2010 Sep 1. PMID: 20811332.
  159. Cunningham J, Beer J, Coldwell RD, Noonan K, Sawyer N, Makin HL. Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol. Nephrol Dial Transplant. 1992;7(1):63-8. PMID: 1316583.
  160. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis. 1997 Jan;29(1):66-71. doi: 10.1016/s0272-6386(97)90009-3. PMID: 9002531.
  161. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002 Jul;62(1):245-52. doi: 10.1046/j.1523-1755.2002.00434.x. PMID: 12081584.
  162. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 1999 Jan;55(1):299-307. doi: 10.1046/j.1523-1755.1999.00240.x. PMID: 9893140.
  163. Delmez J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M, Bleyer AJ. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol. 2007 Dec;68(6):386-91. doi: 10.5414/cnp68386. PMID: 18184521.
  164. Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, Heaton J, Duggal A, Kalra PA. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008 Jul;3(4):1125-30. doi: 10.2215/CJN.05161107. Epub 2008 May 1. PMID: 18450923; PMCID: PMC2440270.
  165. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl. 2003 Jun;(85):S73-8. doi: 10.1046/j.1523-1755.63.s85.18.x. PMID: 12753271.
  166. Hutchison AJ. Oral phosphate binders. Kidney Int. 2009 May;75(9):906-14. doi: 10.1038/ki.2009.60. Epub 2009 Mar 11. PMID: 19279554.
  167. Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA; SPD405-309 Lanthanum Study Group. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract. 2008;110(1):c15-23. doi: 10.1159/000149239. Epub 2008 Jul 31. Erratum in: Nephron Clin Pract. 2008;110(1):c23. PMID: 18667837; PMCID: PMC2790759.
  168. Sprague SM, Ketteler M. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Drug Saf. 2021 Dec;20(12):1463-1472. doi: 10.1080/14740338.2021.1978973. Epub 2021 Oct 22. PMID: 34511018.
  169. Choi YJ, Noh Y, Shin S. Ferric citrate in the management of hyperphosphataemia and iron deficiency anaemia: A meta-analysis in patients with chronic kidney disease. Br J Clin Pharmacol. 2021 Feb;87(2):414-426. doi: 10.1111/bcp.14396. Epub 2020 Jun 17. PMID: 32470149.
  170. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007 Mar;71(5):438-41. doi: 10.1038/sj.ki.5002059. Epub 2007 Jan 3. PMID: 17200680.
  171. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012 Aug;23(8):1407-15. doi: 10.1681/ASN.2012030223. Epub 2012 Jul 19. PMID: 22822075; PMCID: PMC3402292.
  172. Drüeke TB, Massy ZA. Phosphate binders in CKD: bad news or good news? J Am Soc Nephrol. 2012 Aug;23(8):1277-80. doi: 10.1681/ASN.2012060569. Epub 2012 Jul 12. PMID: 22797178.
  173. Neven E, Dams G, Postnov A, Chen B, De Clerck N, De Broe ME, D'Haese PC, Persy V. Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats. Nephrol Dial Transplant. 2009 Jun;24(6):1790-9. doi: 10.1093/ndt/gfn737. Epub 2009 Jan 14. PMID: 19144999.
  174. Nikolov IG, Joki N, Nguyen-Khoa T, Guerrera IC, Maizel J, Benchitrit J, Machado dos Reis L, Edelman A, Lacour B, Jorgetti V, Drüeke TB, Massy ZA. Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transplant. 2012 Feb;27(2):505-13. doi: 10.1093/ndt/gfr254. Epub 2011 Jun 24. PMID: 21705467.
  175. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology (Carlton). 2011 Mar;16(3):290-8. doi: 10.1111/j.1440-1797.2010.01412.x. PMID: 21342323.
  176. Ohtake T, Kobayashi S, Oka M, Furuya R, Iwagami M, Tsutsumi D, Mochida Y, Maesato K, Ishioka K, Moriya H, Hidaka S. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study. J Cardiovasc Pharmacol Ther. 2013 Sep;18(5):439-46. doi: 10.1177/1074248413486355. Epub 2013 Apr 23. PMID: 23615577.
  177. Seifert ME, de las Fuentes L, Rothstein M, Dietzen DJ, Bierhals AJ, Cheng SC, Ross W, Windus D, Dávila-Román VG, Hruska KA. Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. Am J Nephrol. 2013;38(2):158-67. doi: 10.1159/000353569. Epub 2013 Aug 7. PMID: 23941761; PMCID: PMC3874122.
  178. Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH; Sevelamer Study Group. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008 Feb;19(2):405-12. doi: 10.1681/ASN.2006101089. Epub 2008 Jan 16. PMID: 18199805; PMCID: PMC2396748.
  179. Barreto DV, Barreto Fde C, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME. Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study. Nephron Clin Pract. 2008;110(4):c273-83. doi: 10.1159/000170783. Epub 2008 Nov 12. PMID: 19001830.
  180. Lenglet A, Liabeuf S, El Esper N, Brisset S, Mansour J, Lemaire-Hurtel AS, Mary A, Brazier M, Kamel S, Mentaverri R, Choukroun G, Fournier A, Massy ZA. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant. 2017 May 1;32(5):870-879. doi: 10.1093/ndt/gfw042. PMID: 27190329.
  181. Lenglet A, Liabeuf S, Guffroy P, Fournier A, Brazier M, Massy ZA. Use of nicotinamide to treat hyperphosphatemia in dialysis patients. Drugs R D. 2013 Sep;13(3):165-73. doi: 10.1007/s40268-013-0024-6. PMID: 24000048; PMCID: PMC3784056.
  182. Malhotra R, Katz R, Hoofnagle A, Bostom A, Rifkin DE, Mcbride R, Probstfield J, Block G, Ix JH. The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD. Clin J Am Soc Nephrol. 2018 Jan 6;13(1):36-44. doi: 10.2215/CJN.05440517. Epub 2017 Dec 5. PMID: 29208626; PMCID: PMC5753310.
  183. Pergola PE, Rosenbaum DP, Yang Y, Chertow GM. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY). J Am Soc Nephrol. 2021 Jun 1;32(6):1465-1473. doi: 10.1681/ASN.2020101398. Epub 2021 Mar 25. PMID: 33766811; PMCID: PMC8259655.
  184. Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Åstrand M, Johansson S, Knutsson M, Langkilde AM, Chertow GM. Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis. J Am Soc Nephrol. 2017 Jun;28(6):1933-1942. doi: 10.1681/ASN.2016080855. Epub 2017 Feb 3. PMID: 28159782; PMCID: PMC5461797.
  185. Drüeke TB, Massy ZA. Lowering Expectations with Niacin Treatment for CKD-MBD. Clin J Am Soc Nephrol. 2018 Jan 6;13(1):6-8. doi: 10.2215/CJN.12021017. Epub 2017 Dec 5. PMID: 29208625; PMCID: PMC5753325.
  186. D'Alessandro C, Piccoli GB, Cupisti A. The "phosphorus pyramid": a visual tool for dietary phosphate management in dialysis and CKD patients. BMC Nephrol. 2015 Jan 20;16:9. doi: 10.1186/1471-2369-16-9. PMID: 25603926; PMCID: PMC4361095.
  187. Lorenzo V, Martin M, Rufino M et al. Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients. Am J Kidney Dis 2001; 37: 1260–1266.
  188. Shinaberger CS, Greenland S, Kopple JD, Van Wyck D, Mehrotra R, Kovesdy CP, Kalantar-Zadeh K. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008 Dec;88(6):1511-8. doi: 10.3945/ajcn.2008.26665. PMID: 19064510; PMCID: PMC5500249.
  189. Lefebvre A, de Vernejoul MC, Gueris J, Goldfarb B, Graulet AM, Morieux C. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int. 1989 Dec;36(6):1112-8. doi: 10.1038/ki.1989.309. PMID: 2557481.
  190. Graham KA, Hoenich NA, Tarbit M, Ward MK, Goodship TH. Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. J Am Soc Nephrol. 1997 Apr;8(4):627-31. doi: 10.1681/ASN.V84627. PMID: 10495792.
  191. Giangrande A, Castiglioni A, Solbiati L, Allaria P. Ultrasound-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant. 1992;7(5):412-21. PMID: 1321377.
  192. Kitaoka M, Fukagawa M, Ogata E, Kurokawa K. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int. 1994 Oct;46(4):1110-7. doi: 10.1038/ki.1994.373. PMID: 7861705.
  193. Shiizaki K, Hatamura I, Negi S, Narukawa N, Mizobuchi M, Sakaguchi T, Ooshima A, Akizawa T. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int. 2003 Sep;64(3):992-1003. doi: 10.1046/j.1523-1755.2003.00154.x. PMID: 12911549.
  194. Shiizaki K, Negi S, Hatamura I, Sakaguchi T, Saji F, Kunimoto K, Mizobuchi M, Imazeki I, Ooshima A, Akizawa T. Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats. J Am Soc Nephrol. 2005 Jan;16(1):97-108. doi: 10.1681/ASN.2004030236. Epub 2004 Dec 1. PMID: 15574509.
  195. Fletcher S, Kanagasundaram NS, Rayner HC, Irving HC, Fowler RC, Brownjohn AM, Turney JH, Will EJ, Davison AM. Assessment of ultrasound guided percutaneous ethanol injection and parathyroidectomy in patients with tertiary hyperparathyroidism. Nephrol Dial Transplant. 1998 Dec;13(12):3111-7. doi: 10.1093/ndt/13.12.3111. PMID: 9870475.
  196. de Barros Gueiros JE, Chammas MC, Gerhard R, da Silva Dias Boilesen CF, de Oliveira IR, Moysés RM, Jorgetti V. Percutaneous ethanol (PEIT) and calcitrol (PCIT) injection therapy are ineffective in treating severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2004 Mar;19(3):657-63. doi: 10.1093/ndt/gfg586. PMID: 14767023.
  197. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004 Nov;44(5 Suppl 2):34-8. doi: 10.1053/j.ajkd.2004.08.009. PMID: 15486872.
  198. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008 Sep;3(5):1423-9. doi: 10.2215/CJN.01060308. Epub 2008 Jul 2. PMID: 18596117; PMCID: PMC2518803.
  199. Fouque D, Roth H, Darné B, Jean-Bouchet L, Daugas E, Drüeke TB, Hannedouche T, Jean G, London GM; French Phosphorus and Calcium Observatory. Achievement of Kidney Disease: Improving Global Outcomes mineral and bone targets between 2010 and 2014 in incident dialysis patients in France: the Photo-Graphe3 study. Clin Kidney J. 2018 Feb;11(1):73-79. doi: 10.1093/ckj/sfx101. Epub 2017 Sep 23. PMID: 29423206; PMCID: PMC5798128.
  200. Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the Management of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2018 Jun 7;13(6):952-961. doi: 10.2215/CJN.10390917. Epub 2018 Mar 9. PMID: 29523679; PMCID: PMC5989682.
  201. Hindié E, Urenã P, Jeanguillaume C, Mellière D, Berthelot JM, Menoyo-Calonge V, Chiappini-Briffa D, Janin A, Galle P. Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism. Lancet. 1999 Jun 26;353(9171):2200-4. doi: 10.1016/S0140-6736(98)09089-8. PMID: 10392985.
  202. Hindié E, Urenã P, Jeanguillaume C, Mellière D, Berthelot JM, Menoyo-Calonge V, Chiappini-Briffa D, Janin A, Galle P. Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism. Lancet. 1999 Jun 26;353(9171):2200-4. doi: 10.1016/S0140-6736(98)09089-8. PMID: 10392985.
  203. Michaud L, Balogova S, Burgess A, Ohnona J, Huchet V, Kerrou K, Lefèvre M, Tassart M, Montravers F, Périé S, Talbot JN. A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism: Influence of Thyroid Anomalies. Medicine (Baltimore). 2015 Oct;94(41):e1701. doi: 10.1097/MD.0000000000001701. PMID: 26469908; PMCID: PMC4616781.
  204. Chen YH, Chen HT, Lee MC, Liu SH, Wang LY, Lue KH, Chan SC. Preoperative F-18 fluorocholine PET/CT for the detection of hyperfunctioning parathyroid glands in patients with secondary or tertiary hyperparathyroidism: comparison with Tc-99m sestamibi scan and neck ultrasound. Ann Nucl Med. 2020 Aug;34(8):527-537. doi: 10.1007/s12149-020-01479-2. Epub 2020 May 20. PMID: 32436180.
  205. Gagné ER, Ureña P, Leite-Silva S, Zingraff J, Chevalier A, Sarfati E, Dubost C, Drüeke TB. Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol. 1992 Oct;3(4):1008-17. doi: 10.1681/ASN.V341008. PMID: 1450363.
  206. Stracke S, Keller F, Steinbach G, Henne-Bruns D, Wuerl P. Long-term outcome after total parathyroidectomy for the management of secondary hyperparathyroidism. Nephron Clin Pract. 2009;111(2):c102-9. doi: 10.1159/000191200. Epub 2009 Jan 13. PMID: 19142022.
  207. Drüeke TB, Zingraff J. The dilemma of parathyroidectomy in chronic renal failure. Curr Opin Nephrol Hypertens. 1994 Jul;3(4):386-95. doi: 10.1097/00041552-199407000-00004. PMID: 8076142.
  208. Locatelli F, Cannata-Andía JB, Drüeke TB, Hörl WH, Fouque D, Heimburger O, Ritz E. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant. 2002 May;17(5):723-31. doi: 10.1093/ndt/17.5.723. PMID: 11981055.
  209. Stratton J, Simcock M, Thompson H, Farrington K. Predictors of recurrent hyperparathyroidism after total parathyroidectomy in chronic renal failure. Nephron Clin Pract. 2003;95(1):c15-22. doi: 10.1159/000073014. PMID: 14520017.
  210. Malberti F, Marcelli D, Conte F, Limido A, Spotti D, Locatelli F. Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol. 2001 Jun;12(6):1242-1248. doi: 10.1681/ASN.V1261242. PMID: 11373348.
  211. Kim SM, Long J, Montez-Rath ME, Leonard MB, Norton JA, Chertow GM. Rates and Outcomes of Parathyroidectomy for Secondary Hyperparathyroidism in the United States. Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1260-1267. doi: 10.2215/CJN.10370915. Epub 2016 Jun 6. PMID: 27269300; PMCID: PMC4934842.
  212. Lafrance JP, Cardinal H, Leblanc M, Madore F, Pichette V, Roy L, Le Lorier J. Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends. BMC Nephrol. 2013 May 3;14:100. doi: 10.1186/1471-2369-14-100. PMID: 23642012; PMCID: PMC3648401.
  213. Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, Andreucci VE, Fukagawa M, Frimat L, Mendelssohn DC, Port FK, Pisoni RL, Robinson BM. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015 Jan 7;10(1):98-109. doi: 10.2215/CJN.12941213. Epub 2014 Dec 16. PMID: 25516917; PMCID: PMC4284424.
  214. Kestenbaum B, Seliger SL, Gillen DL, Wasse H, Young B, Sherrard DJ, Weiss NS, Stehman-Breen CO. Parathyroidectomy rates among United States dialysis patients: 1990-1999. Kidney Int. 2004 Jan;65(1):282-8. doi: 10.1111/j.1523-1755.2004.00368.x. PMID: 14675061.
  215. Kim WW, Rhee Y, Kim BS, Kim K, Lee CR, Kang SW, Lee J, Jeong JJ, Nam KH, Chung WY. Clinical outcomes of parathyroidectomy versus cinacalcet in the clinical management of secondary hyperparathyroidism. Endocr J. 2019 Oct 28;66(10):881-889. doi: 10.1507/endocrj.EJ19-0036. Epub 2019 Jun 12. PMID: 31189770.
  216. Komaba H, Hamano T, Fujii N, Moriwaki K, Wada A, Masakane I, Nitta K, Fukagawa M. Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis. J Clin Endocrinol Metab. 2022 Jun 16;107(7):2016-2025. doi: 10.1210/clinem/dgac142. PMID: 35277957.

Adrenocortical Carcinoma

ABSTRACT

 

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy arising from the adrenal cortex often with unexpected biological behavior. It can occur at any age, with two peaks of incidence: in the first and between the fifth and seventh decades of life. Although ACC are mostly hormonally active, precursors and metabolites may also be produced by dedifferentiated and immature malignant cells. Distinguishing the etiology of an adrenal mass between benign adenomas, which are quite frequent in the general population, and malignant carcinomas with dismal prognosis is challenging. However, recent advances in genomic pathology and staging allow the development of standardization of pathology reporting and refinement of prognostic grouping for planning the treatment of patients with ACC. No single histopathological, as well as no single imaging method, hormonal work-up, or immunohistochemical labelling, can definitively prove the diagnosis of ACC. Over several decades great efforts have been made to find novel reliable and available diagnostic and prognostic factors including steroid metabolome profiling or target gene identification. Preliminary data show that for localized ACC, molecular markers (gene expression, methylation, and chromosome alterations) could predict cancer recurrence. Nevertheless, many of these markers need further validation and some are difficult to be widely applied in clinical settings. The development of new prognostic tools highlights the need for early identification of high-risk ACC patients who could benefit from individualized management. ACC is frequently diagnosed in advanced stages and therapeutic options are unfortunately limited. The management of patients with ACC requires a multidisciplinary approach. Surgery remains the “gold standard’ treatment whereas a number of systemic therapies including chemotherapy is administered in patients with extensive not amenable to surgical resection disease. Recently, immunotherapy in advanced ACC has also been investigated in different studies. However, the reported rates of overall response rate and progression-free survival (PFS) were generally poor. Thus, new biological markers that could predict patient prognosis and provide individualized therapeutic options, especially targeted treatments, are required.

 

CLINICAL RECOGNITION

 

Adrenocortical cancer (ACC) is a rare disease with an annual incidence of 0.7-2 cases per million per year and two distinct age distribution peaks, the first occurring in early adulthood and the second between 40-50 years with women being more often affected than men (55-60%) (1,2). Although the great majority of ACCs are sporadic in origin, they can also develop as part of familial syndromes the most common being the Beckwith-Wiedeman syndrome (11p151 gene, IGF-2 overexpression), the Li-Fraumeni syndrome (TP53 gene germline and somatic mutation), the Lynch syndrome (MSH2, MLH1, MSH6, PMS2, EPCAM genes), the multiple endocrine neoplasia (MEN) 1 (MEN1 gene), familial adenomatous polyposis (FAP gene, catenin somatic mutations), neurofibromatosis type 1 (NF1 gene) and Carney complex (PRKAR1A gene) syndromes (Table 1) (1- 5). In recent years several multi-center studies have shed light on the pathogenesis of ACC but ‘multi-omic’ multi-studies have recently revealed that only a minority of ACC cases harbor pathogenic driver mutations

 

Table 1. Clinical and Genetic Features of Familial Syndromes Associated with ACC

Genetic disease

Gene and chromosomal involvement

Organ involvement

Beckwith-Wiedemann syndrome

CDKN1C mutation

KCNQ10T1, H19 (epigenetic defects) 11p15 locus alterations

IGF-2 overexpression

Macrosomia, macroglossia, hemihypertrophy (70%), omphalocele, Wilm’s tumor, ACC (15-

20% adrenocortical tumors)

Li-Fraumeni syndrome P53(17p13)

Soft tissue sarcoma, breast cancer, brain

tumors, leukemia, ACC

Multiple Endocrine Neoplasia syndrome 1

Menin (11q13)

Parathyroid, pituitary, pancreatic, bronchial tumors

Adrenal cortex tumors (30%, rarely ACC)

Familial Adenomatous polyposis

APC (5q12-22)

Multiple adenomatous polyps and cancer colon and rectum

Periampullary cancer, thyroid tumors,

hepatoblastoma, rarely ACC

SBLA syndrome

Sarcoma, breast and lung cancer, ACC

Neurofibromatosis

NF1

Six or more light brown dermatological spots ("café au lait spots

At least two neurofibromas

Carney Complex

PRKAR1A not defined

Lentigines, Atrial Myxoma, and Blue Nevi

 

The clinical features of sporadic ACCs are due to tumor mass effects and spread to surrounding or distant tissues and/or to hormonal hypersecretion. A number of cases (≈ 10-15%) are increasingly diagnosed within the group of incidentally discovered adrenal masses (incidentalomas). However, the likelihood of an adrenal incidentaloma being an ACC is rather low (2, 6, 7). Approximately 50-60% of ACCs exhibit evidence of hormonal hypersecretion, usually that of combined glucocorticoid and androgen secretion (Table 2). Nearly 30-40% of patients with primary ACC present with a mass-related syndrome such as abdominal or dorsal pain, a palpable mass, fever of unknown origin, signs of inferior vena cava (IVC) compression, and signs of left-sided portal hypertension. Rarely, complications such as hemorrhage or tumor rupture may also occur.

 

In biochemical studies, the first step is the measurement of steroid hormones which are initially guided by the clinical presentation. According to the ESMO-EURACAN (European Society for Medical Oncology—the European Reference Network for Rare Adult Solid Cancers) Clinical Practice Guidelines from 2020 in cases of suspected ACC, an extensive steroid hormone work-up is recommended assessing gluco-,mineralo-, sex- and precursor-steroids (6-8). For all adrenal masses, diagnosis of pheochromocytoma should be considered based on clinical presentation and imaging measuring plasma-free or urinary-fractionated metanephrines to avoid intraoperative complications. The European Society of Endocrinology (ESE) and European Network Society of Adrenal Tumors (ENSAT) guidelines on adrenal incidentalomas suggest the measurement of sex steroids and precursors of steroidogenesis using multi-steroid profiling by tandem mass spectrometry in patients in whom based on imaging or clinical features an adrenocortical carcinoma is suspected (9). Urine steroid metabolomics for non-invasive and radiation-free detection of a malignant ‘steroid fingerprint’ in adrenocortical carcinoma patients has been prospectively validated (10).

 

Table 2. Signs and Symptoms of ACC and Recommended Testing for Confirmation of Hypersecretory Syndromes

Symptoms/Signs

Hormonal testing (ENSAT 2005, ESMO-

EURACAN - Clinical Practice Guidelines 2020)

Hypercortisolism

Centripetal fat distribution. Skin thinning – striae.

Muscle wasting – myopathy. Osteoporosis. Increased blood pressure (BP),

Diabetes Mellitus, Psychiatric disturbance, Gonadal dysfunction

Overnight dexamethasone suppression test (1mg)

24-hour free cortisol (urine)

Basal ACTH (plasma)

Basal cortisol (serum)

[for diagnosis minimum 3 out of 4 tests)

Androgen hypersecretion

Hirsutism

Menstrual irregularity – infertility

Virilization (baldness, deepening of the voice, clitoris hypertrophy)

DHEA-S

Androstenedione

Testosterone

17-hyrdoxy-progesterone (17OHPG)

Mineralocorticoid hypersecretion

Increased BP

Hypokalemia

Potassium (serum)

Aldosterone to renin ratio

Estrogen hypersecretion

Gynecomastia (men)

Menorrhagia (post-menopausal women)

17β-estradiol

Non-hypersecretory syndrome

 

 

PATHOPHYSIOLOGY

 

Although studies of hereditary neoplasia syndromes have revealed various chromosomal abnormalities related to ACC development, the precise genetic alterations involved are still unknown. Most common mutations implicated in sporadic ACC are insulin-like growth factor 2 (IGF2), catenin (CTNNB1 or ZNRF3), and TP53 mutations (1, 4, 11). The Wnt/β- catenin constitutive activation and insulin growth factor 2 (IGF2 overexpression) are the most important implicated genetic pathways. Germline TP53 mutations and dysregulation of the Gap 2/mitosis transition and the insulin-like growth factor 1 receptor (IGF1R) signaling have also been described. Steroidogenic factor 1 (SF1) plays an important role in adrenal development and is frequently overexpressed in ACC. Recently, ACC global --omics profiling studies revealed frequent detected genetic and epigenetic alterations, including loss of heterozygosity at 17p13, alterations at the 11p15 locus, and mutations in TP53, CTNNB1, ZNRF34, CDKN2A, RB1, MEN1, PRKAR1A, RPL22, TERF2, CCNE1, and NF1 genes. Decreased expression of MLH1, MSH2, MSH6, and/or PMS2 consistent with high microsatellite instability/mismatch repair protein deficiency (MSI-H/MMR-D) status has also been reported (4, 11).

 

DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS

 

A palpable mass causing abdominal pain in the presence of IVC syndrome is highly suggestive of an ACC. This is substantiated further by the presence of symptoms/signs of combined hormonal secretion (cortisol and androgens), virilizing or rarely feminizing symptoms/signs confirmed with the use of specific endocrine testing (Table 2). As the majority of ACCs are relatively large (size > 8cm, weight >100g) at diagnosis, specific imaging features are used to distinguish them from other adrenal lesions (1, 2, 3). If adrenal imaging indicates an indeterminate mass other parameters should be considered including tumor size > 4 cm, combined cortisol/androgen hormone excess, rapidly developing symptoms and/ rapid tumor growth and/or young age (e.g., < 40 years) at presentation, that all might point to an ACC (1, 2, 3, 5, 7). Other adrenal lesions that need to be considered in the differential diagnosis are myelolipomas, adrenal hemorrhage, lymphoma, adrenal cysts, metastases, and mainly adrenal adenomas, the majority of which have distinctive imaging features. There is no role for biopsy in a patient who is considered suitable for surgery of the adrenal mass (5, 6, 7). Computerized Tomography (CT) imaging of the adrenals is the major tool showing a unilateral nonhomogeneous mass, > 5cm in diameter, with irregular margins, necrosis, and occasionally calcifications. Due to the low-fat content X-Ray density is high (>20 Hounsfield Units, HU); in a series of 51 ACC none had a density of less than 13 Hounsfield Units (HU) (6-8). However, a recent study including almost 100 ACCs showed that increasing the unenhanced CT tumor attenuation threshold to 20 HU from the recommended 10 HU increased specificity for ACC at 80% [95% CI 77.9–82.0] vs. 64% [61.4–66.4] while maintaining sensitivity at 99% [94.4– 100] vs. 100% [96.3–100]; (PPV 19.7%, 16.3–23.5) [EURINE-ACT study] (10). The presence of enlarged aorto-caval lymph nodes, local invasion, or metastatic spread, are highly suggestive of ACC. For 3-6 cm size lesions, measuring CT-related tumoral density before and after contrast administration, and estimating washout percentage can be helpful; less than 50% after 15 minutes, is associated with >90% specificity (7, 8). On Magnetic Resonance Imaging (MRI), ACC appears hypo or isointense in relation to the liver on T1-weighted images and following gadolinium enhancement and chemical shift techniques the diagnostic accuracy obtained can be as high as 85- 100% (7, 8). Recently Positron Emission Tomography (PET) imaging with 18F-fluoro-2deoxy- D-glucose (18FDG-PET) has been proposed as possibly the best second-line test to assess indeterminate masses by unenhanced CT exhibiting 95-100% sensitivity and 91-94% specificity that increases further when fused with CT imaging. Furthermore, 18FDG-PET can also be used as a staging procedure identifying metastatic adrenal disease missed by conventional imaging studies including CT of the chest (7, 8). With the proper implementation of imaging studies there is no need for any adrenal biopsy.

 

HISTOPATHOLOGICAL DIAGNOSIS

 

The expression of steroidogenic factor 1(SF1) is a valid marker to document the adrenal origin (distinction of primary adrenocortical tumors and non-adrenocortical tumors) with a sensitivity of 98% and a specificity of 100%. If this marker is not available, a combination of other markers can be used which should include inhibin-alpha, melan-A, and calretinin. The European Network for the Study of Adrenal Tumors (ENSAT) has shown that KI-67 is the most powerful prognostic marker in both localized and advanced ACC indicative of aggressive behavior and that higher Ki-67 levels are consistently associated with a worse prognosis (2, 6, 12, 13). The Weiss system, based on a combination of nine histological criteria that can be applied on hematoxylin and eosin-stained slides for the distinction of benign and malignant adrenocortical tumors, is the best validated score to distinguish adenomas from ACC although with high inter-observer variability. A reticulin algorithm has been used for the diagnosis of ACC which involves an abnormal/absent reticulin framework and at least one of the three following criteria (tumor necrosis, presence of venous invasion and mitotic rate of >5/50 high power field) (13). Studies have proposed the use of proliferative index (Ki-67 index > 5%) and IGF2 over-expression to confirm the diagnosis of ACC (12, 13). It is important to note that no single microscopic criterion on its own is indicative of malignancy and there is subjective variability in interpretation.

 

PROGNOSIS

 

As survival depends on stage at presentation several different classification histopathological systems have evolved with the reported 5-year survival using the ENSAT system being 82% for stage I, 61% for stage II, 50% for stage III, and 13% for stage IV disease (Table 3) (6-8). Tumor size remains an excellent predictor of malignancy as tumors > 6cm have a 25% chance of being malignant compared to 2% of those with a size < 4cm. As there is no single distinctive histopathological feature indicative of malignancy the Weiss score has been used with a score >3 being suggestive of malignancy and recently Ki-67 labelling index >10%. A relatively new system published by a European group in 2015 is the Helsinki score which relies on mitotic rate, necrosis, and Ki-67 index (3x mitotic count [>5/50 high power fields] + 5x presence of necrosis + Ki-67 proliferative index) of ACC and focus on the predicting diagnosis as well as prognosis of ACC. A Helsinki score >8.5 is associated with metastatic potential and warrants the diagnosis of ACC (13). Altered reticulin pattern, Ki-67% labelling index, and overexpression of p53 protein were found to be useful histopathological markers for distinguishing benign adrenocortical tumors from ACCs; however, only pathological p53 nuclear protein expression was found to reach statistically significant association with poor survival and development of metastases, although in a small series of patients (12).

 

Most recently, the S-GRAS score was calculated as a sum of the following points: tumor stage (1–2 = 0; 3 = 1; 4 = 2), grade (Ki67 index 0–9% = 0; 10–19% = 1; ≥20% = 2 points), resection status (R0 = 0; RX = 1; R1 = 2; R2 = 3), age (<50 years = 0; ≥50 years = 1), symptoms (no = 0; yes = 1), generating four groups of ACC (0–1, 2–3, 4–5, and 6–9). The prognostic performance of S-GRAS was found superior to tumor stage and Ki67 in operated ACC patients, independently from adjuvant mitotane. S-GRAS score provides a new important guide for personalized management of ACC especially regarding. radiological surveillance and adjuvant treatment (14). The COMBI score constitutes an additional predictive score incorporating the DNA-based molecular biomarkers to the S-GRAS including alterations in the Wnt/β- catenin and Rb/p53 pathways and hypermethylation of PAX5 (15).  

 

Table 3. Staging System for ACC Proposed by the International Union against Cancer (WHO 2004) and the European Network for the Study of Adrenal Tumors (ENSAT).

Stage

WHO 2004

ENSAT 2008

I

T1,N0,M0

T1,N0,M0

II

T2,N0,M0

T2,N0,M0

III

T1-2,N1,M0

T3,N0,M0

T1-2,N1,M0

IV

T1-4,N0-1,M1

T3,N1,M0 T4,N0-1,M0

T1-4,N0-1, M1

M0: No distant metastasis, M1: Presence of distant metastasis, N0: No positive lymph nodes, N1: Positive lymph node(s), T1: Tumor ≤5cm, T2: Tumor > 5cm, T3: Tumor infiltration to surrounding tissue, T4: Tumor invasion into adjacent organs or venous tumor thrombus in vena cava or renal vein.

 

The median overall survival (OS) of all ACC patients is about 3-4 years (6, 7). The prognosis is, however, relatively heterogeneous. Complete surgical resection provides the only means of cure (6, 7, 16, 17). In addition to radical surgery, disease stage, proliferative activity/tumor grade, and cortisol excess are independent prognostic parameters (6, 7, 16, 17). The five-year survival rate is 60-80% for tumors confined to the adrenal space, 35-50% for locally advanced disease, and significantly lower in cases of metastatic disease ranging from 0% to 28% (6-8). ENSAT staging is considered slightly superior to the Union for International Cancer Control (UICC) staging. Additionally, the association between hypercortisolism and mortality was consistent. As Ki-67 is related to prognosis in both localized and advanced ACC, threshold levels of 10% and 20% have been considered for discriminating low from high Ki-67 labelling index; however, it is not clear whether any single significant threshold can be determined. Patients with stage I-III disease treated with surgical resection had significantly better median OS (63 vs. 8 months; p= 0.001). In stage IV disease, better median OS occurred in patients treated with surgery (19 vs. 6 months; p=0.001), and post-surgical radiation (29 vs. 10 months; p=0.001) or chemotherapy (22 vs. 13 months; p=0.004) (6-8, 16,17). OS varied with increasing age, higher comorbidity index, grade, and stage of ACC at presentation. There was improved survival with surgical resection of the primary tumor, irrespective of disease stage; post-surgical chemotherapy or radiation was of benefit only in stage IV disease (7, 16). The 5 year-survival of adult patients from multiple datasets with ACC after surgery ranges from 40% to 70%. The estimated five-year OS for patients with ACC in recent cohorts is slightly less than 50% (7, 16). Preliminary data also shows that molecular markers (gene expression, methylation, and chromosome alterations) for localized ACC could predict cancer recurrence (18, 19). Nevertheless, many of these markers need further validation and some are difficult to be widely applied in clinical settings.

 

The development of genomics has led to a new classification of ACC by two independent international cohorts; one from ENSAT network in Europe (18) and the other from the Cancer Genome Atlas consortium in America, Europe and Australia (19), with two distinct molecular subgroups, C1A and C1B being associated with poor (5-year survival rate of 20%) and good overall prognosis (5-year survival rate of 91%), respectively. The C1B group is characterized by a low mutation rate, and a very low incidence of mutations of the main driver genes of ACC whereas the C1A group is characterized by high mutation rate and driver gene alterations. This group is further divided into a subgroup of aggressive tumors showing hypermethylation at the level of the CpG islands located in the promoter of genes (“CIMP phenotype”). The prognostic value of paraffin-embedded tumors’ transcriptome analysis was also confirmed as an independent prognostic factor in a multivariable model including tumor stage and Ki-67. Oncocytic adrenocortical tumors did not form any specific cluster as oncocytic carcinomas and oncocytic tumors of uncertain malignant potential were all in ‘C1B’ (20).

 

THERAPY

 

The management of patients with ACC requires a multidisciplinary approach with initial complete surgical resection in limited volume disease (stages I, II and occasionally III). Mitotane (1,1-dichloro-2(ochlorophenyl)- 2-(p-chlorophenyl) ethane [o,p’DDD]) is the only currently available adrenolytic medication achieving an overall response of approximately 30%.

 

Surgery

 

Surgery aims to achieve a complete margin negative (R0) resection as patients with an R0 resection have a 5-year survival rate of 40-50% compared to the < 1year survival of those with incomplete resection (7, 17). Patients with stage III tumors and positive lymph nodes can have a 10-year OS rate of up to 40% after complete resection. When a preoperative diagnosis or high level of suspicion of ACC exists, open surgical oncological resection is recommended as locoregional lymph removal might improve diagnostic accuracy and therapeutic outcome. However, the wide range of reported lymph node involvement in ACC (ranging from 4 to 73%) implies that regional lymphadenectomy is neither formally performed by all surgeons nor accurately assessed or reported by all pathologists (7, 17). Laparoscopic adrenalectomy should be considered for tumors with size up to 6 cm without any evidence of local invasion and open adrenalectomy for unilateral adrenal masses with radiological findings suspicious of malignancy and signs of local invasion (9). There is no strong evidence that one of the minimally invasive or open adrenalectomy is superior concerning the time to recurrence and/or survival of patients with ACC, provided that rupture of tumor capsule is excluded. Routine locoregional lymphadenectomy should be performed with adrenalectomy for highly suspected or proven ACC and it should include (as a minimum) the peri-adrenal and renal hilum nodes. Preservation of the tumor capsule is essential whereas involvement of the IVC or renal vein with tumor thrombus is not a contraindication for surgery. However, even following a complete surgical resection, 50-80% of patients develop locoregional or metastatic recurrence. Although such patients may be candidates for aggressive surgical resection, routine debulking is not recommended except for the control of hormonal hypersecretion (6, 7, 17). Ablative therapies particularly targeting hepatic disease are used to decrease tumor load and hypersecretory syndromes. Individualized treatment decisions are made in cases of tumors with extension into large vessels based on a multidisciplinary surgical team. Such tumors should not be regarded as ‘unrespectable’ until reviewed in an expert center.

 

Mitotane

 

Mitotane has traditionally been used for ACCs to obtain a partial or complete response in 33% of cases mainly by metabolic transformation within the tumor and through oxidative damage. Besides its cytotoxic adrenal action mitotane also inhibits steroidogenesis. Adjuvant mitotane treatment is proposed in those patients without macroscopic residual tumor after surgery but who have a perceived high risk of recurrence (stage III, KI-67%>10%). However, patients at low/moderate risk of recurrence (stage I-II, R0 resection, and Ki-67 ≤ 10%) do not benefit significantly from adjuvant mitotane (ADIUVO trial) (21). An ongoing study, ADIUVO-2, is investigating the effectiveness of mitotane alone compared to mitotane combined with chemotherapy in high-risk ACC patients.

 

When indicated mitotane should be initiated within six weeks and not later than 3 months post-surgery (7, 17). Adjuvant mitotane should be administrated for at least 2 years, but no longer than 5 years. However, the optimal duration of adjuvant mitotane treatment remains unsolved and mainly depends on personal preferences and expertise. According to a recent study, the present findings do not support the concept that extending adjuvant mitotane treatment over two years is beneficial for patients with ACC at low risk of recurrence (22). The tolerability of mitotane may be limited by its side effects mainly nausea, vomiting, neurological (ataxia, lethargy), hepatic and rarely hematological toxicity (7, 22). Measurement of serum mitotane levels, targeting a range of 14-20 mg/l, seems to correlate with a therapeutic response while minimizing toxicity using variable dosing regimens (6-8). Levels above 20 mg/L are linked to a higher risk of central neurological toxicity, though mild symptoms can also occur at lower concentrations. Interestingly, some evidence suggests that steroid secretion inhibition may still occur at lower mitotane levels than 14mg/l, indicating potential therapeutic benefits even outside the standard therapeutic window (23). Additionally, the Ki-67 index, a widely recognized marker of tumor aggressiveness in ACC, is often used to predict disease’s progression and the potential effectiveness of mitotane therapy. While elevated Ki-67 levels are typically associated with poorer prognosis, they may also suggest a greater likelihood of response to mitotane when therapeutic concentrations are achieved (24).

 

Mitotane causes hyperlipidemia and increased hepatic production of hormone-binding globulins (cortisol, sex hormone, thyroid and vitamin D) increasing total hormone concentration while impairing free hormone bioavailability. The induction of hepatic P450- enzymes by mitotane induces the metabolism of steroid compounds requiring high-dose glucocorticoid and mineralocorticoid replacement. Hormonal excess causes significant morbidity in ACC patients. Although mitotane reduces steroidogenesis it has a slow onset of action necessitating the use of other medications targeting adrenal steroidogenesis (ketoconazole, metyrapone, aminoglutethimide, and etomidate). As adrenal insufficiency may occur close supervision is required to titrate adrenal hormonal replacement therapy.

Mitotane remains the primary treatment for ACC, but resistance, both primary and acquired, limits its efficacy. Primary resistance arises from genetic and epigenetic alterations (e.g., TP53, CTNNB1 mutations, gene hypermethylation), the overexpression of drug efflux pumps (e.g., ABCB1), and disruptions in steroidogenic pathways. Acquired resistance develops during treatment, involving pathways like Wnt/β-catenin, PI3K/AKT/mTOR, and genes such as BCL-2 and TP53. Understanding these mechanisms is essential for developing targeted therapies and improving outcomes (25).

 

Cytotoxic Chemotherapy

 

In metastatic ACC or when progression on mitotane, systematic therapy is recommended. Although cisplatin-containing regimens have shown some responses, most studies lack enough power and comparisons between different regimens are only a few. The most encouraging results originate from the combinations of etoposide, doxorubicin, and cisplatin with mitotane (EDP-M) achieving an overall response of 49% of 18 months duration (FIRMA-CT study) (26). This regimen was equally effective as first-line treatment or after failing of the combination of streptozotocin with mitotane and is currently the preferred scheme. In patients who progress under mitotane monotherapy, EDP treatment is also recommended (7, 26). The combination of gemcitabine with capecitabine is used for patients failing EDP- and for non-responding patients. Targeted therapies with tyrosine kinase inhibitors have been also suggested. In a single-arm, phase 2 trial including 18 patients with advanced ACC treated with monotherapy with cabozantinib, the median progression-free survival (PFS) was 6 months, whereas 72·2% of patients were PFS at 4 months (27). Although initially promising, treatment with IGF-1R antagonists did not prove to be efficacious, suggesting that combination therapies may be the way forward (see below).

 

Radiation Therapy

 

Radiotherapy has a role in symptomatic metastatic disease, particularly bone disease with positive responses in up to 50% - 90% of cancer patients. It is a local therapy which is mainly recommended in incomplete resection, recurrent, or metastatic disease. Postoperative adjuvant radiotherapy significantly improved overall survival (OS) and PFS compared with the use of surgery alone in resected localized ACC patients especially those with stage I/II (median Ki-67%=20). However, this finding was mainly in retrospective studies (28).

 

Immunotherapy

 

Several Immunotherapy agents have been evaluated in clinical trials for metastatic ACC patients including the immune checkpoint inhibitors (ICIs) pembrolizumab, nivolumab, and avelumab which are monoclonal antibodies directed toward PD-L1, the ligand-binding partner of PD-1, that is expressed on tumor cells. Four ICIs (pembrolizumab, avelumab, nivolumab, and ipilimumab) have investigated the role of immunotherapy in advanced ACC. Despite the different primary endpoints used in these studies, the reported rates of overall response rate and PFS were generally poor (Table 4) (29-32). Three main potential markers of response to immunotherapy in ACC have been described: Expression of PD-1 and PD-L1, microsatellite instability, and tumor mutational burden (29). PD-1 and PD-L1 are expressed in 26.5% and 24.7% of ACC samples, respectively, with low expression in most tumor samples. In contrast, CTLA-4 expression is observed in 52.5% of ACC samples. Positive PD-1 expression was associated with longer PFS even after considering prognostic factors. In contrast, PD-L1 and CTLA-4 did not correlate with clinical outcomes. Additionally, PD-1 and PD-L1 expression correlated significantly with the amount of CD3+, CD4+, FoxP3+, and CD8+ T cells (33). However, none of these parameters have been validated in prospective studies. Several mechanisms may be responsible for immunotherapy failure, and a greater knowledge of these mechanisms might lead to the development of new strategies to overcome immunotherapy resistance.

 

Two clinical trials using the PD-1 inhibitor pembrolizumab as monotherapy in ACC have been reported (29, 30). The observed median PFS and OS in the first study were 2.1 and 24.9 months, respectively. Six patients in the study had microsatellite-high and/or mismatch repair deficient status (MSI-H/MMR-D), for which pembrolizumab is an FDA-approved therapy. In the second study, 5 of 14 patients (36%), developed stable disease (SD) at 27 weeks and 2 exhibited a partial response. Nivolumab monotherapy was tested in a phase II trial (31). The best response observed in this trial was 1 out of 10 patients with an unconfirmed partial response and 2 out of 10 patients developing SD (31). Avelumab has been evaluated in a phase 1b clinical trial in patients with metastatic ACC who had progressed after first-line platinum-based therapy (32). In this trial, including 50 patients, 3 patients showed a partial response, and 21 (42%) patients had SD (42%). Median PFS and OS were 2.6 and 10.6 months, respectively. Although no head-to-head study exists to compare ICIs efficacy, a retrospective study of 54 patients with advanced ACC analyzed the treatment response in different ICIs, demonstrating that after adjustment for concomitant mitotane use, treatment with nivolumab was associated with a lower risk of progression and death compared to pembrolizumab (34).

 

Table 4. Studies that have Investigated Immunotherapy in Patients with ACC

Molecule

Phase

Population(n)

Prior systemic treatment

Results

Pembrolizomab 200 mg every 3

w (35 cycles)

39

28

PFS=2.1,OS=24.9 ORR (RECIST)=23%

Pembrolizomab 200 mg every 3

w (35 cycles)

II

16

16

SD at 27 w=36%, ORR(RECIST)=14%

Nivolumab       240 mg every 2 w

II

10

10

PFS=1.8, ORR=11%

Avelumab 10 mg/kg every 2 w (±mitotane)

Ib

50

50

PFS=2.6, OS=10.6, ORR=6%

Ipilimumab 1 mg/kg intravenously every 6 weeks with nivolumab 240 mg intravenously every 2 weeks

II

21

21

6-month OS = 76%; the median OS= 15.8 months, ORR=14%

Camrelizumab combined with apatinib

II

21

21

ORR=52%, median PFS=3.3 months, median OS=20.9 months

ORR= objective response rates; PFS= progression-free survival; SD= stable disease; OS= overall survival

 

Combination therapies with these agents are also evolving either with two different ICIs, most frequently ipilimumab and nivolumab or a combination of ICIs with a different targeted molecule and especially a tyrosine kinase inhibitor (TKI) (35,36). Pembrolizumab along with the VEGF-targeted multi-kinase inhibitor lenvatinib was used in a small retrospective case series including 8 heavily pre-treated patients (the median number of prior lines of systemic therapy was 4) with progressive or metastatic ACC (37). The median PFS in these patients was 5.5 months (95% CI 1.8–not reached). Two (25%) patients showed a partial response (PR), one (12.5%) patient had stable disease (SD), and five (62.5%) patients developed progressive disease. Other immunotherapies that have been evaluated include the monoclonal antibodies figitumumab and cixutumumab directed against the ACC-expressed insulin-like growth factor 1 (IGF-1) receptor, the recombinant cytotoxin interleukin-13-pseudomonas exotoxin A, and autologous tumor lysate dendritic cell vaccine (38, 39). All of these agents have shown modest clinical activity. Figitumumab in particular was evaluated in a phase I trial. in 14 patients with metastatic ACC. The best response to treatment observed in this trial was SD seen in 8 of 14 patients. Toxicities were generally mild and included hyperglycemia, nausea, fatigue, and anorexia. Similarly, to figitumumab, cixutumumab (IMC-A12) was evaluated in combination with mitotane in a phase II trial as first-line therapy for patients with advanced or metastatic ACC (39). The study was terminated early due to slow accrual and limited efficacy. The recorded PFS was only 6 weeks (range: 2.66–48), and in 20 evaluable patients, the best objective response rates (ORR) were a partial response (PR) in one patient and SD in a further seven. Toxicities observed included grade 4 hyperglycemia and hyponatremia and one grade 5 multiorgan failure.

 

Immune-Modulators

 

The potential utility of thalidomide treatment in ACC was evaluated in a retrospective cohort study of the European Networks for the Study of Adrenal Tumors registry (40). In this study, 27 patients with progression on mitotane or metastatic ACC were treated with 50–200 mg thalidomide daily. The best response noted was SD in two patients, while the remaining 25 patients had progressive disease. The median PFS was 11.2 weeks, with a median OS of 36.4 weeks. Thalidomide was generally well tolerated, with fatigue and gastrointestinal upset being the most commonly observed side effects.

 

Evolving Therapies

 

Active areas of research in this field include combinations of ICIs, combination TKIs and ICIs, cancer vaccines, and glucocorticoid receptor antagonists combined with ICIs therapies (http://www.clinicaltrials.gov). Targeting mTOR pathway alone with everolimus did not produce significant responses. An extended phase I study of the anti-IGF-1R monoclonal antibody cixutumumab with an mTOR inhibitor showed a partial but short-lived response. Combination treatments such as cabozantinib with atezolizumab in a basket study (CABATEN) or SPENCER study (EO – a novel microbiome-derived therapeutic vaccine with nivolumab) in MSI/PD-L1 negative and low tumor mutational burden tumors have shown a relative response in a subgroup of ACC patients. Other potential targets are antagonists of β-catenin and Wnt signaling pathway and SF-1 inverse agonists. The application of radionuclide therapy using 131I-metomidate has recently been explored. However, despite recent advances in dysregulated molecular pathways in ACCs, these findings have not yet been translated into meaningful clinical benefits.

 

FOLLOW-UP

 

Patients who have undergone a curative resection should be followed up regularly using endocrine markers and abdominal imaging. After complete resection, radiological imaging every 3 months for 2 years and then every 3-6 months for a further 3 years is proposed. However, imaging follow-up beyond 5 years should be adapted in particular cases and be decided by a multidisciplinary team (7). 18FDG-PET should be performed at regular intervals to detect recurrent disease in high-risk patients. Patients on mitotane therapy should be regularly monitored measuring serum mitotane levels ensuring adequate replacement therapy. In case of recurrence not amenable to surgical excision patients should be enrolled in prospective clinical trials.

 

CONCLUSION

 

Besides considerable accumulated knowledge on genetic profiling, the pathogenesis of ACC is still not delineated although groups of patients with a worse outcome could be identified. Stage of the disease remains a strong predictor of OS whereas new evolving biomarkers need to be further validated. Imaging with 18FDGPET is an integral part of the staging procedure but the available medical therapies for patients with advanced disease have not shown a major impact on patients' prognosis. ACC remains a challenging malignancy with limited effective treatment options. Targeted therapies and immunotherapies, especially in combination regimens, are the subject of continued research. The evolving genomic landscape emphasizes the significance of targeted therapies and the need for further research to identify high-risk patients and formulate efficacious therapies for patients with advanced diseases.

 

REFERENCE

 

  1. Petr EJ & Else T. Genetic predisposition to endocrine tumors: Diagnosis, surveillance and challenges in care. Semin Oncol 2016 43 582-590
  2. Kassi E, Angelousi A, Zografos G, Kaltsas G, Chrousos GP. Current Issues in the Diagnosis and Management of Adrenocortical Carcinomas. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-2016 Mar 6.PMID: 25905240 Health Organization (WHO) of Endocrine Tumours. Endocr. Pathol. 2017 28 213–227.
  3. Raymond VM, Everett JN, Furtado LV, Gustafson SL, Jungbluth CR, Gruber SB, Hammer GD, Stoffel EM, Greenson JK, Giordano TJ, et al. Adrenocortical carcinoma is a lynch syndrome-associated cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013 31 3012–3018.
  4. Chatzellis E, Kaltsas G. Adrenal Incidentalomas. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): DText.com, Inc.; 2000-2016 Feb 5.PMID: 25905250.
  5. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab 2013 98 4551- 4564.
  6. Fassnacht M, Dekkers O, Else T, Baudin E, Berruti A, de Krijger RR, Haak HR, Mihai R, Assie G, Terzolo M. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018 179 1-46.
  7. Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M & Pentheroudakis G. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2012 23 131-138.
  8. Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, Pelsma I, Marina L, Lorenz K, Bancos I, Arlt W, Dekkers OM. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023 20 189 1-42.
  9. Bancos I, Taylor AE, Chortis V, Sitch AJ, Jenkinson C, Davidge-Pitts CJ, Lang K, Tsagarakis S, Macech M, Riester A,Deutschbein T, Pupovac ID, Kienitz T, Prete A, Papathomas TG,Gilligan LC, Bancos C, Reimondo G, Haissaguerre M, Marina L, Grytaas MA, Sajwani A, Langton K, Ivison HE, Shackleton CHL, Erickson D, Asia M, Palimeri S, Kondracka A, Spyroglou A, Ronchi CL, Simunov B, Delivanis DA, Sutcliffe RP, Tsirou I, Bednarczuk T, Reincke M, Burger-Stritt S, Feelders RA, Canu L, Haak HR, Eisenhofer G, Dennedy MC, Ueland GA, Ivovic M, Tabarin A, Terzolo M, Quinkler M, Kastelan D, Fassnacht M, Beuschlein F, Ambroziak U, Vassiliadi DA, O'Reilly MW, Young WF Jr, Biehl M, Deeks JJ, Arlt W; ENSAT EURINE-ACT Investigators. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol. 2020 8 773-781. doi: 10.1016/S2213-8587(20)30218-7. Epub 2020 Jul 23.
  10. Pegna GJ, Roper N, Kaplan RN, Bergsland E, Kiseljak-Vassiliades K, Habra MA, Pommier Y, Del Rivero J. The Immunotherapy Landscape in Adrenocortical Cancer. Cancers (Basel). 2021 13 2660. doi: 10.3390/cancers13112660
  11. Angelousi A, Kyriakopoulos G, Athanasouli F, Dimitriadi A, Kassi E, Aggeli C, ZografosG, Kaltsas G. The Role of Immunohistochemical Markers for the Diagnosis and Prognosis of Adrenocortical Neoplasms. J Pers Med. 2021 11 208. doi: 10.3390/jpm11030208
  12. Duregon, E.; Fassina, A.; Volante, M.; Nesi, G.; Santi, R.; Gatti, G.; Cappellesso, R.; Ciaramella, P.D.; Ventura, L.; Gambacorta, M.; et al. The Reticulin Algorithm for Adrenocortical Tumor Diagnosis: A multicentric validation study on 245 unpublished cases. Am. J. Surg. Pathol. 2013 37 1433–1441.
  13. Elhassan Y, Altieri B, Berhane S, Cosentini D, Calabrese A, Haissaguerre M, Kastelan D, Fragoso MC, Bertherat J, Baudin E, et al. Modified GRAS Score for Prognostic Classification of Adrenocortical Carcinoma: An ENSAT Multicentre Study. J. Endocr. Soc. 2021 5 165–166.
  14. Lippert J, Dischinger U, Appenzeller S, Prete A, Kircher S, Skordilis K, Elhassan YS, Altieri B, Fassnacht M, Ronchi CL. Performance of DNA-based biomarkers for classification of adrenocortical carcinoma: a prognostic study. Eur J Endocrinol. 2023 2 189 262-270.
  15. Tella SH, Kommalapati A, Yaturu S, Kebebew E.Predictors of survival in Adrenocortical Carcinoma: An analysis from the National Cancer Database (NCDB). J Clin Endocrinol Metab. 2018 103 3566-3573.
  16. Tacon L, Prichard R, Soon PSH, et al Current and emerging therapies for advanced adrenocortical carcinoma. The Oncologist 2011 16 36-48.
  17. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MCBV, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA; Cancer Genome Atlas Research Network, Hammer GD, Giordano TJ, Verhaak RGW. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016 30 363. doi: 10.1016/j.ccell.2016.07.013.
  18. Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W,Barreau O, Omeiri H, Rodriguez S, Perlemoine K, René-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papathomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libé R, de Reyniès A, Bertherat J. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014 46 607-612. doi: 10.1038/ng.2953.
  19. Jouinot A, Lippert J, Sibony M, Violon F, Jeanpierre L, De Murat D, Armignacco R, Septier A, Perlemoine K, Letourneur F, Izac B, Ragazzon B, Leroy K, Pasmant E, North MO, Gaujoux S, Dousset B, Groussin L, Libe R, Terris B, Fassnacht M, Ronchi CL, Bertherat J, Assie G. Transcriptome in paraffin samples for the diagnosis and prognosis of adrenocortical carcinoma. Eur J Endocrinol. 202221 186 607-617.
  20. Massimo Terzolo, MD, Martin Fassnacht, MD, Paola Perotti, PhD, Rossella Libe, MD, André Lacroix, MD, Darko Kastelan, MD, PhD, Harm Reinout Haak, MD,PhD, Wiebke Arlt, MD, Paola Loli, MD, Bénédicte Decoudier, MD, Helene Lasolle, MD, Irina Bancos, MD, Marcus Quinkler, MD, Maria Candida Barisson Villares Fragoso, PhD,MD, Letizia Canu, MD, PhD, Soraya Puglisi, MD, Matthias Kroiss, MD, Tina Dusek, MD, Isabelle Bourdeau, MD, Eric Baudin, MD, Paola Berchialla, PhD, Felix Beuschlein, MD, Jerome Yves Bertherat, MD,PhD, Alfredo Berruti, MD. Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients, Journal of the Endocrine Society, Volume 5, Issue Supplement_1, April-May 2021, Pages A166–A167
  21. Basile V, Puglisi S, Altieri B, Canu L, Libè R, Ceccato F, Beuschlein F, Quinkler M, Calabrese A, Perotti P, Berchialla P, Dischinger U, Megerle F, Baudin E, Bourdeau I, Lacroix A, Loli P, Berruti A, Kastelan D, Haak HR, Fassnacht M, Terzolo M. What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. J Pers Med. 2021 11 269. doi: 10.3390/jpm11040269.
  22. Ehrlich MI, Labadie BW, Bates SE, Fojo T. Mitotane and the myth of 14 mg/L. Lancet Oncol. 2024 Jan;25(1):12-15. 
  23. Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, Libé R, Ardito A, Al Ghuzlan A, Quinkler M, Oßwald A, Ronchi CL, de Krijger R, Feelders RA, Waldmann J, Willenberg HS, Deutschbein T, Stell A, Reincke M, Papotti M, Baudin E, Tissier F, Haak HR, Loli P, Terzolo M, Allolio B, Müller HH, Fassnacht M. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab. 2015 100 841-849.
  24. Flauto F, De Martino MC, Vitiello C, Pivonello R, Colao A, Damiano V. A Review on Mitotane: A Target Therapy in Adrenocortical Carcinoma. Cancers (Basel). 2024 4 16 4061
  25. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B; FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012 366 2189-2197.
  26. Campbell MT, Balderrama-Brondani V, Jimenez C, Tamsen G, Marcal LP, Varghese J, Shah AY, Long JP, Zhang M, Ochieng J, Haymaker C, Habra MA. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial. Lancet Oncol. 2024 25 649-657. 
  27. Wu L, Chen J, Su T, Jiang L, Han Y, Zhang C, Zhou W, Jiang Y, Zhong X, Wang W. Efficacy and safety of adjuvant radiation therapy in localized adrenocortical carcinoma. Front Endocrinol (Lausanne). 2024 8 14 1308231. 
  28. Raj N, Zheng Y, Kelly V, Katz SS, Chou J, Do RKG, Capanu M, Zamarin D, Saltz LB, Ariyan CE, Untch BR, O'Reilly EM, Gopalan A, Berger MF, Olino K, Segal NH, Reidy-Lagunes DL. PD-1 Blockade in Advanced Adrenocortical Carcinoma. J Clin Oncol. 2020 38 71-80.
  29. Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 7 253.
  30. Carneiro BA, Konda B, Costa RB, Costa RLB, Sagar V, Gursel DB, Kirschner LS, Chae YK, Abdulkadir SA, Rademaker A, Mahalingam D, Shah MH, Giles FJ. Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial. J Clin Endocrinol Metab. 2019 104 6193-6200.
  31. Le Tourneau C, Hoimes C, Zarwan C, Wong DJ, Bauer S, Claus R, Wermke M, Hariharan S, von Heydebreck A, Kasturi V, Chand V, Gulley JL. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer. 2018 6 111.
  32. Landwehr LS, Altieri B, Sbiera I, Remde H, Kircher S, Olabe J, Sbiera S, Kroiss M, Fassnacht M. Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2024 13;109 2325-2334.
  33. Remde H, Schmidt-Pennington L, Reuter M, Landwehr LS, Jensen M, Lahner H, Kimpel O, Altieri B, Laubner K, Schreiner J, Bojunga J, Kircher S, Kunze CA, Pohrt A, Teleanu MV, Hübschmann D, Stenzinger A, Glimm H, Fröhling S, Fassnacht M, Mai K, Kroiss M. Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study. Eur J Endocrinol. 2023 7188 485-493.
  34. Zhu YC, Wei ZG, Wang JJ, Pei YY, Jin J, Li D, Li ZH, Liu ZR, Min Y, Li RD, Yang L, Liu JY, Wei Q, Peng XC. Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial. Nat Commun. 2024 29 15 10371.
  35. Patel SP, Othus M, Chae YK, Huynh T, Tan B, Kuzel T, McLeod C, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke C, Kurzrock R. Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort. J Immunother Cancer. 2024 27 12 009074.
  36. Bedrose S, Miller KC, Altameemi L, Ali MS, Nassar S, Garg N, Daher M, Eaton KD, Yorio JT, Daniel DB, Campbell M, Bible KC, Ryder M, Chintakuntlawar AV, Habra MA. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. J Immunother Cancer. 2020 8 e001009.
  37. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, de Bono JS, Gualberto A, Hammer GD. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol. 2010 65 765-73.
  38. Lerario AM, Worden FP, Ramm CA, Hesseltine EA, Stadler WM, Else T, Shah MH, Agamah E, Rao K, Hammer GD. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer. 2014 5 232-239.
  39. Kroiss M, Deutschbein T, Schlötelburg W, Ronchi CL, Hescot S, Körbl D, Megerle F, Beuschlein F, Neu B, Quinkler M, Baudin E, Hahner S, Heidemeier A, Fassnacht M. Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. Exp Clin Endocrinol Diabetes. 2019 127 578-584.